<SEC-DOCUMENT>0001628280-20-011994.txt : 20200806
<SEC-HEADER>0001628280-20-011994.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806161846
ACCESSION NUMBER:		0001628280-20-011994
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Guardant Health, Inc.
		CENTRAL INDEX KEY:			0001576280
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				454139254
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38683
		FILM NUMBER:		201081949

	BUSINESS ADDRESS:	
		STREET 1:		505 PENOBSCOT DR.
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		855-698-8887

	MAIL ADDRESS:	
		STREET 1:		505 PENOBSCOT DR.
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gh-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a823c88f-2b24-44ac-a516-3f731119002e,g:77fc4dec-5a42-485c-bad8-a10178a2afe8,d:b551ebaf812444a9a6979b345f863c2b--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:gh="http://guardanthealth.com/20200630" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gh-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN18xLTEtMS0xLTA_7a861ac8-8b80-4945-9720-c1b2133a5f6f">false</ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN18yLTEtMS0xLTA_37d8cd0c-f416-46fa-90e5-3d76c6069d9b">2020</ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN18zLTEtMS0xLTA_b13d7e5f-eb94-4fbc-b34d-a660992d6c70">Q2</ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN180LTEtMS0xLTA_dc36c53d-05cb-43e9-8d4d-16d032a231f0">0001576280</ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN181LTEtMS0xLTA_e6aed5c4-b29d-4aeb-9ce6-a572044f69de">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie96d1c24c55f436fa86526b0018deb29_D20200526-20200526" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjAyMQ_60fc0348-aa77-452e-b4e9-5b9e8050b4d4">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gh-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i67ed747d77784f589faa4a5f85f01457_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icccb78a249d8444998f95593e619a75a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887b578e7d524b4ebef1f7577dec56b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c1ec3f9b2e4d6598a8957cb05b297f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54d30e5743544cc491322305e37032f1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11103427b6f4fcdb465ffb3518dbc03_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61571b0d7df44691a978692e9978913e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5eca2f8beb48ab8fa5fdaf8eb8348a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0533482d5645d989843fb090261fd6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3306441994cd4d6b9272a0486826de35_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404d165872a34298a67e1be6b55bbb3c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93fffc7829f64f9eb628786736a5a649_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida600c4d3f69417dac19667d2cea0b78_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d98dcdfd415452e90b92f303d33161e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd582379ae154944b83cf4f0429747ef_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e4ca00724742b3ad83e062217f6ec9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia759beb2854d4b8e94e0d88280e30e87_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7596a4a43a214ae283198a28115a4899_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe01ddc5547497bb9cbffefe0198307_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7a9e78e81243f09669f88dac612492_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6eb90faf2794203b3bd8684e7abdab9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90fb72b236d249d284285a90f9c10645_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c8f7efb1f049aa933ce256d441e6aa_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd93329e3124a4b940d74fa7cce7db9_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2897b34de54e7d8a1d5c0a099fd838_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1e52d6991e406a945e19f8079e528c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i826d38b657564fee8d0b4fdd0b31c604_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e090bb4ef1452aad2ba2b2d002cd6d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i785c17ba787c420ab28a1c4b62223ac2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3d621b157a42a4ba32f5a8491ac8e0_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2bed3171e1440e4b9298bc889bbc683_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a218503f7ab4de98bcdbbd19a9d6c72_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f0a92614b8042f3a19b56e9aa58d828_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a8421103da4d199b14bf4d4fbc932f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf45c465431f4c298552489e3699d202_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9626cc3ab4204665ab265b453bd8bfa9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53668203006e40778ac4cb8f0df51122_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbcbc55c0214bec9a6ff8da8de77f65_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ffdccad09f848609944eaf060120cb2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec3fec4b948243e9a496fe3f77b7ffee_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if388d8698b394ac4be606c9d2c0a3489_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9093c7f6ef64431992d79c742b037e8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db009fab413493492c16a5df3a37c99_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34fbf1ff326b4e6fad49301c40e11116_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedda39033da64349a0b5b298b12b996f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f43eb815ebe4c3591221b47337b07a4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2bdf0b5a9940e1a30cb4c26fe72fc7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacef251d63148388d9668c06174a001_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6343d0bae78b4914a6ff8844d8406e5d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc53cde634d4b8f99ba99c6d5a09cbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4a8454cd7564023a381bc1508d50929_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23eca4810bb642bbaed1dfe851d947c3_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc46147d3eb644e2931be9db99437ce8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i99b5f92b87414a408b2f164b39aa615c_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30305f98796b4fcca95cd1f896a623dc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b42c1beed4e4da581bb9585e8272830_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c3337f5d59424e96a59f60dfdde148_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida41699b64f44ef0b7744e4cfe85a445_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceda03e5ad2c4312bc298cbbc0900364_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468f19c62c24453a865e318ab9ae077d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b8d948d26b4427bf5fba3c70b183fb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc52b81b9be544c2ad19a695298b389c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f9c70752694d2e9ac53b525ded966d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id883a12b90d8439b97224daeaac7b8b7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e3aa6b28344bb5acaedc108f74aed7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69370ff4c9114ca2beb444f079abcd90_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>gh:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie6a2fe3c28ec43dbb430a92bb0b27a35_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75cf41ebff4424583eb30543c5a9ed7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8914a60aeb34d5cbf1aa6e554ff0514_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc08dd4ea5642c4a9d385ae69096000_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7dedd6767d44efaea5866821f7622f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfe70fa79e1446d86a8d5ad87a71189_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64327946d8e47c7ada4e42959049276_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ceb1e91ef3f4683bec1451e6e849728_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f8de2202de40c1b72732f8a439a758_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcfbe838a4a477a9862d666a76f8ece_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4f82709e3c8482f9ce096c69ea147a5_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e54f325c5224e52b4b39dbe334295fe_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678325a887e8435ea4d1cfd5c6e8ff5f_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da5a0d81b1d4f54b60329c88d1ec928_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9eee4d278c492880775de12a0d66be_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c0d23c373e4a908c4afb6361fb820c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee98c0531e114acf831a0fba5e0f8fd1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2571d7c639c4caa8ea6a33dba9c80e7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4054d2241aef4c2ba3378622a152eb57_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:GuardantHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1582366d96764e628ee3c6fc355be309_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeca758827ed4d90be26d059db3913b8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10ea8dacf834b25a24c95505a7ad3ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aa0e810ec7047b19bafc497d6b7e021_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b66109089f4987960aa78d1f42647c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545b9794576a4b6294dc59d727bc8cbb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc6585a30ea4320b71e0d5e211a58bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ededa0af6544088fe566e02b31a759_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f93a110ee94c85804eabd73676b498_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae9bbbae4e046c2bb0f04e87dfc13df_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica84e8b91ec84cb3882f7bb95e6fa3a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i898f46836620466a8ea84a0116365f96_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f2443552e3424c9cbf516e74b17aa4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1748888fa5b94b3fa36d1f69f3d04c7a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1a742dbb670437194ce13edafd7abd7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370642be93cb4475a9cc1be521e0f456_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifffa3df8778245cbbf40df31c03d6572_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if118daccbf7d4722ae57d06c7ab08a96_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca828071cf24136a3e534de37d96e1e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ddc25f26d44b86af3c9495e4039373_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16ba315eedea40c1a18129a03aa19b9c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f4635a39a149c0ba7e63b5acf39b3b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i599892da63584709afb69f4bfb29d368_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7726079bb25453e958c1da1ddfff388_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc2234ad133449eae25a7cb3ee62b6d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3accfc27a1b4335902ce8b5195b1631_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i396f1e67135f4846b62ba49dd35eb38b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54b93d476704da994b4dc2cdf71eb94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2218a15c7148cbb392058e26e2920d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i038f2a7219e747d28931767d8cf4ec43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if93d426946cb489f9e4d1af7e323bd40_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93815114e38b4cd091cb874ecc2d4de4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685b086287f742f1b900f5e38731cbd1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b9a757a022476481b3125b0fc19f81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9644227fc4843f1805c967861ab3dc4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88cf4f13cbb04a52a86b045ee3dd5ea1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibadc73c134c14524b54b1dac274d9bc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae16cdf827984010a2caeb7104021835_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7128cee9cb9340a7a5e59f2f4abfc63b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i421282ed4e594c2fab6a88329510132b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740e186b54a74d929d1a8c08b5e479b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a2f825e010452bab2dda62203c3a5b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4cbb1c832e4835bf864738425a238c_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b488ecc3114e4a8446d2438cd643d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6aacb5f0774eacaab1daef8013d311_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325614ec170f44899e673d4e7d28ca08_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ae71665daa44538cfa2f9ab72a47e5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf3c9fdf9f6945cfa0c0069b6e81a7f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba1eb19db0641239b17259b2bba88e5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d14c1e755e43fc814ff44716975ef7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25536aab95ec4b1685ab607a7f20dc01_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9cfa151d7bf41efb5fd1ac78e966422_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770aeb9e45ec4839b3429acb58b3fc0a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89c44f05033a45128d13bcc19f29dc7e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d6bc51d86cf4c0fbc8f765288d22ea8_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d0234ffd6546dfb79d7bb499864ab5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22d4925f07445f79dacbf83ea12c750_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09af7f320c9b4fcd84fa1e402ca72a9b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic006391af9764d4bb2ecb0b9cb97430b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc782a9fb88492e99beaee2df19e086_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2041cc6a754cf7a43e5f90f2d8f1f9_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4b06a919c94c7c9de034cc0bd35381_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c81bcd5fd9c45d093ba54aaad507758_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313c37eecd85486db947fb46da7fc2ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i494f839d36b341feb8f94f4b06ab22bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i671223423cb94bd8ac77d81000597b42_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab30d7be41ac42b6aaef61bf9bfb2147_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e9fca5442dc404d83a43b8c26016c6f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c6b8bbdadf44c4a7642d85455f2e93_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e95088fcf1140e1808f0690d05a8f92_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e385c44929941159efaa1b380c02f72_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fad1189a7cb465fa38705627b676425_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39db8210bb3a4e9b8d14f31872c89a3c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870e208edb564cf5aaf92b0b2145c9cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c5a8b30538453e89c87e004c795b1e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf9235dd4864475b23df2375dff74b4_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d6d3cc7ee094ad8917062d9acce7467_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc9610ec8ca94eb3a9394e0fca76debc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef5bc66f72741dcab51cdd2f9c4c114_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice197852bbb64a88a0b56ea6fe444696_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3510d8a915044bd2bbd4d045d52db61f_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id02ea36157704a95bf6f694669d5f017_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8512cacee254bfea1d2fb212216dd3f_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f3187d48da4ffda0a02a73d287d04c_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:EarnOutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f640c6e83784ea4850b868a4ac72489_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e633a87d34e43728ef3713950fc0c06_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4b90fbb22c4181ab782534d84b4052_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee5f27fc7c546a0a1c1982c3c8a2e94_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie644dcec06b9490aba117035eebed7ea_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94551a87fe774af98d538c0336237ed4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5868db3ef1f34c348c2af19ecda66e6e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="company"><xbrli:measure>gh:company</xbrli:measure></xbrli:unit><xbrli:context id="i1ce8429656d8474090165e7a3628b1e3_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gh:patent</xbrli:measure></xbrli:unit><xbrli:context id="i0e8f6b7f7cda4a31a4e20791ec53e3af_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="petition"><xbrli:measure>gh:petition</xbrli:measure></xbrli:unit><xbrli:context id="i45b21f81c97c4197bf11064199f6a5f4_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1c8dd73c8f4f9b81c94f3211ecc88f_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i142f8879551e4d50a8780dbc93bb85f2_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie598fb3c2fa14dc9aae676f3defa865c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6abd95f913499ea2e0b739c5e2fd9d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1df678bb52e4460b3bbc3799bc5d17d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id12141ace9b64b28bea2fdaaf6db601b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a7eeee673141b1a6a9a0da13e14018_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69cd2a5c9a414203b8bae90d7516eeb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i050b6f2672cc4818903148e5e1bb1511_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c1dac7222754796a0dd42751b19691a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb665707a6f47049ff619543a4f305f_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icedca10dad7f49b48138ccb3a8b51c92_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c5c7aff6084ff8b5748e3367a09571_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacfffb20a4ae41eea78d5a346088bc97_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfbdc510d6c440d1b2591a18047a2615_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9df8ef4afe54d51bb4c149ba983e328_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a0d4e0481d84fadaad8a7fe2f5e9afc_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599a34c262194cd695c5756264a97154_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129bd7811c824210b6778049ea36e662_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96d1c24c55f436fa86526b0018deb29_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b8d41685a144498da608da0700f3aa_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669e37f9d5744052b446c5ed68ecebe5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab2c5ae4387c4af8a36849259581e3d9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b70fed4f3144ee49ada02413cd6502b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824680c5b5434f179b86fd36d07d8763_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b5ba9fbebd4472beef02e1b7de1466_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb07b2046094271b6b1529b0c747445_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c24d9847164822a50d4cdd9d18c5f2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38caa6a9f90489092e150382af25b47_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bae9317d8ed49b284eae0dbc3a9c989_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8fea26a94e94fd49f58b8b97902f6a8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id38ddeb42dc645d29e1cf520286915fe_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab72dcca1ef42e3ad48caa9176918f9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc5f9cce5c946aeb7649a2b45b18c94_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686af8754af544d19475d9e965340c33_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524d26cd6dab4f5bbddc78f74f78b52e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b9c64f08a24d1fb8df7c8b7394b5e6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1bb229103f423797057daa71d5576d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26596bb7859543f4bb3f7eae23f2540b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe75529581b40f39abaaf5c5922067f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a01140a4fd940ef8d161dee75a36404_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if32fff58d0554a458622af303653e269_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12fb0e2cc01a47eca1252f58c3e04976_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84d05573f20f452f881daacb0e2fafda_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee695d4440547a7bfcb36de34921acc_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2402cd27c104ea38107f29820dae694_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae802d49bd74496ebe815b675137dd94_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib447deb7798c4703841cfadceacfb6f2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad98bc19a43049ad9b63d15d678d5da0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38994038d3c544e391545c7a4e7a5037_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1238eed8c3a8409ea6755199b243129b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf536ddb35a64f85aacee7598268259c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3323a04942704687bb2555b54314aab2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd47da85e7de4d7fadfd20dc20f187d9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9d2e5e2fcdf4b2c8fc419d96dc58c5d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8dbde309aa54633a3e4375f89ae690b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294c1765216e4c6a8e11a0d8b3daaa00_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6174d62dea8d4279975b861469129eef_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa43e28a9ae54214be7d361b2e4321cf_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c8ced2cd65f4b248f2b50a4b222ada8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71599760dfd541cabf39036748115634_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737cf94c5a8046d2a11b701014ec16db_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dec3173cbde4f96afc4de39bf38d895_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8094e7366d1143b68620e23e39605cc1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638ebad1fa064de89eb9cef3d781bcf3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a797c312c54413b66a65e0d28b0956_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d40935270e24e809f8b781d57808fc8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e997052345498c87b595375bf8389a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4547ce0781f4157886f48a25170a1bb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d5b67d8d024c7a948a5649bb02e25b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952e389dbc4144349e3163b45d8a21a5_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a05f1e0143d47aa8aac871e977a2d93_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56241c9ef5b4e06a9097eaf342ad306_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d2e07d74ee40dcbd0c515fc3ac73ea_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7989738be28147c79edc5a175133e7e7_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9c900bb63484126aeed5864a3482233_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5853898710f74fc98551c4698099ad34_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ab6406ad7b4d44aea212764d7260e3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60db419cf834ec9b927bf239d7a59ab_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb034afda014a85b1b0e2b6b26d774f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00416340ee41460f89b3b8e7094a4e0c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0fce7baca6420eadd2052f4a00b6f8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ada0d183d4f48bf8c719b83d32cc159_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b4a8e61a1034084959a4fd4db4b38f7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604a260fb2ce4d20bb48257e8df58cfe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofleases"><xbrli:measure>gh:numberOfLeases</xbrli:measure></xbrli:unit><xbrli:context id="ie657fc31977a42088ce4640db6c02671_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib850ca5924ca4d90bd09e86c08ec11ba_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576280</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMy0xLTEtMA_57f123da-e902-4c80-a630-7610ebc0c552 id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMS0xLTEtMA_f08ce5ca-7cd9-4a37-99c4-0f28c9873c79 id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMS0xLTEtMA_18023dad-efe9-408a-b72c-0ff13ac1ee41 id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMy0xLTEtMA_1cde555c-9ea1-4403-8945-5c3668bb3559" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ib551ebaf812444a9a6979b345f863c2b_1"></div><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, DC 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM3_d40db8ad-b46f-4327-a287-801055fdd530">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="text-indent:-27pt;padding-left:27pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM4_c4792705-f207-47c5-b2a7-1650cc857d58">&#9746;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N180Mzk4MDQ2NTEzNDU1_1bd82737-e9f6-420e-993c-27ed828eeaa4">June&#160;30, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-indent:-27pt;padding-left:27pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM5_212e638f-9134-4f92-99d0-c01dd9f6ba36">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM2_9e06ecf3-bdcd-4be6-ae7d-d651df1c4917">001-38683</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMx_ae05c7c0-c083-468e-949c-0c8044de14d6">GUARDANT HEALTH, INC.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%;"><tr><td style="width:1.0%;"></td><td style="width:37.285%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.428%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6NDNkMzYxZGI4Yzk2NGVmMGJlNjRiMTZhZGZhOGRhNzYvdGFibGVyYW5nZTo0M2QzNjFkYjhjOTY0ZWYwYmU2NGIxNmFkZmE4ZGE3Nl8wLTAtMS0xLTA_f0e67844-e9e9-4e3b-b87e-a7603ff11b10">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6NDNkMzYxZGI4Yzk2NGVmMGJlNjRiMTZhZGZhOGRhNzYvdGFibGVyYW5nZTo0M2QzNjFkYjhjOTY0ZWYwYmU2NGIxNmFkZmE4ZGE3Nl8wLTItMS0xLTA_b61e4572-8f59-41fa-ab0e-a7543e4e24d0">45-4139254</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Identification No.)</span></div></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzQw_bed93401-4525-4c4d-ba7b-ae58226aabd0">505 Penobscot Dr.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM0_640a6101-66ff-49b4-bef6-3fcdb6efea73">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMy_84b70b7c-f1d7-43df-b286-e6b4dadfc176">California</ix:nonNumeric>, <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMz_bef484aa-8453-432b-baf4-1eb8ddbfd657">94063</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzI4_45d65b58-cc65-4abf-adce-acaf06508175">855</ix:nonNumeric>) <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM1_6a1a5a2d-1c48-4dfc-9de0-0879ac84f51b">698-8887</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_______________</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzI5_a1cbb05d-4751-4c15-8ccd-f88ddabd60a4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzQx_b9ec2d13-3081-4618-b49f-0c696ab3592f">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:8pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.262%;"><tr><td style="width:1.0%;"></td><td style="width:25.488%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.050%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.488%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.774%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6MzgyZGU3NTRmNmQ5NDBhMThiM2MzNWNmMzk5N2VlMWQvdGFibGVyYW5nZTozODJkZTc1NGY2ZDk0MGExOGIzYzM1Y2YzOTk3ZWUxZF8wLTAtMS0xLTA_fbbf5b86-4708-45d7-87cd-d69f5f4cd1b5">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;(Do not check if a smaller reporting company)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6MzgyZGU3NTRmNmQ5NDBhMThiM2MzNWNmMzk5N2VlMWQvdGFibGVyYW5nZTozODJkZTc1NGY2ZDk0MGExOGIzYzM1Y2YzOTk3ZWUxZF8yLTMtMS0xLTA_ce9b5c7e-9c79-44cc-b27d-412ac847bf86">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6MzgyZGU3NTRmNmQ5NDBhMThiM2MzNWNmMzk5N2VlMWQvdGFibGVyYW5nZTozODJkZTc1NGY2ZDk0MGExOGIzYzM1Y2YzOTk3ZWUxZF80LTEtMS0xLTA_5540d737-adb2-4d1b-af6a-6b1db8b73fe5">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:24.75pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMw_756c8e48-111b-412e-a7d4-e4a17ce65d61">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="text-indent:24.75pt;text-align:justify;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%;"><tr><td style="width:1.0%;"></td><td style="width:37.285%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.428%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.287%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Title of each class</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Trading Symbol(s)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6ZmQ4N2IyNGQ0OWZiNDI0NTk1NzYzMDllZDhlM2NjNTQvdGFibGVyYW5nZTpmZDg3YjI0ZDQ5ZmI0MjQ1OTU3NjMwOWVkOGUzY2M1NF8xLTAtMS0xLTA_5c731480-d38c-4d84-a95d-4c396f8d3d20">Common Stock, par value $0.00001</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6ZmQ4N2IyNGQ0OWZiNDI0NTk1NzYzMDllZDhlM2NjNTQvdGFibGVyYW5nZTpmZDg3YjI0ZDQ5ZmI0MjQ1OTU3NjMwOWVkOGUzY2M1NF8xLTEtMS0xLTA_9c3e97ef-92e6-45d1-b9ca-a6169ecff8ad">GH</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6ZmQ4N2IyNGQ0OWZiNDI0NTk1NzYzMDllZDhlM2NjNTQvdGFibGVyYW5nZTpmZDg3YjI0ZDQ5ZmI0MjQ1OTU3NjMwOWVkOGUzY2M1NF8xLTItMS0xLTA_3508687e-90b3-49c8-945d-8c36ce5271cf">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:24.75pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of July&#160;31, 2020, the registrant had <ix:nonFraction unitRef="shares" contextRef="i67ed747d77784f589faa4a5f85f01457_I20200731" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMjYz_b3e28998-658f-4fee-9e2a-8c1fd1780169">99,424,269</ix:nonFraction> shares of common stock, $0.00001 par value per share, outstanding.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.115%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">GUARDANT HEALTH, INC.</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORM 10-Q</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:7.149%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:79.701%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_13">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_13">Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_22">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_25">Condensed Consolidated State</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_25">ments of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-11.25pt;padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_28">Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_28">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_31">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_34">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_34">11</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_103">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_103">35</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_142">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_142">Quantitative </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_142">and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_142">58</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_145">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_145">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_145">59</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_148">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_151">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_151">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_151">60</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_154">Item 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_154">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_154">60</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_157">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_157">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_157">60</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_160">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_160">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_160">60</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_163">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_163">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_163">60</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_166">Item 5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_166">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_166">60</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_169">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_169">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_169">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ib551ebaf812444a9a6979b345f863c2b_172">Signatures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_172">63</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q, including the section  titled &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Management</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#8221; contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections as well as the current beliefs and assumptions of our management, including about our business, our financial condition, our results of operations, our cash flows, and the industry and environment in which we operate. Statements that include words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;intend&#8221; and &#8220;expect,&#8221; variations of these words, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and elsewhere in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, in Part II, Item 1A, &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and elsewhere in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each of the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar terms used herein refer collectively to Guardant Health, Inc., a Delaware corporation, and its consolidated subsidiaries, unless otherwise stated.&#160;</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span><br/></span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_10"></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_13"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Unaudited Condensed Consolidated Financial Statements</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_16"></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guardant Health, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.358%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.662%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMy0xLTEtMS0w_ed2e068a-c67c-43c9-a06f-b7de04782d5b">164,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMy0zLTEtMS0w_95c9e548-1984-4967-8f6a-d8903002f386">143,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Short-term marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNC0xLTEtMS0w_372e7b66-9430-4a0b-8ac4-540b2df6c82f">773,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNC0zLTEtMS0w_b2989912-9bdf-4299-97bc-58fbd90d1905">379,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accounts receivable, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNS0xLTEtMS0w_159c7de3-33c0-40f3-927b-170289493fbc">41,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNS0zLTEtMS0w_b39755f7-a79d-4dcc-9552-a14b1424f56f">47,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Inventory</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNi0xLTEtMS0w_6eb491a9-0de6-4cbb-9e19-092d1f54bfd7">20,354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNi0zLTEtMS0w_1f0a4e77-a2ec-4aae-abb0-a22c2de01812">15,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNy0xLTEtMS0w_fa720bba-df2b-4c34-b6f2-a690000fb0a5">11,101</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNy0zLTEtMS0w_e3dd55f3-61b9-43fc-b0d0-08c502729cd6">11,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOC0xLTEtMS0w_7185081b-6046-40ad-b4d5-6975b475e25d">1,010,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOC0zLTEtMS0w_256b0055-5536-4418-823f-141c7a3ec6eb">597,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Long-term marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOS0xLTEtMS0w_94471ef4-a392-44d6-b79a-0d7fb43bf323">146,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOS0zLTEtMS0w_42e13431-147c-4ff1-8c73-0757500c1e6d">268,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Property and equipment, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTAtMS0xLTEtMA_d43d28a7-e121-41a3-8833-87ce31e6bbb0">56,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTAtMy0xLTEtMA_6c2d5599-da6a-4956-845b-54d446996165">43,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTEtMS0xLTEtMA_db51e505-9c87-4f70-9722-89fd62f669c3">38,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTEtMy0xLTEtMA_53289ff8-f99f-4482-91a2-aecda41c29cb">29,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Intangible assets, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTItMS0xLTEtMA_2f6072ec-65be-444a-a300-fb0a49e6164f">17,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTItMy0xLTEtMA_b541fed2-3b03-4cfc-9aca-0fb55a512a41">8,524</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Goodwill</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTMtMS0xLTEtMA_9a74c691-a1ec-4eeb-833c-b0c1dbc29c71">3,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTMtMy0xLTEtMA_57fb0c51-721a-4f4f-a81c-c045a0cda32b">3,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Capitalized license fees</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" name="gh:CapitalizedLicenseFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTQtMS0xLTEtMA_2eb1be34-849b-467f-8d9c-88d60354a154">55</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:CapitalizedLicenseFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTQtMy0xLTEtMA_46710185-eaf5-46dd-995f-820a3fb64432">6,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Other assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTUtMS0xLTEtMA_d39f9230-5933-421b-b0e3-3f53498f96e2">5,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTUtMy0xLTEtMA_af497f04-0329-4c92-8ea1-bf9595389d9b">4,882</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total Assets</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMS0xLTEtMA_18023dad-efe9-408a-b72c-0ff13ac1ee41">1,277,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMy0xLTEtMA_1cde555c-9ea1-4403-8945-5c3668bb3559">962,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accounts payable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTktMS0xLTEtMA_6cb5eeaa-397a-4f32-8214-9ad5edc24bc2">15,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTktMy0xLTEtMA_2a74b5de-0949-4283-9061-de63c959d687">16,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjAtMS0xLTEtMA_f2f9bcf1-cf99-42a3-9369-be070c03bdcc">18,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjAtMy0xLTEtMA_71473908-dcde-4311-a1bd-f33783b6da9b">18,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjEtMS0xLTEtMA_dd6739c6-16eb-4fc9-a297-0b847e4af24e">24,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjEtMy0xLTEtMA_af9efe5f-a794-48cf-bfd8-382345f852b3">25,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Deferred revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjItMS0xLTEtMA_b378b4d1-bdb6-455a-bfde-b59839fb3711">11,485</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjItMy0xLTEtMA_9ac3451f-c254-4176-aa9d-8f68edf6a4c1">12,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjMtMS0xLTEtMA_0068eda1-37c9-49b2-b179-7c8c1cc323d9">70,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjMtMy0xLTEtMA_37a58859-5a37-4cf0-959d-375b01856dec">72,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjQtMS0xLTEtMA_05640224-af0f-4d18-a9a6-b568a62e9dbc">41,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjQtMy0xLTEtMA_59d0f339-4f21-4224-8528-6097adfc7865">33,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obligation related to royalty</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:zerodash" name="gh:AccruedRoyaltiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjUtMS0xLTEtMA_c92c6dba-95cb-48ac-bd28-0bc59b4ae6e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:AccruedRoyaltiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjUtMy0xLTEtMA_5f66af0d-33f3-4aa3-8a26-cbad65d24987">6,880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other long-term liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjYtMS0xLTEtMA_60c71c34-6f45-4906-a0cc-1255e9de3863">1,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjYtMy0xLTEtMA_687e9452-4dfd-44a1-b0c6-4cc0fb1cfcd8">1,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total Liabilities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:130%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMS0xLTEtMA_f08ce5ca-7cd9-4a37-99c4-0f28c9873c79">112,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMy0xLTEtMA_57f123da-e902-4c80-a630-7610ebc0c552">114,542</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Redeemable noncontrolling interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjktMS0xLTEtMA_ad3c8472-516b-4a29-9579-1b7337c4549e">50,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjktMy0xLTEtMA_b667deaa-1a38-4493-bf6c-54f0667ffa2a">49,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE1MjM_c065b7f6-d808-4245-a6c0-386f28cd6be3"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE1MjM_d12ec10a-c671-4344-bd38-9d4cae4fc316">0.00001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTEzODg_471a09f3-a012-4633-b3ac-5f3bfd000b84"><ix:nonFraction unitRef="shares" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTEzODg_d75dab48-0e2f-48aa-83ad-f6c19091b767">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2020 and December&#160;31, 2019; <ix:nonFraction unitRef="shares" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0MzQ_b795cb00-d99c-42f7-ab0f-07cd9a55990d"><ix:nonFraction unitRef="shares" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0MzQ_cad66bfb-e407-4b22-a621-6b83adecf2bd">99,312,237</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0NzY_36e533d1-898c-42cc-ab1f-7fc3258bcf58"><ix:nonFraction unitRef="shares" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0NzY_915782b8-2667-4c17-98b4-b8916c58b20e">94,261,414</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMS0xLTEtMA_f4e777f6-edc9-4a6a-b8a4-8d8306a25a0c">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMy0xLTEtMA_10537087-edb9-4426-a3d1-db8dd01fc500">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Additional paid-in capital</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzItMS0xLTEtMA_6c48d2f3-038f-4295-afba-399b424f4d17">1,544,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzItMy0xLTEtMA_27ceba86-6fb5-4517-bb8b-b3afc2e83e15">1,150,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accumulated other comprehensive income </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzMtMS0xLTEtMA_dc0e31a2-7145-4e6a-803e-8bda783c3cd8">5,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzMtMy0xLTEtMA_788470f2-53ee-4cce-815f-3bd3351c2190">1,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accumulated deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzQtMS0xLTEtMA_56bd6dad-afc1-4313-8fbc-4a2923a92391">435,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzQtMy0xLTEtMA_d28bb67f-a01a-4b1c-be95-22a92048d4d6">352,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total Stockholders&#8217; Equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzUtMS0xLTEtMA_ff0ac429-1a7c-4ed7-82fb-49b627784ec1">1,114,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzUtMy0xLTEtMA_920c4e78-90d9-4c7f-b118-4b46d88f75a6">798,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzYtMS0xLTEtMA_ce452ac1-4ea6-4f56-b808-b9b565812ea8">1,277,536</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzYtMy0xLTEtMA_df61ed2a-bb24-4c44-bad0-6f9974d11aa3">962,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-13.5pt;padding-left:13.5pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c" continuedAt="i5d28967ddb144171a2a576bcf15f2ed5" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of June&#160;30, 2020 and&#160;December&#160;31, 2019, includes $<ix:nonFraction unitRef="usd" contextRef="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMTU3_8233966a-2a7d-4d60-81f2-9142a99e2fc3">38.4</ix:nonFraction> million and&#160;$<ix:nonFraction unitRef="usd" contextRef="i887b578e7d524b4ebef1f7577dec56b5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMTY0_683f4635-0e79-4d33-8b34-015477b321dd">45.1</ix:nonFraction> million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$<ix:nonFraction unitRef="usd" contextRef="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMzE3_2b2acbcc-b6a1-476e-931f-1976d18fa988">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i887b578e7d524b4ebef1f7577dec56b5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMzI0_ebbee8fc-1834-4079-aa0e-c66dd20cc658">5.7</ix:nonFraction> million&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, </ix:footnote></span><ix:continuation id="i5d28967ddb144171a2a576bcf15f2ed5"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investment in Joint Venture</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></ix:continuation></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:29.25pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span><br/></span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guardant Health, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations (unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except per share data)</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.512%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Precision oncology testing</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC0yLTEtMS0w_9e5f8246-3fc6-4d2d-914e-4f064c8a8881">50,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC00LTEtMS0w_8dbc6ff9-dcdd-4fc2-bfb7-9c1f31c3dfb3">42,064</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC02LTEtMS0w_0494541c-bb7f-4cf1-b810-e1931758da08">111,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC04LTEtMS0w_75366ef3-f3e6-4c01-b8bd-fb78c6842ba0">70,901</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development services</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS0yLTEtMS0w_fd074cd6-93f6-4365-8e67-f09237c7ebba">15,344</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS00LTEtMS0w_d15eda54-c4e3-463c-bebd-317b702ed2bb">11,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS02LTEtMS0w_b38316c5-f8c9-4e1b-bbdd-e705960f807d">22,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:RevenuefromDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS04LTEtMS0w_043d6804-878a-4a4f-9acd-71364f5f9062">19,729</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total revenue</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi0yLTEtMS03MjA_1d05125c-7784-4bd3-97b1-d6653120a359">66,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi00LTEtMS03MjI_a9af6032-d5ee-4d27-985c-2041dec51d86">53,975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi02LTEtMS0w_c6c14d8a-cf65-440c-9b07-f3d03a1bea6f">133,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi04LTEtMS0w_6c406c2a-c77a-4978-a531-27ec47a2f995">90,630</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Costs and operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of precision oncology testing</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC0yLTEtMS0w_d64d7a88-0ea0-4ef7-93d4-38cf6c59ba24">17,809</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC00LTEtMS0w_5b8200da-fa5c-41b8-a293-559e0a6b08c1">14,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC02LTEtMS0w_7db61589-4ad6-4355-a0c7-274659ab548c">36,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostsofPrecisionOncologyTesting" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC04LTEtMS0w_dd6240be-38f8-4c8c-97b0-006c1bd7c085">25,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of development services</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS0yLTEtMS0w_4bdb9c82-6d76-485a-80f4-3b6ac4669605">4,626</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS00LTEtMS0w_a7989bea-9e7f-4735-a5f1-29df61ac1f79">2,183</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS02LTEtMS0w_aac6fefd-f87e-497f-a530-3bdfa7162c44">6,941</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:CostofDevelopmentServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS04LTEtMS0w_790ce941-2597-4b08-9566-3fdaef1996f7">4,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtMi0xLTEtMA_2306da8b-a470-41fb-b39a-a66556edc621">36,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtNC0xLTEtMA_194ebd86-35c1-4f3e-833e-8b299561a697">19,532</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtNi0xLTEtMA_8e266049-c7b5-4a53-97d8-70659bdb2d4d">73,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtOC0xLTEtMA_11606025-f7e8-4b6b-ae98-d6577c0811e7">35,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales and marketing expense</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtMi0xLTEtMA_8c33668d-910e-4036-86a9-c947f26dcfe4">25,015</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtNC0xLTEtMA_93f3f7ac-8efe-45ef-99b1-02866005fcc9">19,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtNi0xLTEtMA_76975ac9-8a22-4211-8dff-448d4cceb2f7">50,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtOC0xLTEtMA_12d84fc4-dfa6-4038-9bca-30c7d25ab869">37,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItMi0xLTEtMA_f9d34371-fd30-4e62-bddd-e6bc19f1a29f">37,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItNC0xLTEtMA_7870976a-f32d-4a49-8eae-eae2e5665092">13,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItNi0xLTEtMA_1c701e92-80d1-41b0-8d39-25d6ef677afe">56,971</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItOC0xLTEtMA_a3513027-f462-4db9-b4cd-400b9b8bcff4">26,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total costs and operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtMi0xLTEtNzI0_713f1931-b7c6-493f-b9a0-8e88150c43cd">120,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtNC0xLTEtNzI2_5171b0af-70b2-43dd-91fd-0933a7f0b2ef">69,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtNi0xLTEtMA_9648a4fc-9594-4de1-8ddb-701dd3b024a3">223,377</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtOC0xLTEtMA_37b1168a-a34d-49d3-b081-754f25dae740">129,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Loss from operations</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtMi0xLTEtNzI0_99d3d5ef-7742-49d6-a50e-f3dbd7b168e4">54,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtNC0xLTEtNzI2_959ecfbe-c55f-4d63-a11d-043abbad6b0a">15,268</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtNi0xLTEtMA_fe0c6471-465a-45c0-80d1-5bd5e7917cdc">89,532</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtOC0xLTEtMA_f001ed84-0e6e-4255-8e7c-4dbfc47d9dff">38,932</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtMi0xLTEtMA_14c2d6b4-fa9f-4c41-ae89-742b470252f0">2,640</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtNC0xLTEtMA_2ace9801-d7d3-4dbc-bb24-9c88970c292e">3,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtNi0xLTEtMA_12fcc53a-12ba-4c07-a9b2-865e92968477">5,958</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtOC0xLTEtMA_07a8a35c-08c2-463e-9d11-6d4f3b5149e0">5,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtMi0xLTEtMA_66bb3aa7-62a9-4438-a770-9af89cf1d815">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtNC0xLTEtMA_1c964775-d5d2-4919-b489-153b0d1a01ec">287</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtNi0xLTEtMA_ad629ac5-402c-4020-9839-b550c0dd3518">22</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtOC0xLTEtMA_1ffdc1c7-7e16-4755-a25e-d3c086abb84a">580</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctMi0xLTEtMA_b92132da-6979-43b5-935f-e7e2f6037380">2,285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctNC0xLTEtMA_6fada179-98ad-4ea2-824e-0ff82fa84295">51</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctNi0xLTEtMA_7aa83ec8-c2bb-4803-814b-9602a1a8b0ec">2,076</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctOC0xLTEtMA_9677c99c-513f-424b-8336-f418fe98dff5">96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Loss before provision for income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtMi0xLTEtNzI0_c71dd00c-7ed1-4ec9-bd1e-7034fafa6348">49,705</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtNC0xLTEtNzI2_a9ca9382-6f15-489a-bff1-88d072a19aac">12,507</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtNi0xLTEtMA_8c7d4e06-b120-4e4f-b7bd-f460abb545f9">81,520</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtOC0xLTEtMA_5d34d12a-a7af-49a0-b09d-983d91070bcb">33,832</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for (benefit from) income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktMi0xLTEtMA_a43a2eea-b15e-4de1-b8dd-601800528667">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktNC0xLTEtMA_30b9a027-e4d3-495b-85c1-7781ca039ce6">1,207</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktNi0xLTEtMA_3548265b-5ba6-45af-85c1-df9426a06705">48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktOC0xLTEtMA_a3faaef9-7825-4bf1-9f03-ca2b2a908e2e">1,181</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtMi0xLTEtNzI0_7ae53bcb-9066-48e5-9c1e-143fff956274">49,739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtNC0xLTEtNzI2_b756ac51-7946-4fb3-9ee4-fba338847059">11,300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtNi0xLTEtMA_c6cfeaa3-f2b5-42e7-9727-6f938e20fd23">81,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtOC0xLTEtMA_bf9b8750-26ab-4c81-8a6e-d32bab1b0f38">32,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtMi0xLTEtMA_3fbbed0a-ac4c-45d2-8652-68edc3609113">4,900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtNC0xLTEtMA_7fddc32c-243e-448f-a4f9-5269d4f5bb0f">300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtNi0xLTEtMA_7c8cd13c-c263-438a-a9d8-70ee3edc00e9">800</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtOC0xLTEtMA_66770d39-23bf-4c47-82cd-695060636db4">5,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss attributable to Guardant Health, Inc. common stockholders</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItMi0xLTEtNzI0_74121496-d321-43bc-90ee-2ed06493f23f">54,639</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItNC0xLTEtNzI2_7a83bae1-779b-488e-8f7b-39a3c6c585c5">11,600</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItNi0xLTEtMA_302ef6f8-54c1-4c9c-b743-1865969674a8">82,368</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItOC0xLTEtMA_fe4fc309-e88d-44e2-be44-86cbcfec4101">37,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtMi0xLTEtNzI0_808490c6-b1ee-4e53-8342-8b03021fecae">0.57</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtNC0xLTEtNzI2_b1d10dbd-6501-4c27-a3aa-3f3c3a608204">0.13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtNi0xLTEtMA_792197c4-fca0-480f-94d6-96a3dc75ed64">0.87</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtOC0xLTEtMA_0aaf162f-4d4b-4bb6-9af2-be22a55003f3">0.43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtMi0xLTEtMA_3a246fa7-e9b2-437d-ba9d-3d42177c0fed">96,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtNC0xLTEtMA_0b2a408e-2c63-43b4-8df9-851b2ae676a5">89,036</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtNi0xLTEtMA_2f18180c-5d49-4e6f-ae1f-814660621a78">95,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtOC0xLTEtMA_51552e7b-a6cf-4268-82c5-a3c02c9c1019">87,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guardant Health, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.512%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy0yLTEtMS0w_79ec2120-9962-4c76-9f63-5a53a60ee0ea">49,739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy00LTEtMS0w_03a7fb46-4b81-45a0-80ee-a6491eb0186f">11,300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy02LTEtMS0w_1642a401-da6e-478d-81d4-7a20e9cbc568">81,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy04LTEtMS0w_9f813005-f153-4830-802b-23d1d8a65ead">32,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Other comprehensive income (loss), net of tax impact:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Unrealized gain (loss) on available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS0yLTEtMS0w_133463b2-66c5-495f-b3ac-ed725cf46c84">2,338</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS00LTEtMS0w_68bf9520-1c50-4ca4-9b9c-91adb9b7f84d">852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS02LTEtMS0w_2e56c6dd-3b0b-430f-8b05-cb59836af667">4,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS04LTEtMS0w_fb9df915-1fc2-4a02-896d-9f8c376f6045">1,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi0yLTEtMS0w_df4e5cd0-ce7e-4161-a681-a7de9031c11d">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi00LTEtMS0w_f739efb7-bf26-4e80-ab11-f5b949e435f6">159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi02LTEtMS0w_7c822f83-ba4e-4806-aa75-eddc0885d7b8">48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi04LTEtMS0w_08561bf1-79dd-4f8e-b4d5-4694b57928ca">90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy0yLTEtMS03MzA_4f6dc883-f12e-4bf0-95f2-d13dedb8f2bf">2,313</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy00LTEtMS03MzM_67caa8dd-e795-4c9a-ac22-3e4370bdfb63">1,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy02LTEtMS0w_32c29369-27e6-4319-b2df-15e1e66d5ea4">4,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy04LTEtMS0w_c69dc040-e0f1-4aa6-aa62-b49ccb386bdc">1,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Comprehensive loss</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC0yLTEtMS03MzA_d1ef7e32-8e2e-4a81-8672-9d0785e26180">52,052</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC00LTEtMS03MzM_78b0a575-f9a6-4eeb-8ef3-1fd44444a6f1">10,289</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC02LTEtMS0w_b42d2186-6c5d-42eb-b51d-cfc1216dfd7a">77,287</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC04LTEtMS0w_e522bbcf-8719-4734-90d9-89b714fbbcb7">31,224</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Comprehensive loss attributable to redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS0yLTEtMS0w_e8cf046a-9b6f-4927-a894-9ee5b5cc5100">4,900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS00LTEtMS0w_c534143d-9ed7-403b-9208-265ee632ed90">300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS02LTEtMS0w_03d0fb75-aed7-4bcc-a2f4-83111f0dd9fe">800</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS04LTEtMS0w_f62c2f51-fa7c-4042-8e8c-ae922eb45d72">5,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Comprehensive loss attributable to Guardant Health, Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtMi0xLTEtNzMw_ee4b13cc-396c-402c-b4af-b0f38f749314">56,952</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtNC0xLTEtNzMz_73a260d1-13f0-4454-aae8-b63ce84cce7a">10,589</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtNi0xLTEtMA_b178cf0a-456f-44f6-9c22-bf732b3f4a54">78,087</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtOC0xLTEtMA_94b6eb98-ea61-4b6e-945d-48c14779fc87">36,224</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guardant Health, Inc. </span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share data)</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.668%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.284%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.954%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common&#160;Stock&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;<br/>Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of March&#160;31, 2020</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66c1ec3f9b2e4d6598a8957cb05b297f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMS0xLTEtMA_b6b56f13-ab68-4742-95d3-94240fb3ab5b">45,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i54d30e5743544cc491322305e37032f1_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMy0xLTEtMA_2930e17b-1491-4323-9ce6-31bd5f92be5c">94,509,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54d30e5743544cc491322305e37032f1_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtNS0xLTEtMA_780030e8-f1a2-42c5-8dfb-744d092c2f82">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie11103427b6f4fcdb465ffb3518dbc03_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtNy0xLTEtMA_b59668f6-1da1-4573-9ebd-23d475768fe3">1,157,945</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61571b0d7df44691a978692e9978913e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtOS0xLTEtMA_8feac2aa-9e05-4a40-9aa4-6f2ab075e8a7">7,705</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6d5eca2f8beb48ab8fa5fdaf8eb8348a_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMTEtMS0xLTA_294a941c-1afd-4fca-a51b-e53fcafb2800">380,538</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd0533482d5645d989843fb090261fd6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMTMtMS0xLTA_39275d1e-b2e9-437a-ab51-106695793cf5">785,113</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock in public offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtMC0xLTEtMjYzL3RleHRyZWdpb246NjY4MjYzZmQ5MDk1NDY3MDljOGI4YzBmNDU2MWM2MGVfNDM5ODA0NjUxMTMxNg_875968cf-757f-4eec-9b5f-8720704e796d">1,130</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtMy0xLTEtMA_edc9e846-1666-44a1-b714-bf45d493d170">4,312,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtNy0xLTEtMA_40b6670b-2762-4268-9739-e636662a1444">354,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtMTMtMS0xLTc0OA_c962643d-a349-4c38-a18d-5764edb2184d">354,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTItMy0xLTEtMA_b766997d-db02-46a1-96af-2ad3d72fcd8b">412,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTItNy0xLTEtMA_4efc4ddd-a791-40f9-aa4c-dab00a1f896f">2,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTItMTMtMS0xLTc0OA_ac977816-49ba-4a19-9e37-a3a0d9533337">2,044</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTMtMy0xLTEtMA_ed00b631-38e4-470f-9ecc-246572a1652a">20,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of common stock exercised early</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTQtNy0xLTEtMA_fdca600c-4811-4f0b-8af4-e958014cefb2">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTQtMTMtMS0xLTIwMw_772bff0a-cdb8-4ba3-8c0c-587ac33c934c">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Common stock issued under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtMy0xLTEtMTg5_821f75ca-1030-4c7d-9b0a-b511eadc53d7">58,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtNy0xLTEtMTk1_a3fc0482-170a-41be-bf77-54899a9039d2">3,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtMTMtMS0xLTIwNA_9845335f-e77d-4095-8cca-b1bb2364422a">3,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtNy0xLTEtMA_f1996948-387e-40f9-b0e7-c620f5e07fd4">25,815</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTYtMTMtMS0xLTc1MA_63cb115c-1891-46a8-913a-0dd878487ade">25,815</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3306441994cd4d6b9272a0486826de35_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTYtMS0xLTEtMA_25f26031-7c09-4a71-94a8-597e6ce07dbd">4,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i404d165872a34298a67e1be6b55bbb3c_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTYtMTEtMS0xLTA_75de2df7-8495-4066-b1c8-9f7f382a656d">4,900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTctMTMtMS0xLTc1MA_bd0eb49b-e842-4302-bbf0-35c8826952f5">4,900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93fffc7829f64f9eb628786736a5a649_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTctOS0xLTEtMA_6fced2e4-b5ec-4c35-bdcf-c15c9899421e">2,313</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTgtMTMtMS0xLTc1MA_ae6ce8fc-67c9-4237-b269-33b37bf8f3b3">2,313</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i404d165872a34298a67e1be6b55bbb3c_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTgtMTEtMS0xLTA_8b2b08f5-c0a7-4f19-8fba-342829e69d54">49,739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTktMTMtMS0xLTc1MA_82b29177-a69f-45fa-9775-37999768728f">49,739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida600c4d3f69417dac19667d2cea0b78_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMS0xLTEtNzM2_974fce93-c726-4526-92a0-ee791d72fb0e">50,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMy0xLTEtNzM4_25a2d879-3d2d-4eaf-8129-3f5a0906e189">99,312,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtNS0xLTEtNzQ0_ab787df9-3dd3-41b1-9b1e-12282d927d59">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d98dcdfd415452e90b92f303d33161e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtNy0xLTEtNzQy_f20f8ba8-1e04-4368-9e4b-26c39523bc1e">1,544,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd582379ae154944b83cf4f0429747ef_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtOS0xLTEtNzQw_fde977ce-d8fe-4533-b32c-57b3e8260c0e">5,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i58e4ca00724742b3ad83e062217f6ec9_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMTEtMS0xLTc0Ng_11817ee9-e96f-49ce-bbec-e55159a9f041">435,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMTMtMS0xLTc1MA_dba60839-110c-4c8b-aa98-ce62f60b4f53">1,114,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="margin-bottom:8pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.668%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.284%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.954%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common&#160;Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of March&#160;31, 2019</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia759beb2854d4b8e94e0d88280e30e87_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0xLTEtMS03MDI3_929744da-8e63-4ce5-a86d-18733218fb78">46,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7596a4a43a214ae283198a28115a4899_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0zLTEtMS03MDMx_40fb3b24-9d7e-4ad7-ace7-a4ee4a480459">86,098,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7596a4a43a214ae283198a28115a4899_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy01LTEtMS03MDM0_42a9228a-b7fc-47e9-a3e8-f73cf2d56398">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8fe01ddc5547497bb9cbffefe0198307_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy03LTEtMS03MDM3_464c4e6e-588f-426e-9fd5-8abd55e19f47">771,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d7a9e78e81243f09669f88dac612492_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy05LTEtMS03MDQw_a66875b8-9ef7-42a6-bde2-89dc9ae1ac07">333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic6eb90faf2794203b3bd8684e7abdab9_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0xMS0xLTEtNzA0NA_ce0bf172-fee1-4300-8652-8ded97adcf36">303,209</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90fb72b236d249d284285a90f9c10645_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0xMy0xLTEtNzI5Mg_5acf36f1-68af-4921-ab38-08b12609706b">468,134</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock in public offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC0wLTEtMS03MDEwL3RleHRyZWdpb246ZGQxZWMyNTZjZDk0NDBmMWFkODUzYzRiMzFjODdhMzhfNDM5ODA0NjUxMTIxMw_b7cc07a0-0e75-42fe-90ad-93b43e8f6fa0">723</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC0zLTEtMS03MDMx_f09c782c-bbd2-47e0-858a-df5e0913482a">5,175,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC03LTEtMS03MDM3_9dbacb74-035a-478b-a451-c2d6e0847982">349,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC0xMy0xLTEtNzI5Mg_53d6a11c-cbd7-4094-a14c-6d5f31a060f0">349,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNS0zLTEtMS03MDMx_a0825658-2da6-44ca-a127-ddf43191d9c5">1,531,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNS03LTEtMS03MDM3_dec63db2-b910-4c22-a9f0-dc6ea7afd2d3">4,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNS0xMy0xLTEtNzI5Mg_6a15f777-3c7c-4226-b549-d784a1fc28a4">4,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNi0zLTEtMS03MDMx_c291bf78-1c2a-43d2-a436-e404b3a61af6">1,106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of common stock exercised early</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNy03LTEtMS03MDM3_aa9ea29b-9804-475c-abfc-80aa9123cc04">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNy0xMy0xLTEtNzI5Mg_b4861a8a-e549-40da-9ea9-71617f9a101c">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOC03LTEtMS03MDM3_5ec8e757-89d9-4827-80d3-1da6b1dbc517">3,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOC0xMy0xLTEtNzI5Mg_773ebe62-3856-4bf7-b112-ed828bea9ffa">3,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1c8f7efb1f049aa933ce256d441e6aa_D20190401-20190630" decimals="-3" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOS0xLTEtMS03MDI3_3148357a-eeb0-4252-9a9a-9640108f74b3">300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2dd93329e3124a4b940d74fa7cce7db9_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOS0xMS0xLTEtNzA0NA_eef95c55-2c7d-4719-ad12-fbc5b87ecb0b">300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOS0xMy0xLTEtNzI5Mg_7ab7a45f-15f1-4a6e-910d-0d5ff768414a">300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c2897b34de54e7d8a1d5c0a099fd838_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTAtOS0xLTEtNzA0MA_4e4d85a0-92c0-4ac7-b567-f3a7444060dc">1,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTAtMTMtMS0xLTcyOTI_cd1181b6-2be5-43eb-a8ea-0c7538c686ed">1,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2dd93329e3124a4b940d74fa7cce7db9_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTEtMTEtMS0xLTcwNDQ_d8721388-d7a0-49f6-8a58-274dd9ebe979">11,300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTEtMTMtMS0xLTcyOTI_fdd6061e-1b4f-4764-a073-962792154c0a">11,300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2019</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e1e52d6991e406a945e19f8079e528c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMS0xLTEtNzI5Mg_f726d930-a571-41d8-8e5d-6652bcc27ef9">46,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMy0xLTEtNzI5Mg_cee0bac6-6ad6-40ae-a834-7d1436b78519">92,806,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItNS0xLTEtNzI5Mg_0ae410e2-1a18-4100-a367-ea5e6d0bef4c">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0e090bb4ef1452aad2ba2b2d002cd6d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItNy0xLTEtNzI5Mg_ac96b693-bbfd-4e62-bcb4-2f948da1b210">1,128,938</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i785c17ba787c420ab28a1c4b62223ac2_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItOS0xLTEtNzI5Mg_c3fd6e08-67df-4306-9a8d-063929da72c2">1,344</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied3d621b157a42a4ba32f5a8491ac8e0_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMTEtMS0xLTcyOTI_6ecb558a-c5ce-4893-a226-dc703b272e86">314,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMTMtMS0xLTcyOTI_91afe5c7-f994-4df5-b9e6-890ad4ded936">815,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:8pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.668%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.284%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.954%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common&#160;Stock&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other <br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;<br/>Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2019</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a218503f7ab4de98bcdbbd19a9d6c72_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0xLTEtMS03MDU0_1490105b-916c-4a1c-b6b8-e55b74a0115a">49,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3f0a92614b8042f3a19b56e9aa58d828_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0zLTEtMS03MDU5_2625f8b3-85bd-4ba5-9e68-8ad7b815a51b">94,261,414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f0a92614b8042f3a19b56e9aa58d828_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy01LTEtMS03MDYx_709625e8-1ab9-4cf2-b1ac-2cdf841e5906">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72a8421103da4d199b14bf4d4fbc932f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy03LTEtMS03MDYz_b6078914-6903-4554-837c-dbf237b380a7">1,150,090</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idf45c465431f4c298552489e3699d202_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy05LTEtMS03MDY1_026d80b2-5dfc-4993-be3d-0170ddbee620">1,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9626cc3ab4204665ab265b453bd8bfa9_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0xMS0xLTEtNzA2Nw_b47322a3-e612-4e6c-97b8-543b271506cc">352,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0xMy0xLTEtNzI5NA_812df8ad-5be1-43bb-b043-b92ad54a3834">798,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock in public offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC0wLTEtMS03MDQ5L3RleHRyZWdpb246OTM3MmIyZDg2YjBhNGI3NjliODIwMWRmOWM2MDllMTRfNDM5ODA0NjUxMTIxMA_f54e412b-efc0-46a4-899e-58afc1e28a1c">1,130</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC0zLTEtMS03MDU5_5c6a7293-01df-403d-9d46-2f17d63e48eb">4,312,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC03LTEtMS03MDYz_2d95c537-3b6c-4983-958e-6d50c24d39f1">354,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC0xMy0xLTEtNzI5NA_e0fb7610-68f7-44bc-b19b-150fef5de0f9">354,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNS0zLTEtMS03MDU5_c9a7fc56-9fb5-45dc-b2ff-9e16725f93f9">654,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNS03LTEtMS03MDYz_0da99e9f-090c-432f-86e1-39224e6a9587">3,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNS0xMy0xLTEtNzI5NA_0685c655-d5fe-4661-a090-04152a34c626">3,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNi0zLTEtMS03MDU5_1f497c35-97c1-4f79-9558-f20071309564">25,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of common stock exercised early</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNy03LTEtMS03MDYz_9c8c9f65-c31d-4fbf-8902-5ea0003effab">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNy0xMy0xLTEtNzI5NA_44a7fde5-a888-4430-b486-c6240c2c966d">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Common stock issued under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOC0zLTEtMS03MDU5_b01ec266-2719-43a2-81ed-a1cdeef56d78">58,164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOC03LTEtMS03MDYz_811d3f24-d62c-413e-959c-bf774e7b6065">3,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOC0xMy0xLTEtNzI5NA_537ca0bc-83ab-4593-aee3-625f1b62b640">3,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOS03LTEtMS03MDYz_c409b6d5-5445-4d6e-93ed-56950756e34f">32,153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOS0xMy0xLTEtNzI5NA_f75f0bae-5d08-4bf0-988e-cab9c54cd125">32,153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bbcbc55c0214bec9a6ff8da8de77f65_D20200101-20200630" decimals="-3" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTAtMS0xLTEtNzA1NA_6a565e69-3cd0-4e91-9d57-8bbee1cae2fa">800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5ffdccad09f848609944eaf060120cb2_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTAtMTEtMS0xLTcwNjc_ce2c7393-9d1c-451f-ad49-aa8197094e8d">800</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTAtMTMtMS0xLTcyOTQ_a75219f2-0742-4737-87a3-c028c2727032">800</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec3fec4b948243e9a496fe3f77b7ffee_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTEtOS0xLTEtNzA2NQ_b98ad217-3464-4ae2-985f-36c1e8831b28">4,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTEtMTMtMS0xLTcyOTQ_0d19f9ad-5f1a-4588-9890-eaadd1be3750">4,281</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5ffdccad09f848609944eaf060120cb2_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTItMTEtMS0xLTcwNjc_6af84bf5-d874-4088-a87a-9931b20b0d0f">81,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTItMTMtMS0xLTcyOTQ_263790b3-3015-4b4a-9ab8-ac1ef05fd5a4">81,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida600c4d3f69417dac19667d2cea0b78_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMS0xLTEtNzI5NA_879434b4-db5b-4155-9f23-baecd902ef4f">50,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMy0xLTEtNzI5NA_6e832772-f1a8-4a71-b0b2-db6b71f1a749">99,312,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtNS0xLTEtNzI5NA_6d1c4474-5624-4345-86b1-adcc8a3b2517">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d98dcdfd415452e90b92f303d33161e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtNy0xLTEtNzI5NA_6f828f80-0214-4a7d-9d08-7c3899b92898">1,544,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd582379ae154944b83cf4f0429747ef_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtOS0xLTEtNzI5NA_1ca6f952-6c5a-4137-be91-0abe2cb07fa4">5,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i58e4ca00724742b3ad83e062217f6ec9_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMTEtMS0xLTcyOTQ_b948f117-3b87-466a-92ab-6c245712edbf">435,177</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMTMtMS0xLTcyOTQ_c2256ae6-171b-452d-b6e8-0d4690dba229">1,114,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:31.668%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.284%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.359%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.954%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Redeemable Noncontrolling Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common&#160;Stock&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional <br/>Paid-in <br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;<br/>Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2018</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if388d8698b394ac4be606c9d2c0a3489_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0xLTEtMS0w_9fcbb7e3-8abc-4ea0-9874-0b0d037ac4e0">41,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9093c7f6ef64431992d79c742b037e8_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0zLTEtMS0w_2ed8bf7f-33c0-4c9c-bd2c-8bbf43db0217">85,832,454</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9093c7f6ef64431992d79c742b037e8_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi01LTEtMS0w_ba531a9e-2b38-4778-816b-1ef3e5595864">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4db009fab413493492c16a5df3a37c99_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi03LTEtMS0w_ee34f7f2-568d-4e8e-8c0e-aa54ddbc5d27">764,033</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i34fbf1ff326b4e6fad49301c40e11116_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi05LTEtMS0w_1cedb6c7-e225-4382-b329-ee6cbca21a91">83</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iedda39033da64349a0b5b298b12b996f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0xMS0xLTEtMA_9efe4601-e8af-471e-9505-ed28e6afaa08">280,799</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f43eb815ebe4c3591221b47337b07a4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0xMy0xLTEtMA_b7473040-e02c-4242-87f7-caafe8f849ac">483,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Cumulative effect adjustment for Topic 606 adoption</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa2bdf0b5a9940e1a30cb4c26fe72fc7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMy0xMS0xLTEtMA_5edc5d22-2ec9-4112-a2ff-1c4a188e7916">4,907</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icacef251d63148388d9668c06174a001_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMy0xMy0xLTEtMA_465bf3be-0b56-4664-9b1a-1d3a89fd2406">4,907</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Cumulative effect adjustment for ASU 2018-07 adoption</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6343d0bae78b4914a6ff8844d8406e5d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfNC03LTEtMS0w_14c81155-3b53-4432-91c3-215af2fc4ce0">1,266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0bc53cde634d4b8f99ba99c6d5a09cbc_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfNC0xMS0xLTEtMA_8ae0dcf9-b437-4c40-8d64-ed9765a49f6b">1,266</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock in public offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtMC0xLTEtMjYwL3RleHRyZWdpb246MDM5OTQyZjMzMThjNGMzYmJiOGIzN2JhNWFmYzA4YzlfNDM5ODA0NjUxMTI5OA_13ce8d8e-0259-4792-b6ce-a2cef4a9dc2e">723</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtMy0xLTEtMA_0535ab08-5f13-4b09-9c31-113c15c1872a">5,175,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtNy0xLTEtMA_34e175d4-5d22-4700-a7b5-de2c1f9c23d9">349,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtMTMtMS0xLTc1OQ_a50fe53b-c5fc-445d-a407-a7328bf67f59">349,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Issuance of common stock upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTQtMy0xLTEtMA_1808e864-7570-4298-af86-6c884bc5875e">1,677,990</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTQtNy0xLTEtMA_d02cf2b4-01a7-4808-ba6b-f7788fe0aed1">5,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTQtMTMtMS0xLTc1OQ_153f386b-198e-47a2-b9c8-7b67b139fb91">5,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTUtMy0xLTEtMA_77e6f2b9-48a3-4a71-9884-4b6e78ad1119">1,106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Vesting of common stock exercised early</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTYtNy0xLTEtMA_cb8e5275-d78a-4b77-8830-a5aabaee0a22">69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTYtMTMtMS0xLTc2MQ_dc19c799-26ae-4c4b-b9ea-260a27620787">69</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Common stock issued under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTAtMy0xLTEtNzExNA_17de4041-19ac-4af6-8d13-e392e7756b5c">119,702</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTAtNy0xLTEtNzEyNA_d0aa0f62-3d5d-4423-b742-60a65ffd38c6">1,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTAtMTMtMS0xLTc3MTc_bbc49df4-5687-4283-a647-a9188a0e0126">1,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTctNy0xLTEtMA_3f56d421-7e94-4346-9fa4-e5ec19b089cc">6,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTctMTMtMS0xLTc2MQ_e6a88c8c-c419-46f8-8897-6a456408be0e">6,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment of redeemable noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4a8454cd7564023a381bc1508d50929_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTgtMS0xLTEtMA_b4e954c2-de52-4cdf-a693-537bec76a07e">5,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i23eca4810bb642bbaed1dfe851d947c3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTgtMTEtMS0xLTA_a45f7a72-ca16-44a1-8c8e-54f957828a0d">5,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTgtMTMtMS0xLTc2MQ_0dc446c6-64ce-4a1d-905a-7133622f3c84">5,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive gain, net of tax impact</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc46147d3eb644e2931be9db99437ce8_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTktOS0xLTEtMA_7ed3f764-3aaa-41c5-ad25-d112ec293f4f">1,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTktMTMtMS0xLTc2MQ_c11266d4-5828-4942-893a-f76c6506ef15">1,427</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i23eca4810bb642bbaed1dfe851d947c3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjAtMTEtMS0xLTA_cac1f60f-c285-4e1b-99ea-1a2f59e2d3af">32,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjAtMTMtMS0xLTc2MQ_f65e3b6b-34c8-4dcb-9fdd-8d18fb45a66c">32,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2019</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e1e52d6991e406a945e19f8079e528c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMS0xLTEtNzY1_9523ddd4-e2fa-4a7b-b1e2-a27be836897d">46,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMy0xLTEtNzY3_e85cd210-ec1e-4689-abe9-46d6c623f8ba">92,806,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtNS0xLTEtNzY5_2a7175ef-ee5c-4556-9688-eda213e4a009">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0e090bb4ef1452aad2ba2b2d002cd6d_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtNy0xLTEtNzY5_c0286b14-3992-470a-bcf8-576e830059e6">1,128,938</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i785c17ba787c420ab28a1c4b62223ac2_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtOS0xLTEtNzY5_6a014d9d-49e3-432e-9f99-96ccfe83f3e7">1,344</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied3d621b157a42a4ba32f5a8491ac8e0_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMTEtMS0xLTc2Mw_1f8f4102-52b9-4898-b479-bfae80f893c1">314,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMTMtMS0xLTc2MQ_94ff9db9-5680-4232-b02f-aa9a748c94ed">815,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guardant Health, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:67.341%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.927%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.930%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">OPERATING ACTIVITIES:</span></div></td><td colspan="9" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Net loss   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNC0xLTEtMS0w_88c0167f-91c4-42e2-90fd-c89420bffb99">81,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNC0zLTEtMS0w_ac152cde-898a-4656-af51-685b70a75149">32,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:4.5pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Depreciation and amortization</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNi0xLTEtMS0w_4c25580d-b525-4abf-ab95-6fd6cbba90ef">7,109</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNi0zLTEtMS0w_f409c677-b4ee-4cf6-bb24-bda264fd46f2">5,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:AmortizationOfRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNy0xLTEtMS0w_e56905c9-62e2-4a10-bce3-7d1f69d501d1">3,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:AmortizationOfRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNy0zLTEtMS0w_6558d74c-2079-48e0-8a82-86fab51bb383">1,633</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Charge of in-process research and development costs with no alternative future use</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:ChargeOfInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfOC0xLTEtMS0w_17b79a16-244d-4f23-b13d-07ee29cf16fb">8,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="gh:ChargeOfInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfOC0zLTEtMS0w_9b8db04b-eafe-4b14-9463-861d8bb27f8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Unrealized translation gains (loss) on obligation related to royalty</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTAtMS0xLTEtMA_b4b6b2aa-861a-4ea7-b4b0-5e62f4a7eb37">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTAtMy0xLTEtMA_b3431c45-d2c4-40bc-9e81-7fc6dc1b1634">51</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Re-valuation of contingent consideration</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTEtMS0xLTEtMA_53d216a3-a871-4526-b082-2347690c6bfb">190</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTEtMy0xLTEtMA_387afc32-6820-4b8e-b1e9-be5e9ceb9903">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Non-cash stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTItMS0xLTEtMA_8a57a89f-381b-4b1d-bbe8-dcd1cf1c1202">32,153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTItMy0xLTEtMA_527d73c2-e9ae-47c7-adc1-b18f52266925">6,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Amortization of premium (discount) on marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTMtMS0xLTEtMA_d8f9603e-1b10-4dc8-b09b-72322179e997">1,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTMtMy0xLTEtMA_e58b3866-35d0-44c8-8355-9b629afa8151">1,276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Benefit from income tax differences</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTQtMS0xLTEtMA_8b33117a-d3a6-4ccc-b798-05e5be03958e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTQtMy0xLTEtMA_50c46972-61c2-4fe3-901c-517d988018f0">1,235</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Others</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTUtMS0xLTEtMA_33a4198a-eb41-47bc-8d3f-c42b83ee2338">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTUtMy0xLTEtMA_9fb8c807-d5df-4248-8d1d-731b85f8b003">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities, net of effect of acquisition:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accounts receivable, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTctMS0xLTEtMA_aaf6998b-5c9e-4ecd-b704-9ef6df394b21">6,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTctMy0xLTEtMA_94495d03-616d-4bc3-ade9-a35987e01449">234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Inventory   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTgtMS0xLTEtMA_466f9527-0136-4911-8e2a-fdcda83858c1">5,173</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTgtMy0xLTEtMA_5fc4083f-3b77-4ae6-a202-d4efced60d1e">5,040</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Prepaid expenses and other current assets   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTktMS0xLTEtMA_80c496ff-568a-4c02-9e2e-fff8efc2e249">438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTktMy0xLTEtMA_a065425b-1afa-4dd2-8c04-01fa63ee3078">1,122</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Other assets   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjAtMS0xLTEtMA_898ad991-0cb8-4f62-aa2b-091059ec0679">242</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjAtMy0xLTEtMA_84ed0a21-6be7-43bf-8aae-e37983891cff">1,129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accounts payable   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjEtMS0xLTEtMA_2f16056d-6314-48e2-89ca-a75c1df6a0a2">2,476</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjEtMy0xLTEtMA_d3d9101f-e9c3-45ee-9730-867cb494a0ce">3,412</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued compensation   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjItMS0xLTEtMA_e7d203db-c9b9-4646-aed7-c93a2bab6fdf">31</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjItMy0xLTEtMA_c07059c2-780f-469f-ae67-da9dff3ef8c0">701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:27pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjMtMS0xLTEtMA_e78c8f52-25fe-4cf9-9602-a26d95910bc5">1,820</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjMtMy0xLTEtMA_4036858c-201b-4546-a65d-559bf56d07a3">2,939</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Operating lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="gh:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjQtMS0xLTEtMA_bb5f46d6-c526-4460-bbe7-bc6e9c1b75a4">3,881</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="gh:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjQtMy0xLTEtMA_7d3eac02-3399-4e67-b114-8d54605d5c9e">1,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Deferred revenue   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjUtMS0xLTEtMA_1e615d42-cf95-4262-91fa-3331428261bc">792</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjUtMy0xLTEtMA_a9473f16-baa5-40ea-8bda-5f41a814e1f5">358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjctMS0xLTEtMA_cc69a018-639f-4be0-8acf-bfa436bd99d5">36,647</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjctMy0xLTEtMA_8bc93d31-9374-4af3-b5e3-807703981659">18,139</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">INVESTING ACTIVITIES:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Purchases of marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzAtMS0xLTEtMA_16109485-b3bb-41f6-a226-517e01531d85">465,302</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzAtMy0xLTEtMA_46d77229-acf0-4e64-8d1b-ea0499f33488">418,841</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Maturity of marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzEtMS0xLTEtMA_d09ba1e9-f10d-4ba6-be0c-64f83166cb7e">197,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzEtMy0xLTEtMA_2fecd85d-bb71-4126-aad3-3c40a98a2000">129,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Business acquisition, net of cash acquired</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzItMS0xLTEtMA_3cc8ac7e-8f86-4201-95be-0148c7d36a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzItMy0xLTEtMA_aca39840-d3a9-442f-a0ac-317b11c40840">9,765</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Purchases of property and equipment   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzMtMS0xLTEtMA_00cc8cbb-e89e-416e-8fbf-a53e35516491">19,105</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzMtMy0xLTEtMA_7713f5f1-0c12-46f2-8f24-0b9438741695">5,752</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Purchase of intangible assets </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzQtMS0xLTEtMA_e9318a78-c598-4322-9844-9c17f9034d5e">17,886</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzQtMy0xLTEtMA_58ebf68d-f08a-43f4-a093-a3a54d6f76fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzUtMS0xLTEtMA_7a043122-2eb8-43e7-9578-5433b84cd252">304,745</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzUtMy0xLTEtMA_facd7941-82c7-43ce-98f3-97603615aa75">305,198</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">FINANCING ACTIVITIES:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Payments made on royalty obligations   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzgtMS0xLTEtMA_b62fc134-ee3f-4022-a962-b80652e4d17f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzgtMy0xLTEtMA_d0ba6de0-aa8c-4ca2-b072-4faacc84d54a">151</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Payments made on capital lease obligations   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzktMS0xLTEtMA_0f24f0c9-55c8-4b12-ae9c-d9fd78b566dc">79</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzktMy0xLTEtMA_bd8041a8-2bfd-4fb3-9848-c2449640ef75">62</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Proceeds from issuance of common stock upon exercise of stock options   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDAtMS0xLTEtMA_20e46bcb-20d6-4666-9fdd-f19d0c296ab0">3,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDAtMy0xLTEtMA_18bb4f49-df8d-42a7-95b1-cf4706443980">5,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Proceeds from issuances of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDEtMS0xLTEtMA_bf75a48b-0ccf-4e7b-83d4-8a4183a18fe3">3,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDEtMy0xLTEtMA_d7eae882-4a31-47e2-a0f0-6c092442fd5b">1,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Proceeds from public offering, net of underwriting discounts and commissions</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDItMS0xLTEtMA_54ab1d5e-fff7-4b19-9d51-03ed0ecc45c0">355,730</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDItMy0xLTEtMA_23bf0189-cbdd-4559-a48f-1f77b9af0eac">350,432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Payment of offering costs related to public offering </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDMtMS0xLTEtMA_40e82500-d3e8-42d5-919a-74498b8beb69">369</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDMtMy0xLTEtMA_a7456862-e7f7-492d-8829-e3f4e8965790">326</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:67.341%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.927%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.930%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net cash provided by financing activities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDUtMS0xLTEtMA_e13e0ef0-8008-48ae-9618-0cb1dfc19d79">362,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDUtMy0xLTEtMA_24da6c92-f750-40bc-9bbe-bcc313476727">357,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Net effect of foreign exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDYtMS0xLTEtMA_689ba31c-93fc-4dcc-9b71-ad20edef4598">49</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDYtMy0xLTEtMA_54a0b000-ab8b-4ca1-a256-0c20b8a89086">90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Net increase in cash and cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDctMS0xLTEtMA_a9b5116b-27b1-4cfb-a3a7-540fc72c1dbb">21,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDctMy0xLTEtMA_b1cb3bce-4007-4a44-b2f5-6820627e505a">34,109</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cash and cash equivalents&#8212;Beginning of period   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDgtMS0xLTEtMA_fb23a32b-990d-43c6-b7ca-2b6083b1ae51">143,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f43eb815ebe4c3591221b47337b07a4_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDgtMy0xLTEtMA_081affc4-f91c-4e52-ab93-5422949e75e0">140,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cash and cash equivalents&#8212;End of period   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDktMS0xLTEtMA_3e5c489c-a26e-4dcc-b798-3afd840c5e94">164,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDktMy0xLTEtMA_ac088d38-2f95-49f3-b6e8-8dc30dd0e0b6">174,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:11.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Supplemental Disclosures of Cash Flow Information:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTEtMS0xLTEtMA_69b20c12-4ca0-4964-8386-97aa38908566">11,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTEtMy0xLTEtMA_7c42357c-fe93-4d72-8389-af7a1c4376f9">1,565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Supplemental Disclosures of Noncash Investing and Financing Activities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Purchases of property and equipment included in accounts payable and accrued expenses</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTUtMS0xLTEtMA_18d00b28-9092-4682-b5a2-5f06948be19f">5,396</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTUtMy0xLTEtMA_c789af59-b679-4751-836b-804f64bf5825">3,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Follow-on public offering issuance costs included in accounts payable and accrued expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="gh:OfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTctMS0xLTEtMA_32662837-a345-40d6-8333-9c1bd193e275">761</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" name="gh:OfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTctMy0xLTEtMA_085935d5-cca5-4df6-b750-ed2f5d20e970">486</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Initial fair value of contingent consideration at acquisition date</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTgtMS0xLTEtMA_e8aedf21-3509-4dcd-b3cb-df2a0df94e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTgtMy0xLTEtMA_e426fe05-2f26-44f4-b8c4-bc054c0fb476">1,135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Guardant Health, Inc.</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_37"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zNy9mcmFnOjM0NGRlZmYzZDBiYjRhOTFiN2I4ZDczYmI0OGQ3M2ZiL3RleHRyZWdpb246MzQ0ZGVmZjNkMGJiNGE5MWI3YjhkNzNiYjQ4ZDczZmJfMTc4NQ_1a6a7b6a-8c16-4f04-89e5-291b36317d2f" continuedAt="ibf0c18783ba34dbf973ee459faebe20f" escape="true">Description of Business</ix:nonNumeric></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"><ix:continuation id="ibf0c18783ba34dbf973ee459faebe20f" continuedAt="i4ed30670984544d9b212ba358efa0b2a">Guardant Health, Inc. (the &#8220;Company&#8221;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#8217;s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's Guardant360 tests, the Company has also developed GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker-driven cancers. </ix:continuation></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4ed30670984544d9b212ba358efa0b2a">The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (&#8220;SoftBank&#8221;). Under the terms of the joint venture agreement, the Company held a <ix:nonFraction unitRef="number" contextRef="i99b5f92b87414a408b2f164b39aa615c_I20180531" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zNy9mcmFnOjM0NGRlZmYzZDBiYjRhOTFiN2I4ZDczYmI0OGQ3M2ZiL3RleHRyZWdpb246MzQ0ZGVmZjNkMGJiNGE5MWI3YjhkNzNiYjQ4ZDczZmJfMTU3NA_7aa3091c-8208-41c6-8fda-e9131d5bfe8c">50</ix:nonFraction>% ownership interest in the Joint Venture. As of June&#160;30, 2020, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, Investment in Joint Venture) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.</ix:continuation> </span></div><div id="ib551ebaf812444a9a6979b345f863c2b_40"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.&#160;<ix:nonNumeric contextRef="i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDc_7631bd13-1079-4697-a77a-38fa95fae4dc" continuedAt="i8964ef5d52c349878bc26c1e24eb8ca6" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i8964ef5d52c349878bc26c1e24eb8ca6" continuedAt="i23ce3b6a4cc34d01b89c094b7f9494d5"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDA_413593c7-6717-4605-9d46-4bee41c5876a" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing cash and cash equivalents and marketable securities as of June&#160;30, 2020 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjE5OTAyMzMxNDUwMQ_349af536-cafc-4f28-805c-0a04bfea83e2" continuedAt="i3f568a9909404d30a1dbb20bd75e3087" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. The extent to which the COVID-19 pandemic will ultimately impact the </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i23ce3b6a4cc34d01b89c094b7f9494d5" continuedAt="ic5e00aa30a064a3098b80ef9a2da86bb"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3f568a9909404d30a1dbb20bd75e3087">Company&#8217;s business, results of operations, financial conditions, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside the Company&#8217;s control, such as the duration, scope and severity of the pandemic, steps required or mandated by governments to mitigate the impact of the pandemic, and whether COVID-19 can be effectively prevented, detected, contained and treated, particularly in the markets where the Company operates.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDE_08509627-c514-4b10-9d72-978df5723905" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated balance sheet as of June&#160;30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020 and 2019, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#8217; equity for the three and six months ended June&#160;30, 2020 and 2019, and cash flows for the six months ended June&#160;30, 2020 and 2019, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDI_9cdbec77-010e-4c8c-9bda-4fed237b23d6" continuedAt="i3b7c78e77181430786dc2a367ba6e2f8" escape="true">Foreign Currency Translation</ix:nonNumeric></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3b7c78e77181430786dc2a367ba6e2f8">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and six months ended June&#160;30, 2020 and 2019, foreign currency translation adjustment was immaterial.</ix:continuation> </span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDM_4c3ebde9-a200-4ad6-b4ee-e73f1e1b9d34" continuedAt="i0349524ce5fb4377918a1d09bd6511e4" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Risk</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="ic5e00aa30a064a3098b80ef9a2da86bb" continuedAt="i1a69cadb4c0b48ff9dfd654fb920ba60"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i0349524ce5fb4377918a1d09bd6511e4">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.</ix:continuation> <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjc0ODc3OTEwMzQwNw_723de027-c761-4e1f-aff6-d917cf6ca7ac" continuedAt="i89dd990b75b745869571a6b3baa90072" escape="true">Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</ix:nonNumeric></span></div><ix:continuation id="i89dd990b75b745869571a6b3baa90072"><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.230%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable, Net</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer A   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i30305f98796b4fcca95cd1f896a623dc_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNS02LTEtMS0w_f13ccd47-f93a-45a4-b3d8-2c9e1c22c415">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0b42c1beed4e4da581bb9585e8272830_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNS0xMi0xLTEtMA_83742a76-618e-4e21-92c4-f1700beb3d0b">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer B   </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia1c3337f5d59424e96a59f60dfdde148_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi0yLTEtMS0w_610e92a4-0804-4b86-9705-49c4dea7b841">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ida41699b64f44ef0b7744e4cfe85a445_D20190401-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi00LTEtMS0w_5097a5fa-e094-4068-be22-f48f86acbb45">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iceda03e5ad2c4312bc298cbbc0900364_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi02LTEtMS0w_7996c323-3ae8-4f4d-881a-5f8659a904b2">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i468f19c62c24453a865e318ab9ae077d_D20190101-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi04LTEtMS0w_04b682be-1854-4c76-ae8f-d52629fbd53b">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer C   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i87b8d948d26b4427bf5fba3c70b183fb_D20190401-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNy00LTEtMS0w_1b25c59c-40b1-49f0-8d48-7dd8c4d935aa">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibc52b81b9be544c2ad19a695298b389c_D20190101-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNy04LTEtMS0w_bef05681-0ba9-43df-a797-ebefa39f76d6">12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie0f9c70752694d2e9ac53b525ded966d_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNy0xMi0xLTEtMA_517ec135-0dbf-45a9-9317-cb09d247b96e">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer D   </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="id883a12b90d8439b97224daeaac7b8b7_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfOC0yLTEtMS01NDk5_e7b87d69-61bc-4cca-a92b-5f6a41eab1f4">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i33e3aa6b28344bb5acaedc108f74aed7_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfOC0xMC0xLTEtNTQ5OQ_59990386-d4c0-4094-9302-a3f9ae0d6f71">27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i69370ff4c9114ca2beb444f079abcd90_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfOS0xMC0xLTEtNTU4OQ_f36aa4bc-d788-456a-bbf3-fcdbc9d92af9">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">*&#160;less than 10%</span></div></ix:continuation><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5MjU_3498f080-0e7f-4f32-b8bf-f01dafc95712" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable, Net</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of June&#160;30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDk0NzgwMjM1OTAwMw_78ac2f4c-53ab-445c-92fe-6b0b70f6e888">0.1</ix:nonFraction> million as allowance for credit losses. As of December&#160;31, 2019, the Company had <ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDk0NzgwMjM1ODk5NA_70986a1e-e52f-4110-8b36-7bcb4a54d04d">no</ix:nonFraction> allowance for credit losses.</span></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="gh:AssetAcquisitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTcyOQ_471feda9-b3db-4009-b355-39e81cf3f465" continuedAt="i34011a41ed9b4f66bb2725412e310773" escape="true">Asset Acquisition</ix:nonNumeric></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i34011a41ed9b4f66bb2725412e310773">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Transaction costs associated with the asset acquisition are capitalized. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</ix:continuation>  </span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NTg_96616bca-e60b-43df-9e6d-58a866bb3ab7" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Intangible Assets, net</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;<ix:nonFraction unitRef="segment" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTczMA_c2ca6d7a-a260-4dc6-a274-f8a5e3a7dbd2">one</ix:nonFraction>&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;June&#160;30, 2020, there has been&#160;<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTc0MQ_7c29cdcf-a1f9-4bc0-a4b6-b53c265f4618">no</ix:nonFraction>&#160;impairment of goodwill.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately <ix:nonNumeric contextRef="ie6a2fe3c28ec43dbb430a92bb0b27a35_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTY5OA_41c0273d-37f2-4986-aea7-d5bb91599087">6</ix:nonNumeric>-<ix:nonNumeric contextRef="ia75cf41ebff4424583eb30543c5a9ed7_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTcwNQ_83d7d5bd-a28c-4154-b62a-d19e4471a71d">12</ix:nonNumeric> years.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i1a69cadb4c0b48ff9dfd654fb920ba60" continuedAt="ib6231af06508463badbf0e5f3cf9c758"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5MjY_d26ba796-8e93-4a5f-8d72-4d4a57b9c238" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTcyOA_28cf8ba3-fff4-4743-84bf-47be3bcb5c15" continuedAt="i4d65ce545d8e4593b2b74d1a0a7e848b" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Precision oncology testing</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended June 30, 2020 and 2019, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2MzY5Mg_707626d6-1bc9-434c-b25a-99d9135c82d7">6.5</ix:nonFraction>&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2MzcyNg_f7260943-2441-4328-9eb3-41cfcda1b9d5">3.6</ix:nonFraction>&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration. For the six months ended June 30, 2020 and 2019, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2Mzc2Nw_cca8e8cd-cdcb-402b-a1d1-9685a846e796">12.4</ix:nonFraction>&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2MzgwMA_e3a9543f-cd51-464e-809d-e02890afe2ed">6.4</ix:nonFraction>&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration.  For the three and six months ended June 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib8914a60aeb34d5cbf1aa6e554ff0514_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDU1OA_6980f10a-3e03-4d71-acf0-b49fb49b2dce">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0fc08dd4ea5642c4a9d385ae69096000_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDU3Mg_4316f90e-8d58-4cf3-9253-aa046d075c21">4.1</ix:nonFraction>&#160;million, respectively, in revenue received from Medicare for samples processed in 2019.  For the three and six months ended June 30, 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ica7dedd6767d44efaea5866821f7622f_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDU4Ng_5f7300ff-6442-444d-aea2-121adcef29e2">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icdfe70fa79e1446d86a8d5ad87a71189_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDYwMA_8eec321b-0144-4f54-9eca-66cdf338a7f7">1.4</ix:nonFraction>&#160;million, respectively, in revenue received from Medicare for samples processed in 2018. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="ib6231af06508463badbf0e5f3cf9c758" continuedAt="i11824e43e68f49c4861993f243703cbb"><ix:continuation id="i4d65ce545d8e4593b2b74d1a0a7e848b" continuedAt="ic460f482f9704ffda3c6299f6ac579a9"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Development services</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. The Company revised and increased its total estimated costs relating to one of the development services contracts during the six months ended June 30, 2020.  Had the Company included such additional costs in the original estimated costs, revenues for the six months ended June 30, 2019 would have been lower by $<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="gh:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ5NzM2NQ_2af441f2-576b-4911-8ab4-843f44a81ad5">3.6</ix:nonFraction> million. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contracts with multiple performance obligations</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i11824e43e68f49c4861993f243703cbb" continuedAt="i0657fa83ae0243888268ec764860c05d"><ix:continuation id="ic460f482f9704ffda3c6299f6ac579a9"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contract assets</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. Contract assets are presented under accounts receivable, net and other assets on the Company&#8217;s condensed consolidated balance sheets. As of&#160;June&#160;30, 2020, the Company had contract assets of&#160;$<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjI5NDQ_71e484a6-1de1-4293-acbe-e2f5ee09d8e5">9.5</ix:nonFraction> million of which $<ix:nonFraction unitRef="usd" contextRef="ib64327946d8e47c7ada4e42959049276_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjI5NTY_0b129e7d-8e0a-4499-b489-017c7d87bbed">0.2</ix:nonFraction> million was recorded in other assets. As of December&#160;31, 2019, the Company had contract assets of $<ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjMwMzQ_e482b05f-340b-4941-a884-4f1cd2f04425">6.2</ix:nonFraction> million of which $<ix:nonFraction unitRef="usd" contextRef="i4ceb1e91ef3f4683bec1451e6e849728_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnbilledReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjMwNDY_cbfa1282-6a77-4725-9d18-b0c8d7a5cb39">1.0</ix:nonFraction> million was recorded in other assets. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred revenue</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the deferred revenue balance was $<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM2ODQ_07409612-93ac-4051-ad2b-c7848a56ae50">11.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM2OTE_1167c63d-2a3b-461f-a2a7-0d35da5d5ba3">12.3</ix:nonFraction> million, respectively, which included $<ix:nonFraction unitRef="usd" contextRef="i16f8de2202de40c1b72732f8a439a758_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM3MjQ_46b2fd4f-30de-43c9-885f-3d7a69336520">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddcfbe838a4a477a9862d666a76f8ece_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM3MzE_23780e27-a13a-4574-b6d6-0d0f8a1fbf58">4.8</ix:nonFraction> million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the six months ended June 30, 2020 that was included in the deferred revenue balance as of December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjQwMTQ_87a860d7-a85f-43de-83f7-36fe664770cb">7.6</ix:nonFraction> million, which primarily  represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transaction price allocated to the remaining performance obligations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="gh:CostsofPrecisionOncologyTestingPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5Mzc_d7f1474e-d150-4a35-a69d-d86f3bee7f96" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Costs of Precision Oncology Testing</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDQ_a73c655a-7278-4b5e-85c7-f183ff2894e2" continuedAt="i8b3d3c7cbec9460ba1d993db90b71093" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Development Services</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i0657fa83ae0243888268ec764860c05d" continuedAt="i178e6155ad7841ba8c89464539f24b2c"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i8b3d3c7cbec9460ba1d993db90b71093">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs.</ix:continuation></span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NTI_f87cb6a0-b85c-4cd7-bee1-e50c44ad074c" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Compensation - Stock Compensation (Topic 718), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Improvements to Nonemployee Share-Based Payment Accounting,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock options and stock purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite vesting or service period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NjA_9ac66e56-d0e2-4dae-a18c-6dc7a7b330f9" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5MzA_4a1ec7c5-1f4e-43b6-83b7-5bd53d5f902b" continuedAt="ic2166e399763445c8d4787ecd0f7d486" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Pronouncements Adopted</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, in order to improve financial reporting of expected credit losses on financial instruments and other commitments to extend credit. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. &#160;These changes result in earlier recognition of credit losses. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2020. The cumulative effect upon adoption was not material to the Company&#8217;s condensed consolidated financial statements.  The Company will continue to monitor the developments pertaining to the recent coronavirus (COVID-19) pandemic and its impact on expected credit losses.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i178e6155ad7841ba8c89464539f24b2c"><ix:continuation id="ic2166e399763445c8d4787ecd0f7d486"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the FASB issued ASU 2017-04</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Intangibles&#8212;Goodwill and Other (Topic 350):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Fair Value Measuremen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">t, as part of its disclosure framework project.  The Company adopted this new guidance on January 1, 2020. The adoption of this standard did not have a significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cloud Computing Arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles-Goodwill and Other-Internal&#8212;Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to determine which implementation costs to capitalize as assets or expense as incurred. The Company adopted this new standard on January 1, 2020 on a prospective basis. The adoption of this standard did not have a significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18 -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC 808)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under R</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">evenue from contracts with customers (Topic ASC 606) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">when the counterparty is a customer. The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. &#160;The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. &#160;The Company early adopted this new standard on January 1, 2020.The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements. Under prior GAAP, the Company historically allocated income tax benefit to continuing operations and an offsetting income tax expense to other comprehensive income under the applicable exception to ASC Topic 740.&#160; The new standard eliminates this exception and the Company will now determine the tax effect of pre-tax income or loss from continuing operations without regard to the tax effect of other items.&#160; The Company applied the new intraperiod tax allocation guidance prospectively in the period of adoption.</span></div></ix:continuation></ix:continuation><div id="ib551ebaf812444a9a6979b345f863c2b_46"></div><div style="text-indent:-36pt;padding-left:36pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMjc0ODc3OTA3NjUwMA_c616be22-21e8-4f09-832d-ce65252d4329" continuedAt="i0f89fcf2542341cdac9eef90fb93e2df" escape="true">Investment in Joint Venture </ix:nonNumeric></span></div><ix:continuation id="i0f89fcf2542341cdac9eef90fb93e2df" continuedAt="i3975470e746d41f5acc050e6ba8f0878"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company and an affiliate of SoftBank formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) for the sale, marketing and distribution of the Company&#8217;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 9, 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the joint venture agreement, the Company paid $<ix:nonFraction unitRef="usd" contextRef="ic4f82709e3c8482f9ce096c69ea147a5_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNjg1_2595f419-4541-4585-8952-1e03c931083f">9.0</ix:nonFraction> million for <ix:nonFraction unitRef="shares" contextRef="ic4f82709e3c8482f9ce096c69ea147a5_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="gh:EquityMethodInvestmentSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNjky_e24efcbd-dab6-4720-b3a5-c5574ace9ed3">40,000</ix:nonFraction> shares of common stock, or <ix:nonFraction unitRef="number" contextRef="i99b5f92b87414a408b2f164b39aa615c_I20180531" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNzIy_a2acd420-2d01-48b3-959d-c846ca0eaff6">50</ix:nonFraction>% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $<ix:nonFraction unitRef="usd" contextRef="i5e54f325c5224e52b4b39dbe334295fe_I20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfODA5_75d120a1-42a5-492f-bab7-8ed8af46b87d">41.0</ix:nonFraction> million for <ix:nonFraction unitRef="shares" contextRef="i678325a887e8435ea4d1cfd5c6e8ff5f_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="gh:EquityMethodInvestmentSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfODE2_98ed80a2-054c-4f9e-b976-5b42899647ba">40,000</ix:nonFraction> shares of common stock, or the other <ix:nonFraction unitRef="number" contextRef="i5e54f325c5224e52b4b39dbe334295fe_I20180531" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfODU2_4b444b6e-9009-40c0-ba45-2af5c882d91b">50</ix:nonFraction>% ownership interest, of the Joint Venture. In June 2020, an amended and restated certificate of incorporation of the Joint Venture, as approved by the board of directors of the Joint Venture, was filed with the Secretary of State of the State of Delaware. The amended and restated certificate of incorporation, among other things, increased the number of authorized shares of common stock to <ix:nonFraction unitRef="shares" contextRef="i6da5a0d81b1d4f54b60329c88d1ec928_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk0MA_ce7dde0a-7afe-4a54-9720-7d72096e4408">89,000,000</ix:nonFraction> shares consisting of </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i3975470e746d41f5acc050e6ba8f0878" continuedAt="i584f4779b1844e6fb9d7a758eb42f923"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="shares" contextRef="ieb9eee4d278c492880775de12a0d66be_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk3NQ_2988144d-e6ae-4f56-bd15-a0a059c17bb8">80,000,000</ix:nonFraction> shares of Class A common stock and <ix:nonFraction unitRef="shares" contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk1Mg_1c8ded1a-b44b-4ff1-ab4f-d0d27d6eb68d">9,000,000</ix:nonFraction> shares of Class B (non-voting) common stock; and authorized <ix:nonFraction unitRef="shares" contextRef="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk2Mw_57e51274-1c2e-4ab1-9ad2-e2e4f762aa95">80,000,000</ix:nonFraction> shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for <ix:nonFraction unitRef="shares" contextRef="iee98c0531e114acf831a0fba5e0f8fd1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:PreferredStockSharesIssuedUponConversionOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk5OQ_ed4e29f8-95e2-4bfe-8a9c-1beaafe29731">1,000</ix:nonFraction> shares of Series A preferred stock. As a result, each of the Company and the affiliate of SoftBank held <ix:nonFraction unitRef="shares" contextRef="ia2571d7c639c4caa8ea6a33dba9c80e7_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk4Nw_1b798860-3d91-4eda-be80-a16df6932693"><ix:nonFraction unitRef="shares" contextRef="i4054d2241aef4c2ba3378622a152eb57_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk4Nw_c6e50025-bdf3-47fa-b5c5-43dca26559e4">40,000,000</ix:nonFraction></ix:nonFraction> shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive dividends at the rate of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1582366d96764e628ee3c6fc355be309_D20200101-20200630" decimals="INF" name="us-gaap:PreferredStockDividendRatePerDollarAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUyNA_85daa745-c99f-48ff-875c-58733c609363">0.05</ix:nonFraction> per share if and when declared by the board of directors of the Joint Venture. In June 2020, the board of directors of the Joint Venture authorized the adoption of the Joint Venture&#8217;s 2020 Equity Incentive Plan pursuant to which <ix:nonFraction unitRef="shares" contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzAwNg_1911f9ab-8991-40de-8642-3a57cfac38a0">4,595,555</ix:nonFraction> shares of Class B common stock have been reserved for issuance. As of June 30, 2020, <ix:nonFraction unitRef="shares" contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_1e80ed3a-fc59-41f4-91fa-e7c8035d7db6"><ix:nonFraction unitRef="shares" contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_2a943940-8f89-4a9d-bd8b-2a344f282ec2"><ix:nonFraction unitRef="shares" contextRef="ieb9eee4d278c492880775de12a0d66be_I20200630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_d30f88e1-96ac-49f1-a16b-93975f67eb25"><ix:nonFraction unitRef="shares" contextRef="ieb9eee4d278c492880775de12a0d66be_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_e58c9e69-26c1-483c-8dfe-a81745cdbe57">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Class A and Class B common stock have been issued and outstanding and <ix:nonFraction unitRef="shares" contextRef="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMjE5OTAyMzI3NzcwMA_0ab217d2-8643-4d92-a312-58008ebd6db7"><ix:nonFraction unitRef="shares" contextRef="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMjE5OTAyMzI3NzcwMA_3dd6933d-8a75-4a41-9200-cfdee2bea42a">80,000,000</ix:nonFraction></ix:nonFraction> shares of Series A preferred stock have been issued and outstanding.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the joint venture agreement, neither party is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. The Joint Venture is deemed to be a variable interest entity (&#8220;VIE&#8221;) and the Company has been identified as the VIE&#8217;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, the Joint Venture had total assets of approximately $<ix:nonFraction unitRef="usd" contextRef="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTQ0MQ_8233966a-2a7d-4d60-81f2-9142a99e2fc3">38.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i887b578e7d524b4ebef1f7577dec56b5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTQ0OA_683f4635-0e79-4d33-8b34-015477b321dd">45.1</ix:nonFraction> million, respectively, which were primarily comprised of cash, property and equipment, right-of-use assets and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#8217;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of June&#160;30, 2020 and December&#160;31, 2019, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Put-call arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#8220;put right&#8221;), and the Company has a right to purchase all such shares (the &#8220;call right&#8221;).</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#8217;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;<ix:nonFraction unitRef="number" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" name="gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNDMwMQ_d2296949-4b6b-4beb-9b56-fe8972ae4753">20</ix:nonFraction>%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;<ix:nonFraction unitRef="number" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" name="gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNDY1NA_3a98ea14-0f81-4f48-b4da-da44e2b3dee2">40</ix:nonFraction>%&#160;of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;<ix:nonFraction unitRef="number" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" name="gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNDg2NQ_43c4cb86-9917-45dd-8eae-71cd5253075d">40</ix:nonFraction>%&#160;of the Company's fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i584f4779b1844e6fb9d7a758eb42f923"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">is publicly traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#8217;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.</span></div></ix:continuation><div id="ib551ebaf812444a9a6979b345f863c2b_49"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4. &#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMzI1_7d850edd-75b9-4240-8c0a-040fd586ed3d" continuedAt="i1e266a8d12834384b50f8608fe57c3e6" escape="true">Condensed Consolidated Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i1e266a8d12834384b50f8608fe57c3e6" continuedAt="i733fd467dcc64edd87a0c6f58ac0df62"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMzI5_8334327b-11cd-4930-bdd4-534fcba5fdcf" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consist of the following:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Machinery and equipment</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibeca758827ed4d90be26d059db3913b8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMy0xLTEtMS0w_7fcf1c23-5cae-4fbe-9c5f-0dbf793d1be8">35,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib10ea8dacf834b25a24c95505a7ad3ab_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMy0zLTEtMS0w_2b910b15-5fc6-44d7-8466-1cbfeb235996">29,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Computer hardware   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aa0e810ec7047b19bafc497d6b7e021_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNC0xLTEtMS0w_68135865-8fdd-41af-a421-4aa311f40e1d">9,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33b66109089f4987960aa78d1f42647c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNC0zLTEtMS0w_0f9e97b0-6738-41e2-81cc-bf5320bc0bb3">6,296</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Leasehold improvements   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i545b9794576a4b6294dc59d727bc8cbb_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNS0xLTEtMS0w_f2eabb00-4543-4251-8bd5-c54d04aef5af">29,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7dc6585a30ea4320b71e0d5e211a58bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNS0zLTEtMS0w_a0010608-cbaa-4140-b98c-786ca967319a">21,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Furniture and fixtures   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89ededa0af6544088fe566e02b31a759_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNi0xLTEtMS0w_46b632c8-9133-49b5-9580-648b41346a93">2,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i84f93a110ee94c85804eabd73676b498_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNi0zLTEtMS0w_6bb77a8c-89f7-489f-87c3-6a02aa5075cf">1,962</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Computer software   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibae9bbbae4e046c2bb0f04e87dfc13df_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNy0xLTEtMS0w_9b33917d-3e53-4c52-aaad-493375f3ad6e">1,027</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica84e8b91ec84cb3882f7bb95e6fa3a0_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNy0zLTEtMS0w_44990011-7445-4fbc-9d64-1cdea8cc9c48">829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Construction in progress   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i898f46836620466a8ea84a0116365f96_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOC0xLTEtMS0w_6e9789eb-ff97-4637-aea6-0615cf45e9f3">7,151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia3f2443552e3424c9cbf516e74b17aa4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOC0zLTEtMS0w_ab2e80bf-f3d1-4eae-9bf0-eba9986b7108">6,354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Property and equipment, gross   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOS0xLTEtMS0w_93b55047-993c-4954-91b0-08601cd82279">84,941</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOS0zLTEtMS0w_794b6c99-fc22-4242-b141-f65c654791b8">65,591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Less: accumulated depreciation   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTAtMS0xLTEtMA_346b9fad-c077-4b4d-a2d8-446b57d29b62">27,946</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTAtMy0xLTEtMA_6d7b151b-2d30-4eb9-a95a-8def9e0acd91">21,923</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Property and equipment, net   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTEtMS0xLTEtMA_231a7636-ba76-4854-9edf-1d7b190666f5">56,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTEtMy0xLTEtMA_03a26bcf-dbf4-41eb-8c61-48a790250191">43,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfNDM5ODA0NjUxMTQzNg_bc3448a7-0166-441b-9045-570c7d5a2464">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfNDM5ODA0NjUxMTQ0Nw_c27040c5-62cd-4387-b2db-a4be2387789f">2.2</ix:nonFraction> million for the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMjE3_62adff3d-f393-4ee8-a79b-c07751226557">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMjI0_3be76188-5e96-4814-a45e-8d5089893e0c">4.3</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i733fd467dcc64edd87a0c6f58ac0df62"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMzIy_49b42b7b-1e4e-44e4-9d88-2de40b3d648d" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued royalty obligations   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMy0xLTEtMS0w_d85f5252-1957-40dc-9761-310a719145dd">325</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMy0zLTEtMS0w_36a30bae-33a8-44f9-ad4a-c0f5818bac40">1,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued legal expenses   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:EstimatedLitigationLiabilityLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNC0xLTEtMS0w_91e8476a-6b68-4b8e-a6b6-16d99d9a76bc">2,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:EstimatedLitigationLiabilityLegalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNC0zLTEtMS0w_dacffbdc-b4ac-4b91-9d4d-5cd87b7ee6b0">1,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued tax liabilities   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNS0xLTEtMS0w_17dc44dc-9533-4edf-87ae-36e0108a52a2">3,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNS0zLTEtMS0w_a8de27f1-a55e-4ffc-948a-cb9f09f97cbf">3,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued professional services   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNi0xLTEtMS0w_be10a5db-3c53-4940-b6dc-03ac210ef442">3,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNi0zLTEtMS0w_06c0ad2f-ddf8-47bf-9477-ea445a520d83">3,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical trials and studies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:AccruedClinicalTrialsandStudies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNy0xLTEtMS0w_f01d51b4-b2eb-44c9-8209-1960bf06028a">1,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:AccruedClinicalTrialsandStudies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNy0zLTEtMS0w_7e72d0a4-9bb4-40a9-b20a-887ef9ae9287">2,029</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:AccruedExpensesPropertyandEquipmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOC0xLTEtMS0w_35b6b2c0-cf26-4ca4-bc22-b5bb15f771ad">1,476</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:AccruedExpensesPropertyandEquipmentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOC0zLTEtMS0w_9b8049fe-9d45-43da-8bd9-b12211d8cbfd">2,424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Operating lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOS0xLTEtMS0w_5803041b-385f-4e95-8a06-927548c9cda9">8,240</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOS0zLTEtMS0w_f5c777f2-259e-476e-b358-10f2285c50bf">7,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Others</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTAtMS0xLTEtMA_f0667f4f-9c53-4a4b-a5cf-2a02afafed0c">3,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTAtMy0xLTEtMA_3d0d27b5-2d40-4ece-8fe6-c6c4234569a7">4,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total accrued expenses   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTEtMS0xLTEtMA_a7622a04-0d21-43e3-aade-f0829e697c8a">24,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTEtMy0xLTEtMA_640fbb6c-1e0b-4276-8e27-ace9aaacbc3e">25,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib551ebaf812444a9a6979b345f863c2b_52"></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:6pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAxMQ_f0a9712c-9ca7-4ce1-9e9a-563f76925400" continuedAt="i2986e9442e754e67a7509bce055a3bec" escape="true">Fair Value Measurements, Cash Equivalents and Marketable Securities </ix:nonNumeric></span></div><ix:continuation id="i2986e9442e754e67a7509bce055a3bec" continuedAt="i9c7c4d1c90864b75a1e515d9cd920151"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAxMw_d7a78f04-f0f0-4581-9370-f6d8ddb42f3d" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfMzk5Nw_48afd5ed-f96b-4ff7-a0d3-9eb24c84ac08" continuedAt="iaa40b75bdeae4e7a9cd11bb418566ad1" escape="true">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i9c7c4d1c90864b75a1e515d9cd920151" continuedAt="i764d0efdf11741d4bca2498621924135"><ix:continuation id="iaa40b75bdeae4e7a9cd11bb418566ad1"><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1748888fa5b94b3fa36d1f69f3d04c7a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi0xLTEtMS0w_886fced8-c597-4931-959c-0b335df5a13d">20,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1a742dbb670437194ce13edafd7abd7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi0zLTEtMS0w_3b7ce694-3e2d-4fac-a931-ab8daf7fd14e">20,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i370642be93cb4475a9cc1be521e0f456_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi01LTEtMS0w_dc86deac-ad11-49c7-adb8-c78ddb62fca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifffa3df8778245cbbf40df31c03d6572_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi03LTEtMS0w_8e596d4a-9704-402b-b773-308cf6a6ca4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy0xLTEtMS0w_fb909956-8526-4a78-8005-634c5cd66a9a">20,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy0zLTEtMS0w_2498952d-2628-4ab1-9391-54463fa3f646">20,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy01LTEtMS0w_da2b2761-319a-40e1-abdb-5130763b2f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy03LTEtMS0w_e8c00a73-6306-4078-871e-00a2052da578">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31f4635a39a149c0ba7e63b5acf39b3b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtMS0xLTEtMA_39e33bc9-7957-4d3d-85f6-637455666767">773,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i599892da63584709afb69f4bfb29d368_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtMy0xLTEtMA_3dd434c6-c9d5-4966-ae35-72501ba1609d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7726079bb25453e958c1da1ddfff388_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtNS0xLTEtMA_d955218b-fdcb-4351-996c-e319045fc0a0">773,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cc2234ad133449eae25a7cb3ee62b6d_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtNy0xLTEtMA_fdc1aaf0-2286-498b-b19e-50b938754c83">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total short-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtMS0xLTEtMA_8ef45fa2-41cb-405e-983b-38185fc2589e">773,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtMy0xLTEtMA_76d34d8e-388c-4b4a-9793-c3797448a28c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtNS0xLTEtMA_e80bf319-77dd-40a1-8713-d095fa0ae240">773,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtNy0xLTEtMA_a8340341-6ee3-40f0-82f5-1f81f9f2ee11">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31f4635a39a149c0ba7e63b5acf39b3b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtMS0xLTEtMA_81bf701a-8878-4ecb-a606-d3e69895bdd6">146,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i599892da63584709afb69f4bfb29d368_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtMy0xLTEtMA_e49dd30a-019b-4b8c-b06a-7583cd23ee19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7726079bb25453e958c1da1ddfff388_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtNS0xLTEtMA_d9bece75-c6d6-442e-9485-624c8189d2ef">146,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cc2234ad133449eae25a7cb3ee62b6d_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtNy0xLTEtMA_1437c013-def8-4cd0-8b42-38d058eded00">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total long-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtMS0xLTEtMA_f05b6508-e310-4a0f-ad2d-1faadb41179f">146,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtMy0xLTEtMA_ca111dbc-2223-49e4-8fc0-7fe9320a8d53">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtNS0xLTEtMA_7209fe41-421a-4de8-987a-9da33dd6db69">146,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtNy0xLTEtMA_882ccbb9-5f5e-4621-81b1-8b72f45c9ec8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtMS0xLTEtMA_37aa7a81-fd2f-48c2-94d2-293231cafa03">939,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtMy0xLTEtMA_18ad2e96-4a33-4c0a-86b9-a9532c522801">20,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtNS0xLTEtMA_4a934fd4-a1ec-4d32-8fdd-3621db1a9c4d">919,278</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtNy0xLTEtMA_9f2cefff-2dbd-41a2-83ef-1baa27a568ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtMS0xLTEtMA_e47f8f82-2512-49a3-8bfc-a4c7a3933665">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtMy0xLTEtMA_ed741b56-92aa-453d-a31f-ebd118e09d59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtNS0xLTEtMA_67c84b4a-9506-4580-bcdc-0e64e295d7d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtNy0xLTEtMA_f21170a4-c43f-408d-85cb-a0390e80aae5">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktMS0xLTEtMA_ecdfee3f-4668-4559-9d61-a46eddd8bb41">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktMy0xLTEtMA_ad85214d-165d-4f01-927c-44c7f21338fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktNS0xLTEtMA_8cbe1ef8-93fb-40f8-bdfd-83736ff1f5b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktNy0xLTEtMA_09c20f6a-e8b1-431c-8df9-f4c85ede09b2">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3accfc27a1b4335902ce8b5195b1631_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS0xLTEtMS0w_484cbcd0-4244-4412-a0d4-ca3c127a7961">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i396f1e67135f4846b62ba49dd35eb38b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS0zLTEtMS0w_59d8d22e-82f0-4123-aa97-5ecf8c7517d5">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia54b93d476704da994b4dc2cdf71eb94_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS01LTEtMS0w_bdd4d193-a439-4417-82aa-1a2806bd8799">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d2218a15c7148cbb392058e26e2920d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS03LTEtMS0w_ff21847b-0f42-44a7-b4fd-28be2c232412">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi0xLTEtMS0w_f31a6a65-255e-4385-af32-26963a45ec2e">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi0zLTEtMS0w_153ef1b0-eae1-4d9b-99df-f25e1a96e852">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi01LTEtMS0w_6ddcc9a9-c2bb-4612-9038-fa06f7441799">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi03LTEtMS0w_de4c4a35-c525-4861-9873-ffe17bdf6f00">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Corporate bonds   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6b9a757a022476481b3125b0fc19f81_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC0xLTEtMS0w_cd875283-f6fe-46c9-b9bf-d9f81cc43c0a">16,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9644227fc4843f1805c967861ab3dc4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC0zLTEtMS0w_8ef3a523-733a-4d44-bf91-051a5b77e022">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88cf4f13cbb04a52a86b045ee3dd5ea1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC01LTEtMS0w_1c225ef6-a1c6-46d6-bdd7-d308b8fbc4ee">16,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibadc73c134c14524b54b1dac274d9bc1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC03LTEtMS0w_54bd0a6e-084b-45a6-aa5a-279e8b3ff97b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae16cdf827984010a2caeb7104021835_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS0xLTEtMS0w_d88b71d3-c62a-4ed9-bb9d-88cd12ee29d7">362,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7128cee9cb9340a7a5e59f2f4abfc63b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS0zLTEtMS0w_adb339a2-b7a0-475e-bedb-acc468b9234c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i421282ed4e594c2fab6a88329510132b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS01LTEtMS0w_1055d698-a2e2-4bea-be73-103eb0a6b541">362,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i740e186b54a74d929d1a8c08b5e479b0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS03LTEtMS0w_ab5cc13f-6a25-4650-89a2-e27931cf4685">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total short-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtMS0xLTEtMA_705ba6d9-d5ac-489a-8bc6-67383a41582b">379,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtMy0xLTEtMA_01c708a8-ad06-4f32-9dd1-47caf3ac9e69">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtNS0xLTEtMA_061e5be0-4593-4dc2-90be-b7e8db999390">379,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtNy0xLTEtMA_84d2efea-a942-4bdc-a3ea-bab35b13c1dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae16cdf827984010a2caeb7104021835_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItMS0xLTEtMA_504b1409-b60e-46fd-b44e-5b0481f92d90">268,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7128cee9cb9340a7a5e59f2f4abfc63b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItMy0xLTEtMA_4e5b1c9b-3378-4e63-85e8-42f0da7f15d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i421282ed4e594c2fab6a88329510132b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItNS0xLTEtMA_1bbf37ac-7992-48e9-af07-41b52afdab5a">268,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i740e186b54a74d929d1a8c08b5e479b0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItNy0xLTEtMA_5e221667-1bf0-4f83-bf6e-0603fafe7c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total long-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtMS0xLTEtMA_11ddc2b9-147b-4b91-af07-34e93c240f6f">268,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtMy0xLTEtMA_d5b78c5e-9cdf-457b-9299-40cbe9cf1c82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtNS0xLTEtMA_3a3b0de9-e18b-4dee-add8-1ff6adfa70ae">268,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtNy0xLTEtMA_0b77bd2b-be10-43a3-8ef9-92ef797eebec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtMS0xLTEtMA_2286acc5-ce94-4634-98e8-2ff72fae3de5">659,091</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtMy0xLTEtMA_0117fe5b-f147-4cf4-98d5-dd24d104a22e">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtNS0xLTEtMA_2806eb4d-d64b-40d9-b592-5b69cba0eae5">648,357</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtNy0xLTEtMA_3aac4e18-ebf1-482b-a5db-7dce2b7e42d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctMS0xLTEtMA_331110a8-9cdc-4c40-9a64-9cf0f1a9cb5a">1,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctMy0xLTEtMTIx_feca2a07-d991-485b-9ab3-15ad0496a61a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctNS0xLTEtMA_12074cad-f109-420a-b65f-2e548c2f71a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctNy0xLTEtMA_f8879b87-093f-4852-a0f6-050044a55e3b">1,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtMS0xLTEtMA_e3cb0fac-8ca8-41b0-901e-483a71960584">1,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtMy0xLTEtMA_888123ed-3423-4171-9ef6-0c1c1d5b565a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtNS0xLTEtMA_c386a8d5-5214-4236-81cb-1a28f9a1baeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtNy0xLTEtMA_d991f96a-5cd6-4f1b-9925-906097641deb">1,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i764d0efdf11741d4bca2498621924135"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAwMA_83d5754e-9e71-465c-b2bd-dcd8f36e6383" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June&#160;30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:23.521%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.828%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.828%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.828%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.828%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.186%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.186%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.186%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.193%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:9pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Redeemable Noncontrolling Interest</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fair value &#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1a2f825e010452bab2dda62203c3a5b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0yLTEtMS01MjU_27f4c0ea-e984-4575-8551-567a4cda8ff0">45,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b4cbb1c832e4835bf864738425a238c_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi00LTEtMS01MjU_f98179f1-622a-44a0-8d33-0a1d8e217241">46,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91b488ecc3114e4a8446d2438cd643d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi02LTEtMS0w_abc0d2e7-d0c6-48d3-85c6-98648d726eb7">49,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba6aacb5f0774eacaab1daef8013d311_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi04LTEtMS0w_11543a04-c6c9-4b89-95c9-3ba2b9651e11">41,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i325614ec170f44899e673d4e7d28ca08_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xMC0xLTEtNTU3_91314115-2f62-485b-a3dc-b249a1039032">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87ae71665daa44538cfa2f9ab72a47e5_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xMi0xLTEtNTU3_1057456e-4c25-45a8-86ee-22191eaf7271">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf3c9fdf9f6945cfa0c0069b6e81a7f0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xNC0xLTEtMA_b615a447-ad1c-44e2-ae42-150b56af8bca">1,365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icba1eb19db0641239b17259b2bba88e5_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xNi0xLTEtMA_7c45c8bf-b9a6-4294-9efe-06afd634934c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Initial valuation on the date of acquisition</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1a2f825e010452bab2dda62203c3a5b_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0yLTEtMS01Mjg_4352dd8c-1a36-47f4-8322-2f993ec2c979">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b4cbb1c832e4835bf864738425a238c_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy00LTEtMS01Mjg_71015617-644f-408f-ad0f-8e68f3fd0081">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i91b488ecc3114e4a8446d2438cd643d9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy02LTEtMS01MzE_0e14fe08-0aa2-4254-9eca-09d310a9a45f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba6aacb5f0774eacaab1daef8013d311_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy04LTEtMS01MzE_d255592d-cbce-4df4-9d87-00e5a319cd1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i325614ec170f44899e673d4e7d28ca08_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xMC0xLTEtNTU3_f397a9fb-1c4e-4b91-8ad6-69c205623c43">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87ae71665daa44538cfa2f9ab72a47e5_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xMi0xLTEtNTU3_667d51cf-c8e2-4ebe-b90b-0ad54b669816">1,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf3c9fdf9f6945cfa0c0069b6e81a7f0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNC0xLTEtNTYy_b3c0bf80-3c15-463c-b420-a55981077057">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icba1eb19db0641239b17259b2bba88e5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNi0xLTEtNTYy_8aa4d555-8bad-4456-9d8d-22eab38ff394">1,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Increase (decrease) in fair value </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i32d14c1e755e43fc814ff44716975ef7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0yLTEtMS01Mjg_ae39a9c8-c042-4068-ba71-173f65a1fe42">6,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25536aab95ec4b1685ab607a7f20dc01_D20190401-20190630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC00LTEtMS01Mjg_a94c4f9e-941f-4bbf-bbf2-c2a346a2fbea">922</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9cfa151d7bf41efb5fd1ac78e966422_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy02LTEtMS0w_7d0be82e-c93c-40b8-92f9-5bc42b0e1d9f">3,159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i770aeb9e45ec4839b3429acb58b3fc0a_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy04LTEtMS0w_68502425-eead-48c8-8fba-c65ddc77dddd">5,944</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89c44f05033a45128d13bcc19f29dc7e_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xMC0xLTEtNTU3_f3dc6a55-5bc1-4554-9c3c-5b1b5ab273ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6bc51d86cf4c0fbc8f765288d22ea8_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xMi0xLTEtNTU3_3fe74f5f-ef9f-4fa8-9037-19f5720a80c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i40d0234ffd6546dfb79d7bb499864ab5_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNC0xLTEtMA_431f6c42-ad39-4142-aa42-76f479ee2cc4">190</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if22d4925f07445f79dacbf83ea12c750_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNi0xLTEtMA_f1cbe261-3896-4a96-9a78-6b9154240d83">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i32d14c1e755e43fc814ff44716975ef7_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0yLTEtMS01Mjg_c94e2729-8f95-4d2a-8c05-2b9ec55763e4">1,286</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i25536aab95ec4b1685ab607a7f20dc01_D20190401-20190630" decimals="-3" sign="-" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS00LTEtMS01Mjg_5da8e4b4-d970-4cde-8250-ce6514ef76e0">622</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id9cfa151d7bf41efb5fd1ac78e966422_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC02LTEtMS0w_629f0deb-5199-4394-aa4c-fed32c614e48">2,359</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i770aeb9e45ec4839b3429acb58b3fc0a_D20190101-20190630" decimals="-3" sign="-" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC04LTEtMS0w_6941636f-e342-4a5a-bd2f-e36124afdbaa">944</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89c44f05033a45128d13bcc19f29dc7e_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xMC0xLTEtODUw_2ec382df-bd89-4c59-a444-4460e9b10c6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d6bc51d86cf4c0fbc8f765288d22ea8_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xMi0xLTEtODUy_635778ec-7fdb-4063-a387-ddbfabddea6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40d0234ffd6546dfb79d7bb499864ab5_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xNC0xLTEtMA_50a11103-9116-4b27-89c7-0be2f0fc3798">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if22d4925f07445f79dacbf83ea12c750_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xNi0xLTEtMA_d04ba82d-ea51-4ca5-862b-4bb68709f03a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09af7f320c9b4fcd84fa1e402ca72a9b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtMi0xLTEtODQ2_f86d19ae-a1b6-4b78-af83-ca00700acdb8">50,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic006391af9764d4bb2ecb0b9cb97430b_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtNC0xLTEtNTM2_f69df41e-c109-4182-bba5-262153bbebff">46,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09af7f320c9b4fcd84fa1e402ca72a9b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS02LTEtMS0w_74587a13-b138-4d35-9885-af6854554d70">50,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic006391af9764d4bb2ecb0b9cb97430b_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS04LTEtMS0w_a766136d-0d2e-4345-bb43-ad830be4ab71">46,800</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddc782a9fb88492e99beaee2df19e086_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtMTAtMS0xLTg1MA_2c2bf48c-e5bf-4a2c-9d5b-060cc48fd029">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b2041cc6a754cf7a43e5f90f2d8f1f9_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtMTItMS0xLTg1Mg_6ccb00fb-bbc9-4656-9eaf-b8700bc3dc00">1,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddc782a9fb88492e99beaee2df19e086_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xNC0xLTEtMA_2ed17540-bd38-418e-b797-72da7fbe03bd">1,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b2041cc6a754cf7a43e5f90f2d8f1f9_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xNi0xLTEtMA_a9636f49-6e4b-4a72-a94e-b3f4862576bf">1,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDM5ODA0NjUxNTkzNQ_ec57f863-cce1-4015-a147-342df7e49bd0">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDM5ODA0NjUxNTk0Mg_031089eb-5c15-4e2c-9ba2-1057c19cb8c2">1.4</ix:nonFraction> million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="gh:DebtSecuritiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAwOQ_553f6345-18a6-4c3f-b8f6-6e120a759bc0" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Money market fund   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS0xLTEtMS0w_cd51e57a-9b47-4162-9c23-ba36a0692539">20,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS0zLTEtMS0w_8f51addf-0b21-407f-8a65-1fa6498edad8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS01LTEtMS0w_5bb89816-cdac-415c-9e1e-b2ffb0c0f60e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS03LTEtMS0w_01948ba6-0276-4561-8a63-cc724836618d">20,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy0xLTEtMS0w_13697cd3-ead5-47cf-b041-97ba3977c5cb">913,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy0zLTEtMS0w_b9e6a74c-e4cc-4359-8ec7-2caf039ae947">5,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy01LTEtMS0w_3f1b2927-72e5-4e14-a8a9-8c5feae1f0f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy03LTEtMS0w_ace13f13-da82-49e3-8877-567483fc0da7">919,278</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC0xLTEtMS0w_859eba84-79c3-455f-af35-cf053c2bd257">933,892</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC0zLTEtMS0w_e5ab9fad-149f-4af1-b882-cf0205dd6d78">5,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC01LTEtMS0w_9409b8e7-9e5c-4926-9c15-f9189e8c1316">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:CashCashEquivalentsandDebtSecuritiesFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC03LTEtMS0w_0dead2ec-7581-4f73-bd69-ceb9b204b8f7">939,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Money market fund   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC0xLTEtMS0w_95c32047-231d-4a07-aa82-7c2c96540b8c">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC0zLTEtMS0w_b1ae67f1-b8b3-43a1-88d9-4d35ca9fa466">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC01LTEtMS0w_ea962648-8513-47ea-a8a0-00bd474af010">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC03LTEtMS0w_bfcf2bf0-17b8-46f2-9f97-6bcff494e15a">10,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Corporate bond   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS0xLTEtMS0w_796b51f0-f98e-4fba-870c-28ac9cf565f4">16,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS0zLTEtMS0w_78266262-6cad-459c-8433-0b0c8d5cf125">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS01LTEtMS0w_b1d5cfc7-1dcd-4a27-897c-5dbc8dc98dc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS03LTEtMS0w_951c9625-18c0-4299-bcbf-a5e8a6092cd2">16,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi0xLTEtMS0w_35bcf96d-7291-4d4d-ba92-10d7e6637d3e">630,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi0zLTEtMS0w_07ba31c5-169c-4ede-9b87-616eebca51e9">1,423</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi01LTEtMS0w_e6bc4593-4469-4324-ac01-34e1365e2746">39</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi03LTEtMS0w_93314e90-3601-4b8e-a3f8-b37a56156575">631,667</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy0xLTEtMS0w_a3c4e448-7ebf-4031-88c8-fab491fdad8c">657,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy0zLTEtMS0w_c0e77870-7c5b-4c08-b755-c44834368335">1,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy01LTEtMS0w_3e0f4928-921b-47bf-968d-19ca16caf0e9">39</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:CashCashEquivalentsandDebtSecuritiesFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy03LTEtMS0w_43253862-d5a0-4db9-be67-3142e59f3586">659,091</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#8217;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of credit losses in the three and six months ended June&#160;30, 2020 and 2019, respectively. The maturities of the Company&#8217;s long-term marketable securities range from <ix:nonNumeric contextRef="ie6a2fe3c28ec43dbb430a92bb0b27a35_D20200101-20200630" format="ixt-sec:duryear" name="gh:MarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfMzk4MA_dfb710f3-7a2e-469d-a17f-4c0534632b2a">1.0</ix:nonNumeric> year to <ix:nonNumeric contextRef="ia75cf41ebff4424583eb30543c5a9ed7_D20200101-20200630" format="ixt-sec:duryear" name="gh:MarketableSecuritiesMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfMzk4Ng_892e2b47-ea5d-424f-8e9b-619ed8ac5ed1">1.4</ix:nonNumeric> years as of June&#160;30, 2020.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_58"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzg0_9ecea70f-826a-4c3e-ab63-4f3307363560" continuedAt="i8b9adac55d68494db9bb6ad95708c1b5" escape="true">Intangible Assets, Net and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i8b9adac55d68494db9bb6ad95708c1b5" continuedAt="i2d84fc2511b247db8ce3828be26228a5"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzg4_d7a79e7b-9e81-48d5-9ee4-f3c159cba515" escape="true"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzkx_41dca3aa-1a71-452b-8209-ab3535435f6f" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents details of purchased intangible assets as of&#160;June&#160;30, 2020&#160;and&#160;December&#160;31, 2019: </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:42.855%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.861%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.022%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.022%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.028%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i671223423cb94bd8ac77d81000597b42_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi0yLTEtMS0w_dcd2a446-c0de-4ff5-beef-ceae82fb1012">11,886</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i671223423cb94bd8ac77d81000597b42_I20200630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi00LTEtMS0w_5f71eb82-5d46-4e13-a8a1-8496f1c6f1eb">809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i671223423cb94bd8ac77d81000597b42_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi02LTEtMS0w_5eecfa12-b689-4890-8277-b140bf311e1d">11,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iab30d7be41ac42b6aaef61bf9bfb2147_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi04LTEtMS0w_0e80c6e6-6553-4968-9fe0-2370de8bfd41">10.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e9fca5442dc404d83a43b8c26016c6f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy0yLTEtMS0w_f35828fd-839a-4b22-ab47-5eb7edca616a">5,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e9fca5442dc404d83a43b8c26016c6f_I20200630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy00LTEtMS0w_f6d223e6-6dd8-4c15-bee3-76984448c4b5">629</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e9fca5442dc404d83a43b8c26016c6f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy02LTEtMS0w_19d5c1ee-6b87-43f1-b883-0a6400f953be">4,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i33c6b8bbdadf44c4a7642d85455f2e93_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy04LTEtMS0w_8ec26ea6-cb22-45b9-b7ea-f979431af995">5.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfOC0yLTEtMS0w_7b4f13f3-b80c-4dfa-8f2e-b4a55b5b0a5c">16,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfOC00LTEtMS0w_54c2729a-a2b4-4ab8-b87b-1db4291c0032">1,438</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfOC02LTEtMS0w_4d807ebc-e69d-4384-9aa5-f797d7f18d0c">15,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e95088fcf1140e1808f0690d05a8f92_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTAtMi0xLTEtMA_d719b850-88f4-4cc4-a753-2f83604916e8">1,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e95088fcf1140e1808f0690d05a8f92_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTAtNi0xLTEtMA_f8af28fd-deb4-4d9d-9e30-f129ba873803">1,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTEtMi0xLTEtMA_68afddd7-e209-4a8d-b795-66be5edc0ea6">3,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTEtNi0xLTEtMA_a1779223-8f67-4971-a034-0eaa1a0d82c5">3,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:IntangibleAssetsGrossIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTItMi0xLTEtMA_3d26e66d-36e1-4add-bddb-d6303251f297">21,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTItNC0xLTEtMA_f307dd09-7d0f-4f59-b3a1-811b415bdd5f">1,438</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTItNi0xLTEtMA_93f7d1d5-14ba-41ee-a9b7-5bdc46535932">20,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:13pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:42.855%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.861%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.022%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.022%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.028%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e385c44929941159efaa1b380c02f72_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS0yLTEtMS0w_0c39637e-94dc-432a-a998-f3b5ed878671">5,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6e385c44929941159efaa1b380c02f72_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS00LTEtMS0w_7f55656e-93b3-4292-8e20-5c6962d739ae">373</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e385c44929941159efaa1b380c02f72_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS02LTEtMS0w_d73d7fcf-5ccb-463f-9890-1f046ae3fb9b">4,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0fad1189a7cb465fa38705627b676425_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS04LTEtMS0w_aac39344-f956-4a0f-973e-4152804058b5">9.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi0yLTEtMS0w_e06b69e7-3674-491c-b50f-0e2581671a05">2,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi00LTEtMS0w_bf138f04-c702-479d-a06b-7b8889d8a6d3">303</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi02LTEtMS0w_9270f1f3-566e-40b7-9a85-3cb183c8d514">2,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i39db8210bb3a4e9b8d14f31872c89a3c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi04LTEtMS0w_2c6ed4ed-54de-4879-9240-98d85d1102b4">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNy0yLTEtMS0w_992e61c3-7660-457f-b8b0-abdb8eb0d80f">7,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNy00LTEtMS0w_959878fc-1277-415a-8af3-3291cb734a6b">676</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNy02LTEtMS0w_1780ae84-4a68-43e6-a07c-a230b9483dfc">6,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i870e208edb564cf5aaf92b0b2145c9cf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfOS0yLTEtMS0w_91a20499-6d2f-42de-bcba-d575bef3829c">1,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i870e208edb564cf5aaf92b0b2145c9cf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfOS02LTEtMS0w_3421c681-298d-4772-a73d-7d1e333f11b7">1,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTAtMi0xLTEtMA_3563f299-c81b-4c6d-8dc9-efaab3ed10cc">3,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTAtNi0xLTEtMA_ae42e65e-cadd-44e7-8997-ce540d11a8d8">3,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="gh:IntangibleAssetsGrossIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTEtMi0xLTEtMA_d389aff0-5c6d-449d-8957-eee20ffa3019">12,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTEtNC0xLTEtMA_14a0c2c6-395f-4b00-acb9-8d9c87748294">676</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTEtNi0xLTEtMA_350e833c-ada3-4647-9166-35886f85a255">11,814</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfNDM5ODA0NjUxMTY2OA_e39a01d8-89de-48a4-bf30-6cec4d2274ac">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfNDM5ODA0NjUxMTY5Ng_f9e2384f-eff6-4f4e-aba0-6bb98cdb3add">0.2</ix:nonFraction> million for the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMTg2_8bb4e342-9e13-4fc7-b59e-cf0287b57210">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfNDM5ODA0NjUxMTkyMw_edfd7ba2-84cc-46c8-a780-b1b5398f6895">0.2</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzk0_f6008069-7eb6-4e58-9ae5-7ad8e4f4b9d0" continuedAt="idf3cd3bafc134c1a870354524d994131" escape="true">The following table summarizes estimated future amortization expense of finite-lived intangible assets:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="margin-top:13pt;margin-bottom:13pt;"><ix:continuation id="i2d84fc2511b247db8ce3828be26228a5"><ix:continuation id="idf3cd3bafc134c1a870354524d994131"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.082%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.981%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfMy0yLTEtMS0w_a0765541-3cf0-4845-826e-5153e1fed1a7">994</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNC0yLTEtMS0w_42707749-cbdc-4e92-8df9-c3799936508e">1,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNS0yLTEtMS0w_82a12507-85fc-45ee-a2d4-4f92f82fa470">1,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNi0yLTEtMS0w_8e22c441-b187-4108-9abb-368101277972">1,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNy0yLTEtMS0w_6ac843de-5e77-4e3d-8388-5386e9f5798b">1,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfOC0yLTEtMS0w_24c382e2-fecf-4ff2-a437-788e6c0d97b6">6,760</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfOS0yLTEtMS0w_f6dede70-8c6a-45fb-b28f-eeba42d1db0c">15,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="ib551ebaf812444a9a6979b345f863c2b_67"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="gh:AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMzg5Nw_e4411aa9-0f8b-45dd-b6d6-36c695a4ce79" continuedAt="ie58aac22f2934eca8d2985f3772d3da3" escape="true">Acquisition </ix:nonNumeric></span></div><ix:continuation id="ie58aac22f2934eca8d2985f3772d3da3" continuedAt="idef5c3535554498c8d063dc159ffb290"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent License Acquisition</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the Company entered into a license agreement with a biotechnology&#160;company, KeyGene N.V. (&#8220;KeyGene&#8221;). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the &#8220;SPLA&#8221;) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene&#8217;s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="gh:PaymentInConnectionWithaLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNjA2_11efef3f-6b99-475c-aa47-ecf2a1b1f582">18.5</ix:nonFraction> million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $<ix:nonFraction unitRef="usd" contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="gh:AssetAcquisitionTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfODEz_95194608-c052-432e-b99a-b68d4cd0fd2d">0.6</ix:nonFraction> million of certain capitalizable transaction costs, was allocated to various components of the SPLA.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allocated $<ix:nonFraction unitRef="usd" contextRef="ia5c5a8b30538453e89c87e004c795b1e_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfOTMx_0058979c-c688-47ff-8a0c-734ca72530f4">9.4</ix:nonFraction> million to the patent and covenant rights granted under the SPLA, which have useful lives in the range of <ix:nonNumeric contextRef="i6bf9235dd4864475b23df2375dff74b4_D20200301-20200331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTY0OTI2NzQ0NTc1NQ_8520a1d9-0731-4885-a2cf-cc882f463b9b">6</ix:nonNumeric>-<ix:nonNumeric contextRef="i4d6d3cc7ee094ad8917062d9acce7467_D20200301-20200331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTY0OTI2NzQ0NTc2Mg_01fd6473-70af-4d1c-b8e2-a2ec8776f4ec">12</ix:nonNumeric> years. The Company allocated $<ix:nonFraction unitRef="usd" contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="gh:ChargeOfInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTA2Ng_b67a3b58-8e5a-46b5-87b3-bf1130525ddc">8.5</ix:nonFraction> million to IPR&amp;D technology, which have no alternative future use and was included in research and development expenses for the six months ended June 30, 2020. The remaining $<ix:nonFraction unitRef="usd" contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTIwNw_324f4693-253e-43c8-a906-34c57920365b">1.2</ix:nonFraction> million was allocated to the settlement of the prior dispute between the parties and was included in general and administrative expenses for the six months ended June 30, 2020.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of capitalized license fees relating to the January 2017 license agreement was <ix:nonFraction unitRef="usd" contextRef="icc9610ec8ca94eb3a9394e0fca76debc_D20200401-20200630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDM5ODA0NjUxNTM4NQ_365b9aa6-e62f-4fc5-83d1-b6012e05fe12">nil</ix:nonFraction> and immaterial for the three and six months ended June&#160;30, 2020, respectively. Amortization of capitalized license fees relating to the January 2017 license agreement was $<ix:nonFraction unitRef="usd" contextRef="i5ef5bc66f72741dcab51cdd2f9c4c114_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDM5ODA0NjUxNTM5Mw_6298f65d-587d-495c-95ad-dccc171fdcba">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ice197852bbb64a88a0b56ea6fe444696_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTQ2OQ_b05e134e-c585-4510-a9a2-2ea9bbe5052e">0.5</ix:nonFraction> million for the three and six months ended June&#160;30, 2019, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition of Bellwether Bio</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Company purchased all of the outstanding shares of Bellwether Bio, Inc. (&#8220;Bellwether Bio&#8221;), a privately-held company developing a method for early blood-based cancer detection. The Company accounted for the acquisition as a business combination. The total purchase consideration was $<ix:nonFraction unitRef="usd" contextRef="i3510d8a915044bd2bbd4d045d52db61f_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODkzMA_b23f6a2f-9a15-4c82-ba97-be8f75a205f2">8.7</ix:nonFraction>&#160;million, which consisted of i) $<ix:nonFraction unitRef="usd" contextRef="i3510d8a915044bd2bbd4d045d52db61f_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODk1Nw_716771fe-d3d2-48c1-bd1e-17920a5d18d6">7.6</ix:nonFraction>&#160;million in cash paid upon closing; and ii) future contingent consideration liability with a fair value of $<ix:nonFraction unitRef="usd" contextRef="id02ea36157704a95bf6f694669d5f017_I20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODk4NA_ac50b195-48cb-4350-9d88-544e3b2d55e9">1.1</ix:nonFraction>&#160;million on the acquisition date. The contingent consideration is subject to the achievement of certain commercialization milestones with a maximum payout amount of $<ix:nonFraction unitRef="usd" contextRef="ia8512cacee254bfea1d2fb212216dd3f_I20190430" decimals="-5" format="ixt:numdotdecimal" name="gh:BusinessCombinationContingentConsiderationMaximumAmountPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyOTAxMg_71725edc-4732-4640-b274-442183de1d71">10.0</ix:nonFraction>&#160;million. The Company will also pay additional earn-out consideration of up to $<ix:nonFraction unitRef="usd" contextRef="i52f3187d48da4ffda0a02a73d287d04c_I20190430" decimals="-5" format="ixt:numdotdecimal" name="gh:BusinessCombinationContingentConsiderationMaximumAmountPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyOTA0MQ_5b4cdba9-fc0d-4151-8424-86c792951372">10.0</ix:nonFraction>&#160;million subject to the achievement of certain commercialization milestones and the continued provision of services to the Company by certain former employees and consultants of Bellwether Bio. The contingent consideration and earn-out consideration may be paid, at the Company&#8217;s election, in cash or in the Company&#8217;s common stock. As of June&#160;30, 2020, the Company did not believe the earn-out consideration is probable to be achieved, and therefore, did not record any compensation expense. <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMzkwMg_85a85330-ea5c-44bc-bb9d-5eabfdb180de" continuedAt="ib86b2fd6211d496882ee7a20204c858f" escape="true">The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="idef5c3535554498c8d063dc159ffb290" continuedAt="i1b23d2371343479384eaef29dd2e2a3d"><div style="margin-top:5pt;margin-bottom:13pt;"><ix:continuation id="ib86b2fd6211d496882ee7a20204c858f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:83.256%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cash</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id02ea36157704a95bf6f694669d5f017_I20190430" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfMy0yLTEtMS0w_227a6111-8038-4f96-a14c-b02a952ba55c">521</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id02ea36157704a95bf6f694669d5f017_I20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNC0yLTEtMS0w_99faeae9-b1b0-4263-9f6b-ab5145816e66">6,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id02ea36157704a95bf6f694669d5f017_I20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNS0yLTEtMS0w_ffbd73e0-a838-4d6c-a3be-b423aa5a4122">3,289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id02ea36157704a95bf6f694669d5f017_I20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNi0yLTEtMS0w_6380f168-535e-439a-9b05-ca12974afc8f">1,802</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id02ea36157704a95bf6f694669d5f017_I20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNy0yLTEtMS0w_e8d9357d-0ef9-4f8b-b89d-aed1b1870ef3">8,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMzkwNA_6b808dff-eef1-4d62-b52c-65d3e6fced24" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:67.341%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.211%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.844%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Acquired license</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f640c6e83784ea4850b868a4ac72489_I20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfMi0yLTEtMS0w_5ed5b6c3-32da-4581-8ec9-551223831740">5,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8e633a87d34e43728ef3713950fc0c06_D20190401-20190430" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfMi00LTEtMS0w_d15d63b1-e795-4ac1-b629-694cbaa90708">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">IPR&amp;D</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e4b90fbb22c4181ab782534d84b4052_I20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfMy0yLTEtMS0w_9228fb31-14b5-40c0-a56d-949c9a47728e">1,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id02ea36157704a95bf6f694669d5f017_I20190430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfNC0yLTEtMS0w_ca5a7b7f-6241-4800-8f17-d7021cd3afd4">6,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">*&#160;IPR&amp;D assets are not subject to amortization.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i1b23d2371343479384eaef29dd2e2a3d">In connection with the acquisition of Bellwether Bio, the Company also entered into non-compete agreements with certain key individuals based on their experience and importance to the operation of Bellwether Bio. The Company accounted for the covenants not to compete as purchases of intangible assets separate from the business combination as these non-compete agreements were initiated by the Company to protect its interests. The fair value of acquired covenants not to compete is estimated to be $<ix:nonFraction unitRef="usd" contextRef="ieee5f27fc7c546a0a1c1982c3c8a2e94_I20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyOTA2OQ_6404a71b-c24a-4930-a4c5-ab00980629a9">2.5</ix:nonFraction>&#160;million, which is recorded within intangible assets, net on the condensed consolidated balance sheet and will be amortized over an estimated useful life of <ix:nonNumeric contextRef="ie644dcec06b9490aba117035eebed7ea_D20190401-20190430" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODkwNg_49c72437-63ff-49e2-9d56-04a8975e91e1">6</ix:nonNumeric> years using the straight-line method. Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations.</ix:continuation> </span></div><div id="ib551ebaf812444a9a6979b345f863c2b_73"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTY0OTI2NzQ0MzA4MQ_37061489-0f68-4028-908b-6e7245199626" continuedAt="i641649857a214a7e82c8cce4d5a707ff" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i641649857a214a7e82c8cce4d5a707ff" continuedAt="id9c87e1041854cefa8a2200fe132318a"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has&#160;entered into various operating lease agreements for office space,&#160;with remaining terms ranging from <ix:nonNumeric contextRef="i94551a87fe774af98d538c0336237ed4_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTMx_49769928-47f0-4e78-8d6b-df57bb104644">1</ix:nonNumeric>-<ix:nonNumeric contextRef="i5868db3ef1f34c348c2af19ecda66e6e_I20200630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTQy_270717d5-4cfb-4e09-a197-aa9b27b7eff1">7</ix:nonNumeric> years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement. Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNjA0NzMxMzk1MzkwMA_8f2343b0-0e4b-4aad-944a-787e179265ea">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNjA0NzMxMzk1MzkyNw_127a31ac-fe0c-4e74-97dc-2afafc6c7a1e">0.8</ix:nonFraction> million for the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNzM5_03f135de-984f-4401-b33f-49f028fa6795">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNzQ2_747fa93d-6190-4395-8917-b73aa3f2cbec">1.6</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTA4Nw_ed4e5ac0-34cd-4138-af87-73aa49cb29e0" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.916%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.822%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMi0yLTEtMS0w_328faa74-87b0-4972-af23-8d5669b11ad9">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icccb78a249d8444998f95593e619a75a_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMi00LTEtMS0w_e38e7587-40bf-4ab2-afff-058d89b45093">6.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMy0yLTEtMS0w_d2343a7a-80ce-4994-96c1-a9ae1eac65d8">8.19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMy00LTEtMS0w_dd1c7037-891c-43ec-afd1-de4457e62211">7.77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTA4OQ_c4624552-fc75-4870-8318-d999da93f4d6" continuedAt="i02fb05fc43604a7a9b44b21ad985d730" escape="true">The following table summarizes our future principal contractual obligations for operating lease commitments as of </ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="id9c87e1041854cefa8a2200fe132318a" continuedAt="ib16a2ab13fbe49d9903c74abbecf24fe"><ix:continuation id="i02fb05fc43604a7a9b44b21ad985d730"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2020:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:80.797%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.203%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfMi0xLTEtMS0w_95cef6f7-215d-493e-be75-63efdd81ee16">4,723</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfMy0xLTEtMS0w_6f2fd90c-f660-4bc3-84bf-e8be665e95c4">11,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNC0xLTEtMS0w_de01e4aa-0613-4a27-8840-97617b756f3b">9,840</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNS0xLTEtMS0w_ecc48a97-442c-40d9-93ec-8e5c183ccafb">10,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNi0xLTEtMS0w_2caae149-33f2-4bc2-aa9a-3546c0a308ca">10,780</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNy0xLTEtMS0w_22b9bc24-22dc-4a95-93c1-371fc67241ff">20,251</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfOC0xLTEtMS0w_7a984c52-188b-4fa8-9b9d-81b5c6cb5ec5">67,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:  Imputed Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfOS0xLTEtMS0w_885283c5-c1db-47d3-96e9-837f8ab14533">18,391</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfMTAtMS0xLTEtMA_a4b71bba-912a-4e7f-97d6-688473edee58">49,357</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases are not material to the Company's condensed consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib16a2ab13fbe49d9903c74abbecf24fe">The Company entered into new lease agreements subsequent to June 30, 2020, see Note 16, Subsequent Events.</ix:continuation>  </span></div><div id="ib551ebaf812444a9a6979b345f863c2b_79"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMzEyMA_82149d4a-7bfa-4764-8766-0501fa012132" continuedAt="i941164e12ed54c69ad923a0705cf4e89" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i941164e12ed54c69ad923a0705cf4e89" continuedAt="ieb320b17270c4702a844cf76a2f2d877"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, we have received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. We have also instituted, and may in the future institute, additional legal proceedings to enforce our rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patent Disputes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, the Company filed separate lawsuits against Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) and Personal Genome Diagnostics, Inc. (&#8220;Personal Genome Diagnostics&#8221;) in the United States District Court for the District of Delaware. The Company has alleged that each of the <ix:nonFraction unitRef="company" contextRef="i1ce8429656d8474090165e7a3628b1e3_D20171101-20171130" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofCompaniesthatInfringedonaPatent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTEwNw_5c2dc10b-1550-4b10-a84c-5ee6d83cd301">two</ix:nonFraction> companies has infringed <ix:nonFraction unitRef="patent" contextRef="i0e8f6b7f7cda4a31a4e20791ec53e3af_D20171101-20171130" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTEzNA_f2ce9b50-aec0-4946-9ef5-524a64c4b0d7">four</ix:nonFraction> of the Company&#8217;s digital sequencing technology patents. The <ix:nonFraction unitRef="company" contextRef="i1ce8429656d8474090165e7a3628b1e3_D20171101-20171130" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofCompaniesthatInfringedonaPatent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTE5Nw_d48d46c3-f204-460b-a0b8-af4719678680">two</ix:nonFraction> companies have each asserted counterclaims of </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="ieb320b17270c4702a844cf76a2f2d877"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">patent invalidity, unenforceability under the doctrine of inequitable conduct, and non-infringement. Personal Genome Diagnostics has also alleged antitrust violations related to the enforcement of the Company&#8217;s patent rights. In each lawsuit, the parties are seeking damages, injunctive relief and attorneys&#8217; fees.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2018, Personal Genome Diagnostics filed two petitions for post-grant review with the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) at the United States Patent and Trademark Office, challenging the patentability of <ix:nonFraction unitRef="petition" contextRef="i45b21f81c97c4197bf11064199f6a5f4_D20180301-20180331" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTc3OA_577bb6f8-3d60-44b6-8211-ff1a2b196757">two</ix:nonFraction> of the patents asserted by the Company. The <ix:nonFraction unitRef="petition" contextRef="ieb1c8dd73c8f4f9b81c94f3211ecc88f_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTgyNQ_0fbc1685-5e48-435f-b52b-25e9ff9e06e4">two</ix:nonFraction> post-grant review petitions were dismissed with prejudice in July 2018. Subsequently, Foundation Medicine filed <ix:nonFraction unitRef="petition" contextRef="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTk0MA_e12c7453-b59b-4782-a9df-df5ecce5a467">six</ix:nonFraction> petitions for inter partes review with the PTAB, challenging the patentability of all <ix:nonFraction unitRef="patent" contextRef="i142f8879551e4d50a8780dbc93bb85f2_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMjAyOQ_662d483d-5ef1-4ec0-b679-e5effdc732f7">four</ix:nonFraction> of the patents asserted by the Company. The PTAB denied institution of inter partes review for <ix:nonFraction unitRef="petition" contextRef="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsDenied" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMjEyNw_547d99b2-59da-4cc6-b288-8a0b55aaa7bc">four</ix:nonFraction> of the <ix:nonFraction unitRef="petition" contextRef="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberofPetitionsFiled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMjEzNw_fe6aba6f-0baf-4bf2-909c-e1900e72c25a">six</ix:nonFraction> petitions filed by Foundation Medicine and instituted inter partes review for the remaining two petitions. The Company plans to vigorously defend its patent rights during such PTAB actions. At this time, the Company cannot reasonably ascertain the likelihood that any of the remaining challenged patents will be found to be invalid or unenforceable.</span></div></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div id="ib551ebaf812444a9a6979b345f863c2b_82"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzgzNg_8895a87e-3120-49f7-be8b-118c47aa6f35" continuedAt="ie815ea43ce4c45318839dda986429c28" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="ie815ea43ce4c45318839dda986429c28"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of June&#160;30, 2020 and December&#160;31, 2019, no dividends on common stock had been declared by the Board of Directors.</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMzU2_6ce85ec9-981b-422b-a14f-2c0fc756aef3" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Shares underlying outstanding stock options   </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie598fb3c2fa14dc9aae676f3defa865c_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMi0xLTEtMS0w_46100da7-d9a7-4362-a262-decf8c598440">3,869,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iac6abd95f913499ea2e0b739c5e2fd9d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMi0zLTEtMS0w_1af57a6f-f7e3-4a0c-89bb-de90b0db903c">4,494,889</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMy0xLTEtMS0w_0e1453aa-3d21-4195-9937-dcac0faeb88f">564,008</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id12141ace9b64b28bea2fdaaf6db601b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMy0zLTEtMS0w_e5f6280f-eb8d-4a0b-bf7e-9133ce632d40">496,131</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i45a7eeee673141b1a6a9a0da13e14018_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNC0xLTEtMS0w_d8c039e5-2a17-4c48-8922-e96e7c36167d">2,864,528</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i69cd2a5c9a414203b8bae90d7516eeb2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNC0zLTEtMS0w_142baa75-b884-4e0c-800a-f9e9629c702d">2,726,225</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i050b6f2672cc4818903148e5e1bb1511_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNS0xLTEtMS0w_9a37975c-a8f5-4656-9130-ca2eb2c2058c">1,574,367</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3c1dac7222754796a0dd42751b19691a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNS0zLTEtMS0w_cfe76ecf-5f81-4ebe-ad72-9ade1e64dfb4">689,917</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNi0xLTEtMS0w_7fbc9a46-1476-4a00-bd62-5019b1c08c9a">8,871,905</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNi0zLTEtMS0w_195feb8b-819a-4cad-b3a4-641b7919b4c3">8,407,162</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Follow-on Public Offering</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, the Company completed an underwritten public offering, in which it issued and sold <ix:nonFraction unitRef="shares" contextRef="iebb665707a6f47049ff619543a4f305f_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzgzOA_8d0dcd95-132f-4e16-984a-d14f61c55030">4,312,500</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0Mzg5Ng_63bbde35-51bd-44b1-abde-0aa279b2e825">84.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iebb665707a6f47049ff619543a4f305f_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0Mzg3OA_74c7a084-1253-42d5-a8e7-1eb1d28f91f0">354.6</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company completed an underwritten public offering, in which it issued and sold <ix:nonFraction unitRef="shares" contextRef="icedca10dad7f49b48138ccb3a8b51c92_D20190501-20190531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0Mzg1OA_9975d5d9-303a-4ba8-ace9-33b776d64e9b">5,175,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i74c5c7aff6084ff8b5748e3367a09571_I20190531" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzkwNA_e76b46ae-d15e-4def-84d1-2cdd6cf55e90">71.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="icedca10dad7f49b48138ccb3a8b51c92_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzkxMg_8e4a55f2-9f6f-4c17-a06f-12873f77327c">349.7</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.&#160;<ix:nonNumeric contextRef="iacfffb20a4ae41eea78d5a346088bc97_D20200526-20200526" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTQ5NzU1ODE0NzUxNg_8409531f-9522-4537-9528-9b9e741a3eb4" continuedAt="if7d1fdcc715e43a6b1a51c942695d54e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if7d1fdcc715e43a6b1a51c942695d54e" continuedAt="i40a8a10eecd94d94909280998df455d6"><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk1NA_bcda67ce-9d9e-443d-8cfe-77f6c830b2a3" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company&#8217;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) and related information is as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.259%;"><tr><td style="width:1.0%;"></td><td style="width:29.621%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.841%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.322%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.038%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.680%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.290%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options Outstanding</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares Subject to Options Outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2019</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC0xLTEtMS0w_fcfa9f60-f719-4c7a-8a85-f93b1afcbcab">2,726,225</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC0zLTEtMS0w_56508f26-630e-4999-8cc3-1f7d46f7090a">4,494,889</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC01LTEtMS0w_77dbded5-60bb-407f-b600-cab534542d36">10.90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC03LTEtMS0w_41b4c816-344b-4105-a1ec-5f82e55b614a">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icccb78a249d8444998f95593e619a75a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC05LTEtMS0w_c0258165-0d05-4558-851d-928f44e91a48">306,392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2018 Plan annual increase</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNS0xLTEtMS0w_02177097-46a1-4d65-bf56-a86034a7f625">3,689,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNi0xLTEtMS0w_5a9c97cb-13a7-4699-aa26-451107b0a052">78,476</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNi0zLTEtMS0w_858af417-75db-4dd3-a578-39fd4acb1a18">78,476</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNi01LTEtMS0w_52aec9bb-454c-4176-be3c-b17dca818da1">76.01</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNy0zLTEtMS0w_bb3dce6a-7a91-4514-a4f4-06027a8c1745">654,557</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNy01LTEtMS0w_8540d2e2-7e9b-4950-9e3c-c26f51c65506">5.42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOC0xLTEtMS0w_df0753fd-9f94-4281-903a-1b094576f93d">12,406</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOC0zLTEtMS0w_c646c92c-2964-46bf-bf2e-5553315a1a0c">49,806</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOC01LTEtMS0w_cd36a5a4-e8d2-44e7-ba0a-0d635fe25eba">8.79</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Restricted stock units granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="idfbdc510d6c440d1b2591a18047a2615_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOS0xLTEtMS0w_7703b7b3-318d-428f-969b-c75b47b205ad">126,834</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Restricted stock units canceled</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idfbdc510d6c440d1b2591a18047a2615_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTAtMS0xLTEtMA_03ed9bc1-a200-4e94-9a1a-c1af5c4f4c95">33,355</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Market-based restricted stock units granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtMS0xLTEtNDYwMg_ac598588-b9c2-44a5-b933-07c57ec8b722">3,391,148</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtMS0xLTEtMA_b44ec78a-c2ca-45d1-9dc3-af22fdcc3b82">2,864,528</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtMy0xLTEtMA_7e471b04-960e-419a-b565-aab7f6d5a4f4">3,869,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtNS0xLTEtMA_feddec9b-b166-4136-9727-5e5a0c4bf08e">13.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtNy0xLTEtMA_476fb618-a262-4874-b654-208fb705fd72">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtOS0xLTEtMA_efb26f02-2d3b-482e-a2a5-aea7c315770a">266,316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Vested and Exercisable as of June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItMy0xLTEtMA_b9edd378-36f0-4cc3-bbec-8e8d255e25f0">2,014,893</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItNS0xLTEtMA_e15bb5cc-e4c9-4d90-8ea8-03ca7191728f">6.90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItNy0xLTEtMA_e20a8e3e-62f8-4e5d-b67a-8af25bf7d968">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItOS0xLTEtMA_44604a32-eadd-4b1d-ac50-e9fbaf3ce00d">150,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt;">Effective as of January 1, 2020, an additional <ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzE2_02177097-46a1-4d65-bf56-a86034a7f625">3,689,000</ix:nonFraction>&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $<ix:nonFraction unitRef="usd" contextRef="if9df8ef4afe54d51bb4c149ba983e328_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk1OTkyNA_80f63e03-98cc-4dbd-9c83-ae70536f603c">33.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk1OTk1MQ_c8deac93-6b8e-4dda-a6ec-c7a47e0eb7f0">108.3</ix:nonFraction> million for the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNzA1_be1e3b84-2ac7-4482-9b3f-e2ad467fef96">50.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a0d4e0481d84fadaad8a7fe2f5e9afc_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNzEy_94031c3b-bf4c-40eb-b8ac-7922f5392e8c">116.4</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDAxMw_122d6cdd-0433-4c0d-aa49-4032c0c1eddb">44.61</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDAzOQ_1cae2aef-1b81-444b-a3e2-ef6560e5ba93">51.94</ix:nonFraction> per share for the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usdPerShare" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfODE0_9c521d66-8342-4afa-9fe2-168484be0276">45.52</ix:nonFraction> and&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfODIx_9f38c587-cd34-493d-bf25-094e65250a93">43.35</ix:nonFraction> per share for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future stock-based compensation for unvested options as of June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfOTMz_6ebc9c60-3f85-4b50-aa21-7f323a77add7">22.9</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTAwNg_1d28c789-47c3-42cc-ae84-03f964fc3b8b">2.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk1Mg_3d0f8cae-ca35-4b75-aab8-fd9bd1945e8f" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company&#8217;s restricted stock unit activity excluding the market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.412%;"><tr><td style="width:1.0%;"></td><td style="width:64.666%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.867%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted Stock Units Outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id12141ace9b64b28bea2fdaaf6db601b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMi0yLTEtMS0w_cd71840a-61f0-4113-941c-d8a808639ac8">496,131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id12141ace9b64b28bea2fdaaf6db601b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMi00LTEtMS0w_150a5015-d48b-4ea6-bb97-16ed2cfe6ecd">82.08</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMy0yLTEtMS0w_a50be97f-0efa-4820-9299-54f3d2199cd9">126,834</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMy00LTEtMS0w_c47a317d-df2e-4fb4-bbc9-71123df5a3ec">75.96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNC0yLTEtMS0w_a03d7d98-0969-4a03-9ce0-25b5fd99fee0">25,602</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNC00LTEtMS0w_9fedaf7c-cee7-4ccd-969a-6a762255bf98">80.27</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNS0yLTEtMS0w_0472f76e-5656-4921-9e58-0232343ca8f9">33,355</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNS00LTEtMS0w_42b10ee0-6382-451e-9414-ba56f190f9c1">75.94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNi0yLTEtMS0w_9a73319a-97ef-4c25-b904-e74b2d796f8c">564,008</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNi00LTEtMS0w_ae99549d-7429-4f60-81ce-a2b85d5c657e">81.15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i40a8a10eecd94d94909280998df455d6" continuedAt="i87544107c02f400a8dbf4931163d30b3"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future stock-based compensation for unvested restricted stock units as of June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTI1MQ_b9a5afb9-0a69-4276-baec-45de765bc02d">37.7</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTMyNA_4fab71ba-31b6-4d45-a513-66191df3c24d">3.1</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Market-based Restricted Stock Units</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 26, 2020, the Board of Directors approved and granted <ix:nonFraction unitRef="shares" contextRef="i599a34c262194cd695c5756264a97154_D20200526-20200526" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMjE5OTAyMzI5ODkyNA_01cc97db-dd8f-4abc-83f3-c86fbffa4772"><ix:nonFraction unitRef="shares" contextRef="i129bd7811c824210b6778049ea36e662_D20200526-20200526" decimals="INF" format="ixt:numdotdecimal" name="gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMjE5OTAyMzI5ODkyNA_f010a9da-9df6-4a02-9d0c-a45323d7ae03">1,695,574</ix:nonFraction></ix:nonFraction> market-based restricted stock units (&#8220;MSUs&#8221;) under the 2018 Plan to each of the Company's Chief Executive Officer and the Company's President and Chief Operating Officer, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of <ix:nonNumeric contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526" format="ixt-sec:durday" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjYzOA_0547ee79-6f29-4675-90c3-542a936b64e4">30</ix:nonNumeric> consecutive calendar days. The share price goal can be met any time during the <ix:nonNumeric contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4MjA5Nw_1914ca0f-e0dc-440e-9e2e-33e53cfa2032">seven-year</ix:nonNumeric> performance period from the date of grant. Upon vesting, the MSUs must be held for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjAyMQ_60fc0348-aa77-452e-b4e9-5b9e8050b4d4">six</span> to <ix:nonNumeric contextRef="i35b8d41685a144498da608da0700f3aa_D20200526-20200526" format="ixt-sec:durwordsen" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjAzMA_018b2311-9ef3-44fb-8ed3-438e75839347">twelve months</ix:nonNumeric> depending on the time of vesting within the <ix:nonNumeric contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4MjA5OA_439fe3b7-e4b1-4f93-85a3-bd619ac368eb">seven-year</ix:nonNumeric> performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MTk4NA_1a7b9d5c-aa99-4208-a694-40e4de80dca9" continuedAt="i7e7f09e7eb114dc8bb48eef50f8786b3" escape="true">The following table presents additional information relating to each MSU award:</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="i7e7f09e7eb114dc8bb48eef50f8786b3"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.366%;"><tr><td style="width:1.0%;"></td><td style="width:32.848%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.315%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.469%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.315%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:25.653%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Price Goal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of RSUs</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$120 per share</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i669e37f9d5744052b446c5ed68ecebe5_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjVlMWUxZTRlY2JmMDQ4MTA4N2RlZjBkOTdkM2RjZWI0L3RhYmxlcmFuZ2U6NWUxZTFlNGVjYmYwNDgxMDg3ZGVmMGQ5N2QzZGNlYjRfMS00LTEtMS01MjA3_fa0a6c70-3584-4fee-a943-56ecb2ad5c02">565,192</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$150 per share</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iab2c5ae4387c4af8a36849259581e3d9_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjVlMWUxZTRlY2JmMDQ4MTA4N2RlZjBkOTdkM2RjZWI0L3RhYmxlcmFuZ2U6NWUxZTFlNGVjYmYwNDgxMDg3ZGVmMGQ5N2QzZGNlYjRfMi00LTEtMS01MjA5_d5403bfc-2ee2-4fbf-a140-314ff8ef0fdd">565,191</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$200 per share</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9b70fed4f3144ee49ada02413cd6502b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjVlMWUxZTRlY2JmMDQ4MTA4N2RlZjBkOTdkM2RjZWI0L3RhYmxlcmFuZ2U6NWUxZTFlNGVjYmYwNDgxMDg3ZGVmMGQ5N2QzZGNlYjRfMy00LTEtMS01MjEx_3596d870-5408-4fe3-903a-d9deac8223a7">565,191</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="text-align:center;margin-top:8pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche is recognized based on an accelerated attribution method over the estimated derived service period. If the related share price goal is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal. The derived service period is the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU.  The weighted average grant date fair value of the MSUs was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4MTk0NA_db19363d-b94d-4c21-ba1f-55fe02a82de0">67.00</ix:nonFraction> and the weighted average derived service period was estimated to be in the range of <ix:nonNumeric contextRef="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTA5OTUxMTYzMTc5NDg_40b5a172-f723-4a5d-980f-8b02d4fc8310">0.83</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTA5OTUxMTYzMTc5NTM_96b7b614-5441-4c74-9091-889eb3b4bd70">2.07</ix:nonNumeric> years. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Stock-based compensation recorded for the MSUs for the three months ended June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i824680c5b5434f179b86fd36d07d8763_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MTk4Ng_fd77517b-904f-4dbf-a9cd-f59d8cb68428">18.3</ix:nonFraction>&#160;million and is recorded in general and administrative expenses in our condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ib4b5ba9fbebd4472beef02e1b7de1466_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzNTU5Ng_d85da5c5-3f0a-4639-b689-48b54766134f">208.9</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzNTYxMQ_a5eb0d66-dcf5-4e07-840e-cb018a4ba35e">1.3</ix:nonNumeric> years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the <ix:nonNumeric contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4NDYyMA_41feda8e-8b97-4c79-839a-b7b14b2424fd">seven-year</ix:nonNumeric> performance period will automatically be forfeited and terminated without further consideration.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk2Mw_ad745bf4-ce57-4a84-849e-a3a5cf143600" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the effect of employee and non-employee related stock-based compensation expense:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.458%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.620%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.620%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.620%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.626%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cost of precision oncology testing   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifdb07b2046094271b6b1529b0c747445_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS0yLTEtMS0w_acad28f4-2d57-44b5-8315-4fd3c78dec87">407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11c24d9847164822a50d4cdd9d18c5f2_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS00LTEtMS0w_8cfee26d-f30e-46c0-84b6-a3311b193b75">126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie38caa6a9f90489092e150382af25b47_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS02LTEtMS0w_6ca5ae54-4476-4810-82f5-e1e7d822356e">710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bae9317d8ed49b284eae0dbc3a9c989_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS04LTEtMS0w_53495736-0c89-4206-b083-a40aec35b925">296</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Research and development expense   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8fea26a94e94fd49f58b8b97902f6a8_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi0yLTEtMS0w_c3bbcf84-0557-4c0e-b23d-3f11204f206b">2,622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id38ddeb42dc645d29e1cf520286915fe_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi00LTEtMS0w_fc4ae46f-dae2-434f-b543-8ba3fe6b184a">1,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ab72dcca1ef42e3ad48caa9176918f9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi02LTEtMS0w_d8449246-6a1f-4996-94f0-fc5f274a1aa5">4,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cc5f9cce5c946aeb7649a2b45b18c94_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi04LTEtMS0w_4645cc56-d027-4b2d-b58c-e7d1d89575d4">2,638</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Sales and marketing expense   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i686af8754af544d19475d9e965340c33_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy0yLTEtMS0w_3589599e-8cb0-4c81-a9f4-5308b2ab44eb">2,167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i524d26cd6dab4f5bbddc78f74f78b52e_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy00LTEtMS0w_de53b2a8-94c2-4b95-94e4-79c514b0ba74">646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50b9c64f08a24d1fb8df7c8b7394b5e6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy02LTEtMS0w_591d9513-de60-447b-8b4f-a7d7418c16f2">3,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0f1bb229103f423797057daa71d5576d_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy04LTEtMS0w_28ef9d5e-d36e-493a-840a-1a9e44b63d51">1,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">General and administrative expense   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i26596bb7859543f4bb3f7eae23f2540b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC0yLTEtMS0w_615dd709-6e3b-4e37-b617-2f704cfe2608">20,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fe75529581b40f39abaaf5c5922067f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC00LTEtMS0w_f5b12cfb-0588-4e09-b5b2-bdfe7d7f2f85">1,015</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a01140a4fd940ef8d161dee75a36404_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC02LTEtMS0w_2234b591-e14d-40d0-b63e-4bd87b78f322">22,492</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if32fff58d0554a458622af303653e269_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC04LTEtMS0w_b4f6d36f-b451-4e64-9ff0-085a7cb785cf">1,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total stock-based compensation expense   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS0yLTEtMS0yNzQ2_6fd20c5d-cf4f-49d7-a9ff-cf18dfac5a34">25,815</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS00LTEtMS0yNzQ4_9e14de46-7e11-4647-8ad8-95c88225d001">3,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS02LTEtMS0w_b81034b8-b61b-4ea0-8d66-c4fc3018a1c9">32,153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS04LTEtMS0w_aabfbc21-9c52-438b-9fbd-377a9fa83a99">6,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i87544107c02f400a8dbf4931163d30b3" continuedAt="i382b608cf44b4687836782518abd326d"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of Stock Options</span></div><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk1OQ_494b5357-082f-4be1-b18e-7d675d50571e" continuedAt="id7d3f21b5b76434988d53204af9693c7" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:27.510%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.819%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.819%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.972%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC0yLTEtMS0wL3RleHRyZWdpb246ZThlMjdhZDVkY2VmNDhmNmIzODRmYjJhMjRiOGZlOTlfNjA0NzMxMzk1Mjc4Ng_c3b06735-8fda-4260-84e1-b09d08abf161">5.50</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC0yLTEtMS0wL3RleHRyZWdpb246ZThlMjdhZDVkY2VmNDhmNmIzODRmYjJhMjRiOGZlOTlfNjA0NzMxMzk1Mjc5NA_2d1856bb-a581-456d-ba89-dae3fc1de164">6.10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i12fb0e2cc01a47eca1252f58c3e04976_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC00LTEtMS0wL3RleHRyZWdpb246YzlkY2ZhOTU4ZmI3NDI0NjkyNTNlMDMyNTc1MGU0Y2JfNjA0NzMxMzk1Mjc5OA_9dffd6ae-e4a0-42ab-80f4-1822ec47c000">5.50</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i84d05573f20f452f881daacb0e2fafda_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC00LTEtMS0wL3RleHRyZWdpb246YzlkY2ZhOTU4ZmI3NDI0NjkyNTNlMDMyNTc1MGU0Y2JfNjA0NzMxMzk1MjgwMg_bebf0ce7-2ff8-47a3-a23d-c1b8751f2740">6.16</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC02LTEtMS0wL3RleHRyZWdpb246YmYwODRkNzg2MTA5NDQyZTkwNWU4ZDFmM2NiNjg5MTFfNjA0NzMxMzk1Mjc4Ng_f0b197be-efc8-4147-9cd0-5bac72d8413a">5.50</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC02LTEtMS0wL3RleHRyZWdpb246YmYwODRkNzg2MTA5NDQyZTkwNWU4ZDFmM2NiNjg5MTFfNjA0NzMxMzk1Mjc5Mw_d5c91654-9fd4-4e6d-b702-4d458de21a07">6.10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC04LTEtMS0wL3RleHRyZWdpb246MmY4YTcxNzA0ZTk1NGMzZThiMjU2MDUzZTc5NjlkZmFfNjA0NzMxMzk1Mjc4Ng_5e1542ce-7023-4638-b462-996e7a2a1886">5.50</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC04LTEtMS0wL3RleHRyZWdpb246MmY4YTcxNzA0ZTk1NGMzZThiMjU2MDUzZTc5NjlkZmFfNjA0NzMxMzk1Mjc5Mw_5dade8db-1d9b-4971-92af-870241b2cc7b">6.22</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected volatility   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS0yLTEtMS0wL3RleHRyZWdpb246Yjg5MzcyZTEwZTc3NGMyYTk5NDg0ZWIxMTRkNzg5ZWZfNjA0NzMxMzk1Mjc4MA_b9d95c91-c227-4462-a33c-3392a7d02102">66.5</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS0yLTEtMS0wL3RleHRyZWdpb246Yjg5MzcyZTEwZTc3NGMyYTk5NDg0ZWIxMTRkNzg5ZWZfNjA0NzMxMzk1Mjc4NQ_b1815325-379f-4a50-98c6-5b4486cf33ce">68.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i12fb0e2cc01a47eca1252f58c3e04976_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS00LTEtMS0wL3RleHRyZWdpb246NzFkMTA4YmNjOTc3NGRhNzljMjQ0YWI5ZDVhYWRhZmRfNjA0NzMxMzk1Mjc4Mg_d26503c7-cd8c-4bc9-acea-39fa59b384e1">66.9</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i84d05573f20f452f881daacb0e2fafda_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS00LTEtMS0wL3RleHRyZWdpb246NzFkMTA4YmNjOTc3NGRhNzljMjQ0YWI5ZDVhYWRhZmRfNjA0NzMxMzk1Mjc4Nw_0250abef-cf6e-44ea-8a60-684ae7b4f05f">68.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS02LTEtMS0wL3RleHRyZWdpb246NjY0MzMyNzNlZjU2NDJkY2IzMTNkZDkzN2Q2MjFiMzBfNjA0NzMxMzk1Mjc4Mg_7ca28ec2-ed2e-4c43-a290-dc97f3758a1e">66.5</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS02LTEtMS0wL3RleHRyZWdpb246NjY0MzMyNzNlZjU2NDJkY2IzMTNkZDkzN2Q2MjFiMzBfNjA0NzMxMzk1Mjc4Nw_06d65e16-45b9-4198-a587-5abebb3d16c7">73.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS04LTEtMS0wL3RleHRyZWdpb246M2M1NTRjODA0ZWE2NDdhNWIwYWNlYjY3YzQwZjk5OTdfNjA0NzMxMzk1Mjc4Mg_5684c172-4a66-4cad-a3ce-73e11c679fd4">66.7</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS04LTEtMS0wL3RleHRyZWdpb246M2M1NTRjODA0ZWE2NDdhNWIwYWNlYjY3YzQwZjk5OTdfNjA0NzMxMzk1Mjc4Nw_3ee83d90-5c0f-4ee6-bb35-9653f226f984">68.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi0yLTEtMS0wL3RleHRyZWdpb246YWMwNzgxZjYzMDZjNGUzNjgyODM0ZmNlOWMyNjI1OWJfNjA0NzMxMzk1Mjc3OA_2f908242-a141-4e12-bf6d-ead56abed440">0.4</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi0yLTEtMS0wL3RleHRyZWdpb246YWMwNzgxZjYzMDZjNGUzNjgyODM0ZmNlOWMyNjI1OWJfNjA0NzMxMzk1Mjc4NQ_308b8fea-c444-4f70-a608-b333b35b5207">0.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi00LTEtMS0wL3RleHRyZWdpb246YTFmYzFlZDE0OTk0NDY1ZWIzYjljNjA0MmVlNjRhMjNfNjA0NzMxMzk1Mjc5Ng_1b4f8ae7-1260-426b-b921-e756565b6f66">1.9</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi02LTEtMS0wL3RleHRyZWdpb246ZjMwNTgzZGQ5OTc3NDQwOTlkOTI5MGViYjdjNzZkNDJfNjA0NzMxMzk1Mjc4MA_d9f5d89a-46ad-45bf-a0fc-1e01c0764642">0.4</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi02LTEtMS0wL3RleHRyZWdpb246ZjMwNTgzZGQ5OTc3NDQwOTlkOTI5MGViYjdjNzZkNDJfNjA0NzMxMzk1Mjc4NQ_45d378fa-8bc3-4ac1-a6ac-1a850b0f5fce">1.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi04LTEtMS0wL3RleHRyZWdpb246MzBlMDE5NmY4OWFlNDllN2E0YWFkZDRjOTE5ODEwNGZfNjA0NzMxMzk1Mjc4MA_aa93c66a-f309-4381-b665-71d58e693e86">1.9</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi04LTEtMS0wL3RleHRyZWdpb246MzBlMDE5NmY4OWFlNDllN2E0YWFkZDRjOTE5ODEwNGZfNjA0NzMxMzk1Mjc4NQ_94d46c58-0978-481c-a834-8fbb9752e741">2.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="if9df8ef4afe54d51bb4c149ba983e328_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy0yLTEtMS0wL3RleHRyZWdpb246ZWIxYmViZmNiN2Y4NDRkMDg2MWFlNGU3MWI0MjUyOWRfNjA0NzMxMzk1Mjc3NA_90422a55-b123-4194-8475-d9cc02eb1cf0">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy00LTEtMS0wL3RleHRyZWdpb246NTI1OTkwOGEwOWJhNDM0OTg3OGY5MDg4OGU3MDgyYTlfNjA0NzMxMzk1Mjc3Ng_d7cac75c-4071-4351-afb2-c480c4fb701e">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy02LTEtMS0wL3RleHRyZWdpb246YTdkYzIzODAxN2JlNDA0YmEwNzAzZmE3MWVlODVmZmZfNjA0NzMxMzk1Mjc3Ng_91a766d8-2bc2-40f0-be30-a1e1339893df">&#8212;</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i4a0d4e0481d84fadaad8a7fe2f5e9afc_D20190101-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy04LTEtMS0wL3RleHRyZWdpb246M2U0MmQxZDg2YzdlNGVkNGFmMWQwYWE3YTVjNzMyYzJfNjA0NzMxMzk1Mjc3Ng_1bbd06e5-e879-4bad-836d-3303c2a713b8">&#8212;</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company&#8217;s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">:</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value of Common Stock</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividend Yield</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzU2Mg_36585516-a510-4e53-a29d-80c9f354186b">zero</ix:nonFraction>.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of MSUs</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of the MSUs was determined using a Monte Carlo simulation model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the following: </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="i382b608cf44b4687836782518abd326d" continuedAt="ia4cc1957750547799f476889c997b6e5"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risky Rate</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risky rate represents the Company's cost of equity.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Discount for Lack of Marketability </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of <ix:nonNumeric contextRef="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODI4MQ_40b5a172-f723-4a5d-980f-8b02d4fc8310">0.83</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODMxMA_96b7b614-5441-4c74-9091-889eb3b4bd70">2.07</ix:nonNumeric> years; expected volatility of <ix:nonFraction unitRef="number" contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODM2MQ_bc636b7a-864c-4f40-8e7c-53b40f50c047">65.5</ix:nonFraction>%; a risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODM2Nw_cff766df-d170-41ce-811f-1f3245aaa09f">0.5</ix:nonFraction>%; a <ix:nonFraction unitRef="number" contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODM3Mw_8ddeac5c-e859-4986-b045-8a1c5a60c340">zero</ix:nonFraction> dividend yield; a risky rate (cost of equity) of <ix:nonFraction unitRef="number" contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630" decimals="2" name="gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODQzMA_86ab9303-cbc9-4505-a9a1-6de0eed34dcf">16</ix:nonFraction>%; and a discount for post-vesting restrictions of <ix:nonFraction unitRef="number" contextRef="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODUzNg_ab06cc4a-fb37-4478-9f40-d25693f2e732">10.4</ix:nonFraction>% &#8211; <ix:nonFraction unitRef="number" contextRef="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODU0Mg_e73b957a-a639-4c33-873e-b67f9574e0a1">14.5</ix:nonFraction>%.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2018 Employee Stock Purchase Plan</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of <ix:nonFraction unitRef="shares" contextRef="i3ee695d4440547a7bfcb36de34921acc_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzc1Mw_6aab599f-f326-47ba-8290-c51f600399bf">922,250</ix:nonFraction> shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020, an additional <ix:nonFraction unitRef="shares" contextRef="id2402cd27c104ea38107f29820dae694_I20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzg3OQ_db786d15-1b80-4641-b907-ba14bf01fa64">942,614</ix:nonFraction>&#160;shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;<ix:nonFraction unitRef="number" contextRef="i050b6f2672cc4818903148e5e1bb1511_I20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDE1Nw_f58f45ad-194e-44fb-996f-1c083c8f93ba">10</ix:nonFraction>%&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;<ix:nonFraction unitRef="number" contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDMzMA_efe2e43f-1937-4396-9c27-6f07b4f8ad5b">85</ix:nonFraction>%&#160;of the fair market value of the Company&#8217;s  common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from October&#160;2, 2018 to January 31, 2019, the second offering period ran from February 1, 2019 to July 31, 2019, and the third offering period began on August 1, 2019 and ran to November 14, 2019. For subsequent years starting with 2020, the ESPP provides for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares of common stock purchased under the ESPP were <ix:nonFraction unitRef="shares" contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDM3NA_b001689b-ddd3-4015-be9c-b410d8119958">58,164</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDM4MQ_b706999f-e079-4b0b-9155-c98243915ec6">nil</ix:nonFraction> for the three months ended June 30, 2020 and 2019, respectively, and <ix:nonFraction unitRef="shares" contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDUxNg_1ba6b574-5132-470f-8fc7-d6b19dd409da">58,164</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDI0OA_fd1e774c-77b9-47f9-9660-e8c4ea24cd39">119,702</ix:nonFraction> for the six months ended June 30, 2020 and 2019, respectively. The total compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDMxNw_43e74a31-5b5c-42a2-981f-0451aecb7ede">1.1</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDU4Nw_f1c33c10-2987-4d2f-9b2f-8e2838b94a26">0.4</ix:nonFraction> million for the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTAzMQ_e2cf3555-0112-475a-9f92-f218e7bbd83d">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTAzOA_a1b41ba1-6413-46ec-bcd7-1e4e9e6cc5c6">1.0</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No ESPP shares were granted for the three months ended June 30, 2019. <ix:continuation id="id7d3f21b5b76434988d53204af9693c7" continuedAt="i1864a3c461224249979119b67043a1fc">The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</ix:continuation></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><ix:continuation id="i1864a3c461224249979119b67043a1fc"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:27.357%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.972%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.411%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.972%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.411%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.972%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.564%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.977%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)   </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC0yLTEtMS0xODcz_33c5a729-d7b1-4f15-bf1e-f9c5ca05e173">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC00LTEtMS0xODc4_c7c6297e-4456-4b27-bf34-a3a6652a4933">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC0yLTEtMS0xNzk0_4b1018ab-87b5-4ef6-b927-d0d3bea2fa9e">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC00LTEtMS0xNzk0_7e4cbdf8-a402-43da-874f-c9c9d8fe6dac">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility   </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS0yLTEtMS0xODcz_728f4acf-4faa-40e9-86f5-54d2f47b0169">73.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS00LTEtMS0xODc4_cc6d0455-a226-413a-b9b7-5c7e2b59a8c2">60.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS0yLTEtMS0xNzk0_dd1582c2-6a91-4890-a661-346c73333830">73.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS00LTEtMS0xNzk0_abb16f36-502a-43d5-8d45-0f85e94385f7">60.2</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate   </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi0yLTEtMS0xODcz_dc09cc1a-d56c-4947-8905-beaf4068c15b">0.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi00LTEtMS0xODc4_cd217925-2a84-4f89-b21e-4fc31f20fa5d">2.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi0yLTEtMS0xNzk0_38d16e35-f85c-4caf-91d6-2b24a65fe60b">0.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi00LTEtMS0xNzk0_9ef42f57-156d-4960-963e-bef0df7b1d97">2.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield   </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy0yLTEtMS0xODcz_eda613e1-8695-4b7f-802a-b958ff8728f7">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy00LTEtMS0xODc4_f4053e61-a92c-41d7-aeed-06f35d30ad74">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy0yLTEtMS0xNzk0_507d641b-122d-491b-a9ed-3bf6a342ab06">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy00LTEtMS0xNzk0_1fa1f138-fc6f-4adb-be17-82d1f1af0b98">&#8212;</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the unrecognized stock-based compensation expense related to the ESPP was $<ix:nonFraction unitRef="usd" contextRef="i050b6f2672cc4818903148e5e1bb1511_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTg0OQ_83aa0c3d-032c-4209-aaf7-eedaa32e4279">1.1</ix:nonFraction> million, which is expected to be recognized over the remaining term of the offering period of <ix:nonNumeric contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTkzOA_6eef1c22-f9e8-40bc-9a97-b44d12e4473e">0.4</ix:nonNumeric> years. </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><ix:continuation id="ia4cc1957750547799f476889c997b6e5"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liabilities for Early Exercise of Employee Options</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allowed certain stock option holders to exercise unvested options to purchase shares of the Company&#8217;s common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee&#8217;s employment termination, at the original issuance price, until the options are fully vested. As of June&#160;30, 2020 and December&#160;31, 2019, <ix:nonFraction unitRef="shares" contextRef="ib447deb7798c4703841cfadceacfb6f2_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="gh:CommonStockSubjecttoRepurchaseorCancellation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjMzMA_44c90bb4-a9ba-429e-ad9e-a2662c2a23d1">18,447</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="iad98bc19a43049ad9b63d15d678d5da0_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="gh:CommonStockSubjecttoRepurchaseorCancellation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjM0NA_2b0e8300-e1b3-426d-8373-87c0728b1988">23,981</ix:nonFraction> shares of common stock were subject to repurchase at weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i38994038d3c544e391545c7a4e7a5037_I20191231" decimals="2" name="gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjQyNg_ab66a6fa-65f1-42a5-8471-31c68e1a1631"><ix:nonFraction unitRef="usdPerShare" contextRef="i1238eed8c3a8409ea6755199b243129b_I20200630" decimals="2" name="gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjQyNg_e1d82abf-b9f9-4a14-9ea6-ad58db3fa3e6">4.66</ix:nonFraction></ix:nonFraction> per share. As of June&#160;30, 2020 and December&#160;31, 2019, the cash proceeds received for unvested shares of common stock of $<ix:nonFraction unitRef="usd" contextRef="i1238eed8c3a8409ea6755199b243129b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjUyMw_74fef261-b69c-48e4-ad17-e942ad9077c2">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38994038d3c544e391545c7a4e7a5037_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjUzMA_16680726-9826-4272-9e4f-56e489db641e">0.1</ix:nonFraction> million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheet, respectively. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the condensed consolidated balance sheet and condensed consolidated statement of redeemable noncontrolling interest and stockholders&#8217; equity as such shares are considered legally outstanding.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_91"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RleHRyZWdpb246OWVlZTQxZWZhZWVjNDJiNGJjZjE3YmM2NjNiY2MyODBfODMz_69c249c2-a904-4848-9e8a-d45353d42100" continuedAt="i8f216788ee064e239c131bdb0c9e0035" escape="true">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i8f216788ee064e239c131bdb0c9e0035"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RleHRyZWdpb246OWVlZTQxZWZhZWVjNDJiNGJjZjE3YmM2NjNiY2MyODBfODM0_5e23de7f-1378-431b-844a-d3a044e24030" escape="true"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.921%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.183%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS0yLTEtMS0xOTEz_ee98f325-0138-4505-b963-1c26b675aefc">49,739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS00LTEtMS0xOTE2_06bedb6c-31ee-44c9-ad76-27399a868457">11,300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS02LTEtMS0w_12bedb43-bc62-4f31-93ce-d8c6bb473ba7">81,568</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS04LTEtMS0w_c3efbf0d-37cf-4075-af0b-c9ac937c182c">32,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi0yLTEtMS0w_3fbbed0a-ac4c-45d2-8652-68edc3609113">4,900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi00LTEtMS0w_7fddc32c-243e-448f-a4f9-5269d4f5bb0f">300</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi02LTEtMS0w_7c8cd13c-c263-438a-a9d8-70ee3edc00e9">800</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi04LTEtMS0w_66770d39-23bf-4c47-82cd-695060636db4">5,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy0yLTEtMS0yNzIz_4ea0fc7d-93dd-4bad-ab95-e4e3ab40ace2">54,639</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy00LTEtMS0yNzI1_b784363a-b5d1-4f2c-95db-7bc495817c5f">11,600</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy02LTEtMS0w_780b18da-d061-4b93-8625-23625d427e06">82,368</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy04LTEtMS0w_960a0449-7b20-4105-9b9c-eadca6eb5641">37,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC0yLTEtMS0yNzIz_1e406511-4543-409d-9307-54d8e1398627">0.57</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC00LTEtMS0yNzI1_d86f7e90-02b2-463e-a80a-4a44e792a9eb">0.13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC02LTEtMS0w_a27d38bd-24bd-4c74-ba73-5691ca1cc79f">0.87</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC04LTEtMS0w_5f5af818-d612-426f-989c-cd669749cb48">0.43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS0yLTEtMS0w_3a246fa7-e9b2-437d-ba9d-3d42177c0fed">96,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS00LTEtMS0w_0b2a408e-2c63-43b4-8df9-851b2ae676a5">89,036</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS02LTEtMS0w_2f18180c-5d49-4e6f-ae1f-814660621a78">95,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS04LTEtMS0w_51552e7b-a6cf-4268-82c5-a3c02c9c1019">87,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. <ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RleHRyZWdpb246OWVlZTQxZWZhZWVjNDJiNGJjZjE3YmM2NjNiY2MyODBfODM2_f2364476-2848-4ba3-9ec0-f93466810249" continuedAt="id4f87d205411470f80dbea37cb452e6c" escape="true">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</ix:nonNumeric></span></div><div style="margin-top:5pt;margin-bottom:13pt;"><ix:continuation id="id4f87d205411470f80dbea37cb452e6c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.756%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.921%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.179%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.183%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaf536ddb35a64f85aacee7598268259c_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS0yLTEtMS0w_2d10a321-752e-419d-bc8d-8001e465936d">4,056</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3323a04942704687bb2555b54314aab2_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS00LTEtMS0w_ecc4232b-2844-48bb-ae33-e0a8e6800d84">6,313</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifd47da85e7de4d7fadfd20dc20f187d9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS02LTEtMS0w_608ba19b-b574-4617-9098-336939663c00">4,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie9d2e5e2fcdf4b2c8fc419d96dc58c5d_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS04LTEtMS0w_27d83d82-7bb6-46dc-be90-53296e772d58">6,908</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if8dbde309aa54633a3e4375f89ae690b_D20200401-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi0yLTEtMS0w_cd46f0bf-3336-4a54-a610-536fed742140">542</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i294c1765216e4c6a8e11a0d8b3daaa00_D20190401-20190630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi00LTEtMS0w_89799ba1-5813-41d5-9ba4-6ce9ef5a7f94">122</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6174d62dea8d4279975b861469129eef_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi02LTEtMS0w_551e7ed0-ae96-4c3f-ab3b-6e71954bd1d2">519</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaa43e28a9ae54214be7d361b2e4321cf_D20190101-20190630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi04LTEtMS0w_132b04c1-9cec-434a-aee3-e595f426136a">100</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MSUs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6c8ced2cd65f4b248f2b50a4b222ada8_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy0yLTEtMS01Mzgw_3e86da88-67e8-4601-92d2-17493c00a68e">1,342</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i71599760dfd541cabf39036748115634_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy00LTEtMS01Mzgw_b9d2a898-7d57-4e8b-a217-40b6954efb42">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i737cf94c5a8046d2a11b701014ec16db_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy02LTEtMS01Mzc3_ab4751d4-85fb-49bb-8453-253df2d91795">671</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8dec3173cbde4f96afc4de39bf38d895_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy04LTEtMS01Mzc3_0afe92c1-c289-40e1-bca3-4ed768170273">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8094e7366d1143b68620e23e39605cc1_D20200401-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy0yLTEtMS0w_dde3555d-5a8b-44b2-90ec-94d112fe52ad">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i638ebad1fa064de89eb9cef3d781bcf3_D20190401-20190630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy00LTEtMS0w_b0a4d963-bf93-4242-a715-996d9ca1c042">83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i13a797c312c54413b66a65e0d28b0956_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy02LTEtMS0w_5826bebe-5243-49a3-b4e7-11f09a7c539c">40</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d40935270e24e809f8b781d57808fc8_D20190101-20190630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy04LTEtMS0w_222c4c0b-0146-4099-9be2-3c5992a05d54">71</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i48e997052345498c87b595375bf8389a_D20200401-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC0yLTEtMS0w_26ce7559-a814-4d1f-aa0c-15382d48df5f">20</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic4547ce0781f4157886f48a25170a1bb_D20190401-20190630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC00LTEtMS0w_7058a5e5-8a4e-4289-b7c6-8c8fa8ba1d4d">32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia2d5b67d8d024c7a948a5649bb02e25b_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC02LTEtMS0w_7670552c-435c-48ba-8420-d43c9f8672d8">21</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i952e389dbc4144349e3163b45d8a21a5_D20190101-20190630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC04LTEtMS0w_99cd65cc-4fdd-4933-87dc-1ed78d03a5f5">37</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS0yLTEtMS0yNzMx_da238f04-f06c-4366-a8ad-7c324c8d22f9">5,997</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS00LTEtMS0yNzMz_2c974504-83e1-457c-9e26-585bdf1dc201">6,550</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS02LTEtMS0w_d183bb82-7c8b-476f-897d-5a5baf7e145c">5,451</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS04LTEtMS0w_c3d375b8-10b5-4920-9d32-575473eac1bc">7,116</ix:nonFraction></span></td></tr></table></ix:continuation></div></ix:continuation><div id="ib551ebaf812444a9a6979b345f863c2b_94"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.&#160;<ix:nonNumeric contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85NC9mcmFnOmQ4YTA2ZmI1MDk0ZTQ3N2JiZWRmZDU1ZGQ5YzI4NTIzL3RleHRyZWdpb246ZDhhMDZmYjUwOTRlNDc3YmJlZGZkNTVkZDljMjg1MjNfNTQ5NzU1ODE0MDQwMQ_03ddc491-f805-46ad-9cea-f1e66ec41a4c" continuedAt="i5b285bf1c19142118b1d29bb5c9f6675" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i5b285bf1c19142118b1d29bb5c9f6675" continuedAt="i5133e1afc96b4b8c829fc3ea7f7a869a"><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax expense for the three and six months ended June 30, 2020 was determined based upon estimates of the Company&#8217;s effective income tax rates in various jurisdictions. The difference between the Company&#8217;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.</span></div><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax expense for the three and six months ended June 30, 2020 relates primarily to state minimum income tax and income tax on the Company&#8217;s earnings in foreign jurisdictions. The benefit from income taxes for the six months ended June 30, 2019 relates primarily to the release of a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85NC9mcmFnOmQ4YTA2ZmI1MDk0ZTQ3N2JiZWRmZDU1ZGQ5YzI4NTIzL3RleHRyZWdpb246ZDhhMDZmYjUwOTRlNDc3YmJlZGZkNTVkZDljMjg1MjNfNDk0NzgwMjMyNTk2NQ_cfda2fa8-f6e2-48c8-a90c-5fba621f7cfd">1.2</ix:nonFraction>&#160;million associated with nondeductible intangible assets recorded as part of the Bellwether Bio acquisition, partially offset by state minimum income tax and income tax on the Company's earnings in foreign jurisdictions. In connection with the acquisition of Bellwether Bio, a deferred tax liability was established for the book-tax basis differences related to the non-goodwill intangible assets. The net deferred tax liability from this acquisition creates an additional source of income to offset the Company&#8217;s deferred tax assets. As such, the impact on the acquiring Company&#8217;s deferred tax </span></div></ix:continuation><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5133e1afc96b4b8c829fc3ea7f7a869a">assets and liabilities caused by an acquisition are recorded in the acquiring company&#8217;s consolidated financial statements outside of acquisition accounting.</ix:continuation> </span></div><div id="ib551ebaf812444a9a6979b345f863c2b_97"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">14.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RleHRyZWdpb246ZjViNjdhZGVlYTEwNGIzZGIwMzM5ZDc5NjM1MzQ0ZWRfNTA0_35f87bd8-30b9-44ad-a868-852cf8e72ffc" continuedAt="i92658a82f8564bf2984c838b23623e4e" escape="true">Segment and Geographic Information</ix:nonNumeric></span></div><ix:continuation id="i92658a82f8564bf2984c838b23623e4e"><ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RleHRyZWdpb246ZjViNjdhZGVlYTEwNGIzZGIwMzM5ZDc5NjM1MzQ0ZWRfNTA3_00af7030-a1c3-45f9-86d3-36fc630cee06" escape="true"><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:38.064%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.102%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.921%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.106%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a05f1e0143d47aa8aac871e977a2d93_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS0yLTEtMS0w_076b8b83-6263-4a4c-8716-06b296ede816">61,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id56241c9ef5b4e06a9097eaf342ad306_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS00LTEtMS0w_b01edafe-a5e4-4432-8941-7e99f40e288c">48,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95d2e07d74ee40dcbd0c515fc3ac73ea_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS02LTEtMS0w_1adeb9c4-5b3a-4efa-bd6b-f348b326d1ea">126,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7989738be28147c79edc5a175133e7e7_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS04LTEtMS0w_448b7987-21d0-4865-b2cb-830ea0f62ba7">80,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">International </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">(1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9c900bb63484126aeed5864a3482233_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi0yLTEtMS0w_787c8c34-d73d-4470-a5ea-fe8dec923a57">4,913</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5853898710f74fc98551c4698099ad34_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi00LTEtMS0w_3d112d09-07e8-4cbb-addf-c23acf65d652">4,978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15ab6406ad7b4d44aea212764d7260e3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi02LTEtMS0w_02f29da0-58f9-439b-8918-205148bd1244">7,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie60db419cf834ec9b927bf239d7a59ab_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi04LTEtMS0w_cdaa91ff-1827-4e52-8d7f-b43c9b068c5d">10,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy0yLTEtMS0yNzM3_4fd14be9-fd9d-4db2-b23c-07789bc7e885">66,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy00LTEtMS0yNzM5_2a62bce1-3ecb-4af0-a234-d96cb64ba055">53,975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy02LTEtMS0w_13f2340c-ed94-4e46-ad3b-a7074d747631">133,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy04LTEtMS0w_ef377476-532b-4bc1-a54c-7147daca52b3">90,630</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">(1)&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June&#160;30, 2020&#160;and&#160;2019, respectively.</span></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, substantially all of the Company&#8217;s long-lived assets and right-of-use assets are located in the United States.</span></div></ix:continuation><div style="text-align:justify;margin-bottom:8pt;"><span><br/></span></div><div id="ib551ebaf812444a9a6979b345f863c2b_100"></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.&#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNDU_d3e83ed7-7f72-4502-8c80-c9d8c72ca755" continuedAt="ic9a134b0cabf428e8b2616943734d721" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ic9a134b0cabf428e8b2616943734d721"><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 3, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investment in Joint Venture</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company and its subsidiaries may, in the ordinary course of business, have transactions with unaffiliated companies of which certain of the Company&#8217;s directors are directors and/or executive officers. The Company believes that such transactions are on the same terms generally offered by such other companies to other entities in comparable transactions. The Company does not consider the amounts involved in such transactions to be material in relation to its businesses, the businesses of such other companies or the interests of the directors involved. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Revenue from an entity affiliated with a member of the Company's Board of Directors was $<ix:nonFraction unitRef="usd" contextRef="i0bb034afda014a85b1b0e2b6b26d774f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjUzOTE_71249009-6cb5-445e-9c68-f94c61773cb5">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i00416340ee41460f89b3b8e7094a4e0c_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0MDE_b9bfdb1d-84ca-49c2-982a-fdb8e04b93af">0.5</ix:nonFraction> million for the three months ended June 30, 2020 and 2019, and $<ix:nonFraction unitRef="usd" contextRef="ibc0fce7baca6420eadd2052f4a00b6f8_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0MTE_e8961e55-c2a8-42c6-885d-391b80bbc47a">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0ada0d183d4f48bf8c719b83d32cc159_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0Mzc_b0a0bb96-f5b0-42af-85ac-be02e49d4f16">0.9</ix:nonFraction> million for the six months ended June 30, 2020 and 2019. As of June&#160;30, 2020 and December&#160;31, 2019, the Company has accounts receivable from this entity of $<ix:nonFraction unitRef="usd" contextRef="i5b4a8e61a1034084959a4fd4db4b38f7_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0NzI_36ffcf58-e1ab-445d-a014-3504f54eaa78">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i604a260fb2ce4d20bb48257e8df58cfe_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU1MDA_e9aaf9f0-71f0-4ac8-9b25-21d1813e116b">0.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">16. &#160;<ix:nonNumeric contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNDY_656bb9a2-bd38-4b83-86aa-a702b915a32b" continuedAt="i8ca9479b2661482180ad9db86aa60614" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i8ca9479b2661482180ad9db86aa60614">The Company entered into <ix:nonFraction unitRef="numberofleases" contextRef="ie657fc31977a42088ce4640db6c02671_I20200731" decimals="INF" format="ixt-sec:numwordsen" name="gh:NumberOfOperatingLeasesLeaseNotYetCommenced" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzIxOTkwMjMyNjc5MjM_237bcb11-136a-4ab1-be7a-430ad5a1da00">two</ix:nonFraction> new agreements in July 2020 to lease additional office and laboratory space. The lease agreements each have a target commencement date in the first half of fiscal year 2021, with estimated aggregate base rent payments of $<ix:nonFraction unitRef="usd" contextRef="ib850ca5924ca4d90bd09e86c08ec11ba_D20200701-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNDg_f45afd41-b715-40c4-96b8-a833a9ed6171">239.5</ix:nonFraction>&#160;million over the weighted average estimated lease term of <ix:nonNumeric contextRef="ib850ca5924ca4d90bd09e86c08ec11ba_D20200701-20200731" format="ixt-sec:duryear" name="gh:LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNjM_0802d6d5-f0a7-4789-91e2-28f565c58a22">11.5</ix:nonNumeric> years. One of the lease agreements provides an option to renew the lease term for an additional <ix:nonNumeric contextRef="ie657fc31977a42088ce4640db6c02671_I20200731" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyOTQ_a7db1499-76c1-4195-b32a-0c3453972233">ten years</ix:nonNumeric>. The Company is currently evaluating the accounting for such leases.</ix:continuation>  </span></div><div id="ib551ebaf812444a9a6979b345f863c2b_103"></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_106"></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, beliefs, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">and in Part II, Item 1A, &#8220;Risk Factors&#8221;  of our Quarterly Report on Form 10-Q for the period ended March&#160;31, 2020.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="ib551ebaf812444a9a6979b345f863c2b_109"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we launched our Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. Our Guardant360 test, launched in 2014, has been used by more than 7,000 oncologists, over 50 biopharmaceutical companies and all 28 National Comprehensive Cancer Network, or NCCN, Centers. More than 150,000 Guardant360 tests have been performed to date. Using data collected from our Guardant360 tests, we have also developed our GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker-driven cancers. Our GuardantOMNI test, launched in 2017, has been used by our biopharmaceutical customers as a comprehensive genomic profiling tool to help accelerate clinical development programs in both immuno-oncology and targeted therapy.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Guardant360 and GuardantOMNI tests fuel development of our LUNAR program. Our LUNAR-1 assay is intended to address identification of those who are likely to benefit from adjuvant treatment, detection of minimal residual disease in the blood of cancer patients after surgery, and surveillance of patients who have completed curative cancer treatment to potentially detect recurrence at an earlier stage, and was launched in 2018 for research use and in late 2019 for investigational use. To help demonstrate the utility of our LUNAR-1 assay, we have initiated multiple clinical trials to evaluate recurrence-free survival in patients who receive ctDNA-directed therapy as compared to the current standard-of-care active surveillance. We are developing our LUNAR-2 assay to address early cancer detection in screening eligible asymptomatic individuals and higher risk individuals. Recent data reported at the 2019 National Colorectal Cancer Roundtable shows that although the percentage of U.S. adults who are up to date with recommended colorectal cancer screening has gradually increased from approximately 65% in 2012 to approximately 69% in 2018, this falls short of the 80% screening compliance goal set by the Centers for Disease Control and Prevention. Our LUNAR-2 assay recently demonstrated an average sensitivity of approximately 90%, with specificity of approximately 97%, in a case-control cohort of 113 recently diagnosed patients with stages I, II or III colorectal cancer and 88 colonoscopy-screened negative controls. Recent data reported at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting shows improved performance of the LUNAR-2 assay to detect early-stage colorectal cancer in average-risk adults.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In a blinded cohort analysis of colonoscopy screened negative patients (n=88) and patients newly diagnosed with early stage colorectal cancer (n=113) using a further optimized, integrated genomic and epigenomic analysis, the LUNAR-2 assay demonstrated overall sensitivity of 90.3% and overall specificity of 96.6%. Recent data presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting shows that the LUNAR-2 assay achieved 90% sensitivity and 94% specificity in detecting early-stage colorectal cancer. When restricting analysis of the controls to those who were negative for colorectal cancer by colonoscopy (n=74), the LUNAR-2 assay demonstrated improved specificity (99%) with no reduction in sensitivity.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our GuardantOMNI test has a broader 500-gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications, such as tumor mutational burden and microsatellite instability, and has achieved comparable analytical performance in clinical studies, including for translational science applications in collaboration with several biopharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Merck MSD, Merck KGaA of Darmstadt, Germany and Pfizer.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Guardant360 and GuardantOMNI tests have each been designated by the FDA as a breakthrough device for use as a companion diagnostic in connection with certain specified therapeutic products of our biopharmaceutical customers. Among other things, designation as a breakthrough device provides for priority review by the FDA and more interactive communication with the FDA during the development process. Our Guardant360 and GuardantOMNI tests are both being developed as companion diagnostics under collaborations with biopharmaceutical companies, including AstraZeneca, Amgen, Janssen Biotech and Radius Health.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We perform our Guardant360, GuardantOMNI and other tests in our clinical laboratory located in Redwood City, California. Our laboratory is certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, permitted by the New York State Department of Health, or NYSDOH, and licensed in California and four other states.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The analytical and clinical data that we have generated in our efforts to establish clinical utility, combined with the support we have developed with key opinion leaders, or KOLs, in the oncology space have led to positive coverage decisions by a number of commercial payers. Our Guardant360 test is currently covered by Cigna, Priority Health, multiple Blue Cross Blue Shield plans as well as the health plans associated with eviCore, which have adopted policies that specifically cover Guardant360 test for non-small cell lung cancer, or NSCLC, which we believe gives us a competitive advantage with these payers.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2018, Palmetto GBA, or Palmetto, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare&#8217;s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test for qualifying NSCLC patients. Subsequently in 2018, Noridian Healthcare Solutions, or Noridian, a participant in MolDx and the MAC responsible for adjudicating claims in California, where our laboratory is located, also finalized its LCD for our Guardant360 test. Pursuant to this Noridian LCD, in September 2018, we began to submit claims for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under the LCD, and in October 2018, we began to receive payments for these services from Medicare.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, Palmetto finalized its expanded LCD for our Guardant360 test to provide limited Medicare coverage for use of Guardant360 for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin. In May 2019, Noridian also issued an expanded draft LCD for our Guardant360 test consistent with the expanded draft LCD issued by Palmetto in March 2019. In May 2020, Noridian issued a coverage article and confirmed limited Medicare coverage for our Guardant360 test for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin. Noridian also retired the expanded draft LCD issued in May 2019 as being superseded by the coverage article. We estimate that approximately 85% of Medicare patients are covered under the coverage article issued by Noridian</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in May 2020.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain commercial insurance payors have issued decisions to cover the use of Guardant360 for patients with NSCLC.  For the three months ended June 30, 2020 and 2019, respectively, approximately 42% and 46% of our U.S. clinical tests&#160;were for patients tested for NSCLC, and for the six months ended June 30, 2020 and 2019, respectively, approximately 43% and 46% of our U.S. clinical tests&#160;were for patients tested for NSCLC.</span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the United States, we market our tests to clinical customers through our sales organization, which is engaged in sales efforts and promotional activities primarily targeting oncologists and cancer centers. Outside the United States, we market our tests to clinical customers through distributors and direct contracts with healthcare institutions. We also market our tests to biopharmaceutical customers globally through our business development team, which promotes the broad utility of our tests throughout drug development and commercialization. Additionally, we have established a joint venture with SoftBank to accelerate commercialization of our products including in Asia, the Middle East and Africa, with our initial focus being on Japan. Our products are currently marketed in approximately 40 countries.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent global outbreak of coronavirus 2019, or COVID-19, has disrupted, and we expect will continue to disrupt, our operations. To protect the health and well-being of our workforce, partners, vendors and customers, we have provided </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">free COVID-19 testing for employees working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed California&#8217;s &#8220;shelter in place&#8221; public health orders and the guidance from the Centers for Disease Control and Prevention. Employees who can perform their duties remotely are asked to work from home and those on site are asked to follow our social distance guidelines. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sales, marketing and business development efforts are also constrained by our operational response to the COVID-19 pandemic. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to adjust our operational norms in an effort to help slow the spread of </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">COVID-19 in the coming months, including complying with government directives and guidelines as they are modified and supplemented.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The COVID-19 global pandemic also has started to negatively affect, and we expect will continue to negatively affect, our revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of COVID-19. Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we have been receiving fewer samples for testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, our clinical studies, especially those such as our ECLIPSE trial and the COBRA study that are deemed as preventive care or are not part of a standard of care, as well as our development services arrangements with our biopharmaceutical customers, are expected to take longer to complete, if at all, than what we expected before the outbreak of the COVID-19 pandemic. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The limited availability of broad-based COVID-19 diagnostic testing has hindered recovery efforts to date. As a result, in early April 2020 we initiated a feasibility assessment that has included our research and development team working to determine our ability to bring a new COVID-19 test to market utilizing our current laboratory facilities, as well as our outreach to potential public and private partners for their assistance in operationalizing such test. As part of the initial progress of this assessment, in June 2020 we submitted an Emergency Use Authorization (EUA) package to the FDA for our nasopharyngeal Guardant-19 SARS-CoV-2 test, or Guardant-19 test. We launched the Guardant-19 test as a CLIA-certified test operating under the FDA&#8217;s emergency use authorization to test our employees and made it available to a limited number of third parties for testing. However, we cannot predict the extent to which the Guardant-19 test will be used by third parties and have not yet determined the scale and financial elements of this program. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ultimate impact of the COVID-19 pandemic on our business and financial condition will depend on many factors, including the duration of the outbreak and the mitigation requirements affecting our operations, and healthcare delivery and society in general. As a result, we expect our revenue and results of operations to be adversely affected until testing, treatments and vaccines substantially eliminate the impact of the COVID-19 pandemic.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generated total revenue of $66.3 million and $54.0 million for the three months ended June 30, 2020 and 2019, respectively, and $133.8 million and $90.6 million for the six months ended June 30, 2020 and 2019, respectively. We also incurred net losses of $49.7 million and $11.3 million for the three months ended June 30, 2020 and 2019, respectively, and $81.6 million and $32.7 million for the six months ended June 30, 2020 and 2019, respectively. We have funded our operations to date principally from the sale of our stock and revenue from our precision oncology testing and development services. In June 2020, we completed an underwritten public offering, where we sold 4,312,500 shares of our common stock at a price of $84.00 per share and received net proceeds of approximately $354.6&#160;million after deducting underwriting discounts, commissions and offering expenses payable by us. As of June&#160;30, 2020, we had cash, cash equivalents and marketable securities of $1.1 billion.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_112"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Factors affecting our performance</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Testing volume, pricing and customer mix. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of tests that we perform for patients on behalf of clinicians and the number of tests we perform for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly affect our results of operations, as the average selling price for biopharmaceutical sample testing is currently higher than our average selling price for clinical tests because we are not a contracted provider for, or our tests are not covered by clinical patients&#8217; insurance for, the majority of the tests that we perform for patients on behalf of clinicians. Approximately 37% and 38% of our U.S. clinical tests for the three months ended June 30, 2020 and 2019, respectively, and approximately 37% and 38% of our U.S. clinical tests for the six months ended June 30, 2020 and 2019, respectively, were for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Medicare beneficiaries.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt;">Regulatory approval. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our Guardant360 test was the first comprehensive liquid biopsy test approved by NYSDOH. In addition, we believe our facility was the first comprehensive liquid biopsy laboratory to be CLIA-certified, CAP-accredited and NYSDOH-permitted. In the fourth quarter of 2019, we submitted a premarket approval, or PMA, application to seek the FDA&#8217;s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA. Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established in 2018 and subsequently updated in 2020 provides coverage for molecular diagnostic tests such as our Guardant360 test, if, among other criteria, such tests are offered within their FDA-approved companion diagnostic labeling. We believe that this establishes a competitive advantage for tests receiving FDA approval and that FDA approval will be increasingly necessary for diagnostic tests to gain adoption, both in the United States and abroad. We believe FDA approval, if obtained, will help increase adoption of our tests and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">facilitate favorable reimbursement decisions by Medicare and commercial payers. We also intend to pursue regulatory approvals in specific markets outside of the United States, including in Europe, Japan and China. Any negative regulatory decisions or changes in regulatory requirements affecting our business could adversely impact our operations and financial results.</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Payer coverage and reimbursement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. Payment from commercial payers can vary depending on whether we have entered into a contract with the payers as a &#8220;participating provider&#8221; or do not have a contract and are considered a &#8220;non-participating provider.&#8221; Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of commercial payers, most of which have not contracted with us to be a participating provider. We have received reimbursement for tests of patients with a variety of cancers, though for amounts that on average are significantly lower than for participating providers. We have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our test and, potentially, no reimbursement for non-covered uses identified under the payer&#8217;s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. Current Procedural Terminology, or CPT, coding plays a significant role in how our Guardant360 test is reimbursed both from commercial and governmental payers. Changes to the codes used to report the Guardant360 test to payers may result in significant changes in its reimbursement. If our Guardant360 test receives approval from the FDA, we may be required to obtain a new code to report the Guardant360 test on claims submitted to U.S. payers. If a coding change were to occur, payments for certain uses of the Guardant360 test could be reduced or eliminated by such payers. Cigna, Priority Health, multiple Blue Cross Blue Shield plans as well as the health plans associated with eviCore adopted policies that cover our Guardant360 test for the majority of NSCLC patients we test. If their policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase. In September 2018, we began to submit claims to Medicare for reimbursement with respect to Guardant360 clinical tests performed for NSCLC patients covered under the 2018 Noridian LCD, and in October 2018, we began to receive payments from Medicare</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for these clinical tests. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, we began to receive reimbursement from Medicare for claims submitted, with respect to Guardant360 clinical tests performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin other than NSCLC. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, Noridian issued a coverage article and confirmed limited Medicare coverage for our Guardant360 test for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin who meet the criteria of Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established in March 2018. Noridian also retired the draft LCD issued in May 2019 as being superseded by the coverage article. Future actions taken by Noridian or Palmetto may change Medicare coverage for our Guardant360 test. We estimate total coverage in the United States for the Guardant360 test to be more than 180 million lives, including Medicare&#160;beneficiaries and members of&#160;several commercial health plans. If we fail to obtain or maintain coverage and adequate reimbursement from third-party payers, including from Medicare, we may be unable to increase our testing volume and revenue as expected. Retrospective reimbursement adjustments, such as deductions from further payments and&#160;clawbacks, can also negatively impact our revenue and cause our financial results to fluctuate. Due to the inherent variability of the insurance landscape, historic </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">success of, and payments from, appeals of reimbursement denials by payers are not indicative of future success of and payments from such appeals.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Biopharmaceutical customers. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue also depends on our ability to attract new, and to maintain and expand relationships with existing, biopharmaceutical customers, and we expect to increase our sales and marketing expense in furtherance of this goal. As we continue to develop these relationships, we expect to support a growing number of clinical trials both in the United States and internationally. If our relationships expand with biopharmaceutical customers, we believe we may continue to have opportunities to offer our platform to such customers for companion diagnostic development, novel target discovery and validation as well as clinical trial enrollment, and to grow into other business opportunities. For example, we believe that our genomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, supporting novel drug development and companion diagnostic development.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">Research and development. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A significant aspect of our business is our investment in research and development, including the development of new products, such as those being developed as part of our LUNAR program. In particular, we have invested heavily in clinical studies, including more than 50 clinical outcomes studies, the largest-ever liquid-to-tissue concordance study, and a prospective interventional clinical utility study demonstrating clinical overall response rates in line with tissue biopsy approaches. Our clinical research has resulted in over 150 peer-reviewed publications. With respect to our LUNAR program, we initiated a prospective screening study, which we refer to as the ECLIPSE trial, aiming to recruit approximately 10,000 patients and evaluate the performance of our LUNAR-2 assay in detecting colorectal cancer in average-risk adults, and in collaboration with a National Clinical Trials Network group, initiated a prospective multi-center randomized controlled trial, which we refer to as the COBRA study, in approximately 1,400 patients with resected stage II colon cancer to use our LUNAR-1 assay to evaluate recurrence-free survival in patients who receive ctDNA-directed therapy as compared to the current standard-of-care active surveillance. Furthermore, we are collaborating with investigators from multiple academic cancer centers, including MD Anderson Cancer Center, the University of Colorado, Memorial Sloan Kettering Cancer Center, Massachusetts General Cancer Center, Wake Forest Cancer Center and the University of California San Francisco, as well as several international institutions. The COVID-19 global pandemic has negatively impacted, and is expected to continue to negatively impact, the recruitment for clinical studies, especially those that are deemed as preventive care or are not part of a standard of care, including the ECLIPSE trial and the COBRA study. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers, and expect our investments in clinical studies to increase. We expect to increase our research and development expense with the goal of fueling further innovation.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">International expansion. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy. We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals. In May 2018, we formed and capitalized a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, with SoftBank, relating to the sale, marketing and distribution of our tests generally outside the&#160;Americas&#160;and Europe. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with our initial focus being on Japan. That effort could be negatively impacted by the COVID-19 global pandemic.</span></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt;">General and administrative expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our general and administrative expense, and in particular, our stock-based compensation expense. For example, in May 2020, our Board of Directors approved the grant of a long-term market-based restricted stock unit award to our Chief Executive Officer and our President and Chief Operating Officer (the &#8220;Founders&#8221;). The Founders each received a grant of 1,695,574 market-based restricted stock units which consist of three separate tranches and the vesting of each tranche is subject to the closing price of our common stock closing price being maintained at or above a pre-determined stock price goal for a period of 30 consecutive calendar days any time during the seven-year performance period. Our equity awards, including the Founders&#8217; market-based restricted stock units, are intended to retain and incentivize employees to lead us to sustained, long-term superior financial and operational performance. The market-based restricted stock units, in particular, were designed to focus the Founders on our long-term operational and strategic development, including the successful development and commercialization of our LUNAR program. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A,&#160;&#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December&#160;31, 2019, and Part II, Item 1A, &#8220;Risk Factors&#8221; of our Quarterly Report on Form 10-Q for the period ended March 31, 2020, for more information.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_1568"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Non-GAAP Financial Measure  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;Adjusted EBITDA&#8221;), a non-GAAP financial measure is a key metric to assess period-to-period comparison in evaluating the performance of our core business </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">by removing the impact of income (expenses) attributable to material non-cash items, specifically stock-based compensation and fair value remeasurements due to the subjectivity, management judgment, and market fluctuations involved around these amounts. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We exclude certain other items because we believe that these income (expenses) do not reflect expected future operating expenses. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance.   </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8220;Adjusted EBITDA&#8221; is defined by us as net loss attributable to Guardant Health, Inc. common stockholders before: (i) interest income, (ii) interest expense, (iii) provision for (benefit from) income taxes, (iv) depreciation and amortization expense, (v) other (income) expense, net, (vi) stock-based compensation expense, (vii) A</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">djustments relating to non-controlling interest and contingent consideration </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and, if applicable in a reporting period, and (viii) acquisition-related expenses, and other non-recurring items. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our use of Adjusted EBITDA as a non-GAAP financial measure is not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measure prepared in accordance with GAAP and you should not consider it in isolation or substitute for analysis of our results reported under GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of non-GAAP financial measures may differ from non-GAAP measures used by other companies.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles net loss attributable to Guardant Health, Inc. common stockholders (which is the most directly comparable GAAP operating financial measure) to Adjusted EBITDA.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.823%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss attributable to Guardant Health, Inc. common stockholders</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,639)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,600)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(82,368)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,651)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustments:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,640)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,099)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,958)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,584)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">580&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income) expense, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,285)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,076)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(96)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for (benefit from) income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,207)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,181)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,805&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,657&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,109&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,815&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustments relating to noncontrolling interest and contingent consideration</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Acquisition related expenses</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"> </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Adjusted EBITDA (non-GAAP)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,974)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,753)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,101)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%;">(1) For the six months ended June&#160;30, 2020, acquisition related expenses consist of a dispute settlement expense of $1.2 million and IPR&amp;D technology write off for $8.5 million incurred for the three months ended March 31, 2020 in connection with a settlement and a license purchase agreement. For the three and six months ended June&#160;30, 2019, acquisition related expenses of $0.4 million primarily include certain diligence, accounting, and legal expenses incurred related to our Bellwether acquisition.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_115"></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Components of results of operations</span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We derive our revenue from two sources: (i) precision oncology testing and (ii) development services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Precision oncology testing.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Precision oncology testing revenue is generated from sales of our Guardant360 and GuardantOMNI tests to clinical and biopharmaceutical customers. In the United States, through June&#160;30, 2020, we generally performed tests as an out-of-network service provider without contracts with health insurance companies. We submit claims for payment for tests performed for patients covered by U.S. private payers. We submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin who meet the criteria of Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established in March 2018. Tests for patients covered by Medicare represented approximately 37% and 38% of U.S. tests performed during the three months ended June 30, 2020 and 2019, respectively, and 37% and 38% of U.S. tests performed during the six months ended June 30, 2020 and 2019, respectively. We also provide precision oncology testing to biopharmaceutical customers under contracts for which all recognition criteria are met, and we have recognized revenue on an accrual basis for those services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Development services</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Development services revenue represents services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions. It includes companion diagnostic development and regulatory approval services, clinical trial referrals and liquid biopsy testing development and support. We collaborate with biopharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. Development services revenue can vary over time as different projects start and complete.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Costs and operating expenses</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of precision oncology testing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;Cost of precision oncology testing generally consists of cost of materials, direct labor, including bonus, benefit and stock-based compensation; equipment and infrastructure expenses associated with processing liquid biopsy test samples, including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples; freight; curation of test results for physicians; and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing our tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to the tests. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents.&#160;While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect the cost of precision oncology testing to generally increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of development services</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;Cost of development services includes costs incurred for the performance of development services requested by our customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of revenue. Cost of development services will vary depending on the nature, timing and scope of customer projects.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Research and development expenses consist of costs incurred to develop technology and include salaries and benefits including stock-based compensation, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, other outside costs and costs to develop our technology capabilities. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical companies before technological feasibility has been achieved. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">services are rendered. Costs to develop our technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical trials with a particular focus on our LUNAR program.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales and marketing expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.&#160;Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, medical affairs, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel expenses and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our Guardant360 and GuardantOMNI tests. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative expense</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Our general and administrative expenses include costs for our executive, accounting and finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We expect that our general and administrative expenses will continue to increase in absolute dollars, primarily due to increased stock-based compensation expense, including resulting from the market-based restricted stock units granted to our Founders in May 2020, increased headcount and increased costs associated with operating as a growing public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses being incurred.</span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest income</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income consists of interest earned on our cash, cash equivalents and marketable securities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest expense</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense consists primarily of interest from finance leases or capital leases and royalty obligations.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other income (expense), net</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Other income (expense), net consists of foreign currency exchange gains and losses and the relief fund grant from the Department of Health and Human Services, or HHS, under the U.S. Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_118"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of operations</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table set forth the significant components of our results of operations for the periods presented.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.512%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Precision oncology testing</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development services</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,344&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,729&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total revenue</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Cost of precision oncology testing</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,809&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,650&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of development services</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,626&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,183&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Research and development expense</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,532&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Sales and marketing expense</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,130&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">General and administrative expense</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total costs and operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">120,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,243&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">223,377&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">129,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Loss from operations</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,620)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,268)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(89,532)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,932)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,958&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(287)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(580)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Loss before provision for income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,705)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,507)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,832)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Provision for (benefit from) income taxes</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,207)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,181)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,739)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,300)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32,651)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt;">Amounts include stock-based compensation expense as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.512%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.820%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of precision oncology testing</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sales and marketing expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">646&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:38.25pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total stock-based compensation expense</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,815&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comparison of the Three Months Ended June 30, 2020 and 2019</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Precision oncology testing</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,064&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development services</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,344&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue was $66.3 million for the three months ended June 30, 2020 compared to $54.0 million for the three months ended June 30, 2019, an increase of $12.4 million, or 23%.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Precision oncology testing revenue increased to $51.0 million for the three months ended June 30, 2020 from $42.1 million for the three months ended June 30, 2019, an increase of $8.9 million, or 21%. This increase in precision oncology testing revenue was primarily due to an increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in average selling price per test as a result of expanded coverage of our tests for clinical customers, plus $2.6 million in revenue received during the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> from Medicare for samples processed in 2019 up from $1.4 million in revenue received during the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three months ended June 30, 2019 from Medicare for samples processed in 2018.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Precision oncology revenue from tests for clinical customers was </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$39.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$21.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">three months ended June 30, 2019,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> respectively. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Tests for clinical customers increased to 13,694 for the three months ended June 30, 2020 from 11,875 for the three months ended June 30, 2019 mainly due to an increase in the number of physicians ordering Guardant360 t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ests. In March 2020, we began to receive reimbursement from Medicare for claims submitted with respect to Guardant360 clinical tests performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin other than NSCLC. In </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">May 2020, Noridian issued a coverage article and confirmed limited Medicare coverage for our Guardant360 test for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin who meet the criteria of Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established in March 2018</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Precision oncology revenue from tests for biopharmaceutical customers was $11.4 million in the three months ended June 30, 2020 and $20.2 million in the three months ended June 30, 2019, respectively. Tests for biopharmaceutical customers decreased to 2,805 for the three months ended June 30, 2020 from 5,285 for the three months ended June 30, 2019 primarily due to the timing and progression of clinical trials and studies which resulted in fluctuation in the number of samples received for testing. The average selling price of biopharmaceutical tests was $4,054 for the three months ended June 30, 2020, up from $3,827 for the three months ended June 30, 2019 due to a greater proportion of such tests being the GuardantOMNI test, which has a higher selling price than the Guardant360 test.  As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we began receiving fewer samples for testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Our future sample volumes and precision oncology revenue may be adversely impacted by the COVID-19 pandemic depending on the duration and severity of the pandemic.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development services revenue increased to $15.3 million for the three months ended June 30, 2020 from $11.9 million for the three months ended June 30, 2019, an increase of $3.4 million, or 29%. This increase in development services revenue was due to new collaboration projects from biopharmaceutical customers for companion diagnostic development and regulatory approval services during the three months ended June 30, 2020. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ur development services arrangements with biopharmaceutical customers and development services revenue may be adversely impacted by the COVID-19 pandemic in future periods.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Costs and operating expenses</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of revenue</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross profit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross margin</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span><br/></span></div></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of revenue was $22.4 million for the three months ended June 30, 2020 compared to $16.8 million for the three months ended June 30, 2019, an increase of $5.6 million, or 33%.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of precision oncology testing revenue was $17.8 million for the three months ended June 30, 2020 compared to $14.7 million for the three months ended June 30, 2019, an increase of $3.2 million, or 22%. This increase in cost of precision oncology testing was attributable to an increase in sample volumes and was primarily due to a $3.2 million increase in production labor and overhead costs.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of development services was $4.6 million for the three months ended June 30, 2020 compared to $2.2 million for the three months ended June 30, 2019, an increase of $2.4 million, or 112%. This increase in cost of development services was primarily due to an increase in material and labor costs related to companion diagnostic development and regulatory approval service contracts.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">Gross margin for the three months ended June 30, 2020 was 66% compared to 69% for the three months ended June 30, 2019. The decrease in gross margin was primarily due to overall increase in the costs related to companion diagnostic programs. We expect our gross margin to be adversely impacted by the COVID-19 pandemic for the affected periods. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expense</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,532&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,787&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses were $36.3 million for the three months ended June 30, 2020 compared to $19.5 million for the three months ended June 30, 2019, an increase of $16.8 million, or 86%. This increase in research and development expense was primarily due to an increase of $7.5 million in personnel-related costs for employees in our research and development group, including a $1.2 million increase in stock-based compensation, as we increased our headcount to support continued investment in our technology. The increase is also attributable to an increase of $4.7 million in material costs, an increase of $2.6 million in development consulting fees, an increase of $1.5 million related to allocated facilities and information technology infrastructure costs and an increase of $0.2 million in office administrative costs as we increased our headcount to support continued investment in our technology.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales and marketing expense</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales and marketing</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling and marketing expenses were $25.0 million for the three months ended June 30, 2020 compared to $19.4 million for the three months ended June 30, 2019, an increase of $5.6 million, or 29%. This increase was primarily due to an increase of $3.9 million in personnel-related costs, including a $1.5 million increase in stock-based compensation, associated with the expansion of our commercial organization. The increase is also attributable to an increase of $1.3 million in professional service expenses related to marketing activities, an increase of $1.2 million related to allocated facilities and information technology infrastructure costs, offset by a decrease of $0.7 million related to office administrative costs as a result of the COVID-19 pandemic. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative expense</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,747&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses were $37.2 million for the three months ended June 30, 2020 compared to $13.4 million for the three months ended June 30, 2019, an increase of $23.7 million, or 177%. This increase was primarily due to an increase of $20.6 million in personnel-related costs, including a $19.6 million increase in stock-based compensation primarily in connection with the issuance of market-based restricted stock units to our Founders as well as an increase in our headcount, an increase of $1.6 million in professional service expenses related to outside legal, accounting, consulting and IT services, and an increase of $1.3 million related to allocated facilities and information technology infrastructure cost. We expect our general and administrative expenses to significantly increase in the near term primarily due to the expense recognition associated with the market-based restricted stock units. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest income</span></div><div style="margin-top:12pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,640&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(459)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income was $2.6 million for the three months ended June 30, 2020 compared to $3.1 million for the three months ended June 30, 2019, a decrease of $0.5 million, or 15%. This decrease was primarily due to a significant decrease in interest rate as the U.S. Federal Reserve made emergency cuts and lowered the risk-free interest rate to nearly zero, partially offset by an increase in cash, cash equivalents and marketable securities during the three months ended June 30, 2020 primarily as a result of cash proceeds from our follow-on public offering completed in June 2020. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(287)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">277&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense was immaterial for the three months ended June 30, 2020 compared to $0.3 million for the three months ended June 30, 2019, a decrease of $0.3 million, or 97%. This decrease was primarily due to the settlement of all outstanding balances in March 2020 related to the patent license agreement entered into in January 2017.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other income (expense), net</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense), net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,285&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For the three months ended June 30, 2020, other income (expense), net included receipt of $1.8&#160;million from HHS&#8217;s relief fund under the CARES Act and foreign currency exchange gains of $0.2&#160;million. Other income (expense), net included foreign currency exchange losses of $0.1 million for the three months ended June 30, 2019. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Provision for (benefit from) income taxes</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:38.675%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.790%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.671%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provision for (benefit from) income taxes</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,207)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,241&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*&#160;Not meaningful</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provision for income taxes was immaterial for the three months ended June 30, 2020. Benefit from income taxes for the&#160;three months ended June 30, 2019&#160;relates primarily to the release of a valuation allowance of $1.2&#160;million associated with nondeductible intangible assets recorded as part of the acquisition of Bellwether Bio, Inc., partially offset by state minimum income tax and income tax on our earnings in foreign jurisdictions.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_124"></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comparison of the Six Months Ended June 30, 2020 and 2019 </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Precision oncology testing</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70,901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development services</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,729&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,879&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue was $133.8 million for the six months ended June 30, 2020 compared to $90.6 million for the six months ended June 30, 2019, an increase of $43.2 million, or 48%.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Precision oncology testing revenue increased to $111.2 million for the six months ended June 30, 2020 from $70.9 million for the six months ended June 30, 2019, an increase of $40.3 million, or 57%. This increase in precision oncology testing revenue was primarily due to an increase in tests performed, an increase in average selling price per test for similar reasons as noted above, plus $4.1 million in revenue received from Medicare for samples processed in 2019 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">up from $1.4 million in revenue received during the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">six months ended June 30, 2019 from Medicare for samples processed in 2018. Precision oncology revenue from tests for clinical customers was $77.6 million in the six months ended June 30, 2020 and $39.0 million in the six months ended June 30, 2019, respectively. Tests for clinical customers increased to 28,951 for the six months ended June 30, 2020 from 21,396 for the six months ended June 30, 2019 mainly due to an increase in the number of physicians ordering Guardant360 tests. In March 2020, we began to receive reimbursement from Medicare for claims submitted with respect to Guardant360 clinical tests performed for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin other than NSCLC. In May 2020, Noridian issued a coverage article and confirmed limited Medicare coverage for our Guardant360 test for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">who meet the criteria of Medicare&#8217;s National Coverage Determination for Next Generation Sequencing established in March 2018. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Precision oncology revenue from tests for biopharmaceutical customers was $33.6 million in the six months ended June 30, 2020 and $31.9 million in the six months ended June 30, 2019, respectively. Tests for biopharmaceutical customers decreased to 8,071 for the six months ended June 30, 2020 from 9,046 for the six months ended June 30, 2019 primarily due to the timing and progression of clinical trials and studies which resulted in fluctuation in the number of samples received for testing. The average selling price of biopharmaceutical tests was $4,169 for the six months ended June 30, 2020, up from $3,529 for the six months ended June 30, 2019 due to a greater number of such tests being the GuardantOMNI test, which has a higher selling price than the Guardant360 test. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we began receiving fewer samples for testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Our future sample volumes and precision oncology revenue may be adversely impacted by the COVID-19 pandemic for the affected periods.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Development services revenue increased to $22.6 million for the six months ended June 30, 2020 from $19.7 million for the six months ended June 30, 2019, an increase of $2.9 million, or 15%. This increase in development services revenue was due to progression of collaboration projects from biopharmaceutical customers for companion diagnostic development and regulatory approval services completed during the six months ended June 30, 2020. We expect our development services arrangements with biopharmaceutical custo</span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">mers </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and development services revenue to be adversely impacted by the COVID-19 pandemic depending on the duration and severity of the pandemic.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Revenue and Gross Margin</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(dollars in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,573&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross profit</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,262&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross margin</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of revenue was $42.9 million for the six months ended June 30, 2020 compared to $30.4 million for the six months ended June 30, 2019, an increase of $12.6 million, or 41%.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of precision oncology testing revenue was $36.0 million for the six months ended June 30, 2020 compared to $25.7 million for the six months ended June 30, 2019, an increase of $10.3 million, or 40%. This increase in cost of precision oncology testing was attributable to an increase in sample volumes and was primarily due to a $7.0 million increase in production labor and overhead costs and a $3.3 million increase in material costs.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of development services was $6.9 million for the six months ended June 30, 2020 compared to $4.7 million for the six months ended June 30, 2019, an increase of $2.2 million, or 48%. This increase in cost of development services was primarily due to an increase in labor costs related to companion diagnostic development and regulatory approval service contracts. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gross margin for the six months ended June 30, 2020 was 68% compared to 66% for the six months ended June 30, 2019. Gross margin improvement reflects the impact of increased average selling price per test. Our gross margin may be adversely impacted by the COVID-19 pandemic depending on how long the pandemic lasts and the severity of the situation in coming quarters.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expense</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,487&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses were $73.3 million for the six months ended June 30, 2020 compared to $35.8 million for the six months ended June 30, 2019, an increase of $37.5 million, or 105%. This increase in research and development expense was primarily due to an increase of $11.9 million in personnel-related costs for employees in our research and development group, including a $2.3 million increase in stock-based compensation, as we increased our headcount to support continued investment in our technology, an increase of $8.5 million relating to IPR&amp;D technology expensed in connection with a patent license acquisition that occurred in March 2020, an increase of $7.2 million in material costs related to various programs, an increase of $6.2 million in development consulting fees, an increase of $2.3 million related to allocated facility and information technology infrastructure costs and an increase of $0.7 million in office administrative costs as we increased our headcount to support continued investment in our technology.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales and marketing expense</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales and marketing</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,130&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Selling and marketing expenses were $50.1 million for the six months ended June 30, 2020 compared to $37.2 million for the six months ended June 30, 2019, an increase of $12.9 million, or 35%. This increase was primarily due to an increase of $9.1 million in personnel-related costs, including a $2.5 million increase in stock-based compensation, associated with the expansion of our commercial organization, an increase of $2.1 million in professional service expenses related to marketing activities and an increase of $1.9 million related to allocated facility and information technology infrastructure costs, offset by a decrease of $0.2 million related to office administrative costs as a result of the COVID-19 pandemic.  </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative expense</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,971&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,871&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses were $57.0 million for the six months ended June 30, 2020 compared to $26.1 million for the six months ended June 30, 2019, an increase of $30.9 million, or 118%. This increase was primarily due to an increase of $23.8 million in personnel-related costs, including a $20.5 million increase in stock-based compensation primarily in connection with the issuance of market-based restricted stock units to our Founders as well as an increase in our headcount, an increase of $2.2 million in professional service expenses related to outside legal, accounting, consulting and IT services, an increase of $2.4 million related to allocated facilities and information technology infrastructure costs, an increase of $1.2 million related to settlement costs in connection with a patent license acquisition that occurred in March 2020, and an increase of $0.9 million in office administrative costs. We expect our general and administrative expenses to significantly increase in near term primarily due to the expense recognition associated with the market-based restricted stock units. </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest income</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,958&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income was $6.0 million for the six months ended June 30, 2020 compared to $5.6 million for the six months ended June 30, 2019, an increase of $0.4 million, or 7%. This increase was primarily due to a significant increase in cash, cash equivalents and marketable securities related to the receipt of cash proceeds from our follow-on public offering completed in June 2020, offset by a significant decrease in interest rate as the U.S. Federal Reserve made emergency cuts and lowered the risk-free interest rate to nearly zero.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest expense</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(580)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">558&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(96)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense was immaterial for the six months ended June 30, 2020 compared to $0.6 million for the six months ended June 30, 2019, a decrease of $0.6 million, or 96%. This decrease was primarily due to the settlement of all outstanding balances in March 2020 related to the patent license agreement entered into in January 2017.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other income (expense), net</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income (expense), net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,980&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For the six months ended June 30, 2020, other income (expense), net included receipt of $1.8&#160;million received from HHS&#8217;s relief fund under the CARES Act and foreign currency exchange losses of $0.1&#160;million. Other income (expense), net included foreign currency exchange gains of $0.1 million for the six months ended June 30, 2019.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Provision for (benefit from) income taxes</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:40.926%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.665%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">$</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">%</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provision for (benefit from) income taxes</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,181)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*&#160;Not meaningful</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provision for income taxes was immaterial for the six months ended June 30, 2020. Benefit from income taxes for the&#160;six months ended June 30, 2019&#160;relates primarily to the release of a valuation allowance of $1.2&#160;million associated with nondeductible intangible assets recorded as part of the acquisition of Bellwether Bio, Inc., partially offset by state minimum income tax and income tax on our earnings in foreign jurisdictions.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_127"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and capital resources</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred losses and negative cash flows from operations since our inception, and as of June&#160;30, 2020, we had an accumulated deficit of $435.2 million. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to invest in clinical trials and develop new product offerings from our research programs, including our LUNAR program, expand our sales organization, and increase our marketing efforts to drive market adoption of our Guardant360 and GuardantOMNI tests. Our capital expenditure requirements could also increase if we build additional laboratory capacity.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have funded our operations to date principally from the sale of stock, and revenue from precision oncology testing and development services. As of June&#160;30, 2020, we had cash and cash equivalents of $164.7 million and marketable securities of $919.3 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to provide liquidity while ensuring capital preservation. Currently, our funds are held in marketable securities consisting of United States treasury securities and corporate bonds.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flows from operations, will be sufficient to meet our anticipated cash requirements over at least the next 12 months from the date of this report. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. As revenue from precision oncology testing and development services is expected to grow long-term, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our available cash, cash equivalents and marketable securities and anticipated cash flows from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products as a result of lower than currently expected rates of reimbursement from our customers or other risks described in our Form 10-K for the year ended December&#160;31, 2019 and our Form 10-Q for the quarter ended March 31, 2020, we may seek to sell additional common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available to us on reasonable terms, or at all.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash flows</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flows for the periods presented:</span></div><div style="margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,647)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,139)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(304,745)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(305,198)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">357,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating activities</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in operating activities during the six months ended June 30, 2020 was $36.6 million, which resulted from a net loss of $81.6 million and net change in our operating assets and liabilities of $7.1 million, partially offset by non-cash charges of $52.0 million. Non-cash charges primarily consisted of $32.2 million of stock-based compensation, $8.5 million of charge of in-process research and development costs with no alternative future use, $7.1 million of depreciation and amortization, $3.4 million&#160;of right-of-use assets amortization, and $1.1 million&#160;of amortization of premium on investment. The net change in our operating assets and liabilities was primarily the result of a $5.2 million increase in inventory, a $3.9 million payment of operating lease liabilities, a $2.5 million </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">decrease in accounts payable, a $1.8 million decrease in accrued expenses and a $0.8 million decrease in deferred revenue, partially offset by a $6.9 million decrease in accounts receivables.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in operating activities during the six months ended June 30, 2019 was $18.1 million, which resulted from a net loss of $32.7 million, partially offset by non-cash charges of $10.5 million and net change in our operating assets and liabilities of $4.0 million. Non-cash charges primarily consisted of $5.0 million of depreciation and amortization, $6.4 million of stock-based compensation, and $1.6 million&#160;of right-of-use assets amortization, partially offset by&#160;$1.3 million&#160;of amortization of discount on investment and $1.2 million of benefit from income tax differences. The net change in our operating assets and liabilities was primarily the result of a $3.4 million&#160;increase in accounts payable due to timing of payment, a $2.9 million&#160;increase in accrued expenses, a $1.4 million receipt of tenant improvement allowance net of payment of operating lease liabilities, and a $0.7 million increase in accrued compensation due to increased personnel, partially offset by a $5.0 million increase in inventory due to higher testing volumes.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Investing activities</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in investing activities during the six months ended June 30, 2020 was $304.7 million, which resulted primarily from purchases of marketable securities of $465.3 million, purchases of property and equipment of $19.1 million and purchases of intangible assets and capitalized license obligations of $17.9 million, partially offset by maturities of marketable securities of $197.5 million.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash used in investing activities during the six months ended June 30, 2019 was $305.2 million, which resulted primarily from purchases of marketable securities of $418.8 million, business acquisition, net of cash acquired, of $9.8 million and purchases of property and equipment of $5.8 million, partially offset by maturities of marketable securities of $129.2 million.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financing activities</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash provided by financing activities during the six months ended June 30, 2020 was $362.8 million, which was primarily due to proceeds from a follow-on offering of our common stock, net of underwriting discounts and commissions and offering expenses payable by us, of $354.6 million, proceeds from issuances of common stock under employee stock purchase plan of $4.0 million and proceeds from exercise of stock options of $3.5 million. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash provided by financing activities during the six months ended June 30, 2019 was $357.4 million, which was primarily due to proceeds from a public offering of our common stock, net of underwriting discounts and commissions and offering expenses payable by us, of $349.7 million, proceeds from exercise of stock options of $5.5 million, and proceeds from issuances of common stock under employee stock purchase plan of $1.9 million.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_130"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual obligations and commitments</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as set forth in Note 9, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Commitments and Contingencies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, of the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Management</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8217;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_133"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-balance sheet arrangements</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we have not had any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_136"></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical accounting policies and estimates</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have prepared our financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While our significant accounting policies are described in more detail in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue recognition</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We derive revenue from the provision of precision oncology testing services provided to our ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to our biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from our platform. Development services include companion diagnostic development, information solutions and laboratory services. We currently receive payments from commercial third-party payors, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Effective January 1, 2019, we began recognizing revenue in accordance with ASC Topic 606,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,&#160;or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Precision oncology testing</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize revenue from the sale of our precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, we determine an implied contract exists with our clinical customers. We identify each sale of our liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with our clinical customers represents variable consideration. We estimate the variable consideration under the portfolio approach and consider the historical reimbursement data from third-party payers and patients, as well as known current or anticipated reimbursement trends not reflected in the historical data. We monitor the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. We analyze actual cash collections over the expected reimbursement period and compare it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. We identify our promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Results of our precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by us or billed to customers.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Development services</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We perform development services for our biopharmaceutical customers utilizing our precision oncology information platform. Development services typically represent a single performance obligation as we perform a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage us for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We collaborate with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these collaborations, we generate revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, we are compensated through a combination of an upfront fee and performance-based non-refundable regulatory and other developmental milestone payments. The transaction price of our development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, we consider our historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than us. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, we recognize revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. We also assess the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in our condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contracts with multiple performance obligations</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. We evaluate the terms and conditions included within our contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. We first identify material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, we consider whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, we consider whether we provide a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable interest entity</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We review agreements we enter into with third party entities, pursuant to which we may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, we assess whether or not we are the primary beneficiary of that entity. In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If we determine we are the primary beneficiary of a VIE, we consolidate the statements of operations and financial condition of the VIE into our consolidated financial statements. Accounting for the consolidation is based on our determination if the VIE meets the definition of a business or and asset. Assets, liabilities and noncontrolling interests, excluding goodwill, of VIEs that are not determined to be businesses are recorded at fair value in our financial statements upon consolidation. Assets and liabilities that we have transferred to a VIE, after, or shortly before the date we became the primary </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">beneficiary are recorded at the same amount at which the assets and liabilities would have been measured if they had not been transferred. Our determination about whether we should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, we and an affiliate of SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of our tests in the JV Territory. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with an initial focus on Japan. The Joint Venture is deemed to be a VIE and we are identified as the primary beneficiary of the VIE. Consequently, we have consolidated the financial position, results of operations and cash flows of the Joint Venture in our financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The joint venture agreement also includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. SoftBank will have a put right to cause us to purchase all shares of the Joint Venture held by SoftBank and its affiliates, and we will have a call right to purchase all such shares in the event of (i) certain material disagreement relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of our initial public offering, a change in control, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange; the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interest in the Joint Venture being determined to be materially different from what has been recorded in our condensed consolidated financial statements, including those included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event we exercise our call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;20%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;40%&#160;of our fair value, we will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;40%&#160;of our fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may pay the purchase price for the shares of the Joint Venture in cash, in shares of our common stock, or in a combination thereof. In the event we exercise the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, we will choose the form of consideration.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within our control and has been classified outside of permanent equity in our consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to us on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. We elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-based compensation</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">After the adoption of Accounting Standards Update 2018-07, Compensation&#8212;Stock Compensation (Topic 718):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Improvements to Nonemployee Share-Based Payment Accounting </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">on January 1, 2019, we measure stock-based compensation expense for stock options granted to our employees, directors, and nonemployee consultants on the date of grant and recognize the corresponding compensation expense of those awards over the period that the related services are rendered, which is generally the vesting period of the respective award. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate the fair value of stock options granted to our employees, directors, and nonemployee consultants and stock purchase rights under our 2018 Employee Stock Purchase Plan on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The assumptions used to calculate the fair value of our stock options were:</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected term</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our expected term represents the period that our stock options are expected to be outstanding. After the adoption of Accounting Standards Update 2018-07, Compensation&#8212;Stock Compensation (Topic 718):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Improvements to Nonemployee Share-Based Payment Accounting </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">on January 1, 2019, the expected term of stock options issued to employees, directors and nonemployee consultants is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected volatility</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the commencement of trading of our common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for our common stock. Due to limited historical data for the trading of  our common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus our expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risk-free interest rate is based on the U.S. treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the stock option grants.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend yield</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we use an expected dividend yield of zero.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Black-Scholes assumptions</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average assumptions used in our Black-Scholes option-pricing model were as follows for stock option granted to our employees, directors and nonemployees for the periods presented:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:33.576%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.224%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.228%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 &#8211; 6.10</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 &#8211; 6.16</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 &#8211; 6.10</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.50 &#8211; 6.22</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.5% &#8211; 68.5%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.9% &#8211; 68.3%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.5% &#8211; 73.3%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.7% &#8211; 68.3%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4% &#8211; 0.4%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4% &#8211; 1.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% &#8211; 2.7%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Expected dividend yield </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For market-based restricted stock units, we derive the requisite service period using the Monte Carlo simulation model. The estimated fair value of the market-based restricted stock units was determined using a Monte Carlo simulation model which requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. Stock-based compensation expense will be recorded regardless of achieving the market conditions or not.  If the related market condition is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assumptions used to calculate the fair value of our market-based restricted stock units were as follows:</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value of Common Stock</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of our common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to limited historical data for the trading of the our common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus our expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the market-based restricted stock units. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risky Rate</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risky rate represents our cost of equity.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividend Yield</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Discount for Lack of Marketability </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following assumptions were used to calculate the stock-based compensation for market-based restricted stock units: a weighted-average expected life of 0.83 &#8211; 2.07 years; expected volatility of 65.5%; a risk-free interest rate of 0.5%; a zero dividend yield; a risky rate (cost of equity) of 16%; and a discount for post-vesting restrictions of 10.4% &#8211; 14.5%.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize stock-based compensation expense net of forfeitures as they occur.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may have refinements to our estimates, which could materially impact our future stock-based compensation expense.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_139"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent accounting pronouncements</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See Note 2, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Significant Accounting Policies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_142"></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest rate risk</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents and marketable securities. As of June&#160;30, 2020, we had cash and cash equivalents of $164.7 million held primarily in cash deposits and money market funds. Our marketable securities are held in U.S. government debt securities, U.S. government agency bonds and corporate bonds. As of June&#160;30, 2020, we had short-term marketable securities of $773.2 million and long-term marketable securities of $146.1 million. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. As of&#160;June&#160;30, 2020, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate&#160;$6.1 million&#160;decline of the fair value of our available-for-sale securities and a hypothetical 100 basis point decrease in interest rates would have resulted in an approximate&#160;$1.0 million&#160;increase of the fair value of our </span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign currency risk</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The majority of our revenue is generated in the United States. Through June&#160;30, 2020, we have generated an insignificant amount of revenues denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. As of June&#160;30, 2020, the effect of a hypothetical 10% change in foreign currency exchange rates would not be material to our financial condition or results of operations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_145"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Controls and Procedures</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of disclosure controls and procedures</span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our Chief Executive Officer, or CEO, and our Chief Financial Officer, or CFO with the participation of other members of our management, have evaluated the effectiveness of our &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">as of June&#160;30, 2020</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">, and our CEO and our CFO have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in internal control</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that a number of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Limitations on effectiveness of controls and procedures</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, including our CEO and our CFO, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:6pt;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">59</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_148"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II&#8212;OTHER INFORMATION</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_151"></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Legal Proceedings</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information under the caption &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Commitments and Contingencies - Legal Proceedings</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; in Note 9 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="ib551ebaf812444a9a6979b345f863c2b_154"></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A. Risk Factors</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry as well as&#160;risks that affect businesses in general. In addition to the information set forth in this Quarterly Report on Form 10-Q, you should consider carefully the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended&#160;December&#160;31, 2019 filed with the SEC on March 2, 2020 and in Part II, Item 1A, &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the period ended March 31, 2020 filed with the SEC on May 7, 2020. The risks and uncertainties</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. Besides risk factors disclosed in the Annual Report and this Quarterly Report, additional risks and uncertainties not currently known or we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the unaudited condensed consolidated financial statements and related notes in Part I, Item 1, &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; and Part I, Item 2, &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; of this Quarterly Report. Because of such risk factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div style="text-align:justify;"><span><br/></span></div><div id="ib551ebaf812444a9a6979b345f863c2b_157"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_160"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_163"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="ib551ebaf812444a9a6979b345f863c2b_166"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5. Other Information.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 31, 2020, we entered into a sublease with 3000 Hanover, LLC  (the &#8220;Landlord&#8221;), pursuant to which we have agreed to lease approximately 249,549 rentable square feet of office space located at 3000 Hanover Street, Levels C &amp; D, Palo Alto, CA 94304 (the &#8220;Sublease&#8221;), thereby securing the professional office and laboratory space necessary to support our anticipated future growth. The Sublease is expected to commence on October 1, 2021 and will expire on June 30, 2033, subject to certain extension options as provided for in the Sublease. The Sublease provides for monthly base rent of $920,000 until the first anniversary of the Sublease, $1,184,500 until the second anniversary of the Sublease and $1,522,293 until the third anniversary of the Sublease, and thereafter subject to annual increases of 3%. We are entitled to base rent abatement for the initial five months of the Sublease, and a tenant improvement allowance of $24,705,350. The Landlord will maintain a security deposit in the amount of $11,479,254, subject to a reduction to $7,174,533 upon the fifth (5th) anniversary of the Sublease commencement date. The Sublease contains customary representations, warranties, covenants, indemnification provisions, default provisions, and termination provisions for a lease of this nature.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The foregoing description of the Sublease does not purport to be complete and is qualified in its entirety by reference to the full text of the Sublease, which will be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ending September 30, 2020.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:6pt;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">61</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_169"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6. Exhibits.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:11pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:7.003%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:36.424%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.948%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.771%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.073%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.289%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.603%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.674%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">File No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filing Date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit318-k.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-38683</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/9/2018</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828018012404/exhibit328-k.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-38683</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10/9/2018</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="gh-directorcompensatio.htm">Non-Employee Director Compensation Program, effective as of June 12, 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828020008448/exhibit101-guardant8xk.htm">Form of Performance-Based Restricted Stock Unit Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-386830</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/27/2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1576280/000162828020008448/exhibit102-guardant8xk.htm">Form of Waiver Letter Agreement</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-386830</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/27/2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="gh-0630x2020x10qxex311.htm">Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="gh-0630x2020x10qxex312.htm">Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="gh-0630x2020x10qxex321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="gh-0630x2020x10qxex322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inline </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inline </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inline </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inline </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Label Linkbase Document</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inline </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">___________________________</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Filed herewith.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">**&#160;Furnished herewith.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:6pt;"><span><br/></span></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">62</span></div></div></div><div id="ib551ebaf812444a9a6979b345f863c2b_172"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib551ebaf812444a9a6979b345f863c2b_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:17pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:5.680%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.920%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.160%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.240%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GUARDANT HEALTH, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Derek Bertocci</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derek Bertocci</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>gh-directorcompensatio.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i593fa8d76c0b48b5b455c5e5afc5a403_31"></div><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font><br></font></div></div><div style="text-align:right;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Exhibit 10.1</font></div><div style="text-align:center;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">GUARDANT HEALTH, INC. </font></div><div style="text-align:center;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div style="text-align:center;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">(EFFECTIVE JUNE 12, 2020)</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In order to further align directors&#8217; interests with those of long-term stockholders, on June 12, 2020 the Board of Directors (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) of Guardant Health, Inc. (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) approved a number of modifications to its Non-Employee Director Compensation Program (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;). Specifically, the Board eliminated the cash compensation component of the Program, effective immediately, and concurrently revised the terms of the initial and annual equity awards to be granted under the Program to the Eligible Directors (as defined below) going-forward.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Eligible Directors on the Board shall be eligible to receive compensation as set forth in this Program.  The compensation described in this Program shall be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any of its parents, affiliates or subsidiaries (each, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Eligible Director</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;), who may be eligible to receive such compensation, unless such Eligible Director declines the receipt of such compensation by written notice to the Company. This Program shall become effective upon the date set forth above (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) and shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion. No Eligible Director shall have any rights hereunder, except with respect to equity awards granted pursuant to Section 1 of this Program. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:10.5pt;">Equity Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.  </font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:11.07pt;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.  Eligible Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2018 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (such plan, as may be amended from time to time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Equity Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;) and may be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms approved by the Board prior to or in connection with such grants. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of equity awards hereby are subject in all respects to the terms of the Equity Plan.  Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Equity Plan.</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:10.5pt;">Initial Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.  Each Eligible Director who is initially elected or appointed to serve on the Board after the Effective Date automatically shall be granted an Option with a value of $362,500 and a Restricted Stock Unit award with a value of $362,500 (each, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Initial Award</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;). Each Initial Award shall be granted on the date on which such Eligible Director is appointed or elected to serve on the Board (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Election Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;), and each such award shall vest and become exercisable (as applicable) as to 25% of the Shares subject to such award on the first anniversary of such Election Date, and as to the remaining 75% of the Shares subject to such award in substantially equal installments on each monthly anniversary of the Election Date during the three-year period thereafter, subject to continued service through the applicable vesting date.  </font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:11.07pt;">Annual Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. An Eligible Director who has served on the Board for at least six months as of the date of the annual meeting of the Company&#8217;s stockholders shall be granted, on such annual meeting date, an Option with a value of $212,500 and a Restricted Stock Unit award with a value of $212,500 (together, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Annual Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;). Each Annual Award shall vest and become exercisable (as applicable) in full on the earlier to occur of (i) the one-year anniversary of the applicable grant date and (ii) the date of the next annual meeting of the Company&#8217;s stockholders following the grant date, subject to continued service through the applicable vesting date.</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:10.5pt;">Annual Lead Independent Director Award</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. An Eligible Director who has served on the Board for at least six months as of the date of the annual meeting of the Company&#8217;s stockholders and who </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">also will serve as Lead Independent Director of the Board immediately following such date shall be granted, on such annual meeting date, a Restricted Stock Unit award with a value of $45,000 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Annual LID Award</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221;). Each Annual LID Award shall vest in full on the earlier to occur of (i) the one-year anniversary of the applicable grant date and (ii) the date of the next annual meeting of the Company&#8217;s stockholders following the grant date, subject to continued service through the applicable vesting date. </font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">e.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:11.07pt;">Accelerated Vesting Events</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.  Notwithstanding the foregoing, an Eligible Director&#8217;s Initial Awards, Annual Award(s) and&#47;or Annual LID Award shall vest in full immediately prior to (i) such Eligible Director&#8217;s Termination of Service by the Company without Cause (as defined below) or due to his&#47;her death or Disability (as defined below) or (ii) the occurrence of a Change in Control, in each case, to the extent outstanding at such time.</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">f.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:12.17pt;">Provisions Applicable to Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. With respect to any Award granted under this Program&#58;</font></div><div style="text-indent:-23.27pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">The exercise price per Share with respect to an Option shall be equal to the Fair Market Value of a Share on the applicable grant date.</font></div><div style="text-indent:-26.04pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">An Option shall have a maximum term of ten years from the applicable grant date.</font></div><div style="text-indent:-28.81pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">iii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">The number of Shares subject to an Option shall be determined by dividing the value of the Option by the per share Black-Scholes valuation as of the applicable grant date, utilizing the same assumptions that the Company uses in preparation of its financial statements.</font></div><div style="text-indent:-28.27pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">iv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">The number of Shares subject to a Restricted Stock Unit award shall be determined by dividing the value by the Fair Market Value of the Company&#8217;s common stock on the applicable grant date.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:10.5pt;">Compensation Limits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Notwithstanding anything to the contrary in this Program, all compensation payable under this Program shall be subject to any limits on the maximum amount of non-employee Director compensation set forth in the Equity Plan, as in effect from time to time.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;padding-left:10.5pt;">Certain Defined Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221; means the occurrence of any one or more of the following events unless, to the extent capable of correction, the Eligible Director fully corrects the circumstances constituting Cause within 15 days after receipt of written notice thereof&#58;</font></div><div style="text-indent:-23.27pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">the Eligible Director&#8217;s willful failure to substantially perform his or her duties with the Company (other than any such failure resulting from the Eligible Director&#8217;s incapacity due to physical or mental illness), after a written demand for performance is delivered to the Eligible Director by the Board, which demand specifically identifies the manner in which the Board believes that the Eligible Director has not performed his or her duties&#59;</font></div><div style="text-indent:-26.04pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">the Eligible Director&#8217;s commission of an act of fraud or material dishonesty resulting in reputational, economic or financial injury to the Company&#59;</font></div><div style="text-indent:-28.81pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">iii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">the Eligible Director&#8217;s material misappropriation or embezzlement of the property of the Company or any of its affiliates&#59;</font></div><div style="text-indent:-28.27pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">iv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">the Eligible Director&#8217;s commission of, including any entry by the Eligible Director of a guilty or no contest plea to, a felony (other than a traffic violation) or other crime involving moral turpitude, or the Eligible Director&#8217;s commission of unlawful harassment or discrimination&#59;</font></div><div style="text-indent:-25.5pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">v.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">the Eligible Director&#8217;s willful misconduct or gross negligence with respect to any material aspect of the Company&#8217;s business or a material breach by the Eligible Director </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">of his or her fiduciary duty to the Company, which willful misconduct, gross negligence or material breach has a material and demonstrable adverse effect on the Company&#59; or</font></div><div style="text-indent:-28.27pt;padding-left:108pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">vi.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt;">the Eligible Director&#8217;s material breach of the Eligible Director&#8217;s obligations under a written agreement between the Company and the Eligible Director.</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8221; means a permanent and total disability under Section 22(e)(3) of the Code.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>gh-0630x2020x10qxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i85fc72d3141d44289c2ab1875cb1e5b7_1"></div><div style="min-height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Helmy Eltoukhy, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:11pt;margin-bottom:11pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:9.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.745%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.073%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.089%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:1pt;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Date&#58; </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Helmy Eltoukhy</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Helmy Eltoukhy</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>gh-0630x2020x10qxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib7e280e31d004537827150e88a2f44a7_1"></div><div style="min-height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Derek Bertocci, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Guardant Health, Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:11pt;margin-bottom:11pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:9.396%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.523%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.062%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.019%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:1pt;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Date&#58; </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Derek Bertocci</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Derek Bertocci</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;margin-top:1pt;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>gh-0630x2020x10qxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ida4b70b162b14a20a73ecbaf2f901ccb_1"></div><div style="min-height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="text-align:justify;margin-top:11pt;margin-bottom:11pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:9.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.745%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.073%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.089%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:1pt;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Date&#58; </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Helmy Eltoukhy</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Helmy Eltoukhy</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Executive Officer</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Executive Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font><br></font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>gh-0630x2020x10qxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="icb5cc9d42f9545539cbb60a7483f93d5_1"></div><div style="min-height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report of Guardant Health, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="text-align:justify;margin-top:11pt;margin-bottom:11pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:9.556%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.362%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.062%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:41.020%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:1pt;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Date&#58; </font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 6, 2020</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">&#47;s&#47; Derek Bertocci</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Derek Bertocci</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:1pt;margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Principal Financial Officer)</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><font><br></font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>gh-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a823c88f-2b24-44ac-a516-3f731119002e,g:77fc4dec-5a42-485c-bad8-a10178a2afe8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gh="http://guardanthealth.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://guardanthealth.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gh-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://guardanthealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://guardanthealth.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinJointVenture" roleURI="http://guardanthealth.com/role/InvestmentinJointVenture">
        <link:definition>2108103 - Disclosure - Investment in Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinJointVentureDetails" roleURI="http://guardanthealth.com/role/InvestmentinJointVentureDetails">
        <link:definition>2409404 - Disclosure - Investment in Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponents" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents">
        <link:definition>2110104 - Disclosure - Condensed Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsTables" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables">
        <link:definition>2311302 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails">
        <link:definition>2412405 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails">
        <link:definition>2413406 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails">
        <link:definition>2414407 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecurities" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities">
        <link:definition>2115105 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>2316303 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails">
        <link:definition>2417408 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2420411 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwill" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill">
        <link:definition>2121106 - Disclosure - Intangible Assets, Net and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillTables" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables">
        <link:definition>2322304 - Disclosure - Intangible Assets, Net and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails">
        <link:definition>2423412 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillNarrativeDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails">
        <link:definition>2424413 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails">
        <link:definition>2425414 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisition" roleURI="http://guardanthealth.com/role/Acquisition">
        <link:definition>2126107 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionTables" roleURI="http://guardanthealth.com/role/AcquisitionTables">
        <link:definition>2327305 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionPatentLicenseAcquisitionDetails" roleURI="http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails">
        <link:definition>2428415 - Disclosure - Acquisition - Patent License Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionAcquisitionofBellwetherBioDetails" roleURI="http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails">
        <link:definition>2429416 - Disclosure - Acquisition - Acquisition of Bellwether Bio (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2430417 - Disclosure - Acquisition - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionIntangibleAssetsAcquiredDetails" roleURI="http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails">
        <link:definition>2431418 - Disclosure - Acquisition - Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://guardanthealth.com/role/Leases">
        <link:definition>2132108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://guardanthealth.com/role/LeasesTables">
        <link:definition>2333306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails">
        <link:definition>2434419 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseInformationDetails" roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails">
        <link:definition>2435420 - Disclosure - Leases - Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLiabilityMaturitiesDetails" roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails">
        <link:definition>2436421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1">
        <link:definition>2436421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://guardanthealth.com/role/CommitmentsandContingencies">
        <link:definition>2137109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2438422 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://guardanthealth.com/role/CommonStock">
        <link:definition>2139110 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://guardanthealth.com/role/CommonStockTables">
        <link:definition>2340307 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://guardanthealth.com/role/CommonStockDetails">
        <link:definition>2441423 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://guardanthealth.com/role/StockBasedCompensation">
        <link:definition>2142111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://guardanthealth.com/role/StockBasedCompensationTables">
        <link:definition>2343308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2444424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2445425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockActivityDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails">
        <link:definition>2446426 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails">
        <link:definition>2447427 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2448428 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationofStockOptionsDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails">
        <link:definition>2449429 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2450430 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders">
        <link:definition>2151112 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables">
        <link:definition>2352309 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails">
        <link:definition>2453431 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>2454432 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://guardanthealth.com/role/IncomeTaxes">
        <link:definition>2155113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://guardanthealth.com/role/IncomeTaxesDetails">
        <link:definition>2456433 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformation" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation">
        <link:definition>2157114 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationTables" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables">
        <link:definition>2358310 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationDetails" roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails">
        <link:definition>2459434 - Disclosure - Segment and Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://guardanthealth.com/role/RelatedPartyTransactions">
        <link:definition>2160115 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2461435 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://guardanthealth.com/role/SubsequentEvents">
        <link:definition>2162116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNarrativeDetails" roleURI="http://guardanthealth.com/role/SubsequentEventsNarrativeDetails">
        <link:definition>2463436 - Disclosure - Subsequent Events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" abstract="false" name="AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsExercisedEarly" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_RedeemableNoncontrollingInterestMember" abstract="true" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" abstract="false" name="VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gh_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_EquityMethodInvestmentSharesPurchased" abstract="false" name="EquityMethodInvestmentSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" abstract="false" name="ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PrecisionOncologyTestingMember" abstract="true" name="PrecisionOncologyTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_CapitalizedLicenseFees" abstract="false" name="CapitalizedLicenseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PaymentInConnectionWithaLicenseAgreement" abstract="false" name="PaymentInConnectionWithaLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_AssetAcquisitionDomain" abstract="true" name="AssetAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" abstract="false" name="BusinessCombinationContingentConsiderationMaximumAmountPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" abstract="true" name="PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_NonemployeeStockOptionMember" abstract="true" name="NonemployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_RevenuefromPrecisionOncologyTesting" abstract="false" name="RevenuefromPrecisionOncologyTesting" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_OfferingCostsIncurredButNotYetPaid" abstract="false" name="OfferingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_SoftBankMember" abstract="true" name="SoftBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" abstract="false" name="DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_AccruedClinicalTrialsandStudies" abstract="false" name="AccruedClinicalTrialsandStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_AssetAcquisitionTransactionCosts" abstract="false" name="AssetAcquisitionTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_GuardantHealthAMEAIncMember" abstract="true" name="GuardantHealthAMEAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_EarnOutConsiderationMember" abstract="true" name="EarnOutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_CostofDevelopmentServices" abstract="false" name="CostofDevelopmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CovenantsNotToCompeteMember" abstract="true" name="CovenantsNotToCompeteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_GuardantHealthIncMember" abstract="true" name="GuardantHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_AssetAcquisitionPolicyTextBlock" abstract="false" name="AssetAcquisitionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gh_DebtSecuritiesTableTextBlock" abstract="false" name="DebtSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gh_AmortizationOfRightOfUseAsset" abstract="false" name="AmortizationOfRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_PatentandCovenantRightsMember" abstract="true" name="PatentandCovenantRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_AccruedExpensesPropertyandEquipmentCurrent" abstract="false" name="AccruedExpensesPropertyandEquipmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_KeyGenePatentLicenseAcquisitionMember" abstract="true" name="KeyGenePatentLicenseAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" abstract="false" name="VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gh_CommonStockSubjecttoRepurchaseorCancellation" abstract="false" name="CommonStockSubjecttoRepurchaseorCancellation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_MarketableSecuritiesMaturityPeriod" abstract="false" name="MarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" abstract="false" name="PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_AccruedRoyaltiesNoncurrent" abstract="false" name="AccruedRoyaltiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_NumberOfOperatingLeasesLeaseNotYetCommenced" abstract="false" name="NumberOfOperatingLeasesLeaseNotYetCommenced" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_NumberofPetitionsFiled" abstract="false" name="NumberofPetitionsFiled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_NumberofCompaniesthatInfringedonaPatent" abstract="false" name="NumberofCompaniesthatInfringedonaPatent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_AssetAcquisitionAxis" abstract="true" name="AssetAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gh_ChargeOfInProcessResearchAndDevelopment" abstract="false" name="ChargeOfInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="gh_CostsofPrecisionOncologyTesting" abstract="false" name="CostsofPrecisionOncologyTesting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" abstract="false" name="UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_RevenuefromDevelopmentServices" abstract="false" name="RevenuefromDevelopmentServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_IntangibleAssetsGrossIncludingGoodwill" abstract="false" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CustomerEMember" abstract="true" name="CustomerEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_A2018IncentiveAwardPlanMember" abstract="true" name="A2018IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_CostsofPrecisionOncologyTestingPolicyTextBlock" abstract="false" name="CostsofPrecisionOncologyTestingPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gh_CommercializationMilestonesMember" abstract="true" name="CommercializationMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" abstract="false" name="UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gh_NumberofPetitionsDenied" abstract="false" name="NumberofPetitionsDenied" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_CustomerDMember" abstract="true" name="CustomerDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" abstract="true" name="PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_PreferredStockSharesIssuedUponConversionOfCommonStock" abstract="false" name="PreferredStockSharesIssuedUponConversionOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" abstract="false" name="WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="gh_EstimatedLitigationLiabilityLegalFeesCurrent" abstract="false" name="EstimatedLitigationLiabilityLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_CashCashEquivalentsandDebtSecuritiesFairValue" abstract="false" name="CashCashEquivalentsandDebtSecuritiesFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gh_BellweatherBioInc.Member" abstract="true" name="BellweatherBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" abstract="true" name="PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>gh-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a823c88f-2b24-44ac-a516-3f731119002e,g:77fc4dec-5a42-485c-bad8-a10178a2afe8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://guardanthealth.com/role/CoverPage" xlink:type="simple" xlink:href="gh-20200630.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e34beada-1d11-49f6-babb-14104b029200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_99306b50-f7b0-47b0-8969-ab17d99fb7c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e34beada-1d11-49f6-babb-14104b029200" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_99306b50-f7b0-47b0-8969-ab17d99fb7c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_134e0322-eb69-4551-8727-5f7f8e6a3c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e34beada-1d11-49f6-babb-14104b029200" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_134e0322-eb69-4551-8727-5f7f8e6a3c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_016c46c5-ab98-4be9-93fc-31acb2749418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e34beada-1d11-49f6-babb-14104b029200" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_016c46c5-ab98-4be9-93fc-31acb2749418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_537e2e53-6b55-4b7b-a8e7-37d858fb58a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e34beada-1d11-49f6-babb-14104b029200" xlink:to="loc_us-gaap_InventoryNet_537e2e53-6b55-4b7b-a8e7-37d858fb58a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e48fab76-f5aa-4494-9eca-bf39e97d8260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e34beada-1d11-49f6-babb-14104b029200" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e48fab76-f5aa-4494-9eca-bf39e97d8260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_89bf5c45-c2ce-4867-8d4d-cfa11e330664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_us-gaap_AssetsCurrent_89bf5c45-c2ce-4867-8d4d-cfa11e330664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_e55f14a9-d38e-4dbf-bd91-0fa898b47e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_e55f14a9-d38e-4dbf-bd91-0fa898b47e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3071a46a-a0ab-4984-bea4-17b68f026ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3071a46a-a0ab-4984-bea4-17b68f026ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf496eca-f9ff-49cb-ad97-df31a44e2120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf496eca-f9ff-49cb-ad97-df31a44e2120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_06506ff4-2cc7-412e-9fbe-95835ee3853f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_06506ff4-2cc7-412e-9fbe-95835ee3853f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8a423ede-76a6-4666-a965-069e4e0474d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_us-gaap_Goodwill_8a423ede-76a6-4666-a965-069e4e0474d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CapitalizedLicenseFees_a7012d6c-cc27-4e9f-a710-c6ade7c1c06c" xlink:href="gh-20200630.xsd#gh_CapitalizedLicenseFees"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_gh_CapitalizedLicenseFees_a7012d6c-cc27-4e9f-a710-c6ade7c1c06c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f857e2ce-857a-4304-8a1d-8cb6e40b0c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26113d3f-ddfe-4dba-9ce1-01ee1b16a374" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f857e2ce-857a-4304-8a1d-8cb6e40b0c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_96c4303f-2d00-415d-a6b3-f8abf728a868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a1b78884-326a-4e25-a940-0e1e4104bdda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_96c4303f-2d00-415d-a6b3-f8abf728a868" xlink:to="loc_us-gaap_LiabilitiesCurrent_a1b78884-326a-4e25-a940-0e1e4104bdda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9e9314ff-9c68-4f00-93ab-509c564b6d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_96c4303f-2d00-415d-a6b3-f8abf728a868" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9e9314ff-9c68-4f00-93ab-509c564b6d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedRoyaltiesNoncurrent_187e124d-d9ac-475d-81aa-5ed88cd4801b" xlink:href="gh-20200630.xsd#gh_AccruedRoyaltiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_96c4303f-2d00-415d-a6b3-f8abf728a868" xlink:to="loc_gh_AccruedRoyaltiesNoncurrent_187e124d-d9ac-475d-81aa-5ed88cd4801b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_82df0b54-7afe-48ae-a670-d81358196dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_96c4303f-2d00-415d-a6b3-f8abf728a868" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_82df0b54-7afe-48ae-a670-d81358196dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cec43f23-fe3b-403b-8b63-8bc2900551a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_27fabdf1-0f50-4224-996a-5f062c750dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cec43f23-fe3b-403b-8b63-8bc2900551a3" xlink:to="loc_us-gaap_Liabilities_27fabdf1-0f50-4224-996a-5f062c750dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_eb6b6db9-9ef6-4e8e-91ec-735e67356b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cec43f23-fe3b-403b-8b63-8bc2900551a3" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_eb6b6db9-9ef6-4e8e-91ec-735e67356b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0091e26b-ba66-42f3-a28f-dffcd86a188b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cec43f23-fe3b-403b-8b63-8bc2900551a3" xlink:to="loc_us-gaap_StockholdersEquity_0091e26b-ba66-42f3-a28f-dffcd86a188b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d40368a6-a193-44d8-9355-69953f29355e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_aad770d6-e06d-430f-a0bc-745cc15b6d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d40368a6-a193-44d8-9355-69953f29355e" xlink:to="loc_us-gaap_AccountsPayableCurrent_aad770d6-e06d-430f-a0bc-745cc15b6d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_64e59944-50c0-4975-b2c1-74cc7f072d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d40368a6-a193-44d8-9355-69953f29355e" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_64e59944-50c0-4975-b2c1-74cc7f072d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0f8e9dc3-552a-456c-b99e-926ddc6a8058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d40368a6-a193-44d8-9355-69953f29355e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0f8e9dc3-552a-456c-b99e-926ddc6a8058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_60e1867d-85cb-44d4-a5f9-00ceceeeabab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d40368a6-a193-44d8-9355-69953f29355e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_60e1867d-85cb-44d4-a5f9-00ceceeeabab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_39bcab0f-a350-4c2f-a434-de5b1c619d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_8f6748d7-b5ec-42ef-9960-7d9a0338d251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_39bcab0f-a350-4c2f-a434-de5b1c619d73" xlink:to="loc_us-gaap_CommonStockValueOutstanding_8f6748d7-b5ec-42ef-9960-7d9a0338d251" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c4ab5d80-fa51-45e4-9944-47e2b9171950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_39bcab0f-a350-4c2f-a434-de5b1c619d73" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c4ab5d80-fa51-45e4-9944-47e2b9171950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f8b09379-38a3-4e16-a54f-698ca112d386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_39bcab0f-a350-4c2f-a434-de5b1c619d73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f8b09379-38a3-4e16-a54f-698ca112d386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eaabe05f-14a7-434c-9951-b91d7c8ad35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_39bcab0f-a350-4c2f-a434-de5b1c619d73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eaabe05f-14a7-434c-9951-b91d7c8ad35e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_294a7c12-0153-4d2f-b1e0-45d90cb6beb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a18410a0-671c-47c4-8e14-226964062939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_294a7c12-0153-4d2f-b1e0-45d90cb6beb3" xlink:to="loc_us-gaap_ProfitLoss_a18410a0-671c-47c4-8e14-226964062939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_f4bf8cac-01fa-4115-8c3f-fab8e8fa33df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_294a7c12-0153-4d2f-b1e0-45d90cb6beb3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_f4bf8cac-01fa-4115-8c3f-fab8e8fa33df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ae815798-37da-4d1e-8830-2c62bc4ae819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b50923b3-59d0-46b3-b323-6160cd1e370a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ae815798-37da-4d1e-8830-2c62bc4ae819" xlink:to="loc_us-gaap_Revenues_b50923b3-59d0-46b3-b323-6160cd1e370a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c29cc381-919c-4428-817a-dbfedc67bbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ae815798-37da-4d1e-8830-2c62bc4ae819" xlink:to="loc_us-gaap_CostsAndExpenses_c29cc381-919c-4428-817a-dbfedc67bbcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9f3fc07b-51c0-4879-98f1-df3d807bb4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_27c6ec77-dccd-40d9-bb84-078f27e0e6bd" xlink:href="gh-20200630.xsd#gh_CostsofPrecisionOncologyTesting"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9f3fc07b-51c0-4879-98f1-df3d807bb4a3" xlink:to="loc_gh_CostsofPrecisionOncologyTesting_27c6ec77-dccd-40d9-bb84-078f27e0e6bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServices_ce63f7b6-08c7-47c9-ab22-32ad0305f498" xlink:href="gh-20200630.xsd#gh_CostofDevelopmentServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9f3fc07b-51c0-4879-98f1-df3d807bb4a3" xlink:to="loc_gh_CostofDevelopmentServices_ce63f7b6-08c7-47c9-ab22-32ad0305f498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dcd8710f-b58b-4009-ad9f-f171eccd88eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9f3fc07b-51c0-4879-98f1-df3d807bb4a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dcd8710f-b58b-4009-ad9f-f171eccd88eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_fc9ccb64-06ac-41ff-898c-7b277c64326c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9f3fc07b-51c0-4879-98f1-df3d807bb4a3" xlink:to="loc_us-gaap_SellingAndMarketingExpense_fc9ccb64-06ac-41ff-898c-7b277c64326c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9eb4a5e1-fda3-4404-aa39-4320d5d06811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9f3fc07b-51c0-4879-98f1-df3d807bb4a3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9eb4a5e1-fda3-4404-aa39-4320d5d06811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_569db786-5d28-4d32-8ac4-e0547429f817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ac69ab15-b110-4ade-aa2e-fd203a4b4d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_569db786-5d28-4d32-8ac4-e0547429f817" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ac69ab15-b110-4ade-aa2e-fd203a4b4d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0a166cb5-cc36-4ae9-88f7-d55afda51f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_569db786-5d28-4d32-8ac4-e0547429f817" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0a166cb5-cc36-4ae9-88f7-d55afda51f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9454254c-37f2-4425-87f5-c71feac289df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73f7b97e-cb9d-423f-8c43-0a8a6f85116a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9454254c-37f2-4425-87f5-c71feac289df" xlink:to="loc_us-gaap_OperatingIncomeLoss_73f7b97e-cb9d-423f-8c43-0a8a6f85116a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4bb96499-93e8-460d-990b-63bbd8f62d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9454254c-37f2-4425-87f5-c71feac289df" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4bb96499-93e8-460d-990b-63bbd8f62d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fdfea09e-541a-44b4-b810-3f8300d7fe19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9454254c-37f2-4425-87f5-c71feac289df" xlink:to="loc_us-gaap_InterestExpense_fdfea09e-541a-44b4-b810-3f8300d7fe19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c5bc4ff9-58b6-4825-9b25-1baf329615fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9454254c-37f2-4425-87f5-c71feac289df" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c5bc4ff9-58b6-4825-9b25-1baf329615fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0793163f-c016-4cf3-a62c-2ddcd289c3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_04fa33b6-770e-42a1-9bdc-d8c3e424b916" xlink:href="gh-20200630.xsd#gh_RevenuefromPrecisionOncologyTesting"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0793163f-c016-4cf3-a62c-2ddcd289c3ac" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_04fa33b6-770e-42a1-9bdc-d8c3e424b916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromDevelopmentServices_715b2253-9c4b-45d9-a38a-b40ab776b7c2" xlink:href="gh-20200630.xsd#gh_RevenuefromDevelopmentServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0793163f-c016-4cf3-a62c-2ddcd289c3ac" xlink:to="loc_gh_RevenuefromDevelopmentServices_715b2253-9c4b-45d9-a38a-b40ab776b7c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ea0c2d9-1c4d-460f-a167-666a258cface" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8070d3cc-57be-46aa-b7fb-30517b9ec431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ea0c2d9-1c4d-460f-a167-666a258cface" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8070d3cc-57be-46aa-b7fb-30517b9ec431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_16fda884-af89-4424-9885-f78820c7593a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2ea0c2d9-1c4d-460f-a167-666a258cface" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_16fda884-af89-4424-9885-f78820c7593a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2c08e6bd-cd52-4d0d-a906-2d086640cccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fef667ad-9208-44cd-b7b4-cb4397a0e798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2c08e6bd-cd52-4d0d-a906-2d086640cccf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fef667ad-9208-44cd-b7b4-cb4397a0e798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_64a8674b-1967-4337-bf55-0959e54c2c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2c08e6bd-cd52-4d0d-a906-2d086640cccf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_64a8674b-1967-4337-bf55-0959e54c2c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ac68cd79-5a67-4a6c-abca-e52635ac3f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2d707b10-f8a3-4efc-9353-50f4378e629c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ac68cd79-5a67-4a6c-abca-e52635ac3f89" xlink:to="loc_us-gaap_ProfitLoss_2d707b10-f8a3-4efc-9353-50f4378e629c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1a8caf05-66f9-452d-868f-a4df04ffd964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ac68cd79-5a67-4a6c-abca-e52635ac3f89" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1a8caf05-66f9-452d-868f-a4df04ffd964" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c90e5db-46c0-4536-9a3b-ef59baad0f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a616eede-c194-4c27-b2c7-e9be1e0479d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c90e5db-46c0-4536-9a3b-ef59baad0f76" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a616eede-c194-4c27-b2c7-e9be1e0479d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c6405d7b-c5f5-4a99-9604-559cc64e6285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c90e5db-46c0-4536-9a3b-ef59baad0f76" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c6405d7b-c5f5-4a99-9604-559cc64e6285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cf97e8cb-24cb-49df-bef0-ddc39f1db004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c90e5db-46c0-4536-9a3b-ef59baad0f76" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cf97e8cb-24cb-49df-bef0-ddc39f1db004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e9bdd60-74d0-4f26-bc74-322a29bb8d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c90e5db-46c0-4536-9a3b-ef59baad0f76" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e9bdd60-74d0-4f26-bc74-322a29bb8d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_408e620a-375a-4406-99d8-1a1d2b1d6e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c90e5db-46c0-4536-9a3b-ef59baad0f76" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_408e620a-375a-4406-99d8-1a1d2b1d6e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d057ec3a-5a87-41c9-b703-109b8307bbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1524be6c-7c37-4555-a5a1-2d9180804c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d057ec3a-5a87-41c9-b703-109b8307bbee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1524be6c-7c37-4555-a5a1-2d9180804c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9db08031-5761-46ea-897a-f5d05d44ac30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d057ec3a-5a87-41c9-b703-109b8307bbee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9db08031-5761-46ea-897a-f5d05d44ac30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673628b3-4442-4f69-ba47-8587050b6b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d057ec3a-5a87-41c9-b703-109b8307bbee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673628b3-4442-4f69-ba47-8587050b6b33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e393e954-e795-46bd-b0ed-839059035c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d057ec3a-5a87-41c9-b703-109b8307bbee" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e393e954-e795-46bd-b0ed-839059035c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_293525f4-12a1-4100-aa66-43ac1842dd21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_ProfitLoss_293525f4-12a1-4100-aa66-43ac1842dd21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8ee2fd78-2d60-493a-8771-c183c2d3b559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8ee2fd78-2d60-493a-8771-c183c2d3b559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AmortizationOfRightOfUseAsset_772b4a95-5cb3-4fa8-8d49-91a5ebda472f" xlink:href="gh-20200630.xsd#gh_AmortizationOfRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_gh_AmortizationOfRightOfUseAsset_772b4a95-5cb3-4fa8-8d49-91a5ebda472f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_e847d7eb-f9cf-4f9f-9610-634979054946" xlink:href="gh-20200630.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_e847d7eb-f9cf-4f9f-9610-634979054946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_44d31407-4813-4f6e-9dc2-5d6bde52cf28" xlink:href="gh-20200630.xsd#gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_44d31407-4813-4f6e-9dc2-5d6bde52cf28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_50033dca-fe98-4460-9726-c2c00c9c0090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_50033dca-fe98-4460-9726-c2c00c9c0090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0899b804-f896-4cd6-8693-9fb455ef06d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_ShareBasedCompensation_0899b804-f896-4cd6-8693-9fb455ef06d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32fe4dc9-b409-4a21-ad3a-28ec57e4c0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32fe4dc9-b409-4a21-ad3a-28ec57e4c0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_63dd8282-86ad-4c86-b857-8231440d6d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_63dd8282-86ad-4c86-b857-8231440d6d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_77d5dc0b-486d-4914-ae73-8b007cd35768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_77d5dc0b-486d-4914-ae73-8b007cd35768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ddd76c3-1049-4a47-a251-d40f64f459e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ddd76c3-1049-4a47-a251-d40f64f459e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b302cf7b-9eea-4767-91aa-4d1b135ecd12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b302cf7b-9eea-4767-91aa-4d1b135ecd12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0762bb35-457b-4046-8e0b-9e7c7771e1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0762bb35-457b-4046-8e0b-9e7c7771e1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_522462a8-4300-4d31-93b0-36aaf7300597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_522462a8-4300-4d31-93b0-36aaf7300597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_96f85c20-ef51-4e4f-b38c-fb47dd1cb111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_96f85c20-ef51-4e4f-b38c-fb47dd1cb111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d5ee9985-2373-4fab-8a94-1d68b86b3d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d5ee9985-2373-4fab-8a94-1d68b86b3d31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7fb5fcaf-dade-4524-916b-bee1109af3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7fb5fcaf-dade-4524-916b-bee1109af3e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_b3dc5772-b70b-4dce-bc66-6952bf476d34" xlink:href="gh-20200630.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_b3dc5772-b70b-4dce-bc66-6952bf476d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4069d626-bf92-4b7a-b0a5-36bb9bff167b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17c31a7-375c-44e8-b760-e9af8d843643" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4069d626-bf92-4b7a-b0a5-36bb9bff167b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921e07d0-4421-4f78-b9d5-c13db508a6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_62b93e55-0f37-4c89-aeb3-47fe2945d99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921e07d0-4421-4f78-b9d5-c13db508a6cd" xlink:to="loc_us-gaap_ProceedsFromStockPlans_62b93e55-0f37-4c89-aeb3-47fe2945d99c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_d1e5c771-29a6-479b-bfdd-9be7ea8bcd84" xlink:href="gh-20200630.xsd#gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921e07d0-4421-4f78-b9d5-c13db508a6cd" xlink:to="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_d1e5c771-29a6-479b-bfdd-9be7ea8bcd84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8a61462e-bf7b-4527-9099-a4bcf0d215d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921e07d0-4421-4f78-b9d5-c13db508a6cd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8a61462e-bf7b-4527-9099-a4bcf0d215d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_eeae1c8f-7cbf-4953-9fcf-070ef3e52ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921e07d0-4421-4f78-b9d5-c13db508a6cd" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_eeae1c8f-7cbf-4953-9fcf-070ef3e52ce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d657dcb-91d3-4a11-a214-fdb00f3c078f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921e07d0-4421-4f78-b9d5-c13db508a6cd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0d657dcb-91d3-4a11-a214-fdb00f3c078f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_37a8d207-45e5-4f0d-8740-dfa65d7cec81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921e07d0-4421-4f78-b9d5-c13db508a6cd" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_37a8d207-45e5-4f0d-8740-dfa65d7cec81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gh-20200630.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#DescriptionofBusinessDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="simple" xlink:href="gh-20200630.xsd#InvestmentinJointVenture"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#InvestmentinJointVentureDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9cf34e3c-e55f-41e9-b8ae-6483d2cd43f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_43bb6ccc-6c06-46dd-9d8c-c4f748d378ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9cf34e3c-e55f-41e9-b8ae-6483d2cd43f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_43bb6ccc-6c06-46dd-9d8c-c4f748d378ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_981bafd0-0ea4-49c9-8817-ae1e4e516609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9cf34e3c-e55f-41e9-b8ae-6483d2cd43f7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_981bafd0-0ea4-49c9-8817-ae1e4e516609" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_fdeadb55-d434-46c1-b896-e9fffa45a79d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_fdeadb55-d434-46c1-b896-e9fffa45a79d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_b91f281f-0884-40d3-84db-68180ed66deb" xlink:href="gh-20200630.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_b91f281f-0884-40d3-84db-68180ed66deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_a748552a-4981-481d-b139-c7d0dd1d6eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_a748552a-4981-481d-b139-c7d0dd1d6eae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ad4e9aee-b6b8-4181-a406-cc182966901f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ad4e9aee-b6b8-4181-a406-cc182966901f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedClinicalTrialsandStudies_cad70238-e31f-48ab-97a7-12a85a01dc2a" xlink:href="gh-20200630.xsd#gh_AccruedClinicalTrialsandStudies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_gh_AccruedClinicalTrialsandStudies_cad70238-e31f-48ab-97a7-12a85a01dc2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_a766676c-c668-48a2-b1d7-88321d18fb2a" xlink:href="gh-20200630.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_a766676c-c668-48a2-b1d7-88321d18fb2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0db5b951-4a1f-4317-9628-180367488681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0db5b951-4a1f-4317-9628-180367488681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_694a80fa-f761-4289-82fd-056bb311dde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dc3095d6-9724-4330-911e-1b04cbdb1455" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_694a80fa-f761-4289-82fd-056bb311dde6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecurities"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fafd3bd9-28a6-4db3-a649-3b240f3a2b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_258cd218-fa54-409f-af35-6c591c9ba568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_fafd3bd9-28a6-4db3-a649-3b240f3a2b81" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_258cd218-fa54-409f-af35-6c591c9ba568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a86833f5-1864-4f1e-af6d-4fa042396267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71aa0c34-6e72-4e98-b3b6-9a29f82409a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a86833f5-1864-4f1e-af6d-4fa042396267" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_71aa0c34-6e72-4e98-b3b6-9a29f82409a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_8f1a64b8-0afc-47b2-b6ee-ed432a2b889f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a86833f5-1864-4f1e-af6d-4fa042396267" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_8f1a64b8-0afc-47b2-b6ee-ed432a2b889f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_f170b7a1-8637-4923-9bca-0911a50c9979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a86833f5-1864-4f1e-af6d-4fa042396267" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_f170b7a1-8637-4923-9bca-0911a50c9979" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a789da56-5ed5-4e56-9d3c-48860089d2e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_73f3beac-0b59-45d8-9b98-02771ccc50c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a789da56-5ed5-4e56-9d3c-48860089d2e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_73f3beac-0b59-45d8-9b98-02771ccc50c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_c4c6059a-6e6b-4c6d-acc1-f9001a276617" xlink:href="gh-20200630.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3eee972b-711e-4d3e-9e9a-0173995cebf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_c4c6059a-6e6b-4c6d-acc1-f9001a276617" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3eee972b-711e-4d3e-9e9a-0173995cebf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_57967d94-341f-4ad8-9df5-b21028d08beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_c4c6059a-6e6b-4c6d-acc1-f9001a276617" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_57967d94-341f-4ad8-9df5-b21028d08beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_b3be23d4-895a-4327-8897-66f2ecbbfc29" xlink:href="gh-20200630.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_c4c6059a-6e6b-4c6d-acc1-f9001a276617" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_b3be23d4-895a-4327-8897-66f2ecbbfc29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65e1e96f-80a0-49f5-a4ab-836ba14ae713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a35f309a-ab76-4483-9d3e-17b523228b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65e1e96f-80a0-49f5-a4ab-836ba14ae713" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a35f309a-ab76-4483-9d3e-17b523228b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_650c4dfa-505d-49a7-be79-7767c2d5d807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65e1e96f-80a0-49f5-a4ab-836ba14ae713" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_650c4dfa-505d-49a7-be79-7767c2d5d807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7c7a3b2c-5948-4569-a5b5-faa37c10f591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65e1e96f-80a0-49f5-a4ab-836ba14ae713" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7c7a3b2c-5948-4569-a5b5-faa37c10f591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f833896b-c206-4ecd-a60e-832edb563925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_65e1e96f-80a0-49f5-a4ab-836ba14ae713" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f833896b-c206-4ecd-a60e-832edb563925" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwill"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_4fc9d4d1-1245-465c-9860-6209db933594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3d44fa7e-44cc-4f34-8c91-1da6e4942270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_4fc9d4d1-1245-465c-9860-6209db933594" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3d44fa7e-44cc-4f34-8c91-1da6e4942270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_4c7688aa-0268-468b-b1a8-ed6f9c090326" xlink:href="gh-20200630.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b497c1a8-6245-42d8-96af-f50d48588b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill_4c7688aa-0268-468b-b1a8-ed6f9c090326" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b497c1a8-6245-42d8-96af-f50d48588b2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc1bf9b7-a7cd-4b5c-8266-50431c523e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd0eabaf-217c-4474-89f9-a0cb8ad53b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc1bf9b7-a7cd-4b5c-8266-50431c523e8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd0eabaf-217c-4474-89f9-a0cb8ad53b51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ac28d0f9-944a-4ac4-acaf-e9e1c84a7626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fc1bf9b7-a7cd-4b5c-8266-50431c523e8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ac28d0f9-944a-4ac4-acaf-e9e1c84a7626" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca9bd645-abe5-49d9-8bf1-9f20734115d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_826e85ac-37ab-46b3-ba48-b63765722d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca9bd645-abe5-49d9-8bf1-9f20734115d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_826e85ac-37ab-46b3-ba48-b63765722d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a9609922-0f43-4f90-9bdd-cececc6f67f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca9bd645-abe5-49d9-8bf1-9f20734115d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a9609922-0f43-4f90-9bdd-cececc6f67f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_159169b8-c500-414e-a632-b52a47afb9f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca9bd645-abe5-49d9-8bf1-9f20734115d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_159169b8-c500-414e-a632-b52a47afb9f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_988ab7a6-3bd6-4f55-89fa-ff2240682ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca9bd645-abe5-49d9-8bf1-9f20734115d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_988ab7a6-3bd6-4f55-89fa-ff2240682ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3bf384b6-1530-4886-aa31-aed3c46e988c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca9bd645-abe5-49d9-8bf1-9f20734115d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3bf384b6-1530-4886-aa31-aed3c46e988c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_fc477126-d9c9-4265-8d58-eb173acb9aff" xlink:href="gh-20200630.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca9bd645-abe5-49d9-8bf1-9f20734115d9" xlink:to="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_fc477126-d9c9-4265-8d58-eb173acb9aff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Acquisition" xlink:type="simple" xlink:href="gh-20200630.xsd#Acquisition"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/Acquisition" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionTables" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionPatentLicenseAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionAcquisitionofBellwetherBioDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7796bb55-8aa0-4b11-94c4-b7ec6427f0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3cc6d5f0-927c-4e14-9ebd-16478fc0e7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7796bb55-8aa0-4b11-94c4-b7ec6427f0d8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3cc6d5f0-927c-4e14-9ebd-16478fc0e7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2332e2c9-defd-445a-a267-d1f362739337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7796bb55-8aa0-4b11-94c4-b7ec6427f0d8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2332e2c9-defd-445a-a267-d1f362739337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8e870177-2b0b-42bf-a075-a2128acd09a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7796bb55-8aa0-4b11-94c4-b7ec6427f0d8" xlink:to="loc_us-gaap_Goodwill_8e870177-2b0b-42bf-a075-a2128acd09a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f84bdfc1-acde-496c-92e8-b6f13a9932c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7796bb55-8aa0-4b11-94c4-b7ec6427f0d8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f84bdfc1-acde-496c-92e8-b6f13a9932c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionIntangibleAssetsAcquiredDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:type="simple" xlink:href="gh-20200630.xsd#Leases"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesLeaseInformationDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30de0c6e-d6af-4854-94d9-d24c2bb7cdb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4ae22c19-2b55-41c0-b4a4-f6aa3f222151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30de0c6e-d6af-4854-94d9-d24c2bb7cdb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4ae22c19-2b55-41c0-b4a4-f6aa3f222151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a2110a1-0a1d-4fdc-b10e-2ad5617a61d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30de0c6e-d6af-4854-94d9-d24c2bb7cdb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a2110a1-0a1d-4fdc-b10e-2ad5617a61d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_baacc922-7821-477d-a7eb-fc0f371be667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30de0c6e-d6af-4854-94d9-d24c2bb7cdb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_baacc922-7821-477d-a7eb-fc0f371be667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33a6cc99-17db-43c9-86c8-ffd229cc767a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30de0c6e-d6af-4854-94d9-d24c2bb7cdb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33a6cc99-17db-43c9-86c8-ffd229cc767a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c26070e8-4537-46e5-8d08-602b665f121f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30de0c6e-d6af-4854-94d9-d24c2bb7cdb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c26070e8-4537-46e5-8d08-602b665f121f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_4f14d36d-ffd0-4448-b7f4-185f69a546a7" xlink:href="gh-20200630.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30de0c6e-d6af-4854-94d9-d24c2bb7cdb6" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_4f14d36d-ffd0-4448-b7f4-185f69a546a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a82d557f-4740-4c6a-9aa5-cdb6ce0be35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ab8a84d-c27c-47c2-974d-7292688687b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a82d557f-4740-4c6a-9aa5-cdb6ce0be35b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ab8a84d-c27c-47c2-974d-7292688687b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_187964c7-8afc-4575-a214-9259dc739536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a82d557f-4740-4c6a-9aa5-cdb6ce0be35b" xlink:to="loc_us-gaap_OperatingLeaseLiability_187964c7-8afc-4575-a214-9259dc739536" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gh-20200630.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStock"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockTables" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStockTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommonStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStockDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationValuationofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gh-20200630.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformation"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformationTables"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformationDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="gh-20200630.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gh-20200630.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SubsequentEventsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://guardanthealth.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>gh-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a823c88f-2b24-44ac-a516-3f731119002e,g:77fc4dec-5a42-485c-bad8-a10178a2afe8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CoverPage" xlink:type="simple" xlink:href="gh-20200630.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CoverPage" xlink:type="extended" id="if2268f5721c74ad38abac5652f8f7b89_CoverPage"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended" id="iacec65750e0e40d680e845f6ac2a7487_CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended" id="i86ec3c9ab4434fab8a1fe87cd483d968_CondensedConsolidatedBalanceSheetsunauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e985c260-a53f-4725-a353-ddc0b851d73f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e985c260-a53f-4725-a353-ddc0b851d73f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6edb3789-5066-4bf9-af42-61ae610c927e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6edb3789-5066-4bf9-af42-61ae610c927e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1140d68f-2ba1-4c73-be3c-99e77151b609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1140d68f-2ba1-4c73-be3c-99e77151b609" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1637f3bb-3185-4b3e-a5d0-047bbb8b7ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockSharesIssued_1637f3bb-3185-4b3e-a5d0-047bbb8b7ecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d1b4ae84-687e-4933-bc9e-266c5e6033f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_Assets_d1b4ae84-687e-4933-bc9e-266c5e6033f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0ed9385b-4e5e-4f66-a361-0de0cc33ce75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_Liabilities_0ed9385b-4e5e-4f66-a361-0de0cc33ce75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6485516-15ad-48e5-870d-a4fe268c09f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_StatementTable_e6485516-15ad-48e5-870d-a4fe268c09f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e6485516-15ad-48e5-870d-a4fe268c09f8" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5ab879f4-464b-4fc7-a3f3-c166ec96ae54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5ab879f4-464b-4fc7-a3f3-c166ec96ae54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_1bd2340e-490e-4a18-900d-927462f93056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5ab879f4-464b-4fc7-a3f3-c166ec96ae54" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_1bd2340e-490e-4a18-900d-927462f93056" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended" id="i505289a6de884aa283ab6e9f4c910676_CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended" id="i83bb29467e494d41a9c0928ea0f25c9b_CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="extended" id="id326f61fc9a547a3b45afeb9744ed591_CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8a6542c0-2dec-4e12-abac-6f9e06cc7c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8a6542c0-2dec-4e12-abac-6f9e06cc7c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_402a7ddf-95c7-4875-b848-bce12b584107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_402a7ddf-95c7-4875-b848-bce12b584107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_53bb5a55-035e-4652-b87d-1d91ab57cc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3f8be08f-d655-4c11-b9db-e4d3c1efa4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_SharesOutstanding_3f8be08f-d655-4c11-b9db-e4d3c1efa4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b778131-c4ed-4553-af13-efaa39069ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockholdersEquity_6b778131-c4ed-4553-af13-efaa39069ec0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f2cbd5a-1772-477c-91e6-d20a1f7f764e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f2cbd5a-1772-477c-91e6-d20a1f7f764e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86b2937d-047e-40b3-9825-9761ffa5afe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86b2937d-047e-40b3-9825-9761ffa5afe1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6aabdb2-ddff-44ea-bac5-01e483b0689c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6aabdb2-ddff-44ea-bac5-01e483b0689c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e2b93e84-0be9-4f2a-934f-99c955fa70aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e2b93e84-0be9-4f2a-934f-99c955fa70aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_caf2a07a-fb26-4540-abf0-f0181b46f7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_caf2a07a-fb26-4540-abf0-f0181b46f7fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_0145260d-543f-449a-a859-ba0e874eb783" xlink:href="gh-20200630.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_0145260d-543f-449a-a859-ba0e874eb783" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a2329012-5812-452b-a4f8-ed2dcfbff89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a2329012-5812-452b-a4f8-ed2dcfbff89f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7f184322-4e35-4fa9-8bf9-94b1b665178f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7f184322-4e35-4fa9-8bf9-94b1b665178f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0ba7fbb5-66da-450a-bba2-9d432582cf10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0ba7fbb5-66da-450a-bba2-9d432582cf10" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9013f6b-dade-48e2-b25c-f6f56b6b36f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9013f6b-dade-48e2-b25c-f6f56b6b36f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_136fe3cb-c6c7-4528-a972-378f2825f8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_ProfitLoss_136fe3cb-c6c7-4528-a972-378f2825f8e6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0bb1e188-8ee1-45c3-a2ca-4fbe1caf02e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9df955c8-eec8-4129-87ca-d9314bc93e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_007dcc28-a324-4a46-8705-009293ad837b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_007dcc28-a324-4a46-8705-009293ad837b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:to="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ff743c1-3e0a-448a-a410-4257d8e7c90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ff743c1-3e0a-448a-a410-4257d8e7c90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ff743c1-3e0a-448a-a410-4257d8e7c90a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ff743c1-3e0a-448a-a410-4257d8e7c90a" xlink:to="loc_us-gaap_EquityComponentDomain_6ff743c1-3e0a-448a-a410-4257d8e7c90a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ff743c1-3e0a-448a-a410-4257d8e7c90a" xlink:to="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_dd9e30dd-80c9-46ee-ae6e-dc21f86749a0" xlink:href="gh-20200630.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_dd9e30dd-80c9-46ee-ae6e-dc21f86749a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8194222e-664a-4eb2-87a7-2e6d42de3a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_CommonStockMember_8194222e-664a-4eb2-87a7-2e6d42de3a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_51865900-1bc5-400d-8579-57c0a917c3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_51865900-1bc5-400d-8579-57c0a917c3c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e603bcde-98b5-4015-bdae-b6f466ca62a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e603bcde-98b5-4015-bdae-b6f466ca62a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0120880a-9a5c-47e2-9bd6-17595bd70eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_RetainedEarningsMember_0120880a-9a5c-47e2-9bd6-17595bd70eb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8f3a6a61-f764-4eeb-a673-830caa31e4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_8f3a6a61-f764-4eeb-a673-830caa31e4c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201807Member_6eb84ce9-6e7c-4adb-b6d2-b8582a810016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201807Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201807Member_6eb84ce9-6e7c-4adb-b6d2-b8582a810016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c8581aa7-bacd-4d02-b223-ef8529f4e194" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c8581aa7-bacd-4d02-b223-ef8529f4e194" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8581aa7-bacd-4d02-b223-ef8529f4e194_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c8581aa7-bacd-4d02-b223-ef8529f4e194" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c8581aa7-bacd-4d02-b223-ef8529f4e194_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1475ba6c-422e-4c6f-bf06-ab57273f4663" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c8581aa7-bacd-4d02-b223-ef8529f4e194" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1475ba6c-422e-4c6f-bf06-ab57273f4663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_91e58d98-7a32-43a7-8618-00ff49b853db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1475ba6c-422e-4c6f-bf06-ab57273f4663" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_91e58d98-7a32-43a7-8618-00ff49b853db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="extended" id="i623181fd184f46c982f6956d762d11fb_CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended" id="iee982e822c0e4fa7a46a8e9fa70bcf3c_CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gh-20200630.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="extended" id="i978196d60c534a11a73a1fc9566e1a5a_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="iad0ed437389647ff94df444f97ac2240_DescriptionofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_64c4359d-2ffc-4c26-8d9d-d78b64886317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28e4301a-0daf-4a4a-997e-5a0d918ee084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_64c4359d-2ffc-4c26-8d9d-d78b64886317" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28e4301a-0daf-4a4a-997e-5a0d918ee084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d8a591a-806a-4a3b-a745-e02c549da689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_64c4359d-2ffc-4c26-8d9d-d78b64886317" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d8a591a-806a-4a3b-a745-e02c549da689" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_daa183d5-3f4f-4540-a80a-b0769ae9bcbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d8a591a-806a-4a3b-a745-e02c549da689" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_daa183d5-3f4f-4540-a80a-b0769ae9bcbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_daa183d5-3f4f-4540-a80a-b0769ae9bcbe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_daa183d5-3f4f-4540-a80a-b0769ae9bcbe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_daa183d5-3f4f-4540-a80a-b0769ae9bcbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7bfda289-13f6-4cd8-8a4d-7b6f6f2fcb47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_daa183d5-3f4f-4540-a80a-b0769ae9bcbe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7bfda289-13f6-4cd8-8a4d-7b6f6f2fcb47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_23a10343-702a-46b3-8398-bb09cf323529" xlink:href="gh-20200630.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bfda289-13f6-4cd8-8a4d-7b6f6f2fcb47" xlink:to="loc_gh_GuardantHealthAMEAIncMember_23a10343-702a-46b3-8398-bb09cf323529" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i43bea17628f644cc81b9ca6e902834b1_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ida833854869e446e8db1eaed71f794d0_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="if62e8498502a484fa8d28b347e98f882_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i72c0cc3ff1784be6bc400468ff1ee088_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_dc0e667a-6c26-43a1-a2a2-8f8af7640cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_dc0e667a-6c26-43a1-a2a2-8f8af7640cd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a91cdda1-fbd7-4f1b-9cc2-6cd5687072e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a91cdda1-fbd7-4f1b-9cc2-6cd5687072e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2431ea9d-0c08-4c8e-b30b-8ad9a02499be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2431ea9d-0c08-4c8e-b30b-8ad9a02499be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0b51901-4341-4d64-9249-dfbf8be2d789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0b51901-4341-4d64-9249-dfbf8be2d789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_245ded1d-8e95-4870-bbac-6c06c6d71180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_245ded1d-8e95-4870-bbac-6c06c6d71180" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b7fd64-a332-4c0b-aac5-0d552e689787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b7fd64-a332-4c0b-aac5-0d552e689787" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress_870eb94e-ef9f-44b4-8529-30fcf153af23" xlink:href="gh-20200630.xsd#gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress_870eb94e-ef9f-44b4-8529-30fcf153af23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_d014748a-d917-4989-bdf9-2266eebe07ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_d014748a-d917-4989-bdf9-2266eebe07ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e4b3faf5-6a1f-4646-a234-e40f1b6ba18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e4b3faf5-6a1f-4646-a234-e40f1b6ba18f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a227f45-d8b0-4b11-bc83-aac8172e0ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a227f45-d8b0-4b11-bc83-aac8172e0ae1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d225329-ea44-465c-b198-794b0c64b6d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_srt_RangeAxis_5d225329-ea44-465c-b198-794b0c64b6d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d225329-ea44-465c-b198-794b0c64b6d2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d225329-ea44-465c-b198-794b0c64b6d2" xlink:to="loc_srt_RangeMember_5d225329-ea44-465c-b198-794b0c64b6d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d225329-ea44-465c-b198-794b0c64b6d2" xlink:to="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_650bb264-821f-469d-85f2-6d239d458a81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:to="loc_srt_MinimumMember_650bb264-821f-469d-85f2-6d239d458a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dbf4dc99-4793-42f8-ac91-6272c61e031e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:to="loc_srt_MaximumMember_dbf4dc99-4793-42f8-ac91-6272c61e031e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_08c79aa4-8217-4c35-8ec6-45a80332282a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_08c79aa4-8217-4c35-8ec6-45a80332282a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_08c79aa4-8217-4c35-8ec6-45a80332282a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08c79aa4-8217-4c35-8ec6-45a80332282a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_08c79aa4-8217-4c35-8ec6-45a80332282a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9cd189d5-13ca-45ed-8bde-a7b56227b9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08c79aa4-8217-4c35-8ec6-45a80332282a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9cd189d5-13ca-45ed-8bde-a7b56227b9db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_8e74eff0-3970-42ae-a45d-a7bc7a3c7330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9cd189d5-13ca-45ed-8bde-a7b56227b9db" xlink:to="loc_us-gaap_OtherAssetsMember_8e74eff0-3970-42ae-a45d-a7bc7a3c7330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1169947b-295d-4e56-b545-5486159bc39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1169947b-295d-4e56-b545-5486159bc39e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1169947b-295d-4e56-b545-5486159bc39e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1169947b-295d-4e56-b545-5486159bc39e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1169947b-295d-4e56-b545-5486159bc39e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_82830a64-bb4c-4a6f-85f7-5f4e1a0f9728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1169947b-295d-4e56-b545-5486159bc39e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_82830a64-bb4c-4a6f-85f7-5f4e1a0f9728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b71fe0d8-0a8f-43af-bb33-265e94e2fbe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_82830a64-bb4c-4a6f-85f7-5f4e1a0f9728" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b71fe0d8-0a8f-43af-bb33-265e94e2fbe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_234ccb72-bf19-476a-913c-5dc3c587e6b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_srt_MajorCustomersAxis_234ccb72-bf19-476a-913c-5dc3c587e6b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_234ccb72-bf19-476a-913c-5dc3c587e6b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_234ccb72-bf19-476a-913c-5dc3c587e6b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_234ccb72-bf19-476a-913c-5dc3c587e6b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab877e5e-7731-4860-a34d-d2777a665ffe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_234ccb72-bf19-476a-913c-5dc3c587e6b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab877e5e-7731-4860-a34d-d2777a665ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_MedicareMember_224c49dd-c191-430d-a2ea-b68985a9339d" xlink:href="gh-20200630.xsd#gh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab877e5e-7731-4860-a34d-d2777a665ffe" xlink:to="loc_gh_MedicareMember_224c49dd-c191-430d-a2ea-b68985a9339d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended" id="i3091fbafd1bc47cf8be06d4089c0b0ce_SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5f69976d-4b8f-47a1-9922-087c0eba39b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e6fb6132-c7ff-44cf-8cd6-21f1cd92a5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5f69976d-4b8f-47a1-9922-087c0eba39b6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e6fb6132-c7ff-44cf-8cd6-21f1cd92a5bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5f69976d-4b8f-47a1-9922-087c0eba39b6" xlink:to="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4b48f915-5607-4bf0-a367-3da747de1210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:to="loc_srt_MajorCustomersAxis_4b48f915-5607-4bf0-a367-3da747de1210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4b48f915-5607-4bf0-a367-3da747de1210_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4b48f915-5607-4bf0-a367-3da747de1210" xlink:to="loc_srt_NameOfMajorCustomerDomain_4b48f915-5607-4bf0-a367-3da747de1210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4b48f915-5607-4bf0-a367-3da747de1210" xlink:to="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember_a567e931-5ac2-4e87-bfba-271f7a4f101f" xlink:href="gh-20200630.xsd#gh_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerAMember_a567e931-5ac2-4e87-bfba-271f7a4f101f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember_d317e2be-b7ff-4ceb-9eb6-e44d9b6bdfb0" xlink:href="gh-20200630.xsd#gh_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerBMember_d317e2be-b7ff-4ceb-9eb6-e44d9b6bdfb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember_524816b7-b083-47c0-99f7-67ab6467f084" xlink:href="gh-20200630.xsd#gh_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerCMember_524816b7-b083-47c0-99f7-67ab6467f084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember_10f9992d-e192-4bbe-9389-e273945b61f0" xlink:href="gh-20200630.xsd#gh_CustomerDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerDMember_10f9992d-e192-4bbe-9389-e273945b61f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerEMember_db48cc2a-ba17-43cf-a34d-2c8c31acec55" xlink:href="gh-20200630.xsd#gh_CustomerEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerEMember_db48cc2a-ba17-43cf-a34d-2c8c31acec55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_88270527-673c-4e91-be26-141d03780181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_88270527-673c-4e91-be26-141d03780181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_88270527-673c-4e91-be26-141d03780181_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_88270527-673c-4e91-be26-141d03780181" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_88270527-673c-4e91-be26-141d03780181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fc908896-29d0-4b4b-8f62-58e492f95b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_88270527-673c-4e91-be26-141d03780181" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fc908896-29d0-4b4b-8f62-58e492f95b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_613c76b2-a15b-4f8a-b01d-ab455f7e83ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fc908896-29d0-4b4b-8f62-58e492f95b08" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_613c76b2-a15b-4f8a-b01d-ab455f7e83ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d05fa9b-d70b-442d-aa77-32dcd373f27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d05fa9b-d70b-442d-aa77-32dcd373f27f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1d05fa9b-d70b-442d-aa77-32dcd373f27f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d05fa9b-d70b-442d-aa77-32dcd373f27f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1d05fa9b-d70b-442d-aa77-32dcd373f27f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d05fa9b-d70b-442d-aa77-32dcd373f27f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_917f2f5d-9347-43d3-951a-d03e1e8e4d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:to="loc_us-gaap_SalesRevenueNetMember_917f2f5d-9347-43d3-951a-d03e1e8e4d29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_73e7d300-1ab6-4bd0-8457-0bd307481cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:to="loc_us-gaap_AccountsReceivableMember_73e7d300-1ab6-4bd0-8457-0bd307481cfe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="simple" xlink:href="gh-20200630.xsd#InvestmentinJointVenture"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="extended" id="ie89a2787cbb74adc988d3d9d64eb9a02_InvestmentinJointVenture"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#InvestmentinJointVentureDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="extended" id="id938c2a743344628a233bbbb51095b5b_InvestmentinJointVentureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_7cd4a134-9d9d-4bb6-bd78-ac41fcf89419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_7cd4a134-9d9d-4bb6-bd78-ac41fcf89419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased_dd12b0ac-7a0c-4fa2-aca7-953d214635a8" xlink:href="gh-20200630.xsd#gh_EquityMethodInvestmentSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_EquityMethodInvestmentSharesPurchased_dd12b0ac-7a0c-4fa2-aca7-953d214635a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9e6783df-28a5-4a2d-968a-744799336342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9e6783df-28a5-4a2d-968a-744799336342" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_986b0fde-3eef-4e0f-8b0b-8323796d94c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_986b0fde-3eef-4e0f-8b0b-8323796d94c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_46886f14-7b95-4382-b10d-ded152b129fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_46886f14-7b95-4382-b10d-ded152b129fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e7bcc3fb-4a6a-4e85-98e3-a80bd67e0bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e7bcc3fb-4a6a-4e85-98e3-a80bd67e0bab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_a82fbc47-cbac-4d84-bb55-62abf2163a7c" xlink:href="gh-20200630.xsd#gh_PreferredStockSharesIssuedUponConversionOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_a82fbc47-cbac-4d84-bb55-62abf2163a7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_81f390b4-6133-4698-a0fa-924c0ae6d126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_81f390b4-6133-4698-a0fa-924c0ae6d126" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_83fc3ba4-b26f-4629-850a-2c79540020cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_83fc3ba4-b26f-4629-850a-2c79540020cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_67c354b8-3a7b-4568-b00d-c72840c5726c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_67c354b8-3a7b-4568-b00d-c72840c5726c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7f426ba3-6337-4ea5-abc2-3c214f97a774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7f426ba3-6337-4ea5-abc2-3c214f97a774" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf543428-4bf3-4eba-94e4-d53de454f2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cf543428-4bf3-4eba-94e4-d53de454f2c3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_64b8673c-1624-41d0-8478-9c7284d1aa23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_64b8673c-1624-41d0-8478-9c7284d1aa23" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_344622da-7595-480b-99fa-3a4fc398a57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_Assets_344622da-7595-480b-99fa-3a4fc398a57f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_26a87a83-51e2-4e65-8ac4-98bee8fa762d" xlink:href="gh-20200630.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_26a87a83-51e2-4e65-8ac4-98bee8fa762d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_f8c59a49-15bd-47ea-a4a0-c9d76f5801f6" xlink:href="gh-20200630.xsd#gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_f8c59a49-15bd-47ea-a4a0-c9d76f5801f6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1bf8d10-64a9-4459-b9b0-a4e44ad36464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1bf8d10-64a9-4459-b9b0-a4e44ad36464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a1bf8d10-64a9-4459-b9b0-a4e44ad36464_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1bf8d10-64a9-4459-b9b0-a4e44ad36464" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a1bf8d10-64a9-4459-b9b0-a4e44ad36464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6e3c302e-b5c0-44f5-9326-72270347db8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1bf8d10-64a9-4459-b9b0-a4e44ad36464" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6e3c302e-b5c0-44f5-9326-72270347db8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_c5aa4111-6aa2-4de0-9491-6b6511fdf930" xlink:href="gh-20200630.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e3c302e-b5c0-44f5-9326-72270347db8d" xlink:to="loc_gh_GuardantHealthAMEAIncMember_c5aa4111-6aa2-4de0-9491-6b6511fdf930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0fbc702b-c9d9-4053-b6bb-20b43828552c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_dei_LegalEntityAxis_0fbc702b-c9d9-4053-b6bb-20b43828552c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0fbc702b-c9d9-4053-b6bb-20b43828552c_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0fbc702b-c9d9-4053-b6bb-20b43828552c" xlink:to="loc_dei_EntityDomain_0fbc702b-c9d9-4053-b6bb-20b43828552c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_47b0e592-3684-46ee-8203-605f98b6f745" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0fbc702b-c9d9-4053-b6bb-20b43828552c" xlink:to="loc_dei_EntityDomain_47b0e592-3684-46ee-8203-605f98b6f745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_abed7ee5-cf7f-45b3-961c-d3e5dd485f49" xlink:href="gh-20200630.xsd#gh_SoftBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_47b0e592-3684-46ee-8203-605f98b6f745" xlink:to="loc_gh_SoftBankMember_abed7ee5-cf7f-45b3-961c-d3e5dd485f49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_91bc83b2-a470-47f8-aa94-29d749f2859b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_91bc83b2-a470-47f8-aa94-29d749f2859b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_91bc83b2-a470-47f8-aa94-29d749f2859b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_91bc83b2-a470-47f8-aa94-29d749f2859b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_91bc83b2-a470-47f8-aa94-29d749f2859b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_54f5d691-3ae7-4644-baff-956db71af9fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_91bc83b2-a470-47f8-aa94-29d749f2859b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_54f5d691-3ae7-4644-baff-956db71af9fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_68d1a9e6-a08a-45a5-a292-d67985425434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_54f5d691-3ae7-4644-baff-956db71af9fe" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_68d1a9e6-a08a-45a5-a292-d67985425434" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24" xlink:to="loc_us-gaap_ClassOfStockDomain_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24" xlink:to="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_77eaa314-67fc-4913-8c60-ecbd6d1e12a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:to="loc_us-gaap_CommonClassAMember_77eaa314-67fc-4913-8c60-ecbd6d1e12a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_56504612-b32f-4e61-aa3d-6d27b12a4ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:to="loc_us-gaap_CommonClassBMember_56504612-b32f-4e61-aa3d-6d27b12a4ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_54a478ba-1054-4fd4-a84f-725c3b7ccae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_54a478ba-1054-4fd4-a84f-725c3b7ccae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_09df98d8-26c8-49fb-891d-b4f823c6341e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_srt_CounterpartyNameAxis_09df98d8-26c8-49fb-891d-b4f823c6341e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09df98d8-26c8-49fb-891d-b4f823c6341e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_09df98d8-26c8-49fb-891d-b4f823c6341e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_09df98d8-26c8-49fb-891d-b4f823c6341e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_09df98d8-26c8-49fb-891d-b4f823c6341e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_4f89e3d1-beda-451c-9601-61e9d711ac25" xlink:href="gh-20200630.xsd#gh_SoftBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:to="loc_gh_SoftBankMember_4f89e3d1-beda-451c-9601-61e9d711ac25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthIncMember_f2cc9081-b651-45a7-98c4-e94f0affceec" xlink:href="gh-20200630.xsd#gh_GuardantHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:to="loc_gh_GuardantHealthIncMember_f2cc9081-b651-45a7-98c4-e94f0affceec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="extended" id="i4058a88c49f646bbb53dd3a0518ab71f_CondensedConsolidatedBalanceSheetComponents"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="extended" id="i72d427c16349443fba73e6ab52df0af7_CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended" id="ib0ca8a606867426da237048956fc5078_CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ae19a478-327f-49fb-b2b7-8aec5586aa39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ae19a478-327f-49fb-b2b7-8aec5586aa39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_438aae27-8b8e-4daa-a96f-599760061bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_438aae27-8b8e-4daa-a96f-599760061bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_018827f7-60e8-4d3c-961a-b9042ec689bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_018827f7-60e8-4d3c-961a-b9042ec689bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_065b1c19-b3a6-4987-bb9e-f8d71957aca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_065b1c19-b3a6-4987-bb9e-f8d71957aca1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c5dd6952-b39b-4f83-875e-e1cdb88768a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_065b1c19-b3a6-4987-bb9e-f8d71957aca1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c5dd6952-b39b-4f83-875e-e1cdb88768a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5dd6952-b39b-4f83-875e-e1cdb88768a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c5dd6952-b39b-4f83-875e-e1cdb88768a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c5dd6952-b39b-4f83-875e-e1cdb88768a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c5dd6952-b39b-4f83-875e-e1cdb88768a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_fde5f1e8-f762-49b6-a604-657ebe8f59f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_fde5f1e8-f762-49b6-a604-657ebe8f59f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_25a31e53-e2fb-4375-8bf8-fb3004585866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_ComputerEquipmentMember_25a31e53-e2fb-4375-8bf8-fb3004585866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8f1e9629-97f7-42c5-a977-3b478c9e10ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8f1e9629-97f7-42c5-a977-3b478c9e10ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_93d08c72-9cce-49d1-a7c3-3ee5a0618570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_93d08c72-9cce-49d1-a7c3-3ee5a0618570" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_172296c3-5934-4d89-b3c9-14446c98af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_172296c3-5934-4d89-b3c9-14446c98af49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_32991f5a-046d-45c4-a713-7cd2b27b7780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_ConstructionInProgressMember_32991f5a-046d-45c4-a713-7cd2b27b7780" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended" id="iac781e1a0f8048bda1f1f105f9bc9e2a_CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="extended" id="iba71cd5ad9aa472eb6247c5b56069325_CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecurities"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="extended" id="if69d98a8080e4390b6640c8a39566f38_FairValueMeasurementsCashEquivalentsandMarketableSecurities"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended" id="icbbeb157148c4a798169cd9ef9c91e79_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="i008628e6196f452cb3d992bf29ae40b7_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d659f34-4ac1-4c8e-b6e5-778f84664cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d659f34-4ac1-4c8e-b6e5-778f84664cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_94bb0dba-e6a1-4a16-93ed-2ea0472adeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_94bb0dba-e6a1-4a16-93ed-2ea0472adeb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_8c6fa8ca-df3b-4139-822d-309a19a7e8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_8c6fa8ca-df3b-4139-822d-309a19a7e8d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1575a865-1e2b-4aa1-9343-4a9f5a471bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1575a865-1e2b-4aa1-9343-4a9f5a471bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bda4fae4-3d11-4eae-876b-78e9a0ede808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bda4fae4-3d11-4eae-876b-78e9a0ede808" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aaa06114-c38c-4bb6-947d-35ec43046250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_aaa06114-c38c-4bb6-947d-35ec43046250" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e85b3f6-be81-46e9-b632-af5cd29f6d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e85b3f6-be81-46e9-b632-af5cd29f6d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4e85b3f6-be81-46e9-b632-af5cd29f6d54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e85b3f6-be81-46e9-b632-af5cd29f6d54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4e85b3f6-be81-46e9-b632-af5cd29f6d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ff111b3-5266-46ed-b70e-f1d66804f7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e85b3f6-be81-46e9-b632-af5cd29f6d54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ff111b3-5266-46ed-b70e-f1d66804f7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b9d1a655-5be2-4de6-92db-f567f43ad7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ff111b3-5266-46ed-b70e-f1d66804f7f1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b9d1a655-5be2-4de6-92db-f567f43ad7bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f72485f6-519a-4892-b27a-898855919756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f72485f6-519a-4892-b27a-898855919756" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f72485f6-519a-4892-b27a-898855919756_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f72485f6-519a-4892-b27a-898855919756" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f72485f6-519a-4892-b27a-898855919756_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a03cdccc-f0cb-42ed-b908-a7968daf6e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f72485f6-519a-4892-b27a-898855919756" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a03cdccc-f0cb-42ed-b908-a7968daf6e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_741d436e-1ed1-4624-9348-5eb1fb0e1b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a03cdccc-f0cb-42ed-b908-a7968daf6e74" xlink:to="loc_us-gaap_MoneyMarketFundsMember_741d436e-1ed1-4624-9348-5eb1fb0e1b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1d06c884-fd6a-4b73-8f20-98f801e02a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1d06c884-fd6a-4b73-8f20-98f801e02a2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1d06c884-fd6a-4b73-8f20-98f801e02a2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1d06c884-fd6a-4b73-8f20-98f801e02a2a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1d06c884-fd6a-4b73-8f20-98f801e02a2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1d06c884-fd6a-4b73-8f20-98f801e02a2a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_416613d8-7267-4fc4-993b-1add43a8e502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_416613d8-7267-4fc4-993b-1add43a8e502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_45ac1ddd-e2ad-4a10-9a7d-694c0f97d39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_45ac1ddd-e2ad-4a10-9a7d-694c0f97d39a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49c33d8a-8695-453f-a5a9-39202f01fc26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49c33d8a-8695-453f-a5a9-39202f01fc26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49c33d8a-8695-453f-a5a9-39202f01fc26_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49c33d8a-8695-453f-a5a9-39202f01fc26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_49c33d8a-8695-453f-a5a9-39202f01fc26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49c33d8a-8695-453f-a5a9-39202f01fc26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_da0023d6-8d9b-4107-b302-6ab7a4364c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_da0023d6-8d9b-4107-b302-6ab7a4364c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_70a7b645-6153-44af-9055-ba8c7e980c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_70a7b645-6153-44af-9055-ba8c7e980c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_96a10ac0-c882-459d-8281-49d9ee6178f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_96a10ac0-c882-459d-8281-49d9ee6178f6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="extended" id="i3b5ae8abe9a540f780e14bed6233a5ed_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c93b24b5-71e1-47ce-b47a-a52c81c74e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c93b24b5-71e1-47ce-b47a-a52c81c74e2a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6d0f38a0-c7fd-4382-9bf5-56da054cb551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6d0f38a0-c7fd-4382-9bf5-56da054cb551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aee380d2-8482-41de-b29a-bbe8de1e50ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aee380d2-8482-41de-b29a-bbe8de1e50ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b1959b49-8eee-44be-b408-6a01a46a5717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b1959b49-8eee-44be-b408-6a01a46a5717" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_15017c42-6fda-4f45-8167-71e68a159812" xlink:href="gh-20200630.xsd#gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_15017c42-6fda-4f45-8167-71e68a159812" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c0fbfb46-2680-4dd2-8d50-983ff393f384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c93b24b5-71e1-47ce-b47a-a52c81c74e2a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_b0851617-ad4b-41ff-b0ca-90aca7f8747f" xlink:href="gh-20200630.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_b0851617-ad4b-41ff-b0ca-90aca7f8747f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember_f6759930-2602-47d0-bf1d-65fb8b8ca18f" xlink:href="gh-20200630.xsd#gh_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:to="loc_gh_ContingentConsiderationMember_f6759930-2602-47d0-bf1d-65fb8b8ca18f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a5667d-f56d-440d-a3fe-691a4c29242d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a5667d-f56d-440d-a3fe-691a4c29242d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25a5667d-f56d-440d-a3fe-691a4c29242d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a5667d-f56d-440d-a3fe-691a4c29242d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25a5667d-f56d-440d-a3fe-691a4c29242d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_383eb030-8bc1-4a33-b6ea-64019bc8b24b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a5667d-f56d-440d-a3fe-691a4c29242d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_383eb030-8bc1-4a33-b6ea-64019bc8b24b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dc759c54-4b1b-46bc-855b-3094fedae283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_383eb030-8bc1-4a33-b6ea-64019bc8b24b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dc759c54-4b1b-46bc-855b-3094fedae283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_634f7df2-ca85-4abe-91fe-c3a1cda12376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_634f7df2-ca85-4abe-91fe-c3a1cda12376" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_634f7df2-ca85-4abe-91fe-c3a1cda12376_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_634f7df2-ca85-4abe-91fe-c3a1cda12376" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_634f7df2-ca85-4abe-91fe-c3a1cda12376_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa29db3b-6ff8-44db-a926-2477b5dbc5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_634f7df2-ca85-4abe-91fe-c3a1cda12376" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa29db3b-6ff8-44db-a926-2477b5dbc5bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f5804d9c-05d4-4c6f-9dd0-82262d7443de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa29db3b-6ff8-44db-a926-2477b5dbc5bb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f5804d9c-05d4-4c6f-9dd0-82262d7443de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended" id="ib5abf80e14ff49a19314d1c6bb0fcf5c_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed612839-f1f5-409b-86a8-c1a6d98380b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed612839-f1f5-409b-86a8-c1a6d98380b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_MarketableSecuritiesMaturityPeriod_27f85ca8-b4cd-4470-83b6-51a96f7d57c3" xlink:href="gh-20200630.xsd#gh_MarketableSecuritiesMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:to="loc_gh_MarketableSecuritiesMaturityPeriod_27f85ca8-b4cd-4470-83b6-51a96f7d57c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851a234d-5c62-4382-abf7-2fd96e49c96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851a234d-5c62-4382-abf7-2fd96e49c96a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_851a234d-5c62-4382-abf7-2fd96e49c96a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851a234d-5c62-4382-abf7-2fd96e49c96a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_851a234d-5c62-4382-abf7-2fd96e49c96a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b626ccb0-e0c8-4370-99a8-f4a88fc8eb20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851a234d-5c62-4382-abf7-2fd96e49c96a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b626ccb0-e0c8-4370-99a8-f4a88fc8eb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a9204dce-17ae-456e-a276-9f322a953fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b626ccb0-e0c8-4370-99a8-f4a88fc8eb20" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a9204dce-17ae-456e-a276-9f322a953fe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_00da96dd-f3a3-48ea-88f5-250710b4c80c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_00da96dd-f3a3-48ea-88f5-250710b4c80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a2126f81-20b8-4c17-9aaf-8d113f5ac4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_00da96dd-f3a3-48ea-88f5-250710b4c80c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a2126f81-20b8-4c17-9aaf-8d113f5ac4a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c94feac-ad3a-4df1-a7fb-32390f97d37d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:to="loc_srt_RangeAxis_7c94feac-ad3a-4df1-a7fb-32390f97d37d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c94feac-ad3a-4df1-a7fb-32390f97d37d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7c94feac-ad3a-4df1-a7fb-32390f97d37d" xlink:to="loc_srt_RangeMember_7c94feac-ad3a-4df1-a7fb-32390f97d37d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7c94feac-ad3a-4df1-a7fb-32390f97d37d" xlink:to="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f23b0de7-de3f-4d57-b03e-25bb78ae764a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:to="loc_srt_MinimumMember_f23b0de7-de3f-4d57-b03e-25bb78ae764a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8806491-789a-44cc-b642-f9012b261575" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:to="loc_srt_MaximumMember_b8806491-789a-44cc-b642-f9012b261575" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i6fcc98bedc0a49c2b11450083758c086_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd206d45-5030-42a1-bd80-b427f6f78c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd206d45-5030-42a1-bd80-b427f6f78c37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b257216c-d51d-4c08-9ea9-6939668ce131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b257216c-d51d-4c08-9ea9-6939668ce131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_1d47b37e-0269-4b83-ba63-b5f2aec49459" xlink:href="gh-20200630.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_1d47b37e-0269-4b83-ba63-b5f2aec49459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d194f46a-c7c6-474a-bd58-12acb0ec8db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d194f46a-c7c6-474a-bd58-12acb0ec8db8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e0653a4-06d6-4e97-9626-58015579c657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e0653a4-06d6-4e97-9626-58015579c657" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_22125e23-8afa-4fef-b766-5f955f49d04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_22125e23-8afa-4fef-b766-5f955f49d04a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_995d59f7-9226-4d56-8a06-7bb8cf8de634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_995d59f7-9226-4d56-8a06-7bb8cf8de634" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_521f4ba8-639e-4639-a1e8-a69b826a76b3" xlink:href="gh-20200630.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_521f4ba8-639e-4639-a1e8-a69b826a76b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a38fd6d1-fb5e-4a59-91d7-1f5ec31e43bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a38fd6d1-fb5e-4a59-91d7-1f5ec31e43bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d9362d85-dea7-4617-a5b8-c8c3f465d102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a38fd6d1-fb5e-4a59-91d7-1f5ec31e43bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d9362d85-dea7-4617-a5b8-c8c3f465d102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9362d85-dea7-4617-a5b8-c8c3f465d102_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d9362d85-dea7-4617-a5b8-c8c3f465d102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9362d85-dea7-4617-a5b8-c8c3f465d102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d9362d85-dea7-4617-a5b8-c8c3f465d102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9505b65f-f0ac-405f-aca8-531125f6ebf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9505b65f-f0ac-405f-aca8-531125f6ebf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_26d22589-7a4e-46b8-99c4-f5f6e8b7f3e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_26d22589-7a4e-46b8-99c4-f5f6e8b7f3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_1895b585-a5b4-49bf-b895-7ce6439dbd40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_1895b585-a5b4-49bf-b895-7ce6439dbd40" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwill"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="extended" id="ib5b82c11faa448d39fa195fdaac215c1_IntangibleAssetsNetandGoodwill"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="extended" id="i5131bbe98c2b43cab0fdc03b36c6f8c6_IntangibleAssetsNetandGoodwillTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended" id="i61fd747a96ca4c939fbd6ada14da7894_IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_61161ba0-c5c8-4378-9247-08895e478540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_61161ba0-c5c8-4378-9247-08895e478540" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fb8d1971-f334-46d0-9436-fd2cc88776c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fb8d1971-f334-46d0-9436-fd2cc88776c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3d5ffc9d-cb7e-4ac8-9433-09989d9120ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3d5ffc9d-cb7e-4ac8-9433-09989d9120ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_99857c59-c53e-4a8c-a941-ae6df9f6f519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_99857c59-c53e-4a8c-a941-ae6df9f6f519" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_111665ca-4055-47b0-be49-bdbffafe7808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_111665ca-4055-47b0-be49-bdbffafe7808" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e5cf1ca3-7f88-4a2b-a02e-78eb80ebfde5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_Goodwill_e5cf1ca3-7f88-4a2b-a02e-78eb80ebfde5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_0ab8a4ec-63da-4205-a7f5-0a2e5fdb9903" xlink:href="gh-20200630.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_0ab8a4ec-63da-4205-a7f5-0a2e5fdb9903" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c15292fb-580d-483f-b43c-ffc3afb6dbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c15292fb-580d-483f-b43c-ffc3afb6dbe0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e28f0b8-a792-48ef-8815-de0f02c32f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e28f0b8-a792-48ef-8815-de0f02c32f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e28f0b8-a792-48ef-8815-de0f02c32f6d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e28f0b8-a792-48ef-8815-de0f02c32f6d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e28f0b8-a792-48ef-8815-de0f02c32f6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e28f0b8-a792-48ef-8815-de0f02c32f6d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b9d114f5-0679-4fb1-8b56-ed59fcc9fa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:to="loc_us-gaap_LicensingAgreementsMember_b9d114f5-0679-4fb1-8b56-ed59fcc9fa04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b5265734-4895-4d2f-b3fc-71014960744f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b5265734-4895-4d2f-b3fc-71014960744f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3db2fdc4-a2a6-4b2d-bc61-fbb977f13c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3db2fdc4-a2a6-4b2d-bc61-fbb977f13c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0096f213-bfb0-49d4-9eb4-45e7abd04c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3db2fdc4-a2a6-4b2d-bc61-fbb977f13c61" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0096f213-bfb0-49d4-9eb4-45e7abd04c4c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="extended" id="i4550fc81993f4406813d71e4f191d096_IntangibleAssetsNetandGoodwillNarrativeDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="extended" id="i3dcb6cbc91d44b29863ac0ffee38096a_IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/Acquisition" xlink:type="simple" xlink:href="gh-20200630.xsd#Acquisition"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/Acquisition" xlink:type="extended" id="i38728384f1ad40dababfc0a0c7908128_Acquisition"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionTables" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionTables" xlink:type="extended" id="i3e2c1c4b08d84f8eab3055e6ef9c35e0_AcquisitionTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionPatentLicenseAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails" xlink:type="extended" id="i050e8a7d62744d189bba830a480fff90_AcquisitionPatentLicenseAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentInConnectionWithaLicenseAgreement_fa7745c0-c7de-42f5-a7b8-8b79283580f6" xlink:href="gh-20200630.xsd#gh_PaymentInConnectionWithaLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_PaymentInConnectionWithaLicenseAgreement_fa7745c0-c7de-42f5-a7b8-8b79283580f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionTransactionCosts_dff9f184-4f61-4a0f-8d1c-96b845d90a0a" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_AssetAcquisitionTransactionCosts_dff9f184-4f61-4a0f-8d1c-96b845d90a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cee5c4aa-7651-4f2d-b3b7-89f2ef72296f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cee5c4aa-7651-4f2d-b3b7-89f2ef72296f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_01b79760-ade5-4ed9-9819-39e0c2ca1fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_01b79760-ade5-4ed9-9819-39e0c2ca1fe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_0303eb59-870b-4d74-ab10-cf515b586495" xlink:href="gh-20200630.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_0303eb59-870b-4d74-ab10-cf515b586495" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_39c87679-26e4-45ca-a590-e00ec7a6fbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_LitigationSettlementExpense_39c87679-26e4-45ca-a590-e00ec7a6fbe4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CapitalizedLicenseFees_db9984ed-cbda-483d-8723-8fa06f8d67dd" xlink:href="gh-20200630.xsd#gh_CapitalizedLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_CapitalizedLicenseFees_db9984ed-cbda-483d-8723-8fa06f8d67dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_86130f4a-c187-49c0-91c1-36df06cee129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_86130f4a-c187-49c0-91c1-36df06cee129" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionAxis_fef02db2-715b-49f5-8241-4af02b2ebb85" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:to="loc_gh_AssetAcquisitionAxis_fef02db2-715b-49f5-8241-4af02b2ebb85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionDomain_fef02db2-715b-49f5-8241-4af02b2ebb85_default" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gh_AssetAcquisitionAxis_fef02db2-715b-49f5-8241-4af02b2ebb85" xlink:to="loc_gh_AssetAcquisitionDomain_fef02db2-715b-49f5-8241-4af02b2ebb85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionDomain_88ae83b9-cb43-4c36-bcbf-31b5e46152f7" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gh_AssetAcquisitionAxis_fef02db2-715b-49f5-8241-4af02b2ebb85" xlink:to="loc_gh_AssetAcquisitionDomain_88ae83b9-cb43-4c36-bcbf-31b5e46152f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_KeyGenePatentLicenseAcquisitionMember_2e7bd312-9444-41d2-acaa-3fe6e583aa48" xlink:href="gh-20200630.xsd#gh_KeyGenePatentLicenseAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_AssetAcquisitionDomain_88ae83b9-cb43-4c36-bcbf-31b5e46152f7" xlink:to="loc_gh_KeyGenePatentLicenseAcquisitionMember_2e7bd312-9444-41d2-acaa-3fe6e583aa48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7c6dde2-d57f-4509-8a48-b754d6219040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7c6dde2-d57f-4509-8a48-b754d6219040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7c6dde2-d57f-4509-8a48-b754d6219040_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7c6dde2-d57f-4509-8a48-b754d6219040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7c6dde2-d57f-4509-8a48-b754d6219040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7c6dde2-d57f-4509-8a48-b754d6219040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PatentandCovenantRightsMember_af302373-a0af-4ecb-a8ac-3e3464172d02" xlink:href="gh-20200630.xsd#gh_PatentandCovenantRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:to="loc_gh_PatentandCovenantRightsMember_af302373-a0af-4ecb-a8ac-3e3464172d02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7cd7f4dc-de90-4db0-a747-06f692657953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:to="loc_us-gaap_LicensingAgreementsMember_7cd7f4dc-de90-4db0-a747-06f692657953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_662ef40b-d6b9-4090-a09d-d811474e8d75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:to="loc_srt_RangeAxis_662ef40b-d6b9-4090-a09d-d811474e8d75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_662ef40b-d6b9-4090-a09d-d811474e8d75_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_662ef40b-d6b9-4090-a09d-d811474e8d75" xlink:to="loc_srt_RangeMember_662ef40b-d6b9-4090-a09d-d811474e8d75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_662ef40b-d6b9-4090-a09d-d811474e8d75" xlink:to="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bd9d47e6-637d-46b1-ae94-83001116db64" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:to="loc_srt_MinimumMember_bd9d47e6-637d-46b1-ae94-83001116db64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f980ea0-ea92-45a4-bbe5-e7d66e74dec2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:to="loc_srt_MaximumMember_9f980ea0-ea92-45a4-bbe5-e7d66e74dec2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionAcquisitionofBellwetherBioDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails" xlink:type="extended" id="i815d066f748a4092ad965c968266b012_AcquisitionAcquisitionofBellwetherBioDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_06cebab7-9018-4b5d-a4cd-3111e1197ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_06cebab7-9018-4b5d-a4cd-3111e1197ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c18a138-e67c-4841-bfb9-b28e57106013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c18a138-e67c-4841-bfb9-b28e57106013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8851c618-3503-49ec-8745-fbfac11c55d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8851c618-3503-49ec-8745-fbfac11c55d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_bf374202-0d08-432b-a284-f50bddea6703" xlink:href="gh-20200630.xsd#gh_BusinessCombinationContingentConsiderationMaximumAmountPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_bf374202-0d08-432b-a284-f50bddea6703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_572eda73-481a-44b5-9986-39099db8c9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_572eda73-481a-44b5-9986-39099db8c9e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b77226aa-d5b7-4312-9077-eeef3713df34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b77226aa-d5b7-4312-9077-eeef3713df34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a140b7cf-e614-464c-9911-74e7101d3672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a140b7cf-e614-464c-9911-74e7101d3672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a140b7cf-e614-464c-9911-74e7101d3672_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a140b7cf-e614-464c-9911-74e7101d3672" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a140b7cf-e614-464c-9911-74e7101d3672_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c566d6f-ccf2-409b-9930-18a564da2484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a140b7cf-e614-464c-9911-74e7101d3672" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c566d6f-ccf2-409b-9930-18a564da2484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CovenantsNotToCompeteMember_b9caafaa-0489-41f9-bc77-622eb0a4a4e0" xlink:href="gh-20200630.xsd#gh_CovenantsNotToCompeteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c566d6f-ccf2-409b-9930-18a564da2484" xlink:to="loc_gh_CovenantsNotToCompeteMember_b9caafaa-0489-41f9-bc77-622eb0a4a4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_d3064afb-bbe2-4f60-bc62-3fc46830281e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_d3064afb-bbe2-4f60-bc62-3fc46830281e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_d3064afb-bbe2-4f60-bc62-3fc46830281e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d3064afb-bbe2-4f60-bc62-3fc46830281e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_d3064afb-bbe2-4f60-bc62-3fc46830281e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d3064afb-bbe2-4f60-bc62-3fc46830281e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CommercializationMilestonesMember_ca37fa9d-41fc-486d-b2e0-2f8eb45dcca8" xlink:href="gh-20200630.xsd#gh_CommercializationMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:to="loc_gh_CommercializationMilestonesMember_ca37fa9d-41fc-486d-b2e0-2f8eb45dcca8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EarnOutConsiderationMember_a50828fb-1089-4641-b465-a19cb4535136" xlink:href="gh-20200630.xsd#gh_EarnOutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:to="loc_gh_EarnOutConsiderationMember_a50828fb-1089-4641-b465-a19cb4535136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e87a2d17-f747-4d5e-a873-e9e0d56e653a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e87a2d17-f747-4d5e-a873-e9e0d56e653a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e87a2d17-f747-4d5e-a873-e9e0d56e653a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e87a2d17-f747-4d5e-a873-e9e0d56e653a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e87a2d17-f747-4d5e-a873-e9e0d56e653a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70db2e07-16f3-4fec-8f2a-bed26e30f869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e87a2d17-f747-4d5e-a873-e9e0d56e653a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70db2e07-16f3-4fec-8f2a-bed26e30f869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BellweatherBioInc.Member_137a75c9-75f2-490e-9041-ba71c8ca95ea" xlink:href="gh-20200630.xsd#gh_BellweatherBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70db2e07-16f3-4fec-8f2a-bed26e30f869" xlink:to="loc_gh_BellweatherBioInc.Member_137a75c9-75f2-490e-9041-ba71c8ca95ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i6034783ebbd64444a9a411ff7d001446_AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_92db6057-cba6-47ce-ab24-a1dc7168653d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_92db6057-cba6-47ce-ab24-a1dc7168653d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6370edd4-d2d2-4504-a0a8-f1dd20bdd3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6370edd4-d2d2-4504-a0a8-f1dd20bdd3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b1dc9c22-d82e-47db-8ee1-4662560cbe44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_Goodwill_b1dc9c22-d82e-47db-8ee1-4662560cbe44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f86a9421-ee47-4c56-92ce-3e573d75cd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f86a9421-ee47-4c56-92ce-3e573d75cd55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0c4f3495-1f37-4903-842e-ddba35e4d678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0c4f3495-1f37-4903-842e-ddba35e4d678" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db6a5940-62da-4dbe-91cf-d9d99a9f37c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db6a5940-62da-4dbe-91cf-d9d99a9f37c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_58adc626-5184-4adb-a5d7-de40ff2b3b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db6a5940-62da-4dbe-91cf-d9d99a9f37c0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_58adc626-5184-4adb-a5d7-de40ff2b3b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58adc626-5184-4adb-a5d7-de40ff2b3b06_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58adc626-5184-4adb-a5d7-de40ff2b3b06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58adc626-5184-4adb-a5d7-de40ff2b3b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f257667c-7685-4fc0-8b38-3c7d2792665c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58adc626-5184-4adb-a5d7-de40ff2b3b06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f257667c-7685-4fc0-8b38-3c7d2792665c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BellweatherBioInc.Member_43d1eb8f-5554-4604-9f4b-2f14e1e2c8fe" xlink:href="gh-20200630.xsd#gh_BellweatherBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f257667c-7685-4fc0-8b38-3c7d2792665c" xlink:to="loc_gh_BellweatherBioInc.Member_43d1eb8f-5554-4604-9f4b-2f14e1e2c8fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionIntangibleAssetsAcquiredDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails" xlink:type="extended" id="ia1ed184ed8f5488a868514becf3ecee3_AcquisitionIntangibleAssetsAcquiredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dd02453-de51-4958-a02a-3b6118e1a51b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dd02453-de51-4958-a02a-3b6118e1a51b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_46d66319-3a5d-4a11-bc87-8514d812cd59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_46d66319-3a5d-4a11-bc87-8514d812cd59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ac9c60b3-bd00-4f27-9386-de5dba490ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ac9c60b3-bd00-4f27-9386-de5dba490ce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac9c60b3-bd00-4f27-9386-de5dba490ce5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ac9c60b3-bd00-4f27-9386-de5dba490ce5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac9c60b3-bd00-4f27-9386-de5dba490ce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c8840c9-558d-4903-9230-603de23ae6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ac9c60b3-bd00-4f27-9386-de5dba490ce5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c8840c9-558d-4903-9230-603de23ae6fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BellweatherBioInc.Member_d48916de-df08-4389-9a83-0acbd69ad550" xlink:href="gh-20200630.xsd#gh_BellweatherBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c8840c9-558d-4903-9230-603de23ae6fd" xlink:to="loc_gh_BellweatherBioInc.Member_d48916de-df08-4389-9a83-0acbd69ad550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f8651a34-f4db-42d9-adb4-8820cc5e458d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f8651a34-f4db-42d9-adb4-8820cc5e458d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f8651a34-f4db-42d9-adb4-8820cc5e458d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f8651a34-f4db-42d9-adb4-8820cc5e458d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f8651a34-f4db-42d9-adb4-8820cc5e458d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f8651a34-f4db-42d9-adb4-8820cc5e458d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_d3ffc864-d35c-4e0c-a388-329fa90efde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:to="loc_us-gaap_LicensingAgreementsMember_d3ffc864-d35c-4e0c-a388-329fa90efde8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0e1032c3-fb0b-4272-a2e7-dce8a1e85a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0e1032c3-fb0b-4272-a2e7-dce8a1e85a53" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:type="simple" xlink:href="gh-20200630.xsd#Leases"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended" id="iec01c59c4c274b2594198ebf0afaf89f_Leases"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended" id="if02ef7d35fb44098bde0086b6a090752_LeasesTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i3ffe014a1a004078a7ba3480092f1fb4_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_90429d57-15b6-4556-8243-0d14b07ada3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_90429d57-15b6-4556-8243-0d14b07ada3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9af19b05-753a-4b7b-8f00-a22c7e2a0766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:to="loc_us-gaap_OperatingLeaseExpense_9af19b05-753a-4b7b-8f00-a22c7e2a0766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6478b18d-cd86-4878-ad77-dc370f94b0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6478b18d-cd86-4878-ad77-dc370f94b0f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6478b18d-cd86-4878-ad77-dc370f94b0f8" xlink:to="loc_srt_RangeAxis_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff" xlink:to="loc_srt_RangeMember_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff" xlink:to="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9196f21c-dd9d-4b5b-9ed5-395af7beb58b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:to="loc_srt_MinimumMember_9196f21c-dd9d-4b5b-9ed5-395af7beb58b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af819541-a2fb-418d-b035-8b491a208d90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:to="loc_srt_MaximumMember_af819541-a2fb-418d-b035-8b491a208d90" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesLeaseInformationDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="extended" id="ic0bab6b09f334b8b9d97bec33a14e004_LeasesLeaseInformationDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="extended" id="i73723e94f7164ae5857788c95315e980_LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gh-20200630.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="extended" id="ia3c07c4dbec64707b8134a29c20ac875_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ie3ab563ee648407990412ad60e1bd869_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofCompaniesthatInfringedonaPatent_c8d78f89-df19-4dd3-a50f-5beb646beb6f" xlink:href="gh-20200630.xsd#gh_NumberofCompaniesthatInfringedonaPatent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_gh_NumberofCompaniesthatInfringedonaPatent_c8d78f89-df19-4dd3-a50f-5beb646beb6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_f77f9ea5-7186-436d-9fba-87055d90d652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_f77f9ea5-7186-436d-9fba-87055d90d652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsFiled_90b3964c-1319-49af-9321-20d09217c8bd" xlink:href="gh-20200630.xsd#gh_NumberofPetitionsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_gh_NumberofPetitionsFiled_90b3964c-1319-49af-9321-20d09217c8bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsDenied_697d1699-d5b3-4a5b-ba0c-55acda819ec8" xlink:href="gh-20200630.xsd#gh_NumberofPetitionsDenied"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_gh_NumberofPetitionsDenied_697d1699-d5b3-4a5b-ba0c-55acda819ec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_d18f0421-c14e-4d63-87a7-58f3fa111124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_us-gaap_OtherCommitmentsTable_d18f0421-c14e-4d63-87a7-58f3fa111124" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_63eaf070-bba3-4965-8bd7-680668b89b60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_d18f0421-c14e-4d63-87a7-58f3fa111124" xlink:to="loc_srt_LitigationCaseAxis_63eaf070-bba3-4965-8bd7-680668b89b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_63eaf070-bba3-4965-8bd7-680668b89b60_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_63eaf070-bba3-4965-8bd7-680668b89b60" xlink:to="loc_srt_LitigationCaseTypeDomain_63eaf070-bba3-4965-8bd7-680668b89b60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_63eaf070-bba3-4965-8bd7-680668b89b60" xlink:to="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember_2a0a9be2-6273-4061-b64d-6f5fb159afa0" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember_2a0a9be2-6273-4061-b64d-6f5fb159afa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_79b90038-d628-4faf-af5e-08768c5dfc00" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_79b90038-d628-4faf-af5e-08768c5dfc00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember_f6bc6812-d24b-4afa-950c-0854e69590c7" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember_f6bc6812-d24b-4afa-950c-0854e69590c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStock"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended" id="iad1c7b3bf648445498b32989afe99daf_CommonStock"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockTables" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStockTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommonStockTables" xlink:type="extended" id="i3a315b795b6743388def3830257bdd91_CommonStockTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended" id="i138303e9d56a47eebd66693992219091_CommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96dc9847-4de8-4e86-acde-90cacac920ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96dc9847-4de8-4e86-acde-90cacac920ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c37c6b78-2129-4af3-8cec-0584fb762342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c37c6b78-2129-4af3-8cec-0584fb762342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_5721cc37-85bc-4139-a694-4764cfadb242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_5721cc37-85bc-4139-a694-4764cfadb242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18d57c20-a1e5-44fb-a4c0-cfac4dd87c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18d57c20-a1e5-44fb-a4c0-cfac4dd87c93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_34c616b9-b3cc-472b-abfd-ab4a384166cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_34c616b9-b3cc-472b-abfd-ab4a384166cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4388b836-67df-48db-babb-5330d1503422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_34c616b9-b3cc-472b-abfd-ab4a384166cd" xlink:to="loc_us-gaap_AwardTypeAxis_4388b836-67df-48db-babb-5330d1503422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4388b836-67df-48db-babb-5330d1503422_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4388b836-67df-48db-babb-5330d1503422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4388b836-67df-48db-babb-5330d1503422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4388b836-67df-48db-babb-5330d1503422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b21d56c6-557b-4afe-8cbd-235b324ce83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b21d56c6-557b-4afe-8cbd-235b324ce83d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6759347e-ba8b-4985-8f19-782e4010ea93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6759347e-ba8b-4985-8f19-782e4010ea93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember_e80d90ec-2990-4a72-8b98-344f6871f7f6" xlink:href="gh-20200630.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_gh_A2018IncentiveAwardPlanMember_e80d90ec-2990-4a72-8b98-344f6871f7f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_02e9bcf2-5cb0-4647-8f06-1dcea56b61e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_us-gaap_EmployeeStockMember_02e9bcf2-5cb0-4647-8f06-1dcea56b61e6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended" id="if22839231c2843a69e36fe992dd80758_StockBasedCompensation"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended" id="i9d22ddb1e99a40f28d66a21fbc018d0c_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i10bf0a55bccc4bb4bcf26b4797a11d41_StockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dbe7c9ae-b27c-45a1-85be-e89e2b4f795d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dbe7c9ae-b27c-45a1-85be-e89e2b4f795d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_193925a0-4b63-49a2-a611-ad61fa541e20" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_193925a0-4b63-49a2-a611-ad61fa541e20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_20ca94cf-9548-400a-9518-98c6b4b566ce" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_20ca94cf-9548-400a-9518-98c6b4b566ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_5af361e5-18bf-4818-ab2a-90ad58e65854" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_5af361e5-18bf-4818-ab2a-90ad58e65854" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8bb0442f-3714-49a5-bbb8-6d7bfc5baad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5cc7f68-4c9e-4818-bd52-7478d14bb853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5cc7f68-4c9e-4818-bd52-7478d14bb853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8686e679-2776-4d30-a325-1b5b836bbc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8686e679-2776-4d30-a325-1b5b836bbc8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f476c116-14ad-495b-bafd-dded1ea9caaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f476c116-14ad-495b-bafd-dded1ea9caaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4ba4294-7c1b-4359-adf0-80a55ceeff54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4ba4294-7c1b-4359-adf0-80a55ceeff54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61bd5879-0de8-477c-a851-a44870b0f377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_73ed2d26-81f7-48c4-a33e-7a4d57807a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_73ed2d26-81f7-48c4-a33e-7a4d57807a39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06d8020d-56af-4ebf-a187-83390f7c4e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06d8020d-56af-4ebf-a187-83390f7c4e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5865eb8-43a9-47ac-aa82-0fd0ccfb1b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5865eb8-43a9-47ac-aa82-0fd0ccfb1b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be4c5d0a-1e7d-4da7-adb9-90dd049e2a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be4c5d0a-1e7d-4da7-adb9-90dd049e2a16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_544f503b-baa7-4082-a316-382095e9ea9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_544f503b-baa7-4082-a316-382095e9ea9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f22ab28-efa8-49d9-ba89-bf747b8ca736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cd628d58-1439-4661-85e0-4463316af75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cd628d58-1439-4661-85e0-4463316af75f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_07d914d6-0c07-492e-b944-d507b56269ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_07d914d6-0c07-492e-b944-d507b56269ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3bc72bc-cb97-4334-8517-ffde081d23f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3bc72bc-cb97-4334-8517-ffde081d23f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fe3a966-22e0-4fde-91de-6d9c534a7f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fe3a966-22e0-4fde-91de-6d9c534a7f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_93775c8a-0d98-4459-ba73-9e10fa0c3d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_93775c8a-0d98-4459-ba73-9e10fa0c3d2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1940638d-d084-49ec-9efb-84091608dea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1940638d-d084-49ec-9efb-84091608dea2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e91b318-3d28-4abf-a308-049e5dca0c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1940638d-d084-49ec-9efb-84091608dea2" xlink:to="loc_us-gaap_AwardTypeAxis_6e91b318-3d28-4abf-a308-049e5dca0c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91b318-3d28-4abf-a308-049e5dca0c03_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e91b318-3d28-4abf-a308-049e5dca0c03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e91b318-3d28-4abf-a308-049e5dca0c03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e91b318-3d28-4abf-a308-049e5dca0c03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f22ae02c-0ea3-4408-b210-598d7a7695ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:to="loc_us-gaap_RestrictedStockMember_f22ae02c-0ea3-4408-b210-598d7a7695ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_05bc8891-d669-4e52-81c5-52c1580de591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:to="loc_us-gaap_PerformanceSharesMember_05bc8891-d669-4e52-81c5-52c1580de591" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="iab689fde952745b5950c7a9fda317ea7_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ba6248f1-e643-4c46-97eb-f708f0fb3664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ba6248f1-e643-4c46-97eb-f708f0fb3664" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c858372-0264-4cdd-bbbb-a39fe31c6d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c858372-0264-4cdd-bbbb-a39fe31c6d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_587e8fb6-e3e6-40c7-970d-919742101d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_587e8fb6-e3e6-40c7-970d-919742101d57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b20159af-3820-4a6a-ab5b-f77ea9295a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b20159af-3820-4a6a-ab5b-f77ea9295a41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b87ee8cb-8bf0-4598-8cd9-120ac57783ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b87ee8cb-8bf0-4598-8cd9-120ac57783ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_2b566ec8-1caf-4aac-92b9-93d3b3f45d4f" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_2b566ec8-1caf-4aac-92b9-93d3b3f45d4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_dca4d050-0c43-4def-a2b1-69ff10b83fd6" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_dca4d050-0c43-4def-a2b1-69ff10b83fd6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6fd7cdfe-4444-460b-95d0-be6289a75a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6fd7cdfe-4444-460b-95d0-be6289a75a29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_9b1cab88-9a22-4fc9-88a2-9deb1a7a7ec5" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_9b1cab88-9a22-4fc9-88a2-9deb1a7a7ec5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55435cb8-024d-47bf-8823-c1d662eb010d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55435cb8-024d-47bf-8823-c1d662eb010d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4799c880-9c1d-4065-ae8f-f95333b0b7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4799c880-9c1d-4065-ae8f-f95333b0b7fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9860cb47-a97d-42df-b725-e64e61f6d665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9860cb47-a97d-42df-b725-e64e61f6d665" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_006c9de4-ef3b-43c8-87a9-f081f517076f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_006c9de4-ef3b-43c8-87a9-f081f517076f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20089f86-e3b3-45ba-8057-919979c91b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20089f86-e3b3-45ba-8057-919979c91b93" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_abd40744-1597-43e5-ad91-c5bcc7969b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_abd40744-1597-43e5-ad91-c5bcc7969b2f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_47ff68d1-3040-4f91-a431-3f04a948daa2" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_47ff68d1-3040-4f91-a431-3f04a948daa2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_dc2a0054-bc0b-45ba-80cd-ebbfddb0a0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_dc2a0054-bc0b-45ba-80cd-ebbfddb0a0a8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fe8536f1-5919-4ab3-920d-00d924005efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fe8536f1-5919-4ab3-920d-00d924005efa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_af5adf9a-061d-4457-a3d9-19b17589e76a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_af5adf9a-061d-4457-a3d9-19b17589e76a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_db331652-45ef-4015-9e89-6a45afe2d57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_db331652-45ef-4015-9e89-6a45afe2d57c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0521715a-85a0-40f5-85af-69fcb74a5dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0521715a-85a0-40f5-85af-69fcb74a5dc2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_605e1d2c-b93f-464b-940c-6d3804b1ed0a" xlink:href="gh-20200630.xsd#gh_CommonStockSubjecttoRepurchaseorCancellation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_605e1d2c-b93f-464b-940c-6d3804b1ed0a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_94310696-95ef-4f89-99be-688fd875d5d8" xlink:href="gh-20200630.xsd#gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_94310696-95ef-4f89-99be-688fd875d5d8" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_27aafe70-93f4-435c-ab51-3c6114a9f4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_27aafe70-93f4-435c-ab51-3c6114a9f4f6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c697e31b-f315-45a2-a07c-0d0532a9b877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:to="loc_us-gaap_AwardTypeAxis_c697e31b-f315-45a2-a07c-0d0532a9b877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c697e31b-f315-45a2-a07c-0d0532a9b877_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c697e31b-f315-45a2-a07c-0d0532a9b877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c697e31b-f315-45a2-a07c-0d0532a9b877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c697e31b-f315-45a2-a07c-0d0532a9b877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a3eec907-2f0e-46f5-a07c-293068d08164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a3eec907-2f0e-46f5-a07c-293068d08164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b2546361-b265-44b1-95b1-ab9c90201735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b2546361-b265-44b1-95b1-ab9c90201735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9e2368db-4a75-4995-9d75-74138a7af81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_PerformanceSharesMember_9e2368db-4a75-4995-9d75-74138a7af81f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a64a3e8a-1853-440e-8845-57d98df3647a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_EmployeeStockMember_a64a3e8a-1853-440e-8845-57d98df3647a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonemployeeStockOptionMember_8a6c050d-0d4a-4019-b6f0-26da7f65aa94" xlink:href="gh-20200630.xsd#gh_NonemployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_gh_NonemployeeStockOptionMember_8a6c050d-0d4a-4019-b6f0-26da7f65aa94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d498e106-5598-4ed5-918d-d27ca11cc458" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:to="loc_srt_RangeAxis_d498e106-5598-4ed5-918d-d27ca11cc458" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d498e106-5598-4ed5-918d-d27ca11cc458_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d498e106-5598-4ed5-918d-d27ca11cc458" xlink:to="loc_srt_RangeMember_d498e106-5598-4ed5-918d-d27ca11cc458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d498e106-5598-4ed5-918d-d27ca11cc458" xlink:to="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18f145e4-9fb5-4871-8f6b-c0f5102d7cdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:to="loc_srt_MaximumMember_18f145e4-9fb5-4871-8f6b-c0f5102d7cdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1cd6c5bf-ea2a-4842-80d1-777ae38666b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:to="loc_srt_MinimumMember_1cd6c5bf-ea2a-4842-80d1-777ae38666b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f469abcc-ed4b-41df-9e53-89443b624dc2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:to="loc_srt_TitleOfIndividualAxis_f469abcc-ed4b-41df-9e53-89443b624dc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f469abcc-ed4b-41df-9e53-89443b624dc2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_f469abcc-ed4b-41df-9e53-89443b624dc2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f469abcc-ed4b-41df-9e53-89443b624dc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_f469abcc-ed4b-41df-9e53-89443b624dc2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_14a591a8-6a05-4d44-b90d-ba51c4c777f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:to="loc_srt_ChiefExecutiveOfficerMember_14a591a8-6a05-4d44-b90d-ba51c4c777f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_984cbb11-4bba-4867-99a3-a0f27275dfba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:to="loc_srt_ChiefOperatingOfficerMember_984cbb11-4bba-4867-99a3-a0f27275dfba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended" id="i06fe4a57b7fe460d84f1ed7fa1926218_StockBasedCompensationRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2afea3f4-9b0f-489f-b267-9c4fabcc7d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2afea3f4-9b0f-489f-b267-9c4fabcc7d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d55a5685-a78a-4870-a6c5-54736ede6eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d55a5685-a78a-4870-a6c5-54736ede6eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22b494b0-73a8-4ebc-87c6-dc9b1c5a8245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22b494b0-73a8-4ebc-87c6-dc9b1c5a8245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f1825daa-f58a-4cd6-9fe3-e1abce214ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f1825daa-f58a-4cd6-9fe3-e1abce214ead" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cc92098-acd8-45eb-a0bf-b555bc0a2eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c49e2dc5-cc53-45db-886c-3c118944369b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c49e2dc5-cc53-45db-886c-3c118944369b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_fcec0cac-11c3-4ae3-9120-ca2c98aa3ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_fcec0cac-11c3-4ae3-9120-ca2c98aa3ddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_7e0ec27e-b12c-4aea-9a5d-29c32eeff20a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_7e0ec27e-b12c-4aea-9a5d-29c32eeff20a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_81c4895a-4db2-4c08-a3bb-066797ee8c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_81c4895a-4db2-4c08-a3bb-066797ee8c41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_7b312ab4-10bc-4025-a66d-2c0ab3766e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae551c62-0b48-42aa-be4e-5105c6b4c019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae551c62-0b48-42aa-be4e-5105c6b4c019" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b2e82277-afd6-4f19-8819-12d3aa9df60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae551c62-0b48-42aa-be4e-5105c6b4c019" xlink:to="loc_us-gaap_AwardTypeAxis_b2e82277-afd6-4f19-8819-12d3aa9df60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2e82277-afd6-4f19-8819-12d3aa9df60d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b2e82277-afd6-4f19-8819-12d3aa9df60d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2e82277-afd6-4f19-8819-12d3aa9df60d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6de13b18-6704-47a4-8482-d31e9b6cc2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b2e82277-afd6-4f19-8819-12d3aa9df60d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6de13b18-6704-47a4-8482-d31e9b6cc2a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74b9532a-3abc-4c6b-9fec-27221b442ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6de13b18-6704-47a4-8482-d31e9b6cc2a6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74b9532a-3abc-4c6b-9fec-27221b442ca0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="extended" id="i2df00d0982144e3c98b5c5ef0a0d9083_StockBasedCompensationMarketbasedRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7299322b-441a-42cd-abf8-d8515fbdd880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_5015e75e-7894-4a32-9318-a4abf81450bf" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7299322b-441a-42cd-abf8-d8515fbdd880" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_5015e75e-7894-4a32-9318-a4abf81450bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7299322b-441a-42cd-abf8-d8515fbdd880" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05a74568-1b46-4055-abea-cedd01192366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:to="loc_us-gaap_AwardTypeAxis_05a74568-1b46-4055-abea-cedd01192366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05a74568-1b46-4055-abea-cedd01192366_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_05a74568-1b46-4055-abea-cedd01192366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05a74568-1b46-4055-abea-cedd01192366_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c11d10b3-6422-447c-b9cb-558552e95e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_05a74568-1b46-4055-abea-cedd01192366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c11d10b3-6422-447c-b9cb-558552e95e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ea386c05-17f7-411f-8a85-452c5cc498a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c11d10b3-6422-447c-b9cb-558552e95e40" xlink:to="loc_us-gaap_PerformanceSharesMember_ea386c05-17f7-411f-8a85-452c5cc498a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_32bdf5c5-c4cc-4275-b776-4056e649851a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:to="loc_us-gaap_VestingAxis_32bdf5c5-c4cc-4275-b776-4056e649851a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_32bdf5c5-c4cc-4275-b776-4056e649851a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_32bdf5c5-c4cc-4275-b776-4056e649851a" xlink:to="loc_us-gaap_VestingDomain_32bdf5c5-c4cc-4275-b776-4056e649851a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_32bdf5c5-c4cc-4275-b776-4056e649851a" xlink:to="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_68387a0a-5d68-46dd-b1db-b2905571c180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_68387a0a-5d68-46dd-b1db-b2905571c180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_642cb499-455d-4d94-84b2-cdd29d6dce1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_642cb499-455d-4d94-84b2-cdd29d6dce1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cd2cd8a7-d52d-49d9-9af7-88d6ada8e9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cd2cd8a7-d52d-49d9-9af7-88d6ada8e9fc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i894bfc9559b947eeb186ae52ea0b6408_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_848721bb-f1b8-4646-bb09-0386d0fbb17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c584c564-cc4c-4cc5-a1d3-3d40bf137f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_848721bb-f1b8-4646-bb09-0386d0fbb17e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c584c564-cc4c-4cc5-a1d3-3d40bf137f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9107a966-bf74-461a-ae24-22edfca4da9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_848721bb-f1b8-4646-bb09-0386d0fbb17e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9107a966-bf74-461a-ae24-22edfca4da9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13730515-7a51-448b-b2c8-56986835686d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9107a966-bf74-461a-ae24-22edfca4da9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13730515-7a51-448b-b2c8-56986835686d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13730515-7a51-448b-b2c8-56986835686d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13730515-7a51-448b-b2c8-56986835686d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13730515-7a51-448b-b2c8-56986835686d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13730515-7a51-448b-b2c8-56986835686d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember_643f7515-b599-45b6-a03d-a2a01b40c398" xlink:href="gh-20200630.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_gh_PrecisionOncologyTestingMember_643f7515-b599-45b6-a03d-a2a01b40c398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69bc13d6-342e-4623-ac91-63da3c271369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69bc13d6-342e-4623-ac91-63da3c271369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_f3b1f677-f9a4-4488-a566-987a8e669f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_f3b1f677-f9a4-4488-a566-987a8e669f64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ff3582a-449d-4a91-aa00-dd19e1b53b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ff3582a-449d-4a91-aa00-dd19e1b53b50" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationValuationofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="extended" id="i563b5efdc08e4e0cbed98201cc730722_StockBasedCompensationValuationofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8198a7a8-9d91-49ea-afb9-08de184bf391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8198a7a8-9d91-49ea-afb9-08de184bf391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0116bfd0-65c6-45ef-b499-2f42013463e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0116bfd0-65c6-45ef-b499-2f42013463e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_71f6e874-7ef0-4afd-9b95-8757ad986352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_71f6e874-7ef0-4afd-9b95-8757ad986352" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_080ad47c-afd1-4f22-ac88-0a4445e7c9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_080ad47c-afd1-4f22-ac88-0a4445e7c9f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c02d0401-5014-4437-9bf8-cfe725f9d684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:to="loc_us-gaap_AwardTypeAxis_c02d0401-5014-4437-9bf8-cfe725f9d684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c02d0401-5014-4437-9bf8-cfe725f9d684_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c02d0401-5014-4437-9bf8-cfe725f9d684" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c02d0401-5014-4437-9bf8-cfe725f9d684_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56f6b5ff-48a5-4fa1-b2fa-93d00af72ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c02d0401-5014-4437-9bf8-cfe725f9d684" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56f6b5ff-48a5-4fa1-b2fa-93d00af72ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_911827f1-cd9f-46c8-96db-88cab2e2a7a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56f6b5ff-48a5-4fa1-b2fa-93d00af72ed8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_911827f1-cd9f-46c8-96db-88cab2e2a7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5eebc751-de46-4b7b-98e0-d0bd04fa72d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:to="loc_srt_RangeAxis_5eebc751-de46-4b7b-98e0-d0bd04fa72d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5eebc751-de46-4b7b-98e0-d0bd04fa72d6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5eebc751-de46-4b7b-98e0-d0bd04fa72d6" xlink:to="loc_srt_RangeMember_5eebc751-de46-4b7b-98e0-d0bd04fa72d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5eebc751-de46-4b7b-98e0-d0bd04fa72d6" xlink:to="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_031582d9-44e6-4aa2-a5d4-f35ac87357a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:to="loc_srt_MinimumMember_031582d9-44e6-4aa2-a5d4-f35ac87357a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_915f5d8c-17fa-4bca-806f-d0aa40dd427a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:to="loc_srt_MaximumMember_915f5d8c-17fa-4bca-806f-d0aa40dd427a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i4336977c697948a78a3505f18f1b7f96_StockBasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d45dc093-8c4b-4e74-ae2f-a16b339b46e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d45dc093-8c4b-4e74-ae2f-a16b339b46e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ec43d0b4-9db9-45ab-bae1-14269d257995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ec43d0b4-9db9-45ab-bae1-14269d257995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4d78cf9-ee44-46a2-8f4e-ddbee52b1ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4d78cf9-ee44-46a2-8f4e-ddbee52b1ae4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c65457ef-6042-483b-8cf7-f2568dc34161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c65457ef-6042-483b-8cf7-f2568dc34161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1512393d-f71d-4c9b-8e04-4c854832194e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1512393d-f71d-4c9b-8e04-4c854832194e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47c23cfe-3913-44d2-ab56-2ad20790b075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47c23cfe-3913-44d2-ab56-2ad20790b075" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f13a4195-0e89-4047-a7c5-0c913df9bbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47c23cfe-3913-44d2-ab56-2ad20790b075" xlink:to="loc_us-gaap_AwardTypeAxis_f13a4195-0e89-4047-a7c5-0c913df9bbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f13a4195-0e89-4047-a7c5-0c913df9bbac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f13a4195-0e89-4047-a7c5-0c913df9bbac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f13a4195-0e89-4047-a7c5-0c913df9bbac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a972660d-8204-4281-a3de-4f04ce5fa6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f13a4195-0e89-4047-a7c5-0c913df9bbac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a972660d-8204-4281-a3de-4f04ce5fa6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e33505b5-0c50-49b9-b440-98e74ca5b2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a972660d-8204-4281-a3de-4f04ce5fa6fc" xlink:to="loc_us-gaap_EmployeeStockMember_e33505b5-0c50-49b9-b440-98e74ca5b2af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="extended" id="i2760e0960ba546bd99873ec118412114_NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="extended" id="i37566e65473d41818ac5a1ac34233a15_NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="extended" id="ied0f056c6e3748c28c75a8c7bc49005b_NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended" id="i0754e0ba2a18439fbf04413bf0dee434_NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06ed70e6-8d4c-4a23-aea1-26a1bf2f63f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ffa2409b-c746-49aa-ba38-1f5d068d4a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06ed70e6-8d4c-4a23-aea1-26a1bf2f63f3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ffa2409b-c746-49aa-ba38-1f5d068d4a26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7dd10d36-55d6-4705-b698-ff163c91565f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06ed70e6-8d4c-4a23-aea1-26a1bf2f63f3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7dd10d36-55d6-4705-b698-ff163c91565f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7dd10d36-55d6-4705-b698-ff163c91565f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e834c74a-6ccf-4b9a-be91-025b96eb56fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e834c74a-6ccf-4b9a-be91-025b96eb56fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1e007837-1c64-4262-bd19-9cf33991b89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1e007837-1c64-4262-bd19-9cf33991b89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bb0083e4-0b99-4bc2-ae32-2a9fa7f98a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_PerformanceSharesMember_bb0083e4-0b99-4bc2-ae32-2a9fa7f98a5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_70955525-e2ed-4b4f-927b-f593e84abd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_EmployeeStockMember_70955525-e2ed-4b4f-927b-f593e84abd1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_56cca323-7866-4e9f-862d-d005d614d2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_56cca323-7866-4e9f-862d-d005d614d2ba" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gh-20200630.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended" id="i98b3c0237b264e66826bf52c6f61303d_IncomeTaxes"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/IncomeTaxesDetails" xlink:type="extended" id="i70eefcaf675a4b36b01f083d78d2f84f_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformation"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="extended" id="ib3065d9685a244a88ba6e93501b348c9_SegmentandGeographicInformation"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformationTables"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="extended" id="i344bd72af94d4719b01e80c5fd522679_SegmentandGeographicInformationTables"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="extended" id="i1f050353f09e480dbc7e298f3423432c_SegmentandGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a625aea5-4b6d-4f73-99bf-db8921decb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5ec4e214-b00b-48f5-8fc7-24392d220ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a625aea5-4b6d-4f73-99bf-db8921decb36" xlink:to="loc_us-gaap_Revenues_5ec4e214-b00b-48f5-8fc7-24392d220ed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a6df192f-bad5-49b0-82d3-5c6de790e06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a625aea5-4b6d-4f73-99bf-db8921decb36" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a6df192f-bad5-49b0-82d3-5c6de790e06b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a6df192f-bad5-49b0-82d3-5c6de790e06b" xlink:to="loc_srt_StatementGeographicalAxis_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef" xlink:to="loc_srt_SegmentGeographicalDomain_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef" xlink:to="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_65c5a581-aeb6-4d0f-a2ad-5410c0fa02c1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:to="loc_country_US_65c5a581-aeb6-4d0f-a2ad-5410c0fa02c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5cdce6d5-0c60-4b8e-a044-cc5221a579c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:to="loc_us-gaap_NonUsMember_5cdce6d5-0c60-4b8e-a044-cc5221a579c0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="gh-20200630.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended" id="id4d0fddbf74d4becaf415e2e7e066519_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="ifa3c4a2846354e9a8fee9d02bdd9d8c0_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_43cea7bd-415f-472b-bc43-50d5251cbb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:to="loc_us-gaap_RevenueFromRelatedParties_43cea7bd-415f-472b-bc43-50d5251cbb3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_0f6df865-5d1a-4e25-b58b-6c4a3ba84f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_0f6df865-5d1a-4e25-b58b-6c4a3ba84f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_51e6c393-85af-4fb2-8d26-bbd2c188a28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_51e6c393-85af-4fb2-8d26-bbd2c188a28d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc6d2ee3-a837-4c2b-975d-15021c869395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_51e6c393-85af-4fb2-8d26-bbd2c188a28d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc6d2ee3-a837-4c2b-975d-15021c869395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc6d2ee3-a837-4c2b-975d-15021c869395_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc6d2ee3-a837-4c2b-975d-15021c869395" xlink:to="loc_us-gaap_RelatedPartyDomain_cc6d2ee3-a837-4c2b-975d-15021c869395_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a7994788-6b75-4532-9dd8-952b3650b912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc6d2ee3-a837-4c2b-975d-15021c869395" xlink:to="loc_us-gaap_RelatedPartyDomain_a7994788-6b75-4532-9dd8-952b3650b912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_124b2132-1442-4917-996b-af5348440517" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a7994788-6b75-4532-9dd8-952b3650b912" xlink:to="loc_srt_AffiliatedEntityMember_124b2132-1442-4917-996b-af5348440517" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gh-20200630.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SubsequentEvents" xlink:type="extended" id="iae8a521244804453b17a3e5ddbf0f247_SubsequentEvents"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SubsequentEventsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://guardanthealth.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended" id="i3e4755888ac94e44aeb0ef43314fdac8_SubsequentEventsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_c1f616b5-77d3-4225-8569-a9099ff2dc6c" xlink:href="gh-20200630.xsd#gh_NumberOfOperatingLeasesLeaseNotYetCommenced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_c1f616b5-77d3-4225-8569-a9099ff2dc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_18e95c6a-cfaa-465f-b00b-434c6349ebcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_us-gaap_OperatingLeasePayments_18e95c6a-cfaa-465f-b00b-434c6349ebcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract_a067d9a3-48ff-4a22-8182-faf94f805d33" xlink:href="gh-20200630.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract_a067d9a3-48ff-4a22-8182-faf94f805d33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_cfa09f60-52ff-4d5e-90a7-971ba0865dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_cfa09f60-52ff-4d5e-90a7-971ba0865dd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e613113-91de-4a0b-886f-7d43d4f3174e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e613113-91de-4a0b-886f-7d43d4f3174e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e613113-91de-4a0b-886f-7d43d4f3174e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e613113-91de-4a0b-886f-7d43d4f3174e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e613113-91de-4a0b-886f-7d43d4f3174e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75369d2c-cead-4935-8904-1e8aa0604a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e613113-91de-4a0b-886f-7d43d4f3174e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75369d2c-cead-4935-8904-1e8aa0604a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4b15b957-de7d-4174-88c6-1f0a20b83ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75369d2c-cead-4935-8904-1e8aa0604a58" xlink:to="loc_us-gaap_BuildingMember_4b15b957-de7d-4174-88c6-1f0a20b83ab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c6633102-f8b0-4e54-b5ac-39c180ed75ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c6633102-f8b0-4e54-b5ac-39c180ed75ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c6633102-f8b0-4e54-b5ac-39c180ed75ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6633102-f8b0-4e54-b5ac-39c180ed75ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c6633102-f8b0-4e54-b5ac-39c180ed75ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8fea17e1-4f57-4712-b38c-d6962d503882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6633102-f8b0-4e54-b5ac-39c180ed75ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8fea17e1-4f57-4712-b38c-d6962d503882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7b51a412-9cd5-4e64-831c-7a454ee3b509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8fea17e1-4f57-4712-b38c-d6962d503882" xlink:to="loc_us-gaap_SubsequentEventMember_7b51a412-9cd5-4e64-831c-7a454ee3b509" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>gh-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a823c88f-2b24-44ac-a516-3f731119002e,g:77fc4dec-5a42-485c-bad8-a10178a2afe8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17ab766b-04fc-4356-885e-7cb812aeb912_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SoftBankMember_71554f37-b027-4ccd-9615-e904d9eda52e_terseLabel_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank</link:label>
    <link:label id="lab_gh_SoftBankMember_label_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:label id="lab_gh_SoftBankMember_documentation_en-US" xlink:label="lab_gh_SoftBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SoftBank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember" xlink:href="gh-20200630.xsd#gh_SoftBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SoftBankMember" xlink:to="lab_gh_SoftBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b6e635c8-ed5b-4abc-a2b3-c56b2ebf6b6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7030f11e-b148-4b24-a1fe-9616b563d681_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e3175cdd-d812-46dd-b712-8d26965b0743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cd3f7387-146d-48fe-8434-73934d78017b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e70b840e-87da-4e50-acc4-0c30c959fa47_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_c5f0bfa0-b8d4-4cf2-8c17-a7e7fb663f8c_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_26ea20e6-a028-4cfe-b821-d8bbe81c1ea4_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, patents allegedly infringed upon, number</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_021f967e-bd60-4ed7-b0f2-7550ad9043f7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6589b209-daa0-4d1e-8331-8b668648f2c7_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4ad6e4bc-5eef-42df-a38f-365ae98d9051_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f073a3f7-3f17-4403-b33e-5dc53b37bca7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e00749a6-47ec-42f9-ac6d-3e642b92a3ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_263dc894-28ee-41ee-90f6-5307ed91deda_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired license</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_af4af691-7a42-49e8-a5ad-0ed75f15b0d7_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired license</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_59d4e1a9-b58f-4c90-910c-a23452287c49_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_312964db-ca66-417f-aa5a-029cce99161b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e4440832-531a-4f91-81f6-8f5cb4d47260_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_6d5453c8-a0c0-432a-b051-d5b34d159739_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest, redemption value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_13d423c1-cb6b-480f-ba21-cc5c5da877f1_terseLabel_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and debt securities, fair value</link:label>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_label_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Fair Value</link:label>
    <link:label id="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue_documentation_en-US" xlink:label="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Debt Securities, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:href="gh-20200630.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:to="lab_gh_CashCashEquivalentsandDebtSecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e0cb459c-d26e-4e50-9fcd-ef9ff717d01f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1d4856c0-4aeb-4c2e-8925-f1199d68962c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_181b4b1b-3099-44b3-a24b-495fc95f9ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount for post-vesting restrictions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_b89abe8c-0185-4968-bdec-e416d3bd01a5_terseLabel_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_label_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:label id="lab_gh_GuardantHealthAMEAIncMember_documentation_en-US" xlink:label="lab_gh_GuardantHealthAMEAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health AMEA, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember" xlink:href="gh-20200630.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_GuardantHealthAMEAIncMember" xlink:to="lab_gh_GuardantHealthAMEAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_5989e79a-0e9d-439f-a656-564d6626ca30_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of effect of acquisition:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_81867895-c9c8-4a5a-94fb-76334aa7bc96_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f2cb59c6-fea5-4557-86cd-8dee199c5fe7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fd0b2596-3769-45a4-8cae-129194264e5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3e33a29f-5b32-4740-b2ae-878f1e23c1f5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a1374be5-7992-49a0-8490-b0a11a3263da_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0c6afb96-2c97-41d3-a15d-a8aa3205f42c_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9eb8dfc1-b98b-48e0-a82e-371986b67d0e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_94310586-a6e7-44e4-90eb-6a72e1520454_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerBMember_013db5a6-40ef-439d-b564-5190b0ae74b7_terseLabel_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_gh_CustomerBMember_label_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_gh_CustomerBMember_documentation_en-US" xlink:label="lab_gh_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember" xlink:href="gh-20200630.xsd#gh_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerBMember" xlink:to="lab_gh_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d2ca85e9-5d89-4019-9af1-34778874aa9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c3fc22ae-5faf-4194-88a5-d3a397a76448_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 2 - $150 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b10222c6-dad8-4774-86ba-944ad508d45a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f91be607-342e-4a0f-88d7-683e4a653a06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d37bb8d5-8aa2-4fd4-ae57-7207d2a20866_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f93d8423-b66e-4e84-b18c-40e72c8a5489_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based stock unit vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d07a3717-e445-4504-b6e9-5d40ac066657_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_beb2b244-ba79-4d33-9b20-5c9490d9e8af_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7b8ba6f5-790a-47a0-97d7-37b88a58aaf5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7176201a-1e16-4d36-8cf6-4e310557b209_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_9e3ec8f4-cb18-4c33-bc1c-8f29b5beede4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2607c8c3-b8fe-4010-aa89-70fcd8fa893d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_21c49a03-ef3f-4820-969a-4c4ef1902a4c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate aggregate base rent payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberofCompaniesthatInfringedonaPatent_3c544854-ff5b-4de5-929e-ac7de5b7e5c4_terseLabel_en-US" xlink:label="lab_gh_NumberofCompaniesthatInfringedonaPatent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of companies that infringed on a patent</link:label>
    <link:label id="lab_gh_NumberofCompaniesthatInfringedonaPatent_label_en-US" xlink:label="lab_gh_NumberofCompaniesthatInfringedonaPatent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Companies that Infringed on a Patent</link:label>
    <link:label id="lab_gh_NumberofCompaniesthatInfringedonaPatent_documentation_en-US" xlink:label="lab_gh_NumberofCompaniesthatInfringedonaPatent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Companies that Infringed on a Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofCompaniesthatInfringedonaPatent" xlink:href="gh-20200630.xsd#gh_NumberofCompaniesthatInfringedonaPatent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofCompaniesthatInfringedonaPatent" xlink:to="lab_gh_NumberofCompaniesthatInfringedonaPatent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ec8137fa-f64c-4d22-a828-f851036eb661_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_444b5d4a-0602-468d-bbee-f3e66504df0a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_41461f51-415a-40ff-82e2-94782d62503c_negatedTerseLabel_en-US" xlink:label="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized translation gains (loss) on obligation related to royalty</link:label>
    <link:label id="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_label_en-US" xlink:label="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Translations Gain (Loss) On Obligation Related To Royalty</link:label>
    <link:label id="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_documentation_en-US" xlink:label="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Translations Gain (Loss) On Obligation Related To Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:href="gh-20200630.xsd#gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:to="lab_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_faf1db7f-b198-423f-b6e5-a4b251f56ca0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_087717f6-3895-459c-aff9-c08cfbabb480_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1d9317de-b63e-4fa1-8e41-73833c15c385_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8cd608d0-5d53-4bf4-9cd4-03d4d2ad5978_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cee33578-2ba5-42e2-8747-538c8c8d373e_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Weighted Average Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8ebf5a3b-2513-4a70-b300-4b63888b4293_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_3f8f356f-6136-41ba-9d72-51fe46d0a881_terseLabel_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="gh-20200630.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_gh_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember_5ed57c7b-e432-4814-97f8-84177344ce58_terseLabel_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember_label_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing [Member]</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember_documentation_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" xlink:to="lab_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c876ae60-0072-41fa-a1b4-167fd5e7a7e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_1b66863a-40a5-4619-8db2-fab867b5beaf_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in joint venture</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_99285a69-8553-4564-b95c-2aa6b590686a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1c406125-66f0-4d42-a1f1-3136bd838597_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning number of shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68082907-4cc4-4601-8a21-d3ca4d4ac682_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending number of shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6ef9e573-ec2f-4f5a-b478-9ebdbfd696f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_0df82246-948c-400b-b275-4408a8a2fea8_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_553c678f-9387-417a-90bb-8ba8ef7480c0_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_04f512cd-168d-4293-a53a-eb2e40f4121b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract_fa93f0f7-ab46-443f-b6bc-6dca443f4c21_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average estimate lease term</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Weighted Average Term of Contract</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Weighted Average Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" xlink:href="gh-20200630.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" xlink:to="lab_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_18c95f1f-ab6f-4028-96e4-5111c872b709_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and laboratory space</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_57b2478a-d0d4-4370-b06e-7cb8e66392b9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_798ae925-c645-404a-893d-4f25b559cef9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dc802e90-2181-4ce4-9645-12de5cd6cdc1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax impact:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ad2502b9-6d67-418e-8d5c-7b125468341d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_51d486d0-54b4-4124-aee2-126a434f4686_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4f98e988-5a81-4782-9dff-f4832b83da4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_32f64e09-40d6-4b59-adf9-1465332bf7e3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PatentandCovenantRightsMember_78d80a1a-4d04-41bd-bb43-974b6e4251ed_terseLabel_en-US" xlink:label="lab_gh_PatentandCovenantRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent and Covenant Rights</link:label>
    <link:label id="lab_gh_PatentandCovenantRightsMember_label_en-US" xlink:label="lab_gh_PatentandCovenantRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent and Covenant Rights [Member]</link:label>
    <link:label id="lab_gh_PatentandCovenantRightsMember_documentation_en-US" xlink:label="lab_gh_PatentandCovenantRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent and Covenant Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PatentandCovenantRightsMember" xlink:href="gh-20200630.xsd#gh_PatentandCovenantRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PatentandCovenantRightsMember" xlink:to="lab_gh_PatentandCovenantRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_076ca594-88bb-4f46-a7a5-da86a0a6da7a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_32a9107e-6028-458e-9c7b-2d2cfb347504_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_7b0fc45f-8ecf-4a58-b11f-5214063a30a1_terseLabel_en-US" xlink:label="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases, Lease Not yet Commenced</link:label>
    <link:label id="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_label_en-US" xlink:label="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases, Lease Not yet Commenced</link:label>
    <link:label id="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_documentation_en-US" xlink:label="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Leases, Lease Not yet Commenced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:href="gh-20200630.xsd#gh_NumberOfOperatingLeasesLeaseNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:to="lab_gh_NumberOfOperatingLeasesLeaseNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_647b40e9-9c1a-44be-bc1b-f8afcb6425e4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net effect of foreign exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_8e196224-e145-45cd-a6cf-9e00afe16217_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivables</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_da49ee7b-0f7b-4bd9-8fca-db25083ff19d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a9003fb-cec4-4ff4-9cde-94bf194c4006_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from samples processed in the previous year</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3c3014df-eb83-4c59-adfb-2230b78a19de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_138d6fd6-7068-40b3-9e07-b5b0de75c8b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 3 - $200 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_bf5a3c5b-7524-4292-84d0-27848a242471_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risky rate, cost of equity</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_81516de4-42d3-422a-926f-758274d4b3ef_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_640370bb-0af0-4911-b669-0f638c66267f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b34081ca-8c74-4392-a499-8be86d6969d0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_69029aa2-c4a5-44a4-8ddd-860380bb1cfe_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_0874cf15-6a8f-427b-91a2-5abd2d78afc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance-based Restricted Stock Units Vesting Conditions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_80984fbe-a772-4236-b8ed-ce1a6a2c0d7a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_60270993-4656-4534-9f45-d480fcf48679_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_7a64a8f9-4b42-44f0-9869-892052ec5e5b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_020fa7bb-1d51-4225-a579-8e14e11a413e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income tax differences</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_09c330a2-56be-41d6-9b08-7c0afcc43736_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4ca5e3a8-89bb-45ad-b1bc-157ef9e038ee_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cbfdd67-eef0-41e4-9693-6ba960c5f6dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_51935c57-a53f-42c3-aab1-95b858f149dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ac2c0480-6b8d-43ba-8bf5-cd619d95c439_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContingentConsiderationMember_227b2b5e-f978-46dd-b5d3-1e85def14c2a_terseLabel_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gh_ContingentConsiderationMember_label_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_gh_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_gh_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember" xlink:href="gh-20200630.xsd#gh_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContingentConsiderationMember" xlink:to="lab_gh_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c27e7b79-f09e-4128-99d1-39524c6abdcc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_4af6f2ed-2a31-447f-8ef3-9f5321aa0ede_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_9de9b775-a283-4d6a-9c13-cceb07beda43_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_e157fa57-f4eb-41a5-a192-234c6b361915_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AccruedRoyaltiesNoncurrent_b0152688-82e7-4f57-8a30-85d2668269c8_terseLabel_en-US" xlink:label="lab_gh_AccruedRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation related to royalty</link:label>
    <link:label id="lab_gh_AccruedRoyaltiesNoncurrent_label_en-US" xlink:label="lab_gh_AccruedRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Noncurrent</link:label>
    <link:label id="lab_gh_AccruedRoyaltiesNoncurrent_documentation_en-US" xlink:label="lab_gh_AccruedRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedRoyaltiesNoncurrent" xlink:href="gh-20200630.xsd#gh_AccruedRoyaltiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedRoyaltiesNoncurrent" xlink:to="lab_gh_AccruedRoyaltiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d95370b-ddb9-43b3-92dc-2faaff235ef8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22d9353b-6f96-4efc-b566-70b5204dc95a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4e93f8fc-b95b-485b-b371-6f30c155f33b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2eb1feba-65d9-4511-b0c2-e6e2aa0b167d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_94221957-68d7-4ef2-bece-7b9105513d3d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net of underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fe0fe079-7d4d-4558-9a1e-7fe59ed54a94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_295a9671-ca90-4d3c-8a1b-44cea5a31162_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant&#160;</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b03b55bc-f47e-45de-9080-3a49f17d2287_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_a19beb75-8fc0-43fd-b1c7-8dd9857955e4_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9f888c1e-1357-4488-82eb-5d831fbf48bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5f5918f3-c549-4e13-80f7-65b79471a23f_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_33afc232-dc40-494f-a685-138c32bafea7_terseLabel_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trials and studies</link:label>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_label_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials and Studies</link:label>
    <link:label id="lab_gh_AccruedClinicalTrialsandStudies_documentation_en-US" xlink:label="lab_gh_AccruedClinicalTrialsandStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials and Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedClinicalTrialsandStudies" xlink:href="gh-20200630.xsd#gh_AccruedClinicalTrialsandStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedClinicalTrialsandStudies" xlink:to="lab_gh_AccruedClinicalTrialsandStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c1763584-467d-44aa-b9f4-40b777271e08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_70bc75b5-580c-4e84-880b-31fd618e5029_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ff1cab0e-7ad3-4201-882f-745c62687dbb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5a548cb7-7a16-41ea-9a11-321bbff9ec70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5c8f732f-b843-4e5b-9b94-8e6b0a7e1719_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_937e00de-99bd-4113-8ebb-98d0d5d98be3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f350324e-b196-40d9-9840-96cc53ec6a13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning number of shares, available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_23f5e352-555f-450e-8f21-55cadfd6f68f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending number of shares, available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ebe88753-3e57-4d0c-9834-2c6c70c3c62f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_29d6e66d-9fd8-4b8d-ad0b-132f276e57fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_75d040f0-925d-4f79-b52b-a04eb640e64b_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_label_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Policy Text Block]</link:label>
    <link:label id="lab_gh_AssetAcquisitionPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionPolicyTextBlock" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionPolicyTextBlock" xlink:to="lab_gh_AssetAcquisitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_78eb3f6f-a118-462f-87ac-d368cdfbb260_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_1c077148-ffe8-46cb-9c43-f18f69341b99_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_1db21f2b-8841-4997-903c-bd6f421c2193_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of prior dispute between parties</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_be648532-3ce0-4c6e-bc20-512c26a5785f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_a989faca-4154-4bac-aace-88321eb813c3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2848e1cd-5aef-4f57-9ded-ea198aeacf30_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e2edac8e-91eb-488e-aedf-60c47913ba4d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8d37c551-ffc2-4923-b620-5493fae2dfe6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b119da85-0a42-4ed7-8ec1-d6526a316cf5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6b1d8988-beff-447a-b552-b987f96c9bf3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b3d25e03-695a-4a7c-a515-8fb2ed26365c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d5b475e-87a6-44a1-9080-4ae0a750aa93_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax assets valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9332345c-5527-49a0-be42-0afe9e3c60c0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_705b3ad2-79fc-4cc9-9e39-cc75e42b2bd2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock_f94c7b6b-5271-4798-89a2-485de05bbe7f_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination Disclosure [Text Block]</link:label>
    <link:label id="lab_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" xlink:to="lab_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4ae26379-bc55-45a8-829b-9b5657c3febd_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_edf617ee-4d11-4d24-8a18-f0a0dc02916a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6c156d09-184e-4672-97c7-07f561400088_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0adfd3d9-d66d-479c-a143-f27964863079_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3887a5f3-569f-4537-bee6-d842c324e63b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_392ccee6-9fda-420d-b1db-401e9ceae23c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc6d7d11-3450-4a78-b790-36ecd4c1aa43_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_3af2aa88-ff6f-40f3-a6a1-d916dbc7aa1d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the 2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_9dc9185b-c474-4e76-9ab1-80300316f78b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP obligation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0cf4fae5-ca9f-4d4f-aee9-73ff0fa0ed22_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a8e54433-ed42-44c7-94a7-c31ad70a4584_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_897ee590-3268-4340-b25f-3a53428a5580_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_1776bca7-7252-4915-ae8d-2d70111fed7f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8364af5d-4f41-4c9e-a76c-56f1925f956f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_2e442b5f-50c4-4176-8043-49e2328c5314_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c14181d8-06ef-4eb7-a657-7d62eab60d2a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_52f64e0f-1f09-420b-826d-235359817eb0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c5e7aba0-d237-4d1f-a9f0-62219fadbc84_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_MarketableSecuritiesMaturityPeriod_424ef7e6-9eb5-41f2-81e5-69aed862c88e_terseLabel_en-US" xlink:label="lab_gh_MarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period (years)</link:label>
    <link:label id="lab_gh_MarketableSecuritiesMaturityPeriod_label_en-US" xlink:label="lab_gh_MarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Maturity Period</link:label>
    <link:label id="lab_gh_MarketableSecuritiesMaturityPeriod_documentation_en-US" xlink:label="lab_gh_MarketableSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_MarketableSecuritiesMaturityPeriod" xlink:href="gh-20200630.xsd#gh_MarketableSecuritiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_MarketableSecuritiesMaturityPeriod" xlink:to="lab_gh_MarketableSecuritiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2901c99d-5839-4d41-9080-e97ec51cdaed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_aa95a2e9-83be-4bff-9708-788c2d1c5b91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EarnOutConsiderationMember_5ec4a0e2-58f4-43e3-b8d2-147ac4426beb_terseLabel_en-US" xlink:label="lab_gh_EarnOutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-Out Consideration</link:label>
    <link:label id="lab_gh_EarnOutConsiderationMember_label_en-US" xlink:label="lab_gh_EarnOutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-Out Consideration [Member]</link:label>
    <link:label id="lab_gh_EarnOutConsiderationMember_documentation_en-US" xlink:label="lab_gh_EarnOutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-Out Consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EarnOutConsiderationMember" xlink:href="gh-20200630.xsd#gh_EarnOutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EarnOutConsiderationMember" xlink:to="lab_gh_EarnOutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_81bb50e7-d9e4-45fc-8584-1c7462d25c99_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Joint Venture</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_MedicareMember_9e29f473-c59f-458b-86df-1fb5bd510fef_terseLabel_en-US" xlink:label="lab_gh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_gh_MedicareMember_label_en-US" xlink:label="lab_gh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_gh_MedicareMember_documentation_en-US" xlink:label="lab_gh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_MedicareMember" xlink:href="gh-20200630.xsd#gh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_MedicareMember" xlink:to="lab_gh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_98869d32-ceec-4d04-a9ef-3d3388a994a0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0114f374-06be-4287-92eb-9d02f1b578fe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in public offering, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a045e274-4dff-4aae-a0a3-700f4b285f7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_526329fc-cb25-4e4f-bce4-4c6d5463b227_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_839890f9-6068-489b-89f3-804652248e93_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_aa46761f-1dbc-48cf-9a83-21e1c82741b8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_8e93fecd-c7d2-454e-bf27-30d7ec0563fe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5b030d60-b836-49b7-9ce5-225d5511d4ab_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_61c355f5-71b3-458e-be88-608ae3f74543_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c32f56e5-2119-49f3-a3ae-0215b1367f31_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerEMember_e04edbca-3dab-4b23-be79-cb4178c72507_terseLabel_en-US" xlink:label="lab_gh_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E</link:label>
    <link:label id="lab_gh_CustomerEMember_label_en-US" xlink:label="lab_gh_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E [Member]</link:label>
    <link:label id="lab_gh_CustomerEMember_documentation_en-US" xlink:label="lab_gh_CustomerEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerEMember" xlink:href="gh-20200630.xsd#gh_CustomerEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerEMember" xlink:to="lab_gh_CustomerEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_93b270ac-3285-4749-b989-bf38089c7d17_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning unvested balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f719aed9-25ea-4d71-b69c-8894178f20c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending unvested balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e62d4719-dade-4c42-9419-46b854b97c35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_55a632b8-3150-4ad1-8744-8936b9ff4c65_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d7ceff49-95d2-4915-aa32-dd7fc97ee3dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, grants in period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_cde2dd51-20a7-45ac-94c3-47bf08ac2053_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bf3f80aa-7f63-4384-843f-996d278524a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_14c3eaf0-feac-494c-8791-1063834647da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b6eb8998-dfc5-4d1c-bc5c-8dbe80fee1c1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e833a787-945b-4c5d-857c-5251330b68d7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_0146be9f-5ec3-4d35-92df-e361f570005a_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_b89336a9-d37f-4255-ba45-7be2f3e7df0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, short-term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrent" xlink:to="lab_us-gaap_DebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b7aa4620-4147-40c4-ba09-b317fbe53461_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_33588357-921e-4f94-890e-4e6fbab26b11_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9040c43a-af8e-4ec2-88ab-b5186a8527b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostofDevelopmentServices_e8ecb198-0d91-4cb1-822a-6002b315303b_terseLabel_en-US" xlink:label="lab_gh_CostofDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of development services</link:label>
    <link:label id="lab_gh_CostofDevelopmentServices_label_en-US" xlink:label="lab_gh_CostofDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services</link:label>
    <link:label id="lab_gh_CostofDevelopmentServices_documentation_en-US" xlink:label="lab_gh_CostofDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServices" xlink:href="gh-20200630.xsd#gh_CostofDevelopmentServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostofDevelopmentServices" xlink:to="lab_gh_CostofDevelopmentServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5389d142-43be-4bdd-b422-f56114ed2deb_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_89950067-23fb-491d-87bb-ced40fe0c549_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_170d32bc-bd0b-4e41-87c7-09a098290970_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_KeyGenePatentLicenseAcquisitionMember_97ff79aa-8d33-4409-b14f-4812b6685731_terseLabel_en-US" xlink:label="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KeyGene Patent License Acquisition</link:label>
    <link:label id="lab_gh_KeyGenePatentLicenseAcquisitionMember_label_en-US" xlink:label="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KeyGene Patent License Acquisition [Member]</link:label>
    <link:label id="lab_gh_KeyGenePatentLicenseAcquisitionMember_documentation_en-US" xlink:label="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KeyGene Patent License Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_KeyGenePatentLicenseAcquisitionMember" xlink:href="gh-20200630.xsd#gh_KeyGenePatentLicenseAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_KeyGenePatentLicenseAcquisitionMember" xlink:to="lab_gh_KeyGenePatentLicenseAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_14cbb253-b548-4e4f-9161-81efdf749dd7_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_4e8d6e77-3fca-40e1-bd9d-c87fd502e80d_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f427eb21-9646-4ff0-a2e1-9a8f399c7fd7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerDMember_1bfef466-8f23-4b90-9e94-7ca268103cef_terseLabel_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:label id="lab_gh_CustomerDMember_label_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D [Member]</link:label>
    <link:label id="lab_gh_CustomerDMember_documentation_en-US" xlink:label="lab_gh_CustomerDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember" xlink:href="gh-20200630.xsd#gh_CustomerDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerDMember" xlink:to="lab_gh_CustomerDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d067cf26-1287-4be3-a188-28e3b5e578b3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, period for recognition (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e1a041cc-0d36-4a18-ac3d-503505e6ba55_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_2db42e21-338e-4764-8789-33425311ab2a_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9133d6da-94c0-4216-85b0-dfebaf0cc7ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_BellweatherBioInc.Member_ad007ebc-5870-4754-9517-3e70ac27db0a_terseLabel_en-US" xlink:label="lab_gh_BellweatherBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellweather Bio, Inc.</link:label>
    <link:label id="lab_gh_BellweatherBioInc.Member_label_en-US" xlink:label="lab_gh_BellweatherBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellweather Bio, Inc. [Member]</link:label>
    <link:label id="lab_gh_BellweatherBioInc.Member_documentation_en-US" xlink:label="lab_gh_BellweatherBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellweather Bio, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BellweatherBioInc.Member" xlink:href="gh-20200630.xsd#gh_BellweatherBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_BellweatherBioInc.Member" xlink:to="lab_gh_BellweatherBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b21a3b5-31a8-473d-8456-a5d4f9ebbf6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_ad77c4f6-2433-48e8-98d4-ad217fbdc763_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e69dcee9-aef1-45df-af72-87ced3523282_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd49fb7f-f79a-499f-a151-d0c309351cb5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d080041-b38e-4ebf-975d-853fb13f9f46_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Guardant Health, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5aae6fe1-3875-454a-93fd-b11f26058b8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_dbcab363-80b9-49fa-bcfe-082108ee57c1_terseLabel_en-US" xlink:label="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reclassified and converted into preferred stock (in shares)</link:label>
    <link:label id="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_label_en-US" xlink:label="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued Upon Conversion Of Common Stock</link:label>
    <link:label id="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_documentation_en-US" xlink:label="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued Upon Conversion Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:href="gh-20200630.xsd#gh_PreferredStockSharesIssuedUponConversionOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:to="lab_gh_PreferredStockSharesIssuedUponConversionOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_8359e1be-e591-477b-a0db-b9d530febfa5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_bf6b6458-cea2-4fe2-9b60-a18b417cdbfa_terseLabel_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of precision oncology testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_label_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTesting_documentation_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTesting" xlink:href="gh-20200630.xsd#gh_CostsofPrecisionOncologyTesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsofPrecisionOncologyTesting" xlink:to="lab_gh_CostsofPrecisionOncologyTesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f667c12f-f922-41a8-a48c-6fe2ea3df4ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a147bb97-9fd0-4ebd-a481-e51146fd1ee9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fa5733bf-5999-46c4-929b-6eaf2a681397_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionDomain_8a09fcca-e5cb-4cec-b955-230de4877e5c_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_gh_AssetAcquisitionDomain_label_en-US" xlink:label="lab_gh_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_gh_AssetAcquisitionDomain_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionDomain" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionDomain" xlink:to="lab_gh_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4a25cf3c-0279-44b3-b503-fd6d8abe7a28_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f5ec98c3-0287-40b8-9b0b-96d5fc31399f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_e35f33ed-462d-4fc2-99cb-fdae45b37cb0_terseLabel_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision oncology testing</link:label>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_label_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Precision Oncology Testing</link:label>
    <link:label id="lab_gh_RevenuefromPrecisionOncologyTesting_documentation_en-US" xlink:label="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Precision Oncology Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting" xlink:href="gh-20200630.xsd#gh_RevenuefromPrecisionOncologyTesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenuefromPrecisionOncologyTesting" xlink:to="lab_gh_RevenuefromPrecisionOncologyTesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d61c7681-9cd1-4f58-a33a-a7bf6afc8313_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f296daf9-fa47-4848-a621-b598d57fe173_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_44cb01c8-5eb6-40cb-9be4-04438dd64ecb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Others</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_dc8dde20-9b80-4bd1-80fb-35f37a4f29ad_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_eedf4839-e0a9-4b8e-b2fb-5f8b9e61c6de_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5e5ff0b-42e0-41ad-9c66-09fa7210edea_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_2c1ec5e9-4412-457d-8e57-df4fbbe7186c_terseLabel_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements</link:label>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_label_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements [Policy Text Block]</link:label>
    <link:label id="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Financial Statements [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:href="gh-20200630.xsd#gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:to="lab_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f90084be-d2e4-4954-ae21-b0a8e71cb66e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_be6b910d-11ff-46d9-bcba-f00af71ec65b_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_78cee3c9-421b-42d6-9041-0c452df72a57_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_dddb9d32-48fe-4092-8104-42b7113777a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_42e1335d-43a6-4175-8bf3-3d23e68dc46d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_10e1f001-b642-4663-8126-a3dc03a702a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8a5a6f97-ac1a-4222-87ce-5216536eb3d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ea374bd3-e9a5-4ee9-9ed1-f4deeaa6c477_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bb929c42-012f-44f2-a503-b96fb3bd3db0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d49126d7-6efe-4d3e-92c3-4b82b0000a1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_cb82194c-7401-4d35-8a1d-803eea13c77b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_46392bb0-9a09-4ea9-8ea5-aad51b218ef0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6696060b-d348-4cad-89b6-d33a28f3783c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_1a4a76a7-ea82-487d-bf42-d8d2aaee64e1_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_207b1777-a5a3-40b8-8aea-7a59c08ceb47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e5922d3a-30d5-4d62-a1b7-e714404850aa_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_744c299c-8449-4cad-a9ec-cdaf57c1153d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_6cf99135-3895-487e-a11d-ecddc97aee47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ff1153f8-3185-4d0c-89d7-7020fdc04710_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_40383d80-26e4-49ad-9d26-bc0ed8bda569_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_297b402e-67ff-4d4a-ba0c-5f6868a470d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_88fe4e5e-fe35-4194-998a-7ed95a176e91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average derivative service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9ceac04c-0970-4929-828d-c719d0d943a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_841282d9-6bc9-4ab9-8cc9-3df99424ce95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6d19d6bc-f979-4557-8f78-5f3768ffa048_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_0adf2ed9-3c91-4533-9d9f-8c741b1a9314_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty obligations</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c6bd43d5-f5e8-441a-9ae1-57525361e0db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_88af128e-2d78-48d6-95ed-91ba9374b9b7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7d906043-191b-489d-b4bc-b79a2b72b74c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f1902546-5182-4ac2-afbe-61c2c264d1c1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_af5bff28-ff44-4690-b3df-56a30609e68b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_b9cb2b3a-ce6f-4e83-8e98-d37a51d0ff7c_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_f6b5f8b8-84d2-4c1f-a0a5-fcd0899f63ef_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_db991b17-5878-4fe2-b923-a02b10de19f8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Guardant Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_4dbc968a-0ad2-4160-bfef-a6cdbaf044ad_terseLabel_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of precision oncology testing</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_label_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:label id="lab_gh_PrecisionOncologyTestingMember_documentation_en-US" xlink:label="lab_gh_PrecisionOncologyTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Oncology Testing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember" xlink:href="gh-20200630.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PrecisionOncologyTestingMember" xlink:to="lab_gh_PrecisionOncologyTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_752e0bc0-97dc-439b-9415-226d37cd8714_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_6c6417eb-6e8a-4566-98d2-9a5a4a44ebda_terseLabel_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_label_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Table Text Block]</link:label>
    <link:label id="lab_gh_DebtSecuritiesTableTextBlock_documentation_en-US" xlink:label="lab_gh_DebtSecuritiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesTableTextBlock" xlink:href="gh-20200630.xsd#gh_DebtSecuritiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtSecuritiesTableTextBlock" xlink:to="lab_gh_DebtSecuritiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ffd86727-6ad5-4d86-ad54-62a4c5d8bd2e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d1110d4-0644-4960-83a0-dce3b204e45e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CommercializationMilestonesMember_45a16156-df92-400b-a6ee-4a1d54c3537b_terseLabel_en-US" xlink:label="lab_gh_CommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Milestones</link:label>
    <link:label id="lab_gh_CommercializationMilestonesMember_label_en-US" xlink:label="lab_gh_CommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Milestones [Member]</link:label>
    <link:label id="lab_gh_CommercializationMilestonesMember_documentation_en-US" xlink:label="lab_gh_CommercializationMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CommercializationMilestonesMember" xlink:href="gh-20200630.xsd#gh_CommercializationMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CommercializationMilestonesMember" xlink:to="lab_gh_CommercializationMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5381c2dc-1700-4210-9037-e7952a11e740_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_321f52b4-c93f-448f-8588-8993e4fb23db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fair value of contingent consideration at acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_63adde42-924e-4d2a-9a4f-ea721d1b5913_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability from business acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_28203c41-b936-4e52-9edd-92262b121e53_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cc715c44-c44c-4d0f-ba5d-31f0f983ff68_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CovenantsNotToCompeteMember_60b83a5e-98b2-49ae-9557-831b00227328_terseLabel_en-US" xlink:label="lab_gh_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants Not To Compete</link:label>
    <link:label id="lab_gh_CovenantsNotToCompeteMember_label_en-US" xlink:label="lab_gh_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants Not To Compete [Member]</link:label>
    <link:label id="lab_gh_CovenantsNotToCompeteMember_documentation_en-US" xlink:label="lab_gh_CovenantsNotToCompeteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenants Not To Compete [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CovenantsNotToCompeteMember" xlink:href="gh-20200630.xsd#gh_CovenantsNotToCompeteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CovenantsNotToCompeteMember" xlink:to="lab_gh_CovenantsNotToCompeteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_4d27d454-1465-4695-867f-6c7bb136a491_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_1d7bdf45-fa0d-4828-b2a2-df504411e37b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e54cdf2d-0005-4f03-b049-8da57c2ad7c2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_71eccd3c-478d-4562-a992-1a0b80416446_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e49e939b-c8db-484b-8e86-d22051ef7de4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_9fc2d263-0a66-4441-a8fc-4a24b03046ce_terseLabel_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge of in-process research and development costs with no alternative future use</link:label>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_9a6dcb13-049a-4ef8-bbaf-a1db301fd384_verboseLabel_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development expensed</link:label>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge Of In Process Research And Development</link:label>
    <link:label id="lab_gh_ChargeOfInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge Of In Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment" xlink:href="gh-20200630.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ChargeOfInProcessResearchAndDevelopment" xlink:to="lab_gh_ChargeOfInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_fc22ce53-6e91-4e8c-a2c1-d02b818466b8_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of MSUs (in shares)</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_8e6834f4-6573-4d85-8c75-8669e523539b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionTransactionCosts_4478aed1-15a7-4d00-8bc1-a9a5a4d36cb7_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, transaction costs</link:label>
    <link:label id="lab_gh_AssetAcquisitionTransactionCosts_label_en-US" xlink:label="lab_gh_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:label id="lab_gh_AssetAcquisitionTransactionCosts_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionTransactionCosts" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionTransactionCosts" xlink:to="lab_gh_AssetAcquisitionTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_a9909d68-0d91-485a-b041-0e17c4946f3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PaymentInConnectionWithaLicenseAgreement_33678fd4-b3b9-4d3f-8396-c6919ae34797_terseLabel_en-US" xlink:label="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in connection with a license agreement</link:label>
    <link:label id="lab_gh_PaymentInConnectionWithaLicenseAgreement_label_en-US" xlink:label="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment In Connection With a License Agreement</link:label>
    <link:label id="lab_gh_PaymentInConnectionWithaLicenseAgreement_documentation_en-US" xlink:label="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment In Connection With a License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentInConnectionWithaLicenseAgreement" xlink:href="gh-20200630.xsd#gh_PaymentInConnectionWithaLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaymentInConnectionWithaLicenseAgreement" xlink:to="lab_gh_PaymentInConnectionWithaLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b6933a43-da64-4538-a4fd-19ade05dba2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_e76876e7-9c44-4d71-84f1-e1632e172090_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_11794bc9-84d3-4e9e-aea9-c30823f190f6_totalLabel_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_label_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_gh_IntangibleAssetsGrossIncludingGoodwill_documentation_en-US" xlink:label="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:href="gh-20200630.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:to="lab_gh_IntangibleAssetsGrossIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_1b581a0d-6948-4089-9316-6959f7a1c4b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_c1d7dc9c-9844-4675-b6e9-7dbfa228428d_terseLabel_en-US" xlink:label="lab_gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subject to repurchase (in shares)</link:label>
    <link:label id="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_label_en-US" xlink:label="lab_gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:label id="lab_gh_CommonStockSubjecttoRepurchaseorCancellation_documentation_en-US" xlink:label="lab_gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:href="gh-20200630.xsd#gh_CommonStockSubjecttoRepurchaseorCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:to="lab_gh_CommonStockSubjecttoRepurchaseorCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_8f1bc34a-1f69-4117-8c33-534d01095428_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_898683bb-7188-4037-9b71-1582289b5836_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_aad68100-5326-4265-8e19-448f5b0db7ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_db7a6361-ce39-494a-ad86-56ca5f0aa992_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (unaudited) (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_dd5a13c3-8897-42ed-81e4-baa84ce7ae09_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_99b33234-2fdb-4ec5-bb61-996f4cc2d8be_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds received for unvested shares</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_64945abc-6b9a-4fc5-840e-8174333a3385_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_7f8d7012-6ddd-440d-b400-44b72378a5fc_terseLabel_en-US" xlink:label="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_label_en-US" xlink:label="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period</link:label>
    <link:label id="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_documentation_en-US" xlink:label="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:href="gh-20200630.xsd#gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:to="lab_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5bc3c23d-7b40-4ef4-9a2b-ecd973e7aaf2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4101aefe-5951-480b-a3cd-908ab1e7ff62_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5df60da0-d690-49df-9d9a-5a4baf58b9c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5ffaf953-fc70-4e73-bf7d-dbd0f3fd7ea8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium (discount) on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bfc5fbe3-d471-4dcd-87ad-d8f08fb60439_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b4b4ff97-934e-44b1-bdfb-675facdb8064_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d581c4f1-62f4-450e-9458-24dbfd634e54_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_ccc9e782-74f9-41ea-81f0-e2d5380494b4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3e9f53d2-8e56-4a2f-a50c-0de6c67b970a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5dafee7e-5fb7-4f20-aa78-79b57991c8c1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_d5d2018f-cfd5-4764-b30c-5213cb4c13a2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_2e16ab43-ed57-4d79-b15f-66afb3da65f7_terseLabel_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_label_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Legal Fees, Current</link:label>
    <link:label id="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent_documentation_en-US" xlink:label="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Legal Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:href="gh-20200630.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:to="lab_gh_EstimatedLitigationLiabilityLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_693aa4a8-0a9d-4f30-afc0-f21bb7aea8d9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1a45140c-05ba-46ea-b7a1-f397c5e31320_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_87dbe1fb-a53a-44f6-a36d-0dbbbc71f068_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based stock units holding period during vesting</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c5f4a449-5852-4a6a-95f5-5e632b24db2f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_1ff391b7-1b22-4c46-bf04-5bb33a6adc51_terseLabel_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development services</link:label>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_label_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Development Services</link:label>
    <link:label id="lab_gh_RevenuefromDevelopmentServices_documentation_en-US" xlink:label="lab_gh_RevenuefromDevelopmentServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromDevelopmentServices" xlink:href="gh-20200630.xsd#gh_RevenuefromDevelopmentServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RevenuefromDevelopmentServices" xlink:to="lab_gh_RevenuefromDevelopmentServices" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_9fd858c7-8135-4eec-993b-14670cff8d71_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1b3df866-8985-42d8-962c-ee161360b9d3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_53136ff7-eafd-40f7-8aa1-56b07dfd12ca_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation not recognized, other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c44a4069-fc68-47f4-9fef-c1fdf1eea159_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_7d70d26b-4dd0-4c1d-b6ec-f2849e4ff1ee_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a7b35954-56bd-4a0b-8585-1e975adfc205_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d4c64e55-c571-4778-b3d0-8cdaf859beff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_104a331c-bc31-41c1-8368-0c7cf7372154_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_57de0d81-fa55-4072-8968-3b362779a856_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_66b449fc-faa4-452f-a1bc-dbaa137f06d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e71ba33e-4358-40ba-9f6e-ea99c0525df6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ce6d7340-14ba-4923-a411-b8b6b225e3e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d4bfb851-fdb1-4cee-9a3e-556226d2b9d5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_eb8e308f-4e4b-4fab-bf52-3da8e30a8045_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_3a188128-87a4-4946-b4c5-13b05f2f17d3_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_97c000e2-1bad-4d89-be56-e483fce89547_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_OfferingCostsIncurredButNotYetPaid_a299c62f-2c48-4134-8372-15716f9aa65e_terseLabel_en-US" xlink:label="lab_gh_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-on public offering issuance costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_gh_OfferingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_gh_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_gh_OfferingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_gh_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_OfferingCostsIncurredButNotYetPaid" xlink:href="gh-20200630.xsd#gh_OfferingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_OfferingCostsIncurredButNotYetPaid" xlink:to="lab_gh_OfferingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0b40f316-8a67-465e-a42e-a482eab25e64_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_3a7b37d3-638c-4f72-b3bb-c32e5bb259b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d9bd91d4-5099-4dec-b744-896fc17eb0c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6b1b1e01-2ac8-4b3f-9688-e5366652f94d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_865d0662-8370-4210-bd78-c580a031a692_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a351e83c-4dd8-495b-8550-021a82cd6ae1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_4243b2ca-98e3-4e76-a6d9-738944a5b547_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624397cb-cdf2-49b9-bbf2-84ab6a7e26ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price&#160;</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e2e2b74d-f6fa-442f-bff7-3c891d3c6851_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re-valuation of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_9a60fddb-bf59-4d24-bba4-f3ebc898d958_terseLabel_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, shares purchased (in shares)</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_label_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Purchased</link:label>
    <link:label id="lab_gh_EquityMethodInvestmentSharesPurchased_documentation_en-US" xlink:label="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased" xlink:href="gh-20200630.xsd#gh_EquityMethodInvestmentSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_EquityMethodInvestmentSharesPurchased" xlink:to="lab_gh_EquityMethodInvestmentSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_66056efa-4ce7-4d3a-b623-51d256b17dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3baf8528-de6f-42de-97c3-aa19152d3ae6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_b9340312-7a5a-43ed-8f17-d4f787fe162f_terseLabel_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc.</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_label_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_documentation_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:to="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_0fc8582b-df8a-4574-b291-c7cc3d3d0cea_terseLabel_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_label_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:label id="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_documentation_en-US" xlink:label="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:href="gh-20200630.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="lab_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cae5808e-b986-4bd5-9d4a-d4a450d4b1a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3fd45d98-629a-4567-a7d8-8634b0356b67_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_c9db4990-9783-427c-8884-59c071f7792f_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price of stock issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e8b99513-b8b3-4b10-809f-ac1739b0b6ca_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4f70331e-1808-4a55-baf2-b57928aaf4d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_34a193ce-f592-4cb5-8f90-5a618807ba72_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_81f1d2e1-1e4f-4f89-b245-b910e1846f2f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5aa964e3-f76b-4d35-850a-3c79b5686bc2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_fe10d39e-8882-4cc9-b412-c9f02fff56f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price of common stock (as a percent of the fair value of common stock)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9d2fa35d-8416-479c-892b-b9e2aeb727a3_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_81dcd287-e0ed-45ba-9a4e-0a363d906c49_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dd35e3d8-2f42-40d1-876e-9418e95c7e40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_c73ce89a-fa92-459e-b848-b3a6bb950520_terseLabel_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based restricted stock share price goal</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_label_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</link:label>
    <link:label id="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_documentation_en-US" xlink:label="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:to="lab_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_90f7ee02-fbbd-4124-b57c-5f3d0c6bdede_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_ab9b3b40-7133-44d9-9841-2ea1b1ac14e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_364073e6-6cc5-4dc8-ab2c-47b8460d5fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c2f06827-227f-498f-a60b-301325dd6631_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_7c965d79-19a7-4586-b74b-61254bf82baa_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6329e057-6890-47fb-b865-53b43dae6815_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_ff15ad56-a8e7-4c04-a46e-c2a381ee687c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2ae9448b-de35-44eb-a527-f198e304ae8d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_cdcd773c-f961-4584-915a-28d19844e47c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b342c2f5-47e5-4133-8a7e-d142f787a4e5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_6752662d-6547-406e-bda0-459071b19042_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to additional paid in capital, stock issued, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d54f3435-2bf6-44f0-89eb-fa188079d699_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_159911ed-0de0-40fd-b2f3-dddb9ed0db28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (unaudited) (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_7ab3434f-995c-4801-b302-7848dd82ae56_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 plan annual increase (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ff7bdfa-2583-4e1b-9628-26386421dc55_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Noncash Investing and Financing Activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_003840a7-6f70-4dd5-a135-de164b34c90a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_1bce791c-6e16-43a5-b9e2-a40df6a4a974_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_243236f3-805f-4f9c-a777-eefaf7936df8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8952e7f1-7a13-4f56-85b1-fef7c3fbd9a2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8d7c7b73-8baf-4c8f-ad87-50186fa7cef2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_893a9489-8e6a-4771-bd12-8c907a1c3312_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_ee52c799-9e03-4973-b583-7460bb4f5f07_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_eccec705-5aee-43de-8771-0b3370c62085_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_19208ee4-803c-4ebb-b29e-e1d3166958a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerCMember_47a842d2-5567-4861-b38c-9dea64814080_terseLabel_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_gh_CustomerCMember_label_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_gh_CustomerCMember_documentation_en-US" xlink:label="lab_gh_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember" xlink:href="gh-20200630.xsd#gh_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerCMember" xlink:to="lab_gh_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_1343786f-f12a-44b6-b4ca-155c9bf89941_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0ee8e45d-708d-4f3c-8afe-699cf4acbccc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_80d7232d-b890-48a5-a8ba-c0c9410c7488_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d534ae70-b8b2-42dd-8fd0-025278f58188_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_62b8a94c-b135-4094-bd7a-788e6ccaebb5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_3cb6c9aa-3815-418d-9996-4c0e8ab6bd77_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_5a22630a-c12c-4756-b724-fe81cb942b53_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_c0c11f1b-161e-4892-a67d-ddf0c539e9f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June&#160;30, 2020 and December&#160;31, 2019; 99,312,237 and 94,261,414 shares issued and outstanding as of June&#160;30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bd1e937-44c7-4f8c-ac54-51db1c12a91e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_12604a36-7b90-4bb4-b8e9-f198275345d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8c50fa16-a2b9-4d34-ae04-df3659bdf3fb_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a1ebd581-4400-4e6f-a585-27851f12662e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_76717550-b9e3-4e96-b5be-a395669f2c74_terseLabel_en-US" xlink:label="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subject to repurchase, per share (in usd per share)</link:label>
    <link:label id="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_label_en-US" xlink:label="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share</link:label>
    <link:label id="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_documentation_en-US" xlink:label="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:href="gh-20200630.xsd#gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:to="lab_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_3a380439-ceb1-4867-b2b0-5a3b6957bc1a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_bbadd442-9754-4634-872d-42ba02d5aae7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f958407d-20b9-4911-9705-c1f74e0cd2c1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68bdcea4-7605-4a55-a2ae-116d52ab689b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_abd6cbe2-ac5d-4959-a8a5-c605d1a8cb1e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ed17b41e-1748-42d0-b73a-37442a1960e0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_GuardantHealthIncMember_cc6a1047-709e-47b2-8202-dd6042ccfa09_terseLabel_en-US" xlink:label="lab_gh_GuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_GuardantHealthIncMember_label_en-US" xlink:label="lab_gh_GuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health, Inc. [Member]</link:label>
    <link:label id="lab_gh_GuardantHealthIncMember_documentation_en-US" xlink:label="lab_gh_GuardantHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guardant Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthIncMember" xlink:href="gh-20200630.xsd#gh_GuardantHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_GuardantHealthIncMember" xlink:to="lab_gh_GuardantHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5e7ccc35-7810-4d8b-ae17-f93c6d1bb7d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_6578a03f-4d00-48c7-95c7-e6c8cde054bb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_b3929bbf-5a2f-464e-90a2-303d2d7a2718_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_e3208270-f70b-49ba-a938-6a0f5c68222f_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of fair value that is no less than internal rate of return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_label_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</link:label>
    <link:label id="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:href="gh-20200630.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:to="lab_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CustomerAMember_b8c9ee9f-bae9-4238-8cdc-5bd564e719e1_terseLabel_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_gh_CustomerAMember_label_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_gh_CustomerAMember_documentation_en-US" xlink:label="lab_gh_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember" xlink:href="gh-20200630.xsd#gh_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CustomerAMember" xlink:to="lab_gh_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_b6fde79b-18dd-4cfc-9089-1df5b00fb472_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ed4bedda-2b5a-49f9-a6a0-a8ea4e51cf40_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a4325699-8e02-422b-b3e2-6b2b2a3bf009_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_937aa643-a0bb-4d16-a4da-7c8ffdb76455_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AssetAcquisitionAxis_30ff8f04-e59c-4349-850e-59dffa094b31_terseLabel_en-US" xlink:label="lab_gh_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_gh_AssetAcquisitionAxis_label_en-US" xlink:label="lab_gh_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_gh_AssetAcquisitionAxis_documentation_en-US" xlink:label="lab_gh_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionAxis" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AssetAcquisitionAxis" xlink:to="lab_gh_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_3a85e914-1408-44b8-a38b-a1b505fe5f7a_totalLabel_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, cash and cash equivalents and debt securities available-for-sale</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</link:label>
    <link:label id="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:href="gh-20200630.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:to="lab_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3b5e2a76-63d0-43fb-b7f4-33092874113e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of MSU (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_34bff3e6-ba4c-4599-be77-4f3c41363cfc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend rate (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="lab_us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0dad146-6c41-41b8-85ff-445ffb43f148_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_12a9665e-b265-4449-a7ba-ff77e3e40102_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_c87d8108-966c-4c04-b3e7-adba0bb03ab2_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d27341ff-d3be-436a-89cc-5ee87c9c037c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e5685d7-435e-4e5d-99cf-83476d0aa90a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bd8dc5f-5185-4dbc-b6e8-fd3e807eb607_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6e99c2c7-52c4-42c6-acce-c0167a0d6f6d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_15efa3ca-aa5e-4957-87f9-a8055b6f3534_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_b97bd4a9-e317-4fbb-a82b-f4cc4e0d54b5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c60e4ab5-be1d-472c-bd78-abcfff505a7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f59537d4-1e0a-4f1d-b268-fe599db7600b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_01c595f8-bbd1-45d2-8e6e-5f242cab5568_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f43dba0f-986c-4fbc-b28c-08059e8c68cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5a520abc-418e-4281-9938-5909b5dee722_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4658b2f5-8d45-454e-875d-5905d3af550d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of offering costs related to public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d65b23d7-01b8-42a6-89ce-79a0b811a6f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_22df2178-5b95-487e-9c2d-629efb7a4f1f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b04fc1b3-fc5c-4952-8c7b-ede919d9fcf2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_9118917d-dcec-4964-a1ed-9fc184026f49_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Topic 606 adoption</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f6b1cd28-266a-4636-a9c0-7fd425314b4c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_125c4d4f-2d48-44b2-b3e2-f5264c70e501_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1b924243-dcc7-4e2e-8750-8aeb711f3092_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0848ca2-d875-4fc4-a5e8-ee5cc6e0dd2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_729dbe8c-2e88-4459-ab3f-223585e81205_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7862edd3-7ec5-49dc-9a66-c019d8e20dc5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_df0a44be-a63f-4c30-bc9e-adec40089105_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f204ab95-d53c-4ade-8c9e-1144ca26b5d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate, ESPP</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b989a2e9-f78f-4a91-81c1-b1d1c984ea84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_525e1cd6-9c42-4049-b6d5-2f8122daaa60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bb84fc55-f5cb-48e6-8840-7337c92a072a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberofPetitionsDenied_d3c63dc5-e66c-4db5-8996-5203c53c7676_terseLabel_en-US" xlink:label="lab_gh_NumberofPetitionsDenied" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of petitions denied</link:label>
    <link:label id="lab_gh_NumberofPetitionsDenied_label_en-US" xlink:label="lab_gh_NumberofPetitionsDenied" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Denied</link:label>
    <link:label id="lab_gh_NumberofPetitionsDenied_documentation_en-US" xlink:label="lab_gh_NumberofPetitionsDenied" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Denied</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsDenied" xlink:href="gh-20200630.xsd#gh_NumberofPetitionsDenied"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofPetitionsDenied" xlink:to="lab_gh_NumberofPetitionsDenied" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5e72b33c-acab-4396-8488-d63a3c0d823e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_c2490ee6-47c2-4c30-928c-cded5ee953ab_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3733d808-3585-4ead-8d6c-092071124e07_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccf5ab70-467f-4ba9-8d7b-0f2fcbae1dd8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3ecc62f7-5f57-4fc1-9186-5b89c7559c17_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_99ab1daa-b044-4b25-aec9-af8e9da804d3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_589d19ea-04c9-4697-89c5-95b1395b8922_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_3beaeade-0e71-47d8-824b-a5f1bedddb27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, long-term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_02879f56-d17f-4ca5-9afb-83a1c908dba3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a9c419d1-78fa-41e3-88d6-240ff589596d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5134278d-e4ef-4b90-8191-99ed3d56bcc2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_1e434712-e8d4-4ffc-ae2f-86b6c5012c95_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ad20e1df-377c-4085-9949-08e90155754f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2353f1a5-8e22-404e-9fad-706dcb7c3e71_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3d8761bf-af38-4d99-adee-3884950240ad_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_9ba4af52-0700-410f-a809-968d0adab624_terseLabel_en-US" xlink:label="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of joint venture threshold</link:label>
    <link:label id="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_label_en-US" xlink:label="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase</link:label>
    <link:label id="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_documentation_en-US" xlink:label="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:href="gh-20200630.xsd#gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:to="lab_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_119f09ee-fdeb-4e85-8b4a-36af612267a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_41d468de-9553-488d-94fd-d0dac93dfd4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_65a691a0-1ca4-496d-8669-a537114bf697_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1854b6c2-8742-4855-889e-9af52af94023_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cf1ddae5-315d-46a7-aa8c-d069521fe10d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6e433ce6-3778-408c-8c8c-c2a753b8156a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5cc0efd3-5c32-4afc-95df-7e5f1ca2cfe0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_08eeb2f2-c05b-4534-a41a-dc16caf9d8f3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2f374fb7-9c61-4db5-b622-3739d82a9e9a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cebfe779-bdae-497e-903a-b85864f514a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_358e1cf0-e761-4bce-af5d-8b6a6c6eea70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8b329dd7-b9dc-4e7c-90e1-6b16e111dc5e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a1c0dc0-9d0c-495e-8a83-6d77624f78ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Subject to Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9c15cd74-0b08-4b98-906f-911638625ed7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_ced2aeab-d8a0-495f-9361-ec1382bfb9d1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock subject to repurchase</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_76ff9eb5-8737-4ea7-b638-b9659be2ae89_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_9e651ac5-e176-4d4d-8dd1-bc6c1423d169_negatedTerseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_0af83cb2-b0dd-4e91-ba86-4089ba6ac92a_terseLabel_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total market-based restricted stock units approved and granted</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_label_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period, Gross</link:label>
    <link:label id="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_documentation_en-US" xlink:label="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:to="lab_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fe6265fc-ead5-414c-84f0-60707a3fb487_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_742b8d79-6b21-4dfd-822a-662e64d7481e_terseLabel_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="gh-20200630.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_bf1e1b42-8c26-46d1-9926-6f784ba133f7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_70276151-eb77-4725-ac15-b955bf73bbc2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4affb0de-eac1-4d07-a12e-d614cfbff4e0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_16d0944e-bc0e-45a2-9e4f-f434a8a43ea0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3d448a49-2aed-4da6-9383-f992ae517edd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_ce6fd06f-b3b8-4946-8656-d1b2b9319289_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_f59fe179-20d8-46ac-a7cb-88b38ad22184_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7baf7e3b-50d0-45de-b223-9a500c1b0e80_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ee93761d-9216-4b07-813f-cab725bf7221_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NonemployeeStockOptionMember_fedac72e-ae00-4d27-b741-94341862becb_terseLabel_en-US" xlink:label="lab_gh_NonemployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee stock option</link:label>
    <link:label id="lab_gh_NonemployeeStockOptionMember_label_en-US" xlink:label="lab_gh_NonemployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Stock Option [Member]</link:label>
    <link:label id="lab_gh_NonemployeeStockOptionMember_documentation_en-US" xlink:label="lab_gh_NonemployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonemployeeStockOptionMember" xlink:href="gh-20200630.xsd#gh_NonemployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NonemployeeStockOptionMember" xlink:to="lab_gh_NonemployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_2f587916-c127-4d66-b452-d1c018e739d3_terseLabel_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accrued expenses</link:label>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_label_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses, Property and Equipment, Current</link:label>
    <link:label id="lab_gh_AccruedExpensesPropertyandEquipmentCurrent_documentation_en-US" xlink:label="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses, Property and Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:href="gh-20200630.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:to="lab_gh_AccruedExpensesPropertyandEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_753992ab-142f-41c8-91d8-e896abcf993f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (unaudited) (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4974eb34-4031-4539-80f3-72eeac870e7f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_ec9dd996-9e0d-40e7-a95e-bbd5fbafd268_terseLabel_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_label_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:label id="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_documentation_en-US" xlink:label="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of Precision Oncology Testing [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:href="gh-20200630.xsd#gh_CostsofPrecisionOncologyTestingPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:to="lab_gh_CostsofPrecisionOncologyTestingPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a6a16b5f-184f-410e-bbb5-b75255aacee3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in public offering, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e1f6460c-2735-4263-8f74-73f1d3ef99e3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_2950822d-279b-4234-8d5f-f515ed9162e4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment of redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b5259e5e-b43b-4ef8-a203-6534e1219229_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_88331ac5-a772-4c84-a3ab-20810c917530_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_2f3dd3dd-7580-42e0-8d41-bb715efc059f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress_66fc8608-f786-40ea-9f0f-97c551d411f2_negatedLabel_en-US" xlink:label="lab_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate of development services revenue</link:label>
    <link:label id="lab_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Prior Year Revenue, Change in Measure of Progress</link:label>
    <link:label id="lab_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress_documentation_en-US" xlink:label="lab_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Prior Year Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" xlink:href="gh-20200630.xsd#gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" xlink:to="lab_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_46b2aaa4-236b-43e9-8314-715b0306d420_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_66a6d193-91b1-47f2-909e-d4e38883ec8b_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9a007afb-d3f1-4921-a141-71a7229f20da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_2169d51f-11bf-43f5-8849-382d827f51d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8efe7690-1fe5-4b45-8828-f7b7cdda65e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d4d00e6-b148-4868-99e2-5c79172d198d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_9891f35a-b7fe-4bdc-925d-2cf83afa1cde_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d8c620b7-8a29-4d26-9987-561acda8c577_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_NumberofPetitionsFiled_5b132242-ac52-48fc-9f19-5bc6f4e816c3_terseLabel_en-US" xlink:label="lab_gh_NumberofPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of petitions filed</link:label>
    <link:label id="lab_gh_NumberofPetitionsFiled_label_en-US" xlink:label="lab_gh_NumberofPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Filed</link:label>
    <link:label id="lab_gh_NumberofPetitionsFiled_documentation_en-US" xlink:label="lab_gh_NumberofPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Petitions Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsFiled" xlink:href="gh-20200630.xsd#gh_NumberofPetitionsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_NumberofPetitionsFiled" xlink:to="lab_gh_NumberofPetitionsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember_9c42b65c-0fba-43c7-90ed-3dba4e8913ad_terseLabel_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember_label_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing [Member]</link:label>
    <link:label id="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember_documentation_en-US" xlink:label="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" xlink:to="lab_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d4045bfc-10cb-400d-9f96-fecf8913a167_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liability Maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_23dded49-605d-4ba8-9629-9712d013b6c0_terseLabel_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_label_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_gh_RedeemableNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_gh_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember" xlink:href="gh-20200630.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_RedeemableNoncontrollingInterestMember" xlink:to="lab_gh_RedeemableNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cc64cbc9-f06e-4358-80e8-a3620ff9871a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares underlying outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7fd35e47-fea1-4192-a41c-ba28e12a0998_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b1ea2985-11b7-4c95-ab93-2ff68bd8b0f0_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_02752dea-b839-4fdd-9073-ff0bbd710c54_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dffff430-06f0-4e7f-ab88-01f735f0b2b7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08129695-c177-4c5b-b2a6-2a740814bbab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a70db692-9f77-4100-a4b8-9f834bb194d6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6f71a462-ef5b-4855-b80a-fd0e07bc20fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a6120a20-54ee-4457-a6ed-9052f38864e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_4929295e-3746-4087-a7dd-16f55b8432fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ebd888a4-ab47-4a83-a82a-358ba89d59ce_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in joint venture</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_e5861311-6f8d-4261-a4cb-6722b03675ab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b6c7ec18-25d0-44bc-aa9e-d07a8aeeb8a0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_97d0b302-a061-4c83-b545-86110f39c74b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_8eccd9d8-0fa1-44b1-9ff7-df53a38fef46_terseLabel_en-US" xlink:label="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contingent liability</link:label>
    <link:label id="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_label_en-US" xlink:label="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Maximum Amount Payable</link:label>
    <link:label id="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_documentation_en-US" xlink:label="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Maximum Amount Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:href="gh-20200630.xsd#gh_BusinessCombinationContingentConsiderationMaximumAmountPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:to="lab_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6ba6fe39-2063-476a-87f6-a9ead687de3a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a55cbf98-d48e-4c66-baa5-f4ab02b59344_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f13eed89-dd3f-4f44-abae-66877ea148e0_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_8982bc95-57de-4301-ac49-df97b3ae1f78_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9e2e3ab2-e7f1-4acc-a619-3079540a249f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_aab39c12-461f-441a-8583-7a8e60b3f093_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_c8011683-e136-4866-8326-a9852ef781b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94b490c0-9c13-4771-87ac-abfb4cc75eb6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6ad16b9-146e-4bf3-84cb-3388b4e3b280_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4702c471-e5d1-4130-a8f2-89b7ea79edd2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_2eaa29da-c4b6-4cc2-9b36-b1595ae1a2ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201807Member_92b61e56-8223-4bb3-9f4e-8202a3e1a278_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201807Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2018-07 adoption</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201807Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201807Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2018-07 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201807Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201807Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201807Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201807Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_2ae8ee1e-bbbb-4905-a5fb-7c43a381ad9e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_22a3fac1-007b-493b-abba-a0a87ec1ffd5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9cf117b6-21bd-444c-bb87-f946d95ad08c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and nonfinancial liabilities, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_762f4e7f-1aa0-4839-b319-c39b045b5e0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a165785c-12fe-4142-8fd6-c0ee0515ee8f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_e2520feb-bc90-4957-a29b-fb585ab07711_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_2c395f5f-becb-477a-b9b6-b112bcee81e4_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_136d2684-ca84-4715-ac31-90debd9e9fb0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3d8f2b9a-9715-472f-941c-12167a0feabf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche 1 - $120 per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7e427037-05ac-49b5-9303-74edbb939b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_220ff0a4-aedd-442f-a8fa-b48930e2f3d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_13cb40dd-52e1-4a32-8977-779d9f32c387_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Level 3 Activity</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_a55566f2-4761-40d1-b904-9ea032ebf012_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9ec6e70b-30be-4784-a90f-f273ca4ac838_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9b5f6e5a-9287-486f-b47c-4d203f1ec3dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bb24bb46-38bc-4723-9559-af8adadc51f0_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_fb4672e2-189e-4725-843e-b3763dee78eb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreements and other covenant rights</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2dec2efc-7cac-4176-8df8-6e857fdd5e38_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ace4ecef-9005-4942-8400-28eef863b492_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6adbbbac-916c-4096-aad6-1547062b135d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2c47ef1e-9306-47fc-b267-a3658a428ed1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08d536bd-251e-46a4-9439-4394760ce997_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_bf2fc9e9-ceae-4fdf-9a6f-7228b660d2e2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eed7864b-3dc7-4e87-a161-a388d9857c1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fee0aee3-7afc-47f6-8ad4-d6ef59b2a128_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_95fa7b9c-e656-41c3-9a07-755c09df3d8a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f04733de-5f08-4b01-a69c-1ba4b021d9b0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f9b307ce-1eb5-4bb2-ba1a-340216798791_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160; Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6c128634-a394-4053-9c01-b0f05d9fb01a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_939b4756-742a-4644-bf04-69ffd50e65a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_bda6d590-595f-46e1-8ea2-378ec3f264dc_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7fd75b1-5d83-4ea9-bd23-1f6e42b7fc05_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_86bd3a86-d02d-48db-8138-b813038df73c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2742d7af-e0a5-4f68-adce-9e35af2b475f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b22adf69-09c2-4541-aa69-7e04f1024bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_05044c9f-1557-4661-99f2-139ccb150af3_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_daa915cb-983e-4d0a-b9f2-728ee2c99dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_87bc19b3-7197-416a-af6a-13237fcaf410_negatedTerseLabel_en-US" xlink:label="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made on royalty obligations</link:label>
    <link:label id="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_label_en-US" xlink:label="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Related to Settlement of Debt and Buyout of Royalty Obligations</link:label>
    <link:label id="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_documentation_en-US" xlink:label="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Related to Settlement of Debt and Buyout of Royalty Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:href="gh-20200630.xsd#gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:to="lab_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_624cd67d-6ed4-47cf-b254-b27fef2cef92_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6547087d-bdde-43ee-a431-4327854fa267_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_0539f30d-2fc3-4968-bace-0d73066a56f0_verboseLabel_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the 2018 Incentive Award Plan</link:label>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_label_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_gh_A2018IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_gh_A2018IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember" xlink:href="gh-20200630.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_A2018IncentiveAwardPlanMember" xlink:to="lab_gh_A2018IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_eb70f349-07d8-47c6-9378-981dcb53e028_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_66b20a15-e0d9-4537-b3bc-e1b121517486_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted average exercise price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_AmortizationOfRightOfUseAsset_eb26f845-a57f-4c7a-870d-8a43ebd209b0_terseLabel_en-US" xlink:label="lab_gh_AmortizationOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_gh_AmortizationOfRightOfUseAsset_label_en-US" xlink:label="lab_gh_AmortizationOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Right Of Use Asset</link:label>
    <link:label id="lab_gh_AmortizationOfRightOfUseAsset_documentation_en-US" xlink:label="lab_gh_AmortizationOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AmortizationOfRightOfUseAsset" xlink:href="gh-20200630.xsd#gh_AmortizationOfRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_AmortizationOfRightOfUseAsset" xlink:to="lab_gh_AmortizationOfRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a8e5296e-f329-4727-9844-d3a59fd60d0a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_CapitalizedLicenseFees_4a94162f-744a-476e-bf67-0902759080c9_terseLabel_en-US" xlink:label="lab_gh_CapitalizedLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized license fees</link:label>
    <link:label id="lab_gh_CapitalizedLicenseFees_label_en-US" xlink:label="lab_gh_CapitalizedLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized License Fees</link:label>
    <link:label id="lab_gh_CapitalizedLicenseFees_documentation_en-US" xlink:label="lab_gh_CapitalizedLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CapitalizedLicenseFees" xlink:href="gh-20200630.xsd#gh_CapitalizedLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_CapitalizedLicenseFees" xlink:to="lab_gh_CapitalizedLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_144717cd-931f-4c31-8c95-85de12d09c67_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_7129fafd-a016-4053-be10-453e9c071480_terseLabel_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock exercised early</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_label_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised Early</link:label>
    <link:label id="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_documentation_en-US" xlink:label="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised Early</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:href="gh-20200630.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:to="lab_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_ee34d83a-95cc-4352-9202-a0c0f9a0896e_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_abcac095-f76b-4664-8249-d0cdde04c511_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_04449f81-b2bf-4866-be49-a4db5157bed2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefOperatingOfficerMember_6edb33f3-370a-4d07-a39c-ec7b821dc54c_terseLabel_en-US" xlink:label="lab_srt_ChiefOperatingOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and Chief Operating Officer</link:label>
    <link:label id="lab_srt_ChiefOperatingOfficerMember_label_en-US" xlink:label="lab_srt_ChiefOperatingOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefOperatingOfficerMember" xlink:to="lab_srt_ChiefOperatingOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_19e56135-2b31-42ff-b721-b560602bc47b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a17de45e-dfa3-454b-959d-46eadd88a4a4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_fec3983f-5766-424a-86ca-9be68ccfa500_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from cash collections exceeding estimated variable consideration</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6025c386-0605-4216-a292-50b7b3183336_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>gh-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a823c88f-2b24-44ac-a516-3f731119002e,g:77fc4dec-5a42-485c-bad8-a10178a2afe8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://guardanthealth.com/role/CoverPage" xlink:type="simple" xlink:href="gh-20200630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_00a5ff39-8d4c-49e1-b968-0378b6151827" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_DocumentType_00a5ff39-8d4c-49e1-b968-0378b6151827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5fb48834-43e6-4e42-8fda-5b81e471e9e8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_DocumentQuarterlyReport_5fb48834-43e6-4e42-8fda-5b81e471e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4f6ddc05-fafa-4d75-9937-a4e86593de63" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_DocumentPeriodEndDate_4f6ddc05-fafa-4d75-9937-a4e86593de63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8e02d0c8-6a77-46e4-a30d-1bb92059d29d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_DocumentTransitionReport_8e02d0c8-6a77-46e4-a30d-1bb92059d29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e64500df-514b-4e87-bd74-d898a9db4ed1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityFileNumber_e64500df-514b-4e87-bd74-d898a9db4ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_55ba1853-021b-4a71-810f-975f06f3a2cb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityRegistrantName_55ba1853-021b-4a71-810f-975f06f3a2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f14ea4b3-8906-4b59-9b4b-11b2c322ee56" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f14ea4b3-8906-4b59-9b4b-11b2c322ee56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f817fde0-1866-4748-b3bf-68038d3f4c0b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityTaxIdentificationNumber_f817fde0-1866-4748-b3bf-68038d3f4c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f8030d8e-4609-4069-8aea-13c399a6f8e4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityAddressAddressLine1_f8030d8e-4609-4069-8aea-13c399a6f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ab155a9a-34e0-4682-bfb8-49888a10e697" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityAddressCityOrTown_ab155a9a-34e0-4682-bfb8-49888a10e697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_39d55ed2-9cab-4a25-9816-eb1e86db5c4c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityAddressStateOrProvince_39d55ed2-9cab-4a25-9816-eb1e86db5c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c8e4e682-889f-4dae-b6c1-d19bc4c008c0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityAddressPostalZipCode_c8e4e682-889f-4dae-b6c1-d19bc4c008c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_06f701e6-dd53-4fc3-9ce2-2160c3b97147" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_CityAreaCode_06f701e6-dd53-4fc3-9ce2-2160c3b97147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a8feab47-7b6c-4de9-b26b-6a0559cf2d6e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_LocalPhoneNumber_a8feab47-7b6c-4de9-b26b-6a0559cf2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_16ba2616-17a0-4f53-bd61-d4a128325037" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityCurrentReportingStatus_16ba2616-17a0-4f53-bd61-d4a128325037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fabe5361-4392-4308-815d-9a91e0124a88" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityInteractiveDataCurrent_fabe5361-4392-4308-815d-9a91e0124a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_82caade4-99e4-4e54-9eb0-669c7dcbdb39" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityFilerCategory_82caade4-99e4-4e54-9eb0-669c7dcbdb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_64be7397-dc1d-4a6a-916b-fb80226a7f0a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntitySmallBusiness_64be7397-dc1d-4a6a-916b-fb80226a7f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_53d69538-fca3-4483-973c-25a04bf6ff83" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityEmergingGrowthCompany_53d69538-fca3-4483-973c-25a04bf6ff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a59f7ac5-228e-4836-b991-fc311a2ca417" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityShellCompany_a59f7ac5-228e-4836-b991-fc311a2ca417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6cdc5a33-938f-4592-83ea-e71ee90c00c4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_Security12bTitle_6cdc5a33-938f-4592-83ea-e71ee90c00c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d164833d-3350-4fed-8670-2a7babdb841b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_TradingSymbol_d164833d-3350-4fed-8670-2a7babdb841b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dde3bd73-b7eb-4580-81d5-07ce7aa46c46" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_SecurityExchangeName_dde3bd73-b7eb-4580-81d5-07ce7aa46c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b6b97668-7e17-49a7-bd5f-e8b45dcdc6cb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b6b97668-7e17-49a7-bd5f-e8b45dcdc6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8a235b6a-7650-49ab-8c19-d15e147dd294" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_AmendmentFlag_8a235b6a-7650-49ab-8c19-d15e147dd294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_de3ca344-5fa5-4505-ae1b-f249c946794a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_DocumentFiscalYearFocus_de3ca344-5fa5-4505-ae1b-f249c946794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_27669d05-1500-448a-b808-bf5ad75c8654" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_DocumentFiscalPeriodFocus_27669d05-1500-448a-b808-bf5ad75c8654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_adb6a388-daa8-42dc-bc16-036f1ad9079a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_EntityCentralIndexKey_adb6a388-daa8-42dc-bc16-036f1ad9079a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_08f02775-8e4f-4dfe-9697-927d8c4397ed" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35e512e2-526a-4275-8fb8-302ee0d4b007" xlink:to="loc_dei_CurrentFiscalYearEndDate_08f02775-8e4f-4dfe-9697-927d8c4397ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_854d3d24-1f9e-43cd-88b3-7eb5f548d7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_854d3d24-1f9e-43cd-88b3-7eb5f548d7bb" xlink:to="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e655ddb-1ced-48c1-8e15-89b69d38cbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2e655ddb-1ced-48c1-8e15-89b69d38cbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b829dfd8-ecae-4da6-aa23-b68516a0e061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b829dfd8-ecae-4da6-aa23-b68516a0e061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2c687bcc-1a34-4585-9258-769cb4370956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2c687bcc-1a34-4585-9258-769cb4370956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9fc70c45-26ea-45c4-a86c-78e5b541e241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:to="loc_us-gaap_InventoryNet_9fc70c45-26ea-45c4-a86c-78e5b541e241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a655bbb-8708-451e-b25b-15e4a5e2a769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a655bbb-8708-451e-b25b-15e4a5e2a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_28798714-1464-4d63-a957-788c008d635f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_228ac8ad-5983-4635-ae35-bd9ae91a1560" xlink:to="loc_us-gaap_AssetsCurrent_28798714-1464-4d63-a957-788c008d635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_928da01a-6e48-4ea7-bb02-91f55865af6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_928da01a-6e48-4ea7-bb02-91f55865af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b65a85d-1973-43b0-979f-073b03b4cd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b65a85d-1973-43b0-979f-073b03b4cd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0106dde8-e24c-45f8-987e-5b097b2efb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0106dde8-e24c-45f8-987e-5b097b2efb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d55901e1-c0a2-4e19-9858-7fe485734a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d55901e1-c0a2-4e19-9858-7fe485734a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_994ccf3e-b860-4dcc-b8b1-cd0ebf3b6463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_Goodwill_994ccf3e-b860-4dcc-b8b1-cd0ebf3b6463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CapitalizedLicenseFees_01d9ec22-0b65-458f-8cfd-5e7b68122dbc" xlink:href="gh-20200630.xsd#gh_CapitalizedLicenseFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_gh_CapitalizedLicenseFees_01d9ec22-0b65-458f-8cfd-5e7b68122dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_efe076e4-27f5-489f-9810-cd948d9ff9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_efe076e4-27f5-489f-9810-cd948d9ff9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7c564abb-cca9-414d-b1f6-f66d652ab7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0a74a626-708a-4f4f-ab59-2a6e174b7d31" xlink:to="loc_us-gaap_Assets_7c564abb-cca9-414d-b1f6-f66d652ab7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_854d3d24-1f9e-43cd-88b3-7eb5f548d7bb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_496fa3ce-1592-480e-879d-e0d761767b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_496fa3ce-1592-480e-879d-e0d761767b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_de1d7587-cc7c-47b6-8198-3d94391f1b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_496fa3ce-1592-480e-879d-e0d761767b1c" xlink:to="loc_us-gaap_AccountsPayableCurrent_de1d7587-cc7c-47b6-8198-3d94391f1b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_01b3f127-e449-4946-973b-982ffceaaac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_496fa3ce-1592-480e-879d-e0d761767b1c" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_01b3f127-e449-4946-973b-982ffceaaac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8c348494-8570-469b-8b02-179dd3b3aa0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_496fa3ce-1592-480e-879d-e0d761767b1c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8c348494-8570-469b-8b02-179dd3b3aa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_18198713-0831-43f2-80d9-39de59f00fab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_496fa3ce-1592-480e-879d-e0d761767b1c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_18198713-0831-43f2-80d9-39de59f00fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_32dd5366-9b6c-4ab0-9b63-8b5b812a2650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_496fa3ce-1592-480e-879d-e0d761767b1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_32dd5366-9b6c-4ab0-9b63-8b5b812a2650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b38e9e19-5586-49fb-9bd5-03857013e188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b38e9e19-5586-49fb-9bd5-03857013e188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedRoyaltiesNoncurrent_375bbdfc-f712-45cd-912c-4bcf744a9ab1" xlink:href="gh-20200630.xsd#gh_AccruedRoyaltiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_gh_AccruedRoyaltiesNoncurrent_375bbdfc-f712-45cd-912c-4bcf744a9ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8f6ac36c-e82e-40f7-a77d-c01e00594730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8f6ac36c-e82e-40f7-a77d-c01e00594730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c2d22d10-7e5d-4af9-952d-63831fa1f187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_us-gaap_Liabilities_c2d22d10-7e5d-4af9-952d-63831fa1f187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_efa74bf9-d445-4c9b-8ed9-33391e9f1de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_efa74bf9-d445-4c9b-8ed9-33391e9f1de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4ca13dab-2f89-40ab-b98a-c4b03a62ce89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4ca13dab-2f89-40ab-b98a-c4b03a62ce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_bb32c4af-baf6-46a0-bfb9-7544d8dc1ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4ca13dab-2f89-40ab-b98a-c4b03a62ce89" xlink:to="loc_us-gaap_CommonStockValueOutstanding_bb32c4af-baf6-46a0-bfb9-7544d8dc1ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1732c681-701d-4dfb-8e3d-a555db597fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4ca13dab-2f89-40ab-b98a-c4b03a62ce89" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1732c681-701d-4dfb-8e3d-a555db597fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd8a8d18-bac3-4bcd-bd74-91e31db25233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4ca13dab-2f89-40ab-b98a-c4b03a62ce89" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd8a8d18-bac3-4bcd-bd74-91e31db25233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_49802161-a247-445a-a2d0-4ccf217bf0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4ca13dab-2f89-40ab-b98a-c4b03a62ce89" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_49802161-a247-445a-a2d0-4ccf217bf0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bef54f76-e252-4740-99fa-3bb334033629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4ca13dab-2f89-40ab-b98a-c4b03a62ce89" xlink:to="loc_us-gaap_StockholdersEquity_bef54f76-e252-4740-99fa-3bb334033629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_78583503-8e98-49d5-bbcd-4c4d356488f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1553e1f9-274d-4401-b041-27d7efa0cacc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_78583503-8e98-49d5-bbcd-4c4d356488f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_58def8c1-3840-41e8-8cfd-e3d688dda425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6485516-15ad-48e5-870d-a4fe268c09f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_58def8c1-3840-41e8-8cfd-e3d688dda425" xlink:to="loc_us-gaap_StatementTable_e6485516-15ad-48e5-870d-a4fe268c09f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6485516-15ad-48e5-870d-a4fe268c09f8" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5ab879f4-464b-4fc7-a3f3-c166ec96ae54" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3806d15e-2b1f-4b5f-ab7f-5a0cad8ab443" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5ab879f4-464b-4fc7-a3f3-c166ec96ae54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_1bd2340e-490e-4a18-900d-927462f93056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5ab879f4-464b-4fc7-a3f3-c166ec96ae54" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_1bd2340e-490e-4a18-900d-927462f93056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6485516-15ad-48e5-870d-a4fe268c09f8" xlink:to="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e985c260-a53f-4725-a353-ddc0b851d73f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e985c260-a53f-4725-a353-ddc0b851d73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6edb3789-5066-4bf9-af42-61ae610c927e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6edb3789-5066-4bf9-af42-61ae610c927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1140d68f-2ba1-4c73-be3c-99e77151b609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1140d68f-2ba1-4c73-be3c-99e77151b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1637f3bb-3185-4b3e-a5d0-047bbb8b7ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_CommonStockSharesIssued_1637f3bb-3185-4b3e-a5d0-047bbb8b7ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d1b4ae84-687e-4933-bc9e-266c5e6033f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_Assets_d1b4ae84-687e-4933-bc9e-266c5e6033f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0ed9385b-4e5e-4f66-a361-0de0cc33ce75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4b993e0-7dc3-4ae9-81de-f5988c90442d" xlink:to="loc_us-gaap_Liabilities_0ed9385b-4e5e-4f66-a361-0de0cc33ce75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ef26eb1f-a5ea-4eaa-a4e7-6b5487015b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_RevenuesAbstract_ef26eb1f-a5ea-4eaa-a4e7-6b5487015b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromPrecisionOncologyTesting_6e8d7e2d-a5d9-4a24-9ba5-ad5afa647661" xlink:href="gh-20200630.xsd#gh_RevenuefromPrecisionOncologyTesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ef26eb1f-a5ea-4eaa-a4e7-6b5487015b03" xlink:to="loc_gh_RevenuefromPrecisionOncologyTesting_6e8d7e2d-a5d9-4a24-9ba5-ad5afa647661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RevenuefromDevelopmentServices_aefdfe02-9154-4c39-9304-567e2e10ef06" xlink:href="gh-20200630.xsd#gh_RevenuefromDevelopmentServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ef26eb1f-a5ea-4eaa-a4e7-6b5487015b03" xlink:to="loc_gh_RevenuefromDevelopmentServices_aefdfe02-9154-4c39-9304-567e2e10ef06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_545ba42e-e626-4a20-b783-2bd63bff4b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ef26eb1f-a5ea-4eaa-a4e7-6b5487015b03" xlink:to="loc_us-gaap_Revenues_545ba42e-e626-4a20-b783-2bd63bff4b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTesting_6acf6a66-fe47-4eec-b14d-5691b0a86c8c" xlink:href="gh-20200630.xsd#gh_CostsofPrecisionOncologyTesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:to="loc_gh_CostsofPrecisionOncologyTesting_6acf6a66-fe47-4eec-b14d-5691b0a86c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostofDevelopmentServices_d4086c2e-b2b4-478e-8f87-2298fe79f8b9" xlink:href="gh-20200630.xsd#gh_CostofDevelopmentServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:to="loc_gh_CostofDevelopmentServices_d4086c2e-b2b4-478e-8f87-2298fe79f8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_197094c5-6077-4802-964b-0a7084de22e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_197094c5-6077-4802-964b-0a7084de22e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_bffdd9e1-145c-41f9-80c4-84164424fed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:to="loc_us-gaap_SellingAndMarketingExpense_bffdd9e1-145c-41f9-80c4-84164424fed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_97bc7f67-1de9-4498-afb3-cdd52138c8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_97bc7f67-1de9-4498-afb3-cdd52138c8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f906be14-d71e-42b6-a7b7-b014367badd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5b4fd93-9861-4f89-8029-e8de2db5f678" xlink:to="loc_us-gaap_CostsAndExpenses_f906be14-d71e-42b6-a7b7-b014367badd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_11ae92ad-1e64-4398-adf8-3ab9b12350b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_OperatingIncomeLoss_11ae92ad-1e64-4398-adf8-3ab9b12350b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2ffeb568-9cd5-4a7b-9f7a-d337cb9d4bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2ffeb568-9cd5-4a7b-9f7a-d337cb9d4bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_23d51fdc-38c6-4dc6-873d-917e293a2f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_InterestExpense_23d51fdc-38c6-4dc6-873d-917e293a2f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f55d60f9-c5b6-439e-b524-2d11f80e0af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f55d60f9-c5b6-439e-b524-2d11f80e0af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2ef4e3b3-9412-4ae7-8a47-64aaa8371b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2ef4e3b3-9412-4ae7-8a47-64aaa8371b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5d9bd3a5-41f8-4187-9298-232cdb7064e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5d9bd3a5-41f8-4187-9298-232cdb7064e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_994cc5b1-97c6-45f1-87f5-66bdc322dfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_ProfitLoss_994cc5b1-97c6-45f1-87f5-66bdc322dfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_bc056685-bb11-45b0-8762-574d27ce1693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_bc056685-bb11-45b0-8762-574d27ce1693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f602611f-9e18-40f7-aba1-a3617b66cd9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f602611f-9e18-40f7-aba1-a3617b66cd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_905e6a86-9a91-4a23-b477-98be5cd6762f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_905e6a86-9a91-4a23-b477-98be5cd6762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_fe5a290e-1dd5-40a9-92ea-b1ec2b501566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e131dd6f-169f-4880-b100-8eb8270115b5" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_fe5a290e-1dd5-40a9-92ea-b1ec2b501566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dc47510e-f2b4-437e-b42e-6d1dd4470cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_93526079-721f-451d-9238-780efa1053c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dc47510e-f2b4-437e-b42e-6d1dd4470cf7" xlink:to="loc_us-gaap_ProfitLoss_93526079-721f-451d-9238-780efa1053c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ace34d42-a4c2-4d1e-8902-958654c22e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dc47510e-f2b4-437e-b42e-6d1dd4470cf7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ace34d42-a4c2-4d1e-8902-958654c22e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e50b9717-b0d0-4e27-ae82-cbfaec6d8a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ace34d42-a4c2-4d1e-8902-958654c22e3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e50b9717-b0d0-4e27-ae82-cbfaec6d8a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b58db8af-7b7b-4ca8-8852-4fbfeed7105e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ace34d42-a4c2-4d1e-8902-958654c22e3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b58db8af-7b7b-4ca8-8852-4fbfeed7105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_528899ca-07cf-4f0e-9649-afbb43945a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ace34d42-a4c2-4d1e-8902-958654c22e3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_528899ca-07cf-4f0e-9649-afbb43945a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ef0f6d99-ff78-4993-a5e4-2b11a5879c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dc47510e-f2b4-437e-b42e-6d1dd4470cf7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ef0f6d99-ff78-4993-a5e4-2b11a5879c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_f129b5b5-5397-48e2-9111-48c45e4ab806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dc47510e-f2b4-437e-b42e-6d1dd4470cf7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_f129b5b5-5397-48e2-9111-48c45e4ab806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_309edef0-905d-479b-b473-b5e426e64a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dc47510e-f2b4-437e-b42e-6d1dd4470cf7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_309edef0-905d-479b-b473-b5e426e64a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_743f7349-f75e-44c4-964a-199e4808af8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_743f7349-f75e-44c4-964a-199e4808af8e" xlink:to="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ff743c1-3e0a-448a-a410-4257d8e7c90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ff743c1-3e0a-448a-a410-4257d8e7c90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ff743c1-3e0a-448a-a410-4257d8e7c90a" xlink:to="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_dd9e30dd-80c9-46ee-ae6e-dc21f86749a0" xlink:href="gh-20200630.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_dd9e30dd-80c9-46ee-ae6e-dc21f86749a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8194222e-664a-4eb2-87a7-2e6d42de3a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_CommonStockMember_8194222e-664a-4eb2-87a7-2e6d42de3a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_51865900-1bc5-400d-8579-57c0a917c3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_51865900-1bc5-400d-8579-57c0a917c3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e603bcde-98b5-4015-bdae-b6f466ca62a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e603bcde-98b5-4015-bdae-b6f466ca62a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0120880a-9a5c-47e2-9bd6-17595bd70eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fb0f1201-8a25-42f4-a082-165f1e80a609" xlink:to="loc_us-gaap_RetainedEarningsMember_0120880a-9a5c-47e2-9bd6-17595bd70eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_e985e4a1-fc95-46a9-8545-ee84b5d9dfa5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_8f3a6a61-f764-4eeb-a673-830caa31e4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_8f3a6a61-f764-4eeb-a673-830caa31e4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201807Member_6eb84ce9-6e7c-4adb-b6d2-b8582a810016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201807Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a1bfc184-36a2-4f14-a899-a0b2c18565d0" xlink:to="loc_us-gaap_AccountingStandardsUpdate201807Member_6eb84ce9-6e7c-4adb-b6d2-b8582a810016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c8581aa7-bacd-4d02-b223-ef8529f4e194" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c8581aa7-bacd-4d02-b223-ef8529f4e194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1475ba6c-422e-4c6f-bf06-ab57273f4663" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c8581aa7-bacd-4d02-b223-ef8529f4e194" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1475ba6c-422e-4c6f-bf06-ab57273f4663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_91e58d98-7a32-43a7-8618-00ff49b853db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1475ba6c-422e-4c6f-bf06-ab57273f4663" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_91e58d98-7a32-43a7-8618-00ff49b853db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd6bd58c-907b-4e58-9642-20cd5700033f" xlink:to="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8a6542c0-2dec-4e12-abac-6f9e06cc7c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8a6542c0-2dec-4e12-abac-6f9e06cc7c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_402a7ddf-95c7-4875-b848-bce12b584107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_402a7ddf-95c7-4875-b848-bce12b584107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_53bb5a55-035e-4652-b87d-1d91ab57cc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_59517dc7-5bbc-46bd-8c5e-981e64e00986" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_53bb5a55-035e-4652-b87d-1d91ab57cc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3f8be08f-d655-4c11-b9db-e4d3c1efa4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_SharesOutstanding_3f8be08f-d655-4c11-b9db-e4d3c1efa4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b778131-c4ed-4553-af13-efaa39069ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockholdersEquity_6b778131-c4ed-4553-af13-efaa39069ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f2cbd5a-1772-477c-91e6-d20a1f7f764e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f2cbd5a-1772-477c-91e6-d20a1f7f764e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86b2937d-047e-40b3-9825-9761ffa5afe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_86b2937d-047e-40b3-9825-9761ffa5afe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6aabdb2-ddff-44ea-bac5-01e483b0689c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e6aabdb2-ddff-44ea-bac5-01e483b0689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e2b93e84-0be9-4f2a-934f-99c955fa70aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e2b93e84-0be9-4f2a-934f-99c955fa70aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_caf2a07a-fb26-4540-abf0-f0181b46f7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_caf2a07a-fb26-4540-abf0-f0181b46f7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_0145260d-543f-449a-a859-ba0e874eb783" xlink:href="gh-20200630.xsd#gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly_0145260d-543f-449a-a859-ba0e874eb783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a2329012-5812-452b-a4f8-ed2dcfbff89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a2329012-5812-452b-a4f8-ed2dcfbff89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7f184322-4e35-4fa9-8bf9-94b1b665178f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7f184322-4e35-4fa9-8bf9-94b1b665178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0ba7fbb5-66da-450a-bba2-9d432582cf10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0ba7fbb5-66da-450a-bba2-9d432582cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9013f6b-dade-48e2-b25c-f6f56b6b36f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9013f6b-dade-48e2-b25c-f6f56b6b36f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_136fe3cb-c6c7-4528-a972-378f2825f8e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_ProfitLoss_136fe3cb-c6c7-4528-a972-378f2825f8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0bb1e188-8ee1-45c3-a2ca-4fbe1caf02e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_SharesOutstanding_0bb1e188-8ee1-45c3-a2ca-4fbe1caf02e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9df955c8-eec8-4129-87ca-d9314bc93e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_890233e1-e098-4ab3-9163-24cfa08682c8" xlink:to="loc_us-gaap_StockholdersEquity_9df955c8-eec8-4129-87ca-d9314bc93e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_007dcc28-a324-4a46-8705-009293ad837b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4e0511a7-ed85-457a-a374-a91a06ef4e4c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_007dcc28-a324-4a46-8705-009293ad837b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e6f6c3c1-0d11-411e-8023-8176673bce72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90bfe119-46a7-48b1-8c1d-1f242e7fd8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e6f6c3c1-0d11-411e-8023-8176673bce72" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90bfe119-46a7-48b1-8c1d-1f242e7fd8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ca142962-f3a9-4bd8-98ae-b12c78ce0e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ca142962-f3a9-4bd8-98ae-b12c78ce0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1949f5fa-fe5c-42bd-9103-f0811d20e004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ca142962-f3a9-4bd8-98ae-b12c78ce0e23" xlink:to="loc_us-gaap_ProfitLoss_1949f5fa-fe5c-42bd-9103-f0811d20e004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ca142962-f3a9-4bd8-98ae-b12c78ce0e23" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5532c78e-1643-4278-a745-1cbf217183a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5532c78e-1643-4278-a745-1cbf217183a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AmortizationOfRightOfUseAsset_83228254-1ee3-4182-b279-642704a01961" xlink:href="gh-20200630.xsd#gh_AmortizationOfRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_gh_AmortizationOfRightOfUseAsset_83228254-1ee3-4182-b279-642704a01961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_1eefa33c-586a-497a-9535-a5b5199af512" xlink:href="gh-20200630.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_1eefa33c-586a-497a-9535-a5b5199af512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3b43e4ae-bcc9-4f64-ae8c-e993b1b54eba" xlink:href="gh-20200630.xsd#gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty_3b43e4ae-bcc9-4f64-ae8c-e993b1b54eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0f50542a-9b29-4337-852c-dfcf4b41ccbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0f50542a-9b29-4337-852c-dfcf4b41ccbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9bb8463e-8487-4d6b-83d6-7eefe474ad3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_us-gaap_ShareBasedCompensation_9bb8463e-8487-4d6b-83d6-7eefe474ad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9f25288b-68de-459b-acd9-d128b8aaae1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9f25288b-68de-459b-acd9-d128b8aaae1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_08e38f20-b41d-4a55-a763-a07ce1d9272c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_08e38f20-b41d-4a55-a763-a07ce1d9272c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1eea34b7-3061-484e-b6b4-a886cb12900f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1eea34b7-3061-484e-b6b4-a886cb12900f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_382e8bd2-3e72-4959-9c0e-6acf1915dd73" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2471ed04-dd6c-4638-961a-1c9d80f0d922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2471ed04-dd6c-4638-961a-1c9d80f0d922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e84915b2-ca36-4c3d-9ebd-a6e9cd4752b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e84915b2-ca36-4c3d-9ebd-a6e9cd4752b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c85b5dcd-5b44-4c01-80be-58a033d6bbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c85b5dcd-5b44-4c01-80be-58a033d6bbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_79a548ea-3be5-4c9c-be4a-84a43565c0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_79a548ea-3be5-4c9c-be4a-84a43565c0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0f4d1294-36ac-41ba-8b5a-4b289a589392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0f4d1294-36ac-41ba-8b5a-4b289a589392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a75702b9-cc7a-4b7a-94a6-60cfbbcf0041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_a75702b9-cc7a-4b7a-94a6-60cfbbcf0041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b6fd7792-8774-45e3-982e-c769c3a3987a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b6fd7792-8774-45e3-982e-c769c3a3987a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_f2815799-ee46-4df0-bb48-beca16e1c886" xlink:href="gh-20200630.xsd#gh_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_gh_IncreaseDecreaseInOperatingLeaseLiabilities_f2815799-ee46-4df0-bb48-beca16e1c886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a92eebd7-5f1d-4991-a651-35a52741361c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_16ada8f6-4e94-48b5-89cf-353ba3540af2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a92eebd7-5f1d-4991-a651-35a52741361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4f3bd7e9-dca4-43a3-ae71-15773210035b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ca142962-f3a9-4bd8-98ae-b12c78ce0e23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4f3bd7e9-dca4-43a3-ae71-15773210035b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_73050146-abce-46ab-8ae4-c8af26061060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_73050146-abce-46ab-8ae4-c8af26061060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_02b2ae20-899e-46dc-be34-a6acd32b4e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_02b2ae20-899e-46dc-be34-a6acd32b4e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bbd331f2-518f-44bc-bab4-66ca7f187263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_bbd331f2-518f-44bc-bab4-66ca7f187263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2424de81-5638-4d04-93a0-a5a15fa7eecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2424de81-5638-4d04-93a0-a5a15fa7eecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5ebb8c00-7098-429f-83eb-1d0542a12793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5ebb8c00-7098-429f-83eb-1d0542a12793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4569c66a-d669-4b89-b4fa-3bd3613ada8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb801bc5-456d-4cc8-857c-e1f5b0bc4759" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4569c66a-d669-4b89-b4fa-3bd3613ada8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_465ba039-d9b7-44c0-917e-5f0909b6da5f" xlink:href="gh-20200630.xsd#gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:to="loc_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations_465ba039-d9b7-44c0-917e-5f0909b6da5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a8e5b17f-8020-431e-9a7d-96a878b889f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a8e5b17f-8020-431e-9a7d-96a878b889f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_739e27d3-dbfc-46cf-b6f2-36ddb6de14ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_739e27d3-dbfc-46cf-b6f2-36ddb6de14ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d402d869-cfae-4576-96b9-f166e95cd75a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d402d869-cfae-4576-96b9-f166e95cd75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_340cdde8-fb83-4555-9221-cdfa20ec8e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_340cdde8-fb83-4555-9221-cdfa20ec8e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_7ab0ccc3-a86c-4386-8120-d73b65c7bb32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_7ab0ccc3-a86c-4386-8120-d73b65c7bb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44379cd4-ec2e-4364-9e54-621766a3cd13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6234dd65-ee6b-4004-b5d6-dcda78830ebb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44379cd4-ec2e-4364-9e54-621766a3cd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c3739e0-8a92-4fa2-b33e-12c4543623e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c3739e0-8a92-4fa2-b33e-12c4543623e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a8b64b03-bd89-469c-a423-1739c0c0da31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a8b64b03-bd89-469c-a423-1739c0c0da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86d9cab5-3527-4a9d-bc32-9605e1ef5e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86d9cab5-3527-4a9d-bc32-9605e1ef5e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92281380-6429-4e90-9134-dc54d28a4e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92281380-6429-4e90-9134-dc54d28a4e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f928630-a91e-4d5e-a1d3-2711bbf3361a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f928630-a91e-4d5e-a1d3-2711bbf3361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_af94d800-5492-4755-a850-2178f5cc7171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3f928630-a91e-4d5e-a1d3-2711bbf3361a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_af94d800-5492-4755-a850-2178f5cc7171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1dc5bad4-f44c-4771-ae0f-f6c956963a80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7f482f85-2090-4d9b-a09c-fe6a934d412e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1dc5bad4-f44c-4771-ae0f-f6c956963a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a2b007f1-8f7d-4ec9-95ba-35c8d101f694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1dc5bad4-f44c-4771-ae0f-f6c956963a80" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a2b007f1-8f7d-4ec9-95ba-35c8d101f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_OfferingCostsIncurredButNotYetPaid_20e514de-04a0-4464-9988-698cc0d2050d" xlink:href="gh-20200630.xsd#gh_OfferingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1dc5bad4-f44c-4771-ae0f-f6c956963a80" xlink:to="loc_gh_OfferingCostsIncurredButNotYetPaid_20e514de-04a0-4464-9988-698cc0d2050d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f716eb7-ad00-4b8e-a9fb-ac1b4371e43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1dc5bad4-f44c-4771-ae0f-f6c956963a80" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6f716eb7-ad00-4b8e-a9fb-ac1b4371e43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="gh-20200630.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eaf6c0ad-a70a-4bde-9082-b66d7e2ec840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_523158de-03ab-42b1-9262-593c7e476637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eaf6c0ad-a70a-4bde-9082-b66d7e2ec840" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_523158de-03ab-42b1-9262-593c7e476637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93f48551-4c60-4dd6-8238-e71124aed84e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d8a591a-806a-4a3b-a745-e02c549da689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93f48551-4c60-4dd6-8238-e71124aed84e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d8a591a-806a-4a3b-a745-e02c549da689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_daa183d5-3f4f-4540-a80a-b0769ae9bcbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d8a591a-806a-4a3b-a745-e02c549da689" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_daa183d5-3f4f-4540-a80a-b0769ae9bcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7bfda289-13f6-4cd8-8a4d-7b6f6f2fcb47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_daa183d5-3f4f-4540-a80a-b0769ae9bcbe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7bfda289-13f6-4cd8-8a4d-7b6f6f2fcb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_23a10343-702a-46b3-8398-bb09cf323529" xlink:href="gh-20200630.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7bfda289-13f6-4cd8-8a4d-7b6f6f2fcb47" xlink:to="loc_gh_GuardantHealthAMEAIncMember_23a10343-702a-46b3-8398-bb09cf323529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_64c4359d-2ffc-4c26-8d9d-d78b64886317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4d8a591a-806a-4a3b-a745-e02c549da689" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_64c4359d-2ffc-4c26-8d9d-d78b64886317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28e4301a-0daf-4a4a-997e-5a0d918ee084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_64c4359d-2ffc-4c26-8d9d-d78b64886317" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_28e4301a-0daf-4a4a-997e-5a0d918ee084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9421bf2e-f36e-4668-9c71-b8c5505d04a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c0262da5-0eff-4ff5-8655-e2340971d9ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9421bf2e-f36e-4668-9c71-b8c5505d04a4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c0262da5-0eff-4ff5-8655-e2340971d9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0cc614d4-6e40-4dda-9a1d-2143eefbd82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0cc614d4-6e40-4dda-9a1d-2143eefbd82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1b1e20a6-775c-4afa-8b47-c7d074c5bd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_UseOfEstimates_1b1e20a6-775c-4afa-8b47-c7d074c5bd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_b05d8790-9fd7-407e-a5be-82e990b45962" xlink:href="gh-20200630.xsd#gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock_b05d8790-9fd7-407e-a5be-82e990b45962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c5973e7f-4d84-4d29-9368-6c5dcadd8fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c5973e7f-4d84-4d29-9368-6c5dcadd8fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_cd748767-7c94-4471-a883-9de58404d1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_cd748767-7c94-4471-a883-9de58404d1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_8ea0e498-7c68-4753-88ab-1969dad74b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_8ea0e498-7c68-4753-88ab-1969dad74b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionPolicyTextBlock_26592d88-7636-47e9-98ff-baae86463d74" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_gh_AssetAcquisitionPolicyTextBlock_26592d88-7636-47e9-98ff-baae86463d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4c402217-18d9-4b7c-9fda-438ca454062e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4c402217-18d9-4b7c-9fda-438ca454062e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8c7ebf73-25df-4a7e-a6a3-27a43d975a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8c7ebf73-25df-4a7e-a6a3-27a43d975a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_583ba127-fc26-487f-b05d-fe23b95699c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_583ba127-fc26-487f-b05d-fe23b95699c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_503149f5-d3bd-4e71-a291-a713a42b6cfc" xlink:href="gh-20200630.xsd#gh_CostsofPrecisionOncologyTestingPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_gh_CostsofPrecisionOncologyTestingPolicyTextBlock_503149f5-d3bd-4e71-a291-a713a42b6cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b022c845-de11-4abb-9b6e-2241c07dd679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b022c845-de11-4abb-9b6e-2241c07dd679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a5b42bd1-6b5f-4292-98c0-e0a711a3bb42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a5b42bd1-6b5f-4292-98c0-e0a711a3bb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a9131052-4705-47c4-abc6-93a07d75aa2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a9131052-4705-47c4-abc6-93a07d75aa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6f01ef83-697d-4829-a005-9463d664f523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6f01ef83-697d-4829-a005-9463d664f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e8e908bd-9f6d-49f0-a2de-5725057ae61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61325c71-7ba8-471e-9c1a-611211af73ce" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e8e908bd-9f6d-49f0-a2de-5725057ae61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e0f61be-ece9-4768-8592-79c6b4c994f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d013a0a9-10ee-48ad-9382-f6b7c84dbaac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e0f61be-ece9-4768-8592-79c6b4c994f4" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d013a0a9-10ee-48ad-9382-f6b7c84dbaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_45a59572-f913-44a4-aaf4-b03bc2fcc393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45a59572-f913-44a4-aaf4-b03bc2fcc393" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d225329-ea44-465c-b198-794b0c64b6d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_srt_RangeAxis_5d225329-ea44-465c-b198-794b0c64b6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d225329-ea44-465c-b198-794b0c64b6d2" xlink:to="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_650bb264-821f-469d-85f2-6d239d458a81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:to="loc_srt_MinimumMember_650bb264-821f-469d-85f2-6d239d458a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dbf4dc99-4793-42f8-ac91-6272c61e031e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb5e4619-8aa4-48fb-a889-0347a3ae5639" xlink:to="loc_srt_MaximumMember_dbf4dc99-4793-42f8-ac91-6272c61e031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_08c79aa4-8217-4c35-8ec6-45a80332282a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_08c79aa4-8217-4c35-8ec6-45a80332282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9cd189d5-13ca-45ed-8bde-a7b56227b9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08c79aa4-8217-4c35-8ec6-45a80332282a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9cd189d5-13ca-45ed-8bde-a7b56227b9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_8e74eff0-3970-42ae-a45d-a7bc7a3c7330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9cd189d5-13ca-45ed-8bde-a7b56227b9db" xlink:to="loc_us-gaap_OtherAssetsMember_8e74eff0-3970-42ae-a45d-a7bc7a3c7330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1169947b-295d-4e56-b545-5486159bc39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1169947b-295d-4e56-b545-5486159bc39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_82830a64-bb4c-4a6f-85f7-5f4e1a0f9728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1169947b-295d-4e56-b545-5486159bc39e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_82830a64-bb4c-4a6f-85f7-5f4e1a0f9728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b71fe0d8-0a8f-43af-bb33-265e94e2fbe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_82830a64-bb4c-4a6f-85f7-5f4e1a0f9728" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b71fe0d8-0a8f-43af-bb33-265e94e2fbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_234ccb72-bf19-476a-913c-5dc3c587e6b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_srt_MajorCustomersAxis_234ccb72-bf19-476a-913c-5dc3c587e6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab877e5e-7731-4860-a34d-d2777a665ffe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_234ccb72-bf19-476a-913c-5dc3c587e6b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab877e5e-7731-4860-a34d-d2777a665ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_MedicareMember_224c49dd-c191-430d-a2ea-b68985a9339d" xlink:href="gh-20200630.xsd#gh_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab877e5e-7731-4860-a34d-d2777a665ffe" xlink:to="loc_gh_MedicareMember_224c49dd-c191-430d-a2ea-b68985a9339d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d4124f3-9aa7-4a42-8304-0f004d596016" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_dc0e667a-6c26-43a1-a2a2-8f8af7640cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_dc0e667a-6c26-43a1-a2a2-8f8af7640cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a91cdda1-fbd7-4f1b-9cc2-6cd5687072e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a91cdda1-fbd7-4f1b-9cc2-6cd5687072e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2431ea9d-0c08-4c8e-b30b-8ad9a02499be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2431ea9d-0c08-4c8e-b30b-8ad9a02499be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0b51901-4341-4d64-9249-dfbf8be2d789" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0b51901-4341-4d64-9249-dfbf8be2d789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_245ded1d-8e95-4870-bbac-6c06c6d71180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_245ded1d-8e95-4870-bbac-6c06c6d71180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b7fd64-a332-4c0b-aac5-0d552e689787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d3b7fd64-a332-4c0b-aac5-0d552e689787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress_870eb94e-ef9f-44b4-8529-30fcf153af23" xlink:href="gh-20200630.xsd#gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress_870eb94e-ef9f-44b4-8529-30fcf153af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_d014748a-d917-4989-bdf9-2266eebe07ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_d014748a-d917-4989-bdf9-2266eebe07ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e4b3faf5-6a1f-4646-a234-e40f1b6ba18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e4b3faf5-6a1f-4646-a234-e40f1b6ba18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a227f45-d8b0-4b11-bc83-aac8172e0ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00eb9c0e-85ca-486d-82b6-4ba73e194739" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6a227f45-d8b0-4b11-bc83-aac8172e0ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_272ac005-67ef-468a-9b66-8475c355e02a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_272ac005-67ef-468a-9b66-8475c355e02a" xlink:to="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4b48f915-5607-4bf0-a367-3da747de1210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:to="loc_srt_MajorCustomersAxis_4b48f915-5607-4bf0-a367-3da747de1210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4b48f915-5607-4bf0-a367-3da747de1210" xlink:to="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerAMember_a567e931-5ac2-4e87-bfba-271f7a4f101f" xlink:href="gh-20200630.xsd#gh_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerAMember_a567e931-5ac2-4e87-bfba-271f7a4f101f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerBMember_d317e2be-b7ff-4ceb-9eb6-e44d9b6bdfb0" xlink:href="gh-20200630.xsd#gh_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerBMember_d317e2be-b7ff-4ceb-9eb6-e44d9b6bdfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerCMember_524816b7-b083-47c0-99f7-67ab6467f084" xlink:href="gh-20200630.xsd#gh_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerCMember_524816b7-b083-47c0-99f7-67ab6467f084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerDMember_10f9992d-e192-4bbe-9389-e273945b61f0" xlink:href="gh-20200630.xsd#gh_CustomerDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerDMember_10f9992d-e192-4bbe-9389-e273945b61f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CustomerEMember_db48cc2a-ba17-43cf-a34d-2c8c31acec55" xlink:href="gh-20200630.xsd#gh_CustomerEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_521e231f-7b37-4d05-9df1-44072fe76615" xlink:to="loc_gh_CustomerEMember_db48cc2a-ba17-43cf-a34d-2c8c31acec55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_88270527-673c-4e91-be26-141d03780181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_88270527-673c-4e91-be26-141d03780181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fc908896-29d0-4b4b-8f62-58e492f95b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_88270527-673c-4e91-be26-141d03780181" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fc908896-29d0-4b4b-8f62-58e492f95b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_613c76b2-a15b-4f8a-b01d-ab455f7e83ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fc908896-29d0-4b4b-8f62-58e492f95b08" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_613c76b2-a15b-4f8a-b01d-ab455f7e83ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d05fa9b-d70b-442d-aa77-32dcd373f27f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d05fa9b-d70b-442d-aa77-32dcd373f27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d05fa9b-d70b-442d-aa77-32dcd373f27f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_917f2f5d-9347-43d3-951a-d03e1e8e4d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:to="loc_us-gaap_SalesRevenueNetMember_917f2f5d-9347-43d3-951a-d03e1e8e4d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_73e7d300-1ab6-4bd0-8457-0bd307481cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3d1d329a-11cb-41ff-a565-db62b92c282d" xlink:to="loc_us-gaap_AccountsReceivableMember_73e7d300-1ab6-4bd0-8457-0bd307481cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5f69976d-4b8f-47a1-9922-087c0eba39b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dc388609-b104-4e8c-b3bb-daea2e661e54" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5f69976d-4b8f-47a1-9922-087c0eba39b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e6fb6132-c7ff-44cf-8cd6-21f1cd92a5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5f69976d-4b8f-47a1-9922-087c0eba39b6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e6fb6132-c7ff-44cf-8cd6-21f1cd92a5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="simple" xlink:href="gh-20200630.xsd#InvestmentinJointVenture"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVenture" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6327301f-754c-4ae6-866f-a0ee598d09f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_730f6125-cf18-4d06-8999-93e7be143bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6327301f-754c-4ae6-866f-a0ee598d09f9" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_730f6125-cf18-4d06-8999-93e7be143bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#InvestmentinJointVentureDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/InvestmentinJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_22fea065-01e4-46e9-a2e4-2ea1f7338fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_22fea065-01e4-46e9-a2e4-2ea1f7338fbf" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1bf8d10-64a9-4459-b9b0-a4e44ad36464" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1bf8d10-64a9-4459-b9b0-a4e44ad36464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6e3c302e-b5c0-44f5-9326-72270347db8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1bf8d10-64a9-4459-b9b0-a4e44ad36464" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6e3c302e-b5c0-44f5-9326-72270347db8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthAMEAIncMember_c5aa4111-6aa2-4de0-9491-6b6511fdf930" xlink:href="gh-20200630.xsd#gh_GuardantHealthAMEAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e3c302e-b5c0-44f5-9326-72270347db8d" xlink:to="loc_gh_GuardantHealthAMEAIncMember_c5aa4111-6aa2-4de0-9491-6b6511fdf930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0fbc702b-c9d9-4053-b6bb-20b43828552c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_dei_LegalEntityAxis_0fbc702b-c9d9-4053-b6bb-20b43828552c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_47b0e592-3684-46ee-8203-605f98b6f745" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0fbc702b-c9d9-4053-b6bb-20b43828552c" xlink:to="loc_dei_EntityDomain_47b0e592-3684-46ee-8203-605f98b6f745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_abed7ee5-cf7f-45b3-961c-d3e5dd485f49" xlink:href="gh-20200630.xsd#gh_SoftBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_47b0e592-3684-46ee-8203-605f98b6f745" xlink:to="loc_gh_SoftBankMember_abed7ee5-cf7f-45b3-961c-d3e5dd485f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_91bc83b2-a470-47f8-aa94-29d749f2859b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_91bc83b2-a470-47f8-aa94-29d749f2859b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_54f5d691-3ae7-4644-baff-956db71af9fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_91bc83b2-a470-47f8-aa94-29d749f2859b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_54f5d691-3ae7-4644-baff-956db71af9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_68d1a9e6-a08a-45a5-a292-d67985425434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_54f5d691-3ae7-4644-baff-956db71af9fe" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_68d1a9e6-a08a-45a5-a292-d67985425434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_us-gaap_StatementClassOfStockAxis_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_56a43cd2-0dc3-4cf0-bd29-3be5c8816d24" xlink:to="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_77eaa314-67fc-4913-8c60-ecbd6d1e12a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:to="loc_us-gaap_CommonClassAMember_77eaa314-67fc-4913-8c60-ecbd6d1e12a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_56504612-b32f-4e61-aa3d-6d27b12a4ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:to="loc_us-gaap_CommonClassBMember_56504612-b32f-4e61-aa3d-6d27b12a4ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_54a478ba-1054-4fd4-a84f-725c3b7ccae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_77727204-bdee-4712-afd5-72c8a7ba8585" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_54a478ba-1054-4fd4-a84f-725c3b7ccae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_09df98d8-26c8-49fb-891d-b4f823c6341e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_srt_CounterpartyNameAxis_09df98d8-26c8-49fb-891d-b4f823c6341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_09df98d8-26c8-49fb-891d-b4f823c6341e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SoftBankMember_4f89e3d1-beda-451c-9601-61e9d711ac25" xlink:href="gh-20200630.xsd#gh_SoftBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:to="loc_gh_SoftBankMember_4f89e3d1-beda-451c-9601-61e9d711ac25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_GuardantHealthIncMember_f2cc9081-b651-45a7-98c4-e94f0affceec" xlink:href="gh-20200630.xsd#gh_GuardantHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a0f940-6c48-46a6-a40a-ba87199aa44f" xlink:to="loc_gh_GuardantHealthIncMember_f2cc9081-b651-45a7-98c4-e94f0affceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3f25b3f2-51c7-4759-8de8-9e791f0435bf" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_7cd4a134-9d9d-4bb6-bd78-ac41fcf89419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_7cd4a134-9d9d-4bb6-bd78-ac41fcf89419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EquityMethodInvestmentSharesPurchased_dd12b0ac-7a0c-4fa2-aca7-953d214635a8" xlink:href="gh-20200630.xsd#gh_EquityMethodInvestmentSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_EquityMethodInvestmentSharesPurchased_dd12b0ac-7a0c-4fa2-aca7-953d214635a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9e6783df-28a5-4a2d-968a-744799336342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9e6783df-28a5-4a2d-968a-744799336342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_986b0fde-3eef-4e0f-8b0b-8323796d94c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue_986b0fde-3eef-4e0f-8b0b-8323796d94c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_46886f14-7b95-4382-b10d-ded152b129fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_46886f14-7b95-4382-b10d-ded152b129fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e7bcc3fb-4a6a-4e85-98e3-a80bd67e0bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e7bcc3fb-4a6a-4e85-98e3-a80bd67e0bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_a82fbc47-cbac-4d84-bb55-62abf2163a7c" xlink:href="gh-20200630.xsd#gh_PreferredStockSharesIssuedUponConversionOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_PreferredStockSharesIssuedUponConversionOfCommonStock_a82fbc47-cbac-4d84-bb55-62abf2163a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_81f390b4-6133-4698-a0fa-924c0ae6d126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_81f390b4-6133-4698-a0fa-924c0ae6d126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_83fc3ba4-b26f-4629-850a-2c79540020cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_83fc3ba4-b26f-4629-850a-2c79540020cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_67c354b8-3a7b-4568-b00d-c72840c5726c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_67c354b8-3a7b-4568-b00d-c72840c5726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7f426ba3-6337-4ea5-abc2-3c214f97a774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7f426ba3-6337-4ea5-abc2-3c214f97a774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf543428-4bf3-4eba-94e4-d53de454f2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cf543428-4bf3-4eba-94e4-d53de454f2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_64b8673c-1624-41d0-8478-9c7284d1aa23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_64b8673c-1624-41d0-8478-9c7284d1aa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_344622da-7595-480b-99fa-3a4fc398a57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_us-gaap_Assets_344622da-7595-480b-99fa-3a4fc398a57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_26a87a83-51e2-4e65-8ac4-98bee8fa762d" xlink:href="gh-20200630.xsd#gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn_26a87a83-51e2-4e65-8ac4-98bee8fa762d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_f8c59a49-15bd-47ea-a4a0-c9d76f5801f6" xlink:href="gh-20200630.xsd#gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_21b2ea7f-873d-4ee9-82ff-b3151877e8a0" xlink:to="loc_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase_f8c59a49-15bd-47ea-a4a0-c9d76f5801f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_020185a2-c642-4229-a97b-9907b6384815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_c1c04357-d826-4a61-a2a0-e775c38273b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_020185a2-c642-4229-a97b-9907b6384815" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_c1c04357-d826-4a61-a2a0-e775c38273b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_16f68eb1-0ee4-46ce-8b3f-77958a738e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_47a7b68a-b903-49b0-885a-97da673776a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_16f68eb1-0ee4-46ce-8b3f-77958a738e60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_47a7b68a-b903-49b0-885a-97da673776a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c973fe22-df2b-4bdf-9a77-9b2cbceffe96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_16f68eb1-0ee4-46ce-8b3f-77958a738e60" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c973fe22-df2b-4bdf-9a77-9b2cbceffe96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_23132daa-f50e-4d24-a6b4-9b382ddb1b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_065b1c19-b3a6-4987-bb9e-f8d71957aca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_23132daa-f50e-4d24-a6b4-9b382ddb1b91" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_065b1c19-b3a6-4987-bb9e-f8d71957aca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c5dd6952-b39b-4f83-875e-e1cdb88768a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_065b1c19-b3a6-4987-bb9e-f8d71957aca1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c5dd6952-b39b-4f83-875e-e1cdb88768a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c5dd6952-b39b-4f83-875e-e1cdb88768a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_fde5f1e8-f762-49b6-a604-657ebe8f59f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_fde5f1e8-f762-49b6-a604-657ebe8f59f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_25a31e53-e2fb-4375-8bf8-fb3004585866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_ComputerEquipmentMember_25a31e53-e2fb-4375-8bf8-fb3004585866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8f1e9629-97f7-42c5-a977-3b478c9e10ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8f1e9629-97f7-42c5-a977-3b478c9e10ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_93d08c72-9cce-49d1-a7c3-3ee5a0618570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_93d08c72-9cce-49d1-a7c3-3ee5a0618570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_172296c3-5934-4d89-b3c9-14446c98af49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_172296c3-5934-4d89-b3c9-14446c98af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_32991f5a-046d-45c4-a713-7cd2b27b7780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4443873-46cc-4ab8-8b2e-70e89a1008f4" xlink:to="loc_us-gaap_ConstructionInProgressMember_32991f5a-046d-45c4-a713-7cd2b27b7780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_065b1c19-b3a6-4987-bb9e-f8d71957aca1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ae19a478-327f-49fb-b2b7-8aec5586aa39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ae19a478-327f-49fb-b2b7-8aec5586aa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_438aae27-8b8e-4daa-a96f-599760061bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_438aae27-8b8e-4daa-a96f-599760061bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_018827f7-60e8-4d3c-961a-b9042ec689bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_764668c5-2405-4277-beb6-6985d6f161cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_018827f7-60e8-4d3c-961a-b9042ec689bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7400ee-3d6d-496d-83c6-10a8e3173bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_43b38ac0-47a2-4975-a6e0-6f409652bfbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7400ee-3d6d-496d-83c6-10a8e3173bcb" xlink:to="loc_us-gaap_Depreciation_43b38ac0-47a2-4975-a6e0-6f409652bfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c28308d9-f500-47bb-ab1c-e2b4af29a6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c28308d9-f500-47bb-ab1c-e2b4af29a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_428083d5-f72d-40a6-a991-3655b4a24168" xlink:href="gh-20200630.xsd#gh_EstimatedLitigationLiabilityLegalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_gh_EstimatedLitigationLiabilityLegalFeesCurrent_428083d5-f72d-40a6-a991-3655b4a24168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_798b6fcb-7dc5-4cc9-9a19-9c547ba6015b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_798b6fcb-7dc5-4cc9-9a19-9c547ba6015b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8ae50fe9-683c-431a-8674-3ec070e4f1fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8ae50fe9-683c-431a-8674-3ec070e4f1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedClinicalTrialsandStudies_5a6718b4-ff74-45c0-bb93-0baa058f28e7" xlink:href="gh-20200630.xsd#gh_AccruedClinicalTrialsandStudies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_gh_AccruedClinicalTrialsandStudies_5a6718b4-ff74-45c0-bb93-0baa058f28e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_f1547881-2eb9-49cc-aafa-1f07d171e39e" xlink:href="gh-20200630.xsd#gh_AccruedExpensesPropertyandEquipmentCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_gh_AccruedExpensesPropertyandEquipmentCurrent_f1547881-2eb9-49cc-aafa-1f07d171e39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2676ee41-646f-4f5e-8263-ffc8fcc601f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2676ee41-646f-4f5e-8263-ffc8fcc601f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8a0d3574-3099-478e-aeb7-e883f32971f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8a0d3574-3099-478e-aeb7-e883f32971f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_714d2a58-cbf8-4c00-8739-e3245f97bbab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_521c6090-46d2-459a-8c56-7db09467fe98" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_714d2a58-cbf8-4c00-8739-e3245f97bbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_655a5e12-55f5-4fd2-bc57-d3b83bd546af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_817fea1b-c78c-4c83-bc9d-5c3459e77532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_655a5e12-55f5-4fd2-bc57-d3b83bd546af" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_817fea1b-c78c-4c83-bc9d-5c3459e77532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54e3e015-15c8-4a3c-b9d9-d6a9eb20cbb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b4996632-26d9-4206-9f9b-dd2c10bc7bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54e3e015-15c8-4a3c-b9d9-d6a9eb20cbb2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b4996632-26d9-4206-9f9b-dd2c10bc7bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a3d238f1-a8d8-4fd6-83e5-652a81fd75d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54e3e015-15c8-4a3c-b9d9-d6a9eb20cbb2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a3d238f1-a8d8-4fd6-83e5-652a81fd75d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesTableTextBlock_2f61480b-4509-47e6-a96d-742d3f9c1a21" xlink:href="gh-20200630.xsd#gh_DebtSecuritiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54e3e015-15c8-4a3c-b9d9-d6a9eb20cbb2" xlink:to="loc_gh_DebtSecuritiesTableTextBlock_2f61480b-4509-47e6-a96d-742d3f9c1a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9a9b4fe3-d5f7-44b5-9382-cd337b2e8ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9a9b4fe3-d5f7-44b5-9382-cd337b2e8ddd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e85b3f6-be81-46e9-b632-af5cd29f6d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e85b3f6-be81-46e9-b632-af5cd29f6d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ff111b3-5266-46ed-b70e-f1d66804f7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e85b3f6-be81-46e9-b632-af5cd29f6d54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ff111b3-5266-46ed-b70e-f1d66804f7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b9d1a655-5be2-4de6-92db-f567f43ad7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ff111b3-5266-46ed-b70e-f1d66804f7f1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b9d1a655-5be2-4de6-92db-f567f43ad7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f72485f6-519a-4892-b27a-898855919756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f72485f6-519a-4892-b27a-898855919756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a03cdccc-f0cb-42ed-b908-a7968daf6e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f72485f6-519a-4892-b27a-898855919756" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a03cdccc-f0cb-42ed-b908-a7968daf6e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_741d436e-1ed1-4624-9348-5eb1fb0e1b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a03cdccc-f0cb-42ed-b908-a7968daf6e74" xlink:to="loc_us-gaap_MoneyMarketFundsMember_741d436e-1ed1-4624-9348-5eb1fb0e1b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1d06c884-fd6a-4b73-8f20-98f801e02a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1d06c884-fd6a-4b73-8f20-98f801e02a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1d06c884-fd6a-4b73-8f20-98f801e02a2a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_416613d8-7267-4fc4-993b-1add43a8e502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_416613d8-7267-4fc4-993b-1add43a8e502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_45ac1ddd-e2ad-4a10-9a7d-694c0f97d39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff5eb0f5-5e7d-465e-a2de-a55d25949d13" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_45ac1ddd-e2ad-4a10-9a7d-694c0f97d39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49c33d8a-8695-453f-a5a9-39202f01fc26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49c33d8a-8695-453f-a5a9-39202f01fc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_49c33d8a-8695-453f-a5a9-39202f01fc26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_da0023d6-8d9b-4107-b302-6ab7a4364c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_da0023d6-8d9b-4107-b302-6ab7a4364c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_70a7b645-6153-44af-9055-ba8c7e980c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_70a7b645-6153-44af-9055-ba8c7e980c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_96a10ac0-c882-459d-8281-49d9ee6178f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18e6a4b0-0d02-4197-b1c5-eb9f41d73a4a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_96a10ac0-c882-459d-8281-49d9ee6178f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3086aaa2-2a6e-44a9-870a-c9e9199aa83c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d659f34-4ac1-4c8e-b6e5-778f84664cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d659f34-4ac1-4c8e-b6e5-778f84664cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_94bb0dba-e6a1-4a16-93ed-2ea0472adeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_94bb0dba-e6a1-4a16-93ed-2ea0472adeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_8c6fa8ca-df3b-4139-822d-309a19a7e8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_8c6fa8ca-df3b-4139-822d-309a19a7e8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1575a865-1e2b-4aa1-9343-4a9f5a471bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1575a865-1e2b-4aa1-9343-4a9f5a471bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bda4fae4-3d11-4eae-876b-78e9a0ede808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bda4fae4-3d11-4eae-876b-78e9a0ede808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aaa06114-c38c-4bb6-947d-35ec43046250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c36cd9f5-ab54-4e70-94c2-b2b7a019b95c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_aaa06114-c38c-4bb6-947d-35ec43046250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_def95c02-7f01-4543-ac2a-1269482153e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_def95c02-7f01-4543-ac2a-1269482153e3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4b4c0de3-0c1f-4b8e-a58c-8132ba9371c5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_RedeemableNoncontrollingInterestMember_b0851617-ad4b-41ff-b0ca-90aca7f8747f" xlink:href="gh-20200630.xsd#gh_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:to="loc_gh_RedeemableNoncontrollingInterestMember_b0851617-ad4b-41ff-b0ca-90aca7f8747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ContingentConsiderationMember_f6759930-2602-47d0-bf1d-65fb8b8ca18f" xlink:href="gh-20200630.xsd#gh_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5f0a301d-0337-4995-bdad-0a8311e09e9e" xlink:to="loc_gh_ContingentConsiderationMember_f6759930-2602-47d0-bf1d-65fb8b8ca18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a5667d-f56d-440d-a3fe-691a4c29242d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a5667d-f56d-440d-a3fe-691a4c29242d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_383eb030-8bc1-4a33-b6ea-64019bc8b24b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25a5667d-f56d-440d-a3fe-691a4c29242d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_383eb030-8bc1-4a33-b6ea-64019bc8b24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dc759c54-4b1b-46bc-855b-3094fedae283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_383eb030-8bc1-4a33-b6ea-64019bc8b24b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dc759c54-4b1b-46bc-855b-3094fedae283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_634f7df2-ca85-4abe-91fe-c3a1cda12376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_634f7df2-ca85-4abe-91fe-c3a1cda12376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa29db3b-6ff8-44db-a926-2477b5dbc5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_634f7df2-ca85-4abe-91fe-c3a1cda12376" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa29db3b-6ff8-44db-a926-2477b5dbc5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f5804d9c-05d4-4c6f-9dd0-82262d7443de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa29db3b-6ff8-44db-a926-2477b5dbc5bb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f5804d9c-05d4-4c6f-9dd0-82262d7443de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c93b24b5-71e1-47ce-b47a-a52c81c74e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d3a59ac-ca80-49c9-99d9-729dab81d5e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c93b24b5-71e1-47ce-b47a-a52c81c74e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c93b24b5-71e1-47ce-b47a-a52c81c74e2a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6d0f38a0-c7fd-4382-9bf5-56da054cb551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6d0f38a0-c7fd-4382-9bf5-56da054cb551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aee380d2-8482-41de-b29a-bbe8de1e50ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aee380d2-8482-41de-b29a-bbe8de1e50ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b1959b49-8eee-44be-b408-6a01a46a5717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_b1959b49-8eee-44be-b408-6a01a46a5717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_15017c42-6fda-4f45-8167-71e68a159812" xlink:href="gh-20200630.xsd#gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod_15017c42-6fda-4f45-8167-71e68a159812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c0fbfb46-2680-4dd2-8d50-983ff393f384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f68dbebe-9e73-4874-bb45-b1e85756fb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c0fbfb46-2680-4dd2-8d50-983ff393f384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_75c7df5d-ff11-484a-a8df-250de2d3d3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_75c7df5d-ff11-484a-a8df-250de2d3d3da" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851a234d-5c62-4382-abf7-2fd96e49c96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851a234d-5c62-4382-abf7-2fd96e49c96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b626ccb0-e0c8-4370-99a8-f4a88fc8eb20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851a234d-5c62-4382-abf7-2fd96e49c96a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b626ccb0-e0c8-4370-99a8-f4a88fc8eb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a9204dce-17ae-456e-a276-9f322a953fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b626ccb0-e0c8-4370-99a8-f4a88fc8eb20" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a9204dce-17ae-456e-a276-9f322a953fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_00da96dd-f3a3-48ea-88f5-250710b4c80c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29f1b26a-f9b5-4074-9b41-de06cd2a0b6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_00da96dd-f3a3-48ea-88f5-250710b4c80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a2126f81-20b8-4c17-9aaf-8d113f5ac4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_00da96dd-f3a3-48ea-88f5-250710b4c80c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a2126f81-20b8-4c17-9aaf-8d113f5ac4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c94feac-ad3a-4df1-a7fb-32390f97d37d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:to="loc_srt_RangeAxis_7c94feac-ad3a-4df1-a7fb-32390f97d37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7c94feac-ad3a-4df1-a7fb-32390f97d37d" xlink:to="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f23b0de7-de3f-4d57-b03e-25bb78ae764a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:to="loc_srt_MinimumMember_f23b0de7-de3f-4d57-b03e-25bb78ae764a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8806491-789a-44cc-b642-f9012b261575" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3e1b7869-0310-4135-a682-770c9b8d0db2" xlink:to="loc_srt_MaximumMember_b8806491-789a-44cc-b642-f9012b261575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9b74dc5-f340-44cb-af46-8d45b622d321" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed612839-f1f5-409b-86a8-c1a6d98380b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ed612839-f1f5-409b-86a8-c1a6d98380b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_MarketableSecuritiesMaturityPeriod_27f85ca8-b4cd-4470-83b6-51a96f7d57c3" xlink:href="gh-20200630.xsd#gh_MarketableSecuritiesMaturityPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_853e3ea2-7db9-4ee6-9f8c-374d72e39e71" xlink:to="loc_gh_MarketableSecuritiesMaturityPeriod_27f85ca8-b4cd-4470-83b6-51a96f7d57c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f8aadb52-9436-4551-864d-888b33687f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a38fd6d1-fb5e-4a59-91d7-1f5ec31e43bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f8aadb52-9436-4551-864d-888b33687f95" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a38fd6d1-fb5e-4a59-91d7-1f5ec31e43bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d9362d85-dea7-4617-a5b8-c8c3f465d102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a38fd6d1-fb5e-4a59-91d7-1f5ec31e43bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d9362d85-dea7-4617-a5b8-c8c3f465d102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d9362d85-dea7-4617-a5b8-c8c3f465d102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9505b65f-f0ac-405f-aca8-531125f6ebf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9505b65f-f0ac-405f-aca8-531125f6ebf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_26d22589-7a4e-46b8-99c4-f5f6e8b7f3e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_26d22589-7a4e-46b8-99c4-f5f6e8b7f3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_1895b585-a5b4-49bf-b895-7ce6439dbd40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c77ae41c-aa63-4210-8618-664d01c2f18b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_1895b585-a5b4-49bf-b895-7ce6439dbd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a38fd6d1-fb5e-4a59-91d7-1f5ec31e43bf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd206d45-5030-42a1-bd80-b427f6f78c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd206d45-5030-42a1-bd80-b427f6f78c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b257216c-d51d-4c08-9ea9-6939668ce131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b257216c-d51d-4c08-9ea9-6939668ce131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_1d47b37e-0269-4b83-ba63-b5f2aec49459" xlink:href="gh-20200630.xsd#gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost_1d47b37e-0269-4b83-ba63-b5f2aec49459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d194f46a-c7c6-474a-bd58-12acb0ec8db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d194f46a-c7c6-474a-bd58-12acb0ec8db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e0653a4-06d6-4e97-9626-58015579c657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e0653a4-06d6-4e97-9626-58015579c657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_22125e23-8afa-4fef-b766-5f955f49d04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_22125e23-8afa-4fef-b766-5f955f49d04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_995d59f7-9226-4d56-8a06-7bb8cf8de634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_995d59f7-9226-4d56-8a06-7bb8cf8de634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_521f4ba8-639e-4639-a1e8-a69b826a76b3" xlink:href="gh-20200630.xsd#gh_CashCashEquivalentsandDebtSecuritiesFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_43a8a848-5b7c-4597-8d88-f0b153329d3c" xlink:to="loc_gh_CashCashEquivalentsandDebtSecuritiesFairValue_521f4ba8-639e-4639-a1e8-a69b826a76b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwill"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c307aba-9035-407c-b6b5-888d1a43badb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0556375d-6ace-437d-9a87-e4276252fb61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c307aba-9035-407c-b6b5-888d1a43badb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0556375d-6ace-437d-9a87-e4276252fb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_752ccb98-3a64-44c8-a4d3-1dbf93852e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_72978813-fffd-429a-be86-65378a6cdfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_752ccb98-3a64-44c8-a4d3-1dbf93852e76" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_72978813-fffd-429a-be86-65378a6cdfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_934e2eb3-ccf3-4fa8-89b1-4aa36028c859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_752ccb98-3a64-44c8-a4d3-1dbf93852e76" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_934e2eb3-ccf3-4fa8-89b1-4aa36028c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ebe9d9e5-6b8c-4f1a-9c03-a614ede4c20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_752ccb98-3a64-44c8-a4d3-1dbf93852e76" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ebe9d9e5-6b8c-4f1a-9c03-a614ede4c20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_51a6a520-0032-4551-a945-f2bc84034c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_51a6a520-0032-4551-a945-f2bc84034c13" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e28f0b8-a792-48ef-8815-de0f02c32f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e28f0b8-a792-48ef-8815-de0f02c32f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e28f0b8-a792-48ef-8815-de0f02c32f6d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b9d114f5-0679-4fb1-8b56-ed59fcc9fa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:to="loc_us-gaap_LicensingAgreementsMember_b9d114f5-0679-4fb1-8b56-ed59fcc9fa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b5265734-4895-4d2f-b3fc-71014960744f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09622cf7-a71b-4f2f-8065-535d29b0a607" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b5265734-4895-4d2f-b3fc-71014960744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3db2fdc4-a2a6-4b2d-bc61-fbb977f13c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f3fc8c5e-ad02-4eca-a731-4676d0ccb05d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3db2fdc4-a2a6-4b2d-bc61-fbb977f13c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0096f213-bfb0-49d4-9eb4-45e7abd04c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3db2fdc4-a2a6-4b2d-bc61-fbb977f13c61" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0096f213-bfb0-49d4-9eb4-45e7abd04c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e8f5e61-19ce-4eda-9987-1407f23d6601" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_61161ba0-c5c8-4378-9247-08895e478540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_61161ba0-c5c8-4378-9247-08895e478540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fb8d1971-f334-46d0-9436-fd2cc88776c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fb8d1971-f334-46d0-9436-fd2cc88776c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3d5ffc9d-cb7e-4ac8-9433-09989d9120ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3d5ffc9d-cb7e-4ac8-9433-09989d9120ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_99857c59-c53e-4a8c-a941-ae6df9f6f519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_99857c59-c53e-4a8c-a941-ae6df9f6f519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_111665ca-4055-47b0-be49-bdbffafe7808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_111665ca-4055-47b0-be49-bdbffafe7808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e5cf1ca3-7f88-4a2b-a02e-78eb80ebfde5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_Goodwill_e5cf1ca3-7f88-4a2b-a02e-78eb80ebfde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_IntangibleAssetsGrossIncludingGoodwill_0ab8a4ec-63da-4205-a7f5-0a2e5fdb9903" xlink:href="gh-20200630.xsd#gh_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_gh_IntangibleAssetsGrossIncludingGoodwill_0ab8a4ec-63da-4205-a7f5-0a2e5fdb9903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c15292fb-580d-483f-b43c-ffc3afb6dbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad3816e0-b2a3-4b8b-8d58-c53a9a0c99ba" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c15292fb-580d-483f-b43c-ffc3afb6dbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a815f96d-007b-4046-bedd-6f10bb2abd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6261351e-411f-40d8-bfd7-0bfad42f116b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a815f96d-007b-4046-bedd-6f10bb2abd4f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6261351e-411f-40d8-bfd7-0bfad42f116b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3eac5c2d-4d81-459a-8c78-c808205e791b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3eac5c2d-4d81-459a-8c78-c808205e791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6d73373b-5df5-4ca3-916d-6fd3905008d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6d73373b-5df5-4ca3-916d-6fd3905008d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ae790f0b-9e27-4214-8191-dc230a29e566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ae790f0b-9e27-4214-8191-dc230a29e566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7c0131d6-2e5c-4284-afd5-3be16f94956f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7c0131d6-2e5c-4284-afd5-3be16f94956f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7f211941-df49-459b-a7e8-525a5cf61a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7f211941-df49-459b-a7e8-525a5cf61a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_0945ab75-a6dc-43df-98d2-f98713b387fa" xlink:href="gh-20200630.xsd#gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:to="loc_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_0945ab75-a6dc-43df-98d2-f98713b387fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06497394-3e38-4821-8573-3fcdb9c6f885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99009101-6a5e-45c8-91f4-144c789630a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_06497394-3e38-4821-8573-3fcdb9c6f885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Acquisition" xlink:type="simple" xlink:href="gh-20200630.xsd#Acquisition"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_147eab9a-81e1-4179-8a36-654ab28b7ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock_491b9c78-fffa-421f-a130-51fe5acb1c5c" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_147eab9a-81e1-4179-8a36-654ab28b7ed1" xlink:to="loc_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock_491b9c78-fffa-421f-a130-51fe5acb1c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionTables" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ea578f9f-9a20-44d2-85fe-91d9ad0e9eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1e59f4e5-f0e8-4ecd-acf8-77b7609308f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ea578f9f-9a20-44d2-85fe-91d9ad0e9eb7" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1e59f4e5-f0e8-4ecd-acf8-77b7609308f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_e7e1870e-fd3a-4a81-af95-082f31ab5f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ea578f9f-9a20-44d2-85fe-91d9ad0e9eb7" xlink:to="loc_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_e7e1870e-fd3a-4a81-af95-082f31ab5f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionPatentLicenseAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_762370e1-a07c-4eaa-8d8c-e8d8dbe6af3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_762370e1-a07c-4eaa-8d8c-e8d8dbe6af3c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionAxis_fef02db2-715b-49f5-8241-4af02b2ebb85" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:to="loc_gh_AssetAcquisitionAxis_fef02db2-715b-49f5-8241-4af02b2ebb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionDomain_88ae83b9-cb43-4c36-bcbf-31b5e46152f7" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_AssetAcquisitionAxis_fef02db2-715b-49f5-8241-4af02b2ebb85" xlink:to="loc_gh_AssetAcquisitionDomain_88ae83b9-cb43-4c36-bcbf-31b5e46152f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_KeyGenePatentLicenseAcquisitionMember_2e7bd312-9444-41d2-acaa-3fe6e583aa48" xlink:href="gh-20200630.xsd#gh_KeyGenePatentLicenseAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_AssetAcquisitionDomain_88ae83b9-cb43-4c36-bcbf-31b5e46152f7" xlink:to="loc_gh_KeyGenePatentLicenseAcquisitionMember_2e7bd312-9444-41d2-acaa-3fe6e583aa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7c6dde2-d57f-4509-8a48-b754d6219040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7c6dde2-d57f-4509-8a48-b754d6219040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7c6dde2-d57f-4509-8a48-b754d6219040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PatentandCovenantRightsMember_af302373-a0af-4ecb-a8ac-3e3464172d02" xlink:href="gh-20200630.xsd#gh_PatentandCovenantRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:to="loc_gh_PatentandCovenantRightsMember_af302373-a0af-4ecb-a8ac-3e3464172d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7cd7f4dc-de90-4db0-a747-06f692657953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cab9b848-e5e1-41b7-8c9d-bc628a675609" xlink:to="loc_us-gaap_LicensingAgreementsMember_7cd7f4dc-de90-4db0-a747-06f692657953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_662ef40b-d6b9-4090-a09d-d811474e8d75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:to="loc_srt_RangeAxis_662ef40b-d6b9-4090-a09d-d811474e8d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_662ef40b-d6b9-4090-a09d-d811474e8d75" xlink:to="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bd9d47e6-637d-46b1-ae94-83001116db64" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:to="loc_srt_MinimumMember_bd9d47e6-637d-46b1-ae94-83001116db64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f980ea0-ea92-45a4-bbe5-e7d66e74dec2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a09ee47a-ab99-4b11-a7eb-dfc85239dfff" xlink:to="loc_srt_MaximumMember_9f980ea0-ea92-45a4-bbe5-e7d66e74dec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f9ee192d-3bdb-451f-9784-41326651895c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PaymentInConnectionWithaLicenseAgreement_fa7745c0-c7de-42f5-a7b8-8b79283580f6" xlink:href="gh-20200630.xsd#gh_PaymentInConnectionWithaLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_PaymentInConnectionWithaLicenseAgreement_fa7745c0-c7de-42f5-a7b8-8b79283580f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_AssetAcquisitionTransactionCosts_dff9f184-4f61-4a0f-8d1c-96b845d90a0a" xlink:href="gh-20200630.xsd#gh_AssetAcquisitionTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_AssetAcquisitionTransactionCosts_dff9f184-4f61-4a0f-8d1c-96b845d90a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cee5c4aa-7651-4f2d-b3b7-89f2ef72296f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cee5c4aa-7651-4f2d-b3b7-89f2ef72296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_01b79760-ade5-4ed9-9819-39e0c2ca1fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_01b79760-ade5-4ed9-9819-39e0c2ca1fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ChargeOfInProcessResearchAndDevelopment_0303eb59-870b-4d74-ab10-cf515b586495" xlink:href="gh-20200630.xsd#gh_ChargeOfInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_ChargeOfInProcessResearchAndDevelopment_0303eb59-870b-4d74-ab10-cf515b586495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_39c87679-26e4-45ca-a590-e00ec7a6fbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_LitigationSettlementExpense_39c87679-26e4-45ca-a590-e00ec7a6fbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CapitalizedLicenseFees_db9984ed-cbda-483d-8723-8fa06f8d67dd" xlink:href="gh-20200630.xsd#gh_CapitalizedLicenseFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_gh_CapitalizedLicenseFees_db9984ed-cbda-483d-8723-8fa06f8d67dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_86130f4a-c187-49c0-91c1-36df06cee129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_decc3d27-5f9e-4b41-b237-aa3634cca813" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_86130f4a-c187-49c0-91c1-36df06cee129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionAcquisitionofBellwetherBioDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_22b739b6-f699-47c6-93f0-9dd248159b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_22b739b6-f699-47c6-93f0-9dd248159b6f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a140b7cf-e614-464c-9911-74e7101d3672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a140b7cf-e614-464c-9911-74e7101d3672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c566d6f-ccf2-409b-9930-18a564da2484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a140b7cf-e614-464c-9911-74e7101d3672" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c566d6f-ccf2-409b-9930-18a564da2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CovenantsNotToCompeteMember_b9caafaa-0489-41f9-bc77-622eb0a4a4e0" xlink:href="gh-20200630.xsd#gh_CovenantsNotToCompeteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c566d6f-ccf2-409b-9930-18a564da2484" xlink:to="loc_gh_CovenantsNotToCompeteMember_b9caafaa-0489-41f9-bc77-622eb0a4a4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_d3064afb-bbe2-4f60-bc62-3fc46830281e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_d3064afb-bbe2-4f60-bc62-3fc46830281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d3064afb-bbe2-4f60-bc62-3fc46830281e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CommercializationMilestonesMember_ca37fa9d-41fc-486d-b2e0-2f8eb45dcca8" xlink:href="gh-20200630.xsd#gh_CommercializationMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:to="loc_gh_CommercializationMilestonesMember_ca37fa9d-41fc-486d-b2e0-2f8eb45dcca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_EarnOutConsiderationMember_a50828fb-1089-4641-b465-a19cb4535136" xlink:href="gh-20200630.xsd#gh_EarnOutConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4e556e99-74cc-41e5-8aa8-b81e494ba657" xlink:to="loc_gh_EarnOutConsiderationMember_a50828fb-1089-4641-b465-a19cb4535136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e87a2d17-f747-4d5e-a873-e9e0d56e653a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e87a2d17-f747-4d5e-a873-e9e0d56e653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70db2e07-16f3-4fec-8f2a-bed26e30f869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e87a2d17-f747-4d5e-a873-e9e0d56e653a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70db2e07-16f3-4fec-8f2a-bed26e30f869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BellweatherBioInc.Member_137a75c9-75f2-490e-9041-ba71c8ca95ea" xlink:href="gh-20200630.xsd#gh_BellweatherBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70db2e07-16f3-4fec-8f2a-bed26e30f869" xlink:to="loc_gh_BellweatherBioInc.Member_137a75c9-75f2-490e-9041-ba71c8ca95ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65db508a-3473-41f2-8269-0fc498fc020f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_06cebab7-9018-4b5d-a4cd-3111e1197ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_06cebab7-9018-4b5d-a4cd-3111e1197ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c18a138-e67c-4841-bfb9-b28e57106013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c18a138-e67c-4841-bfb9-b28e57106013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8851c618-3503-49ec-8745-fbfac11c55d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8851c618-3503-49ec-8745-fbfac11c55d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_bf374202-0d08-432b-a284-f50bddea6703" xlink:href="gh-20200630.xsd#gh_BusinessCombinationContingentConsiderationMaximumAmountPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable_bf374202-0d08-432b-a284-f50bddea6703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_572eda73-481a-44b5-9986-39099db8c9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_572eda73-481a-44b5-9986-39099db8c9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b77226aa-d5b7-4312-9077-eeef3713df34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b8c2a037-0797-4cf7-9da3-a97a5ecedb38" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b77226aa-d5b7-4312-9077-eeef3713df34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b216143c-3ec1-4f19-87f2-bb65559f3830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db6a5940-62da-4dbe-91cf-d9d99a9f37c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b216143c-3ec1-4f19-87f2-bb65559f3830" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db6a5940-62da-4dbe-91cf-d9d99a9f37c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_58adc626-5184-4adb-a5d7-de40ff2b3b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db6a5940-62da-4dbe-91cf-d9d99a9f37c0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_58adc626-5184-4adb-a5d7-de40ff2b3b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f257667c-7685-4fc0-8b38-3c7d2792665c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58adc626-5184-4adb-a5d7-de40ff2b3b06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f257667c-7685-4fc0-8b38-3c7d2792665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BellweatherBioInc.Member_43d1eb8f-5554-4604-9f4b-2f14e1e2c8fe" xlink:href="gh-20200630.xsd#gh_BellweatherBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f257667c-7685-4fc0-8b38-3c7d2792665c" xlink:to="loc_gh_BellweatherBioInc.Member_43d1eb8f-5554-4604-9f4b-2f14e1e2c8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_db6a5940-62da-4dbe-91cf-d9d99a9f37c0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_92db6057-cba6-47ce-ab24-a1dc7168653d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_92db6057-cba6-47ce-ab24-a1dc7168653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6370edd4-d2d2-4504-a0a8-f1dd20bdd3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6370edd4-d2d2-4504-a0a8-f1dd20bdd3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b1dc9c22-d82e-47db-8ee1-4662560cbe44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_Goodwill_b1dc9c22-d82e-47db-8ee1-4662560cbe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f86a9421-ee47-4c56-92ce-3e573d75cd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f86a9421-ee47-4c56-92ce-3e573d75cd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0c4f3495-1f37-4903-842e-ddba35e4d678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05e5b418-98f2-4a87-be49-f15851bbb894" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0c4f3495-1f37-4903-842e-ddba35e4d678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#AcquisitionIntangibleAssetsAcquiredDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d71e62a3-f812-4f41-9929-961439fba8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d71e62a3-f812-4f41-9929-961439fba8b6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ac9c60b3-bd00-4f27-9386-de5dba490ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ac9c60b3-bd00-4f27-9386-de5dba490ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c8840c9-558d-4903-9230-603de23ae6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ac9c60b3-bd00-4f27-9386-de5dba490ce5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c8840c9-558d-4903-9230-603de23ae6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_BellweatherBioInc.Member_d48916de-df08-4389-9a83-0acbd69ad550" xlink:href="gh-20200630.xsd#gh_BellweatherBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c8840c9-558d-4903-9230-603de23ae6fd" xlink:to="loc_gh_BellweatherBioInc.Member_d48916de-df08-4389-9a83-0acbd69ad550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f8651a34-f4db-42d9-adb4-8820cc5e458d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f8651a34-f4db-42d9-adb4-8820cc5e458d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f8651a34-f4db-42d9-adb4-8820cc5e458d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_d3ffc864-d35c-4e0c-a388-329fa90efde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:to="loc_us-gaap_LicensingAgreementsMember_d3ffc864-d35c-4e0c-a388-329fa90efde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_0e1032c3-fb0b-4272-a2e7-dce8a1e85a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_257dd05f-aee3-46a8-ae1d-5d361fcc00ab" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_0e1032c3-fb0b-4272-a2e7-dce8a1e85a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_9e5588f7-8726-4927-a477-997572d1c0f0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dd02453-de51-4958-a02a-3b6118e1a51b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3dd02453-de51-4958-a02a-3b6118e1a51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_46d66319-3a5d-4a11-bc87-8514d812cd59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_696ef38f-1972-4b92-b6bc-f745857801d7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_46d66319-3a5d-4a11-bc87-8514d812cd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/Leases" xlink:type="simple" xlink:href="gh-20200630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9ca5814d-f34e-4601-9fd1-fcb73626ffd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_16760c28-088a-4f3f-bcdb-fb39f7d2fa9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ca5814d-f34e-4601-9fd1-fcb73626ffd7" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_16760c28-088a-4f3f-bcdb-fb39f7d2fa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5aef05f9-7a97-4874-82db-795b15d0d51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_57933404-fd0c-4a6e-b35a-266df47d0f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5aef05f9-7a97-4874-82db-795b15d0d51f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_57933404-fd0c-4a6e-b35a-266df47d0f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f2da0001-a81f-4606-bdb0-4b6d5b0b9910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5aef05f9-7a97-4874-82db-795b15d0d51f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f2da0001-a81f-4606-bdb0-4b6d5b0b9910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f5cd285d-6366-46d8-94b8-33e55fbdc75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6478b18d-cd86-4878-ad77-dc370f94b0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f5cd285d-6366-46d8-94b8-33e55fbdc75f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6478b18d-cd86-4878-ad77-dc370f94b0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6478b18d-cd86-4878-ad77-dc370f94b0f8" xlink:to="loc_srt_RangeAxis_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_21cff1a8-30db-4ca5-aa37-8ac8db19d9ff" xlink:to="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9196f21c-dd9d-4b5b-9ed5-395af7beb58b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:to="loc_srt_MinimumMember_9196f21c-dd9d-4b5b-9ed5-395af7beb58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af819541-a2fb-418d-b035-8b491a208d90" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5d5859fe-044a-43ee-9826-c2a0fccf2b46" xlink:to="loc_srt_MaximumMember_af819541-a2fb-418d-b035-8b491a208d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6478b18d-cd86-4878-ad77-dc370f94b0f8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_90429d57-15b6-4556-8243-0d14b07ada3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_90429d57-15b6-4556-8243-0d14b07ada3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9af19b05-753a-4b7b-8f00-a22c7e2a0766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_27b4ec86-4154-4275-b8f7-9c64d43eac20" xlink:to="loc_us-gaap_OperatingLeaseExpense_9af19b05-753a-4b7b-8f00-a22c7e2a0766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_22abf023-1fd3-474c-aedd-6fcdac2c3148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_09dfb250-f368-4552-adce-2d4b62e7e826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22abf023-1fd3-474c-aedd-6fcdac2c3148" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_09dfb250-f368-4552-adce-2d4b62e7e826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_34e91f9f-4eb8-4462-8144-068b8cea3404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22abf023-1fd3-474c-aedd-6fcdac2c3148" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_34e91f9f-4eb8-4462-8144-068b8cea3404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fe74d144-53c5-4d96-9382-04d911851332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fe74d144-53c5-4d96-9382-04d911851332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9879f0a2-1643-4d84-9bed-9eb24ca2c436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9879f0a2-1643-4d84-9bed-9eb24ca2c436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_233f3fdd-87a4-4381-b125-7f48755b6de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_233f3fdd-87a4-4381-b125-7f48755b6de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4af46882-5e3f-490a-9ddd-4f0a91f7234a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4af46882-5e3f-490a-9ddd-4f0a91f7234a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f6b9bd58-53df-4f3c-b1de-b01d6d8f463d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f6b9bd58-53df-4f3c-b1de-b01d6d8f463d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_4f0af87c-66a6-4004-9924-f4f10b500012" xlink:href="gh-20200630.xsd#gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_4f0af87c-66a6-4004-9924-f4f10b500012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0ee69adc-7e74-4ffd-99d5-b0b0329f3d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0ee69adc-7e74-4ffd-99d5-b0b0329f3d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7797e077-36f4-4aa5-b06a-c94be44916fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7797e077-36f4-4aa5-b06a-c94be44916fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_785307ed-3945-47aa-a028-9fb752cb2a00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15146392-1578-4e82-99dd-c24a0083c607" xlink:to="loc_us-gaap_OperatingLeaseLiability_785307ed-3945-47aa-a028-9fb752cb2a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="simple" xlink:href="gh-20200630.xsd#LeasesScheduleofOperatingLiabilityMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gh-20200630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be526b01-0d4b-4415-9c3e-7f9f0a1ad201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bdae78de-8e52-49c2-b1fa-6676d4ec8503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be526b01-0d4b-4415-9c3e-7f9f0a1ad201" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bdae78de-8e52-49c2-b1fa-6676d4ec8503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2582e1c2-0e09-4ff1-9ae7-07fa937f835d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_d18f0421-c14e-4d63-87a7-58f3fa111124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2582e1c2-0e09-4ff1-9ae7-07fa937f835d" xlink:to="loc_us-gaap_OtherCommitmentsTable_d18f0421-c14e-4d63-87a7-58f3fa111124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_63eaf070-bba3-4965-8bd7-680668b89b60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_d18f0421-c14e-4d63-87a7-58f3fa111124" xlink:to="loc_srt_LitigationCaseAxis_63eaf070-bba3-4965-8bd7-680668b89b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_63eaf070-bba3-4965-8bd7-680668b89b60" xlink:to="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember_2a0a9be2-6273-4061-b64d-6f5fb159afa0" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember_2a0a9be2-6273-4061-b64d-6f5fb159afa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_79b90038-d628-4faf-af5e-08768c5dfc00" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member_79b90038-d628-4faf-af5e-08768c5dfc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember_f6bc6812-d24b-4afa-950c-0854e69590c7" xlink:href="gh-20200630.xsd#gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7123f82e-10b2-45ed-95cd-50df3b53c525" xlink:to="loc_gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember_f6bc6812-d24b-4afa-950c-0854e69590c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_d18f0421-c14e-4d63-87a7-58f3fa111124" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofCompaniesthatInfringedonaPatent_c8d78f89-df19-4dd3-a50f-5beb646beb6f" xlink:href="gh-20200630.xsd#gh_NumberofCompaniesthatInfringedonaPatent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_gh_NumberofCompaniesthatInfringedonaPatent_c8d78f89-df19-4dd3-a50f-5beb646beb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_f77f9ea5-7186-436d-9fba-87055d90d652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_f77f9ea5-7186-436d-9fba-87055d90d652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsFiled_90b3964c-1319-49af-9321-20d09217c8bd" xlink:href="gh-20200630.xsd#gh_NumberofPetitionsFiled"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_gh_NumberofPetitionsFiled_90b3964c-1319-49af-9321-20d09217c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberofPetitionsDenied_697d1699-d5b3-4a5b-ba0c-55acda819ec8" xlink:href="gh-20200630.xsd#gh_NumberofPetitionsDenied"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_2f660b0a-9a62-45f4-aa62-21a81b855e41" xlink:to="loc_gh_NumberofPetitionsDenied_697d1699-d5b3-4a5b-ba0c-55acda819ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStock" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_58555f09-faff-46aa-991f-0cc23306ca8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_590e9ed6-54d6-4d11-b2fd-edc99ac35fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_58555f09-faff-46aa-991f-0cc23306ca8f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_590e9ed6-54d6-4d11-b2fd-edc99ac35fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockTables" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c32a12c6-6409-4d5e-9a10-b2d399547ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_3c941f7a-3e38-4be9-9ab0-83b9cabe0607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c32a12c6-6409-4d5e-9a10-b2d399547ab5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_3c941f7a-3e38-4be9-9ab0-83b9cabe0607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/CommonStockDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ad36e7c6-31ea-40b2-86b9-7a14dfbd8371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_34c616b9-b3cc-472b-abfd-ab4a384166cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ad36e7c6-31ea-40b2-86b9-7a14dfbd8371" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_34c616b9-b3cc-472b-abfd-ab4a384166cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4388b836-67df-48db-babb-5330d1503422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_34c616b9-b3cc-472b-abfd-ab4a384166cd" xlink:to="loc_us-gaap_AwardTypeAxis_4388b836-67df-48db-babb-5330d1503422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4388b836-67df-48db-babb-5330d1503422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b21d56c6-557b-4afe-8cbd-235b324ce83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b21d56c6-557b-4afe-8cbd-235b324ce83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6759347e-ba8b-4985-8f19-782e4010ea93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6759347e-ba8b-4985-8f19-782e4010ea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_A2018IncentiveAwardPlanMember_e80d90ec-2990-4a72-8b98-344f6871f7f6" xlink:href="gh-20200630.xsd#gh_A2018IncentiveAwardPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_gh_A2018IncentiveAwardPlanMember_e80d90ec-2990-4a72-8b98-344f6871f7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_02e9bcf2-5cb0-4647-8f06-1dcea56b61e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b6b455-d2da-410b-9817-7aa7f1cc34ac" xlink:to="loc_us-gaap_EmployeeStockMember_02e9bcf2-5cb0-4647-8f06-1dcea56b61e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_34c616b9-b3cc-472b-abfd-ab4a384166cd" xlink:to="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96dc9847-4de8-4e86-acde-90cacac920ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_96dc9847-4de8-4e86-acde-90cacac920ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c37c6b78-2129-4af3-8cec-0584fb762342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c37c6b78-2129-4af3-8cec-0584fb762342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_5721cc37-85bc-4139-a694-4764cfadb242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_5721cc37-85bc-4139-a694-4764cfadb242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18d57c20-a1e5-44fb-a4c0-cfac4dd87c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_51e2d84b-958a-4ff9-adca-7027d01cab07" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18d57c20-a1e5-44fb-a4c0-cfac4dd87c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4dfdb29b-991f-4771-8c00-c95fa8b0d97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4a86f341-8a2f-4f82-9da8-dff1143ab07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4dfdb29b-991f-4771-8c00-c95fa8b0d97a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4a86f341-8a2f-4f82-9da8-dff1143ab07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ae2ed-b9e1-4c81-8a0e-84d44ffb3ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_068949eb-f2fa-4a2a-880b-6f9adae6eeab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ae2ed-b9e1-4c81-8a0e-84d44ffb3ca9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_068949eb-f2fa-4a2a-880b-6f9adae6eeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5740fe79-5175-4b41-947f-5cef759e3f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ae2ed-b9e1-4c81-8a0e-84d44ffb3ca9" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5740fe79-5175-4b41-947f-5cef759e3f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_e08ab53e-e8f6-440d-a4b4-c9be91f90e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ae2ed-b9e1-4c81-8a0e-84d44ffb3ca9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_e08ab53e-e8f6-440d-a4b4-c9be91f90e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bc93d034-e7d0-4df6-aa6f-85f7248cc3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ae2ed-b9e1-4c81-8a0e-84d44ffb3ca9" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bc93d034-e7d0-4df6-aa6f-85f7248cc3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b3b4094d-fbf0-4ddc-8072-1afc51c2c89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ae2ed-b9e1-4c81-8a0e-84d44ffb3ca9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b3b4094d-fbf0-4ddc-8072-1afc51c2c89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea3a73b6-88ec-4afd-bae0-96d5c28960b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1940638d-d084-49ec-9efb-84091608dea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea3a73b6-88ec-4afd-bae0-96d5c28960b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1940638d-d084-49ec-9efb-84091608dea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e91b318-3d28-4abf-a308-049e5dca0c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1940638d-d084-49ec-9efb-84091608dea2" xlink:to="loc_us-gaap_AwardTypeAxis_6e91b318-3d28-4abf-a308-049e5dca0c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e91b318-3d28-4abf-a308-049e5dca0c03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f22ae02c-0ea3-4408-b210-598d7a7695ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:to="loc_us-gaap_RestrictedStockMember_f22ae02c-0ea3-4408-b210-598d7a7695ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_05bc8891-d669-4e52-81c5-52c1580de591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d72ae0ad-7d85-4854-a120-8410a51d0726" xlink:to="loc_us-gaap_PerformanceSharesMember_05bc8891-d669-4e52-81c5-52c1580de591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1940638d-d084-49ec-9efb-84091608dea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dbe7c9ae-b27c-45a1-85be-e89e2b4f795d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dbe7c9ae-b27c-45a1-85be-e89e2b4f795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_193925a0-4b63-49a2-a611-ad61fa541e20" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable_193925a0-4b63-49a2-a611-ad61fa541e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_20ca94cf-9548-400a-9518-98c6b4b566ce" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_20ca94cf-9548-400a-9518-98c6b4b566ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_5af361e5-18bf-4818-ab2a-90ad58e65854" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross_5af361e5-18bf-4818-ab2a-90ad58e65854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8bb0442f-3714-49a5-bbb8-6d7bfc5baad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward_d0e77caf-fbd6-43f9-9696-090a7456d24a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8bb0442f-3714-49a5-bbb8-6d7bfc5baad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5cc7f68-4c9e-4818-bd52-7478d14bb853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5cc7f68-4c9e-4818-bd52-7478d14bb853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8686e679-2776-4d30-a325-1b5b836bbc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8686e679-2776-4d30-a325-1b5b836bbc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f476c116-14ad-495b-bafd-dded1ea9caaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f476c116-14ad-495b-bafd-dded1ea9caaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4ba4294-7c1b-4359-adf0-80a55ceeff54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a4ba4294-7c1b-4359-adf0-80a55ceeff54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61bd5879-0de8-477c-a851-a44870b0f377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f844d4a8-afe3-45e2-b97b-3be001da9bb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61bd5879-0de8-477c-a851-a44870b0f377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_73ed2d26-81f7-48c4-a33e-7a4d57807a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_73ed2d26-81f7-48c4-a33e-7a4d57807a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06d8020d-56af-4ebf-a187-83390f7c4e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06d8020d-56af-4ebf-a187-83390f7c4e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5865eb8-43a9-47ac-aa82-0fd0ccfb1b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a5865eb8-43a9-47ac-aa82-0fd0ccfb1b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be4c5d0a-1e7d-4da7-adb9-90dd049e2a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be4c5d0a-1e7d-4da7-adb9-90dd049e2a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_544f503b-baa7-4082-a316-382095e9ea9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_544f503b-baa7-4082-a316-382095e9ea9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f22ab28-efa8-49d9-ba89-bf747b8ca736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c1ecfc2b-2dfe-4df4-a840-2e374749b3db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f22ab28-efa8-49d9-ba89-bf747b8ca736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cd628d58-1439-4661-85e0-4463316af75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cd628d58-1439-4661-85e0-4463316af75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_266359ce-8357-4448-a37a-ab01f805c250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_07d914d6-0c07-492e-b944-d507b56269ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_07d914d6-0c07-492e-b944-d507b56269ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3bc72bc-cb97-4334-8517-ffde081d23f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f3bc72bc-cb97-4334-8517-ffde081d23f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fe3a966-22e0-4fde-91de-6d9c534a7f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fe3a966-22e0-4fde-91de-6d9c534a7f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_93775c8a-0d98-4459-ba73-9e10fa0c3d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_eb4b8abc-9b09-4415-a16a-d8c475bc0351" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_93775c8a-0d98-4459-ba73-9e10fa0c3d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da335218-3317-4352-ba20-ad57becbe358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da335218-3317-4352-ba20-ad57becbe358" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c697e31b-f315-45a2-a07c-0d0532a9b877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:to="loc_us-gaap_AwardTypeAxis_c697e31b-f315-45a2-a07c-0d0532a9b877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c697e31b-f315-45a2-a07c-0d0532a9b877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a3eec907-2f0e-46f5-a07c-293068d08164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a3eec907-2f0e-46f5-a07c-293068d08164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b2546361-b265-44b1-95b1-ab9c90201735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b2546361-b265-44b1-95b1-ab9c90201735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9e2368db-4a75-4995-9d75-74138a7af81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_PerformanceSharesMember_9e2368db-4a75-4995-9d75-74138a7af81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a64a3e8a-1853-440e-8845-57d98df3647a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_us-gaap_EmployeeStockMember_a64a3e8a-1853-440e-8845-57d98df3647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NonemployeeStockOptionMember_8a6c050d-0d4a-4019-b6f0-26da7f65aa94" xlink:href="gh-20200630.xsd#gh_NonemployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4d05722-6369-430c-b034-97be982d2f6e" xlink:to="loc_gh_NonemployeeStockOptionMember_8a6c050d-0d4a-4019-b6f0-26da7f65aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d498e106-5598-4ed5-918d-d27ca11cc458" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:to="loc_srt_RangeAxis_d498e106-5598-4ed5-918d-d27ca11cc458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d498e106-5598-4ed5-918d-d27ca11cc458" xlink:to="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18f145e4-9fb5-4871-8f6b-c0f5102d7cdc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:to="loc_srt_MaximumMember_18f145e4-9fb5-4871-8f6b-c0f5102d7cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1cd6c5bf-ea2a-4842-80d1-777ae38666b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b66fe56-b4cd-4bbe-a487-829b7d9810cc" xlink:to="loc_srt_MinimumMember_1cd6c5bf-ea2a-4842-80d1-777ae38666b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f469abcc-ed4b-41df-9e53-89443b624dc2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:to="loc_srt_TitleOfIndividualAxis_f469abcc-ed4b-41df-9e53-89443b624dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_f469abcc-ed4b-41df-9e53-89443b624dc2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_14a591a8-6a05-4d44-b90d-ba51c4c777f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:to="loc_srt_ChiefExecutiveOfficerMember_14a591a8-6a05-4d44-b90d-ba51c4c777f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefOperatingOfficerMember_984cbb11-4bba-4867-99a3-a0f27275dfba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_50880c81-e54f-4bae-b827-06d5478ebcdf" xlink:to="loc_srt_ChiefOperatingOfficerMember_984cbb11-4bba-4867-99a3-a0f27275dfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_02376776-4c97-4c76-93fc-d77d60aa79c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ba6248f1-e643-4c46-97eb-f708f0fb3664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ba6248f1-e643-4c46-97eb-f708f0fb3664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c858372-0264-4cdd-bbbb-a39fe31c6d5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c858372-0264-4cdd-bbbb-a39fe31c6d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_587e8fb6-e3e6-40c7-970d-919742101d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_587e8fb6-e3e6-40c7-970d-919742101d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b20159af-3820-4a6a-ab5b-f77ea9295a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b20159af-3820-4a6a-ab5b-f77ea9295a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b87ee8cb-8bf0-4598-8cd9-120ac57783ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b87ee8cb-8bf0-4598-8cd9-120ac57783ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_2b566ec8-1caf-4aac-92b9-93d3b3f45d4f" xlink:href="gh-20200630.xsd#gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross_2b566ec8-1caf-4aac-92b9-93d3b3f45d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_dca4d050-0c43-4def-a2b1-69ff10b83fd6" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod_dca4d050-0c43-4def-a2b1-69ff10b83fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6fd7cdfe-4444-460b-95d0-be6289a75a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6fd7cdfe-4444-460b-95d0-be6289a75a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_9b1cab88-9a22-4fc9-88a2-9deb1a7a7ec5" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting_9b1cab88-9a22-4fc9-88a2-9deb1a7a7ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55435cb8-024d-47bf-8823-c1d662eb010d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55435cb8-024d-47bf-8823-c1d662eb010d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4799c880-9c1d-4065-ae8f-f95333b0b7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4799c880-9c1d-4065-ae8f-f95333b0b7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9860cb47-a97d-42df-b725-e64e61f6d665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9860cb47-a97d-42df-b725-e64e61f6d665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_006c9de4-ef3b-43c8-87a9-f081f517076f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_006c9de4-ef3b-43c8-87a9-f081f517076f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20089f86-e3b3-45ba-8057-919979c91b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20089f86-e3b3-45ba-8057-919979c91b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_abd40744-1597-43e5-ad91-c5bcc7969b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_abd40744-1597-43e5-ad91-c5bcc7969b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_47ff68d1-3040-4f91-a431-3f04a948daa2" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate_47ff68d1-3040-4f91-a431-3f04a948daa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_dc2a0054-bc0b-45ba-80cd-ebbfddb0a0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_dc2a0054-bc0b-45ba-80cd-ebbfddb0a0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fe8536f1-5919-4ab3-920d-00d924005efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fe8536f1-5919-4ab3-920d-00d924005efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_af5adf9a-061d-4457-a3d9-19b17589e76a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_af5adf9a-061d-4457-a3d9-19b17589e76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_db331652-45ef-4015-9e89-6a45afe2d57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_db331652-45ef-4015-9e89-6a45afe2d57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0521715a-85a0-40f5-85af-69fcb74a5dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0521715a-85a0-40f5-85af-69fcb74a5dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_605e1d2c-b93f-464b-940c-6d3804b1ed0a" xlink:href="gh-20200630.xsd#gh_CommonStockSubjecttoRepurchaseorCancellation"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_CommonStockSubjecttoRepurchaseorCancellation_605e1d2c-b93f-464b-940c-6d3804b1ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_94310696-95ef-4f89-99be-688fd875d5d8" xlink:href="gh-20200630.xsd#gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare_94310696-95ef-4f89-99be-688fd875d5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_27aafe70-93f4-435c-ab51-3c6114a9f4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a54dff73-936a-4374-aaa9-abc98047a1df" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_27aafe70-93f4-435c-ab51-3c6114a9f4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a304ac0e-0c9d-4a19-8e06-960fe784201c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae551c62-0b48-42aa-be4e-5105c6b4c019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a304ac0e-0c9d-4a19-8e06-960fe784201c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae551c62-0b48-42aa-be4e-5105c6b4c019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b2e82277-afd6-4f19-8819-12d3aa9df60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae551c62-0b48-42aa-be4e-5105c6b4c019" xlink:to="loc_us-gaap_AwardTypeAxis_b2e82277-afd6-4f19-8819-12d3aa9df60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6de13b18-6704-47a4-8482-d31e9b6cc2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b2e82277-afd6-4f19-8819-12d3aa9df60d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6de13b18-6704-47a4-8482-d31e9b6cc2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_74b9532a-3abc-4c6b-9fec-27221b442ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6de13b18-6704-47a4-8482-d31e9b6cc2a6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_74b9532a-3abc-4c6b-9fec-27221b442ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae551c62-0b48-42aa-be4e-5105c6b4c019" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2afea3f4-9b0f-489f-b267-9c4fabcc7d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2afea3f4-9b0f-489f-b267-9c4fabcc7d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d55a5685-a78a-4870-a6c5-54736ede6eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d55a5685-a78a-4870-a6c5-54736ede6eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22b494b0-73a8-4ebc-87c6-dc9b1c5a8245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22b494b0-73a8-4ebc-87c6-dc9b1c5a8245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f1825daa-f58a-4cd6-9fe3-e1abce214ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f1825daa-f58a-4cd6-9fe3-e1abce214ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cc92098-acd8-45eb-a0bf-b555bc0a2eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_844c2dae-a079-44f5-b2df-071415ca9f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7cc92098-acd8-45eb-a0bf-b555bc0a2eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19f02479-8c4f-475b-b1c8-bc7a76dfa648" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c49e2dc5-cc53-45db-886c-3c118944369b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c49e2dc5-cc53-45db-886c-3c118944369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_fcec0cac-11c3-4ae3-9120-ca2c98aa3ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_fcec0cac-11c3-4ae3-9120-ca2c98aa3ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_7e0ec27e-b12c-4aea-9a5d-29c32eeff20a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_7e0ec27e-b12c-4aea-9a5d-29c32eeff20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_81c4895a-4db2-4c08-a3bb-066797ee8c41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_81c4895a-4db2-4c08-a3bb-066797ee8c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_7b312ab4-10bc-4025-a66d-2c0ab3766e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_ecdc3a5f-abda-403a-b16f-b5ce630012fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_7b312ab4-10bc-4025-a66d-2c0ab3766e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd018dad-db6c-46d3-9021-a5dd0f73afe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd018dad-db6c-46d3-9021-a5dd0f73afe7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05a74568-1b46-4055-abea-cedd01192366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:to="loc_us-gaap_AwardTypeAxis_05a74568-1b46-4055-abea-cedd01192366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c11d10b3-6422-447c-b9cb-558552e95e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_05a74568-1b46-4055-abea-cedd01192366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c11d10b3-6422-447c-b9cb-558552e95e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ea386c05-17f7-411f-8a85-452c5cc498a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c11d10b3-6422-447c-b9cb-558552e95e40" xlink:to="loc_us-gaap_PerformanceSharesMember_ea386c05-17f7-411f-8a85-452c5cc498a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_32bdf5c5-c4cc-4275-b776-4056e649851a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:to="loc_us-gaap_VestingAxis_32bdf5c5-c4cc-4275-b776-4056e649851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_32bdf5c5-c4cc-4275-b776-4056e649851a" xlink:to="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_68387a0a-5d68-46dd-b1db-b2905571c180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_68387a0a-5d68-46dd-b1db-b2905571c180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_642cb499-455d-4d94-84b2-cdd29d6dce1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_642cb499-455d-4d94-84b2-cdd29d6dce1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cd2cd8a7-d52d-49d9-9af7-88d6ada8e9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f22defe6-8f14-4bc5-8ce2-f09ffc8d9ee2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cd2cd8a7-d52d-49d9-9af7-88d6ada8e9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7299322b-441a-42cd-abf8-d8515fbdd880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ede1ff69-d28d-4e08-a16b-0ab72d2842a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7299322b-441a-42cd-abf8-d8515fbdd880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_5015e75e-7894-4a32-9318-a4abf81450bf" xlink:href="gh-20200630.xsd#gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7299322b-441a-42cd-abf8-d8515fbdd880" xlink:to="loc_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest_5015e75e-7894-4a32-9318-a4abf81450bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_383b03a3-feb3-4247-b34e-63df53cd05b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9107a966-bf74-461a-ae24-22edfca4da9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_383b03a3-feb3-4247-b34e-63df53cd05b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9107a966-bf74-461a-ae24-22edfca4da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13730515-7a51-448b-b2c8-56986835686d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9107a966-bf74-461a-ae24-22edfca4da9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13730515-7a51-448b-b2c8-56986835686d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13730515-7a51-448b-b2c8-56986835686d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_PrecisionOncologyTestingMember_643f7515-b599-45b6-a03d-a2a01b40c398" xlink:href="gh-20200630.xsd#gh_PrecisionOncologyTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_gh_PrecisionOncologyTestingMember_643f7515-b599-45b6-a03d-a2a01b40c398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69bc13d6-342e-4623-ac91-63da3c271369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69bc13d6-342e-4623-ac91-63da3c271369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_f3b1f677-f9a4-4488-a566-987a8e669f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_f3b1f677-f9a4-4488-a566-987a8e669f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ff3582a-449d-4a91-aa00-dd19e1b53b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e48f380f-0e72-43aa-ae13-986bf8505ce2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6ff3582a-449d-4a91-aa00-dd19e1b53b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_848721bb-f1b8-4646-bb09-0386d0fbb17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9107a966-bf74-461a-ae24-22edfca4da9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_848721bb-f1b8-4646-bb09-0386d0fbb17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c584c564-cc4c-4cc5-a1d3-3d40bf137f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_848721bb-f1b8-4646-bb09-0386d0fbb17e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c584c564-cc4c-4cc5-a1d3-3d40bf137f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationValuationofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a1bb7c8-ab3d-4a11-ab1a-c30f4d28c60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a1bb7c8-ab3d-4a11-ab1a-c30f4d28c60c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c02d0401-5014-4437-9bf8-cfe725f9d684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:to="loc_us-gaap_AwardTypeAxis_c02d0401-5014-4437-9bf8-cfe725f9d684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56f6b5ff-48a5-4fa1-b2fa-93d00af72ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c02d0401-5014-4437-9bf8-cfe725f9d684" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56f6b5ff-48a5-4fa1-b2fa-93d00af72ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_911827f1-cd9f-46c8-96db-88cab2e2a7a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56f6b5ff-48a5-4fa1-b2fa-93d00af72ed8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_911827f1-cd9f-46c8-96db-88cab2e2a7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5eebc751-de46-4b7b-98e0-d0bd04fa72d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:to="loc_srt_RangeAxis_5eebc751-de46-4b7b-98e0-d0bd04fa72d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5eebc751-de46-4b7b-98e0-d0bd04fa72d6" xlink:to="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_031582d9-44e6-4aa2-a5d4-f35ac87357a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:to="loc_srt_MinimumMember_031582d9-44e6-4aa2-a5d4-f35ac87357a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_915f5d8c-17fa-4bca-806f-d0aa40dd427a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3d258659-519b-4293-9a54-2d4d597a2683" xlink:to="loc_srt_MaximumMember_915f5d8c-17fa-4bca-806f-d0aa40dd427a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cec1dd4a-ce71-4f4b-85dc-dbe63d3daf25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8198a7a8-9d91-49ea-afb9-08de184bf391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8198a7a8-9d91-49ea-afb9-08de184bf391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0116bfd0-65c6-45ef-b499-2f42013463e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0116bfd0-65c6-45ef-b499-2f42013463e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_71f6e874-7ef0-4afd-9b95-8757ad986352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_71f6e874-7ef0-4afd-9b95-8757ad986352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_080ad47c-afd1-4f22-ac88-0a4445e7c9f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a594808-9281-4166-b635-8cefd70df068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_080ad47c-afd1-4f22-ac88-0a4445e7c9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e602e8d-668b-4442-bb9e-dca16986ad41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47c23cfe-3913-44d2-ab56-2ad20790b075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e602e8d-668b-4442-bb9e-dca16986ad41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47c23cfe-3913-44d2-ab56-2ad20790b075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f13a4195-0e89-4047-a7c5-0c913df9bbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47c23cfe-3913-44d2-ab56-2ad20790b075" xlink:to="loc_us-gaap_AwardTypeAxis_f13a4195-0e89-4047-a7c5-0c913df9bbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a972660d-8204-4281-a3de-4f04ce5fa6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f13a4195-0e89-4047-a7c5-0c913df9bbac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a972660d-8204-4281-a3de-4f04ce5fa6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e33505b5-0c50-49b9-b440-98e74ca5b2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a972660d-8204-4281-a3de-4f04ce5fa6fc" xlink:to="loc_us-gaap_EmployeeStockMember_e33505b5-0c50-49b9-b440-98e74ca5b2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_47c23cfe-3913-44d2-ab56-2ad20790b075" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d45dc093-8c4b-4e74-ae2f-a16b339b46e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d45dc093-8c4b-4e74-ae2f-a16b339b46e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ec43d0b4-9db9-45ab-bae1-14269d257995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ec43d0b4-9db9-45ab-bae1-14269d257995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4d78cf9-ee44-46a2-8f4e-ddbee52b1ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b4d78cf9-ee44-46a2-8f4e-ddbee52b1ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c65457ef-6042-483b-8cf7-f2568dc34161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c65457ef-6042-483b-8cf7-f2568dc34161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1512393d-f71d-4c9b-8e04-4c854832194e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_14001522-06d5-42d3-bc7b-159dbae9082f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1512393d-f71d-4c9b-8e04-4c854832194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0c2026de-0605-4ed1-b0e4-47e0f05aca37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d2660358-e258-4ca6-970d-1fe1bb82e553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0c2026de-0605-4ed1-b0e4-47e0f05aca37" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d2660358-e258-4ca6-970d-1fe1bb82e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c8bbaeda-9736-4336-b75f-edddb958e0c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6f165d39-3f76-4199-a84f-6ed9af5ad282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c8bbaeda-9736-4336-b75f-edddb958e0c5" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6f165d39-3f76-4199-a84f-6ed9af5ad282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636ef111-87c8-411f-a5c5-6d6a70d69e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c8bbaeda-9736-4336-b75f-edddb958e0c5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636ef111-87c8-411f-a5c5-6d6a70d69e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_915ff48e-155f-4d89-b86f-bd501f93d428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7d5c7129-8e15-4591-b731-36674082c248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_915ff48e-155f-4d89-b86f-bd501f93d428" xlink:to="loc_us-gaap_ProfitLoss_7d5c7129-8e15-4591-b731-36674082c248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0d126f5c-4407-477e-b324-77467225d0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_915ff48e-155f-4d89-b86f-bd501f93d428" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0d126f5c-4407-477e-b324-77467225d0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5a370aed-b4aa-4117-b8bd-22f24ce801f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_915ff48e-155f-4d89-b86f-bd501f93d428" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5a370aed-b4aa-4117-b8bd-22f24ce801f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_82eecc50-bf83-4b33-91e8-64d4b6d3f5cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_915ff48e-155f-4d89-b86f-bd501f93d428" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_82eecc50-bf83-4b33-91e8-64d4b6d3f5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9c12102a-e6af-445a-917d-1ccf453d140d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_915ff48e-155f-4d89-b86f-bd501f93d428" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9c12102a-e6af-445a-917d-1ccf453d140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9cbcb715-e052-4a71-8733-f78870173021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7dd10d36-55d6-4705-b698-ff163c91565f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9cbcb715-e052-4a71-8733-f78870173021" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7dd10d36-55d6-4705-b698-ff163c91565f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7dd10d36-55d6-4705-b698-ff163c91565f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bd4e4ccb-d600-4d8f-9669-89b811ac0cfb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e834c74a-6ccf-4b9a-be91-025b96eb56fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e834c74a-6ccf-4b9a-be91-025b96eb56fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1e007837-1c64-4262-bd19-9cf33991b89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1e007837-1c64-4262-bd19-9cf33991b89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_bb0083e4-0b99-4bc2-ae32-2a9fa7f98a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_PerformanceSharesMember_bb0083e4-0b99-4bc2-ae32-2a9fa7f98a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_70955525-e2ed-4b4f-927b-f593e84abd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_EmployeeStockMember_70955525-e2ed-4b4f-927b-f593e84abd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_56cca323-7866-4e9f-862d-d005d614d2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dad2291a-e622-479f-b7fa-1bebf709166d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_56cca323-7866-4e9f-862d-d005d614d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06ed70e6-8d4c-4a23-aea1-26a1bf2f63f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7dd10d36-55d6-4705-b698-ff163c91565f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06ed70e6-8d4c-4a23-aea1-26a1bf2f63f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ffa2409b-c746-49aa-ba38-1f5d068d4a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_06ed70e6-8d4c-4a23-aea1-26a1bf2f63f3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ffa2409b-c746-49aa-ba38-1f5d068d4a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gh-20200630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c74c6d3e-6046-43cb-be0a-64ca0f9678a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2de76129-e606-4f76-ab22-39d80af32aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c74c6d3e-6046-43cb-be0a-64ca0f9678a0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2de76129-e606-4f76-ab22-39d80af32aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8c9c9495-c39e-4604-b9f8-0c9b11e771ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_935d1af5-2b9c-4fa8-b9b1-a24fc889de99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8c9c9495-c39e-4604-b9f8-0c9b11e771ec" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_935d1af5-2b9c-4fa8-b9b1-a24fc889de99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformation"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2373495c-bc3b-483e-ae2a-11e51fd46ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_42f71d30-a0df-4420-b0d4-e4d6408abb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2373495c-bc3b-483e-ae2a-11e51fd46ea9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_42f71d30-a0df-4420-b0d4-e4d6408abb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3fd04471-2696-4392-b2b8-82d48c7d9c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_326287f9-9444-42d1-95f2-151a963bb1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3fd04471-2696-4392-b2b8-82d48c7d9c35" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_326287f9-9444-42d1-95f2-151a963bb1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SegmentandGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SegmentandGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e2fd5364-a3a2-484e-b146-4952f39ab1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a6df192f-bad5-49b0-82d3-5c6de790e06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e2fd5364-a3a2-484e-b146-4952f39ab1bd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a6df192f-bad5-49b0-82d3-5c6de790e06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a6df192f-bad5-49b0-82d3-5c6de790e06b" xlink:to="loc_srt_StatementGeographicalAxis_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_94c77cb2-5a70-4069-b8a9-91b0bfbe72ef" xlink:to="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_65c5a581-aeb6-4d0f-a2ad-5410c0fa02c1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:to="loc_country_US_65c5a581-aeb6-4d0f-a2ad-5410c0fa02c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5cdce6d5-0c60-4b8e-a044-cc5221a579c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_78088043-d316-4e39-aa15-be0734c926ee" xlink:to="loc_us-gaap_NonUsMember_5cdce6d5-0c60-4b8e-a044-cc5221a579c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a625aea5-4b6d-4f73-99bf-db8921decb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a6df192f-bad5-49b0-82d3-5c6de790e06b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a625aea5-4b6d-4f73-99bf-db8921decb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5ec4e214-b00b-48f5-8fc7-24392d220ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a625aea5-4b6d-4f73-99bf-db8921decb36" xlink:to="loc_us-gaap_Revenues_5ec4e214-b00b-48f5-8fc7-24392d220ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="gh-20200630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b90f367c-593e-465e-847e-44e978d4873d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e7d8c92a-0209-42f9-a8d0-eb106ec756d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b90f367c-593e-465e-847e-44e978d4873d" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e7d8c92a-0209-42f9-a8d0-eb106ec756d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f25e0133-6c8d-4647-82dc-dd21ae4f478f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_51e6c393-85af-4fb2-8d26-bbd2c188a28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f25e0133-6c8d-4647-82dc-dd21ae4f478f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_51e6c393-85af-4fb2-8d26-bbd2c188a28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc6d2ee3-a837-4c2b-975d-15021c869395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_51e6c393-85af-4fb2-8d26-bbd2c188a28d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc6d2ee3-a837-4c2b-975d-15021c869395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a7994788-6b75-4532-9dd8-952b3650b912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cc6d2ee3-a837-4c2b-975d-15021c869395" xlink:to="loc_us-gaap_RelatedPartyDomain_a7994788-6b75-4532-9dd8-952b3650b912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_124b2132-1442-4917-996b-af5348440517" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a7994788-6b75-4532-9dd8-952b3650b912" xlink:to="loc_srt_AffiliatedEntityMember_124b2132-1442-4917-996b-af5348440517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_51e6c393-85af-4fb2-8d26-bbd2c188a28d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_43cea7bd-415f-472b-bc43-50d5251cbb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:to="loc_us-gaap_RevenueFromRelatedParties_43cea7bd-415f-472b-bc43-50d5251cbb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_0f6df865-5d1a-4e25-b58b-6c4a3ba84f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9f24c83c-14e6-45c6-b2c6-1dde0e03df3d" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_0f6df865-5d1a-4e25-b58b-6c4a3ba84f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gh-20200630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_11b274fe-2487-48e8-8135-4f34b46c24bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_58c3a6e3-b633-400e-ac0d-481a2628daa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_11b274fe-2487-48e8-8135-4f34b46c24bb" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_58c3a6e3-b633-400e-ac0d-481a2628daa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://guardanthealth.com/role/SubsequentEventsNarrativeDetails" xlink:type="simple" xlink:href="gh-20200630.xsd#SubsequentEventsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://guardanthealth.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4b935310-6878-4c75-8817-42dd3c4996be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4b935310-6878-4c75-8817-42dd3c4996be" xlink:to="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e613113-91de-4a0b-886f-7d43d4f3174e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e613113-91de-4a0b-886f-7d43d4f3174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75369d2c-cead-4935-8904-1e8aa0604a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0e613113-91de-4a0b-886f-7d43d4f3174e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75369d2c-cead-4935-8904-1e8aa0604a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4b15b957-de7d-4174-88c6-1f0a20b83ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75369d2c-cead-4935-8904-1e8aa0604a58" xlink:to="loc_us-gaap_BuildingMember_4b15b957-de7d-4174-88c6-1f0a20b83ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c6633102-f8b0-4e54-b5ac-39c180ed75ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c6633102-f8b0-4e54-b5ac-39c180ed75ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8fea17e1-4f57-4712-b38c-d6962d503882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6633102-f8b0-4e54-b5ac-39c180ed75ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8fea17e1-4f57-4712-b38c-d6962d503882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7b51a412-9cd5-4e64-831c-7a454ee3b509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8fea17e1-4f57-4712-b38c-d6962d503882" xlink:to="loc_us-gaap_SubsequentEventMember_7b51a412-9cd5-4e64-831c-7a454ee3b509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_c2c604fb-1e99-4f14-90cf-835afd3bb08c" xlink:to="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_c1f616b5-77d3-4225-8569-a9099ff2dc6c" xlink:href="gh-20200630.xsd#gh_NumberOfOperatingLeasesLeaseNotYetCommenced"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_gh_NumberOfOperatingLeasesLeaseNotYetCommenced_c1f616b5-77d3-4225-8569-a9099ff2dc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_18e95c6a-cfaa-465f-b00b-434c6349ebcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_us-gaap_OperatingLeasePayments_18e95c6a-cfaa-465f-b00b-434c6349ebcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract_a067d9a3-48ff-4a22-8182-faf94f805d33" xlink:href="gh-20200630.xsd#gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract_a067d9a3-48ff-4a22-8182-faf94f805d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_cfa09f60-52ff-4d5e-90a7-971ba0865dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a4966e6c-ebad-4d75-a054-7c2244d7225d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_cfa09f60-52ff-4d5e-90a7-971ba0865dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>gh-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:gh="http://guardanthealth.com/20200630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gh-20200630.xsd" xlink:type="simple"/>
    <context id="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i67ed747d77784f589faa4a5f85f01457_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icccb78a249d8444998f95593e619a75a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i887b578e7d524b4ebef1f7577dec56b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i66c1ec3f9b2e4d6598a8957cb05b297f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i54d30e5743544cc491322305e37032f1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie11103427b6f4fcdb465ffb3518dbc03_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i61571b0d7df44691a978692e9978913e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6d5eca2f8beb48ab8fa5fdaf8eb8348a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icd0533482d5645d989843fb090261fd6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3306441994cd4d6b9272a0486826de35_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i404d165872a34298a67e1be6b55bbb3c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i93fffc7829f64f9eb628786736a5a649_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ida600c4d3f69417dac19667d2cea0b78_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0d98dcdfd415452e90b92f303d33161e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icd582379ae154944b83cf4f0429747ef_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i58e4ca00724742b3ad83e062217f6ec9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia759beb2854d4b8e94e0d88280e30e87_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7596a4a43a214ae283198a28115a4899_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8fe01ddc5547497bb9cbffefe0198307_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4d7a9e78e81243f09669f88dac612492_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic6eb90faf2794203b3bd8684e7abdab9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i90fb72b236d249d284285a90f9c10645_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if1c8f7efb1f049aa933ce256d441e6aa_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2dd93329e3124a4b940d74fa7cce7db9_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8c2897b34de54e7d8a1d5c0a099fd838_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8e1e52d6991e406a945e19f8079e528c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i826d38b657564fee8d0b4fdd0b31c604_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie0e090bb4ef1452aad2ba2b2d002cd6d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i785c17ba787c420ab28a1c4b62223ac2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ied3d621b157a42a4ba32f5a8491ac8e0_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if2bed3171e1440e4b9298bc889bbc683_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0a218503f7ab4de98bcdbbd19a9d6c72_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f0a92614b8042f3a19b56e9aa58d828_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i72a8421103da4d199b14bf4d4fbc932f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf45c465431f4c298552489e3699d202_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9626cc3ab4204665ab265b453bd8bfa9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i53668203006e40778ac4cb8f0df51122_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7bbcbc55c0214bec9a6ff8da8de77f65_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5ffdccad09f848609944eaf060120cb2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iec3fec4b948243e9a496fe3f77b7ffee_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if388d8698b394ac4be606c9d2c0a3489_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic9093c7f6ef64431992d79c742b037e8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4db009fab413493492c16a5df3a37c99_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i34fbf1ff326b4e6fad49301c40e11116_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iedda39033da64349a0b5b298b12b996f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9f43eb815ebe4c3591221b47337b07a4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa2bdf0b5a9940e1a30cb4c26fe72fc7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icacef251d63148388d9668c06174a001_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6343d0bae78b4914a6ff8844d8406e5d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0bc53cde634d4b8f99ba99c6d5a09cbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201807Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id4a8454cd7564023a381bc1508d50929_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i23eca4810bb642bbaed1dfe851d947c3_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibc46147d3eb644e2931be9db99437ce8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i99b5f92b87414a408b2f164b39aa615c_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30305f98796b4fcca95cd1f896a623dc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0b42c1beed4e4da581bb9585e8272830_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia1c3337f5d59424e96a59f60dfdde148_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ida41699b64f44ef0b7744e4cfe85a445_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iceda03e5ad2c4312bc298cbbc0900364_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i468f19c62c24453a865e318ab9ae077d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i87b8d948d26b4427bf5fba3c70b183fb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibc52b81b9be544c2ad19a695298b389c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie0f9c70752694d2e9ac53b525ded966d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id883a12b90d8439b97224daeaac7b8b7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i33e3aa6b28344bb5acaedc108f74aed7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i69370ff4c9114ca2beb444f079abcd90_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie6a2fe3c28ec43dbb430a92bb0b27a35_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia75cf41ebff4424583eb30543c5a9ed7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8914a60aeb34d5cbf1aa6e554ff0514_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0fc08dd4ea5642c4a9d385ae69096000_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ica7dedd6767d44efaea5866821f7622f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="icdfe70fa79e1446d86a8d5ad87a71189_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib64327946d8e47c7ada4e42959049276_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4ceb1e91ef3f4683bec1451e6e849728_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16f8de2202de40c1b72732f8a439a758_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iddcfbe838a4a477a9862d666a76f8ece_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4f82709e3c8482f9ce096c69ea147a5_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i5e54f325c5224e52b4b39dbe334295fe_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i678325a887e8435ea4d1cfd5c6e8ff5f_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i6da5a0d81b1d4f54b60329c88d1ec928_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ieb9eee4d278c492880775de12a0d66be_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i31c0d23c373e4a908c4afb6361fb820c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iee98c0531e114acf831a0fba5e0f8fd1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gh:SoftBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia2571d7c639c4caa8ea6a33dba9c80e7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:SoftBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4054d2241aef4c2ba3378622a152eb57_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gh:GuardantHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1582366d96764e628ee3c6fc355be309_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gh:GuardantHealthAMEAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibeca758827ed4d90be26d059db3913b8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib10ea8dacf834b25a24c95505a7ad3ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9aa0e810ec7047b19bafc497d6b7e021_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i33b66109089f4987960aa78d1f42647c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i545b9794576a4b6294dc59d727bc8cbb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7dc6585a30ea4320b71e0d5e211a58bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89ededa0af6544088fe566e02b31a759_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i84f93a110ee94c85804eabd73676b498_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibae9bbbae4e046c2bb0f04e87dfc13df_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ica84e8b91ec84cb3882f7bb95e6fa3a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i898f46836620466a8ea84a0116365f96_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia3f2443552e3424c9cbf516e74b17aa4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1748888fa5b94b3fa36d1f69f3d04c7a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id1a742dbb670437194ce13edafd7abd7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i370642be93cb4475a9cc1be521e0f456_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifffa3df8778245cbbf40df31c03d6572_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if118daccbf7d4722ae57d06c7ab08a96_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5ca828071cf24136a3e534de37d96e1e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i69ddc25f26d44b86af3c9495e4039373_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i16ba315eedea40c1a18129a03aa19b9c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i31f4635a39a149c0ba7e63b5acf39b3b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i599892da63584709afb69f4bfb29d368_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic7726079bb25453e958c1da1ddfff388_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1cc2234ad133449eae25a7cb3ee62b6d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id3accfc27a1b4335902ce8b5195b1631_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i396f1e67135f4846b62ba49dd35eb38b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia54b93d476704da994b4dc2cdf71eb94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d2218a15c7148cbb392058e26e2920d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i038f2a7219e747d28931767d8cf4ec43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if93d426946cb489f9e4d1af7e323bd40_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93815114e38b4cd091cb874ecc2d4de4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i685b086287f742f1b900f5e38731cbd1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6b9a757a022476481b3125b0fc19f81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia9644227fc4843f1805c967861ab3dc4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i88cf4f13cbb04a52a86b045ee3dd5ea1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibadc73c134c14524b54b1dac274d9bc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae16cdf827984010a2caeb7104021835_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7128cee9cb9340a7a5e59f2f4abfc63b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i421282ed4e594c2fab6a88329510132b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i740e186b54a74d929d1a8c08b5e479b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib1a2f825e010452bab2dda62203c3a5b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7b4cbb1c832e4835bf864738425a238c_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i91b488ecc3114e4a8446d2438cd643d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba6aacb5f0774eacaab1daef8013d311_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i325614ec170f44899e673d4e7d28ca08_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i87ae71665daa44538cfa2f9ab72a47e5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iaf3c9fdf9f6945cfa0c0069b6e81a7f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icba1eb19db0641239b17259b2bba88e5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i32d14c1e755e43fc814ff44716975ef7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i25536aab95ec4b1685ab607a7f20dc01_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id9cfa151d7bf41efb5fd1ac78e966422_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i770aeb9e45ec4839b3429acb58b3fc0a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i89c44f05033a45128d13bcc19f29dc7e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d6bc51d86cf4c0fbc8f765288d22ea8_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i40d0234ffd6546dfb79d7bb499864ab5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if22d4925f07445f79dacbf83ea12c750_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i09af7f320c9b4fcd84fa1e402ca72a9b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic006391af9764d4bb2ecb0b9cb97430b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iddc782a9fb88492e99beaee2df19e086_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3b2041cc6a754cf7a43e5f90f2d8f1f9_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gh:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="icc4b06a919c94c7c9de034cc0bd35381_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0c81bcd5fd9c45d093ba54aaad507758_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i313c37eecd85486db947fb46da7fc2ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i494f839d36b341feb8f94f4b06ab22bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i671223423cb94bd8ac77d81000597b42_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iab30d7be41ac42b6aaef61bf9bfb2147_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1e9fca5442dc404d83a43b8c26016c6f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i33c6b8bbdadf44c4a7642d85455f2e93_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e95088fcf1140e1808f0690d05a8f92_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6e385c44929941159efaa1b380c02f72_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0fad1189a7cb465fa38705627b676425_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39db8210bb3a4e9b8d14f31872c89a3c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i870e208edb564cf5aaf92b0b2145c9cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia5c5a8b30538453e89c87e004c795b1e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6bf9235dd4864475b23df2375dff74b4_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4d6d3cc7ee094ad8917062d9acce7467_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:PatentandCovenantRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icc9610ec8ca94eb3a9394e0fca76debc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5ef5bc66f72741dcab51cdd2f9c4c114_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ice197852bbb64a88a0b56ea6fe444696_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gh:AssetAcquisitionAxis">gh:KeyGenePatentLicenseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3510d8a915044bd2bbd4d045d52db61f_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="id02ea36157704a95bf6f694669d5f017_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ia8512cacee254bfea1d2fb212216dd3f_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i52f3187d48da4ffda0a02a73d287d04c_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">gh:EarnOutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i2f640c6e83784ea4850b868a4ac72489_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i8e633a87d34e43728ef3713950fc0c06_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i1e4b90fbb22c4181ab782534d84b4052_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ieee5f27fc7c546a0a1c1982c3c8a2e94_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ie644dcec06b9490aba117035eebed7ea_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gh:BellweatherBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gh:CovenantsNotToCompeteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i94551a87fe774af98d538c0336237ed4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5868db3ef1f34c348c2af19ecda66e6e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1ce8429656d8474090165e7a3628b1e3_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i0e8f6b7f7cda4a31a4e20791ec53e3af_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i45b21f81c97c4197bf11064199f6a5f4_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ieb1c8dd73c8f4f9b81c94f3211ecc88f_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i142f8879551e4d50a8780dbc93bb85f2_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ie598fb3c2fa14dc9aae676f3defa865c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iac6abd95f913499ea2e0b739c5e2fd9d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1df678bb52e4460b3bbc3799bc5d17d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id12141ace9b64b28bea2fdaaf6db601b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45a7eeee673141b1a6a9a0da13e14018_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i69cd2a5c9a414203b8bae90d7516eeb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:A2018IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i050b6f2672cc4818903148e5e1bb1511_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3c1dac7222754796a0dd42751b19691a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebb665707a6f47049ff619543a4f305f_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icedca10dad7f49b48138ccb3a8b51c92_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i74c5c7aff6084ff8b5748e3367a09571_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="iacfffb20a4ae41eea78d5a346088bc97_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="idfbdc510d6c440d1b2591a18047a2615_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if9df8ef4afe54d51bb4c149ba983e328_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4a0d4e0481d84fadaad8a7fe2f5e9afc_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i599a34c262194cd695c5756264a97154_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i129bd7811c824210b6778049ea36e662_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="ie96d1c24c55f436fa86526b0018deb29_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i35b8d41685a144498da608da0700f3aa_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i669e37f9d5744052b446c5ed68ecebe5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab2c5ae4387c4af8a36849259581e3d9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b70fed4f3144ee49ada02413cd6502b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i824680c5b5434f179b86fd36d07d8763_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib4b5ba9fbebd4472beef02e1b7de1466_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifdb07b2046094271b6b1529b0c747445_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i11c24d9847164822a50d4cdd9d18c5f2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie38caa6a9f90489092e150382af25b47_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0bae9317d8ed49b284eae0dbc3a9c989_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gh:PrecisionOncologyTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib8fea26a94e94fd49f58b8b97902f6a8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id38ddeb42dc645d29e1cf520286915fe_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6ab72dcca1ef42e3ad48caa9176918f9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4cc5f9cce5c946aeb7649a2b45b18c94_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i686af8754af544d19475d9e965340c33_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i524d26cd6dab4f5bbddc78f74f78b52e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i50b9c64f08a24d1fb8df7c8b7394b5e6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0f1bb229103f423797057daa71d5576d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i26596bb7859543f4bb3f7eae23f2540b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4fe75529581b40f39abaaf5c5922067f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3a01140a4fd940ef8d161dee75a36404_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if32fff58d0554a458622af303653e269_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i12fb0e2cc01a47eca1252f58c3e04976_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i84d05573f20f452f881daacb0e2fafda_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3ee695d4440547a7bfcb36de34921acc_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id2402cd27c104ea38107f29820dae694_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i885fd3554c684c98aa5154623a11510d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iae802d49bd74496ebe815b675137dd94_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib447deb7798c4703841cfadceacfb6f2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iad98bc19a43049ad9b63d15d678d5da0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i38994038d3c544e391545c7a4e7a5037_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1238eed8c3a8409ea6755199b243129b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gh:NonemployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaf536ddb35a64f85aacee7598268259c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3323a04942704687bb2555b54314aab2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifd47da85e7de4d7fadfd20dc20f187d9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie9d2e5e2fcdf4b2c8fc419d96dc58c5d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if8dbde309aa54633a3e4375f89ae690b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i294c1765216e4c6a8e11a0d8b3daaa00_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6174d62dea8d4279975b861469129eef_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaa43e28a9ae54214be7d361b2e4321cf_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6c8ced2cd65f4b248f2b50a4b222ada8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i71599760dfd541cabf39036748115634_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i737cf94c5a8046d2a11b701014ec16db_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8dec3173cbde4f96afc4de39bf38d895_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8094e7366d1143b68620e23e39605cc1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i638ebad1fa064de89eb9cef3d781bcf3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i13a797c312c54413b66a65e0d28b0956_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2d40935270e24e809f8b781d57808fc8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i48e997052345498c87b595375bf8389a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic4547ce0781f4157886f48a25170a1bb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia2d5b67d8d024c7a948a5649bb02e25b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i952e389dbc4144349e3163b45d8a21a5_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3a05f1e0143d47aa8aac871e977a2d93_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id56241c9ef5b4e06a9097eaf342ad306_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i95d2e07d74ee40dcbd0c515fc3ac73ea_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7989738be28147c79edc5a175133e7e7_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic9c900bb63484126aeed5864a3482233_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5853898710f74fc98551c4698099ad34_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i15ab6406ad7b4d44aea212764d7260e3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie60db419cf834ec9b927bf239d7a59ab_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0bb034afda014a85b1b0e2b6b26d774f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i00416340ee41460f89b3b8e7094a4e0c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibc0fce7baca6420eadd2052f4a00b6f8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0ada0d183d4f48bf8c719b83d32cc159_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5b4a8e61a1034084959a4fd4db4b38f7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i604a260fb2ce4d20bb48257e8df58cfe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie657fc31977a42088ce4640db6c02671_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib850ca5924ca4d90bd09e86c08ec11ba_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576280</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>gh:segment</measure>
    </unit>
    <unit id="company">
        <measure>gh:company</measure>
    </unit>
    <unit id="patent">
        <measure>gh:patent</measure>
    </unit>
    <unit id="petition">
        <measure>gh:petition</measure>
    </unit>
    <unit id="numberofleases">
        <measure>gh:numberOfLeases</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN18xLTEtMS0xLTA_7a861ac8-8b80-4945-9720-c1b2133a5f6f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN18yLTEtMS0xLTA_37d8cd0c-f416-46fa-90e5-3d76c6069d9b">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN18zLTEtMS0xLTA_b13d7e5f-eb94-4fbc-b34d-a660992d6c70">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN180LTEtMS0xLTA_dc36c53d-05cb-43e9-8d4d-16d032a231f0">0001576280</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80L2ZyYWc6NzI5MTQ0NjhlYzg1NDk3Zjg0NmEwYzVhMDk3ZWM3ODkvdGFibGU6MzBmZWJkZmQwNjIyNGUyYzliMjkwMTQzYWNiODdhZTcvdGFibGVyYW5nZTozMGZlYmRmZDA2MjI0ZTJjOWIyOTAxNDNhY2I4N2FlN181LTEtMS0xLTA_e6aed5c4-b29d-4aeb-9ce6-a572044f69de">--12-31</dei:CurrentFiscalYearEndDate>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting
      contextRef="ie96d1c24c55f436fa86526b0018deb29_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjAyMQ_60fc0348-aa77-452e-b4e9-5b9e8050b4d4">P6M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting>
    <dei:DocumentType
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM3_d40db8ad-b46f-4327-a287-801055fdd530">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM4_c4792705-f207-47c5-b2a7-1650cc857d58">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N180Mzk4MDQ2NTEzNDU1_1bd82737-e9f6-420e-993c-27ed828eeaa4">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM5_212e638f-9134-4f92-99d0-c01dd9f6ba36">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM2_9e06ecf3-bdcd-4be6-ae7d-d651df1c4917">001-38683</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMx_ae05c7c0-c083-468e-949c-0c8044de14d6">GUARDANT HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6NDNkMzYxZGI4Yzk2NGVmMGJlNjRiMTZhZGZhOGRhNzYvdGFibGVyYW5nZTo0M2QzNjFkYjhjOTY0ZWYwYmU2NGIxNmFkZmE4ZGE3Nl8wLTAtMS0xLTA_f0e67844-e9e9-4e3b-b87e-a7603ff11b10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6NDNkMzYxZGI4Yzk2NGVmMGJlNjRiMTZhZGZhOGRhNzYvdGFibGVyYW5nZTo0M2QzNjFkYjhjOTY0ZWYwYmU2NGIxNmFkZmE4ZGE3Nl8wLTItMS0xLTA_b61e4572-8f59-41fa-ab0e-a7543e4e24d0">45-4139254</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzQw_bed93401-4525-4c4d-ba7b-ae58226aabd0">505 Penobscot Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM0_640a6101-66ff-49b4-bef6-3fcdb6efea73">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMy_84b70b7c-f1d7-43df-b286-e6b4dadfc176">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMz_bef484aa-8453-432b-baf4-1eb8ddbfd657">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzI4_45d65b58-cc65-4abf-adce-acaf06508175">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzM1_6a1a5a2d-1c48-4dfc-9de0-0879ac84f51b">698-8887</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzI5_a1cbb05d-4751-4c15-8ccd-f88ddabd60a4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzQx_b9ec2d13-3081-4618-b49f-0c696ab3592f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6MzgyZGU3NTRmNmQ5NDBhMThiM2MzNWNmMzk5N2VlMWQvdGFibGVyYW5nZTozODJkZTc1NGY2ZDk0MGExOGIzYzM1Y2YzOTk3ZWUxZF8wLTAtMS0xLTA_fbbf5b86-4708-45d7-87cd-d69f5f4cd1b5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6MzgyZGU3NTRmNmQ5NDBhMThiM2MzNWNmMzk5N2VlMWQvdGFibGVyYW5nZTozODJkZTc1NGY2ZDk0MGExOGIzYzM1Y2YzOTk3ZWUxZF8yLTMtMS0xLTA_ce9b5c7e-9c79-44cc-b27d-412ac847bf86">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6MzgyZGU3NTRmNmQ5NDBhMThiM2MzNWNmMzk5N2VlMWQvdGFibGVyYW5nZTozODJkZTc1NGY2ZDk0MGExOGIzYzM1Y2YzOTk3ZWUxZF80LTEtMS0xLTA_5540d737-adb2-4d1b-af6a-6b1db8b73fe5">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMzMw_756c8e48-111b-412e-a7d4-e4a17ce65d61">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6ZmQ4N2IyNGQ0OWZiNDI0NTk1NzYzMDllZDhlM2NjNTQvdGFibGVyYW5nZTpmZDg3YjI0ZDQ5ZmI0MjQ1OTU3NjMwOWVkOGUzY2M1NF8xLTAtMS0xLTA_5c731480-d38c-4d84-a95d-4c396f8d3d20">Common Stock, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6ZmQ4N2IyNGQ0OWZiNDI0NTk1NzYzMDllZDhlM2NjNTQvdGFibGVyYW5nZTpmZDg3YjI0ZDQ5ZmI0MjQ1OTU3NjMwOWVkOGUzY2M1NF8xLTEtMS0xLTA_9c3e97ef-92e6-45d1-b9ca-a6169ecff8ad">GH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGFibGU6ZmQ4N2IyNGQ0OWZiNDI0NTk1NzYzMDllZDhlM2NjNTQvdGFibGVyYW5nZTpmZDg3YjI0ZDQ5ZmI0MjQ1OTU3NjMwOWVkOGUzY2M1NF8xLTItMS0xLTA_3508687e-90b3-49c8-945d-8c36ce5271cf">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i67ed747d77784f589faa4a5f85f01457_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xL2ZyYWc6YWIxNDQ5YzRlOTI4NDFmZTljNTc1ZGQ2ZDBmYWI5NjcvdGV4dHJlZ2lvbjphYjE0NDljNGU5Mjg0MWZlOWM1NzVkZDZkMGZhYjk2N18yMjYz_b3e28998-658f-4fee-9e2a-8c1fd1780169"
      unitRef="shares">99424269</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMy0xLTEtMS0w_ed2e068a-c67c-43c9-a06f-b7de04782d5b"
      unitRef="usd">164671000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMy0zLTEtMS0w_95c9e548-1984-4967-8f6a-d8903002f386"
      unitRef="usd">143228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNC0xLTEtMS0w_372e7b66-9430-4a0b-8ac4-540b2df6c82f"
      unitRef="usd">773160000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNC0zLTEtMS0w_b2989912-9bdf-4299-97bc-58fbd90d1905"
      unitRef="usd">379574000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNS0xLTEtMS0w_159c7de3-33c0-40f3-927b-170289493fbc"
      unitRef="usd">41017000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNS0zLTEtMS0w_b39755f7-a79d-4dcc-9552-a14b1424f56f"
      unitRef="usd">47986000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNi0xLTEtMS0w_6eb491a9-0de6-4cbb-9e19-092d1f54bfd7"
      unitRef="usd">20354000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNi0zLTEtMS0w_1f0a4e77-a2ec-4aae-abb0-a22c2de01812"
      unitRef="usd">15181000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNy0xLTEtMS0w_fa720bba-df2b-4c34-b6f2-a690000fb0a5"
      unitRef="usd">11101000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfNy0zLTEtMS0w_e3dd55f3-61b9-43fc-b0d0-08c502729cd6"
      unitRef="usd">11389000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOC0xLTEtMS0w_7185081b-6046-40ad-b4d5-6975b475e25d"
      unitRef="usd">1010303000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOC0zLTEtMS0w_256b0055-5536-4418-823f-141c7a3ec6eb"
      unitRef="usd">597358000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOS0xLTEtMS0w_94471ef4-a392-44d6-b79a-0d7fb43bf323"
      unitRef="usd">146118000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfOS0zLTEtMS0w_42e13431-147c-4ff1-8c73-0757500c1e6d"
      unitRef="usd">268783000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTAtMS0xLTEtMA_d43d28a7-e121-41a3-8833-87ce31e6bbb0"
      unitRef="usd">56995000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTAtMy0xLTEtMA_6c2d5599-da6a-4956-845b-54d446996165"
      unitRef="usd">43668000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTEtMS0xLTEtMA_db51e505-9c87-4f70-9722-89fd62f669c3"
      unitRef="usd">38503000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTEtMy0xLTEtMA_53289ff8-f99f-4482-91a2-aecda41c29cb"
      unitRef="usd">29140000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTItMS0xLTEtMA_2f6072ec-65be-444a-a300-fb0a49e6164f"
      unitRef="usd">17148000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTItMy0xLTEtMA_b541fed2-3b03-4cfc-9aca-0fb55a512a41"
      unitRef="usd">8524000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTMtMS0xLTEtMA_9a74c691-a1ec-4eeb-833c-b0c1dbc29c71"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTMtMy0xLTEtMA_57fb0c51-721a-4f4f-a81c-c045a0cda32b"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:CapitalizedLicenseFees
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTQtMS0xLTEtMA_2eb1be34-849b-467f-8d9c-88d60354a154"
      unitRef="usd">55000</gh:CapitalizedLicenseFees>
    <gh:CapitalizedLicenseFees
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTQtMy0xLTEtMA_46710185-eaf5-46dd-995f-820a3fb64432"
      unitRef="usd">6890000</gh:CapitalizedLicenseFees>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTUtMS0xLTEtMA_d39f9230-5933-421b-b0e3-3f53498f96e2"
      unitRef="usd">5124000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTUtMy0xLTEtMA_af497f04-0329-4c92-8ea1-bf9595389d9b"
      unitRef="usd">4882000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMS0xLTEtMA_18023dad-efe9-408a-b72c-0ff13ac1ee41"
      unitRef="usd">1277536000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMy0xLTEtMA_1cde555c-9ea1-4403-8945-5c3668bb3559"
      unitRef="usd">962535000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTktMS0xLTEtMA_6cb5eeaa-397a-4f32-8214-9ad5edc24bc2"
      unitRef="usd">15982000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTktMy0xLTEtMA_2a74b5de-0949-4283-9061-de63c959d687"
      unitRef="usd">16197000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjAtMS0xLTEtMA_f2f9bcf1-cf99-42a3-9369-be070c03bdcc"
      unitRef="usd">18526000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjAtMy0xLTEtMA_71473908-dcde-4311-a1bd-f33783b6da9b"
      unitRef="usd">18557000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjEtMS0xLTEtMA_dd6739c6-16eb-4fc9-a297-0b847e4af24e"
      unitRef="usd">24055000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjEtMy0xLTEtMA_af9efe5f-a794-48cf-bfd8-382345f852b3"
      unitRef="usd">25703000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjItMS0xLTEtMA_b378b4d1-bdb6-455a-bfde-b59839fb3711"
      unitRef="usd">11485000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjItMy0xLTEtMA_9ac3451f-c254-4176-aa9d-8f68edf6a4c1"
      unitRef="usd">12277000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjMtMS0xLTEtMA_0068eda1-37c9-49b2-b179-7c8c1cc323d9"
      unitRef="usd">70048000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjMtMy0xLTEtMA_37a58859-5a37-4cf0-959d-375b01856dec"
      unitRef="usd">72734000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjQtMS0xLTEtMA_05640224-af0f-4d18-a9a6-b568a62e9dbc"
      unitRef="usd">41117000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjQtMy0xLTEtMA_59d0f339-4f21-4224-8528-6097adfc7865"
      unitRef="usd">33256000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <gh:AccruedRoyaltiesNoncurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjUtMS0xLTEtMA_c92c6dba-95cb-48ac-bd28-0bc59b4ae6e2"
      unitRef="usd">0</gh:AccruedRoyaltiesNoncurrent>
    <gh:AccruedRoyaltiesNoncurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjUtMy0xLTEtMA_5f66af0d-33f3-4aa3-8a26-cbad65d24987"
      unitRef="usd">6880000</gh:AccruedRoyaltiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjYtMS0xLTEtMA_60c71c34-6f45-4906-a0cc-1255e9de3863"
      unitRef="usd">1382000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjYtMy0xLTEtMA_687e9452-4dfd-44a1-b0c6-4cc0fb1cfcd8"
      unitRef="usd">1672000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMS0xLTEtMA_f08ce5ca-7cd9-4a37-99c4-0f28c9873c79"
      unitRef="usd">112547000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMy0xLTEtMA_57f123da-e902-4c80-a630-7610ebc0c552"
      unitRef="usd">114542000</us-gaap:Liabilities>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjktMS0xLTEtMA_ad3c8472-516b-4a29-9579-1b7337c4549e"
      unitRef="usd">50400000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjktMy0xLTEtMA_b667deaa-1a38-4493-bf6c-54f0667ffa2a"
      unitRef="usd">49600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE1MjM_c065b7f6-d808-4245-a6c0-386f28cd6be3"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE1MjM_d12ec10a-c671-4344-bd38-9d4cae4fc316"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTEzODg_471a09f3-a012-4633-b3ac-5f3bfd000b84"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTEzODg_d75dab48-0e2f-48aa-83ad-f6c19091b767"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0MzQ_b795cb00-d99c-42f7-ab0f-07cd9a55990d"
      unitRef="shares">99312237</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0MzQ_cad66bfb-e407-4b22-a621-6b83adecf2bd"
      unitRef="shares">99312237</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0NzY_36e533d1-898c-42cc-ab1f-7fc3258bcf58"
      unitRef="shares">94261414</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjk5YTE2MzcxM2JmYzRlODA5NGM5NTcxNWQ1MGFjMTg5XzQzOTgwNDY1MTE0NzY_915782b8-2667-4c17-98b4-b8916c58b20e"
      unitRef="shares">94261414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMS0xLTEtMA_f4e777f6-edc9-4a6a-b8a4-8d8306a25a0c"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzEtMy0xLTEtMA_10537087-edb9-4426-a3d1-db8dd01fc500"
      unitRef="usd">1000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzItMS0xLTEtMA_6c48d2f3-038f-4295-afba-399b424f4d17"
      unitRef="usd">1544373000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzItMy0xLTEtMA_27ceba86-6fb5-4517-bb8b-b3afc2e83e15"
      unitRef="usd">1150090000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzMtMS0xLTEtMA_dc0e31a2-7145-4e6a-803e-8bda783c3cd8"
      unitRef="usd">5392000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzMtMy0xLTEtMA_788470f2-53ee-4cce-815f-3bd3351c2190"
      unitRef="usd">1111000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzQtMS0xLTEtMA_56bd6dad-afc1-4313-8fbc-4a2923a92391"
      unitRef="usd">-435177000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzQtMy0xLTEtMA_d28bb67f-a01a-4b1c-be95-22a92048d4d6"
      unitRef="usd">-352809000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzUtMS0xLTEtMA_ff0ac429-1a7c-4ed7-82fb-49b627784ec1"
      unitRef="usd">1114589000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzUtMy0xLTEtMA_920c4e78-90d9-4c7f-b118-4b46d88f75a6"
      unitRef="usd">798393000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzYtMS0xLTEtMA_ce452ac1-4ea6-4f56-b808-b9b565812ea8"
      unitRef="usd">1277536000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMzYtMy0xLTEtMA_df61ed2a-bb24-4c44-bad0-6f9974d11aa3"
      unitRef="usd">962535000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMTU3_8233966a-2a7d-4d60-81f2-9142a99e2fc3"
      unitRef="usd">38400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i887b578e7d524b4ebef1f7577dec56b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMTY0_683f4635-0e79-4d33-8b34-015477b321dd"
      unitRef="usd">45100000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMzE3_2b2acbcc-b6a1-476e-931f-1976d18fa988"
      unitRef="usd">4000000.0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i887b578e7d524b4ebef1f7577dec56b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfMzI0_ebbee8fc-1834-4079-aa0e-c66dd20cc658"
      unitRef="usd">5700000</us-gaap:Liabilities>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC0yLTEtMS0w_9e5f8246-3fc6-4d2d-914e-4f064c8a8881"
      unitRef="usd">50991000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC00LTEtMS0w_8dbc6ff9-dcdd-4fc2-bfb7-9c1f31c3dfb3"
      unitRef="usd">42064000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC02LTEtMS0w_0494541c-bb7f-4cf1-b810-e1931758da08"
      unitRef="usd">111237000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromPrecisionOncologyTesting
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNC04LTEtMS0w_75366ef3-f3e6-4c01-b8bd-fb78c6842ba0"
      unitRef="usd">70901000</gh:RevenuefromPrecisionOncologyTesting>
    <gh:RevenuefromDevelopmentServices
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS0yLTEtMS0w_fd074cd6-93f6-4365-8e67-f09237c7ebba"
      unitRef="usd">15344000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS00LTEtMS0w_d15eda54-c4e3-463c-bebd-317b702ed2bb"
      unitRef="usd">11911000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS02LTEtMS0w_b38316c5-f8c9-4e1b-bbdd-e705960f807d"
      unitRef="usd">22608000</gh:RevenuefromDevelopmentServices>
    <gh:RevenuefromDevelopmentServices
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNS04LTEtMS0w_043d6804-878a-4a4f-9acd-71364f5f9062"
      unitRef="usd">19729000</gh:RevenuefromDevelopmentServices>
    <us-gaap:Revenues
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi0yLTEtMS03MjA_1d05125c-7784-4bd3-97b1-d6653120a359"
      unitRef="usd">66335000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi00LTEtMS03MjI_a9af6032-d5ee-4d27-985c-2041dec51d86"
      unitRef="usd">53975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi02LTEtMS0w_c6c14d8a-cf65-440c-9b07-f3d03a1bea6f"
      unitRef="usd">133845000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfNi04LTEtMS0w_6c406c2a-c77a-4978-a531-27ec47a2f995"
      unitRef="usd">90630000</us-gaap:Revenues>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC0yLTEtMS0w_d64d7a88-0ea0-4ef7-93d4-38cf6c59ba24"
      unitRef="usd">17809000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC00LTEtMS0w_5b8200da-fa5c-41b8-a293-559e0a6b08c1"
      unitRef="usd">14650000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC02LTEtMS0w_7db61589-4ad6-4355-a0c7-274659ab548c"
      unitRef="usd">36000000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostsofPrecisionOncologyTesting
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOC04LTEtMS0w_dd6240be-38f8-4c8c-97b0-006c1bd7c085"
      unitRef="usd">25673000</gh:CostsofPrecisionOncologyTesting>
    <gh:CostofDevelopmentServices
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS0yLTEtMS0w_4bdb9c82-6d76-485a-80f4-3b6ac4669605"
      unitRef="usd">4626000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS00LTEtMS0w_a7989bea-9e7f-4735-a5f1-29df61ac1f79"
      unitRef="usd">2183000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS02LTEtMS0w_aac6fefd-f87e-497f-a530-3bdfa7162c44"
      unitRef="usd">6941000</gh:CostofDevelopmentServices>
    <gh:CostofDevelopmentServices
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfOS04LTEtMS0w_790ce941-2597-4b08-9566-3fdaef1996f7"
      unitRef="usd">4695000</gh:CostofDevelopmentServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtMi0xLTEtMA_2306da8b-a470-41fb-b39a-a66556edc621"
      unitRef="usd">36319000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtNC0xLTEtMA_194ebd86-35c1-4f3e-833e-8b299561a697"
      unitRef="usd">19532000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtNi0xLTEtMA_8e266049-c7b5-4a53-97d8-70659bdb2d4d"
      unitRef="usd">73335000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTAtOC0xLTEtMA_11606025-f7e8-4b6b-ae98-d6577c0811e7"
      unitRef="usd">35848000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtMi0xLTEtMA_8c33668d-910e-4036-86a9-c947f26dcfe4"
      unitRef="usd">25015000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtNC0xLTEtMA_93f3f7ac-8efe-45ef-99b1-02866005fcc9"
      unitRef="usd">19439000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtNi0xLTEtMA_76975ac9-8a22-4211-8dff-448d4cceb2f7"
      unitRef="usd">50130000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTEtOC0xLTEtMA_12d84fc4-dfa6-4038-9bca-30c7d25ab869"
      unitRef="usd">37246000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItMi0xLTEtMA_f9d34371-fd30-4e62-bddd-e6bc19f1a29f"
      unitRef="usd">37186000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItNC0xLTEtMA_7870976a-f32d-4a49-8eae-eae2e5665092"
      unitRef="usd">13439000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItNi0xLTEtMA_1c701e92-80d1-41b0-8d39-25d6ef677afe"
      unitRef="usd">56971000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTItOC0xLTEtMA_a3513027-f462-4db9-b4cd-400b9b8bcff4"
      unitRef="usd">26100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtMi0xLTEtNzI0_713f1931-b7c6-493f-b9a0-8e88150c43cd"
      unitRef="usd">120955000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtNC0xLTEtNzI2_5171b0af-70b2-43dd-91fd-0933a7f0b2ef"
      unitRef="usd">69243000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtNi0xLTEtMA_9648a4fc-9594-4de1-8ddb-701dd3b024a3"
      unitRef="usd">223377000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTMtOC0xLTEtMA_37b1168a-a34d-49d3-b081-754f25dae740"
      unitRef="usd">129562000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtMi0xLTEtNzI0_99d3d5ef-7742-49d6-a50e-f3dbd7b168e4"
      unitRef="usd">-54620000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtNC0xLTEtNzI2_959ecfbe-c55f-4d63-a11d-043abbad6b0a"
      unitRef="usd">-15268000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtNi0xLTEtMA_fe0c6471-465a-45c0-80d1-5bd5e7917cdc"
      unitRef="usd">-89532000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTQtOC0xLTEtMA_f001ed84-0e6e-4255-8e7c-4dbfc47d9dff"
      unitRef="usd">-38932000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtMi0xLTEtMA_14c2d6b4-fa9f-4c41-ae89-742b470252f0"
      unitRef="usd">2640000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtNC0xLTEtMA_2ace9801-d7d3-4dbc-bb24-9c88970c292e"
      unitRef="usd">3099000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtNi0xLTEtMA_12fcc53a-12ba-4c07-a9b2-865e92968477"
      unitRef="usd">5958000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTUtOC0xLTEtMA_07a8a35c-08c2-463e-9d11-6d4f3b5149e0"
      unitRef="usd">5584000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtMi0xLTEtMA_66bb3aa7-62a9-4438-a770-9af89cf1d815"
      unitRef="usd">10000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtNC0xLTEtMA_1c964775-d5d2-4919-b489-153b0d1a01ec"
      unitRef="usd">287000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtNi0xLTEtMA_ad629ac5-402c-4020-9839-b550c0dd3518"
      unitRef="usd">22000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTYtOC0xLTEtMA_1ffdc1c7-7e16-4755-a25e-d3c086abb84a"
      unitRef="usd">580000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctMi0xLTEtMA_b92132da-6979-43b5-935f-e7e2f6037380"
      unitRef="usd">2285000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctNC0xLTEtMA_6fada179-98ad-4ea2-824e-0ff82fa84295"
      unitRef="usd">-51000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctNi0xLTEtMA_7aa83ec8-c2bb-4803-814b-9602a1a8b0ec"
      unitRef="usd">2076000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTctOC0xLTEtMA_9677c99c-513f-424b-8336-f418fe98dff5"
      unitRef="usd">96000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtMi0xLTEtNzI0_c71dd00c-7ed1-4ec9-bd1e-7034fafa6348"
      unitRef="usd">-49705000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtNC0xLTEtNzI2_a9ca9382-6f15-489a-bff1-88d072a19aac"
      unitRef="usd">-12507000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtNi0xLTEtMA_8c7d4e06-b120-4e4f-b7bd-f460abb545f9"
      unitRef="usd">-81520000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTgtOC0xLTEtMA_5d34d12a-a7af-49a0-b09d-983d91070bcb"
      unitRef="usd">-33832000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktMi0xLTEtMA_a43a2eea-b15e-4de1-b8dd-601800528667"
      unitRef="usd">34000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktNC0xLTEtMA_30b9a027-e4d3-495b-85c1-7781ca039ce6"
      unitRef="usd">-1207000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktNi0xLTEtMA_3548265b-5ba6-45af-85c1-df9426a06705"
      unitRef="usd">48000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMTktOC0xLTEtMA_a3faaef9-7825-4bf1-9f03-ca2b2a908e2e"
      unitRef="usd">-1181000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtMi0xLTEtNzI0_7ae53bcb-9066-48e5-9c1e-143fff956274"
      unitRef="usd">-49739000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtNC0xLTEtNzI2_b756ac51-7946-4fb3-9ee4-fba338847059"
      unitRef="usd">-11300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtNi0xLTEtMA_c6cfeaa3-f2b5-42e7-9727-6f938e20fd23"
      unitRef="usd">-81568000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjAtOC0xLTEtMA_bf9b8750-26ab-4c81-8a6e-d32bab1b0f38"
      unitRef="usd">-32651000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtMi0xLTEtMA_3fbbed0a-ac4c-45d2-8652-68edc3609113"
      unitRef="usd">4900000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtNC0xLTEtMA_7fddc32c-243e-448f-a4f9-5269d4f5bb0f"
      unitRef="usd">300000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtNi0xLTEtMA_7c8cd13c-c263-438a-a9d8-70ee3edc00e9"
      unitRef="usd">800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjEtOC0xLTEtMA_66770d39-23bf-4c47-82cd-695060636db4"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItMi0xLTEtNzI0_74121496-d321-43bc-90ee-2ed06493f23f"
      unitRef="usd">-54639000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItNC0xLTEtNzI2_7a83bae1-779b-488e-8f7b-39a3c6c585c5"
      unitRef="usd">-11600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItNi0xLTEtMA_302ef6f8-54c1-4c9c-b743-1865969674a8"
      unitRef="usd">-82368000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjItOC0xLTEtMA_fe4fc309-e88d-44e2-be44-86cbcfec4101"
      unitRef="usd">-37651000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtMi0xLTEtNzI0_808490c6-b1ee-4e53-8342-8b03021fecae"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtNC0xLTEtNzI2_b1d10dbd-6501-4c27-a3aa-3f3c3a608204"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtNi0xLTEtMA_792197c4-fca0-480f-94d6-96a3dc75ed64"
      unitRef="usdPerShare">-0.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjMtOC0xLTEtMA_0aaf162f-4d4b-4bb6-9af2-be22a55003f3"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtMi0xLTEtMA_3a246fa7-e9b2-437d-ba9d-3d42177c0fed"
      unitRef="shares">96011000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtNC0xLTEtMA_0b2a408e-2c63-43b4-8df9-851b2ae676a5"
      unitRef="shares">89036000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtNi0xLTEtMA_2f18180c-5d49-4e6f-ae1f-814660621a78"
      unitRef="shares">95196000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yMi9mcmFnOmE0YTcyYTc4ZmFjZTQxM2RiMDk3ZWI5YTZhYjdkMDFkL3RhYmxlOmNiMjJlYWQ1N2I3YTQyNDFiMTY2NTBlMTAwNzFlMGQxL3RhYmxlcmFuZ2U6Y2IyMmVhZDU3YjdhNDI0MWIxNjY1MGUxMDA3MWUwZDFfMjQtOC0xLTEtMA_51552e7b-a6cf-4268-82c5-a3c02c9c1019"
      unitRef="shares">87494000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy0yLTEtMS0w_79ec2120-9962-4c76-9f63-5a53a60ee0ea"
      unitRef="usd">-49739000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy00LTEtMS0w_03a7fb46-4b81-45a0-80ee-a6491eb0186f"
      unitRef="usd">-11300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy02LTEtMS0w_1642a401-da6e-478d-81d4-7a20e9cbc568"
      unitRef="usd">-81568000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMy04LTEtMS0w_9f813005-f153-4830-802b-23d1d8a65ead"
      unitRef="usd">-32651000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS0yLTEtMS0w_133463b2-66c5-495f-b3ac-ed725cf46c84"
      unitRef="usd">-2338000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS00LTEtMS0w_68bf9520-1c50-4ca4-9b9c-91adb9b7f84d"
      unitRef="usd">852000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS02LTEtMS0w_2e56c6dd-3b0b-430f-8b05-cb59836af667"
      unitRef="usd">4233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNS04LTEtMS0w_fb9df915-1fc2-4a02-896d-9f8c376f6045"
      unitRef="usd">1337000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi0yLTEtMS0w_df4e5cd0-ce7e-4161-a681-a7de9031c11d"
      unitRef="usd">25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi00LTEtMS0w_f739efb7-bf26-4e80-ab11-f5b949e435f6"
      unitRef="usd">159000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi02LTEtMS0w_7c822f83-ba4e-4806-aa75-eddc0885d7b8"
      unitRef="usd">48000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNi04LTEtMS0w_08561bf1-79dd-4f8e-b4d5-4694b57928ca"
      unitRef="usd">90000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy0yLTEtMS03MzA_4f6dc883-f12e-4bf0-95f2-d13dedb8f2bf"
      unitRef="usd">-2313000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy00LTEtMS03MzM_67caa8dd-e795-4c9a-ac22-3e4370bdfb63"
      unitRef="usd">1011000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy02LTEtMS0w_32c29369-27e6-4319-b2df-15e1e66d5ea4"
      unitRef="usd">4281000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfNy04LTEtMS0w_c69dc040-e0f1-4aa6-aa62-b49ccb386bdc"
      unitRef="usd">1427000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC0yLTEtMS03MzA_d1ef7e32-8e2e-4a81-8672-9d0785e26180"
      unitRef="usd">-52052000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC00LTEtMS03MzM_78b0a575-f9a6-4eeb-8ef3-1fd44444a6f1"
      unitRef="usd">-10289000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC02LTEtMS0w_b42d2186-6c5d-42eb-b51d-cfc1216dfd7a"
      unitRef="usd">-77287000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOC04LTEtMS0w_e522bbcf-8719-4734-90d9-89b714fbbcb7"
      unitRef="usd">-31224000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS0yLTEtMS0w_e8cf046a-9b6f-4927-a894-9ee5b5cc5100"
      unitRef="usd">4900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS00LTEtMS0w_c534143d-9ed7-403b-9208-265ee632ed90"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS02LTEtMS0w_03d0fb75-aed7-4bcc-a2f4-83111f0dd9fe"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfOS04LTEtMS0w_f62c2f51-fa7c-4042-8e8c-ae922eb45d72"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtMi0xLTEtNzMw_ee4b13cc-396c-402c-b4af-b0f38f749314"
      unitRef="usd">-56952000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtNC0xLTEtNzMz_73a260d1-13f0-4454-aae8-b63ce84cce7a"
      unitRef="usd">-10589000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtNi0xLTEtMA_b178cf0a-456f-44f6-9c22-bf732b3f4a54"
      unitRef="usd">-78087000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yNS9mcmFnOjhkYzYxYjU1MjgxMTQzYWFiNzlkZTU1NGYyMjE0Y2ZlL3RhYmxlOmY2Y2Q5ZmJjOGY3ZDRhMjJhNmM4YmViZTBlYzRmZTNhL3RhYmxlcmFuZ2U6ZjZjZDlmYmM4ZjdkNGEyMmE2YzhiZWJlMGVjNGZlM2FfMTAtOC0xLTEtMA_94b6eb98-ea61-4b6e-945d-48c14779fc87"
      unitRef="usd">-36224000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i66c1ec3f9b2e4d6598a8957cb05b297f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMS0xLTEtMA_b6b56f13-ab68-4742-95d3-94240fb3ab5b"
      unitRef="usd">45500000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i54d30e5743544cc491322305e37032f1_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMy0xLTEtMA_2930e17b-1491-4323-9ce6-31bd5f92be5c"
      unitRef="shares">94509011</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i54d30e5743544cc491322305e37032f1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtNS0xLTEtMA_780030e8-f1a2-42c5-8dfb-744d092c2f82"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie11103427b6f4fcdb465ffb3518dbc03_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtNy0xLTEtMA_b59668f6-1da1-4573-9ebd-23d475768fe3"
      unitRef="usd">1157945000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61571b0d7df44691a978692e9978913e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtOS0xLTEtMA_8feac2aa-9e05-4a40-9aa4-6f2ab075e8a7"
      unitRef="usd">7705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d5eca2f8beb48ab8fa5fdaf8eb8348a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMTEtMS0xLTA_294a941c-1afd-4fca-a51b-e53fcafb2800"
      unitRef="usd">-380538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd0533482d5645d989843fb090261fd6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTAtMTMtMS0xLTA_39275d1e-b2e9-437a-ab51-106695793cf5"
      unitRef="usd">785113000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtMC0xLTEtMjYzL3RleHRyZWdpb246NjY4MjYzZmQ5MDk1NDY3MDljOGI4YzBmNDU2MWM2MGVfNDM5ODA0NjUxMTMxNg_875968cf-757f-4eec-9b5f-8720704e796d"
      unitRef="usd">1130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtMy0xLTEtMA_edc9e846-1666-44a1-b714-bf45d493d170"
      unitRef="shares">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtNy0xLTEtMA_40b6670b-2762-4268-9739-e636662a1444"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTEtMTMtMS0xLTc0OA_c962643d-a349-4c38-a18d-5764edb2184d"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTItMy0xLTEtMA_b766997d-db02-46a1-96af-2ad3d72fcd8b"
      unitRef="shares">412554</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTItNy0xLTEtMA_4efc4ddd-a791-40f9-aa4c-dab00a1f896f"
      unitRef="usd">2044000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTItMTMtMS0xLTc0OA_ac977816-49ba-4a19-9e37-a3a0d9533337"
      unitRef="usd">2044000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTMtMy0xLTEtMA_ed00b631-38e4-470f-9ecc-246572a1652a"
      unitRef="shares">20008</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTQtNy0xLTEtMA_fdca600c-4811-4f0b-8af4-e958014cefb2"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTQtMTMtMS0xLTIwMw_772bff0a-cdb8-4ba3-8c0c-587ac33c934c"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i77a568b319414605a2f2f1d0c2c9706f_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtMy0xLTEtMTg5_821f75ca-1030-4c7d-9b0a-b511eadc53d7"
      unitRef="shares">58164</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtNy0xLTEtMTk1_a3fc0482-170a-41be-bf77-54899a9039d2"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtMTMtMS0xLTIwNA_9845335f-e77d-4095-8cca-b1bb2364422a"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia77c46fbd6e54965b37d97e1bc9f0d07_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTUtNy0xLTEtMA_f1996948-387e-40f9-b0e7-c620f5e07fd4"
      unitRef="usd">25815000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTYtMTMtMS0xLTc1MA_63cb115c-1891-46a8-913a-0dd878487ade"
      unitRef="usd">25815000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i3306441994cd4d6b9272a0486826de35_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTYtMS0xLTEtMA_25f26031-7c09-4a71-94a8-597e6ce07dbd"
      unitRef="usd">4900000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i404d165872a34298a67e1be6b55bbb3c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTYtMTEtMS0xLTA_75de2df7-8495-4066-b1c8-9f7f382a656d"
      unitRef="usd">-4900000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTctMTMtMS0xLTc1MA_bd0eb49b-e842-4302-bbf0-35c8826952f5"
      unitRef="usd">-4900000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i93fffc7829f64f9eb628786736a5a649_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTctOS0xLTEtMA_6fced2e4-b5ec-4c35-bdcf-c15c9899421e"
      unitRef="usd">-2313000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTgtMTMtMS0xLTc1MA_ae6ce8fc-67c9-4237-b269-33b37bf8f3b3"
      unitRef="usd">-2313000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i404d165872a34298a67e1be6b55bbb3c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTgtMTEtMS0xLTA_8b2b08f5-c0a7-4f19-8fba-342829e69d54"
      unitRef="usd">-49739000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMTktMTMtMS0xLTc1MA_82b29177-a69f-45fa-9775-37999768728f"
      unitRef="usd">-49739000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ida600c4d3f69417dac19667d2cea0b78_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMS0xLTEtNzM2_974fce93-c726-4526-92a0-ee791d72fb0e"
      unitRef="usd">50400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMy0xLTEtNzM4_25a2d879-3d2d-4eaf-8129-3f5a0906e189"
      unitRef="shares">99312237</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtNS0xLTEtNzQ0_ab787df9-3dd3-41b1-9b1e-12282d927d59"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d98dcdfd415452e90b92f303d33161e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtNy0xLTEtNzQy_f20f8ba8-1e04-4368-9e4b-26c39523bc1e"
      unitRef="usd">1544373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd582379ae154944b83cf4f0429747ef_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtOS0xLTEtNzQw_fde977ce-d8fe-4533-b32c-57b3e8260c0e"
      unitRef="usd">5392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58e4ca00724742b3ad83e062217f6ec9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMTEtMS0xLTc0Ng_11817ee9-e96f-49ce-bbec-e55159a9f041"
      unitRef="usd">-435177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjVlN2YzZDRiZWM2ODQxYTc4ZGIwMDJiOWUzNDYyMzZjL3RhYmxlcmFuZ2U6NWU3ZjNkNGJlYzY4NDFhNzhkYjAwMmI5ZTM0NjIzNmNfMjAtMTMtMS0xLTc1MA_dba60839-110c-4c8b-aa98-ce62f60b4f53"
      unitRef="usd">1114589000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ia759beb2854d4b8e94e0d88280e30e87_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0xLTEtMS03MDI3_929744da-8e63-4ce5-a86d-18733218fb78"
      unitRef="usd">46500000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i7596a4a43a214ae283198a28115a4899_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0zLTEtMS03MDMx_40fb3b24-9d7e-4ad7-ace7-a4ee4a480459"
      unitRef="shares">86098474</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7596a4a43a214ae283198a28115a4899_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy01LTEtMS03MDM0_42a9228a-b7fc-47e9-a3e8-f73cf2d56398"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8fe01ddc5547497bb9cbffefe0198307_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy03LTEtMS03MDM3_464c4e6e-588f-426e-9fd5-8abd55e19f47"
      unitRef="usd">771009000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d7a9e78e81243f09669f88dac612492_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy05LTEtMS03MDQw_a66875b8-9ef7-42a6-bde2-89dc9ae1ac07"
      unitRef="usd">333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6eb90faf2794203b3bd8684e7abdab9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0xMS0xLTEtNzA0NA_ce0bf172-fee1-4300-8652-8ded97adcf36"
      unitRef="usd">-303209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90fb72b236d249d284285a90f9c10645_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMy0xMy0xLTEtNzI5Mg_5acf36f1-68af-4921-ab38-08b12609706b"
      unitRef="usd">468134000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC0wLTEtMS03MDEwL3RleHRyZWdpb246ZGQxZWMyNTZjZDk0NDBmMWFkODUzYzRiMzFjODdhMzhfNDM5ODA0NjUxMTIxMw_b7cc07a0-0e75-42fe-90ad-93b43e8f6fa0"
      unitRef="usd">723000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC0zLTEtMS03MDMx_f09c782c-bbd2-47e0-858a-df5e0913482a"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC03LTEtMS03MDM3_9dbacb74-035a-478b-a451-c2d6e0847982"
      unitRef="usd">349709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNC0xMy0xLTEtNzI5Mg_53d6a11c-cbd7-4094-a14c-6d5f31a060f0"
      unitRef="usd">349709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNS0zLTEtMS03MDMx_a0825658-2da6-44ca-a127-ddf43191d9c5"
      unitRef="shares">1531672</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNS03LTEtMS03MDM3_dec63db2-b910-4c22-a9f0-dc6ea7afd2d3"
      unitRef="usd">4992000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNS0xMy0xLTEtNzI5Mg_6a15f777-3c7c-4226-b549-d784a1fc28a4"
      unitRef="usd">4992000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia2ff694a3d5847718060acf0be9f7f14_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNi0zLTEtMS03MDMx_c291bf78-1c2a-43d2-a436-e404b3a61af6"
      unitRef="shares">1106</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNy03LTEtMS03MDM3_aa9ea29b-9804-475c-abfc-80aa9123cc04"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfNy0xMy0xLTEtNzI5Mg_b4861a8a-e549-40da-9ea9-71617f9a101c"
      unitRef="usd">13000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib002f540b0304a92b921c03edfa719fd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOC03LTEtMS03MDM3_5ec8e757-89d9-4827-80d3-1da6b1dbc517"
      unitRef="usd">3215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOC0xMy0xLTEtNzI5Mg_773ebe62-3856-4bf7-b112-ed828bea9ffa"
      unitRef="usd">3215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="if1c8f7efb1f049aa933ce256d441e6aa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOS0xLTEtMS03MDI3_3148357a-eeb0-4252-9a9a-9640108f74b3"
      unitRef="usd">300000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i2dd93329e3124a4b940d74fa7cce7db9_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOS0xMS0xLTEtNzA0NA_eef95c55-2c7d-4719-ad12-fbc5b87ecb0b"
      unitRef="usd">-300000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfOS0xMy0xLTEtNzI5Mg_7ab7a45f-15f1-4a6e-910d-0d5ff768414a"
      unitRef="usd">-300000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c2897b34de54e7d8a1d5c0a099fd838_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTAtOS0xLTEtNzA0MA_4e4d85a0-92c0-4ac7-b567-f3a7444060dc"
      unitRef="usd">1011000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTAtMTMtMS0xLTcyOTI_cd1181b6-2be5-43eb-a8ea-0c7538c686ed"
      unitRef="usd">1011000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i2dd93329e3124a4b940d74fa7cce7db9_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTEtMTEtMS0xLTcwNDQ_d8721388-d7a0-49f6-8a58-274dd9ebe979"
      unitRef="usd">-11300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTEtMTMtMS0xLTcyOTI_fdd6061e-1b4f-4764-a073-962792154c0a"
      unitRef="usd">-11300000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i8e1e52d6991e406a945e19f8079e528c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMS0xLTEtNzI5Mg_f726d930-a571-41d8-8e5d-6652bcc27ef9"
      unitRef="usd">46800000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMy0xLTEtNzI5Mg_cee0bac6-6ad6-40ae-a834-7d1436b78519"
      unitRef="shares">92806252</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItNS0xLTEtNzI5Mg_0ae410e2-1a18-4100-a367-ea5e6d0bef4c"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0e090bb4ef1452aad2ba2b2d002cd6d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItNy0xLTEtNzI5Mg_ac96b693-bbfd-4e62-bcb4-2f948da1b210"
      unitRef="usd">1128938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i785c17ba787c420ab28a1c4b62223ac2_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItOS0xLTEtNzI5Mg_c3fd6e08-67df-4306-9a8d-063929da72c2"
      unitRef="usd">1344000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied3d621b157a42a4ba32f5a8491ac8e0_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMTEtMS0xLTcyOTI_6ecb558a-c5ce-4893-a226-dc703b272e86"
      unitRef="usd">-314809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmU1OTZkMWMxOTMwZjRkZGQ5OTE0OWZkYjk2MjE0MDkxL3RhYmxlcmFuZ2U6ZTU5NmQxYzE5MzBmNGRkZDk5MTQ5ZmRiOTYyMTQwOTFfMTItMTMtMS0xLTcyOTI_91afe5c7-f994-4df5-b9e6-890ad4ded936"
      unitRef="usd">815474000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i0a218503f7ab4de98bcdbbd19a9d6c72_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0xLTEtMS03MDU0_1490105b-916c-4a1c-b6b8-e55b74a0115a"
      unitRef="usd">49600000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i3f0a92614b8042f3a19b56e9aa58d828_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0zLTEtMS03MDU5_2625f8b3-85bd-4ba5-9e68-8ad7b815a51b"
      unitRef="shares">94261414</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3f0a92614b8042f3a19b56e9aa58d828_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy01LTEtMS03MDYx_709625e8-1ab9-4cf2-b1ac-2cdf841e5906"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72a8421103da4d199b14bf4d4fbc932f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy03LTEtMS03MDYz_b6078914-6903-4554-837c-dbf237b380a7"
      unitRef="usd">1150090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf45c465431f4c298552489e3699d202_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy05LTEtMS03MDY1_026d80b2-5dfc-4993-be3d-0170ddbee620"
      unitRef="usd">1111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9626cc3ab4204665ab265b453bd8bfa9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0xMS0xLTEtNzA2Nw_b47322a3-e612-4e6c-97b8-543b271506cc"
      unitRef="usd">-352809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMy0xMy0xLTEtNzI5NA_812df8ad-5be1-43bb-b043-b92ad54a3834"
      unitRef="usd">798393000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC0wLTEtMS03MDQ5L3RleHRyZWdpb246OTM3MmIyZDg2YjBhNGI3NjliODIwMWRmOWM2MDllMTRfNDM5ODA0NjUxMTIxMA_f54e412b-efc0-46a4-899e-58afc1e28a1c"
      unitRef="usd">1130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC0zLTEtMS03MDU5_5c6a7293-01df-403d-9d46-2f17d63e48eb"
      unitRef="shares">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC03LTEtMS03MDYz_2d95c537-3b6c-4983-958e-6d50c24d39f1"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNC0xMy0xLTEtNzI5NA_e0fb7610-68f7-44bc-b19b-150fef5de0f9"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNS0zLTEtMS03MDU5_c9a7fc56-9fb5-45dc-b2ff-9e16725f93f9"
      unitRef="shares">654557</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNS03LTEtMS03MDYz_0da99e9f-090c-432f-86e1-39224e6a9587"
      unitRef="usd">3548000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNS0xMy0xLTEtNzI5NA_0685c655-d5fe-4661-a090-04152a34c626"
      unitRef="usd">3548000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNi0zLTEtMS03MDU5_1f497c35-97c1-4f79-9558-f20071309564"
      unitRef="shares">25602</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNy03LTEtMS03MDYz_9c8c9f65-c31d-4fbf-8902-5ea0003effab"
      unitRef="usd">26000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfNy0xMy0xLTEtNzI5NA_44a7fde5-a888-4430-b486-c6240c2c966d"
      unitRef="usd">26000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i261e2f9dca1e48c4be7a5e7c1a247ec0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOC0zLTEtMS03MDU5_b01ec266-2719-43a2-81ed-a1cdeef56d78"
      unitRef="shares">58164</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOC03LTEtMS03MDYz_811d3f24-d62c-413e-959c-bf774e7b6065"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOC0xMy0xLTEtNzI5NA_537ca0bc-83ab-4593-aee3-625f1b62b640"
      unitRef="usd">3956000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i53668203006e40778ac4cb8f0df51122_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOS03LTEtMS03MDYz_c409b6d5-5445-4d6e-93ed-56950756e34f"
      unitRef="usd">32153000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfOS0xMy0xLTEtNzI5NA_f75f0bae-5d08-4bf0-988e-cab9c54cd125"
      unitRef="usd">32153000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i7bbcbc55c0214bec9a6ff8da8de77f65_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTAtMS0xLTEtNzA1NA_6a565e69-3cd0-4e91-9d57-8bbee1cae2fa"
      unitRef="usd">800000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i5ffdccad09f848609944eaf060120cb2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTAtMTEtMS0xLTcwNjc_ce2c7393-9d1c-451f-ad49-aa8197094e8d"
      unitRef="usd">-800000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTAtMTMtMS0xLTcyOTQ_a75219f2-0742-4737-87a3-c028c2727032"
      unitRef="usd">-800000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iec3fec4b948243e9a496fe3f77b7ffee_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTEtOS0xLTEtNzA2NQ_b98ad217-3464-4ae2-985f-36c1e8831b28"
      unitRef="usd">4281000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTEtMTMtMS0xLTcyOTQ_0d19f9ad-5f1a-4588-9890-eaadd1be3750"
      unitRef="usd">4281000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i5ffdccad09f848609944eaf060120cb2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTItMTEtMS0xLTcwNjc_6af84bf5-d874-4088-a87a-9931b20b0d0f"
      unitRef="usd">-81568000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTItMTMtMS0xLTcyOTQ_263790b3-3015-4b4a-9ab8-ac1ef05fd5a4"
      unitRef="usd">-81568000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ida600c4d3f69417dac19667d2cea0b78_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMS0xLTEtNzI5NA_879434b4-db5b-4155-9f23-baecd902ef4f"
      unitRef="usd">50400000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMy0xLTEtNzI5NA_6e832772-f1a8-4a71-b0b2-db6b71f1a749"
      unitRef="shares">99312237</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3dbb5caba3ed46aeb395b4981e36ee63_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtNS0xLTEtNzI5NA_6d1c4474-5624-4345-86b1-adcc8a3b2517"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d98dcdfd415452e90b92f303d33161e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtNy0xLTEtNzI5NA_6f828f80-0214-4a7d-9d08-7c3899b92898"
      unitRef="usd">1544373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icd582379ae154944b83cf4f0429747ef_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtOS0xLTEtNzI5NA_1ca6f952-6c5a-4137-be91-0abe2cb07fa4"
      unitRef="usd">5392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58e4ca00724742b3ad83e062217f6ec9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMTEtMS0xLTcyOTQ_b948f117-3b87-466a-92ab-6c245712edbf"
      unitRef="usd">-435177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOmYwMWY3NzA3MzZhMzQ5ZDFhODM4YTI5OGRkZTAwNjllL3RhYmxlcmFuZ2U6ZjAxZjc3MDczNmEzNDlkMWE4MzhhMjk4ZGRlMDA2OWVfMTMtMTMtMS0xLTcyOTQ_c2256ae6-171b-452d-b6e8-0d4690dba229"
      unitRef="usd">1114589000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="if388d8698b394ac4be606c9d2c0a3489_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0xLTEtMS0w_9fcbb7e3-8abc-4ea0-9874-0b0d037ac4e0"
      unitRef="usd">41800000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ic9093c7f6ef64431992d79c742b037e8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0zLTEtMS0w_2ed8bf7f-33c0-4c9c-bd2c-8bbf43db0217"
      unitRef="shares">85832454</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic9093c7f6ef64431992d79c742b037e8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi01LTEtMS0w_ba531a9e-2b38-4778-816b-1ef3e5595864"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4db009fab413493492c16a5df3a37c99_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi03LTEtMS0w_ee34f7f2-568d-4e8e-8c0e-aa54ddbc5d27"
      unitRef="usd">764033000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34fbf1ff326b4e6fad49301c40e11116_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi05LTEtMS0w_1cedb6c7-e225-4382-b329-ee6cbca21a91"
      unitRef="usd">-83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedda39033da64349a0b5b298b12b996f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0xMS0xLTEtMA_9efe4601-e8af-471e-9505-ed28e6afaa08"
      unitRef="usd">-280799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f43eb815ebe4c3591221b47337b07a4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMi0xMy0xLTEtMA_b7473040-e02c-4242-87f7-caafe8f849ac"
      unitRef="usd">483152000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa2bdf0b5a9940e1a30cb4c26fe72fc7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMy0xMS0xLTEtMA_5edc5d22-2ec9-4112-a2ff-1c4a188e7916"
      unitRef="usd">4907000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icacef251d63148388d9668c06174a001_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMy0xMy0xLTEtMA_465bf3be-0b56-4664-9b1a-1d3a89fd2406"
      unitRef="usd">4907000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6343d0bae78b4914a6ff8844d8406e5d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfNC03LTEtMS0w_14c81155-3b53-4432-91c3-215af2fc4ce0"
      unitRef="usd">1266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0bc53cde634d4b8f99ba99c6d5a09cbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfNC0xMS0xLTEtMA_8ae0dcf9-b437-4c40-8d64-ed9765a49f6b"
      unitRef="usd">-1266000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtMC0xLTEtMjYwL3RleHRyZWdpb246MDM5OTQyZjMzMThjNGMzYmJiOGIzN2JhNWFmYzA4YzlfNDM5ODA0NjUxMTI5OA_13ce8d8e-0259-4792-b6ce-a2cef4a9dc2e"
      unitRef="usd">723000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtMy0xLTEtMA_0535ab08-5f13-4b09-9c31-113c15c1872a"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtNy0xLTEtMA_34e175d4-5d22-4700-a7b5-de2c1f9c23d9"
      unitRef="usd">349709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTMtMTMtMS0xLTc1OQ_a50fe53b-c5fc-445d-a407-a7328bf67f59"
      unitRef="usd">349709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTQtMy0xLTEtMA_1808e864-7570-4298-af86-6c884bc5875e"
      unitRef="shares">1677990</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTQtNy0xLTEtMA_d02cf2b4-01a7-4808-ba6b-f7788fe0aed1"
      unitRef="usd">5530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTQtMTMtMS0xLTc1OQ_153f386b-198e-47a2-b9c8-7b67b139fb91"
      unitRef="usd">5530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTUtMy0xLTEtMA_77e6f2b9-48a3-4a71-9884-4b6e78ad1119"
      unitRef="shares">1106</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTYtNy0xLTEtMA_cb8e5275-d78a-4b77-8830-a5aabaee0a22"
      unitRef="usd">69000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTYtMTMtMS0xLTc2MQ_dc19c799-26ae-4c4b-b9ea-260a27620787"
      unitRef="usd">69000</gh:StockIssuedDuringPeriodValueStockOptionsExercisedEarly>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i944e491f9bd14471af0acdd3d09d643f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTAtMy0xLTEtNzExNA_17de4041-19ac-4af6-8d13-e392e7756b5c"
      unitRef="shares">119702</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTAtNy0xLTEtNzEyNA_d0aa0f62-3d5d-4423-b742-60a65ffd38c6"
      unitRef="usd">1933000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTAtMTMtMS0xLTc3MTc_bbc49df4-5687-4283-a647-a9188a0e0126"
      unitRef="usd">1933000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic1151333e10a462b9c9b02c5be3629e1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTctNy0xLTEtMA_3f56d421-7e94-4346-9fa4-e5ec19b089cc"
      unitRef="usd">6398000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTctMTMtMS0xLTc2MQ_e6a88c8c-c419-46f8-8897-6a456408be0e"
      unitRef="usd">6398000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="id4a8454cd7564023a381bc1508d50929_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTgtMS0xLTEtMA_b4e954c2-de52-4cdf-a693-537bec76a07e"
      unitRef="usd">5000000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i23eca4810bb642bbaed1dfe851d947c3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTgtMTEtMS0xLTA_a45f7a72-ca16-44a1-8c8e-54f957828a0d"
      unitRef="usd">-5000000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTgtMTMtMS0xLTc2MQ_0dc446c6-64ce-4a1d-905a-7133622f3c84"
      unitRef="usd">-5000000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc46147d3eb644e2931be9db99437ce8_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTktOS0xLTEtMA_7ed3f764-3aaa-41c5-ad25-d112ec293f4f"
      unitRef="usd">1427000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMTktMTMtMS0xLTc2MQ_c11266d4-5828-4942-893a-f76c6506ef15"
      unitRef="usd">1427000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i23eca4810bb642bbaed1dfe851d947c3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjAtMTEtMS0xLTA_cac1f60f-c285-4e1b-99ea-1a2f59e2d3af"
      unitRef="usd">-32651000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjAtMTMtMS0xLTc2MQ_f65e3b6b-34c8-4dcb-9fdd-8d18fb45a66c"
      unitRef="usd">-32651000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i8e1e52d6991e406a945e19f8079e528c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMS0xLTEtNzY1_9523ddd4-e2fa-4a7b-b1e2-a27be836897d"
      unitRef="usd">46800000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMy0xLTEtNzY3_e85cd210-ec1e-4689-abe9-46d6c623f8ba"
      unitRef="shares">92806252</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i826d38b657564fee8d0b4fdd0b31c604_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtNS0xLTEtNzY5_2a7175ef-ee5c-4556-9688-eda213e4a009"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0e090bb4ef1452aad2ba2b2d002cd6d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtNy0xLTEtNzY5_c0286b14-3992-470a-bcf8-576e830059e6"
      unitRef="usd">1128938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i785c17ba787c420ab28a1c4b62223ac2_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtOS0xLTEtNzY5_6a014d9d-49e3-432e-9f99-96ccfe83f3e7"
      unitRef="usd">1344000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied3d621b157a42a4ba32f5a8491ac8e0_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMTEtMS0xLTc2Mw_1f8f4102-52b9-4898-b479-bfae80f893c1"
      unitRef="usd">-314809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8yOC9mcmFnOmY4N2MyYWIxNGU1NjRkNTU4ODI4NGY1ODNkYmRkMGVhL3RhYmxlOjU3NzY3YjljNzczYzQ5Zjg4ZjViMWY2MzQ3ODhhMDllL3RhYmxlcmFuZ2U6NTc3NjdiOWM3NzNjNDlmODhmNWIxZjYzNDc4OGEwOWVfMjEtMTMtMS0xLTc2MQ_94ff9db9-5680-4232-b02f-aa9a748c94ed"
      unitRef="usd">815474000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNC0xLTEtMS0w_88c0167f-91c4-42e2-90fd-c89420bffb99"
      unitRef="usd">-81568000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNC0zLTEtMS0w_ac152cde-898a-4656-af51-685b70a75149"
      unitRef="usd">-32651000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNi0xLTEtMS0w_4c25580d-b525-4abf-ab95-6fd6cbba90ef"
      unitRef="usd">7109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNi0zLTEtMS0w_f409c677-b4ee-4cf6-bb24-bda264fd46f2"
      unitRef="usd">5011000</us-gaap:DepreciationDepletionAndAmortization>
    <gh:AmortizationOfRightOfUseAsset
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNy0xLTEtMS0w_e56905c9-62e2-4a10-bce3-7d1f69d501d1"
      unitRef="usd">3386000</gh:AmortizationOfRightOfUseAsset>
    <gh:AmortizationOfRightOfUseAsset
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNy0zLTEtMS0w_6558d74c-2079-48e0-8a82-86fab51bb383"
      unitRef="usd">1633000</gh:AmortizationOfRightOfUseAsset>
    <gh:ChargeOfInProcessResearchAndDevelopment
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfOC0xLTEtMS0w_17b79a16-244d-4f23-b13d-07ee29cf16fb"
      unitRef="usd">8500000</gh:ChargeOfInProcessResearchAndDevelopment>
    <gh:ChargeOfInProcessResearchAndDevelopment
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfOC0zLTEtMS0w_9b8db04b-eafe-4b14-9463-861d8bb27f8c"
      unitRef="usd">0</gh:ChargeOfInProcessResearchAndDevelopment>
    <gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTAtMS0xLTEtMA_b4b6b2aa-861a-4ea7-b4b0-5e62f4a7eb37"
      unitRef="usd">0</gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty>
    <gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTAtMy0xLTEtMA_b3431c45-d2c4-40bc-9e81-7fc6dc1b1634"
      unitRef="usd">51000</gh:UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTEtMS0xLTEtMA_53d216a3-a871-4526-b082-2347690c6bfb"
      unitRef="usd">-190000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTEtMy0xLTEtMA_387afc32-6820-4b8e-b1e9-be5e9ceb9903"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ShareBasedCompensation
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTItMS0xLTEtMA_8a57a89f-381b-4b1d-bbe8-dcd1cf1c1202"
      unitRef="usd">32153000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTItMy0xLTEtMA_527d73c2-e9ae-47c7-adc1-b18f52266925"
      unitRef="usd">6398000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTMtMS0xLTEtMA_d8f9603e-1b10-4dc8-b09b-72322179e997"
      unitRef="usd">-1065000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTMtMy0xLTEtMA_e58b3866-35d0-44c8-8355-9b629afa8151"
      unitRef="usd">1276000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTQtMS0xLTEtMA_8b33117a-d3a6-4ccc-b798-05e5be03958e"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTQtMy0xLTEtMA_50c46972-61c2-4fe3-901c-517d988018f0"
      unitRef="usd">1235000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTUtMS0xLTEtMA_33a4198a-eb41-47bc-8d3f-c42b83ee2338"
      unitRef="usd">-19000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTUtMy0xLTEtMA_9fb8c807-d5df-4248-8d1d-731b85f8b003"
      unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTctMS0xLTEtMA_aaf6998b-5c9e-4ecd-b704-9ef6df394b21"
      unitRef="usd">-6894000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTctMy0xLTEtMA_94495d03-616d-4bc3-ade9-a35987e01449"
      unitRef="usd">-234000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTgtMS0xLTEtMA_466f9527-0136-4911-8e2a-fdcda83858c1"
      unitRef="usd">5173000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTgtMy0xLTEtMA_5fc4083f-3b77-4ae6-a202-d4efced60d1e"
      unitRef="usd">5040000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTktMS0xLTEtMA_80c496ff-568a-4c02-9e2e-fff8efc2e249"
      unitRef="usd">-438000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMTktMy0xLTEtMA_a065425b-1afa-4dd2-8c04-01fa63ee3078"
      unitRef="usd">-1122000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjAtMS0xLTEtMA_898ad991-0cb8-4f62-aa2b-091059ec0679"
      unitRef="usd">242000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjAtMy0xLTEtMA_84ed0a21-6be7-43bf-8aae-e37983891cff"
      unitRef="usd">1129000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjEtMS0xLTEtMA_2f16056d-6314-48e2-89ca-a75c1df6a0a2"
      unitRef="usd">-2476000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjEtMy0xLTEtMA_d3d9101f-e9c3-45ee-9730-867cb494a0ce"
      unitRef="usd">3412000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjItMS0xLTEtMA_e7d203db-c9b9-4646-aed7-c93a2bab6fdf"
      unitRef="usd">-31000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjItMy0xLTEtMA_c07059c2-780f-469f-ae67-da9dff3ef8c0"
      unitRef="usd">701000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjMtMS0xLTEtMA_e78c8f52-25fe-4cf9-9602-a26d95910bc5"
      unitRef="usd">-1820000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjMtMy0xLTEtMA_4036858c-201b-4546-a65d-559bf56d07a3"
      unitRef="usd">2939000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <gh:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjQtMS0xLTEtMA_bb5f46d6-c526-4460-bbe7-bc6e9c1b75a4"
      unitRef="usd">-3881000</gh:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gh:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjQtMy0xLTEtMA_7d3eac02-3399-4e67-b114-8d54605d5c9e"
      unitRef="usd">1435000</gh:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjUtMS0xLTEtMA_1e615d42-cf95-4262-91fa-3331428261bc"
      unitRef="usd">-792000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjUtMy0xLTEtMA_a9473f16-baa5-40ea-8bda-5f41a814e1f5"
      unitRef="usd">358000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjctMS0xLTEtMA_cc69a018-639f-4be0-8acf-bfa436bd99d5"
      unitRef="usd">-36647000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMjctMy0xLTEtMA_8bc93d31-9374-4af3-b5e3-807703981659"
      unitRef="usd">-18139000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzAtMS0xLTEtMA_16109485-b3bb-41f6-a226-517e01531d85"
      unitRef="usd">465302000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzAtMy0xLTEtMA_46d77229-acf0-4e64-8d1b-ea0499f33488"
      unitRef="usd">418841000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzEtMS0xLTEtMA_d09ba1e9-f10d-4ba6-be0c-64f83166cb7e"
      unitRef="usd">197548000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzEtMy0xLTEtMA_2fecd85d-bb71-4126-aad3-3c40a98a2000"
      unitRef="usd">129160000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzItMS0xLTEtMA_3cc8ac7e-8f86-4201-95be-0148c7d36a48"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzItMy0xLTEtMA_aca39840-d3a9-442f-a0ac-317b11c40840"
      unitRef="usd">9765000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzMtMS0xLTEtMA_00cc8cbb-e89e-416e-8fbf-a53e35516491"
      unitRef="usd">19105000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzMtMy0xLTEtMA_7713f5f1-0c12-46f2-8f24-0b9438741695"
      unitRef="usd">5752000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzQtMS0xLTEtMA_e9318a78-c598-4322-9844-9c17f9034d5e"
      unitRef="usd">17886000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzQtMy0xLTEtMA_58ebf68d-f08a-43f4-a093-a3a54d6f76fd"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzUtMS0xLTEtMA_7a043122-2eb8-43e7-9578-5433b84cd252"
      unitRef="usd">-304745000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzUtMy0xLTEtMA_facd7941-82c7-43ce-98f3-97603615aa75"
      unitRef="usd">-305198000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzgtMS0xLTEtMA_b62fc134-ee3f-4022-a962-b80652e4d17f"
      unitRef="usd">0</gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations>
    <gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzgtMy0xLTEtMA_d0ba6de0-aa8c-4ca2-b072-4faacc84d54a"
      unitRef="usd">151000</gh:PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzktMS0xLTEtMA_0f24f0c9-55c8-4b12-ae9c-d9fd78b566dc"
      unitRef="usd">79000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfMzktMy0xLTEtMA_bd8041a8-2bfd-4fb3-9848-c2449640ef75"
      unitRef="usd">62000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDAtMS0xLTEtMA_20e46bcb-20d6-4666-9fdd-f19d0c296ab0"
      unitRef="usd">3548000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDAtMy0xLTEtMA_18bb4f49-df8d-42a7-95b1-cf4706443980"
      unitRef="usd">5530000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDEtMS0xLTEtMA_bf75a48b-0ccf-4e7b-83d4-8a4183a18fe3"
      unitRef="usd">3956000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDEtMy0xLTEtMA_d7eae882-4a31-47e2-a0f0-6c092442fd5b"
      unitRef="usd">1933000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDItMS0xLTEtMA_54ab1d5e-fff7-4b19-9d51-03ed0ecc45c0"
      unitRef="usd">355730000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDItMy0xLTEtMA_23bf0189-cbdd-4559-a48f-1f77b9af0eac"
      unitRef="usd">350432000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDMtMS0xLTEtMA_40e82500-d3e8-42d5-919a-74498b8beb69"
      unitRef="usd">369000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDMtMy0xLTEtMA_a7456862-e7f7-492d-8829-e3f4e8965790"
      unitRef="usd">326000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDUtMS0xLTEtMA_e13e0ef0-8008-48ae-9618-0cb1dfc19d79"
      unitRef="usd">362786000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDUtMy0xLTEtMA_24da6c92-f750-40bc-9bbe-bcc313476727"
      unitRef="usd">357356000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDYtMS0xLTEtMA_689ba31c-93fc-4dcc-9b71-ad20edef4598"
      unitRef="usd">49000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDYtMy0xLTEtMA_54a0b000-ab8b-4ca1-a256-0c20b8a89086"
      unitRef="usd">90000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDctMS0xLTEtMA_a9b5116b-27b1-4cfb-a3a7-540fc72c1dbb"
      unitRef="usd">21443000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDctMy0xLTEtMA_b1cb3bce-4007-4a44-b2f5-6820627e505a"
      unitRef="usd">34109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDgtMS0xLTEtMA_fb23a32b-990d-43c6-b7ca-2b6083b1ae51"
      unitRef="usd">143228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9f43eb815ebe4c3591221b47337b07a4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDgtMy0xLTEtMA_081affc4-f91c-4e52-ab93-5422949e75e0"
      unitRef="usd">140544000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDktMS0xLTEtMA_3e5c489c-a26e-4dcc-b798-3afd840c5e94"
      unitRef="usd">164671000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNDktMy0xLTEtMA_ac088d38-2f95-49f3-b6e8-8dc30dd0e0b6"
      unitRef="usd">174653000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTEtMS0xLTEtMA_69b20c12-4ca0-4964-8386-97aa38908566"
      unitRef="usd">11373000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTEtMy0xLTEtMA_7c42357c-fe93-4d72-8389-af7a1c4376f9"
      unitRef="usd">1565000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTUtMS0xLTEtMA_18d00b28-9092-4682-b5a2-5f06948be19f"
      unitRef="usd">5396000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTUtMy0xLTEtMA_c789af59-b679-4751-836b-804f64bf5825"
      unitRef="usd">3874000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <gh:OfferingCostsIncurredButNotYetPaid
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTctMS0xLTEtMA_32662837-a345-40d6-8333-9c1bd193e275"
      unitRef="usd">761000</gh:OfferingCostsIncurredButNotYetPaid>
    <gh:OfferingCostsIncurredButNotYetPaid
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTctMy0xLTEtMA_085935d5-cca5-4df6-b750-ed2f5d20e970"
      unitRef="usd">486000</gh:OfferingCostsIncurredButNotYetPaid>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTgtMS0xLTEtMA_e8aedf21-3509-4dcd-b3cb-df2a0df94e3f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if2bed3171e1440e4b9298bc889bbc683_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zMS9mcmFnOmVjZTQzOGQ4YTI5YjQwYjVhNTdmNGNlYzVhNDUxNTllL3RhYmxlOmYyMWU4OWIyYTdkOTQ4NGVhOWUwNzVlNTI4YjFiZDk5L3RhYmxlcmFuZ2U6ZjIxZTg5YjJhN2Q5NDg0ZWE5ZTA3NWU1MjhiMWJkOTlfNTgtMy0xLTEtMA_e426fe05-2f26-44f4-b8c4-bc054c0fb476"
      unitRef="usd">1135000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zNy9mcmFnOjM0NGRlZmYzZDBiYjRhOTFiN2I4ZDczYmI0OGQ3M2ZiL3RleHRyZWdpb246MzQ0ZGVmZjNkMGJiNGE5MWI3YjhkNzNiYjQ4ZDczZmJfMTc4NQ_1a6a7b6a-8c16-4f04-89e5-291b36317d2f">Description of BusinessGuardant Health, Inc. (the &#x201c;Company&#x201d;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#x2019;s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's Guardant360 tests, the Company has also developed GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker-driven cancers. The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the &#x201c;Joint Venture&#x201d;) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (&#x201c;SoftBank&#x201d;). Under the terms of the joint venture agreement, the Company held a 50% ownership interest in the Joint Venture. As of June&#160;30, 2020, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, Investment in Joint Venture) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i99b5f92b87414a408b2f164b39aa615c_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8zNy9mcmFnOjM0NGRlZmYzZDBiYjRhOTFiN2I4ZDczYmI0OGQ3M2ZiL3RleHRyZWdpb246MzQ0ZGVmZjNkMGJiNGE5MWI3YjhkNzNiYjQ4ZDczZmJfMTU3NA_7aa3091c-8208-41c6-8fda-e9131d5bfe8c"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDc_7631bd13-1079-4697-a77a-38fa95fae4dc">Summary of Significant Accounting Policies &lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#x2019; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that its existing cash and cash equivalents and marketable securities as of June&#160;30, 2020 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates. The extent to which the COVID-19 pandemic will ultimately impact the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Company&#x2019;s business, results of operations, financial conditions, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside the Company&#x2019;s control, such as the duration, scope and severity of the pandemic, steps required or mandated by governments to mitigate the impact of the pandemic, and whether COVID-19 can be effectively prevented, detected, contained and treated, particularly in the markets where the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated balance sheet as of June&#160;30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020 and 2019, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#x2019; equity for the three and six months ended June&#160;30, 2020 and 2019, and cash flows for the six months ended June&#160;30, 2020 and 2019, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#x2019; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and six months ended June&#160;30, 2020 and 2019, foreign currency translation adjustment was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.230%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer A   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer B   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer C   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer D   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;"&gt;*&#160;less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses. As of June&#160;30, 2020, the Company recorded $0.1 million as allowance for credit losses. As of December&#160;31, 2019, the Company had no allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Asset Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Transaction costs associated with the asset acquisition are capitalized. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets related to in-process research and development costs (&#x201c;IPR&amp;amp;D&#x201d;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;June&#160;30, 2020, there has been&#160;no&#160;impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended June 30, 2020 and 2019, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$6.5&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$3.6&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration. For the six months ended June 30, 2020 and 2019, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$12.4&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$6.4&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration.  For the three and six months ended June 30, 2020, the Company recorded $2.6&#160;million and $4.1&#160;million, respectively, in revenue received from Medicare for samples processed in 2019.  For the three and six months ended June 30, 2019, the Company recorded $1.4&#160;million and $1.4&#160;million, respectively, in revenue received from Medicare for samples processed in 2018. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Development services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#x2019;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. The Company revised and increased its total estimated costs relating to one of the development services contracts during the six months ended June 30, 2020.  Had the Company included such additional costs in the original estimated costs, revenues for the six months ended June 30, 2019 would have been lower by $3.6 million. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. Contract assets are presented under accounts receivable, net and other assets on the Company&#x2019;s condensed consolidated balance sheets. As of&#160;June&#160;30, 2020, the Company had contract assets of&#160;$9.5 million of which $0.2 million was recorded in other assets. As of December&#160;31, 2019, the Company had contract assets of $6.2 million of which $1.0 million was recorded in other assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the deferred revenue balance was $11.5 million and $12.3 million, respectively, which included $6.4 million and $4.8 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the six months ended June 30, 2020 that was included in the deferred revenue balance as of December&#160;31, 2019 was $7.6 million, which primarily  represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Costs of Precision Oncology Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Development Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of development service includes costs incurred for the performance of development services requested by the Company&#x2019;s biopharmaceutical customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation related to stock options granted to the Company&#x2019;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Starting January 1, 2019, upon adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07,&#160;Compensation - Stock Compensation (Topic 718), &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Improvements to Nonemployee Share-Based Payment Accounting,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock options and stock purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#x2019;s condensed consolidated statement of operations on a straight-line basis over the requisite vesting or service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, in order to improve financial reporting of expected credit losses on financial instruments and other commitments to extend credit. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. &#160;These changes result in earlier recognition of credit losses. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2020. The cumulative effect upon adoption was not material to the Company&#x2019;s condensed consolidated financial statements.  The Company will continue to monitor the developments pertaining to the recent coronavirus (COVID-19) pandemic and its impact on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;the FASB issued ASU 2017-04&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;, Intangibles&#x2014;Goodwill and Other (Topic 350):&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Fair Value Measuremen&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;t, as part of its disclosure framework project.  The Company adopted this new guidance on January 1, 2020. The adoption of this standard did not have a significant impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-15&#x2014;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles-Goodwill and Other-Internal&#x2014;Use Software (Subtopic 350-40)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;: Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, to determine which implementation costs to capitalize as assets or expense as incurred. The Company adopted this new standard on January 1, 2020 on a prospective basis. The adoption of this standard did not have a significant impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18 -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (ASC 808)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under R&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;evenue from contracts with customers (Topic ASC 606) &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;when the counterparty is a customer. The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. &#160;The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. &#160;The Company early adopted this new standard on January 1, 2020.The adoption of this standard did not have a significant impact to the Company&#x2019;s condensed consolidated financial statements. Under prior GAAP, the Company historically allocated income tax benefit to continuing operations and an offsetting income tax expense to other comprehensive income under the applicable exception to ASC Topic 740.&#160; The new standard eliminates this exception and the Company will now determine the tax effect of pre-tax income or loss from continuing operations without regard to the tax effect of other items.&#160; The Company applied the new intraperiod tax allocation guidance prospectively in the period of adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDA_413593c7-6717-4605-9d46-4bee41c5876a">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#x2019; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that its existing cash and cash equivalents and marketable securities as of June&#160;30, 2020 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#x2019;s cost structure. If the Company&#x2019;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjE5OTAyMzMxNDUwMQ_349af536-cafc-4f28-805c-0a04bfea83e2">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates. The extent to which the COVID-19 pandemic will ultimately impact the &lt;/span&gt;&lt;/div&gt;Company&#x2019;s business, results of operations, financial conditions, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside the Company&#x2019;s control, such as the duration, scope and severity of the pandemic, steps required or mandated by governments to mitigate the impact of the pandemic, and whether COVID-19 can be effectively prevented, detected, contained and treated, particularly in the markets where the Company operates.</us-gaap:UseOfEstimates>
    <gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDE_08509627-c514-4b10-9d72-978df5723905">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unaudited Interim Condensed Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated balance sheet as of June&#160;30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020 and 2019, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#x2019; equity for the three and six months ended June&#160;30, 2020 and 2019, and cash flows for the six months ended June&#160;30, 2020 and 2019, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#x2019;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</gh:UnauditedInterimCondensedFinancialStatementsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDI_9cdbec77-010e-4c8c-9bda-4fed237b23d6">Foreign Currency TranslationThe functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#x2019; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and six months ended June&#160;30, 2020 and 2019, foreign currency translation adjustment was immaterial.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDM_4c3ebde9-a200-4ad6-b4ee-e73f1e1b9d34">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#x2019;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#x2019;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#x2019;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount.&lt;/span&gt;&lt;/div&gt;A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#x2019;s total revenue or accounts receivable balance.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjc0ODc3OTEwMzQwNw_723de027-c761-4e1f-aff6-d917cf6ca7ac">Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#x2019;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#x2019;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.230%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer A   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer B   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer C   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer D   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Customer E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;"&gt;*&#160;less than 10%&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30305f98796b4fcca95cd1f896a623dc_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNS02LTEtMS0w_f13ccd47-f93a-45a4-b3d8-2c9e1c22c415"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0b42c1beed4e4da581bb9585e8272830_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNS0xMi0xLTEtMA_83742a76-618e-4e21-92c4-f1700beb3d0b"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia1c3337f5d59424e96a59f60dfdde148_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi0yLTEtMS0w_610e92a4-0804-4b86-9705-49c4dea7b841"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ida41699b64f44ef0b7744e4cfe85a445_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi00LTEtMS0w_5097a5fa-e094-4068-be22-f48f86acbb45"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iceda03e5ad2c4312bc298cbbc0900364_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi02LTEtMS0w_7996c323-3ae8-4f4d-881a-5f8659a904b2"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i468f19c62c24453a865e318ab9ae077d_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNi04LTEtMS0w_04b682be-1854-4c76-ae8f-d52629fbd53b"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i87b8d948d26b4427bf5fba3c70b183fb_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNy00LTEtMS0w_1b25c59c-40b1-49f0-8d48-7dd8c4d935aa"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibc52b81b9be544c2ad19a695298b389c_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNy04LTEtMS0w_bef05681-0ba9-43df-a797-ebefa39f76d6"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie0f9c70752694d2e9ac53b525ded966d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfNy0xMi0xLTEtMA_517ec135-0dbf-45a9-9317-cb09d247b96e"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id883a12b90d8439b97224daeaac7b8b7_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfOC0yLTEtMS01NDk5_e7b87d69-61bc-4cca-a92b-5f6a41eab1f4"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i33e3aa6b28344bb5acaedc108f74aed7_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfOC0xMC0xLTEtNTQ5OQ_59990386-d4c0-4094-9302-a3f9ae0d6f71"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i69370ff4c9114ca2beb444f079abcd90_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RhYmxlOmQ0OWFjNmQxODYxYTRjNWU4ZjcyMmM3NmUxZTExOWJjL3RhYmxlcmFuZ2U6ZDQ5YWM2ZDE4NjFhNGM1ZThmNzIyYzc2ZTFlMTE5YmNfOS0xMC0xLTEtNTU4OQ_f36aa4bc-d788-456a-bbf3-fcdbc9d92af9"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5MjU_3498f080-0e7f-4f32-b8bf-f01dafc95712">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#x2019;s best estimate of the amount of probable credit losses. As of June&#160;30, 2020, the Company recorded $0.1 million as allowance for credit losses. As of December&#160;31, 2019, the Company had no allowance for credit losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDk0NzgwMjM1OTAwMw_78ac2f4c-53ab-445c-92fe-6b0b70f6e888"
      unitRef="usd">100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDk0NzgwMjM1ODk5NA_70986a1e-e52f-4110-8b36-7bcb4a54d04d"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <gh:AssetAcquisitionPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTcyOQ_471feda9-b3db-4009-b355-39e81cf3f465">Asset AcquisitionIf an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Transaction costs associated with the asset acquisition are capitalized. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.</gh:AssetAcquisitionPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NTg_96616bca-e60b-43df-9e6d-58a866bb3ab7">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets related to in-process research and development costs (&#x201c;IPR&amp;amp;D&#x201d;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;June&#160;30, 2020, there has been&#160;no&#160;impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-12 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTczMA_c2ca6d7a-a260-4dc6-a274-f8a5e3a7dbd2"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTc0MQ_7c29cdcf-a1f9-4bc0-a4b6-b53c265f4618"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie6a2fe3c28ec43dbb430a92bb0b27a35_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTY5OA_41c0273d-37f2-4986-aea7-d5bb91599087">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia75cf41ebff4424583eb30543c5a9ed7_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTcwNQ_83d7d5bd-a28c-4154-b62a-d19e4471a71d">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5MjY_d26ba796-8e93-4a5f-8d72-4d4a57b9c238">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#x2019;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ3NTcyOA_28cf8ba3-fff4-4743-84bf-47be3bcb5c15">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#x2019;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Precision oncology testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended June 30, 2020 and 2019, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$6.5&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$3.6&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration. For the six months ended June 30, 2020 and 2019, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$12.4&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;$6.4&#160;million&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration.  For the three and six months ended June 30, 2020, the Company recorded $2.6&#160;million and $4.1&#160;million, respectively, in revenue received from Medicare for samples processed in 2019.  For the three and six months ended June 30, 2019, the Company recorded $1.4&#160;million and $1.4&#160;million, respectively, in revenue received from Medicare for samples processed in 2018. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#x2019;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Development services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#x2019;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. The Company revised and increased its total estimated costs relating to one of the development services contracts during the six months ended June 30, 2020.  Had the Company included such additional costs in the original estimated costs, revenues for the six months ended June 30, 2019 would have been lower by $3.6 million. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#x2019;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contracts with multiple performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. Contract assets are presented under accounts receivable, net and other assets on the Company&#x2019;s condensed consolidated balance sheets. As of&#160;June&#160;30, 2020, the Company had contract assets of&#160;$9.5 million of which $0.2 million was recorded in other assets. As of December&#160;31, 2019, the Company had contract assets of $6.2 million of which $1.0 million was recorded in other assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the deferred revenue balance was $11.5 million and $12.3 million, respectively, which included $6.4 million and $4.8 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the six months ended June 30, 2020 that was included in the deferred revenue balance as of December&#160;31, 2019 was $7.6 million, which primarily  represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Transaction price allocated to the remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2MzY5Mg_707626d6-1bc9-434c-b25a-99d9135c82d7"
      unitRef="usd">6500000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2MzcyNg_f7260943-2441-4328-9eb3-41cfcda1b9d5"
      unitRef="usd">3600000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2Mzc2Nw_cca8e8cd-cdcb-402b-a1d1-9685a846e796"
      unitRef="usd">12400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfNDM5ODA0NjU2MzgwMA_e3a9543f-cd51-464e-809d-e02890afe2ed"
      unitRef="usd">6400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8914a60aeb34d5cbf1aa6e554ff0514_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDU1OA_6980f10a-3e03-4d71-acf0-b49fb49b2dce"
      unitRef="usd">2600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fc08dd4ea5642c4a9d385ae69096000_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDU3Mg_4316f90e-8d58-4cf3-9253-aa046d075c21"
      unitRef="usd">4100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica7dedd6767d44efaea5866821f7622f_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDU4Ng_5f7300ff-6442-444d-aea2-121adcef29e2"
      unitRef="usd">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdfe70fa79e1446d86a8d5ad87a71189_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzUwMDYwMA_8eec321b-0144-4f54-9eca-66cdf338a7f7"
      unitRef="usd">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <gh:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMTY0OTI2NzQ5NzM2NQ_2af441f2-576b-4911-8ab4-843f44a81ad5"
      unitRef="usd">-3600000</gh:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjI5NDQ_71e484a6-1de1-4293-acbe-e2f5ee09d8e5"
      unitRef="usd">9500000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="ib64327946d8e47c7ada4e42959049276_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjI5NTY_0b129e7d-8e0a-4499-b489-017c7d87bbed"
      unitRef="usd">200000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjMwMzQ_e482b05f-340b-4941-a884-4f1cd2f04425"
      unitRef="usd">6200000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i4ceb1e91ef3f4683bec1451e6e849728_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjMwNDY_cbfa1282-6a77-4725-9d18-b0c8d7a5cb39"
      unitRef="usd">1000000.0</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM2ODQ_07409612-93ac-4051-ad2b-c7848a56ae50"
      unitRef="usd">11500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM2OTE_1167c63d-2a3b-461f-a2a7-0d35da5d5ba3"
      unitRef="usd">12300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i16f8de2202de40c1b72732f8a439a758_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM3MjQ_46b2fd4f-30de-43c9-885f-3d7a69336520"
      unitRef="usd">6400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iddcfbe838a4a477a9862d666a76f8ece_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjM3MzE_23780e27-a13a-4574-b6d6-0d0f8a1fbf58"
      unitRef="usd">4800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMjQwMTQ_87a860d7-a85f-43de-83f7-36fe664770cb"
      unitRef="usd">7600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <gh:CostsofPrecisionOncologyTestingPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5Mzc_d7f1474e-d150-4a35-a69d-d86f3bee7f96">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Costs of Precision Oncology Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#x2019;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.&lt;/span&gt;&lt;/div&gt;</gh:CostsofPrecisionOncologyTestingPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NDQ_a73c655a-7278-4b5e-85c7-f183ff2894e2">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cost of Development Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of development service includes costs incurred for the performance of development services requested by the Company&#x2019;s biopharmaceutical customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expenses &lt;/span&gt;&lt;/div&gt;Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NTI_f87cb6a0-b85c-4cd7-bee1-e50c44ad074c">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Stock-based compensation related to stock options granted to the Company&#x2019;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Starting January 1, 2019, upon adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-07,&#160;Compensation - Stock Compensation (Topic 718), &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Improvements to Nonemployee Share-Based Payment Accounting,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock options and stock purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#x2019;s condensed consolidated statement of operations on a straight-line basis over the requisite vesting or service period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5NjA_9ac66e56-d0e2-4dae-a18c-6dc7a7b330f9">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80MC9mcmFnOjczNDJkOTA1M2EyNTRkMTg4OTA1MTQxN2MwNDE0NjkwL3RleHRyZWdpb246NzM0MmQ5MDUzYTI1NGQxODg5MDUxNDE3YzA0MTQ2OTBfMzM5MzA_4a1ec7c5-1f4e-43b6-83b7-5bd53d5f902b">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, in order to improve financial reporting of expected credit losses on financial instruments and other commitments to extend credit. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. &#160;These changes result in earlier recognition of credit losses. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2020. The cumulative effect upon adoption was not material to the Company&#x2019;s condensed consolidated financial statements.  The Company will continue to monitor the developments pertaining to the recent coronavirus (COVID-19) pandemic and its impact on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;the FASB issued ASU 2017-04&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;, Intangibles&#x2014;Goodwill and Other (Topic 350):&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Fair Value Measuremen&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;t, as part of its disclosure framework project.  The Company adopted this new guidance on January 1, 2020. The adoption of this standard did not have a significant impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018, the FASB issued ASU 2018-15&#x2014;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles-Goodwill and Other-Internal&#x2014;Use Software (Subtopic 350-40)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;: Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, to determine which implementation costs to capitalize as assets or expense as incurred. The Company adopted this new standard on January 1, 2020 on a prospective basis. The adoption of this standard did not have a significant impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU 2018-18 -&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (ASC 808)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under R&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;evenue from contracts with customers (Topic ASC 606) &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;when the counterparty is a customer. The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. &#160;The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. &#160;The Company early adopted this new standard on January 1, 2020.The adoption of this standard did not have a significant impact to the Company&#x2019;s condensed consolidated financial statements. Under prior GAAP, the Company historically allocated income tax benefit to continuing operations and an offsetting income tax expense to other comprehensive income under the applicable exception to ASC Topic 740.&#160; The new standard eliminates this exception and the Company will now determine the tax effect of pre-tax income or loss from continuing operations without regard to the tax effect of other items.&#160; The Company applied the new intraperiod tax allocation guidance prospectively in the period of adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMjc0ODc3OTA3NjUwMA_c616be22-21e8-4f09-832d-ce65252d4329">Investment in Joint Venture &lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, the Company and an affiliate of SoftBank formed and capitalized Guardant Health AMEA, Inc. (the &#x201c;Joint Venture&#x201d;) for the sale, marketing and distribution of the Company&#x2019;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 9, 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. In June 2020, an amended and restated certificate of incorporation of the Joint Venture, as approved by the board of directors of the Joint Venture, was filed with the Secretary of State of the State of Delaware. The amended and restated certificate of incorporation, among other things, increased the number of authorized shares of common stock to 89,000,000 shares consisting of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;80,000,000 shares of Class A common stock and 9,000,000 shares of Class B (non-voting) common stock; and authorized 80,000,000 shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for 1,000 shares of Series A preferred stock. As a result, each of the Company and the affiliate of SoftBank held 40,000,000 shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive dividends at the rate of $0.05 per share if and when declared by the board of directors of the Joint Venture. In June 2020, the board of directors of the Joint Venture authorized the adoption of the Joint Venture&#x2019;s 2020 Equity Incentive Plan pursuant to which 4,595,555 shares of Class B common stock have been reserved for issuance. As of June 30, 2020, no shares of Class A and Class B common stock have been issued and outstanding and 80,000,000 shares of Series A preferred stock have been issued and outstanding.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the joint venture agreement, neither party is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. The Joint Venture is deemed to be a variable interest entity (&#x201c;VIE&#x201d;) and the Company has been identified as the VIE&#x2019;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, the Joint Venture had total assets of approximately $38.4 million and $45.1 million, respectively, which were primarily comprised of cash, property and equipment, right-of-use assets and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#x2019;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of June&#160;30, 2020 and December&#160;31, 2019, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Put-call arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#x201c;put right&#x201d;), and the Company has a right to purchase all such shares (the &#x201c;call right&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#x2019;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#x2019;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#x2019;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#x2019;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;20%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;40%&#160;of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;40%&#160;of the Company's fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;is publicly traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#x2019;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company&#x2019;s initial public offering (the &#x201c;IPO&#x201d;) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="ic4f82709e3c8482f9ce096c69ea147a5_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNjg1_2595f419-4541-4585-8952-1e03c931083f"
      unitRef="usd">9000000.0</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <gh:EquityMethodInvestmentSharesPurchased
      contextRef="ic4f82709e3c8482f9ce096c69ea147a5_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNjky_e24efcbd-dab6-4720-b3a5-c5574ace9ed3"
      unitRef="shares">40000</gh:EquityMethodInvestmentSharesPurchased>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i99b5f92b87414a408b2f164b39aa615c_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNzIy_a2acd420-2d01-48b3-959d-c846ca0eaff6"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue
      contextRef="i5e54f325c5224e52b4b39dbe334295fe_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfODA5_75d120a1-42a5-492f-bab7-8ed8af46b87d"
      unitRef="usd">41000000.0</us-gaap:RedeemableNoncontrollingInterestEquityRedemptionValue>
    <gh:EquityMethodInvestmentSharesPurchased
      contextRef="i678325a887e8435ea4d1cfd5c6e8ff5f_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfODE2_98ed80a2-054c-4f9e-b976-5b42899647ba"
      unitRef="shares">40000</gh:EquityMethodInvestmentSharesPurchased>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5e54f325c5224e52b4b39dbe334295fe_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfODU2_4b444b6e-9009-40c0-ba45-2af5c882d91b"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6da5a0d81b1d4f54b60329c88d1ec928_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk0MA_ce7dde0a-7afe-4a54-9720-7d72096e4408"
      unitRef="shares">89000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ieb9eee4d278c492880775de12a0d66be_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk3NQ_2988144d-e6ae-4f56-bd15-a0a059c17bb8"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk1Mg_1c8ded1a-b44b-4ff1-ab4f-d0d27d6eb68d"
      unitRef="shares">9000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk2Mw_57e51274-1c2e-4ab1-9ad2-e2e4f762aa95"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesAuthorized>
    <gh:PreferredStockSharesIssuedUponConversionOfCommonStock
      contextRef="iee98c0531e114acf831a0fba5e0f8fd1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk5OQ_ed4e29f8-95e2-4bfe-8a9c-1beaafe29731"
      unitRef="shares">1000</gh:PreferredStockSharesIssuedUponConversionOfCommonStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia2571d7c639c4caa8ea6a33dba9c80e7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk4Nw_1b798860-3d91-4eda-be80-a16df6932693"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4054d2241aef4c2ba3378622a152eb57_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2Mjk4Nw_c6e50025-bdf3-47fa-b5c5-43dca26559e4"
      unitRef="shares">40000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="i1582366d96764e628ee3c6fc355be309_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUyNA_85daa745-c99f-48ff-875c-58733c609363"
      unitRef="usdPerShare">0.05</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzAwNg_1911f9ab-8991-40de-8642-3a57cfac38a0"
      unitRef="shares">4595555</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_1e80ed3a-fc59-41f4-91fa-e7c8035d7db6"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i31c0d23c373e4a908c4afb6361fb820c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_2a943940-8f89-4a9d-bd8b-2a344f282ec2"
      unitRef="shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieb9eee4d278c492880775de12a0d66be_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_d30f88e1-96ac-49f1-a16b-93975f67eb25"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ieb9eee4d278c492880775de12a0d66be_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTY0OTI2NzQ2MzUzMA_e58c9e69-26c1-483c-8dfe-a81745cdbe57"
      unitRef="shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMjE5OTAyMzI3NzcwMA_0ab217d2-8643-4d92-a312-58008ebd6db7"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib31c15d9d38b4894b0c35bd703dbc8c3_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMjE5OTAyMzI3NzcwMA_3dd6933d-8a75-4a41-9200-cfdee2bea42a"
      unitRef="shares">80000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:Assets
      contextRef="i24ad3ecd9d8e4eba968d646b47f8075b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTQ0MQ_8233966a-2a7d-4d60-81f2-9142a99e2fc3"
      unitRef="usd">38400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i887b578e7d524b4ebef1f7577dec56b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfMTQ0OA_683f4635-0e79-4d33-8b34-015477b321dd"
      unitRef="usd">45100000</us-gaap:Assets>
    <gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNDMwMQ_d2296949-4b6b-4beb-9b56-fe8972ae4753"
      unitRef="number">0.20</gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn>
    <gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNDY1NA_3a98ea14-0f81-4f48-b4da-da44e2b3dee2"
      unitRef="number">0.40</gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase>
    <gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80Ni9mcmFnOjhhMTAyYWZkMzljZTQ2YjVhMGEzODNlY2U2NzEzODkwL3RleHRyZWdpb246OGExMDJhZmQzOWNlNDZiNWEwYTM4M2VjZTY3MTM4OTBfNDg2NQ_43c4cb86-9917-45dd-8eae-71cd5253075d"
      unitRef="number">0.40</gh:VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMzI1_7d850edd-75b9-4240-8c0a-040fd586ed3d">Condensed Consolidated Balance Sheet Components&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Construction in progress   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Less: accumulated depreciation   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation expense related to property and equipment was $3.2 million and $2.2 million for the three months ended June 30, 2020 and 2019, respectively, and $6.2 million and $4.3 million for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued royalty obligations   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued legal expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued tax liabilities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued professional services   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical trials and studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Purchases of property and equipment included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total accrued expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMzI5_8334327b-11cd-4930-bdd4-534fcba5fdcf">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Computer hardware   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Leasehold improvements   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Furniture and fixtures   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Computer software   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Construction in progress   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Property and equipment, gross   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Less: accumulated depreciation   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(21,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Property and equipment, net   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;56,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibeca758827ed4d90be26d059db3913b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMy0xLTEtMS0w_7fcf1c23-5cae-4fbe-9c5f-0dbf793d1be8"
      unitRef="usd">35584000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib10ea8dacf834b25a24c95505a7ad3ab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMy0zLTEtMS0w_2b910b15-5fc6-44d7-8466-1cbfeb235996"
      unitRef="usd">29119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9aa0e810ec7047b19bafc497d6b7e021_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNC0xLTEtMS0w_68135865-8fdd-41af-a421-4aa311f40e1d"
      unitRef="usd">9105000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i33b66109089f4987960aa78d1f42647c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNC0zLTEtMS0w_0f9e97b0-6738-41e2-81cc-bf5320bc0bb3"
      unitRef="usd">6296000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i545b9794576a4b6294dc59d727bc8cbb_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNS0xLTEtMS0w_f2eabb00-4543-4251-8bd5-c54d04aef5af"
      unitRef="usd">29349000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7dc6585a30ea4320b71e0d5e211a58bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNS0zLTEtMS0w_a0010608-cbaa-4140-b98c-786ca967319a"
      unitRef="usd">21031000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i89ededa0af6544088fe566e02b31a759_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNi0xLTEtMS0w_46b632c8-9133-49b5-9580-648b41346a93"
      unitRef="usd">2725000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i84f93a110ee94c85804eabd73676b498_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNi0zLTEtMS0w_6bb77a8c-89f7-489f-87c3-6a02aa5075cf"
      unitRef="usd">1962000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibae9bbbae4e046c2bb0f04e87dfc13df_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNy0xLTEtMS0w_9b33917d-3e53-4c52-aaad-493375f3ad6e"
      unitRef="usd">1027000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica84e8b91ec84cb3882f7bb95e6fa3a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfNy0zLTEtMS0w_44990011-7445-4fbc-9d64-1cdea8cc9c48"
      unitRef="usd">829000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i898f46836620466a8ea84a0116365f96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOC0xLTEtMS0w_6e9789eb-ff97-4637-aea6-0615cf45e9f3"
      unitRef="usd">7151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia3f2443552e3424c9cbf516e74b17aa4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOC0zLTEtMS0w_ab2e80bf-f3d1-4eae-9bf0-eba9986b7108"
      unitRef="usd">6354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOS0xLTEtMS0w_93b55047-993c-4954-91b0-08601cd82279"
      unitRef="usd">84941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfOS0zLTEtMS0w_794b6c99-fc22-4242-b141-f65c654791b8"
      unitRef="usd">65591000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTAtMS0xLTEtMA_346b9fad-c077-4b4d-a2d8-446b57d29b62"
      unitRef="usd">27946000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTAtMy0xLTEtMA_6d7b151b-2d30-4eb9-a95a-8def9e0acd91"
      unitRef="usd">21923000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTEtMS0xLTEtMA_231a7636-ba76-4854-9edf-1d7b190666f5"
      unitRef="usd">56995000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOjRlZTE5Y2QxNTNkMTRkODliYjBlM2YwNDBhNTI4NzM1L3RhYmxlcmFuZ2U6NGVlMTljZDE1M2QxNGQ4OWJiMGUzZjA0MGE1Mjg3MzVfMTEtMy0xLTEtMA_03a26bcf-dbf4-41eb-8c61-48a790250191"
      unitRef="usd">43668000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfNDM5ODA0NjUxMTQzNg_bc3448a7-0166-441b-9045-570c7d5a2464"
      unitRef="usd">3200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfNDM5ODA0NjUxMTQ0Nw_c27040c5-62cd-4387-b2db-a4be2387789f"
      unitRef="usd">2200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMjE3_62adff3d-f393-4ee8-a79b-c07751226557"
      unitRef="usd">6200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMjI0_3be76188-5e96-4814-a45e-8d5089893e0c"
      unitRef="usd">4300000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RleHRyZWdpb246OWUzNTFlNGU3ZTA5NGE1OTg0NjU3NjI5ODUzZTE0NDhfMzIy_49b42b7b-1e4e-44e4-9d88-2de40b3d648d">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued royalty obligations   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued legal expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued tax liabilities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Accrued professional services   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical trials and studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Purchases of property and equipment included in accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Others&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total accrued expenses   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMy0xLTEtMS0w_d85f5252-1957-40dc-9761-310a719145dd"
      unitRef="usd">325000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMy0zLTEtMS0w_36a30bae-33a8-44f9-ad4a-c0f5818bac40"
      unitRef="usd">1564000</us-gaap:AccruedRoyaltiesCurrent>
    <gh:EstimatedLitigationLiabilityLegalFeesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNC0xLTEtMS0w_91e8476a-6b68-4b8e-a6b6-16d99d9a76bc"
      unitRef="usd">2598000</gh:EstimatedLitigationLiabilityLegalFeesCurrent>
    <gh:EstimatedLitigationLiabilityLegalFeesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNC0zLTEtMS0w_dacffbdc-b4ac-4b91-9d4d-5cd87b7ee6b0"
      unitRef="usd">1046000</gh:EstimatedLitigationLiabilityLegalFeesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNS0xLTEtMS0w_17dc44dc-9533-4edf-87ae-36e0108a52a2"
      unitRef="usd">3268000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNS0zLTEtMS0w_a8de27f1-a55e-4ffc-948a-cb9f09f97cbf"
      unitRef="usd">3050000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNi0xLTEtMS0w_be10a5db-3c53-4940-b6dc-03ac210ef442"
      unitRef="usd">3275000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNi0zLTEtMS0w_06c0ad2f-ddf8-47bf-9477-ea445a520d83"
      unitRef="usd">3464000</us-gaap:AccruedProfessionalFeesCurrent>
    <gh:AccruedClinicalTrialsandStudies
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNy0xLTEtMS0w_f01d51b4-b2eb-44c9-8209-1960bf06028a"
      unitRef="usd">1734000</gh:AccruedClinicalTrialsandStudies>
    <gh:AccruedClinicalTrialsandStudies
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfNy0zLTEtMS0w_7e72d0a4-9bb4-40a9-b20a-887ef9ae9287"
      unitRef="usd">2029000</gh:AccruedClinicalTrialsandStudies>
    <gh:AccruedExpensesPropertyandEquipmentCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOC0xLTEtMS0w_35b6b2c0-cf26-4ca4-bc22-b5bb15f771ad"
      unitRef="usd">1476000</gh:AccruedExpensesPropertyandEquipmentCurrent>
    <gh:AccruedExpensesPropertyandEquipmentCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOC0zLTEtMS0w_9b8049fe-9d45-43da-8bd9-b12211d8cbfd"
      unitRef="usd">2424000</gh:AccruedExpensesPropertyandEquipmentCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOS0xLTEtMS0w_5803041b-385f-4e95-8a06-927548c9cda9"
      unitRef="usd">8240000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfOS0zLTEtMS0w_f5c777f2-259e-476e-b358-10f2285c50bf"
      unitRef="usd">7140000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTAtMS0xLTEtMA_f0667f4f-9c53-4a4b-a5cf-2a02afafed0c"
      unitRef="usd">3139000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTAtMy0xLTEtMA_3d0d27b5-2d40-4ece-8fe6-c6c4234569a7"
      unitRef="usd">4986000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTEtMS0xLTEtMA_a7622a04-0d21-43e3-aade-f0829e697c8a"
      unitRef="usd">24055000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl80OS9mcmFnOjllMzUxZTRlN2UwOTRhNTk4NDY1NzYyOTg1M2UxNDQ4L3RhYmxlOmNkZTg1YTdhYzkzNzQyMTBiZjQ3MDgzZjJlZDlhNDlhL3RhYmxlcmFuZ2U6Y2RlODVhN2FjOTM3NDIxMGJmNDcwODNmMmVkOWE0OWFfMTEtMy0xLTEtMA_640fbb6c-1e0b-4276-8e27-ace9aaacbc3e"
      unitRef="usd">25703000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAxMQ_f0a9712c-9ca7-4ce1-9e9a-563f76925400">Fair Value Measurements, Cash Equivalents and Marketable Securities &lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;919,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;379,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;379,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;659,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;648,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.521%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.186%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.186%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.186%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.193%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:9pt;text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;Redeemable Noncontrolling Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Fair value &#x2014;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Initial valuation on the date of acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Increase (decrease) in fair value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(622)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Fair value &#x2014; end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, contingent consideration liability of $1.2 million and $1.4 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarizes the Company&#x2019;s cash equivalents and marketable securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;913,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;919,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;933,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Corporate bond   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;630,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;631,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;657,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;659,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#x2019;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of credit losses in the three and six months ended June&#160;30, 2020 and 2019, respectively. The maturities of the Company&#x2019;s long-term marketable securities range from 1.0 year to 1.4 years as of June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAxMw_d7a78f04-f0f0-4581-9370-f6d8ddb42f3d">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfMzk5Nw_48afd5ed-f96b-4ff7-a0d3-9eb24c84ac08">The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;773,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;146,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;919,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Corporate bonds   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total short-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;379,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;379,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total long-term marketable securities   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;268,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;659,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;648,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Financial Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1748888fa5b94b3fa36d1f69f3d04c7a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi0xLTEtMS0w_886fced8-c597-4931-959c-0b335df5a13d"
      unitRef="usd">20237000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id1a742dbb670437194ce13edafd7abd7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi0zLTEtMS0w_3b7ce694-3e2d-4fac-a931-ab8daf7fd14e"
      unitRef="usd">20237000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i370642be93cb4475a9cc1be521e0f456_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi01LTEtMS0w_dc86deac-ad11-49c7-adb8-c78ddb62fca3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifffa3df8778245cbbf40df31c03d6572_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNi03LTEtMS0w_8e596d4a-9704-402b-b773-308cf6a6ca4f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy0xLTEtMS0w_fb909956-8526-4a78-8005-634c5cd66a9a"
      unitRef="usd">20237000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy0zLTEtMS0w_2498952d-2628-4ab1-9391-54463fa3f646"
      unitRef="usd">20237000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy01LTEtMS0w_da2b2761-319a-40e1-abdb-5130763b2f28"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfNy03LTEtMS0w_e8c00a73-6306-4078-871e-00a2052da578"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i31f4635a39a149c0ba7e63b5acf39b3b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtMS0xLTEtMA_39e33bc9-7957-4d3d-85f6-637455666767"
      unitRef="usd">773160000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i599892da63584709afb69f4bfb29d368_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtMy0xLTEtMA_3dd434c6-c9d5-4966-ae35-72501ba1609d"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ic7726079bb25453e958c1da1ddfff388_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtNS0xLTEtMA_d955218b-fdcb-4351-996c-e319045fc0a0"
      unitRef="usd">773160000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i1cc2234ad133449eae25a7cb3ee62b6d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTAtNy0xLTEtMA_fdc1aaf0-2286-498b-b19e-50b938754c83"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtMS0xLTEtMA_8ef45fa2-41cb-405e-983b-38185fc2589e"
      unitRef="usd">773160000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtMy0xLTEtMA_76d34d8e-388c-4b4a-9793-c3797448a28c"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtNS0xLTEtMA_e80bf319-77dd-40a1-8713-d095fa0ae240"
      unitRef="usd">773160000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTEtNy0xLTEtMA_a8340341-6ee3-40f0-82f5-1f81f9f2ee11"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i31f4635a39a149c0ba7e63b5acf39b3b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtMS0xLTEtMA_81bf701a-8878-4ecb-a606-d3e69895bdd6"
      unitRef="usd">146118000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i599892da63584709afb69f4bfb29d368_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtMy0xLTEtMA_e49dd30a-019b-4b8c-b06a-7583cd23ee19"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="ic7726079bb25453e958c1da1ddfff388_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtNS0xLTEtMA_d9bece75-c6d6-442e-9485-624c8189d2ef"
      unitRef="usd">146118000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i1cc2234ad133449eae25a7cb3ee62b6d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTMtNy0xLTEtMA_1437c013-def8-4cd0-8b42-38d058eded00"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtMS0xLTEtMA_f05b6508-e310-4a0f-ad2d-1faadb41179f"
      unitRef="usd">146118000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtMy0xLTEtMA_ca111dbc-2223-49e4-8fc0-7fe9320a8d53"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtNS0xLTEtMA_7209fe41-421a-4de8-987a-9da33dd6db69"
      unitRef="usd">146118000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTQtNy0xLTEtMA_882ccbb9-5f5e-4621-81b1-8b72f45c9ec8"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtMS0xLTEtMA_37aa7a81-fd2f-48c2-94d2-293231cafa03"
      unitRef="usd">939515000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtMy0xLTEtMA_18ad2e96-4a33-4c0a-86b9-a9532c522801"
      unitRef="usd">20237000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtNS0xLTEtMA_4a934fd4-a1ec-4d32-8fdd-3621db1a9c4d"
      unitRef="usd">919278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTUtNy0xLTEtMA_9f2cefff-2dbd-41a2-83ef-1baa27a568ae"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtMS0xLTEtMA_e47f8f82-2512-49a3-8bfc-a4c7a3933665"
      unitRef="usd">1175000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtMy0xLTEtMA_ed741b56-92aa-453d-a31f-ebd118e09d59"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtNS0xLTEtMA_67c84b4a-9506-4580-bcdc-0e64e295d7d3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTgtNy0xLTEtMA_f21170a4-c43f-408d-85cb-a0390e80aae5"
      unitRef="usd">1175000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if118daccbf7d4722ae57d06c7ab08a96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktMS0xLTEtMA_ecdfee3f-4668-4559-9d61-a46eddd8bb41"
      unitRef="usd">1175000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5ca828071cf24136a3e534de37d96e1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktMy0xLTEtMA_ad85214d-165d-4f01-927c-44c7f21338fe"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i69ddc25f26d44b86af3c9495e4039373_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktNS0xLTEtMA_8cbe1ef8-93fb-40f8-bdfd-83736ff1f5b4"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmM0YmFlODcwMThhNzQ2MzI5MTRmMTlkNzM0NDQ2MjBlL3RhYmxlcmFuZ2U6YzRiYWU4NzAxOGE3NDYzMjkxNGYxOWQ3MzQ0NDYyMGVfMTktNy0xLTEtMA_09c20f6a-e8b1-431c-8df9-f4c85ede09b2"
      unitRef="usd">1175000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id3accfc27a1b4335902ce8b5195b1631_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS0xLTEtMS0w_484cbcd0-4244-4412-a0d4-ca3c127a7961"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i396f1e67135f4846b62ba49dd35eb38b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS0zLTEtMS0w_59d8d22e-82f0-4123-aa97-5ecf8c7517d5"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia54b93d476704da994b4dc2cdf71eb94_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS01LTEtMS0w_bdd4d193-a439-4417-82aa-1a2806bd8799"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2d2218a15c7148cbb392058e26e2920d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNS03LTEtMS0w_ff21847b-0f42-44a7-b4fd-28be2c232412"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi0xLTEtMS0w_f31a6a65-255e-4385-af32-26963a45ec2e"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi0zLTEtMS0w_153ef1b0-eae1-4d9b-99df-f25e1a96e852"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi01LTEtMS0w_6ddcc9a9-c2bb-4612-9038-fa06f7441799"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfNi03LTEtMS0w_de4c4a35-c525-4861-9873-ffe17bdf6f00"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ib6b9a757a022476481b3125b0fc19f81_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC0xLTEtMS0w_cd875283-f6fe-46c9-b9bf-d9f81cc43c0a"
      unitRef="usd">16690000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ia9644227fc4843f1805c967861ab3dc4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC0zLTEtMS0w_8ef3a523-733a-4d44-bf91-051a5b77e022"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i88cf4f13cbb04a52a86b045ee3dd5ea1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC01LTEtMS0w_1c225ef6-a1c6-46d6-bdd7-d308b8fbc4ee"
      unitRef="usd">16690000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ibadc73c134c14524b54b1dac274d9bc1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOC03LTEtMS0w_54bd0a6e-084b-45a6-aa5a-279e8b3ff97b"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="iae16cdf827984010a2caeb7104021835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS0xLTEtMS0w_d88b71d3-c62a-4ed9-bb9d-88cd12ee29d7"
      unitRef="usd">362884000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i7128cee9cb9340a7a5e59f2f4abfc63b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS0zLTEtMS0w_adb339a2-b7a0-475e-bedb-acc468b9234c"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i421282ed4e594c2fab6a88329510132b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS01LTEtMS0w_1055d698-a2e2-4bea-be73-103eb0a6b541"
      unitRef="usd">362884000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i740e186b54a74d929d1a8c08b5e479b0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfOS03LTEtMS0w_ab5cc13f-6a25-4650-89a2-e27931cf4685"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtMS0xLTEtMA_705ba6d9-d5ac-489a-8bc6-67383a41582b"
      unitRef="usd">379574000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtMy0xLTEtMA_01c708a8-ad06-4f32-9dd1-47caf3ac9e69"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtNS0xLTEtMA_061e5be0-4593-4dc2-90be-b7e8db999390"
      unitRef="usd">379574000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTAtNy0xLTEtMA_84d2efea-a942-4bdc-a3ea-bab35b13c1dd"
      unitRef="usd">0</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="iae16cdf827984010a2caeb7104021835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItMS0xLTEtMA_504b1409-b60e-46fd-b44e-5b0481f92d90"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i7128cee9cb9340a7a5e59f2f4abfc63b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItMy0xLTEtMA_4e5b1c9b-3378-4e63-85e8-42f0da7f15d7"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i421282ed4e594c2fab6a88329510132b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItNS0xLTEtMA_1bbf37ac-7992-48e9-af07-41b52afdab5a"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i740e186b54a74d929d1a8c08b5e479b0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTItNy0xLTEtMA_5e221667-1bf0-4f83-bf6e-0603fafe7c92"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtMS0xLTEtMA_11ddc2b9-147b-4b91-af07-34e93c240f6f"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtMy0xLTEtMA_d5b78c5e-9cdf-457b-9299-40cbe9cf1c82"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtNS0xLTEtMA_3a3b0de9-e18b-4dee-add8-1ff6adfa70ae"
      unitRef="usd">268783000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTMtNy0xLTEtMA_0b77bd2b-be10-43a3-8ef9-92ef797eebec"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtMS0xLTEtMA_2286acc5-ce94-4634-98e8-2ff72fae3de5"
      unitRef="usd">659091000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtMy0xLTEtMA_0117fe5b-f147-4cf4-98d5-dd24d104a22e"
      unitRef="usd">10734000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtNS0xLTEtMA_2806eb4d-d64b-40d9-b592-5b69cba0eae5"
      unitRef="usd">648357000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTQtNy0xLTEtMA_3aac4e18-ebf1-482b-a5db-7dce2b7e42d9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctMS0xLTEtMA_331110a8-9cdc-4c40-9a64-9cf0f1a9cb5a"
      unitRef="usd">1365000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctMy0xLTEtMTIx_feca2a07-d991-485b-9ab3-15ad0496a61a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctNS0xLTEtMA_12074cad-f109-420a-b65f-2e548c2f71a1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTctNy0xLTEtMA_f8879b87-093f-4852-a0f6-050044a55e3b"
      unitRef="usd">1365000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i038f2a7219e747d28931767d8cf4ec43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtMS0xLTEtMA_e3cb0fac-8ca8-41b0-901e-483a71960584"
      unitRef="usd">1365000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if93d426946cb489f9e4d1af7e323bd40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtMy0xLTEtMA_888123ed-3423-4171-9ef6-0c1c1d5b565a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i93815114e38b4cd091cb874ecc2d4de4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtNS0xLTEtMA_c386a8d5-5214-4236-81cb-1a28f9a1baeb"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmQyOTAxYTJkYjM4NDRjZWI4NmM3YzViMjgzMWFhNDc1L3RhYmxlcmFuZ2U6ZDI5MDFhMmRiMzg0NGNlYjg2YzdjNWIyODMxYWE0NzVfMTgtNy0xLTEtMA_d991f96a-5cd6-4f1b-9925-906097641deb"
      unitRef="usd">1365000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAwMA_83d5754e-9e71-465c-b2bd-dcd8f36e6383">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.521%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.828%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.186%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.186%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.186%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.193%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:9pt;text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;Redeemable Noncontrolling Interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Fair value &#x2014;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Initial valuation on the date of acquisition&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Increase (decrease) in fair value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(622)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(944)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Fair value &#x2014; end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib1a2f825e010452bab2dda62203c3a5b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0yLTEtMS01MjU_27f4c0ea-e984-4575-8551-567a4cda8ff0"
      unitRef="usd">45500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7b4cbb1c832e4835bf864738425a238c_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi00LTEtMS01MjU_f98179f1-622a-44a0-8d33-0a1d8e217241"
      unitRef="usd">46500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i91b488ecc3114e4a8446d2438cd643d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi02LTEtMS0w_abc0d2e7-d0c6-48d3-85c6-98648d726eb7"
      unitRef="usd">49600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iba6aacb5f0774eacaab1daef8013d311_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi04LTEtMS0w_11543a04-c6c9-4b89-95c9-3ba2b9651e11"
      unitRef="usd">41800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i325614ec170f44899e673d4e7d28ca08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xMC0xLTEtNTU3_91314115-2f62-485b-a3dc-b249a1039032"
      unitRef="usd">1175000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i87ae71665daa44538cfa2f9ab72a47e5_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xMi0xLTEtNTU3_1057456e-4c25-45a8-86ee-22191eaf7271"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iaf3c9fdf9f6945cfa0c0069b6e81a7f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xNC0xLTEtMA_b615a447-ad1c-44e2-ae42-150b56af8bca"
      unitRef="usd">1365000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icba1eb19db0641239b17259b2bba88e5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNi0xNi0xLTEtMA_7c45c8bf-b9a6-4294-9efe-06afd634934c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib1a2f825e010452bab2dda62203c3a5b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0yLTEtMS01Mjg_4352dd8c-1a36-47f4-8322-2f993ec2c979"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7b4cbb1c832e4835bf864738425a238c_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy00LTEtMS01Mjg_71015617-644f-408f-ad0f-8e68f3fd0081"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i91b488ecc3114e4a8446d2438cd643d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy02LTEtMS01MzE_0e14fe08-0aa2-4254-9eca-09d310a9a45f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iba6aacb5f0774eacaab1daef8013d311_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy04LTEtMS01MzE_d255592d-cbce-4df4-9d87-00e5a319cd1f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i325614ec170f44899e673d4e7d28ca08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xMC0xLTEtNTU3_f397a9fb-1c4e-4b91-8ad6-69c205623c43"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i87ae71665daa44538cfa2f9ab72a47e5_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xMi0xLTEtNTU3_667d51cf-c8e2-4ebe-b90b-0ad54b669816"
      unitRef="usd">1065000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iaf3c9fdf9f6945cfa0c0069b6e81a7f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNC0xLTEtNTYy_b3c0bf80-3c15-463c-b420-a55981077057"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icba1eb19db0641239b17259b2bba88e5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNi0xLTEtNTYy_8aa4d555-8bad-4456-9d8d-22eab38ff394"
      unitRef="usd">1065000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i32d14c1e755e43fc814ff44716975ef7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0yLTEtMS01Mjg_ae39a9c8-c042-4068-ba71-173f65a1fe42"
      unitRef="usd">6186000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i25536aab95ec4b1685ab607a7f20dc01_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC00LTEtMS01Mjg_a94c4f9e-941f-4bbf-bbf2-c2a346a2fbea"
      unitRef="usd">922000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="id9cfa151d7bf41efb5fd1ac78e966422_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy02LTEtMS0w_7d0be82e-c93c-40b8-92f9-5bc42b0e1d9f"
      unitRef="usd">3159000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i770aeb9e45ec4839b3429acb58b3fc0a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy04LTEtMS0w_68502425-eead-48c8-8fba-c65ddc77dddd"
      unitRef="usd">5944000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i89c44f05033a45128d13bcc19f29dc7e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xMC0xLTEtNTU3_f3dc6a55-5bc1-4554-9c3c-5b1b5ab273ea"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i1d6bc51d86cf4c0fbc8f765288d22ea8_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xMi0xLTEtNTU3_3fe74f5f-ef9f-4fa8-9037-19f5720a80c7"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i40d0234ffd6546dfb79d7bb499864ab5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNC0xLTEtMA_431f6c42-ad39-4142-aa42-76f479ee2cc4"
      unitRef="usd">-190000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="if22d4925f07445f79dacbf83ea12c750_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfNy0xNi0xLTEtMA_f1cbe261-3896-4a96-9a78-6b9154240d83"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i32d14c1e755e43fc814ff44716975ef7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0yLTEtMS01Mjg_c94e2729-8f95-4d2a-8c05-2b9ec55763e4"
      unitRef="usd">-1286000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i25536aab95ec4b1685ab607a7f20dc01_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS00LTEtMS01Mjg_5da8e4b4-d970-4cde-8250-ce6514ef76e0"
      unitRef="usd">-622000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="id9cfa151d7bf41efb5fd1ac78e966422_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC02LTEtMS0w_629f0deb-5199-4394-aa4c-fed32c614e48"
      unitRef="usd">-2359000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i770aeb9e45ec4839b3429acb58b3fc0a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC04LTEtMS0w_6941636f-e342-4a5a-bd2f-e36124afdbaa"
      unitRef="usd">-944000</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i89c44f05033a45128d13bcc19f29dc7e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xMC0xLTEtODUw_2ec382df-bd89-4c59-a444-4460e9b10c6b"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i1d6bc51d86cf4c0fbc8f765288d22ea8_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xMi0xLTEtODUy_635778ec-7fdb-4063-a387-ddbfabddea6e"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="i40d0234ffd6546dfb79d7bb499864ab5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xNC0xLTEtMA_50a11103-9116-4b27-89c7-0be2f0fc3798"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod
      contextRef="if22d4925f07445f79dacbf83ea12c750_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOC0xNi0xLTEtMA_d04ba82d-ea51-4ca5-862b-4bb68709f03a"
      unitRef="usd">0</gh:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i09af7f320c9b4fcd84fa1e402ca72a9b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtMi0xLTEtODQ2_f86d19ae-a1b6-4b78-af83-ca00700acdb8"
      unitRef="usd">50400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic006391af9764d4bb2ecb0b9cb97430b_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtNC0xLTEtNTM2_f69df41e-c109-4182-bba5-262153bbebff"
      unitRef="usd">46800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i09af7f320c9b4fcd84fa1e402ca72a9b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS02LTEtMS0w_74587a13-b138-4d35-9885-af6854554d70"
      unitRef="usd">50400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic006391af9764d4bb2ecb0b9cb97430b_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS04LTEtMS0w_a766136d-0d2e-4345-bb43-ad830be4ab71"
      unitRef="usd">46800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iddc782a9fb88492e99beaee2df19e086_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtMTAtMS0xLTg1MA_2c2bf48c-e5bf-4a2c-9d5b-060cc48fd029"
      unitRef="usd">1175000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3b2041cc6a754cf7a43e5f90f2d8f1f9_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfMTAtMTItMS0xLTg1Mg_6ccb00fb-bbc9-4656-9eaf-b8700bc3dc00"
      unitRef="usd">1065000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iddc782a9fb88492e99beaee2df19e086_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xNC0xLTEtMA_2ed17540-bd38-418e-b797-72da7fbe03bd"
      unitRef="usd">1175000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3b2041cc6a754cf7a43e5f90f2d8f1f9_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOjI2N2ZkMzhiYmI5MTRmMGZhYzUzNGU2OTc0NDgxYTA3L3RhYmxlcmFuZ2U6MjY3ZmQzOGJiYjkxNGYwZmFjNTM0ZTY5NzQ0ODFhMDdfOS0xNi0xLTEtMA_a9636f49-6e4b-4a72-a94e-b3f4862576bf"
      unitRef="usd">1065000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i16ba315eedea40c1a18129a03aa19b9c_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDM5ODA0NjUxNTkzNQ_ec57f863-cce1-4015-a147-342df7e49bd0"
      unitRef="usd">1200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i685b086287f742f1b900f5e38731cbd1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDM5ODA0NjUxNTk0Mg_031089eb-5c15-4e2c-9ba2-1057c19cb8c2"
      unitRef="usd">1400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <gh:DebtSecuritiesTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfNDAwOQ_553f6345-18a6-4c3f-b8f6-6e120a759bc0">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarizes the Company&#x2019;s cash equivalents and marketable securities&#x2019; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;913,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;919,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;933,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;939,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Money market fund   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Corporate bond   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;630,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;631,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;657,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;659,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gh:DebtSecuritiesTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS0xLTEtMS0w_cd51e57a-9b47-4162-9c23-ba36a0692539"
      unitRef="usd">20237000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS0zLTEtMS0w_8f51addf-0b21-407f-8a65-1fa6498edad8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS01LTEtMS0w_5bb89816-cdac-415c-9e1e-b2ffb0c0f60e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icc4b06a919c94c7c9de034cc0bd35381_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNS03LTEtMS0w_01948ba6-0276-4561-8a63-cc724836618d"
      unitRef="usd">20237000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy0xLTEtMS0w_13697cd3-ead5-47cf-b041-97ba3977c5cb"
      unitRef="usd">913655000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy0zLTEtMS0w_b9e6a74c-e4cc-4359-8ec7-2caf039ae947"
      unitRef="usd">5623000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy01LTEtMS0w_3f1b2927-72e5-4e14-a8a9-8c5feae1f0f0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c81bcd5fd9c45d093ba54aaad507758_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfNy03LTEtMS0w_ace13f13-da82-49e3-8877-567483fc0da7"
      unitRef="usd">919278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC0xLTEtMS0w_859eba84-79c3-455f-af35-cf053c2bd257"
      unitRef="usd">933892000</gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC0zLTEtMS0w_e5ab9fad-149f-4af1-b882-cf0205dd6d78"
      unitRef="usd">5623000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC01LTEtMS0w_9409b8e7-9e5c-4926-9c15-f9189e8c1316"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsandDebtSecuritiesFairValue
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmEwY2NmYTgxYTc1YzQyYTY4NzAwMTg1OGJkNzczNDk0L3RhYmxlcmFuZ2U6YTBjY2ZhODFhNzVjNDJhNjg3MDAxODU4YmQ3NzM0OTRfOC03LTEtMS0w_0dead2ec-7581-4f73-bd69-ceb9b204b8f7"
      unitRef="usd">939515000</gh:CashCashEquivalentsandDebtSecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC0xLTEtMS0w_95c32047-231d-4a07-aa82-7c2c96540b8c"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC0zLTEtMS0w_b1ae67f1-b8b3-43a1-88d9-4d35ca9fa466"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC01LTEtMS0w_ea962648-8513-47ea-a8a0-00bd474af010"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if91cbbd535f24bc9ab0d438df3e8b9b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNC03LTEtMS0w_bfcf2bf0-17b8-46f2-9f97-6bcff494e15a"
      unitRef="usd">10734000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS0xLTEtMS0w_796b51f0-f98e-4fba-870c-28ac9cf565f4"
      unitRef="usd">16679000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS0zLTEtMS0w_78266262-6cad-459c-8433-0b0c8d5cf125"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS01LTEtMS0w_b1d5cfc7-1dcd-4a27-897c-5dbc8dc98dc3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i313c37eecd85486db947fb46da7fc2ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNS03LTEtMS0w_951c9625-18c0-4299-bcbf-a5e8a6092cd2"
      unitRef="usd">16690000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi0xLTEtMS0w_35bcf96d-7291-4d4d-ba92-10d7e6637d3e"
      unitRef="usd">630283000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi0zLTEtMS0w_07ba31c5-169c-4ede-9b87-616eebca51e9"
      unitRef="usd">1423000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi01LTEtMS0w_e6bc4593-4469-4324-ac01-34e1365e2746"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i494f839d36b341feb8f94f4b06ab22bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNi03LTEtMS0w_93314e90-3601-4b8e-a3f8-b37a56156575"
      unitRef="usd">631667000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy0xLTEtMS0w_a3c4e448-7ebf-4031-88c8-fab491fdad8c"
      unitRef="usd">657696000</gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy0zLTEtMS0w_c0e77870-7c5b-4c08-b755-c44834368335"
      unitRef="usd">1434000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy01LTEtMS0w_3e0f4928-921b-47bf-968d-19ca16caf0e9"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <gh:CashCashEquivalentsandDebtSecuritiesFairValue
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RhYmxlOmYyNDc1ZTA2Yjk0MDRkYjE4NGZkZWVlNDkwM2M1ODI0L3RhYmxlcmFuZ2U6ZjI0NzVlMDZiOTQwNGRiMTg0ZmRlZWU0OTAzYzU4MjRfNy03LTEtMS0w_43253862-d5a0-4db9-be67-3142e59f3586"
      unitRef="usd">659091000</gh:CashCashEquivalentsandDebtSecuritiesFairValue>
    <gh:MarketableSecuritiesMaturityPeriod
      contextRef="ie6a2fe3c28ec43dbb430a92bb0b27a35_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfMzk4MA_dfb710f3-7a2e-469d-a17f-4c0534632b2a">P1Y</gh:MarketableSecuritiesMaturityPeriod>
    <gh:MarketableSecuritiesMaturityPeriod
      contextRef="ia75cf41ebff4424583eb30543c5a9ed7_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81Mi9mcmFnOjYwY2ZhOGUzODFmMzRjMWI5MjdhNDMyOTAxZjFlMzZiL3RleHRyZWdpb246NjBjZmE4ZTM4MWYzNGMxYjkyN2E0MzI5MDFmMWUzNmJfMzk4Ng_892e2b47-ea5d-424f-8e9b-619ed8ac5ed1">P1Y4M24D</gh:MarketableSecuritiesMaturityPeriod>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzg0_9ecea70f-826a-4c3e-ab63-4f3307363560">Intangible Assets, Net and Goodwill&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents details of purchased intangible assets as of&#160;June&#160;30, 2020&#160;and&#160;December&#160;31, 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.861%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:24.75pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:13pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.861%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of finite-lived intangible assets was $0.5 million and $0.2 million for the three months ended June 30, 2020 and 2019, respectively, and $0.8 million and $0.2 million for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes estimated future amortization expense of finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.082%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.981%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzg4_d7a79e7b-9e81-48d5-9ee4-f3c159cba515">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents details of purchased intangible assets as of&#160;June&#160;30, 2020&#160;and&#160;December&#160;31, 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.861%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:24.75pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:13pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.861%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzkx_41dca3aa-1a71-452b-8209-ab3535435f6f">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents details of purchased intangible assets as of&#160;June&#160;30, 2020&#160;and&#160;December&#160;31, 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.861%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:24.75pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Non-compete agreements and other covenant rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:13pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.855%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.861%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.022%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.028%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remaining Weighted Average Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Intangible assets subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acquired license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-compete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total intangible assets subject to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intangible assets not subject to amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i671223423cb94bd8ac77d81000597b42_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi0yLTEtMS0w_dcd2a446-c0de-4ff5-beef-ceae82fb1012"
      unitRef="usd">11886000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i671223423cb94bd8ac77d81000597b42_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi00LTEtMS0w_5f71eb82-5d46-4e13-a8a1-8496f1c6f1eb"
      unitRef="usd">809000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i671223423cb94bd8ac77d81000597b42_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi02LTEtMS0w_5eecfa12-b689-4890-8277-b140bf311e1d"
      unitRef="usd">11077000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iab30d7be41ac42b6aaef61bf9bfb2147_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNi04LTEtMS0w_0e80c6e6-6553-4968-9fe0-2370de8bfd41">P10Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1e9fca5442dc404d83a43b8c26016c6f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy0yLTEtMS0w_f35828fd-839a-4b22-ab47-5eb7edca616a"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1e9fca5442dc404d83a43b8c26016c6f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy00LTEtMS0w_f6d223e6-6dd8-4c15-bee3-76984448c4b5"
      unitRef="usd">629000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1e9fca5442dc404d83a43b8c26016c6f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy02LTEtMS0w_19d5c1ee-6b87-43f1-b883-0a6400f953be"
      unitRef="usd">4471000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i33c6b8bbdadf44c4a7642d85455f2e93_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfNy04LTEtMS0w_8ec26ea6-cb22-45b9-b7ea-f979431af995">P5Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfOC0yLTEtMS0w_7b4f13f3-b80c-4dfa-8f2e-b4a55b5b0a5c"
      unitRef="usd">16986000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfOC00LTEtMS0w_54c2729a-a2b4-4ab8-b87b-1db4291c0032"
      unitRef="usd">1438000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfOC02LTEtMS0w_4d807ebc-e69d-4384-9aa5-f797d7f18d0c"
      unitRef="usd">15548000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2e95088fcf1140e1808f0690d05a8f92_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTAtMi0xLTEtMA_d719b850-88f4-4cc4-a753-2f83604916e8"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2e95088fcf1140e1808f0690d05a8f92_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTAtNi0xLTEtMA_f8af28fd-deb4-4d9d-9e30-f129ba873803"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTEtMi0xLTEtMA_68afddd7-e209-4a8d-b795-66be5edc0ea6"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTEtNi0xLTEtMA_a1779223-8f67-4971-a034-0eaa1a0d82c5"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:IntangibleAssetsGrossIncludingGoodwill
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTItMi0xLTEtMA_3d26e66d-36e1-4add-bddb-d6303251f297"
      unitRef="usd">21876000</gh:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTItNC0xLTEtMA_f307dd09-7d0f-4f59-b3a1-811b415bdd5f"
      unitRef="usd">1438000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmY0NGE3YTMxYjdhZTRjZWRiNTA0MTY5ZGI1OTQ0Yzk3L3RhYmxlcmFuZ2U6ZjQ0YTdhMzFiN2FlNGNlZGI1MDQxNjlkYjU5NDRjOTdfMTItNi0xLTEtMA_93f7d1d5-14ba-41ee-a9b7-5bdc46535932"
      unitRef="usd">20438000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6e385c44929941159efaa1b380c02f72_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS0yLTEtMS0w_0c39637e-94dc-432a-a998-f3b5ed878671"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6e385c44929941159efaa1b380c02f72_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS00LTEtMS0w_7f55656e-93b3-4292-8e20-5c6962d739ae"
      unitRef="usd">373000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6e385c44929941159efaa1b380c02f72_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS02LTEtMS0w_d73d7fcf-5ccb-463f-9890-1f046ae3fb9b"
      unitRef="usd">4727000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0fad1189a7cb465fa38705627b676425_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNS04LTEtMS0w_aac39344-f956-4a0f-973e-4152804058b5">P9Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi0yLTEtMS0w_e06b69e7-3674-491c-b50f-0e2581671a05"
      unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi00LTEtMS0w_bf138f04-c702-479d-a06b-7b8889d8a6d3"
      unitRef="usd">303000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8952c6e2ca614080afa7e0c4a576f1cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi02LTEtMS0w_9270f1f3-566e-40b7-9a85-3cb183c8d514"
      unitRef="usd">2197000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i39db8210bb3a4e9b8d14f31872c89a3c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNi04LTEtMS0w_2c6ed4ed-54de-4879-9240-98d85d1102b4">P5Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNy0yLTEtMS0w_992e61c3-7660-457f-b8b0-abdb8eb0d80f"
      unitRef="usd">7600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNy00LTEtMS0w_959878fc-1277-415a-8af3-3291cb734a6b"
      unitRef="usd">676000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfNy02LTEtMS0w_1780ae84-4a68-43e6-a07c-a230b9483dfc"
      unitRef="usd">6924000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i870e208edb564cf5aaf92b0b2145c9cf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfOS0yLTEtMS0w_91a20499-6d2f-42de-bcba-d575bef3829c"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i870e208edb564cf5aaf92b0b2145c9cf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfOS02LTEtMS0w_3421c681-298d-4772-a73d-7d1e333f11b7"
      unitRef="usd">1600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTAtMi0xLTEtMA_3563f299-c81b-4c6d-8dc9-efaab3ed10cc"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTAtNi0xLTEtMA_ae42e65e-cadd-44e7-8997-ce540d11a8d8"
      unitRef="usd">3290000</us-gaap:Goodwill>
    <gh:IntangibleAssetsGrossIncludingGoodwill
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTEtMi0xLTEtMA_d389aff0-5c6d-449d-8957-eee20ffa3019"
      unitRef="usd">12490000</gh:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTEtNC0xLTEtMA_14a0c2c6-395f-4b00-acb9-8d9c87748294"
      unitRef="usd">676000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOjkzZTgwYmM1YWJkZDQ3MmFhNzA2MmZiZDJiYjhiZWQyL3RhYmxlcmFuZ2U6OTNlODBiYzVhYmRkNDcyYWE3MDYyZmJkMmJiOGJlZDJfMTEtNi0xLTEtMA_350e833c-ada3-4647-9166-35886f85a255"
      unitRef="usd">11814000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfNDM5ODA0NjUxMTY2OA_e39a01d8-89de-48a4-bf30-6cec4d2274ac"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfNDM5ODA0NjUxMTY5Ng_f9e2384f-eff6-4f4e-aba0-6bb98cdb3add"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMTg2_8bb4e342-9e13-4fc7-b59e-cf0287b57210"
      unitRef="usd">800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfNDM5ODA0NjUxMTkyMw_edfd7ba2-84cc-46c8-a780-b1b5398f6895"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RleHRyZWdpb246NDUwYzE1N2EwZDkwNDM5OWIwNGFhOTBlODNmMDExYWRfMzk0_f6008069-7eb6-4e58-9ae5-7ad8e4f4b9d0">The following table summarizes estimated future amortization expense of finite-lived intangible assets:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.082%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.981%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfMy0yLTEtMS0w_a0765541-3cf0-4845-826e-5153e1fed1a7"
      unitRef="usd">994000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNC0yLTEtMS0w_42707749-cbdc-4e92-8df9-c3799936508e"
      unitRef="usd">1947000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNS0yLTEtMS0w_82a12507-85fc-45ee-a2d4-4f92f82fa470"
      unitRef="usd">1947000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNi0yLTEtMS0w_8e22c441-b187-4108-9abb-368101277972"
      unitRef="usd">1947000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfNy0yLTEtMS0w_6ac843de-5e77-4e3d-8388-5386e9f5798b"
      unitRef="usd">1953000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfOC0yLTEtMS0w_24c382e2-fecf-4ff2-a437-788e6c0d97b6"
      unitRef="usd">6760000</gh:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl81OC9mcmFnOjQ1MGMxNTdhMGQ5MDQzOTliMDRhYTkwZTgzZjAxMWFkL3RhYmxlOmVmODlmNDA0ZWVlOTQ2NDM5NzA1OWNkMWY0OTk3MjZhL3RhYmxlcmFuZ2U6ZWY4OWY0MDRlZWU5NDY0Mzk3MDU5Y2QxZjQ5OTcyNmFfOS0yLTEtMS0w_f6dede70-8c6a-45fb-b28f-eeba42d1db0c"
      unitRef="usd">15548000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <gh:AssetAcquisitionAndBusinessCombinationDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMzg5Nw_e4411aa9-0f8b-45dd-b6d6-36c695a4ce79">Acquisition &lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Patent License Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the Company entered into a license agreement with a biotechnology&#160;company, KeyGene N.V. (&#x201c;KeyGene&#x201d;). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the &#x201c;SPLA&#x201d;) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene&#x2019;s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $18.5 million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $0.6 million of certain capitalizable transaction costs, was allocated to various components of the SPLA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company allocated $9.4 million to the patent and covenant rights granted under the SPLA, which have useful lives in the range of 6-12 years. The Company allocated $8.5 million to IPR&amp;amp;D technology, which have no alternative future use and was included in research and development expenses for the six months ended June 30, 2020. The remaining $1.2 million was allocated to the settlement of the prior dispute between the parties and was included in general and administrative expenses for the six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amortization of capitalized license fees relating to the January 2017 license agreement was nil and immaterial for the three and six months ended June&#160;30, 2020, respectively. Amortization of capitalized license fees relating to the January 2017 license agreement was $0.2 million and $0.5 million for the three and six months ended June&#160;30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Acquisition of Bellwether Bio&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, the Company purchased all of the outstanding shares of Bellwether Bio, Inc. (&#x201c;Bellwether Bio&#x201d;), a privately-held company developing a method for early blood-based cancer detection. The Company accounted for the acquisition as a business combination. The total purchase consideration was $8.7&#160;million, which consisted of i) $7.6&#160;million in cash paid upon closing; and ii) future contingent consideration liability with a fair value of $1.1&#160;million on the acquisition date. The contingent consideration is subject to the achievement of certain commercialization milestones with a maximum payout amount of $10.0&#160;million. The Company will also pay additional earn-out consideration of up to $10.0&#160;million subject to the achievement of certain commercialization milestones and the continued provision of services to the Company by certain former employees and consultants of Bellwether Bio. The contingent consideration and earn-out consideration may be paid, at the Company&#x2019;s election, in cash or in the Company&#x2019;s common stock. As of June&#160;30, 2020, the Company did not believe the earn-out consideration is probable to be achieved, and therefore, did not record any compensation expense. The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.256%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.211%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Acquired license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;"&gt;*&#160;IPR&amp;amp;D assets are not subject to amortization.&lt;/span&gt;&lt;/div&gt;In connection with the acquisition of Bellwether Bio, the Company also entered into non-compete agreements with certain key individuals based on their experience and importance to the operation of Bellwether Bio. The Company accounted for the covenants not to compete as purchases of intangible assets separate from the business combination as these non-compete agreements were initiated by the Company to protect its interests. The fair value of acquired covenants not to compete is estimated to be $2.5&#160;million, which is recorded within intangible assets, net on the condensed consolidated balance sheet and will be amortized over an estimated useful life of 6 years using the straight-line method. Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations.</gh:AssetAcquisitionAndBusinessCombinationDisclosureTextBlock>
    <gh:PaymentInConnectionWithaLicenseAgreement
      contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNjA2_11efef3f-6b99-475c-aa47-ecf2a1b1f582"
      unitRef="usd">18500000</gh:PaymentInConnectionWithaLicenseAgreement>
    <gh:AssetAcquisitionTransactionCosts
      contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfODEz_95194608-c052-432e-b99a-b68d4cd0fd2d"
      unitRef="usd">600000</gh:AssetAcquisitionTransactionCosts>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia5c5a8b30538453e89c87e004c795b1e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfOTMx_0058979c-c688-47ff-8a0c-734ca72530f4"
      unitRef="usd">9400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6bf9235dd4864475b23df2375dff74b4_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTY0OTI2NzQ0NTc1NQ_8520a1d9-0731-4885-a2cf-cc882f463b9b">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4d6d3cc7ee094ad8917062d9acce7467_D20200301-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTY0OTI2NzQ0NTc2Mg_01fd6473-70af-4d1c-b8e2-a2ec8776f4ec">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <gh:ChargeOfInProcessResearchAndDevelopment
      contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTA2Ng_b67a3b58-8e5a-46b5-87b3-bf1130525ddc"
      unitRef="usd">8500000</gh:ChargeOfInProcessResearchAndDevelopment>
    <us-gaap:LitigationSettlementExpense
      contextRef="id8460a799f9b4c5e9b4f90ae38c87587_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTIwNw_324f4693-253e-43c8-a906-34c57920365b"
      unitRef="usd">1200000</us-gaap:LitigationSettlementExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icc9610ec8ca94eb3a9394e0fca76debc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDM5ODA0NjUxNTM4NQ_365b9aa6-e62f-4fc5-83d1-b6012e05fe12"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5ef5bc66f72741dcab51cdd2f9c4c114_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDM5ODA0NjUxNTM5Mw_6298f65d-587d-495c-95ad-dccc171fdcba"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ice197852bbb64a88a0b56ea6fe444696_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMTQ2OQ_b05e134e-c585-4510-a9a2-2ea9bbe5052e"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i3510d8a915044bd2bbd4d045d52db61f_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODkzMA_b23f6a2f-9a15-4c82-ba97-be8f75a205f2"
      unitRef="usd">8700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3510d8a915044bd2bbd4d045d52db61f_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODk1Nw_716771fe-d3d2-48c1-bd1e-17920a5d18d6"
      unitRef="usd">7600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id02ea36157704a95bf6f694669d5f017_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODk4NA_ac50b195-48cb-4350-9d88-544e3b2d55e9"
      unitRef="usd">1100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <gh:BusinessCombinationContingentConsiderationMaximumAmountPayable
      contextRef="ia8512cacee254bfea1d2fb212216dd3f_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyOTAxMg_71725edc-4732-4640-b274-442183de1d71"
      unitRef="usd">10000000.0</gh:BusinessCombinationContingentConsiderationMaximumAmountPayable>
    <gh:BusinessCombinationContingentConsiderationMaximumAmountPayable
      contextRef="i52f3187d48da4ffda0a02a73d287d04c_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyOTA0MQ_5b4cdba9-fc0d-4151-8424-86c792951372"
      unitRef="usd">10000000.0</gh:BusinessCombinationContingentConsiderationMaximumAmountPayable>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMzkwMg_85a85330-ea5c-44bc-bb9d-5eabfdb180de">The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.256%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id02ea36157704a95bf6f694669d5f017_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfMy0yLTEtMS0w_227a6111-8038-4f96-a14c-b02a952ba55c"
      unitRef="usd">521000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id02ea36157704a95bf6f694669d5f017_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNC0yLTEtMS0w_99faeae9-b1b0-4263-9f6b-ab5145816e66"
      unitRef="usd">6700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="id02ea36157704a95bf6f694669d5f017_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNS0yLTEtMS0w_ffbd73e0-a838-4d6c-a3be-b423aa5a4122"
      unitRef="usd">3289000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="id02ea36157704a95bf6f694669d5f017_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNi0yLTEtMS0w_6380f168-535e-439a-9b05-ca12974afc8f"
      unitRef="usd">1802000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="id02ea36157704a95bf6f694669d5f017_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOjk3YjhlZWJiMDM2NTQ1M2M5NWFjM2YwZTA5Yzg5NzEyL3RhYmxlcmFuZ2U6OTdiOGVlYmIwMzY1NDUzYzk1YWMzZjBlMDljODk3MTJfNy0yLTEtMS0w_e8d9357d-0ef9-4f8b-b89d-aed1b1870ef3"
      unitRef="usd">8708000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfMzkwNA_6b808dff-eef1-4d62-b52c-65d3e6fced24">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.341%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.211%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Acquired license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;"&gt;*&#160;IPR&amp;amp;D assets are not subject to amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i2f640c6e83784ea4850b868a4ac72489_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfMi0yLTEtMS0w_5ed5b6c3-32da-4581-8ec9-551223831740"
      unitRef="usd">5100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8e633a87d34e43728ef3713950fc0c06_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfMi00LTEtMS0w_d15d63b1-e795-4ac1-b629-694cbaa90708">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i1e4b90fbb22c4181ab782534d84b4052_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfMy0yLTEtMS0w_9228fb31-14b5-40c0-a56d-949c9a47728e"
      unitRef="usd">1600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id02ea36157704a95bf6f694669d5f017_I20190430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RhYmxlOmNkYTI2M2U3MmQ5OTRlMGY5N2U0OTU3NWM1OGI0NjUxL3RhYmxlcmFuZ2U6Y2RhMjYzZTcyZDk5NGUwZjk3ZTQ5NTc1YzU4YjQ2NTFfNC0yLTEtMS0w_ca5a7b7f-6241-4800-8f17-d7021cd3afd4"
      unitRef="usd">6700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ieee5f27fc7c546a0a1c1982c3c8a2e94_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyOTA2OQ_6404a71b-c24a-4930-a4c5-ab00980629a9"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie644dcec06b9490aba117035eebed7ea_D20190401-20190430"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl82Ny9mcmFnOjJkMzA5OWQxYzBiZDQ2MjFiNjI0YTEzZTExNDA1OGM5L3RleHRyZWdpb246MmQzMDk5ZDFjMGJkNDYyMWI2MjRhMTNlMTE0MDU4YzlfNDk0NzgwMjMyODkwNg_49c72437-63ff-49e2-9d56-04a8975e91e1">P6Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTY0OTI2NzQ0MzA4MQ_37061489-0f68-4028-908b-6e7245199626">Leases&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has&#160;entered into various operating lease agreements for office space,&#160;with remaining terms ranging from 1-7 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement. Operating lease expense was $1.9 million and $0.8 million for the three months ended June 30, 2020 and 2019, respectively, and $3.4 million and $1.6 million for the six months ended June 30, 2020 and 2019, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.916%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.822%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes our future principal contractual obligations for operating lease commitments as of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:80.797%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.203%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:  Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Finance leases are not material to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company entered into new lease agreements subsequent to June 30, 2020, see Note 16, Subsequent Events.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i94551a87fe774af98d538c0336237ed4_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTMx_49769928-47f0-4e78-8d6b-df57bb104644">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5868db3ef1f34c348c2af19ecda66e6e_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTQy_270717d5-4cfb-4e09-a197-aa9b27b7eff1">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNjA0NzMxMzk1MzkwMA_8f2343b0-0e4b-4aad-944a-787e179265ea"
      unitRef="usd">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNjA0NzMxMzk1MzkyNw_127a31ac-fe0c-4e74-97dc-2afafc6c7a1e"
      unitRef="usd">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNzM5_03f135de-984f-4401-b33f-49f028fa6795"
      unitRef="usd">3400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfNzQ2_747fa93d-6190-4395-8917-b73aa3f2cbec"
      unitRef="usd">1600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTA4Nw_ed4e5ac0-34cd-4138-af87-73aa49cb29e0">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.916%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.822%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMi0yLTEtMS0w_328faa74-87b0-4972-af23-8d5669b11ad9">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMi00LTEtMS0w_e38e7587-40bf-4ab2-afff-058d89b45093">P6Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMy0yLTEtMS0w_d2343a7a-80ce-4994-96c1-a9ae1eac65d8"
      unitRef="number">0.0819</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOmU5OThmMWJlM2JmOTQ2NDQ4ZWZlMjg3ZGZmNmQ0YzE4L3RhYmxlcmFuZ2U6ZTk5OGYxYmUzYmY5NDY0NDhlZmUyODdkZmY2ZDRjMThfMy00LTEtMS0w_dd1c7037-891c-43ec-afd1-de4457e62211"
      unitRef="number">0.0777</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RleHRyZWdpb246NjA3NTRiNTcwMWUzNDM4NWE3ZmY5YzYzNjU3ZjIxMjhfMTA4OQ_c4624552-fc75-4870-8318-d999da93f4d6">The following table summarizes our future principal contractual obligations for operating lease commitments as of &lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:80.797%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.203%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less:  Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfMi0xLTEtMS0w_95cef6f7-215d-493e-be75-63efdd81ee16"
      unitRef="usd">4723000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfMy0xLTEtMS0w_6f2fd90c-f660-4bc3-84bf-e8be665e95c4"
      unitRef="usd">11619000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNC0xLTEtMS0w_de01e4aa-0613-4a27-8840-97617b756f3b"
      unitRef="usd">9840000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNS0xLTEtMS0w_ecc48a97-442c-40d9-93ec-8e5c183ccafb"
      unitRef="usd">10535000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNi0xLTEtMS0w_2caae149-33f2-4bc2-aa9a-3546c0a308ca"
      unitRef="usd">10780000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfNy0xLTEtMS0w_22b9bc24-22dc-4a95-93c1-371fc67241ff"
      unitRef="usd">20251000</gh:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfOC0xLTEtMS0w_7a984c52-188b-4fa8-9b9d-81b5c6cb5ec5"
      unitRef="usd">67748000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfOS0xLTEtMS0w_885283c5-c1db-47d3-96e9-837f8ab14533"
      unitRef="usd">18391000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83My9mcmFnOjYwNzU0YjU3MDFlMzQzODVhN2ZmOWM2MzY1N2YyMTI4L3RhYmxlOjVkMGFmYzJlOWFlNTRjNDU4N2QzYTBiYzg5ZWIxOGE4L3RhYmxlcmFuZ2U6NWQwYWZjMmU5YWU1NGM0NTg3ZDNhMGJjODllYjE4YThfMTAtMS0xLTEtMA_a4b71bba-912a-4e7f-97d6-688473edee58"
      unitRef="usd">49357000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMzEyMA_82149d4a-7bfa-4764-8766-0501fa012132">Commitments and Contingencies &lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, we have received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. We have also instituted, and may in the future institute, additional legal proceedings to enforce our rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Patent Disputes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2017, the Company filed separate lawsuits against Foundation Medicine, Inc. (&#x201c;Foundation Medicine&#x201d;) and Personal Genome Diagnostics, Inc. (&#x201c;Personal Genome Diagnostics&#x201d;) in the United States District Court for the District of Delaware. The Company has alleged that each of the two companies has infringed four of the Company&#x2019;s digital sequencing technology patents. The two companies have each asserted counterclaims of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;patent invalidity, unenforceability under the doctrine of inequitable conduct, and non-infringement. Personal Genome Diagnostics has also alleged antitrust violations related to the enforcement of the Company&#x2019;s patent rights. In each lawsuit, the parties are seeking damages, injunctive relief and attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2018, Personal Genome Diagnostics filed two petitions for post-grant review with the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) at the United States Patent and Trademark Office, challenging the patentability of two of the patents asserted by the Company. The two post-grant review petitions were dismissed with prejudice in July 2018. Subsequently, Foundation Medicine filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company. The PTAB denied institution of inter partes review for four of the six petitions filed by Foundation Medicine and instituted inter partes review for the remaining two petitions. The Company plans to vigorously defend its patent rights during such PTAB actions. At this time, the Company cannot reasonably ascertain the likelihood that any of the remaining challenged patents will be found to be invalid or unenforceable.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <gh:NumberofCompaniesthatInfringedonaPatent
      contextRef="i1ce8429656d8474090165e7a3628b1e3_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTEwNw_5c2dc10b-1550-4b10-a84c-5ee6d83cd301"
      unitRef="company">2</gh:NumberofCompaniesthatInfringedonaPatent>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i0e8f6b7f7cda4a31a4e20791ec53e3af_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTEzNA_f2ce9b50-aec0-4946-9ef5-524a64c4b0d7"
      unitRef="patent">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <gh:NumberofCompaniesthatInfringedonaPatent
      contextRef="i1ce8429656d8474090165e7a3628b1e3_D20171101-20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTE5Nw_d48d46c3-f204-460b-a0b8-af4719678680"
      unitRef="company">2</gh:NumberofCompaniesthatInfringedonaPatent>
    <gh:NumberofPetitionsFiled
      contextRef="i45b21f81c97c4197bf11064199f6a5f4_D20180301-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTc3OA_577bb6f8-3d60-44b6-8211-ff1a2b196757"
      unitRef="petition">2</gh:NumberofPetitionsFiled>
    <gh:NumberofPetitionsFiled
      contextRef="ieb1c8dd73c8f4f9b81c94f3211ecc88f_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTgyNQ_0fbc1685-5e48-435f-b52b-25e9ff9e06e4"
      unitRef="petition">2</gh:NumberofPetitionsFiled>
    <gh:NumberofPetitionsFiled
      contextRef="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMTk0MA_e12c7453-b59b-4782-a9df-df5ecce5a467"
      unitRef="petition">6</gh:NumberofPetitionsFiled>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i142f8879551e4d50a8780dbc93bb85f2_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMjAyOQ_662d483d-5ef1-4ec0-b679-e5effdc732f7"
      unitRef="patent">4</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <gh:NumberofPetitionsDenied
      contextRef="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMjEyNw_547d99b2-59da-4cc6-b288-8a0b55aaa7bc"
      unitRef="petition">4</gh:NumberofPetitionsDenied>
    <gh:NumberofPetitionsFiled
      contextRef="i4c739651a60b46e6a5dfe5a968d72973_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl83OS9mcmFnOjc5ZjRmYWJhYjAzNTQzYTQ5Y2M2ZTExYzYwNjViMTU4L3RleHRyZWdpb246NzlmNGZhYmFiMDM1NDNhNDljYzZlMTFjNjA2NWIxNThfMjEzNw_fe6aba6f-0baf-4bf2-909c-e1900e72c25a"
      unitRef="petition">6</gh:NumberofPetitionsFiled>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzgzNg_8895a87e-3120-49f7-be8b-118c47aa6f35">Common Stock&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s common stockholders are entitled to dividends if and when declared by the Company&#x2019;s Board of Directors (the &#x201c;Board of Directors&#x201d;). As of June&#160;30, 2020 and December&#160;31, 2019, no dividends on common stock had been declared by the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Shares underlying outstanding stock options   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,869,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,494,889&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Shares underlying unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;564,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;496,131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares available for issuance under the 2018 Incentive Award Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,864,528&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,726,225&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,574,367&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;689,917&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,871,905&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,407,162&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Follow-on Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2020, the Company completed an underwritten public offering, in which it issued and sold 4,312,500 shares of its common stock at a price of $84.00 per share. The Company received net proceeds of $354.6&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2019, the Company completed an underwritten public offering, in which it issued and sold 5,175,000 shares of its common stock at a price of $71.00 per share. The Company received net proceeds of $349.7&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMzU2_6ce85ec9-981b-422b-a14f-2c0fc756aef3">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s common stock has been reserved for the following potential future issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.314%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.943%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Shares underlying outstanding stock options   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,869,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,494,889&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Shares underlying unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;564,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;496,131&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares available for issuance under the 2018 Incentive Award Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,864,528&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,726,225&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares available for issuance under the 2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,574,367&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;689,917&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:24.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,871,905&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,407,162&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie598fb3c2fa14dc9aae676f3defa865c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMi0xLTEtMS0w_46100da7-d9a7-4362-a262-decf8c598440"
      unitRef="shares">3869002</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iac6abd95f913499ea2e0b739c5e2fd9d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMi0zLTEtMS0w_1af57a6f-f7e3-4a0c-89bb-de90b0db903c"
      unitRef="shares">4494889</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMy0xLTEtMS0w_0e1453aa-3d21-4195-9937-dcac0faeb88f"
      unitRef="shares">564008</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id12141ace9b64b28bea2fdaaf6db601b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfMy0zLTEtMS0w_e5f6280f-eb8d-4a0b-bf7e-9133ce632d40"
      unitRef="shares">496131</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i45a7eeee673141b1a6a9a0da13e14018_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNC0xLTEtMS0w_d8c039e5-2a17-4c48-8922-e96e7c36167d"
      unitRef="shares">2864528</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i69cd2a5c9a414203b8bae90d7516eeb2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNC0zLTEtMS0w_142baa75-b884-4e0c-800a-f9e9629c702d"
      unitRef="shares">2726225</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i050b6f2672cc4818903148e5e1bb1511_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNS0xLTEtMS0w_9a37975c-a8f5-4656-9130-ca2eb2c2058c"
      unitRef="shares">1574367</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3c1dac7222754796a0dd42751b19691a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNS0zLTEtMS0w_cfe76ecf-5f81-4ebe-ad72-9ade1e64dfb4"
      unitRef="shares">689917</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNi0xLTEtMS0w_7fbc9a46-1476-4a00-bd62-5019b1c08c9a"
      unitRef="shares">8871905</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RhYmxlOjljZjEwMjVhMTlmOTQ3Y2NhZjc3MTZjZTA5NmNjODU0L3RhYmxlcmFuZ2U6OWNmMTAyNWExOWY5NDdjY2FmNzcxNmNlMDk2Y2M4NTRfNi0zLTEtMS0w_195feb8b-819a-4cad-b3a4-641b7919b4c3"
      unitRef="shares">8407162</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iebb665707a6f47049ff619543a4f305f_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzgzOA_8d0dcd95-132f-4e16-984a-d14f61c55030"
      unitRef="shares">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0Mzg5Ng_63bbde35-51bd-44b1-abde-0aa279b2e825"
      unitRef="usdPerShare">84.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iebb665707a6f47049ff619543a4f305f_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0Mzg3OA_74c7a084-1253-42d5-a8e7-1eb1d28f91f0"
      unitRef="usd">354600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icedca10dad7f49b48138ccb3a8b51c92_D20190501-20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0Mzg1OA_9975d5d9-303a-4ba8-ace9-33b776d64e9b"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i74c5c7aff6084ff8b5748e3367a09571_I20190531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzkwNA_e76b46ae-d15e-4def-84d1-2cdd6cf55e90"
      unitRef="usdPerShare">71.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icedca10dad7f49b48138ccb3a8b51c92_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84Mi9mcmFnOjcxMTRjZDhiMzE0NzQxNWJiNWZiNzZmNGQ3MTU1MWFlL3RleHRyZWdpb246NzExNGNkOGIzMTQ3NDE1YmI1ZmI3NmY0ZDcxNTUxYWVfMTY0OTI2NzQ0MzkxMg_8e4a55f2-9f6f-4c17-a06f-12873f77327c"
      unitRef="usd">349700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iacfffb20a4ae41eea78d5a346088bc97_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTQ5NzU1ODE0NzUxNg_8409531f-9522-4537-9528-9b9e741a3eb4">Stock-Based Compensation&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#x201c;2012 Plan&#x201d;) and the 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d;) and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.259%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.621%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.841%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.680%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.290%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,726,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,494,889&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2018 Plan annual increase&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,689,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(78,476)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(654,557)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,406&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,806)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(126,834)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Restricted stock units canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,355&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Market-based restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,391,148)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,864,528&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,869,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;266,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Vested and Exercisable as of June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,014,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-22.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt;"&gt;Effective as of January 1, 2020, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $33.1 million and $108.3 million for the three months ended June 30, 2020 and 2019, respectively, and $50.3 million and $116.4 million for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted-average grant date fair value of options granted was $44.61 and $51.94 per share for the three months ended June 30, 2020 and 2019, respectively, and $45.52 and&#160;$43.35 per share for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future stock-based compensation for unvested options as of June&#160;30, 2020 was $22.9 million, which is expected to be recognized over a weighted-average period of 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company&#x2019;s restricted stock unit activity excluding the market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.412%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.867%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;496,131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;82.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,834&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,602)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,355)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;564,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Future stock-based compensation for unvested restricted stock units as of June&#160;30, 2020 was $37.7 million, which is expected to be recognized over a weighted-average period of 3.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Market-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 26, 2020, the Board of Directors approved and granted 1,695,574 market-based restricted stock units (&#x201c;MSUs&#x201d;) under the 2018 Plan to each of the Company's Chief Executive Officer and the Company's President and Chief Operating Officer, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of 30 consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjAyMQ_60fc0348-aa77-452e-b4e9-5b9e8050b4d4"&gt;six&lt;/span&gt; to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. The following table presents additional information relating to each MSU award:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.366%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.315%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.315%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.653%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Price Goal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$120 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$150 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$200 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche is recognized based on an accelerated attribution method over the estimated derived service period. If the related share price goal is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal. The derived service period is the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU.  The weighted average grant date fair value of the MSUs was $67.00 and the weighted average derived service period was estimated to be in the range of 0.83 &#x2013; 2.07 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Stock-based compensation recorded for the MSUs for the three months ended June 30, 2020 was $18.3&#160;million and is recorded in general and administrative expenses in our condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of June&#160;30, 2020 was $208.9 million, which is expected to be recognized over a weighted-average period of 1.3 years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the effect of employee and non-employee related stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.458%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.626%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Cost of precision oncology testing   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Research and development expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Sales and marketing expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;General and administrative expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total stock-based compensation expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Valuation of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.510%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.819%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.819%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.824%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.5% &#x2013; 68.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.9% &#x2013; 68.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.5% &#x2013; 73.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.7% &#x2013; 68.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.4% &#x2013; 0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.4% &#x2013; 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.9% &#x2013; 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company&#x2019;s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the Company&#x2019;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the commencement of trading of the Company&#x2019;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#x2019;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Valuation of MSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair value of the MSUs was determined using a Monte Carlo simulation model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Due to limited historical data for the trading of the Company&#x2019;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Expected Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Risky Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The risky rate represents the Company's cost of equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Discount for Lack of Marketability &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of 0.83 &#x2013; 2.07 years; expected volatility of 65.5%; a risk-free interest rate of 0.5%; a zero dividend yield; a risky rate (cost of equity) of 16%; and a discount for post-vesting restrictions of 10.4% &#x2013; 14.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2018, the Company&#x2019;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). A total of 922,250 shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020, an additional 942,614&#160;shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;10%&#160;of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;85%&#160;of the fair market value of the Company&#x2019;s  common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from October&#160;2, 2018 to January 31, 2019, the second offering period ran from February 1, 2019 to July 31, 2019, and the third offering period began on August 1, 2019 and ran to November 14, 2019. For subsequent years starting with 2020, the ESPP provides for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Shares of common stock purchased under the ESPP were 58,164 and nil for the three months ended June 30, 2020 and 2019, respectively, and 58,164 and 119,702 for the six months ended June 30, 2020 and 2019, respectively. The total compensation expense related to the ESPP was $1.1 million&#160;and $0.4 million for the three months ended June 30, 2020 and 2019, respectively, and $1.6 million and $1.0 million for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;No ESPP shares were granted for the three months ended June 30, 2019. The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.357%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.411%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.411%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the unrecognized stock-based compensation expense related to the ESPP was $1.1 million, which is expected to be recognized over the remaining term of the offering period of 0.4 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liabilities for Early Exercise of Employee Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company allowed certain stock option holders to exercise unvested options to purchase shares of the Company&#x2019;s common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee&#x2019;s employment termination, at the original issuance price, until the options are fully vested. As of June&#160;30, 2020 and December&#160;31, 2019, 18,447 shares and 23,981 shares of common stock were subject to repurchase at weighted-average price of $4.66 per share. As of June&#160;30, 2020 and December&#160;31, 2019, the cash proceeds received for unvested shares of common stock of $0.1 million and $0.1 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheet, respectively. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the condensed consolidated balance sheet and condensed consolidated statement of redeemable noncontrolling interest and stockholders&#x2019; equity as such shares are considered legally outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk1NA_bcda67ce-9d9e-443d-8cfe-77f6c830b2a3">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company&#x2019;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#x201c;2012 Plan&#x201d;) and the 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d;) and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.259%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.621%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.841%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.322%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.038%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.680%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.290%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;br/&gt;Available for Grant&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares Subject to Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Exercise Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,726,225&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,494,889&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;2018 Plan annual increase&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,689,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(78,476)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,476&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(654,557)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,406&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,806)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(126,834)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Restricted stock units canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,355&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:20.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Market-based restricted stock units granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,391,148)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,864,528&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,869,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;266,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Vested and Exercisable as of June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,014,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-22.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt;"&gt;Effective as of January 1, 2020, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC0xLTEtMS0w_fcfa9f60-f719-4c7a-8a85-f93b1afcbcab"
      unitRef="shares">2726225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC0zLTEtMS0w_56508f26-630e-4999-8cc3-1f7d46f7090a"
      unitRef="shares">4494889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC01LTEtMS0w_77dbded5-60bb-407f-b600-cab534542d36"
      unitRef="usdPerShare">10.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC03LTEtMS0w_41b4c816-344b-4105-a1ec-5f82e55b614a">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="icccb78a249d8444998f95593e619a75a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNC05LTEtMS0w_c0258165-0d05-4558-851d-928f44e91a48"
      unitRef="usd">306392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNS0xLTEtMS0w_02177097-46a1-4d65-bf56-a86034a7f625"
      unitRef="shares">3689000</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNi0xLTEtMS0w_5a9c97cb-13a7-4699-aa26-451107b0a052"
      unitRef="shares">78476</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNi0zLTEtMS0w_858af417-75db-4dd3-a578-39fd4acb1a18"
      unitRef="shares">78476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNi01LTEtMS0w_52aec9bb-454c-4176-be3c-b17dca818da1"
      unitRef="usdPerShare">76.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNy0zLTEtMS0w_bb3dce6a-7a91-4514-a4f4-06027a8c1745"
      unitRef="shares">654557</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfNy01LTEtMS0w_8540d2e2-7e9b-4950-9e3c-c26f51c65506"
      unitRef="usdPerShare">5.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOC0xLTEtMS0w_df0753fd-9f94-4281-903a-1b094576f93d"
      unitRef="shares">12406</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOC0zLTEtMS0w_c646c92c-2964-46bf-bf2e-5553315a1a0c"
      unitRef="shares">49806</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOC01LTEtMS0w_cd36a5a4-e8d2-44e7-ba0a-0d635fe25eba"
      unitRef="usdPerShare">8.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross
      contextRef="idfbdc510d6c440d1b2591a18047a2615_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfOS0xLTEtMS0w_7703b7b3-318d-428f-969b-c75b47b205ad"
      unitRef="shares">126834</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross
      contextRef="idfbdc510d6c440d1b2591a18047a2615_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTAtMS0xLTEtMA_03ed9bc1-a200-4e94-9a1a-c1af5c4f4c95"
      unitRef="shares">33355</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross
      contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtMS0xLTEtNDYwMg_ac598588-b9c2-44a5-b933-07c57ec8b722"
      unitRef="shares">3391148</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtMS0xLTEtMA_b44ec78a-c2ca-45d1-9dc3-af22fdcc3b82"
      unitRef="shares">2864528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtMy0xLTEtMA_7e471b04-960e-419a-b565-aab7f6d5a4f4"
      unitRef="shares">3869002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtNS0xLTEtMA_feddec9b-b166-4136-9727-5e5a0c4bf08e"
      unitRef="usdPerShare">13.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtNy0xLTEtMA_476fb618-a262-4874-b654-208fb705fd72">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTEtOS0xLTEtMA_efb26f02-2d3b-482e-a2a5-aea7c315770a"
      unitRef="usd">266316000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItMy0xLTEtMA_b9edd378-36f0-4cc3-bbec-8e8d255e25f0"
      unitRef="shares">2014893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItNS0xLTEtMA_e15bb5cc-e4c9-4d90-8ea8-03ca7191728f"
      unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItNy0xLTEtMA_e20a8e3e-62f8-4e5d-b67a-8af25bf7d968">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmFiNzc4ODdiYjMzYjQxMjVhMTBlMjc5YzkzN2RmOTA5L3RhYmxlcmFuZ2U6YWI3Nzg4N2JiMzNiNDEyNWExMGUyNzljOTM3ZGY5MDlfMTItOS0xLTEtMA_44604a32-eadd-4b1d-ac50-e9fbaf3ce00d"
      unitRef="usd">150268000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzE2_02177097-46a1-4d65-bf56-a86034a7f625"
      unitRef="shares">3689000</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if9df8ef4afe54d51bb4c149ba983e328_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk1OTkyNA_80f63e03-98cc-4dbd-9c83-ae70536f603c"
      unitRef="usd">33100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk1OTk1MQ_c8deac93-6b8e-4dda-a6ec-c7a47e0eb7f0"
      unitRef="usd">108300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNzA1_be1e3b84-2ac7-4482-9b3f-e2ad467fef96"
      unitRef="usd">50300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4a0d4e0481d84fadaad8a7fe2f5e9afc_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNzEy_94031c3b-bf4c-40eb-b8ac-7922f5392e8c"
      unitRef="usd">116400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDAxMw_122d6cdd-0433-4c0d-aa49-4032c0c1eddb"
      unitRef="usdPerShare">44.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDAzOQ_1cae2aef-1b81-444b-a3e2-ef6560e5ba93"
      unitRef="usdPerShare">51.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfODE0_9c521d66-8342-4afa-9fe2-168484be0276"
      unitRef="usdPerShare">45.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfODIx_9f38c587-cd34-493d-bf25-094e65250a93"
      unitRef="usdPerShare">43.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfOTMz_6ebc9c60-3f85-4b50-aa21-7f323a77add7"
      unitRef="usd">22900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTAwNg_1d28c789-47c3-42cc-ae84-03f964fc3b8b">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk1Mg_3d0f8cae-ca35-4b75-aab8-fd9bd1945e8f">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company&#x2019;s restricted stock unit activity excluding the market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.412%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.666%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.865%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.867%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;496,131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;82.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,834&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(25,602)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,355)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance as of June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;564,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id12141ace9b64b28bea2fdaaf6db601b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMi0yLTEtMS0w_cd71840a-61f0-4113-941c-d8a808639ac8"
      unitRef="shares">496131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="id12141ace9b64b28bea2fdaaf6db601b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMi00LTEtMS0w_150a5015-d48b-4ea6-bb97-16ed2cfe6ecd"
      unitRef="usdPerShare">82.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMy0yLTEtMS0w_a50be97f-0efa-4820-9299-54f3d2199cd9"
      unitRef="shares">126834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfMy00LTEtMS0w_c47a317d-df2e-4fb4-bbc9-71123df5a3ec"
      unitRef="usdPerShare">75.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNC0yLTEtMS0w_a03d7d98-0969-4a03-9ce0-25b5fd99fee0"
      unitRef="shares">25602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNC00LTEtMS0w_9fedaf7c-cee7-4ccd-969a-6a762255bf98"
      unitRef="usdPerShare">80.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNS0yLTEtMS0w_0472f76e-5656-4921-9e58-0232343ca8f9"
      unitRef="shares">33355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNS00LTEtMS0w_42b10ee0-6382-451e-9414-ba56f190f9c1"
      unitRef="usdPerShare">75.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNi0yLTEtMS0w_9a73319a-97ef-4c25-b904-e74b2d796f8c"
      unitRef="shares">564008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjMxNWNiZjZlZTU4YjRhNTE5YTVjODA3NzRhMDc4OTEzL3RhYmxlcmFuZ2U6MzE1Y2JmNmVlNThiNGE1MTlhNWM4MDc3NGEwNzg5MTNfNi00LTEtMS0w_ae99549d-7429-4f60-81ce-a2b85d5c657e"
      unitRef="usdPerShare">81.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if1df678bb52e4460b3bbc3799bc5d17d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTI1MQ_b9a5afb9-0a69-4276-baec-45de765bc02d"
      unitRef="usd">37700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i654d832d9e2f4c56b70640689c3caf8e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTMyNA_4fab71ba-31b6-4d45-a513-66191df3c24d">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross
      contextRef="i599a34c262194cd695c5756264a97154_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMjE5OTAyMzI5ODkyNA_01cc97db-dd8f-4abc-83f3-c86fbffa4772"
      unitRef="shares">1695574</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross>
    <gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross
      contextRef="i129bd7811c824210b6778049ea36e662_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMjE5OTAyMzI5ODkyNA_f010a9da-9df6-4a02-9d0c-a45323d7ae03"
      unitRef="shares">1695574</gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod
      contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjYzOA_0547ee79-6f29-4675-90c3-542a936b64e4">P30D</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4MjA5Nw_1914ca0f-e0dc-440e-9e2e-33e53cfa2032">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting
      contextRef="i35b8d41685a144498da608da0700f3aa_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjAzMA_018b2311-9ef3-44fb-8ed3-438e75839347">P12M</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4MjA5OA_439fe3b7-e4b1-4f93-85a3-bd619ac368eb">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MTk4NA_1a7b9d5c-aa99-4208-a694-40e4de80dca9">The following table presents additional information relating to each MSU award:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.366%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.848%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.315%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.315%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.653%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Price Goal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$120 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565,192&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$150 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tranche 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$200 per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565,191&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="i669e37f9d5744052b446c5ed68ecebe5_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjVlMWUxZTRlY2JmMDQ4MTA4N2RlZjBkOTdkM2RjZWI0L3RhYmxlcmFuZ2U6NWUxZTFlNGVjYmYwNDgxMDg3ZGVmMGQ5N2QzZGNlYjRfMS00LTEtMS01MjA3_fa0a6c70-3584-4fee-a943-56ecb2ad5c02"
      unitRef="shares">565192</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="iab2c5ae4387c4af8a36849259581e3d9_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjVlMWUxZTRlY2JmMDQ4MTA4N2RlZjBkOTdkM2RjZWI0L3RhYmxlcmFuZ2U6NWUxZTFlNGVjYmYwNDgxMDg3ZGVmMGQ5N2QzZGNlYjRfMi00LTEtMS01MjA5_d5403bfc-2ee2-4fbf-a140-314ff8ef0fdd"
      unitRef="shares">565191</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest
      contextRef="i9b70fed4f3144ee49ada02413cd6502b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjVlMWUxZTRlY2JmMDQ4MTA4N2RlZjBkOTdkM2RjZWI0L3RhYmxlcmFuZ2U6NWUxZTFlNGVjYmYwNDgxMDg3ZGVmMGQ5N2QzZGNlYjRfMy00LTEtMS01MjEx_3596d870-5408-4fe3-903a-d9deac8223a7"
      unitRef="shares">565191</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4MTk0NA_db19363d-b94d-4c21-ba1f-55fe02a82de0"
      unitRef="usdPerShare">67.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTA5OTUxMTYzMTc5NDg_40b5a172-f723-4a5d-980f-8b02d4fc8310">P0Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTA5OTUxMTYzMTc5NTM_96b7b614-5441-4c74-9091-889eb3b4bd70">P2Y25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i824680c5b5434f179b86fd36d07d8763_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MTk4Ng_fd77517b-904f-4dbf-a9cd-f59d8cb68428"
      unitRef="usd">18300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ib4b5ba9fbebd4472beef02e1b7de1466_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzNTU5Ng_d85da5c5-3f0a-4639-b689-48b54766134f"
      unitRef="usd">208900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzNTYxMQ_a5eb0d66-dcf5-4e07-840e-cb018a4ba35e">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8306d3cba5fe4b3e95763d8e9c72af5e_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ4NDYyMA_41feda8e-8b97-4c79-839a-b7b14b2424fd">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk2Mw_ad745bf4-ce57-4a84-849e-a3a5cf143600">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the effect of employee and non-employee related stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.458%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.620%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.626%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Cost of precision oncology testing   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Research and development expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Sales and marketing expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;General and administrative expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Total stock-based compensation expense   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifdb07b2046094271b6b1529b0c747445_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS0yLTEtMS0w_acad28f4-2d57-44b5-8315-4fd3c78dec87"
      unitRef="usd">407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11c24d9847164822a50d4cdd9d18c5f2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS00LTEtMS0w_8cfee26d-f30e-46c0-84b6-a3311b193b75"
      unitRef="usd">126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie38caa6a9f90489092e150382af25b47_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS02LTEtMS0w_6ca5ae54-4476-4810-82f5-e1e7d822356e"
      unitRef="usd">710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bae9317d8ed49b284eae0dbc3a9c989_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNS04LTEtMS0w_53495736-0c89-4206-b083-a40aec35b925"
      unitRef="usd">296000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib8fea26a94e94fd49f58b8b97902f6a8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi0yLTEtMS0w_c3bbcf84-0557-4c0e-b23d-3f11204f206b"
      unitRef="usd">2622000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id38ddeb42dc645d29e1cf520286915fe_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi00LTEtMS0w_fc4ae46f-dae2-434f-b543-8ba3fe6b184a"
      unitRef="usd">1428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ab72dcca1ef42e3ad48caa9176918f9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi02LTEtMS0w_d8449246-6a1f-4996-94f0-fc5f274a1aa5"
      unitRef="usd">4986000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4cc5f9cce5c946aeb7649a2b45b18c94_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNi04LTEtMS0w_4645cc56-d027-4b2d-b58c-e7d1d89575d4"
      unitRef="usd">2638000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i686af8754af544d19475d9e965340c33_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy0yLTEtMS0w_3589599e-8cb0-4c81-a9f4-5308b2ab44eb"
      unitRef="usd">2167000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i524d26cd6dab4f5bbddc78f74f78b52e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy00LTEtMS0w_de53b2a8-94c2-4b95-94e4-79c514b0ba74"
      unitRef="usd">646000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50b9c64f08a24d1fb8df7c8b7394b5e6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy02LTEtMS0w_591d9513-de60-447b-8b4f-a7d7418c16f2"
      unitRef="usd">3965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f1bb229103f423797057daa71d5576d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfNy04LTEtMS0w_28ef9d5e-d36e-493a-840a-1a9e44b63d51"
      unitRef="usd">1472000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26596bb7859543f4bb3f7eae23f2540b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC0yLTEtMS0w_615dd709-6e3b-4e37-b617-2f704cfe2608"
      unitRef="usd">20619000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4fe75529581b40f39abaaf5c5922067f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC00LTEtMS0w_f5b12cfb-0588-4e09-b5b2-bdfe7d7f2f85"
      unitRef="usd">1015000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a01140a4fd940ef8d161dee75a36404_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC02LTEtMS0w_2234b591-e14d-40d0-b63e-4bd87b78f322"
      unitRef="usd">22492000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if32fff58d0554a458622af303653e269_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOC04LTEtMS0w_b4f6d36f-b451-4e64-9ff0-085a7cb785cf"
      unitRef="usd">1992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS0yLTEtMS0yNzQ2_6fd20c5d-cf4f-49d7-a9ff-cf18dfac5a34"
      unitRef="usd">25815000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS00LTEtMS0yNzQ4_9e14de46-7e11-4647-8ad8-95c88225d001"
      unitRef="usd">3215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS02LTEtMS0w_b81034b8-b61b-4ea0-8d66-c4fc3018a1c9"
      unitRef="usd">32153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJiZmFjMGY0ZmU0MjRjYmRiZTYyOGI0MjY5OTllZTE5L3RhYmxlcmFuZ2U6YmJmYWMwZjRmZTQyNGNiZGJlNjI4YjQyNjk5OWVlMTlfOS04LTEtMS0w_aabfbc21-9c52-438b-9fbd-377a9fa83a99"
      unitRef="usd">6398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjk1OQ_494b5357-082f-4be1-b18e-7d675d50571e">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.510%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.819%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.819%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.824%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Expected term (in years)   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.16&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.50 &#x2013; 6.22&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Expected volatility   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.5% &#x2013; 68.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.9% &#x2013; 68.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.5% &#x2013; 73.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;66.7% &#x2013; 68.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.4% &#x2013; 0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.4% &#x2013; 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.9% &#x2013; 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;"&gt;Expected dividend yield   &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#x2014;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.357%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.411%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.411%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.972%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.564%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term (in years)   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC0yLTEtMS0wL3RleHRyZWdpb246ZThlMjdhZDVkY2VmNDhmNmIzODRmYjJhMjRiOGZlOTlfNjA0NzMxMzk1Mjc4Ng_c3b06735-8fda-4260-84e1-b09d08abf161">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC0yLTEtMS0wL3RleHRyZWdpb246ZThlMjdhZDVkY2VmNDhmNmIzODRmYjJhMjRiOGZlOTlfNjA0NzMxMzk1Mjc5NA_2d1856bb-a581-456d-ba89-dae3fc1de164">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i12fb0e2cc01a47eca1252f58c3e04976_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC00LTEtMS0wL3RleHRyZWdpb246YzlkY2ZhOTU4ZmI3NDI0NjkyNTNlMDMyNTc1MGU0Y2JfNjA0NzMxMzk1Mjc5OA_9dffd6ae-e4a0-42ab-80f4-1822ec47c000">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i84d05573f20f452f881daacb0e2fafda_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC00LTEtMS0wL3RleHRyZWdpb246YzlkY2ZhOTU4ZmI3NDI0NjkyNTNlMDMyNTc1MGU0Y2JfNjA0NzMxMzk1MjgwMg_bebf0ce7-2ff8-47a3-a23d-c1b8751f2740">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC02LTEtMS0wL3RleHRyZWdpb246YmYwODRkNzg2MTA5NDQyZTkwNWU4ZDFmM2NiNjg5MTFfNjA0NzMxMzk1Mjc4Ng_f0b197be-efc8-4147-9cd0-5bac72d8413a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC02LTEtMS0wL3RleHRyZWdpb246YmYwODRkNzg2MTA5NDQyZTkwNWU4ZDFmM2NiNjg5MTFfNjA0NzMxMzk1Mjc5Mw_d5c91654-9fd4-4e6d-b702-4d458de21a07">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC04LTEtMS0wL3RleHRyZWdpb246MmY4YTcxNzA0ZTk1NGMzZThiMjU2MDUzZTc5NjlkZmFfNjA0NzMxMzk1Mjc4Ng_5e1542ce-7023-4638-b462-996e7a2a1886">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNC04LTEtMS0wL3RleHRyZWdpb246MmY4YTcxNzA0ZTk1NGMzZThiMjU2MDUzZTc5NjlkZmFfNjA0NzMxMzk1Mjc5Mw_5dade8db-1d9b-4971-92af-870241b2cc7b">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS0yLTEtMS0wL3RleHRyZWdpb246Yjg5MzcyZTEwZTc3NGMyYTk5NDg0ZWIxMTRkNzg5ZWZfNjA0NzMxMzk1Mjc4MA_b9d95c91-c227-4462-a33c-3392a7d02102"
      unitRef="number">0.665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS0yLTEtMS0wL3RleHRyZWdpb246Yjg5MzcyZTEwZTc3NGMyYTk5NDg0ZWIxMTRkNzg5ZWZfNjA0NzMxMzk1Mjc4NQ_b1815325-379f-4a50-98c6-5b4486cf33ce"
      unitRef="number">0.685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i12fb0e2cc01a47eca1252f58c3e04976_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS00LTEtMS0wL3RleHRyZWdpb246NzFkMTA4YmNjOTc3NGRhNzljMjQ0YWI5ZDVhYWRhZmRfNjA0NzMxMzk1Mjc4Mg_d26503c7-cd8c-4bc9-acea-39fa59b384e1"
      unitRef="number">0.669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i84d05573f20f452f881daacb0e2fafda_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS00LTEtMS0wL3RleHRyZWdpb246NzFkMTA4YmNjOTc3NGRhNzljMjQ0YWI5ZDVhYWRhZmRfNjA0NzMxMzk1Mjc4Nw_0250abef-cf6e-44ea-8a60-684ae7b4f05f"
      unitRef="number">0.683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS02LTEtMS0wL3RleHRyZWdpb246NjY0MzMyNzNlZjU2NDJkY2IzMTNkZDkzN2Q2MjFiMzBfNjA0NzMxMzk1Mjc4Mg_7ca28ec2-ed2e-4c43-a290-dc97f3758a1e"
      unitRef="number">0.665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS02LTEtMS0wL3RleHRyZWdpb246NjY0MzMyNzNlZjU2NDJkY2IzMTNkZDkzN2Q2MjFiMzBfNjA0NzMxMzk1Mjc4Nw_06d65e16-45b9-4198-a587-5abebb3d16c7"
      unitRef="number">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS04LTEtMS0wL3RleHRyZWdpb246M2M1NTRjODA0ZWE2NDdhNWIwYWNlYjY3YzQwZjk5OTdfNjA0NzMxMzk1Mjc4Mg_5684c172-4a66-4cad-a3ce-73e11c679fd4"
      unitRef="number">0.667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNS04LTEtMS0wL3RleHRyZWdpb246M2M1NTRjODA0ZWE2NDdhNWIwYWNlYjY3YzQwZjk5OTdfNjA0NzMxMzk1Mjc4Nw_3ee83d90-5c0f-4ee6-bb35-9653f226f984"
      unitRef="number">0.683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi0yLTEtMS0wL3RleHRyZWdpb246YWMwNzgxZjYzMDZjNGUzNjgyODM0ZmNlOWMyNjI1OWJfNjA0NzMxMzk1Mjc3OA_2f908242-a141-4e12-bf6d-ead56abed440"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8c90502ef5bd496c804cbebe876cf892_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi0yLTEtMS0wL3RleHRyZWdpb246YWMwNzgxZjYzMDZjNGUzNjgyODM0ZmNlOWMyNjI1OWJfNjA0NzMxMzk1Mjc4NQ_308b8fea-c444-4f70-a608-b333b35b5207"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi00LTEtMS0wL3RleHRyZWdpb246YTFmYzFlZDE0OTk0NDY1ZWIzYjljNjA0MmVlNjRhMjNfNjA0NzMxMzk1Mjc5Ng_1b4f8ae7-1260-426b-b921-e756565b6f66"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0738983bd5fa45478b2585b00ccb2cce_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi02LTEtMS0wL3RleHRyZWdpb246ZjMwNTgzZGQ5OTc3NDQwOTlkOTI5MGViYjdjNzZkNDJfNjA0NzMxMzk1Mjc4MA_d9f5d89a-46ad-45bf-a0fc-1e01c0764642"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i374e4c55330346ff9b0362dd8ddf90b7_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi02LTEtMS0wL3RleHRyZWdpb246ZjMwNTgzZGQ5OTc3NDQwOTlkOTI5MGViYjdjNzZkNDJfNjA0NzMxMzk1Mjc4NQ_45d378fa-8bc3-4ac1-a6ac-1a850b0f5fce"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i350151f0e91546cc8d8a90132c031c09_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi04LTEtMS0wL3RleHRyZWdpb246MzBlMDE5NmY4OWFlNDllN2E0YWFkZDRjOTE5ODEwNGZfNjA0NzMxMzk1Mjc4MA_aa93c66a-f309-4381-b665-71d58e693e86"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5980c73d3e8444869736ad96bd9a0ac8_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNi04LTEtMS0wL3RleHRyZWdpb246MzBlMDE5NmY4OWFlNDllN2E0YWFkZDRjOTE5ODEwNGZfNjA0NzMxMzk1Mjc4NQ_94d46c58-0978-481c-a834-8fbb9752e741"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if9df8ef4afe54d51bb4c149ba983e328_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy0yLTEtMS0wL3RleHRyZWdpb246ZWIxYmViZmNiN2Y4NDRkMDg2MWFlNGU3MWI0MjUyOWRfNjA0NzMxMzk1Mjc3NA_90422a55-b123-4194-8475-d9cc02eb1cf0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy00LTEtMS0wL3RleHRyZWdpb246NTI1OTkwOGEwOWJhNDM0OTg3OGY5MDg4OGU3MDgyYTlfNjA0NzMxMzk1Mjc3Ng_d7cac75c-4071-4351-afb2-c480c4fb701e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy02LTEtMS0wL3RleHRyZWdpb246YTdkYzIzODAxN2JlNDA0YmEwNzAzZmE3MWVlODVmZmZfNjA0NzMxMzk1Mjc3Ng_91a766d8-2bc2-40f0-be30-a1e1339893df"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4a0d4e0481d84fadaad8a7fe2f5e9afc_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOmJmYTgxODA3NDA3ZjQwMDJiN2MwZGY3OTIwODMxYjdmL3RhYmxlcmFuZ2U6YmZhODE4MDc0MDdmNDAwMmI3YzBkZjc5MjA4MzFiN2ZfNy04LTEtMS0wL3RleHRyZWdpb246M2U0MmQxZDg2YzdlNGVkNGFmMWQwYWE3YTVjNzMyYzJfNjA0NzMxMzk1Mjc3Ng_1bbd06e5-e879-4bad-836d-3303c2a713b8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic24160e876cf456cb7df6b5b604764e2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzU2Mg_36585516-a510-4e53-a29d-80c9f354186b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODI4MQ_40b5a172-f723-4a5d-980f-8b02d4fc8310">P0Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODMxMA_96b7b614-5441-4c74-9091-889eb3b4bd70">P2Y25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODM2MQ_bc636b7a-864c-4f40-8e7c-53b40f50c047"
      unitRef="number">0.655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODM2Nw_cff766df-d170-41ce-811f-1f3245aaa09f"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODM3Mw_8ddeac5c-e859-4986-b045-8a1c5a60c340"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate
      contextRef="ic4ef223e52a24f5a8d35f465e072b820_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODQzMA_86ab9303-cbc9-4505-a9a1-6de0eed34dcf"
      unitRef="number">0.16</gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="i8c93771b689a458aa8a9011e777434f5_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODUzNg_ab06cc4a-fb37-4478-9f40-d25693f2e732"
      unitRef="number">0.104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="id124c65b720d487f82782dd688a3d4f9_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDM5ODA0NjUzODU0Mg_e73b957a-a639-4c33-873e-b67f9574e0a1"
      unitRef="number">0.145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3ee695d4440547a7bfcb36de34921acc_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzc1Mw_6aab599f-f326-47ba-8290-c51f600399bf"
      unitRef="shares">922250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id2402cd27c104ea38107f29820dae694_I20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMzg3OQ_db786d15-1b80-4641-b907-ba14bf01fa64"
      unitRef="shares">942614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i050b6f2672cc4818903148e5e1bb1511_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDE1Nw_f58f45ad-194e-44fb-996f-1c083c8f93ba"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNDMzMA_efe2e43f-1937-4396-9c27-6f07b4f8ad5b"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDM3NA_b001689b-ddd3-4015-be9c-b410d8119958"
      unitRef="shares">58164</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDM4MQ_b706999f-e079-4b0b-9155-c98243915ec6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDUxNg_1ba6b574-5132-470f-8fc7-d6b19dd409da"
      unitRef="shares">58164</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDI0OA_fd1e774c-77b9-47f9-9660-e8c4ea24cd39"
      unitRef="shares">119702</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDMxNw_43e74a31-5b5c-42a2-981f-0451aecb7ede"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjA0NzMxMzk2MDU4Nw_f1c33c10-2987-4d2f-9b2f-8e2838b94a26"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTAzMQ_e2cf3555-0112-475a-9f92-f218e7bbd83d"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTAzOA_a1b41ba1-6413-46ec-bcd7-1e4e9e6cc5c6"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC0yLTEtMS0xODcz_33c5a729-d7b1-4f15-bf1e-f9c5ca05e173">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC00LTEtMS0xODc4_c7c6297e-4456-4b27-bf34-a3a6652a4933">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC0yLTEtMS0xNzk0_4b1018ab-87b5-4ef6-b927-d0d3bea2fa9e">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNC00LTEtMS0xNzk0_7e4cbdf8-a402-43da-874f-c9c9d8fe6dac">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS0yLTEtMS0xODcz_728f4acf-4faa-40e9-86f5-54d2f47b0169"
      unitRef="number">0.732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS00LTEtMS0xODc4_cc6d0455-a226-413a-b9b7-5c7e2b59a8c2"
      unitRef="number">0.602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS0yLTEtMS0xNzk0_dd1582c2-6a91-4890-a661-346c73333830"
      unitRef="number">0.732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNS00LTEtMS0xNzk0_abb16f36-502a-43d5-8d45-0f85e94385f7"
      unitRef="number">0.602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi0yLTEtMS0xODcz_dc09cc1a-d56c-4947-8905-beaf4068c15b"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi00LTEtMS0xODc4_cd217925-2a84-4f89-b21e-4fc31f20fa5d"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi0yLTEtMS0xNzk0_38d16e35-f85c-4caf-91d6-2b24a65fe60b"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNi00LTEtMS0xNzk0_9ef42f57-156d-4960-963e-bef0df7b1d97"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy0yLTEtMS0xODcz_eda613e1-8695-4b7f-802a-b958ff8728f7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i343c8fa6863a4db8a2993859cfa1ac05_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy00LTEtMS0xODc4_f4053e61-a92c-41d7-aeed-06f35d30ad74"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy0yLTEtMS0xNzk0_507d641b-122d-491b-a9ed-3bf6a342ab06"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iae802d49bd74496ebe815b675137dd94_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RhYmxlOjBkNmFlMmEyNzE1MzRlMzk5MTlhYzkxNzFjZWEzYzYxL3RhYmxlcmFuZ2U6MGQ2YWUyYTI3MTUzNGUzOTkxOWFjOTE3MWNlYTNjNjFfNy00LTEtMS0xNzk0_1fa1f138-fc6f-4adb-be17-82d1f1af0b98"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i050b6f2672cc4818903148e5e1bb1511_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTg0OQ_83aa0c3d-032c-4209-aaf7-eedaa32e4279"
      unitRef="usd">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i885fd3554c684c98aa5154623a11510d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNTkzOA_6eef1c22-f9e8-40bc-9a97-b44d12e4473e">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <gh:CommonStockSubjecttoRepurchaseorCancellation
      contextRef="ib447deb7798c4703841cfadceacfb6f2_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjMzMA_44c90bb4-a9ba-429e-ad9e-a2662c2a23d1"
      unitRef="shares">18447</gh:CommonStockSubjecttoRepurchaseorCancellation>
    <gh:CommonStockSubjecttoRepurchaseorCancellation
      contextRef="iad98bc19a43049ad9b63d15d678d5da0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjM0NA_2b0e8300-e1b3-426d-8373-87c0728b1988"
      unitRef="shares">23981</gh:CommonStockSubjecttoRepurchaseorCancellation>
    <gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare
      contextRef="i38994038d3c544e391545c7a4e7a5037_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjQyNg_ab66a6fa-65f1-42a5-8471-31c68e1a1631"
      unitRef="usdPerShare">4.66</gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare>
    <gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare
      contextRef="i1238eed8c3a8409ea6755199b243129b_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjQyNg_e1d82abf-b9f9-4a14-9ea6-ad58db3fa3e6"
      unitRef="usdPerShare">4.66</gh:WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i1238eed8c3a8409ea6755199b243129b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjUyMw_74fef261-b69c-48e4-ad17-e942ad9077c2"
      unitRef="usd">100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i38994038d3c544e391545c7a4e7a5037_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfNjUzMA_16680726-9826-4272-9e4f-56e489db641e"
      unitRef="usd">100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RleHRyZWdpb246OWVlZTQxZWZhZWVjNDJiNGJjZjE3YmM2NjNiY2MyODBfODMz_69c249c2-a904-4848-9e8a-d45353d42100">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.921%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.183%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(81,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Adjustment of redeemable noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(82,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.921%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.183%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,056&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,908&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;542&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ESPP obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock subject to repurchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RleHRyZWdpb246OWVlZTQxZWZhZWVjNDJiNGJjZjE3YmM2NjNiY2MyODBfODM0_5e23de7f-1378-431b-844a-d3a044e24030">&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:13pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.921%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.183%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(49,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(81,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(32,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Adjustment of redeemable noncontrolling interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(54,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(82,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(37,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:-9pt;padding-left:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS0yLTEtMS0xOTEz_ee98f325-0138-4505-b963-1c26b675aefc"
      unitRef="usd">-49739000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS00LTEtMS0xOTE2_06bedb6c-31ee-44c9-ad76-27399a868457"
      unitRef="usd">-11300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS02LTEtMS0w_12bedb43-bc62-4f31-93ce-d8c6bb473ba7"
      unitRef="usd">-81568000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNS04LTEtMS0w_c3efbf0d-37cf-4075-af0b-c9ac937c182c"
      unitRef="usd">-32651000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi0yLTEtMS0w_3fbbed0a-ac4c-45d2-8652-68edc3609113"
      unitRef="usd">4900000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi00LTEtMS0w_7fddc32c-243e-448f-a4f9-5269d4f5bb0f"
      unitRef="usd">300000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi02LTEtMS0w_7c8cd13c-c263-438a-a9d8-70ee3edc00e9"
      unitRef="usd">800000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNi04LTEtMS0w_66770d39-23bf-4c47-82cd-695060636db4"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy0yLTEtMS0yNzIz_4ea0fc7d-93dd-4bad-ab95-e4e3ab40ace2"
      unitRef="usd">-54639000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy00LTEtMS0yNzI1_b784363a-b5d1-4f2c-95db-7bc495817c5f"
      unitRef="usd">-11600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy02LTEtMS0w_780b18da-d061-4b93-8625-23625d427e06"
      unitRef="usd">-82368000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfNy04LTEtMS0w_960a0449-7b20-4105-9b9c-eadca6eb5641"
      unitRef="usd">-37651000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC0yLTEtMS0yNzIz_1e406511-4543-409d-9307-54d8e1398627"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC00LTEtMS0yNzI1_d86f7e90-02b2-463e-a80a-4a44e792a9eb"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC02LTEtMS0w_a27d38bd-24bd-4c74-ba73-5691ca1cc79f"
      unitRef="usdPerShare">-0.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOC04LTEtMS0w_5f5af818-d612-426f-989c-cd669749cb48"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS0yLTEtMS0w_3a246fa7-e9b2-437d-ba9d-3d42177c0fed"
      unitRef="shares">96011000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS00LTEtMS0w_0b2a408e-2c63-43b4-8df9-851b2ae676a5"
      unitRef="shares">89036000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS02LTEtMS0w_2f18180c-5d49-4e6f-ae1f-814660621a78"
      unitRef="shares">95196000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOjNlZWZmYzY2ZmZiYzQzOGFiZGNhZjg0MDBlOGFjMDQzL3RhYmxlcmFuZ2U6M2VlZmZjNjZmZmJjNDM4YWJkY2FmODQwMGU4YWMwNDNfOS04LTEtMS0w_51552e7b-a6cf-4268-82c5-a3c02c9c1019"
      unitRef="shares">87494000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RleHRyZWdpb246OWVlZTQxZWZhZWVjNDJiNGJjZjE3YmM2NjNiY2MyODBfODM2_f2364476-2848-4ba3-9ec0-f93466810249">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.756%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.921%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.179%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.183%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,056&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,908&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;542&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;MSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;671&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ESPP obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock subject to repurchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,451&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf536ddb35a64f85aacee7598268259c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS0yLTEtMS0w_2d10a321-752e-419d-bc8d-8001e465936d"
      unitRef="shares">4056000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3323a04942704687bb2555b54314aab2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS00LTEtMS0w_ecc4232b-2844-48bb-ae33-e0a8e6800d84"
      unitRef="shares">6313000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifd47da85e7de4d7fadfd20dc20f187d9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS02LTEtMS0w_608ba19b-b574-4617-9098-336939663c00"
      unitRef="shares">4200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie9d2e5e2fcdf4b2c8fc419d96dc58c5d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNS04LTEtMS0w_27d83d82-7bb6-46dc-be90-53296e772d58"
      unitRef="shares">6908000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if8dbde309aa54633a3e4375f89ae690b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi0yLTEtMS0w_cd46f0bf-3336-4a54-a610-536fed742140"
      unitRef="shares">542000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i294c1765216e4c6a8e11a0d8b3daaa00_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi00LTEtMS0w_89799ba1-5813-41d5-9ba4-6ce9ef5a7f94"
      unitRef="shares">122000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6174d62dea8d4279975b861469129eef_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi02LTEtMS0w_551e7ed0-ae96-4c3f-ab3b-6e71954bd1d2"
      unitRef="shares">519000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa43e28a9ae54214be7d361b2e4321cf_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNi04LTEtMS0w_132b04c1-9cec-434a-aee3-e595f426136a"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c8ced2cd65f4b248f2b50a4b222ada8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy0yLTEtMS01Mzgw_3e86da88-67e8-4601-92d2-17493c00a68e"
      unitRef="shares">1342000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i71599760dfd541cabf39036748115634_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy00LTEtMS01Mzgw_b9d2a898-7d57-4e8b-a217-40b6954efb42"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i737cf94c5a8046d2a11b701014ec16db_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy02LTEtMS01Mzc3_ab4751d4-85fb-49bb-8453-253df2d91795"
      unitRef="shares">671000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8dec3173cbde4f96afc4de39bf38d895_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy04LTEtMS01Mzc3_0afe92c1-c289-40e1-bca3-4ed768170273"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8094e7366d1143b68620e23e39605cc1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy0yLTEtMS0w_dde3555d-5a8b-44b2-90ec-94d112fe52ad"
      unitRef="shares">37000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i638ebad1fa064de89eb9cef3d781bcf3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy00LTEtMS0w_b0a4d963-bf93-4242-a715-996d9ca1c042"
      unitRef="shares">83000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13a797c312c54413b66a65e0d28b0956_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy02LTEtMS0w_5826bebe-5243-49a3-b4e7-11f09a7c539c"
      unitRef="shares">40000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2d40935270e24e809f8b781d57808fc8_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfNy04LTEtMS0w_222c4c0b-0146-4099-9be2-3c5992a05d54"
      unitRef="shares">71000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i48e997052345498c87b595375bf8389a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC0yLTEtMS0w_26ce7559-a814-4d1f-aa0c-15382d48df5f"
      unitRef="shares">20000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic4547ce0781f4157886f48a25170a1bb_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC00LTEtMS0w_7058a5e5-8a4e-4289-b7c6-8c8fa8ba1d4d"
      unitRef="shares">32000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia2d5b67d8d024c7a948a5649bb02e25b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC02LTEtMS0w_7670552c-435c-48ba-8420-d43c9f8672d8"
      unitRef="shares">21000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i952e389dbc4144349e3163b45d8a21a5_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOC04LTEtMS0w_99cd65cc-4fdd-4933-87dc-1ed78d03a5f5"
      unitRef="shares">37000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS0yLTEtMS0yNzMx_da238f04-f06c-4366-a8ad-7c324c8d22f9"
      unitRef="shares">5997000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS00LTEtMS0yNzMz_2c974504-83e1-457c-9e26-585bdf1dc201"
      unitRef="shares">6550000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS02LTEtMS0w_d183bb82-7c8b-476f-897d-5a5baf7e145c"
      unitRef="shares">5451000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85MS9mcmFnOjllZWU0MWVmYWVlYzQyYjRiY2YxN2JjNjYzYmNjMjgwL3RhYmxlOmQ1ZmNlZmU3OWVmZjQxZTY4MTYxZjk5MDhlMzE3N2U1L3RhYmxlcmFuZ2U6ZDVmY2VmZTc5ZWZmNDFlNjgxNjFmOTkwOGUzMTc3ZTVfOS04LTEtMS0w_c3d375b8-10b5-4920-9d32-575473eac1bc"
      unitRef="shares">7116000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85NC9mcmFnOmQ4YTA2ZmI1MDk0ZTQ3N2JiZWRmZDU1ZGQ5YzI4NTIzL3RleHRyZWdpb246ZDhhMDZmYjUwOTRlNDc3YmJlZGZkNTVkZDljMjg1MjNfNTQ5NzU1ODE0MDQwMQ_03ddc491-f805-46ad-9cea-f1e66ec41a4c">Income Taxes&lt;div style="text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The income tax expense for the three and six months ended June 30, 2020 was determined based upon estimates of the Company&#x2019;s effective income tax rates in various jurisdictions. The difference between the Company&#x2019;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The income tax expense for the three and six months ended June 30, 2020 relates primarily to state minimum income tax and income tax on the Company&#x2019;s earnings in foreign jurisdictions. The benefit from income taxes for the six months ended June 30, 2019 relates primarily to the release of a valuation allowance of $1.2&#160;million associated with nondeductible intangible assets recorded as part of the Bellwether Bio acquisition, partially offset by state minimum income tax and income tax on the Company's earnings in foreign jurisdictions. In connection with the acquisition of Bellwether Bio, a deferred tax liability was established for the book-tax basis differences related to the non-goodwill intangible assets. The net deferred tax liability from this acquisition creates an additional source of income to offset the Company&#x2019;s deferred tax assets. As such, the impact on the acquiring Company&#x2019;s deferred tax &lt;/span&gt;&lt;/div&gt;assets and liabilities caused by an acquisition are recorded in the acquiring company&#x2019;s consolidated financial statements outside of acquisition accounting.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85NC9mcmFnOmQ4YTA2ZmI1MDk0ZTQ3N2JiZWRmZDU1ZGQ5YzI4NTIzL3RleHRyZWdpb246ZDhhMDZmYjUwOTRlNDc3YmJlZGZkNTVkZDljMjg1MjNfNDk0NzgwMjMyNTk2NQ_cfda2fa8-f6e2-48c8-a90c-5fba621f7cfd"
      unitRef="usd">-1200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RleHRyZWdpb246ZjViNjdhZGVlYTEwNGIzZGIwMzM5ZDc5NjM1MzQ0ZWRfNTA0_35f87bd8-30b9-44ad-a868-852cf8e72ffc">Segment and Geographic Information&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.921%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.106%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;International &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;"&gt;(1)&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June&#160;30, 2020&#160;and&#160;2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, substantially all of the Company&#x2019;s long-lived assets and right-of-use assets are located in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RleHRyZWdpb246ZjViNjdhZGVlYTEwNGIzZGIwMzM5ZDc5NjM1MzQ0ZWRfNTA3_00af7030-a1c3-45f9-86d3-36fc630cee06">&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company&#x2019;s revenue by geographic areas based on the customers&#x2019; locations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.064%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.102%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.921%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.106%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;126,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;International &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-indent:27pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Total revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;66,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;"&gt;(1)&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June&#160;30, 2020&#160;and&#160;2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="i3a05f1e0143d47aa8aac871e977a2d93_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS0yLTEtMS0w_076b8b83-6263-4a4c-8716-06b296ede816"
      unitRef="usd">61422000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id56241c9ef5b4e06a9097eaf342ad306_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS00LTEtMS0w_b01edafe-a5e4-4432-8941-7e99f40e288c"
      unitRef="usd">48997000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95d2e07d74ee40dcbd0c515fc3ac73ea_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS02LTEtMS0w_1adeb9c4-5b3a-4efa-bd6b-f348b326d1ea"
      unitRef="usd">126035000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7989738be28147c79edc5a175133e7e7_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNS04LTEtMS0w_448b7987-21d0-4865-b2cb-830ea0f62ba7"
      unitRef="usd">80242000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9c900bb63484126aeed5864a3482233_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi0yLTEtMS0w_787c8c34-d73d-4470-a5ea-fe8dec923a57"
      unitRef="usd">4913000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5853898710f74fc98551c4698099ad34_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi00LTEtMS0w_3d112d09-07e8-4cbb-addf-c23acf65d652"
      unitRef="usd">4978000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15ab6406ad7b4d44aea212764d7260e3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi02LTEtMS0w_02f29da0-58f9-439b-8918-205148bd1244"
      unitRef="usd">7810000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie60db419cf834ec9b927bf239d7a59ab_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNi04LTEtMS0w_cdaa91ff-1827-4e52-8d7f-b43c9b068c5d"
      unitRef="usd">10388000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy0yLTEtMS0yNzM3_4fd14be9-fd9d-4db2-b23c-07789bc7e885"
      unitRef="usd">66335000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09be9bcd45564bba849b3b2c629fb7bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy00LTEtMS0yNzM5_2a62bce1-3ecb-4af0-a234-d96cb64ba055"
      unitRef="usd">53975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy02LTEtMS0w_13f2340c-ed94-4e46-ad3b-a7074d747631"
      unitRef="usd">133845000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl85Ny9mcmFnOmY1YjY3YWRlZWExMDRiM2RiMDMzOWQ3OTYzNTM0NGVkL3RhYmxlOmRkNmIyZTFlMWU4ZDQ5NzY4NmI4ZjJhNzdmNGMyNWUyL3RhYmxlcmFuZ2U6ZGQ2YjJlMWUxZThkNDk3Njg2YjhmMmE3N2Y0YzI1ZTJfNy04LTEtMS0w_ef377476-532b-4bc1-a54c-7147daca52b3"
      unitRef="usd">90630000</us-gaap:Revenues>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNDU_d3e83ed7-7f72-4502-8c80-c9d8c72ca755">Related Party Transactions&lt;div style="text-align:justify;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As discussed in Note 3, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Investment in Joint Venture&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company and its subsidiaries may, in the ordinary course of business, have transactions with unaffiliated companies of which certain of the Company&#x2019;s directors are directors and/or executive officers. The Company believes that such transactions are on the same terms generally offered by such other companies to other entities in comparable transactions. The Company does not consider the amounts involved in such transactions to be material in relation to its businesses, the businesses of such other companies or the interests of the directors involved. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Revenue from an entity affiliated with a member of the Company's Board of Directors was $0.6 million and $0.5 million for the three months ended June 30, 2020 and 2019, and $1.5 million and $0.9 million for the six months ended June 30, 2020 and 2019. As of June&#160;30, 2020 and December&#160;31, 2019, the Company has accounts receivable from this entity of $2.0 million and $0.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i0bb034afda014a85b1b0e2b6b26d774f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjUzOTE_71249009-6cb5-445e-9c68-f94c61773cb5"
      unitRef="usd">600000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i00416340ee41460f89b3b8e7094a4e0c_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0MDE_b9bfdb1d-84ca-49c2-982a-fdb8e04b93af"
      unitRef="usd">500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ibc0fce7baca6420eadd2052f4a00b6f8_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0MTE_e8961e55-c2a8-42c6-885d-391b80bbc47a"
      unitRef="usd">1500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i0ada0d183d4f48bf8c719b83d32cc159_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0Mzc_b0a0bb96-f5b0-42af-85ac-be02e49d4f16"
      unitRef="usd">900000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i5b4a8e61a1034084959a4fd4db4b38f7_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU0NzI_36ffcf58-e1ab-445d-a014-3504f54eaa78"
      unitRef="usd">2000000.0</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i604a260fb2ce4d20bb48257e8df58cfe_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzQzOTgwNDY1MjU1MDA_e9aaf9f0-71f0-4ac8-9b25-21d1813e116b"
      unitRef="usd">900000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNDY_656bb9a2-bd38-4b83-86aa-a702b915a32b">Subsequent EventsThe Company entered into two new agreements in July 2020 to lease additional office and laboratory space. The lease agreements each have a target commencement date in the first half of fiscal year 2021, with estimated aggregate base rent payments of $239.5&#160;million over the weighted average estimated lease term of 11.5 years. One of the lease agreements provides an option to renew the lease term for an additional ten years. The Company is currently evaluating the accounting for such leases.</us-gaap:SubsequentEventsTextBlock>
    <gh:NumberOfOperatingLeasesLeaseNotYetCommenced
      contextRef="ie657fc31977a42088ce4640db6c02671_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzIxOTkwMjMyNjc5MjM_237bcb11-136a-4ab1-be7a-430ad5a1da00"
      unitRef="numberofleases">2</gh:NumberOfOperatingLeasesLeaseNotYetCommenced>
    <us-gaap:OperatingLeasePayments
      contextRef="ib850ca5924ca4d90bd09e86c08ec11ba_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNDg_f45afd41-b715-40c4-96b8-a833a9ed6171"
      unitRef="usd">239500000</us-gaap:OperatingLeasePayments>
    <gh:LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract
      contextRef="ib850ca5924ca4d90bd09e86c08ec11ba_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyNjM_0802d6d5-f0a7-4789-91e2-28f565c58a22">P11Y6M</gh:LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="ie657fc31977a42088ce4640db6c02671_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xMDAvZnJhZzo5MmMxMDAxMjMyYTk0YWMzYWI1NmE0NzQxZjBiNjgxYy90ZXh0cmVnaW9uOjkyYzEwMDEyMzJhOTRhYzNhYjU2YTQ3NDFmMGI2ODFjXzE2NDkyNjc0NTAyOTQ_a7db1499-76c1-4195-b32a-0c3453972233">P10Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMy0xLTEtMA_1cde555c-9ea1-4403-8945-5c3668bb3559"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMy0xLTEtMA_1cde555c-9ea1-4403-8945-5c3668bb3559"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMS0xLTEtMA_18023dad-efe9-408a-b72c-0ff13ac1ee41"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMS0xLTEtMA_18023dad-efe9-408a-b72c-0ff13ac1ee41"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMS0xLTEtMA_f08ce5ca-7cd9-4a37-99c4-0f28c9873c79"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMS0xLTEtMA_f08ce5ca-7cd9-4a37-99c4-0f28c9873c79"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMy0xLTEtMA_57f123da-e902-4c80-a630-7610ebc0c552"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMy0xLTEtMA_57f123da-e902-4c80-a630-7610ebc0c552"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of June&#160;30, 2020 and&#160;December&#160;31, 2019, includes $38.4 million and&#160;$45.1 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#x201c;VIE&#x201d;) and VIE&#x2019;s subsidiaries, and&#160;$4.0 million and $5.7 million&#160;of liabilities of the consolidated VIE and VIE&#x2019;s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <xhtml:span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investment in Joint Venture</xhtml:span><xhtml:span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMy0xLTEtMA_1cde555c-9ea1-4403-8945-5c3668bb3559"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMTYtMS0xLTEtMA_18023dad-efe9-408a-b72c-0ff13ac1ee41"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMS0xLTEtMA_f08ce5ca-7cd9-4a37-99c4-0f28c9873c79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RhYmxlOmQ1MjdiOGQ3NDZkNTRlNmZiZjNhYmYwY2ZjZmM1ZDQ3L3RhYmxlcmFuZ2U6ZDUyN2I4ZDc0NmQ1NGU2ZmJmM2FiZjBjZmNmYzVkNDdfMjctMy0xLTEtMA_57f123da-e902-4c80-a630-7610ebc0c552"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl8xNi9mcmFnOjJmZTQwMjBmNmJjYjQ5M2M4YTk2NGEzMDYyYmExMGMyL3RleHRyZWdpb246MmZlNDAyMGY2YmNiNDkzYzhhOTY0YTMwNjJiYTEwYzJfNjAx_36d4c52d-3683-4d89-8ae1-3cbc81807b6c"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589986015912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GUARDANT HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4139254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Penobscot Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">698-8887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,424,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001576280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589985789992">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 164,671<span></span>
</td>
<td class="nump">$ 143,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">773,160<span></span>
</td>
<td class="nump">379,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,017<span></span>
</td>
<td class="nump">47,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,354<span></span>
</td>
<td class="nump">15,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,101<span></span>
</td>
<td class="nump">11,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,010,303<span></span>
</td>
<td class="nump">597,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">146,118<span></span>
</td>
<td class="nump">268,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,995<span></span>
</td>
<td class="nump">43,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,503<span></span>
</td>
<td class="nump">29,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,148<span></span>
</td>
<td class="nump">8,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CapitalizedLicenseFees', window );">Capitalized license fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="nump">6,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,124<span></span>
</td>
<td class="nump">4,882<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,277,536<span></span>
</td>
<td class="nump">962,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,982<span></span>
</td>
<td class="nump">16,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,526<span></span>
</td>
<td class="nump">18,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,055<span></span>
</td>
<td class="nump">25,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,485<span></span>
</td>
<td class="nump">12,277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,048<span></span>
</td>
<td class="nump">72,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,117<span></span>
</td>
<td class="nump">33,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedRoyaltiesNoncurrent', window );">Obligation related to royalty</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,382<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">112,547<span></span>
</td>
<td class="nump">114,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,400<span></span>
</td>
<td class="nump">49,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June&#160;30, 2020 and December&#160;31, 2019; 99,312,237 and 94,261,414 shares issued and outstanding as of June&#160;30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,544,373<span></span>
</td>
<td class="nump">1,150,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,392<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(435,177)<span></span>
</td>
<td class="num">(352,809)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,114,589<span></span>
</td>
<td class="nump">798,393<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Redeemable Noncontrolling Interest and Stockholders&#8217; Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,277,536<span></span>
</td>
<td class="nump">$ 962,535<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of June&#160;30, 2020 and&#160;December&#160;31, 2019, includes $38.4 million and&#160;$45.1 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$4.0 million and $5.7 million&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investment in Joint Venture</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CapitalizedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CapitalizedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589985404296">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,312,237<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,312,237<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,277,536<span></span>
</td>
<td class="nump">$ 962,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">112,547<span></span>
</td>
<td class="nump">114,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,400<span></span>
</td>
<td class="nump">45,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of June&#160;30, 2020 and&#160;December&#160;31, 2019, includes $38.4 million and&#160;$45.1 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$4.0 million and $5.7 million&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investment in Joint Venture</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589986612264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromPrecisionOncologyTesting', window );">Precision oncology testing</a></td>
<td class="nump">$ 50,991<span></span>
</td>
<td class="nump">$ 42,064<span></span>
</td>
<td class="nump">$ 111,237<span></span>
</td>
<td class="nump">$ 70,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_RevenuefromDevelopmentServices', window );">Development services</a></td>
<td class="nump">15,344<span></span>
</td>
<td class="nump">11,911<span></span>
</td>
<td class="nump">22,608<span></span>
</td>
<td class="nump">19,729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">66,335<span></span>
</td>
<td class="nump">53,975<span></span>
</td>
<td class="nump">133,845<span></span>
</td>
<td class="nump">90,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostsofPrecisionOncologyTesting', window );">Cost of precision oncology testing</a></td>
<td class="nump">17,809<span></span>
</td>
<td class="nump">14,650<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">25,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostofDevelopmentServices', window );">Cost of development services</a></td>
<td class="nump">4,626<span></span>
</td>
<td class="nump">2,183<span></span>
</td>
<td class="nump">6,941<span></span>
</td>
<td class="nump">4,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">36,319<span></span>
</td>
<td class="nump">19,532<span></span>
</td>
<td class="nump">73,335<span></span>
</td>
<td class="nump">35,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="nump">25,015<span></span>
</td>
<td class="nump">19,439<span></span>
</td>
<td class="nump">50,130<span></span>
</td>
<td class="nump">37,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">37,186<span></span>
</td>
<td class="nump">13,439<span></span>
</td>
<td class="nump">56,971<span></span>
</td>
<td class="nump">26,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and operating expenses</a></td>
<td class="nump">120,955<span></span>
</td>
<td class="nump">69,243<span></span>
</td>
<td class="nump">223,377<span></span>
</td>
<td class="nump">129,562<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(54,620)<span></span>
</td>
<td class="num">(15,268)<span></span>
</td>
<td class="num">(89,532)<span></span>
</td>
<td class="num">(38,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,640<span></span>
</td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">5,958<span></span>
</td>
<td class="nump">5,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">2,285<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
<td class="num">(49,705)<span></span>
</td>
<td class="num">(12,507)<span></span>
</td>
<td class="num">(81,520)<span></span>
</td>
<td class="num">(33,832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(1,207)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(1,181)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(49,739)<span></span>
</td>
<td class="num">(11,300)<span></span>
</td>
<td class="num">(81,568)<span></span>
</td>
<td class="num">(32,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(4,900)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Guardant Health, Inc. common stockholders</a></td>
<td class="num">$ (54,639)<span></span>
</td>
<td class="num">$ (11,600)<span></span>
</td>
<td class="num">$ (82,368)<span></span>
</td>
<td class="num">$ (37,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)</a></td>
<td class="nump">96,011<span></span>
</td>
<td class="nump">89,036<span></span>
</td>
<td class="nump">95,196<span></span>
</td>
<td class="nump">87,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostofDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostofDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsofPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsofPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_RevenuefromPrecisionOncologyTesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from Precision Oncology Testing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_RevenuefromPrecisionOncologyTesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590078349640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (49,739)<span></span>
</td>
<td class="num">$ (11,300)<span></span>
</td>
<td class="num">$ (81,568)<span></span>
</td>
<td class="num">$ (32,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax impact:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(2,338)<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">4,233<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,313)<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(52,052)<span></span>
</td>
<td class="num">(10,289)<span></span>
</td>
<td class="num">(77,287)<span></span>
</td>
<td class="num">(31,224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to redeemable noncontrolling interest</a></td>
<td class="num">(4,900)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Guardant Health, Inc.</a></td>
<td class="num">$ (56,952)<span></span>
</td>
<td class="num">$ (10,589)<span></span>
</td>
<td class="num">$ (78,087)<span></span>
</td>
<td class="num">$ (36,224)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589983299656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest</div></th>
<th class="th"><div>Common&#160;Stock&#160;</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>&#160; Accumulated Deficit</div></th>
<th class="th">
<div>&#160; Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,832,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">483,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 764,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">(280,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance (Topic 606 adoption) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,907<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance (ASU 2018-07 adoption) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of offering costs</a></td>
<td class="nump">349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,677,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(32,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,806,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">815,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,128,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
<td class="num">(314,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,098,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">468,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">771,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="num">(303,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of offering costs</a></td>
<td class="nump">349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,531,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">4,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(11,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,806,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">815,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,128,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
<td class="num">(314,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">798,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,150,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
<td class="num">(352,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of offering costs</a></td>
<td class="nump">$ 354,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">654,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 3,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">32,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">4,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(81,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,312,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">1,114,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,544,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,392<span></span>
</td>
<td class="num">(435,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(4,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,509,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">785,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,157,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,705<span></span>
</td>
<td class="num">(380,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of offering costs</a></td>
<td class="nump">354,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly', window );">Vesting of common stock exercised early</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(2,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(49,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,312,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">1,114,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,544,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,392<span></span>
</td>
<td class="num">$ (435,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="nump">$ 1,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised Early</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=120519210&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201807Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201807Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982995864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders&#8217; Equity (unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="nump">$ 1,130<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
<td class="nump">$ 1,130<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590070052584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (81,568)<span></span>
</td>
<td class="num">$ (32,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,109<span></span>
</td>
<td class="nump">5,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AmortizationOfRightOfUseAsset', window );">Amortization of right-of-use assets</a></td>
<td class="nump">3,386<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ChargeOfInProcessResearchAndDevelopment', window );">Charge of in-process research and development costs with no alternative future use</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty', window );">Unrealized translation gains (loss) on obligation related to royalty</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Re-valuation of contingent consideration</a></td>
<td class="num">(190)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">32,153<span></span>
</td>
<td class="nump">6,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on marketable securities</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="num">(1,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Benefit from income tax differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Others</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities, net of effect of acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">6,894<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(5,173)<span></span>
</td>
<td class="num">(5,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,476)<span></span>
</td>
<td class="nump">3,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,820)<span></span>
</td>
<td class="nump">2,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(3,881)<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(792)<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(36,647)<span></span>
</td>
<td class="num">(18,139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(465,302)<span></span>
</td>
<td class="num">(418,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of marketable securities</a></td>
<td class="nump">197,548<span></span>
</td>
<td class="nump">129,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisition, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(19,105)<span></span>
</td>
<td class="num">(5,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(17,886)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(304,745)<span></span>
</td>
<td class="num">(305,198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations', window );">Payments made on royalty obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments made on capital lease obligations</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">3,548<span></span>
</td>
<td class="nump">5,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuances of common stock under employee stock purchase plan</a></td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering, net of underwriting discounts and commissions</a></td>
<td class="nump">355,730<span></span>
</td>
<td class="nump">350,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs related to public offering</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">362,786<span></span>
</td>
<td class="nump">357,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Net effect of foreign exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">21,443<span></span>
</td>
<td class="nump">34,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="nump">143,228<span></span>
</td>
<td class="nump">140,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;End of period</a></td>
<td class="nump">164,671<span></span>
</td>
<td class="nump">174,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">11,373<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">5,396<span></span>
</td>
<td class="nump">3,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_OfferingCostsIncurredButNotYetPaid', window );">Follow-on public offering issuance costs included in accounts payable and accrued expenses</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AmortizationOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AmortizationOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ChargeOfInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge Of In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ChargeOfInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_OfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_OfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Related to Settlement of Debt and Buyout of Royalty Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized Translations Gain (Loss) On Obligation Related To Royalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978006776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of BusinessGuardant Health, Inc. (the &#8220;Company&#8221;) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which the Company enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company&#8217;s capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, the Company has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Using data collected from the Company's Guardant360 tests, the Company has also developed GuardantINFORM platform to further accelerate precision oncology drug development by biopharmaceutical companies by offering them an in-silico research platform to further unlock insights into tumor evolution and treatment resistance across various biomarker-driven cancers. The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In May 2018, the Company formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) in the United States with an affiliate of SoftBank Vision Fund (AIV M1) L.P. (&#8220;SoftBank&#8221;). Under the terms of the joint venture agreement, the Company held a 50% ownership interest in the Joint Venture. As of June&#160;30, 2020, the Joint Venture has subsidiaries in Singapore and Japan (see Note 3, Investment in Joint Venture) and the Company has a subsidiary in Switzerland, which was incorporated in 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979535352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing cash and cash equivalents and marketable securities as of June&#160;30, 2020 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. The extent to which the COVID-19 pandemic will ultimately impact the </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company&#8217;s business, results of operations, financial conditions, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside the Company&#8217;s control, such as the duration, scope and severity of the pandemic, steps required or mandated by governments to mitigate the impact of the pandemic, and whether COVID-19 can be effectively prevented, detected, contained and treated, particularly in the markets where the Company operates. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated balance sheet as of June&#160;30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020 and 2019, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#8217; equity for the three and six months ended June&#160;30, 2020 and 2019, and cash flows for the six months ended June&#160;30, 2020 and 2019, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and six months ended June&#160;30, 2020 and 2019, foreign currency translation adjustment was immaterial. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Risk</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:17.230%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable, Net</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer A   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer B   </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer C   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer D   </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">*&#160;less than 10%</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable, Net</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of June&#160;30, 2020, the Company recorded $0.1 million as allowance for credit losses. As of December&#160;31, 2019, the Company had no allowance for credit losses.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Acquisition</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Transaction costs associated with the asset acquisition are capitalized. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Intangible Assets, net</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;June&#160;30, 2020, there has been&#160;no&#160;impairment of goodwill.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-12 years.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Precision oncology testing</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended June 30, 2020 and 2019, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$6.5&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$3.6&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration. For the six months ended June 30, 2020 and 2019, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$12.4&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$6.4&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration.  For the three and six months ended June 30, 2020, the Company recorded $2.6&#160;million and $4.1&#160;million, respectively, in revenue received from Medicare for samples processed in 2019.  For the three and six months ended June 30, 2019, the Company recorded $1.4&#160;million and $1.4&#160;million, respectively, in revenue received from Medicare for samples processed in 2018. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Development services</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. The Company revised and increased its total estimated costs relating to one of the development services contracts during the six months ended June 30, 2020.  Had the Company included such additional costs in the original estimated costs, revenues for the six months ended June 30, 2019 would have been lower by $3.6 million. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contracts with multiple performance obligations</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contract assets</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. Contract assets are presented under accounts receivable, net and other assets on the Company&#8217;s condensed consolidated balance sheets. As of&#160;June&#160;30, 2020, the Company had contract assets of&#160;$9.5 million of which $0.2 million was recorded in other assets. As of December&#160;31, 2019, the Company had contract assets of $6.2 million of which $1.0 million was recorded in other assets. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred revenue</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the deferred revenue balance was $11.5 million and $12.3 million, respectively, which included $6.4 million and $4.8 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the six months ended June 30, 2020 that was included in the deferred revenue balance as of December&#160;31, 2019 was $7.6 million, which primarily  represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transaction price allocated to the remaining performance obligations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Costs of Precision Oncology Testing</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Development Services</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Compensation - Stock Compensation (Topic 718), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Improvements to Nonemployee Share-Based Payment Accounting,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock options and stock purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite vesting or service period.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Pronouncements Adopted</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, in order to improve financial reporting of expected credit losses on financial instruments and other commitments to extend credit. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. &#160;These changes result in earlier recognition of credit losses. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2020. The cumulative effect upon adoption was not material to the Company&#8217;s condensed consolidated financial statements.  The Company will continue to monitor the developments pertaining to the recent coronavirus (COVID-19) pandemic and its impact on expected credit losses.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the FASB issued ASU 2017-04</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Intangibles&#8212;Goodwill and Other (Topic 350):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Fair Value Measuremen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">t, as part of its disclosure framework project.  The Company adopted this new guidance on January 1, 2020. The adoption of this standard did not have a significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cloud Computing Arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles-Goodwill and Other-Internal&#8212;Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to determine which implementation costs to capitalize as assets or expense as incurred. The Company adopted this new standard on January 1, 2020 on a prospective basis. The adoption of this standard did not have a significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18 -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC 808)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under R</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">evenue from contracts with customers (Topic ASC 606) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">when the counterparty is a customer. The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. &#160;The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. &#160;The Company early adopted this new standard on January 1, 2020.The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements. Under prior GAAP, the Company historically allocated income tax benefit to continuing operations and an offsetting income tax expense to other comprehensive income under the applicable exception to ASC Topic 740.&#160; The new standard eliminates this exception and the Company will now determine the tax effect of pre-tax income or loss from continuing operations without regard to the tax effect of other items.&#160; The Company applied the new intraperiod tax allocation guidance prospectively in the period of adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978121960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Joint Venture<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Joint Venture</a></td>
<td class="text">Investment in Joint Venture <div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company and an affiliate of SoftBank formed and capitalized Guardant Health AMEA, Inc. (the &#8220;Joint Venture&#8221;) for the sale, marketing and distribution of the Company&#8217;s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 9, 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. In June 2020, an amended and restated certificate of incorporation of the Joint Venture, as approved by the board of directors of the Joint Venture, was filed with the Secretary of State of the State of Delaware. The amended and restated certificate of incorporation, among other things, increased the number of authorized shares of common stock to 89,000,000 shares consisting of </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">80,000,000 shares of Class A common stock and 9,000,000 shares of Class B (non-voting) common stock; and authorized 80,000,000 shares of Series A preferred stock. Pursuant to the amended and restated certificate of incorporation, each share of common stock held by the Company and the affiliate of SoftBank was reclassified and exchanged for 1,000 shares of Series A preferred stock. As a result, each of the Company and the affiliate of SoftBank held 40,000,000 shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive dividends at the rate of $0.05 per share if and when declared by the board of directors of the Joint Venture. In June 2020, the board of directors of the Joint Venture authorized the adoption of the Joint Venture&#8217;s 2020 Equity Incentive Plan pursuant to which 4,595,555 shares of Class B common stock have been reserved for issuance. As of June 30, 2020, no shares of Class A and Class B common stock have been issued and outstanding and 80,000,000 shares of Series A preferred stock have been issued and outstanding.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the joint venture agreement, neither party is obligated to make any further capital contribution, in cash or otherwise, to the Joint Venture. The Joint Venture is deemed to be a variable interest entity (&#8220;VIE&#8221;) and the Company has been identified as the VIE&#8217;s primary beneficiary.  As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, the Joint Venture had total assets of approximately $38.4 million and $45.1 million, respectively, which were primarily comprised of cash, property and equipment, right-of-use assets and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company&#8217;s general credit or assets.&#160; Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of June&#160;30, 2020 and December&#160;31, 2019, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Put-call arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the &#8220;put right&#8221;), and the Company has a right to purchase all such shares (the &#8220;call right&#8221;).</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture&#8217;s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company&#8217;s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within&#160;20&#160;business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm&#8217;s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank&#8217;s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a&#160;20%&#160;internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than&#160;40%&#160;of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of&#160;40%&#160;of the Company's fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">is publicly traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company&#8217;s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;) and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978050616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Condensed Consolidated Balance Sheet Components</a></td>
<td class="text">Condensed Consolidated Balance Sheet Components<div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consist of the following:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Machinery and equipment</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Computer hardware   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Leasehold improvements   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Furniture and fixtures   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,962&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Computer software   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Construction in progress   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,354&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Property and equipment, gross   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Less: accumulated depreciation   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,946)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,923)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Property and equipment, net   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation expense related to property and equipment was $3.2 million and $2.2 million for the three months ended June 30, 2020 and 2019, respectively, and $6.2 million and $4.3 million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued royalty obligations   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued legal expenses   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued tax liabilities   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued professional services   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical trials and studies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,029&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,476&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,424&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Operating lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Others</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total accrued expenses   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589977735432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements, Cash Equivalents and Marketable Securities</a></td>
<td class="text">Fair Value Measurements, Cash Equivalents and Marketable Securities <div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total short-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total long-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">919,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Corporate bonds   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total short-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">379,574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">379,574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total long-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">659,091&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">648,357&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data and other observable inputs.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June&#160;30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:23.521%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.186%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.186%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.186%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.193%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:9pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Redeemable Noncontrolling Interest</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fair value &#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Initial valuation on the date of acquisition</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Increase (decrease) in fair value </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(190)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,286)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(622)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,359)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(944)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, contingent consideration liability of $1.2 million and $1.4 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheets. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Money market fund   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">913,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">919,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">933,892&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Money market fund   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Corporate bond   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,679&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">630,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">631,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">657,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">659,091&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company&#8217;s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of credit losses in the three and six months ended June&#160;30, 2020 and 2019, respectively. The maturities of the Company&#8217;s long-term marketable securities range from 1.0 year to 1.4 years as of June&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978025352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net and Goodwill</a></td>
<td class="text">Intangible Assets, Net and Goodwill<div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents details of purchased intangible assets as of&#160;June&#160;30, 2020&#160;and&#160;December&#160;31, 2019: </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:42.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.861%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.028%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,438)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,438)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:13pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:42.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.861%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.028%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(373)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(303)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of finite-lived intangible assets was $0.5 million and $0.2 million for the three months ended June 30, 2020 and 2019, respectively, and $0.8 million and $0.2 million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes estimated future amortization expense of finite-lived intangible assets:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.082%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.981%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,953&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979347448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text">Acquisition <div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent License Acquisition</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the Company entered into a license agreement with a biotechnology&#160;company, KeyGene N.V. (&#8220;KeyGene&#8221;). An arbitration was initiated between the parties in 2018. In March 2020, the Company and KeyGene entered into a settlement and patent license agreement (the &#8220;SPLA&#8221;) to resolve the dispute and to acquire an extended worldwide non-exclusive license to certain patent rights with respect to KeyGene&#8217;s Next Generation Sequencing technologies along with certain covenant rights and research and development technology for a one-time payment of $18.5 million, ending all future royalty obligations to KeyGene. This transaction was accounted for as an asset acquisition as the purchase did not meet the definition of a business. The total consideration, including $0.6 million of certain capitalizable transaction costs, was allocated to various components of the SPLA.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allocated $9.4 million to the patent and covenant rights granted under the SPLA, which have useful lives in the range of 6-12 years. The Company allocated $8.5 million to IPR&amp;D technology, which have no alternative future use and was included in research and development expenses for the six months ended June 30, 2020. The remaining $1.2 million was allocated to the settlement of the prior dispute between the parties and was included in general and administrative expenses for the six months ended June 30, 2020.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amortization of capitalized license fees relating to the January 2017 license agreement was nil and immaterial for the three and six months ended June&#160;30, 2020, respectively. Amortization of capitalized license fees relating to the January 2017 license agreement was $0.2 million and $0.5 million for the three and six months ended June&#160;30, 2019, respectively.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition of Bellwether Bio</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Company purchased all of the outstanding shares of Bellwether Bio, Inc. (&#8220;Bellwether Bio&#8221;), a privately-held company developing a method for early blood-based cancer detection. The Company accounted for the acquisition as a business combination. The total purchase consideration was $8.7&#160;million, which consisted of i) $7.6&#160;million in cash paid upon closing; and ii) future contingent consideration liability with a fair value of $1.1&#160;million on the acquisition date. The contingent consideration is subject to the achievement of certain commercialization milestones with a maximum payout amount of $10.0&#160;million. The Company will also pay additional earn-out consideration of up to $10.0&#160;million subject to the achievement of certain commercialization milestones and the continued provision of services to the Company by certain former employees and consultants of Bellwether Bio. The contingent consideration and earn-out consideration may be paid, at the Company&#8217;s election, in cash or in the Company&#8217;s common stock. As of June&#160;30, 2020, the Company did not believe the earn-out consideration is probable to be achieved, and therefore, did not record any compensation expense. The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.256%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cash</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,802)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:67.341%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.211%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.844%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Acquired license</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">IPR&amp;D</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">*&#160;IPR&amp;D assets are not subject to amortization.</span></div>In connection with the acquisition of Bellwether Bio, the Company also entered into non-compete agreements with certain key individuals based on their experience and importance to the operation of Bellwether Bio. The Company accounted for the covenants not to compete as purchases of intangible assets separate from the business combination as these non-compete agreements were initiated by the Company to protect its interests. The fair value of acquired covenants not to compete is estimated to be $2.5&#160;million, which is recorded within intangible assets, net on the condensed consolidated balance sheet and will be amortized over an estimated useful life of 6 years using the straight-line method. Acquisition-related contingent consideration is measured at fair value on a quarterly basis and change in estimated contingent consideration to be paid are included in operating expenses in the condensed consolidated statements of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition And Business Combination Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978099928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has&#160;entered into various operating lease agreements for office space,&#160;with remaining terms ranging from 1-7 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether it will renew the lease, as such, the Company does not include renewal options in its lease terms for calculating its lease liability, as the renewal options allow it to maintain operational flexibility and the Company is not reasonably certain it will exercise these renewal options at the time of the lease commencement. Operating lease expense was $1.9 million and $0.8 million for the three months ended June 30, 2020 and 2019, respectively, and $3.4 million and $1.6 million for the six months ended June 30, 2020 and 2019, respectively, which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.916%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.822%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our future principal contractual obligations for operating lease commitments as of </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2020:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:80.797%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.203%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:  Imputed Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,391)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,357&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance leases are not material to the Company's condensed consolidated financial statements.</span></div>The Company entered into new lease agreements subsequent to June 30, 2020, see Note 16, Subsequent Events.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979593368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Proceedings</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to commitments and obligations incurred in the ordinary course of business, from time to time the Company may be subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations and other matters. For example, we have received, and may in the future continue to receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. We have also instituted, and may in the future institute, additional legal proceedings to enforce our rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company and its affiliates are parties to the legal claims and proceedings described below. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, it is not reasonably possible for the Company to determine that a loss is probable for a claim, or to reasonably estimate the amount of loss or a range of loss, because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability or seek an indeterminate amount of damages. It is not uncommon for claims to be resolved over a number of years. The Company reviews loss contingencies at least quarterly to determine whether the loss probability has changed and whether it can make a reasonable estimate of the possible loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability in the amount of its estimate for the ultimate loss. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Patent Disputes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, the Company filed separate lawsuits against Foundation Medicine, Inc. (&#8220;Foundation Medicine&#8221;) and Personal Genome Diagnostics, Inc. (&#8220;Personal Genome Diagnostics&#8221;) in the United States District Court for the District of Delaware. The Company has alleged that each of the two companies has infringed four of the Company&#8217;s digital sequencing technology patents. The two companies have each asserted counterclaims of </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">patent invalidity, unenforceability under the doctrine of inequitable conduct, and non-infringement. Personal Genome Diagnostics has also alleged antitrust violations related to the enforcement of the Company&#8217;s patent rights. In each lawsuit, the parties are seeking damages, injunctive relief and attorneys&#8217; fees.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2018, Personal Genome Diagnostics filed two petitions for post-grant review with the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) at the United States Patent and Trademark Office, challenging the patentability of two of the patents asserted by the Company. The two post-grant review petitions were dismissed with prejudice in July 2018. Subsequently, Foundation Medicine filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company. The PTAB denied institution of inter partes review for four of the six petitions filed by Foundation Medicine and instituted inter partes review for the remaining two petitions. The Company plans to vigorously defend its patent rights during such PTAB actions. At this time, the Company cannot reasonably ascertain the likelihood that any of the remaining challenged patents will be found to be invalid or unenforceable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978057944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s common stockholders are entitled to dividends if and when declared by the Company&#8217;s Board of Directors (the &#8220;Board of Directors&#8221;). As of June&#160;30, 2020 and December&#160;31, 2019, no dividends on common stock had been declared by the Board of Directors.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Shares underlying outstanding stock options   </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,869,002</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,494,889</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">564,008</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">496,131</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,864,528</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,726,225</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,574,367</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">689,917</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,871,905</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,407,162</span></td></tr></table></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Follow-on Public Offering</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, the Company completed an underwritten public offering, in which it issued and sold 4,312,500 shares of its common stock at a price of $84.00 per share. The Company received net proceeds of $354.6&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2019, the Company completed an underwritten public offering, in which it issued and sold 5,175,000 shares of its common stock at a price of $71.00 per share. The Company received net proceeds of $349.7&#160;million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979602472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th"><div>May 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Option Activity</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company&#8217;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) and related information is as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.259%;"><tr><td style="width:1.0%;"/><td style="width:29.621%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.841%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.322%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.038%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.680%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.290%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options Outstanding</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares Subject to Options Outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2019</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,726,225</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,494,889</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2018 Plan annual increase</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,689,000</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(78,476)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,476</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(654,557)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,406</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,806)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Restricted stock units granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,834)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Restricted stock units canceled</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,355</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Market-based restricted stock units granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,391,148)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,864,528</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,869,002</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266,316&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Vested and Exercisable as of June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,014,893</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.9</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt;">Effective as of January 1, 2020, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $33.1 million and $108.3 million for the three months ended June 30, 2020 and 2019, respectively, and $50.3 million and $116.4 million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant date fair value of options granted was $44.61 and $51.94 per share for the three months ended June 30, 2020 and 2019, respectively, and $45.52 and&#160;$43.35 per share for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future stock-based compensation for unvested options as of June&#160;30, 2020 was $22.9 million, which is expected to be recognized over a weighted-average period of 2.5 years.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company&#8217;s restricted stock unit activity excluding the market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.412%;"><tr><td style="width:1.0%;"/><td style="width:64.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.867%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted Stock Units Outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">496,131</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.08&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,834</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,602)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,355)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">564,008</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future stock-based compensation for unvested restricted stock units as of June&#160;30, 2020 was $37.7 million, which is expected to be recognized over a weighted-average period of 3.1 years.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Market-based Restricted Stock Units</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 26, 2020, the Board of Directors approved and granted 1,695,574 market-based restricted stock units (&#8220;MSUs&#8221;) under the 2018 Plan to each of the Company's Chief Executive Officer and the Company's President and Chief Operating Officer, which is subject to the achievement of market-based share price goals established by the Board of Directors. The MSUs consist of three separate tranches and the vesting of each tranche is subject to the Company's common stock closing price being maintained at or above a predetermined share price goal for a period of 30 consecutive calendar days. The share price goal can be met any time during the seven-year performance period from the date of grant. Upon vesting, the MSUs must be held for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1NTFlYmFmODEyNDQ0YTlhNjk3OWIzNDVmODYzYzJiL3NlYzpiNTUxZWJhZjgxMjQ0NGE5YTY5NzliMzQ1Zjg2M2MyYl84NS9mcmFnOmI4ZDdlNmQ4ZjhkOTQyYTJiMzI5MmVjNTRkYTQ5NjJjL3RleHRyZWdpb246YjhkN2U2ZDhmOGQ5NDJhMmIzMjkyZWM1NGRhNDk2MmNfMTY0OTI2NzQ3MjAyMQ_60fc0348-aa77-452e-b4e9-5b9e8050b4d4">six</span> to twelve months depending on the time of vesting within the seven-year performance period. The vesting of the MSUs can also be triggered upon a change in control event and achievement of a certain change in control price goal, or when there is a qualifying termination or in the event of death or disability. The following table presents additional information relating to each MSU award:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.366%;"><tr><td style="width:1.0%;"/><td style="width:32.848%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.315%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.315%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:25.653%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Price Goal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of RSUs</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$120 per share</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565,192</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$150 per share</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565,191</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$200 per share</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565,191</span></td></tr></table></div><div style="text-align:center;margin-top:8pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The grant date fair values of the MSUs were determined using a Monte Carlo valuation model for each tranche. The related stock-based compensation expense for each tranche is recognized based on an accelerated attribution method over the estimated derived service period. If the related share price goal is achieved earlier than its expected derived service period, the stock-based compensation expense will be recognized as a cumulative catch-up expense from the grant date to that point in time in achieving the share price goal. The derived service period is the median duration of the successful stock price paths to meet the price goal for each tranche as simulated in the Monte Carlo valuation model.  The Monte Carlo valuation model uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the MSU.  The weighted average grant date fair value of the MSUs was $67.00 and the weighted average derived service period was estimated to be in the range of 0.83 &#8211; 2.07 years. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Stock-based compensation recorded for the MSUs for the three months ended June 30, 2020 was $18.3&#160;million and is recorded in general and administrative expenses in our condensed consolidated statement of operations. Future stock-based compensation for unvested MSUs as of June&#160;30, 2020 was $208.9 million, which is expected to be recognized over a weighted-average period of 1.3 years. In the event of a change in control, a qualifying termination, death, disability or the share price goal occurring earlier than the estimated derived service period, the stock-based compensation relating to these MSUs could be accelerated. Any MSUs that remain unvested at the end of the seven-year performance period will automatically be forfeited and terminated without further consideration.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the effect of employee and non-employee related stock-based compensation expense:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:48.458%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.626%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cost of precision oncology testing   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Research and development expense   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Sales and marketing expense   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">646&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">General and administrative expense   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total stock-based compensation expense   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,815&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of Stock Options</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.510%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.819%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.819%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.824%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.10</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.16</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.10</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.22</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected volatility   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.5% &#8211; 68.5%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.9% &#8211; 68.3%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.5% &#8211; 73.3%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.7% &#8211; 68.3%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.4% &#8211; 0.4%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.9%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.4% &#8211; 1.6%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.9% &#8211; 2.7%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company&#8217;s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">:</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value of Common Stock</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the Company&#8217;s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the commencement of trading of the Company&#8217;s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company's common stock. Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-Free Interest Rate</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Dividend Yield</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of MSUs</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of the MSUs was determined using a Monte Carlo simulation model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the following: </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Volatility</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to limited historical data for the trading of the Company&#8217;s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies and implied volatility of publicly traded options in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected Term</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term represents the derived service period for the respective tranches which has been estimated using the Monte Carlo simulation model. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risky Rate</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risky rate represents the Company's cost of equity.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Discount for Lack of Marketability </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discount for lack of marketability represents the discount applied for post vest term restrictions and has been derived using the Monte Carlo simulation model.  </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following assumptions were used to calculate the stock-based compensation for MSUs: a weighted-average expected term of 0.83 &#8211; 2.07 years; expected volatility of 65.5%; a risk-free interest rate of 0.5%; a zero dividend yield; a risky rate (cost of equity) of 16%; and a discount for post-vesting restrictions of 10.4% &#8211; 14.5%.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2018 Employee Stock Purchase Plan</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018, the Company&#8217;s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). A total of 922,250 shares of common stock were initially reserved for issuance under the ESPP. Effective as of January 1, 2020, an additional 942,614&#160;shares of common stock became available for issuance under the ESPP, as a result of the operation of an automatic annual increase provision therein.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to&#160;10%&#160;of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to&#160;85%&#160;of the fair market value of the Company&#8217;s  common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from October&#160;2, 2018 to January 31, 2019, the second offering period ran from February 1, 2019 to July 31, 2019, and the third offering period began on August 1, 2019 and ran to November 14, 2019. For subsequent years starting with 2020, the ESPP provides for separate&#160;six-month offering periods beginning on May 15 and November 15 of each year. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares of common stock purchased under the ESPP were 58,164 and nil for the three months ended June 30, 2020 and 2019, respectively, and 58,164 and 119,702 for the six months ended June 30, 2020 and 2019, respectively. The total compensation expense related to the ESPP was $1.1 million&#160;and $0.4 million for the three months ended June 30, 2020 and 2019, respectively, and $1.6 million and $1.0 million for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The valuation assumptions used were substantially consistent with the assumption used to value stock options with the exception of the expected term which was based on the term of each purchase period. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No ESPP shares were granted for the three months ended June 30, 2019. The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.357%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.411%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.411%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.977%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)   </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility   </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.2%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate   </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield   </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr></table></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the unrecognized stock-based compensation expense related to the ESPP was $1.1 million, which is expected to be recognized over the remaining term of the offering period of 0.4 years. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liabilities for Early Exercise of Employee Options</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company allowed certain stock option holders to exercise unvested options to purchase shares of the Company&#8217;s common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee&#8217;s employment termination, at the original issuance price, until the options are fully vested. As of June&#160;30, 2020 and December&#160;31, 2019, 18,447 shares and 23,981 shares of common stock were subject to repurchase at weighted-average price of $4.66 per share. As of June&#160;30, 2020 and December&#160;31, 2019, the cash proceeds received for unvested shares of common stock of $0.1 million and $0.1 million, respectively, was recorded within other long-term liabilities on the condensed consolidated balance sheet, respectively. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the condensed consolidated balance sheet and condensed consolidated statement of redeemable noncontrolling interest and stockholders&#8217; equity as such shares are considered legally outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589977756584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders<div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.921%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.183%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,739)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,300)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32,651)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,900)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(300)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(800)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,639)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,600)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(82,368)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,651)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.57)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.87)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.43)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,036&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.921%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.183%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,056</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,313</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,200</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,908</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">542</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">519</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MSUs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,342</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,997</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,550</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,451</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,116</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589977811784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax expense for the three and six months ended June 30, 2020 was determined based upon estimates of the Company&#8217;s effective income tax rates in various jurisdictions. The difference between the Company&#8217;s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets.</span></div><div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The income tax expense for the three and six months ended June 30, 2020 relates primarily to state minimum income tax and income tax on the Company&#8217;s earnings in foreign jurisdictions. The benefit from income taxes for the six months ended June 30, 2019 relates primarily to the release of a valuation allowance of $1.2&#160;million associated with nondeductible intangible assets recorded as part of the Bellwether Bio acquisition, partially offset by state minimum income tax and income tax on the Company's earnings in foreign jurisdictions. In connection with the acquisition of Bellwether Bio, a deferred tax liability was established for the book-tax basis differences related to the non-goodwill intangible assets. The net deferred tax liability from this acquisition creates an additional source of income to offset the Company&#8217;s deferred tax assets. As such, the impact on the acquiring Company&#8217;s deferred tax </span></div>assets and liabilities caused by an acquisition are recorded in the acquiring company&#8217;s consolidated financial statements outside of acquisition accounting.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589977733704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">Segment and Geographic Information<div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.921%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.106%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,242&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">International </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">(1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,978&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">(1)&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June&#160;30, 2020&#160;and&#160;2019, respectively.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019, substantially all of the Company&#8217;s long-lived assets and right-of-use assets are located in the United States.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978013464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-align:justify;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 3, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investment in Joint Venture</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company and an affiliate of SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company and its subsidiaries may, in the ordinary course of business, have transactions with unaffiliated companies of which certain of the Company&#8217;s directors are directors and/or executive officers. The Company believes that such transactions are on the same terms generally offered by such other companies to other entities in comparable transactions. The Company does not consider the amounts involved in such transactions to be material in relation to its businesses, the businesses of such other companies or the interests of the directors involved. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Revenue from an entity affiliated with a member of the Company's Board of Directors was $0.6 million and $0.5 million for the three months ended June 30, 2020 and 2019, and $1.5 million and $0.9 million for the six months ended June 30, 2020 and 2019. As of June&#160;30, 2020 and December&#160;31, 2019, the Company has accounts receivable from this entity of $2.0 million and $0.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979980904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company entered into two new agreements in July 2020 to lease additional office and laboratory space. The lease agreements each have a target commencement date in the first half of fiscal year 2021, with estimated aggregate base rent payments of $239.5&#160;million over the weighted average estimated lease term of 11.5 years. One of the lease agreements provides an option to renew the lease term for an additional ten years. The Company is currently evaluating the accounting for such leases.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589986077592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying condensed consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders&#8217; interests in the Joint Venture are shown in the condensed consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing cash and cash equivalents and marketable securities as of June&#160;30, 2020 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying condensed consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company&#8217;s cost structure. If the Company&#8217;s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations,&#160;goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates. The extent to which the COVID-19 pandemic will ultimately impact the </span></div>Company&#8217;s business, results of operations, financial conditions, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside the Company&#8217;s control, such as the duration, scope and severity of the pandemic, steps required or mandated by governments to mitigate the impact of the pandemic, and whether COVID-19 can be effectively prevented, detected, contained and treated, particularly in the markets where the Company operates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Condensed Financial Statements</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated balance sheet as of June&#160;30, 2020, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020 and 2019, the condensed consolidated statements of redeemable noncontrolling interest and stockholders&#8217; equity for the three and six months ended June&#160;30, 2020 and 2019, and cash flows for the six months ended June&#160;30, 2020 and 2019, and the related interim condensed consolidated disclosures are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Rule&#160;10-01 of Regulation S-X of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring accruals that the Company believes are necessary to fairly state the financial position and the results of the Company&#8217;s operations and cash flows for interim periods in accordance with GAAP. Interim-period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">Foreign Currency TranslationThe functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S.&#160;dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders&#8217; equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the condensed consolidated statements of operations. For the three and six months ended June&#160;30, 2020 and 2019, foreign currency translation adjustment was immaterial.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Risk</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company&#8217;s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company&#8217;s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company&#8217;s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount.</span></div>A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company&#8217;s total revenue or accounts receivable balance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounts Receivable, Net</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable based on historical collection trends, the financial condition of payment partners, and external market factors and provides for an allowance for potential credit losses based on management&#8217;s best estimate of the amount of probable credit losses. As of June&#160;30, 2020, the Company recorded $0.1 million as allowance for credit losses. As of December&#160;31, 2019, the Company had no allowance for credit losses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionPolicyTextBlock', window );">Asset Acquisition</a></td>
<td class="text">Asset AcquisitionIf an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The total consideration is allocated to the various intangible assets acquired on a relative fair value basis. Transaction costs associated with the asset acquisition are capitalized. Cash paid in connection of purchase of in-process research and development technology in an asset acquisition is presented within the investing section of the condensed consolidated statement of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, net</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Intangible Assets, net</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets related to in-process research and development costs (&#8220;IPR&amp;D&#8221;) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&amp;D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in&#160;one&#160;segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of&#160;June&#160;30, 2020, there has been&#160;no&#160;impairment of goodwill.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-12 years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company&#8217;s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company&#8217;s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Precision oncology testing</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer&#160;as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected reimbursement period and compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected reimbursement period, subject to assessment of the risk of future revenue reversal. For the three months ended June 30, 2020 and 2019, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$6.5&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$3.6&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration. For the six months ended June 30, 2020 and 2019, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$12.4&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">$6.4&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as revenue, respectively, resulting from cash collections over the expected reimbursement period exceeding the estimated variable consideration.  For the three and six months ended June 30, 2020, the Company recorded $2.6&#160;million and $4.1&#160;million, respectively, in revenue received from Medicare for samples processed in 2019.  For the three and six months ended June 30, 2019, the Company recorded $1.4&#160;million and $1.4&#160;million, respectively, in revenue received from Medicare for samples processed in 2018. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.  Results of the Company&#8217;s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Development services</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company&#8217;s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. The Company assesses the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. The Company revised and increased its total estimated costs relating to one of the development services contracts during the six months ended June 30, 2020.  Had the Company included such additional costs in the original estimated costs, revenues for the six months ended June 30, 2019 would have been lower by $3.6 million. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company&#8217;s condensed consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contracts with multiple performance obligations</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contract assets</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. Contract assets are presented under accounts receivable, net and other assets on the Company&#8217;s condensed consolidated balance sheets. As of&#160;June&#160;30, 2020, the Company had contract assets of&#160;$9.5 million of which $0.2 million was recorded in other assets. As of December&#160;31, 2019, the Company had contract assets of $6.2 million of which $1.0 million was recorded in other assets. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred revenue</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company's performance of the related services. Contract liabilities are relieved&#160;as the Company performs its obligations under the contract and revenue is consequently recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the deferred revenue balance was $11.5 million and $12.3 million, respectively, which included $6.4 million and $4.8 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the six months ended June 30, 2020 that was included in the deferred revenue balance as of December&#160;31, 2019 was $7.6 million, which primarily  represented revenue from&#160;provision of development services under the collaboration agreements with biopharmaceutical customers.&#160;</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Transaction price allocated to the remaining performance obligations</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CostsofPrecisionOncologyTestingPolicyTextBlock', window );">Costs of Precision Oncology Testing</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Costs of Precision Oncology Testing</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company&#8217;s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Cost of Development Services</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Development Services</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of development service includes costs incurred for the performance of development services requested by the Company&#8217;s biopharmaceutical customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses </span></div>Research and development expenses are comprised of costs incurred to develop technology and include compensation and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stock-based compensation related to stock options granted to the Company&#8217;s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Starting January 1, 2019, upon adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2018-07,&#160;Compensation - Stock Compensation (Topic 718), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Improvements to Nonemployee Share-Based Payment Accounting,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock options and stock purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Forfeitures are accounted for as they occur.  </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For market-based restricted stock units, the Company derives the requisite service period using the Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using an accelerated attribution model commencing on the grant date. Stock-based compensation expense will be recorded regardless of whether the market conditions are achieved or not.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company&#8217;s condensed consolidated statement of operations on a straight-line basis over the requisite vesting or service period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Adopted</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Pronouncements Adopted</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, in order to improve financial reporting of expected credit losses on financial instruments and other commitments to extend credit. ASU 2016-13 requires that an entity measure and recognize expected credit losses for financial assets held at amortized cost and replaces the incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. &#160;These changes result in earlier recognition of credit losses. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2020. The cumulative effect upon adoption was not material to the Company&#8217;s condensed consolidated financial statements.  The Company will continue to monitor the developments pertaining to the recent coronavirus (COVID-19) pandemic and its impact on expected credit losses.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the FASB issued ASU 2017-04</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">, Intangibles&#8212;Goodwill and Other (Topic 350):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Fair Value Measuremen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">t, as part of its disclosure framework project.  The Company adopted this new guidance on January 1, 2020. The adoption of this standard did not have a significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cloud Computing Arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued ASU 2018-15&#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles-Goodwill and Other-Internal&#8212;Use Software (Subtopic 350-40)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to determine which implementation costs to capitalize as assets or expense as incurred. The Company adopted this new standard on January 1, 2020 on a prospective basis. The adoption of this standard did not have a significant impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU 2018-18 -</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC 808)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under R</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">evenue from contracts with customers (Topic ASC 606) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">when the counterparty is a customer. The Company adopted this new standard on January 1, 2020. The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. &#160;The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. &#160;The Company early adopted this new standard on January 1, 2020.The adoption of this standard did not have a significant impact to the Company&#8217;s condensed consolidated financial statements. Under prior GAAP, the Company historically allocated income tax benefit to continuing operations and an offsetting income tax expense to other comprehensive income under the applicable exception to ASC Topic 740.&#160; The new standard eliminates this exception and the Company will now determine the tax effect of pre-tax income or loss from continuing operations without regard to the tax effect of other items.&#160; The Company applied the new intraperiod tax allocation guidance prospectively in the period of adoption.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments consist of cash equivalents, marketable securities, accounts receivable, net, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date. </span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AssetAcquisitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AssetAcquisitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CostsofPrecisionOncologyTestingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of Precision Oncology Testing [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CostsofPrecisionOncologyTestingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited Interim Condensed Financial Statements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982728472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text">Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company&#8217;s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company&#8217;s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:<div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:17.230%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts Receivable, Net</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer A   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer B   </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer C   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer D   </span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Customer E</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">*&#160;less than 10%</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982480344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consist of the following:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Machinery and equipment</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,584&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Computer hardware   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Leasehold improvements   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Furniture and fixtures   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,962&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Computer software   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,027&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Construction in progress   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,354&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Property and equipment, gross   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,941&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65,591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Less: accumulated depreciation   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27,946)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21,923)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:45pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Property and equipment, net   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,668&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued royalty obligations   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">325&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued legal expenses   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,598&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued tax liabilities   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Accrued professional services   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical trials and studies</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,029&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Purchases of property and equipment included in accrued expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,476&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,424&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Operating lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,240&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,140&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Others</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total accrued expenses   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590070091784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:<div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total short-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773,160&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total long-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">146,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">919,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Corporate bonds   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total short-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">379,574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">379,574&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total long-term marketable securities   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268,783&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">659,091&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">648,357&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Financial Liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contingent consideration</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Level 3 Activity</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activities for the Level 3 financial instruments for the three and six months ended June&#160;30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:23.521%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.828%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.186%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.186%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.186%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.193%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:9pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Redeemable Noncontrolling Interest</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Consideration</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="45" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fair value &#8212;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">beginning of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,365&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Initial valuation on the date of acquisition</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Increase (decrease) in fair value </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(190)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,286)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(622)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,359)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(944)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Fair value &#8212; end of period</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,400&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46,800&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,175&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtSecuritiesTableTextBlock', window );">Schedule of Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarizes the Company&#8217;s cash equivalents and marketable securities&#8217; amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Money market fund   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">913,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">919,278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">933,892&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">939,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Money market fund   </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Corporate bond   </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,679&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">U.S. government debt securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">630,283&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,423&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">631,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">657,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(39)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">659,091&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589981145752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents details of purchased intangible assets as of&#160;June&#160;30, 2020&#160;and&#160;December&#160;31, 2019: </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:42.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.861%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.028%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,438)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,438)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:13pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:42.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.861%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.028%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(373)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(303)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents details of purchased intangible assets as of&#160;June&#160;30, 2020&#160;and&#160;December&#160;31, 2019: </span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:42.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.861%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.028%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(809)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,077&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:24.75pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Non-compete agreements and other covenant rights</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,438)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,438)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:13pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:42.855%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.861%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.022%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.603%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.028%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Carrying Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remaining Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in years)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Intangible assets subject to amortization:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired license</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(373)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-compete agreements</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(303)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,197&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:38.25pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total intangible assets subject to amortization</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,924&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,290&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:49.5pt;padding-right:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total purchased intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,490&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(676)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,814&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text">The following table summarizes estimated future amortization expense of finite-lived intangible assets:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.082%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.981%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,953&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,760&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979600632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:83.256%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cash</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">521&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,289&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,802)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of Intangible Assets Acquired</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:67.341%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.211%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.844%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Acquired license</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">IPR&amp;D</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">*&#160;IPR&amp;D assets are not subject to amortization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978081192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.916%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.822%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average discount rate</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liability Maturities</a></td>
<td class="text">The following table summarizes our future principal contractual obligations for operating lease commitments as of <div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">June&#160;30, 2020:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%;"><tr><td style="width:1.0%;"/><td style="width:80.797%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.203%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,535&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,780&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025 and thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,251&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease payments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less:  Imputed Interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,391)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49,357&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589977978680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock by Class</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s common stock has been reserved for the following potential future issuances:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.314%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.943%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Shares underlying outstanding stock options   </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,869,002</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,494,889</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Shares underlying unvested restricted stock units</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">564,008</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">496,131</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares available for issuance under the 2018 Incentive Award Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,864,528</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,726,225</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares available for issuance under the 2018 Employee Stock Purchase Plan</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,574,367</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">689,917</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total   </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,871,905</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,407,162</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979295336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company&#8217;s stock option activity under the 2012 Stock Plan (as amended and restated, the &#8220;2012 Plan&#8221;) and the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) and related information is as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.259%;"><tr><td style="width:1.0%;"/><td style="width:29.621%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.841%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.322%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.038%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.680%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.290%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options Outstanding</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares<br/>Available for Grant&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares Subject to Options Outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2019</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,726,225</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,494,889</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,392&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2018 Plan annual increase</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,689,000</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(78,476)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78,476</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(654,557)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,406</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,806)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Restricted stock units granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126,834)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Restricted stock units canceled</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,355</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Market-based restricted stock units granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,391,148)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,864,528</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,869,002</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266,316&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Vested and Exercisable as of June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,014,893</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.9</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,268&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:22.5pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:13.18pt;">Effective as of January 1, 2020, an additional 3,689,000&#160;shares of common stock became available for issuance under the 2018 Plan, as a result of the operation of an automatic annual increase provision therein.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company&#8217;s restricted stock unit activity excluding the market-based restricted stock units under the 2012 Plan and the 2018 Plan and related information is as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.412%;"><tr><td style="width:1.0%;"/><td style="width:64.666%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.865%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.867%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted Stock Units Outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of December&#160;31, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">496,131</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.08&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,834</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,602)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80.27&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canceled</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,355)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance as of June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">564,008</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of Performance-based Restricted Stock Units Vesting Conditions</a></td>
<td class="text">The following table presents additional information relating to each MSU award:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.366%;"><tr><td style="width:1.0%;"/><td style="width:32.848%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.315%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.315%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:25.653%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Price Goal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of RSUs</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$120 per share</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565,192</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$150 per share</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565,191</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tranche 3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$200 per share</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565,191</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the effect of employee and non-employee related stock-based compensation expense:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:48.458%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.620%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.626%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Cost of precision oncology testing   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">407&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">296&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Research and development expense   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,638&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Sales and marketing expense   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">646&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,965&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">General and administrative expense   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,015&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,492&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:36pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Total stock-based compensation expense   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,815&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The grant date fair value of stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.510%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.819%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.819%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.824%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected term (in years)   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.10</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.16</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.10</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.50 &#8211; 6.22</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected volatility   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.5% &#8211; 68.5%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.9% &#8211; 68.3%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.5% &#8211; 73.3%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">66.7% &#8211; 68.3%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Risk-free interest rate   </span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.4% &#8211; 0.4%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.9%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.4% &#8211; 1.6%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.9% &#8211; 2.7%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;">Expected dividend yield   </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#8212;%</span></div></td></tr></table></div>The grant date fair value of the stock purchase right granted under the ESPP was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.357%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.411%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.411%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.972%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.564%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.977%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term (in years)   </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility   </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.2%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.2%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate   </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield   </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978002968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:</span></div><div style="margin-top:5pt;margin-bottom:13pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.921%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.183%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49,739)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,300)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(81,568)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32,651)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;padding-right:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Adjustment of redeemable noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,900)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(300)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(800)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(54,639)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,600)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(82,368)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(37,651)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.57)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.87)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.43)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,011&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,036&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.756%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.921%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.179%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.183%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,056</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,313</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,200</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,908</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">542</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">519</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">MSUs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,342</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">671</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP obligation</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,997</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,550</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,451</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,116</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979938616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s revenue by geographic areas based on the customers&#8217; locations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.064%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.102%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.921%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.106%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,242&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">International </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;">(1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,913&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,978&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66,335&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,975&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,630&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;">(1)&#160;No single country outside of the United States accounted for more than 10% of total revenue during the three and six months ended June&#160;30, 2020&#160;and&#160;2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978012344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details)<br></strong></div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in joint venture</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982904696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue from cash collections exceeding estimated variable consideration</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress', window );">Change in estimate of development services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from samples processed in the previous year</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Cumulative Catch-up Adjustment to Prior Year Revenue, Change in Measure of Progress</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589981142552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Credit Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerAMember', window );">Customer A | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerAMember', window );">Customer A | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerBMember', window );">Customer B | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerCMember', window );">Customer C | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerCMember', window );">Customer C | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerDMember', window );">Customer D | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerDMember', window );">Customer D | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gh_CustomerEMember', window );">Customer E | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gh_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gh_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589981351624">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investment in Joint Venture (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,871,905<span></span>
</td>
<td class="nump">8,407,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,312,237<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,312,237<span></span>
</td>
<td class="nump">94,261,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,277,536<span></span>
</td>
<td class="nump">$ 962,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn', window );">Threshold percentage of fair value that is no less than internal rate of return</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase', window );">Fair value of joint venture threshold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,400<span></span>
</td>
<td class="nump">$ 45,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payments to acquire interest in joint venture</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquityMethodInvestmentSharesPurchased', window );">Equity method investment, shares purchased (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Class B</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,595,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Series A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Preferred stock dividend rate (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Series A | SoftBank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | Series A | Guardant Health, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | SoftBank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EquityMethodInvestmentSharesPurchased', window );">Equity method investment, shares purchased (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue', window );">Redeemable noncontrolling interest, redemption value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember', window );">Guardant Health AMEA, Inc | SoftBank | Series A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PreferredStockSharesIssuedUponConversionOfCommonStock', window );">Common stock reclassified and converted into preferred stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of June&#160;30, 2020 and&#160;December&#160;31, 2019, includes $38.4 million and&#160;$45.1 million&#160;of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (&#8220;VIE&#8221;) and VIE&#8217;s subsidiaries, and&#160;$4.0 million and $5.7 million&#160;of liabilities of the consolidated VIE and VIE&#8217;s subsidiaries, respectively, for which their creditors do not have recourse to the general credit of the Company. See&#160;Note 3, <span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investment in Joint Venture</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EquityMethodInvestmentSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EquityMethodInvestmentSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PreferredStockSharesIssuedUponConversionOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Shares Issued Upon Conversion Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PreferredStockSharesIssuedUponConversionOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount per share used to calculated dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 24(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gh_GuardantHealthAMEAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gh_GuardantHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gh_GuardantHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gh_SoftBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gh_SoftBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589985810392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 84,941<span></span>
</td>
<td class="nump">$ 65,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(27,946)<span></span>
</td>
<td class="num">(21,923)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">56,995<span></span>
</td>
<td class="nump">43,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">35,584<span></span>
</td>
<td class="nump">29,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,105<span></span>
</td>
<td class="nump">6,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">29,349<span></span>
</td>
<td class="nump">21,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,725<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,151<span></span>
</td>
<td class="nump">$ 6,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982374216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589983091176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty obligations</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_EstimatedLitigationLiabilityLegalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">2,598<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued tax liabilities</a></td>
<td class="nump">3,268<span></span>
</td>
<td class="nump">3,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">3,275<span></span>
</td>
<td class="nump">3,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedClinicalTrialsandStudies', window );">Accrued clinical trials and studies</a></td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AccruedExpensesPropertyandEquipmentCurrent', window );">Purchases of property and equipment included in accrued expenses</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">2,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">8,240<span></span>
</td>
<td class="nump">7,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">3,139<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 24,055<span></span>
</td>
<td class="nump">$ 25,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedClinicalTrialsandStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials and Studies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedClinicalTrialsandStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AccruedExpensesPropertyandEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses, Property and Equipment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AccruedExpensesPropertyandEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_EstimatedLitigationLiabilityLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Litigation Liability, Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_EstimatedLitigationLiabilityLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589981679560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">$ 10,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">773,160<span></span>
</td>
<td class="nump">379,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">146,118<span></span>
</td>
<td class="nump">268,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">939,515<span></span>
</td>
<td class="nump">659,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">773,160<span></span>
</td>
<td class="nump">379,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">146,118<span></span>
</td>
<td class="nump">268,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">919,278<span></span>
</td>
<td class="nump">648,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial and nonfinancial liabilities, fair value disclosure</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">773,160<span></span>
</td>
<td class="nump">362,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">146,118<span></span>
</td>
<td class="nump">268,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">773,160<span></span>
</td>
<td class="nump">362,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">146,118<span></span>
</td>
<td class="nump">268,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Debt securities, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Debt securities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589986640744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gh_RedeemableNoncontrollingInterestMember', window );">Redeemable Noncontrolling Interest | Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; beginning of period</a></td>
<td class="nump">45,500<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="nump">49,600<span></span>
</td>
<td class="nump">41,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase (decrease) in fair value</a></td>
<td class="nump">6,186<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">5,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod', window );">Net loss for the period</a></td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(622)<span></span>
</td>
<td class="num">(2,359)<span></span>
</td>
<td class="num">(944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; end of period</a></td>
<td class="nump">50,400<span></span>
</td>
<td class="nump">46,800<span></span>
</td>
<td class="nump">50,400<span></span>
</td>
<td class="nump">46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember', window );">Contingent Consideration | Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; beginning of period</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Initial fair value of contingent consideration at acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase (decrease) in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod', window );">Net loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value &#8212; end of period</a></td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gh_RedeemableNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gh_RedeemableNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gh_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589985517176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_MarketableSecuritiesMaturityPeriod', window );">Maturity period (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_MarketableSecuritiesMaturityPeriod', window );">Maturity period (years)</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_MarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_MarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590070110952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 164,671<span></span>
</td>
<td class="nump">$ 143,228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost', window );">Amortized cost, cash and cash equivalents and debt securities available-for-sale</a></td>
<td class="nump">933,892<span></span>
</td>
<td class="nump">657,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">5,623<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CashCashEquivalentsandDebtSecuritiesFairValue', window );">Cash, cash equivalents and debt securities, fair value</a></td>
<td class="nump">939,515<span></span>
</td>
<td class="nump">659,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value, cash and cash equivalents</a></td>
<td class="nump">20,237<span></span>
</td>
<td class="nump">10,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost, debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value, debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost, debt securities, available-for-sale</a></td>
<td class="nump">913,655<span></span>
</td>
<td class="nump">630,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">5,623<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value, debt securities</a></td>
<td class="nump">$ 919,278<span></span>
</td>
<td class="nump">$ 631,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CashCashEquivalentsandDebtSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Debt Securities, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CashCashEquivalentsandDebtSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589980659736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">$ 16,986<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(1,438)<span></span>
</td>
<td class="num">(676)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">15,548<span></span>
</td>
<td class="nump">6,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_IntangibleAssetsGrossIncludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">21,876<span></span>
</td>
<td class="nump">12,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">20,438<span></span>
</td>
<td class="nump">11,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">IPR&amp;D</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">11,886<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(809)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 11,077<span></span>
</td>
<td class="nump">$ 4,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Remaining Weighted Average Useful Life</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements and other covenant rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, gross carrying amount</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, accumulated amortization</a></td>
<td class="num">(629)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 4,471<span></span>
</td>
<td class="nump">$ 2,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Remaining Weighted Average Useful Life</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979230744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590077505704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">1,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">1,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">1,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">2025 and thereafter</a></td>
<td class="nump">6,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, net</a></td>
<td class="nump">$ 15,548<span></span>
</td>
<td class="nump">$ 6,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Amortization Expense After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589981353752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Patent License Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ChargeOfInProcessResearchAndDevelopment', window );">In process research and development expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CapitalizedLicenseFees', window );">Capitalized license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember', window );">Patent and Covenant Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember', window );">Patent and Covenant Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember', window );">KeyGene Patent License Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_PaymentInConnectionWithaLicenseAgreement', window );">Payment in connection with a license agreement</a></td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionTransactionCosts', window );">Asset acquisition, transaction costs</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ChargeOfInProcessResearchAndDevelopment', window );">In process research and development expensed</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement of prior dispute between parties</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember', window );">KeyGene Patent License Acquisition | Patent and Covenant Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember', window );">KeyGene Patent License Acquisition | Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CapitalizedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CapitalizedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ChargeOfInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge Of In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ChargeOfInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_PaymentInConnectionWithaLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment In Connection With a License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_PaymentInConnectionWithaLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_PatentandCovenantRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_AssetAcquisitionAxis=gh_KeyGenePatentLicenseAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982304536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Acquisition of Bellwether Bio (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid upon closing</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent liability from business acquisition</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=gh_CommercializationMilestonesMember', window );">Commercialization Milestones | Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable', window );">Maximum contingent liability</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=gh_EarnOutConsiderationMember', window );">Earn-Out Consideration | Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable', window );">Maximum contingent liability</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_CovenantsNotToCompeteMember', window );">Covenants Not To Compete | Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_BusinessCombinationContingentConsiderationMaximumAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Maximum Amount Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_BusinessCombinationContingentConsiderationMaximumAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=gh_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=gh_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=gh_EarnOutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=gh_EarnOutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_CovenantsNotToCompeteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gh_CovenantsNotToCompeteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589985651224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisition - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,290<span></span>
</td>
<td class="nump">$ 3,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Net liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,802)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590093398536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Intangible Assets Acquired (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc. | Acquired license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member', window );">Bellweather Bio, Inc. | IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identified intangible assets</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gh_BellweatherBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589986122808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979307096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Information (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.19%<span></span>
</td>
<td class="nump">7.77%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979359976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Liability Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 4,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">11,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">9,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">10,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">10,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2025 and thereafter</a></td>
<td class="nump">20,251<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">67,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest</a></td>
<td class="num">(18,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 49,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589986191608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>petition </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>petition</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>company </div>
<div>patent</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Gain contingency, patents allegedly infringed upon, number | patent</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember', window );">Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofCompaniesthatInfringedonaPatent', window );">Number of companies that infringed on a patent | company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member', window );">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPetitionsFiled', window );">Number of petitions filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember', window );">Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPetitionsFiled', window );">Number of petitions filed</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberofPetitionsDenied', window );">Number of petitions denied</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofCompaniesthatInfringedonaPatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Companies that Infringed on a Patent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofCompaniesthatInfringedonaPatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofPetitionsDenied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Petitions Denied</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofPetitionsDenied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberofPetitionsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Petitions Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberofPetitionsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590069731768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">8,871,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,871,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,871,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,407,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of offering costs (in shares)</a></td>
<td class="nump">4,312,500<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price of stock issued (in usd per share)</a></td>
<td class="nump">$ 84.00<span></span>
</td>
<td class="nump">$ 71.00<span></span>
</td>
<td class="nump">$ 84.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of offering costs</a></td>
<td class="nump">$ 354,600<span></span>
</td>
<td class="nump">$ 349,700<span></span>
</td>
<td class="nump">$ 354,600<span></span>
</td>
<td class="nump">$ 349,709<span></span>
</td>
<td class="nump">$ 354,600<span></span>
</td>
<td class="nump">$ 349,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares underlying outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,869,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,869,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,869,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,494,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">564,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember', window );">Shares available for issuance under the 2018 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,864,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,726,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,574,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,574,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,574,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_A2018IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590069834936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning number of shares, available for grant (in shares)</a></td>
<td class="nump">2,726,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable', window );">2018 plan annual increase (in shares)</a></td>
<td class="nump">3,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(78,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross', window );">Canceled (in shares)</a></td>
<td class="nump">12,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending number of shares, available for grant (in shares)</a></td>
<td class="nump">2,864,528<span></span>
</td>
<td class="nump">2,726,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning number of shares, outstanding (in shares)</a></td>
<td class="nump">4,494,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">78,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(654,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(49,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending number of shares, outstanding (in shares)</a></td>
<td class="nump">3,869,002<span></span>
</td>
<td class="nump">4,494,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, number of options (in shares)</a></td>
<td class="nump">2,014,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">76.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">5.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">8.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">13.18<span></span>
</td>
<td class="nump">$ 10.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, weighted average exercise price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 266,316<span></span>
</td>
<td class="nump">$ 306,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 150,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(126,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross', window );">Canceled (in shares)</a></td>
<td class="nump">33,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward', window );"><strong>Shares Available for Grant&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Granted (in shares)</a></td>
<td class="num">(3,391,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589983843336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, grants in period (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.61<span></span>
</td>
<td class="nump">$ 51.94<span></span>
</td>
<td class="nump">$ 45.52<span></span>
</td>
<td class="nump">$ 43.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock based compensation not recognized, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Total market-based restricted stock units approved and granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,815<span></span>
</td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">$ 32,153<span></span>
</td>
<td class="nump">$ 6,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercises in period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,100<span></span>
</td>
<td class="nump">$ 108,300<span></span>
</td>
<td class="nump">$ 50,300<span></span>
</td>
<td class="nump">$ 116,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="nump">68.30%<span></span>
</td>
<td class="nump">73.30%<span></span>
</td>
<td class="nump">68.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
<td class="nump">66.90%<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
<td class="nump">66.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares underlying unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Total market-based restricted stock units approved and granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,391,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod', window );">Market-based restricted stock share price goal</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Market-based stock unit vesting period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of MSU (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate', window );">Risky rate, cost of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Total market-based restricted stock units approved and granted</a></td>
<td class="nump">1,695,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units | President and Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross', window );">Total market-based restricted stock units approved and granted</a></td>
<td class="nump">1,695,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting', window );">Market-based stock units holding period during vesting</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for post-vesting restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting', window );">Market-based stock units holding period during vesting</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted-average derivative service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for post-vesting restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for issuance under the 2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock based compensation not recognized, period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock based compensation not recognized, other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.20%<span></span>
</td>
<td class="nump">60.20%<span></span>
</td>
<td class="nump">73.20%<span></span>
</td>
<td class="nump">60.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,614<span></span>
</td>
<td class="nump">922,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate, ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price of common stock (as a percent of the fair value of common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,164<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,164<span></span>
</td>
<td class="nump">119,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gh_NonemployeeStockOptionMember', window );">Nonemployee stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_CommonStockSubjecttoRepurchaseorCancellation', window );">Stock subject to repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare', window );">Stock subject to repurchase, per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Cash proceeds received for unvested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_CommonStockSubjecttoRepurchaseorCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Subject to Repurchase or Cancellation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_CommonStockSubjecttoRepurchaseorCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gh_NonemployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gh_NonemployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589985631400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Activity (Details) - Shares underlying unvested restricted stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning unvested balance (in shares) | shares</a></td>
<td class="nump">496,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">126,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(25,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(33,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending unvested balance (in shares) | shares</a></td>
<td class="nump">564,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Beginning balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 82.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted (unaudited) (in usd per share) | $ / shares</a></td>
<td class="nump">75.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested (unaudited) (in usd per share) | $ / shares</a></td>
<td class="nump">80.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Canceled (unaudited) (in usd per share) | $ / shares</a></td>
<td class="nump">75.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Ending balance of options outstanding (in usd per share) | $ / shares</a></td>
<td class="nump">$ 81.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982309256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Market-based Restricted Stock Units (Details) - Number of RSUs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 1 - $120 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="nump">565,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 2 - $150 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="nump">565,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Tranche 3 - $200 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest', window );">Number of MSUs (in shares)</a></td>
<td class="nump">565,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589985574744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 25,815<span></span>
</td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">$ 32,153<span></span>
</td>
<td class="nump">$ 6,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember', window );">Cost of precision oncology testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,622<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,167<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">3,965<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 20,619<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 22,492<span></span>
</td>
<td class="nump">$ 1,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=gh_PrecisionOncologyTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590069832056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation of Stock Options (Details) - Stock options issued and outstanding<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">66.50%<span></span>
</td>
<td class="nump">66.90%<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
<td class="nump">66.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.50%<span></span>
</td>
<td class="nump">68.30%<span></span>
</td>
<td class="nump">73.30%<span></span>
</td>
<td class="nump">68.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589982806584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Employee Stock Purchase Plan (Details) - Shares available for issuance under the 2018 Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">73.20%<span></span>
</td>
<td class="nump">60.20%<span></span>
</td>
<td class="nump">73.20%<span></span>
</td>
<td class="nump">60.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979279000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (49,739)<span></span>
</td>
<td class="num">$ (11,300)<span></span>
</td>
<td class="num">$ (81,568)<span></span>
</td>
<td class="num">$ (32,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Adjustment of redeemable noncontrolling interest</a></td>
<td class="num">(4,900)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Guardant Health, Inc. common stockholders</a></td>
<td class="num">$ (54,639)<span></span>
</td>
<td class="num">$ (11,600)<span></span>
</td>
<td class="num">$ (82,368)<span></span>
</td>
<td class="num">$ (37,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)</a></td>
<td class="nump">96,011<span></span>
</td>
<td class="nump">89,036<span></span>
</td>
<td class="nump">95,196<span></span>
</td>
<td class="nump">87,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589986843240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">6,550<span></span>
</td>
<td class="nump">5,451<span></span>
</td>
<td class="nump">7,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,056<span></span>
</td>
<td class="nump">6,313<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">6,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember', window );">Common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589978109544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax assets valuation allowance</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140590070001272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 66,335<span></span>
</td>
<td class="nump">$ 53,975<span></span>
</td>
<td class="nump">$ 133,845<span></span>
</td>
<td class="nump">$ 90,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">61,422<span></span>
</td>
<td class="nump">48,997<span></span>
</td>
<td class="nump">126,035<span></span>
</td>
<td class="nump">80,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 4,913<span></span>
</td>
<td class="nump">$ 4,978<span></span>
</td>
<td class="nump">$ 7,810<span></span>
</td>
<td class="nump">$ 10,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589981106792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details) - Affiliated entity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable from related parties</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589979989176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Narrative (Details) - Office and laboratory space - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>numberOfLeases</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_NumberOfOperatingLeasesLeaseNotYetCommenced', window );">Number Of Operating Leases, Lease Not yet Commenced | numberOfLeases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Estimate aggregate base rent payments | $</a></td>
<td class="nump">$ 239.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract', window );">Weighted-average estimate lease term</a></td>
<td class="text">11 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal terms</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Weighted Average Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gh_NumberOfOperatingLeasesLeaseNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Leases, Lease Not yet Commenced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gh_NumberOfOperatingLeasesLeaseNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M975P<$__B#:7B681^2O<GAX>N.*@8_<PFW'*.N'@]IXUHP<SU],HN$"_V\5
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M-<#\?R6E/MS4'72?I6[^!E!+ P04    " !4@@91:L_BG0 $  !E#0  &
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M(+^_R_/JX4W]<Q3;WW6Y_!M02P,$%     @ 5((&48],/<'( @  +P<  !@
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M3(D>U<"E;YRQ+!^7NSZYW)0K 0T&HF?Q)N9=M]M5]ILPD/M[2*R5:CHM?OY
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MVY3_FK4$)E%@&L+*ZW"75JVQTSI(()I,%<5N2/_/Y7_%Y4#<!#9)_13]A5.
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MOP5[I]R*+:342VR='WYW=A 1HOL0;"._:5K8$&PE?ZXU&K?C GR_M#9T'WA
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MM!YED(>LR.%WI.-;*UF!:#JMGK#QOI)NDA; XC!*8OC4ZU98RKLG6XN=]37
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ML<D%EB@:5M8LY$7MQ0(FI-V82BBR1" 0LZ)^"X"YK&>Q;SM"DDA&YC+C^KA
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MZ(MF3MX_RZ'A. :;?0:)1*SW&++O=;N:+$ESH..S)Y"BQ!#(9=HN+(-NLL/
M4\SQHFD=#3NMCC+KP$,F[>'@T*2JF3HI:BN+N;>-U!MUI]=F,'3:HIJIV&0O
M/+X?M<E$#:@RCM!]A\40Q"7-M_MP'@&W71G'IH=9RM_PP.!B?Q'#B^4(!_U+
M\9:#?B1>S:;B78[\JI5*.SRV%,6@&_UGP_/)1/P IHO]<#*<S5]C+PZ/V1(O
MIL/Y9/92_!;].1)S",\?#4G%.P@7'AA3*MVM:>HY+)VO*V?+>/S>#.E1S!OQ
M/<?K4V2D[[H@_IX6L_=J1?<CLFBUM[,1T1E.X?QTDK:UWAHV'9[AP3>=HRE*
MW_1.M) =Q;KIL8#L#?#18Z^QX]XW 73M.G[YX#Y &M/G@>YN]W%ED;XI[(^G
M+S-X?ULKO 9H6D%T,CI_-4A;;'L1;!6_,"QM"+:,/PN2*$(^@.<KBU?/YH(-
M=)^<KO\"4$L#!!0    ( %2"!E$?UVE.RP0  (H*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;)U6[V_;-A#]5PY&AB6 *EO^$3M!$B!I5[1#BQ5M
MMV(8]H&6SA91B=1(JG;VU^\=92MVV@;;/M@B*;Z[=X]W)UYMK/OL2^9 V[HR
M_GI0AM!<#H<^+[E6/K4-&[Q965>K@*E;#WWC6!415%?#\6AT/JR5-H.;J[CV
MSMU<V394VO [1[ZM:^7N[[BRF^M!-M@OO-?K,LC"\.:J46O^P.'7YIW#;-A;
M*73-QFMKR/'J>G";7=Y-97_<\)OFC3\8DT2RM/:S3%X7UX.1$.**\R 6%!Y?
M^#E7E1@"C;]V-@>]2P$>CO?67\;8$<M2>7YNJT^Z".7U8#&@@E>JK<)[NWG%
MNWAF8B^WE8__M.GV9MB<MS[8>@<&@UJ;[JFV.QT. (O1=P#C'6 <>7>.(LL7
M*JB;*V<WY&0WK,D@AAK1(*>-',J'X/!6 Q=NWC!"\E?# %NR,LQWN+L.-_X.
M[IS>6A-*3S^9@HMC_! <>B+C/9&[\9,&?VY-2I-10N/1>/2$O4D?V"3:FSP9
M&/UQN_3!X>S_?,+FM+<YC3:G_UFL?X.CCR73<ULWRMQ3J3RQ">RX(&V"I2_*
M:=MZ0KDY%;194R4H4FO'C"H(GE""9%<KG3/Y1N6<(%="B=*0XA,$S-6>G#)K
MF:V<K2E[-J=[5LZ3MS4#3IM2YR5\YE5;8,'@YZBV#L]&"L43V#@VO$GIUG<L
M/*FF<58!B$)HG0[W"86#<'+@=,%PLX]C!<VMN&T!0K H^<_H,=A8Z,Z-,D6T
MT;$&,S$4':OJ@4NI K#WQ%OM@U K6 !0&)$P\(YT@!!5U6&CR4@Z$;?B_IAJ
M81&.L:&7X+%+;6!Q%_B.G"B?JRIOJ^YH'MY76BUU%?50/OIY;$Y5:'S"$=SE
MH )^^U.V!AM7%6+KC/2:[,GJCBK:K<?>906EV44+^Z!YRR[7PK1D_PWOH=-8
M=X??BX.#J)%5>4RME'YYE'6\1=?'<X.@3K+T JVGJF(7!<&34;KH%T2:Z*%$
MGB*/8E-@:0J$DN:^I"-R/,HN$G#T#<=N7(EL8G&23H]=9.GY5RZ\WOX?!T<)
M[VEI43.[V@+"6/.L5Z1!.4BEG39.(V&UZ V=A!2.H#L^-@JR45XJM^8NBU$:
MT _'%]26_5GZB-@+ALQ+).HD2R)#.FV-:E$'7)S1I_CAX.*9^H(S6/-!/3^D
M()WBR&,=G]%Y.L9O^C6PT#ZWK4&ZJ,"T2.'H!YJG\SD>TGM65E(Q-@JD$N\^
MQ/IO1&%;1ZL6E<T(!E+I!CF$6HVMLY5\6E9ZK;J<BGWH4<*(3#IT?4K%:C[2
MX))^!WGY6 CD2)!#+23*4*)]0%5$^CXJ@;8B]J*4)S1-YN.)3#+*LN0<,6(\
MIHMD,1W)<$+9*)E-9C*>RGB^B.NS?6WA(%>0%&O)>);11QMBN1R'TZC[+I83
M.I\G\^F"WK#WE_2Z;EHPI=>Q=:,AG6:+9'*1G7W'SKX]:!93TXMD,IO32]VE
MT+ZU0G0I<G16=AI&T"@.>L"//C9-*<<B]EE;Z4()B56T(P@?L! )I]_ZS T/
M[@<U(VWE%B1FD2S=5:%?[2]:M]W]XF%[=TM[BZS71KK?"M!1.I\-R'4WGVX2
M;!-O&R@SW%WBL,1ED9ULP/N5M6$_$0?]]?/F'U!+ P04    " !4@@91<ZM1
MU_ (  "B%@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM6&UOW+@1
M_BO$%CBTP-ZNO4DNP<4V8#N]7@[-G7%)>A^*?N!*U(HQ12HDM>O]]WUF2+WY
MK4';+_9*&L[K,\^,='9P_C;42D5QUQ@;SA=UC.V/ZW4H:M7(L'*MLGA2.=_(
MB$N_6X?6*UGRH<:L-R<G/ZP;J>WBXHSOW?B+,]=%HZVZ\2)T32/]\4H9=SA?
MG"[Z&[_K71WIQOKBK)4[]5'%S^V-Q]5ZT%+J1MF@G15>5>>+R],?KUZ2/ O\
M0ZM#F/P6%,G6N5NZ>%^>+T[((654$4F#Q+^]NE;&D"*X\37K7 PFZ>#T=Z_]
M)XX=L6QE4-?._*'+6)\OWBQ$J2K9F?B[._RL<CRO2%_A3."_XI!D7VT6HNA"
M=$T^# \:;=-_>9?S,#GPYN2) YM\8,-^)T/LY3L9Y<69=P?A21K:Z >'RJ?A
MG+94E(_1XZG&N7AQ[9I&1V0Y!B%M*:Z=C=KNE"VT"F?K"!,DN"ZRNJND;O.$
MNA_$!RBH@_BK+54Y/[^&:X-_F]Z_J\VS"G_I[$J\.%F*S<GFY!E]+X9X7["^
M%_]-O.*=#H5QH?-*_/-R&Z(':/[UC-67@]67;/7E_RO+_X,Z\7>UDT;<>%<H
M5>)V$.^!_K+4W ;1B>+><;<U>B?I:1#:%IWWJL0/$6LEG(<*="L.=3[@NA+;
M+L"?$):B\JX1$3U*6M-_'(%WK;1'H/0HM@KMOOV"%B01*?;2:Q6/I*8P4C?)
M <,>MZ/'2_+#=/2[EV-;J2&43\?VRI;.0Q@,Q:)TLW41@6GH2UIED0(#?XE2
M-B :'-BYO?*6,@ );?<JQ"$#G!'$X1% C+"U$NA_H>YDTQJU% <E:KE78*1"
M@5#*)9^@8'/*JBX2@ HN2L>YR;)PB34N^Z"@%\5H<4&UX!#9-+PP<)]BJJ1!
MVF4)AZ-&XG<(5U*(,%=YJCJ%L11[[0Q'0+E5T.F.] !9I0P4*@4&1)=@=7\[
M.[T2?^2@8,SA$=(1N_AT;(/$<@#6D/!)&2ET99'Y L#IO/!$D<F1H-0MTM)
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MZ'&0S=)@,IW!-)\'\W@&GY4EW?,@G\7!/,IHE$:S()XF\-'GYP?*Y*I;"U[
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M<=9@1)/'3:JPWIDX53DD5#05*,&DUS'8QX;@#II[*Q.YGD,E(Y\<P)^)P)G
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MW+]OZ@:KL!$9@$GZ 9F6;_(;[?*6^4.NSH(( OBWT8LC;E<J65%PDW>T(Q9
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M46[39BN9I7NT4Q3Z8H2I:XU?B+[?&D8?#/A,2]@1@!\?/ML%LW$T=GQD^W8
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M U5DJ'S$=U3::L'%KD9HYL.!4<#U\$*=!S9T88N@75PKDJ0I.0X.4.TQH/D
MK#&4,F6<*%1M$M(@+,YE'[M=<8F@S%\S<I7<;>M4$6OT(->SB'-OP&8D;3L2
M<99M:4.,6DAE.S-67E2B*NK(U6+1E-2BT'E2:LS&>L.!7NP[ \+DW;I:87:Y
MJ3)H8TANX3":K#=9L867$ EYD9^W#QX;'I]A.W*SC]K-WK&;72.K&#S0S27N
M(+;O[FE#OC%@!ZH3W:LI\J3(BB52)9,)/A&A1_U&U#_X/_$]:GBA D)^#RT0
ML!)"0BU9L6'?LR$J<*(@0,H>!E,1.K-I1$]&4W&-M$TGG#K-91MLY_C11$1A
M)$;.+!K3[$D@?GD0&<"H$X%5W_%00@6!$\YHZQEE3-R^>3 (@ZFQ,\7D)]@Z
MT*^@9LP-.F<TFW(IV4:_?CN^.IY3<>;7:\%7._ALLZK760SRKI-50;+18\_)
M6SE]YJA&QLI&U5G<'J3T@M[/,9=W+:K!:]AXMKKI/7;'7AM"(A=6L?LD>G@,
MS*/=H(O-(HK<\=-NV)0^X=EL\&ST=&?<9&2>37;'?3X<ZA$&PVXH?_!ID\%C
MWXW,XRY>8H.6[#8UV"K*^DT_^>E];W2VU8-MBVWWF8WNH@X+D1^Q'DIC&8RZ
MDO&^9NINHZA?XG%;^%82T@[3+&KMEJDF*6_KFINX5(2,!N(I#)$#9O+.L24E
M][BIS-=^#M0N*?NBB*T01%$[$[?_:-(E PSB2EN8Z!2KRP#[].R6,%UO23SK
M=X= Y!O-G_;J+WNZ>$@D)-[>1D; @U+8.:A"A][Q0<= P&U6 9A+==%#4W^+
MJS3^+G[)BCD@[9J/IDW3Q>U,\@NYZI>5[*4D]&2GPVXB)NNDW\BVK1;2TTY.
MT^N7V_QMKT#4#5>H%UK#0U./G;:U&Q<3*CW7-4J_MV\[#RR?MFG?1?ZD=_Y&
MFYZ1/GN*$:N8.QW4LI2&,9+LX 2T/018(804Y5:D!0PS+VI]6I%*/N^(JR+G
M8 ZRP61#Y;Y6"76*C-L,Q=N3_^\=DJ'0I_RK, RLUW2B81-4TJUIM3QH7P\;
M  WYE-0%>5WHZ.:6SAES<X&A#2 ?KCXY^DR&HU%>F+L-+44Z+K?I_>%.CRO>
M-EQS9FK-R946*:5=I,.XJPX>SZ?3";47#U0_8@XLR<:]WF#:E? E+G4ZULPS
ME0!1C"=M).2S+ N4TCPJ5[JJ8+N-N5Q.&V076[')FFJ'_4/$62Z[8S7M6:8A
MU2.EVX\Q<%7 &0?L ''@.EB%7O\ 8L#;EFWUEM&9<[)-L!*UEF"E'"5 D8JS
M>NOJ,/>>PMP'&^8^DYUR#^9("(1H!P+]ZEZ#;O* !B+0!3';#83?E*HFZBV-
MQJR'*&/3]'[PZOG&6QLN_\[A\DO/?5M/!/X@<FV(O$V\U6"S;0-MJRT('G F
M]4FFKN^ &L:PZ4O'- +R7IMF&*U![!^R+-QA:L?ER)<' F1;IC_0(C.=C9WN
MQ>%XU?#Q(;DEXB(A;:TX&)KV+<%&Z\/=/#VM+@Q].]FF'2_O$KD9)!LVBWQV
M$+G^8WR; Q7%H^&^5//L3+<R^\] @Q],!XYTDRP_W=%H=V2@(R)%W3G%\-VB
M9K>-M^\)!%C;(49IS-DEKA^ ^LTYA"!5)463ZUCU:TR6OS !T39 .-WN#\O,
ML/5@V-X%!#,CWFC;H9D;VIWR%"M"?>RD3WYA9ZTLK#0?*XEA(V$OA[4>#O=+
MN$]Z?P.&2"5\>G:HZ[0'UT>:@<\/VC?&1RCBGCZG/.E(3.$U]1!"UQW0M3.-
MID^'&CWC=EA$DZG6'RJ.Q']NT\2!\&G2L&P+08&KLZ!WMM-BKKDU9;*B^RE\
M]/<!23^ 49\!TW#G() =.J!, 1BFI]3FF:C H/O>Z65[T'@O%?W+<>^NKZ[L
M::4K+LWU$VP]"P(G&!^]WL.6HG)E@@89<WEC#/? +1_:QOW1.T:S,' B/_RS
M-XQH[Y]_N:AW]8\2A@T)EN.7[@([[=8BUD6@S-12$9FV%\=G%EQGT'D2(#>G
M_B))LUXAK"Q7E)"4\%,X>-HD9EF$&TSSO:>&"T7G&R7=&>PZY!NK[L<D^U0E
MMY9/<:TTB*SEKN%"/\10#<.[U:C=,-T1.P?<[UQ#%6(Z?MJF Y3AF+S_\66O
M"=4+559\KIO%%;7 VOLF!=WBXA+8-(Z96$D-<= !)<A2<V/L=G<"'5GHHRY;
MV@2FM 'UUE;MS0W3EI9T.'!\H?=R7G8F[L]XI2;K+V.+SWJEROV5YG(94YM4
M7#9+.O"UZ_"E%GV9X#>X/@.*KRNQF2O>%R5G=9 ]Y7$,L1312P8S3M.ZZQ"L
M*%.0:AMJ#^PK=7?.!RV[=%'D6:J<KZH6^HZ%/V:B.FK&[;$^[>_:.[.[;GS4
M=AABQE/'CT+=QU;9S[G&U5O3QXB)%_R,NVL:.0]V>VW3W=0PFCL^I-J]M^<=
MN$_WYZZL^6ZT<VG/]7[FE;W]8F6H5H1?I 1MHV=7QX/^],#!C6.;JS)#K^@R
MG4/-2#%H1O[;U$##7$@#*?$_J$-LGL1LMS*TUP=^*[383$1DRJUD'V<NA [W
MGA_\.0W^OSUA0 XY^#MT4C 9N<%3$7GTO__^>,<?7P9T:M"]^S.M_,O]4V*-
MX$W>.P!^\.SI,6CT^*-F7:_9GRWTNS*[3LN9>FB/GG]5NA92)N:\0[&R[7X@
M@<%M#ML_][+]&TZJB$-9TEVO8=_5YL74/[4+[EV>Q9>MA7<9YD-)2!O&( ?)
M51?'>;[S(9D%NZ,NM7O7V%#SV?W4SKE[UQ*7LMU6YXGZ#*)_ZFY;Z'!+E?.=
M(9/RFLX_TCA$RGZ7G>\G-P1L6@;N(5-BE-^[H.H(%"EA.+$BXE P<F93_][*
MX##;E#_NW4NP]^.?A&X4]?/.'Z"1&]YQM:(T)I$R[:NG?]GB",FTN[<?BGO>
M, RLY"WM71+",;HHPF?Z69$OS]D)LIY]&VP_<H]D;J[K\L_B#H580S7IF?+S
MIB1]LVSWC'H%L>JF@+)'$^0<@P6(N_[AR@]0QW,?<QV&;EH"%*C<R>F,GZ^2
M9+1;"Y&T5+^*-7;?WH0R%ZFLW?%!GKXP@<TRI,5DSST^W$._K+OH_=:0?K;Y
M,2[A-"@&Y*)^>>*YD_&)#F_V0UUL^.>'\Z)&,<AO5S+&IC0 WR^*HK8?Z!>-
M[>]17_T34$L#!!0    ( %2"!E%TD>708@0  ,$+   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;,56;6_C-@S^*T0V# W@2_R>N$L#M%VWNV$M@N9N
M]V'8!\5F8EUE*2?)3?OO1\E)+NW:8AC:[8M-R>+#AZ1(<[)1^L;4B!;N&B'-
M2:^V=GT\')JRQH:9@5JCI"]+I1MF::E70[/6R"JOU(AA'(;YL&%<]J83OS?3
MTXEJK> 29QI,VS1,WY^A4)N37M3;;5SS56W=QG Z6;,5SM%^6L\TK89[E(HW
M* U7$C0N3WJGT?%9ZL[[ []SW)@#&9PG"Z5NW.)#==(+'2$46%J'P.AUB^<H
MA ,B&E^WF+V]2:=X*._0?_:^DR\+9O!<B<^\LO5);]R#"I>L%?9:;=[CUI_,
MX95*&/^$37=V-.I!V1JKFJTR,6BX[-[L;AN' X5Q^(Q"O%6(/>_.D&?Y$[-L
M.M%J ]J=)C0G>%>]-I'CTB5E;C5]Y:1GIU>4]]^4,3!##?.::813:S5?M)8M
M!()5\$O+=,6DA??(A*T#^"#+ 9RKIJ&HSJTJ;VHE*M1F,K3$R.$.RZWUL\YZ
M_(SU'"Z5M+6!"UEA]5!_2)[LW8EW[IS%+P+^VLH!)&$ <1B'+^ E^_ D'B]Y
M!N^":<GEZC \?YPNC-5TF_Y\ 3_=XZ<>/_V?PO_?68>/-<)2":IR"AAT  :M
MH4UM:[#TN53-FJ!].:JEWZ**XB4P64'%16NQ DFDA".U)E+&DV+_B%39D3('
MI(Z)E49\<,M@SN\>;KB[0H^H.)".6LG:BA.A/AQQ25Q5:XBF"0#O2ES; WH5
M%5X?KG:\OX>CM A&2=%W8A0%21AZ<1P%63[V8A('>1;UX;3Z0C5.3<ZZ@&BL
MD'JN\U(J61)'30%UX>32HD9C"3HH'-R1!ST:^V<6A.Z]9_"OXQ4\D0]BFZ5!
M_LV=?.=.'"0[=T:=.U>OF+MGN(2#;-3OA"C9"N/=3DH[GWTCQNH=NT5-_Y6.
MAX'6$ !ELKN$+JBO>=.>8EOD01A%,"Z",,FAR(*HR&$\"M(BI4LH2_050+6T
M9O(>-LPX>FQ+21GNZX2J!Y@0CB-7%7T@7^BZ8+6S^)I> #>>DV$-H9@WJ<G
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M'8]>OTR VA=$NV!7QZF]=BQO@/A9RJ,+*0C(>>$<'Q;!0/^,6_X%4$L#!!0
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MV["'Q")Y]]WW'8]'SK;6/?B:*(C'1AM_,:A#6'_(,E_4U$@_LFLR6*FL:V3
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MK@('S3%$89N&7*'87,:3!U 5O%@[6[8%/D!JX95,5&Y466H2'Z4/,=2B<JK
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M1HX-L%Y97 _=@ /T[[[Y7U!+ P04    " !4@@91O^)G\-L"  !#!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6REE4MOVS ,@/\*X0T[%;'C)%W;
M)0&:KL-6H%C1[G$8=E!LVA8J2YY$Q\V_'R4G;@:TQ89=8E$B/SXD,O/.V'M7
M(1(\U$J[1501-6=Q[+(*:^%&ID'-)X6QM2 6;1F[QJ+(@U&MXC1)CN-:2!TM
MYV'OQB[GIB4E-=Y8<&U="[M=H3+=(AI'^XU;65;D-^+EO!$EWB%];6XL2_%
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MR>CM+ +;CZQ>(-.$,;$VQ$,G+"N>\FB] I\7QM!>\ Z&_XWE;U!+ P04
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M?2TV1$1DYO'UN-4Q9!DIZ2@VJ>R9P+R%,L6YB)H@Z7#E<'2Z^H+$*@@^A]Y
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M4:G^X?M+VYAEREN*W-=@Y&1H(A4K\),O6\TFOWL7+ &ZH1<).#Y6>"J,0$T
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MUDV'5N(@F( YU!MR?V-SG&P'Z,:=6B2$C>,"+F/:=M0/!RD@73VGQ(F0?HQ
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MRAJ!6:MY4EMW6F 5($L+,#N'VUPKU /@,A5UYM+FU@#+<RXXLY@!T>.6JC
M1GJH4#O&U*6.KBV0<B@K)I_>O+J(A^?O#<6Q3%"7>@H#H&GAS32:"GWC.0RN
M,@*4&?6BK[>A_13Y@V>:,,&H+O].W_Q__@=X$9+].Z54T7V6AN*19.CB9#YX
METDS59V.G#4Z*KD2- ;-)72'->\BKOJ( _A,;E\*C?BL;X!N/?I;O^:/>W9Z
MP34&7!%FF:"&T=!IAN\:]5_2VUHR*B(Q/WHF+]LZPQR.Z1F.X;47QA$)_>8"
MXA&M1V?TBH=.&K9VO<G2><=>VWV>05PUZV/_Q.=>[#>O6STY=<#41G1@!9/D
M]_JEY@QWYB%A;/S4-^ KW8S&7MO_6.;-//UCWOR5;IG><&DH9DZNT<GY:0"Z
MF?3-PJK*3]=$62+LQ8)^CJB= >WG2MENX0+TO]O9;U!+ P04    " !4@@91
M6<RZBP@$  #_"   &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RU5MMN
MXS80_96!D(<$$&*)NM@*; .Y[*(M-E@CV;8/11]H:6P12XE:DHJ3O^^0LI5D
M&QM]Z8M$4C/GS.60U'RG]'=3(UIX;F1K%D%M;7<UF9BRQH:;2]5A2U\V2C?<
MTE1O)Z;3R"OOU,@)BZ)\TG#1!LNY7UOIY5SU5HH65QI,WS1<O]R@5+M%$ >'
MA0>QK:U;F"SG'=_B(]K?NY6FV61$J42#K1&J!8V;17 =7]UDSMX;_"%P9]Z,
MP66R5NJ[F_Q:+8+(!8022^L0.+V>\!:E=$ 4QH\]9C!2.L>WXP/Z9Y\[Y;+F
M!F^5_%-4MEX$LP JW/!>V@>U^P7W^?@ 2R6-?\)NL,VF 92]L:K9.U,$C6B'
M-W_>U^&-PRPZXL#V#LS'/1#Y*.^XY<NY5CO0SIK0W,"GZKTI.-&ZICQ:35\%
M^=GEK6HK*C%60".CI*BXI<D-E[PM$1Z],&Y5TZD66VO@_!M?2S07\XDE=H<Q
M*?=,-P,3.\*4P[UJ;6W@$S%6[_TG%/48.CN$?L-. O[6MY>01"&PB$4G\)*Q
M%(G'2X[@O<_Y :6OQ)TPI52FUVC@K^NUL9J$]/<)NG2D2SU=>H3ND?97U4L$
MM8&5IEVF[4L(*XK! F\K^/2C%QW)WWY4ZI/0;B-?F8Z7N AHIQK43Q@L#QP>
M' _@(;24;$F]%\:Z4&R-L%&2-JMHMU= 1<:QR'"')39KU)#$;B4NX+QO>5\)
MJM0%G(N6W%5OB,%<P#TO:PI,_\0(9Y!D839+:<"*,"80IZ_>$FS-=;7C&H'6
MHPSRD!4Y?$':=;62%8BFT^H)&Z]$\DW2 E@<1DD,GWO="DM=\F0;\6Q]QU@X
M91G$89&S5Q:C-M:SD"N;PHP57OQ6]\-)06D0SY;\#4S#.(LID"1+X5@%MUJ1
MY1G,TK!(8QKDE%\14^#&7-&Y4_9-/XBI0NI'*;BG.6=3LL^I;I1#P9*+HP2N
M16>0Y6%19#1(DS#/9W!"@]FHP>P_:_"Z+'5/,7X1?"VDL +-1\H["?BQ\@[(
M^-RYH\;\/W([L&CUPB754*VEV/I*N]XDS%4N#K,\'2TE;KE\C8I1TV9.$VD^
MFEC^#/*U()"$C"J?A%$6C3:DE0UUFH@(S:4LRL%RFM$S?4-84KE$2596"RZ-
M;[.QE _9Q^$T22F&B-2XZG59<Q<35:C[4!0DTE+V=) ZM?*?"QR'Z30GL)2E
M\)6\J0SMEO(ES'?IS$*61D[C]/Q*K= N[C@I@)0\R^&;LA3LO]!IWZ94 5=0
MEH73*/E0BI,WEU*#>NNO7M?[OK7#_32NCK?[]7"IO9H/OP;W7&\%M5'BAERC
MRRF)4 _7[3"QJO-7W%I9NC#]L*8_%-3.@+YOE+*'B2,8_WF6_P!02P,$%
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M8HLT"'@^%4(W&R.@?=FZ_ ]02P,$%     @ 5((&4=^QZ -.!   <A   !D
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M?[=7TGAAEC*0WN"?]LZR#-Y86ZZE4C#HY</G\)''U@.YX*#?&V;Y(=S$>I[
MD(.'L$?EDT[ED_]6^>(OQWO2/B3A?MR'U(I:&H8MT0NI:"N2W->F3H;*61W=
M>?*J-?+*P5S:UJ%]\2-X':3\'*2$5YV^GPBK1O'5K/"^6-W=5;+@R8Q!N%Z?
M=>EG\ N%([BXO'HJ].K%2^CW3MGPK-.@%?#9CL>6LD,PUO/M7'SG81TNG-#6
M>?D[7L"CAV1+=T:>1K>,@YWXYO(-:Z=?=]I].V;MR/SKWGYX/@BWE#P-%%8<
MFAV=L5*N'>;MQMM5'* +ZWD<QV7-WS]TP8'ME;5^NPD)NB_J] ]02P,$%
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M9DW?*M3N +VOE+)/"Q=@^/IM_P=02P,$%     @ 5((&47-,0@;U @  &P8
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MPZ)8O&#?J2>TQ/;>.R-*+PZ<3@EG89ZEQ"@@761A,DO.!/[$A?1OL@_V',T
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MQ$<NIX'KI0/<])5/2>1.ATHY""(G]@* A^<&R09;#KIR/[34X=[JC%";'O1
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M:77W&:I[:-3*?OJ9J09#N5TNI<!(R01X/U>J63^P@N%;X/F_ 5!+ P04
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M<#:B[%7M.-5^&%F[$68M#0U$3BQH D5E-]#_C93F\&$==#/M_#]02P,$%
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M0>0$H<",'('9UQ/>H1 .9&7\[9G!4-(EGMLG^F??N^UESPS>*?&3YU0N@IL
M<BQ8(^A1M??8]S-WO$P)XY_0=K'3CP%DC2%5]<E60<5E]V;/_3F<)4RF%Q+B
M/B'VNKM"7N6:$4L3K5K0+MK2G.%;]=E6')?NH^Q(VUUN\RA=H\DTK_T)J0)6
MC;$!QL#;-1+CPKQ+0K)E7'"8]<A5AXPO(#?L!::3$<31Y.;_[-"*&Q3&@\+8
MXV87<%\:IG,F">Z1"2IAN?FT',&#S*ZPIP-[ZMG3"^Q=LS<\YW8:1[!C MT1
M[$AE1_CUU8;" V%E?E\I-!L*S:XV\:V5J$W):^"24*,A:\ ?93UX0DF-QM<.
M^CIT'HVCZ,UKZL*S@7!W:\/T@4L# @M+BL8?Y@'H;EX[AU3M9V2OR$Z<-TM[
MQ5&[ +M?*$4GQXW=\--(_P%02P,$%     @ 5((&4119P.C#!   NQ0  !D
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M& R4=WLMA^GWOF"QITR"@NQTF'<9ZQ<GCBW4<:)X9;N0.ZYT3V.'N6X[B3
M_7S'N7J<F,:F;637_P!02P,$%     @ 5((&49D8%Q&. @  S08  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&ULI55=;YLP%/TK%NI#*VV! .W6B" U
M(=,VJ5/5J-O#M <';H)58S/;--U^_:X-86F:1-'V O;U/>=^^')(UE(]ZA+
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M'FO,P1%YFV5RW]F747@3Q;LN=G=P;O6G2M(G/?[WI7D >:_E)OL'@<=*>*R
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M$$X#R?;%2_B22?5*7USN"%X3K@W4\PUC\FF@W^NK[SBS_P%02P,$%     @
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M_M"S(IM%7S(J=!82&NG#%;&%6W,\]%\CO34+PQ>CX6<W%=BD5UW(C:[2(C:
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M%$_SQPW!,1%&0,^O.%>'@7%0W6!-_P502P,$%     @ 5((&4:AY2O"! @
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MB;<A*&N WY=2FI>);;C=_3KY U!+ P04    " !4@@91'92_2/($   ]%P
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M^5UM_J)XDET5/G&E>)0]KH#.0:0"^ON"<_7VDDY0WIB/_P-02P,$%     @
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M4[%SY5X 3BPHHV[@>4,WPX0YLXF-W8C9A.>*$@8W LD\R[#XN0#*BZGC.X?
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M5[J1VV&J+V<09H->WW*N#A/3S>OK?O8+4$L#!!0    ( %2"!E'LGV#N(P,
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MEFUOVC 0@/^*%>U#*PWR1D*H  EH]R95JXK:?C;) 583F]D.M-)^_&PG).F
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M *ZB @  ! @  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULS55-;]I
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MJ<'Y)3ZNFI'3;(PL79M?2(-#PRUS'-.@; #>+Z4TFXU]H!O\R3]02P,$%
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M$L;]PJ[R#3R(<V-55H$I@XS+\LF>*AT. ,33# @K0/@WH'\$T*L O5,C]"M
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M!9T1?2^ZG+W*C55;-URLE*51Q2U3&E=1%PYTOE;*/F^* /4 //T-4$L#!!0
M   ( %2"!E',P.%4K0,  ,4+   9    >&PO=V]R:W-H965T<R]S:&5E=#8V
M+GAM;*U678_:.!3]*U8T#S/2#/D.801(#+#;J=IJ5#KMPVH?3&*(=Q*;M9VA
M_?>]3D(:@@>A[KY [)QS['MR?7W'>RY>9$:(0M^+G,F)E2FUN[=MF62DP'+
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M0>R629*I,V<+M("V3BKI@:'K<V\[#@+/ZPWM[:$_QZB>-^@W4+-CE.-YH=^
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M@S .^CSC7.TW1J 9^M%O4$L#!!0    ( %2"!E$F*,@BO (  )D&   9
M>&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;(U5VV[;, S]%<+H0PNTL>,TR5HD
M 9JVPSKTA@9='X8]*#;M&-7%E>2D ?KQH^3$RX;4V(LE4>3A(2G2HY72KV:!
M:.%=<&G&P<+:\CP,3;) P4Q'E2CI)E-:,$M'G8>FU,A2;R1X&$?1(!2LD,%D
MY&6/>C)2E>6%Q$<-IA*"Z?44N5J-@VZP%3P5^<(Z03@9E2S'&=KG\E'3*6Q0
MTD*@-(62H#$;!Q?=\^G0Z7N%'P6NS,X>7"1SI5[=X28=!Y$CA!P3ZQ 8+4N\
M1,X=$-%XVV &C4MGN+O?HG_UL5,L<V;P4O&7(K6+<? E@!0S5G'[I%;?<!-/
MW^$EBAO_A=5&-PH@J8Q58F-,#$0AZY6];_*P8]#K?V(0;PQBS[MVY%E>,<LF
M(ZU6H)TVH;F-#]5;$[E"NJ+,K*;;@NSL9%;-#;Y5*"U<+^EKX 3NF=;,)0L.
MK]"R@ILCDCYD69$@,)D"9W-%&DJOP92,A"?P+PX<0"'AKN"<<F]&H26NSF.8
M;'A-:U[Q)[RZ<*>D71BXEBFF?]N'%&,3:+P-=!JW GZO> =ZW6.(HSAZGEW!
MX<&1K,0<]4-VBU17T^*DUV2SYYWT_C.;\/.6-.#&HC"_6O!/&_Q3CW_Z"?Z]
M)TRE@(<278UD#C7YXWJ%>V5A3;U\J02U3H(I?$!;F'7J:J]][]6U\7(2C\+E
M'J+]AFB_E>BUL06U##V7/->8NYWK'6IC2DK)UL(_M0\XV,>FAC[;9=,[Z_3W
M,QHTC :MC%Y\?V)ZPI:4N1P!MQ2Y3YQ%+?:1:4?M=BG;3!L8@/#OM:7(PX;I
ML!6S+B1E"E>,>UY[:]8.THUJ8OOXA#OC0J#._5 TD*A*VGIR--)F[E[4X^:/
M>CVT[YC."VDHAQF91ITAU4[7@[ ^6%7ZX3-7ED:9WR[HWX':*=!]II3='IR#
MYF\T^0U02P,$%     @ 5((&4?");$]% @  @@L   T   !X;"]S='EL97,N
M>&ULU5;?:]LP$/Y7A#I&"Z..DR:EJVW8"H7!-@K-P]Z*8I]M@7YXLIPY_>LG
M68[MI'4)?=B2/$1WWYV^^R1=(@6EWC!XS $TJCD398ASK8O/GE?&.7!27LH"
MA(FD4G&BC:LRKRP4D*2TDSCSII/)PN.$"AP%HN+W7)<HEI70(;[J(.2&;TF(
M_<451H[N3B80XJ?SC[\KJ6\_(#>>?3H[FSQ=W.[CYTW@ GNODLX/(+V<V,\H
MM0N/%5@<5N M]C'JZX.HWV!NB+UV]Z,@E:(_A!EV@*E,.* U82&^(XRN%+6S
M4L(IVSAX:H%8,JF0-J=OI/@6*9]=V'>>;8R6AU,A55/;57#?JS9]+[#UK$#*
M6"=PBAT0!071&I2X-TZ3W( O0JBUEYO"*,P4V?C3.>XG-(,ILI(J =65\?$6
MB@(&J96C:);;4<O"LT&M)3=&0DDF!6DT;&>TAJ&-@;%'^ZOYE>YPU^G@3"?V
M1$5G&D&MZ6B<8_F';(Y[2/L^7E30M=1?*[,<T?BV5^!!04KKQJ_33L 8NS_.
M3HJ";;XPF@D.;O$'%XP"LIV'<JGHLZEF6R4V "B,UJ TC8?('T6*)=1ZVTYU
M.JYY>H*:_^T^9R! $384;7K_F'?YW8IGU_]+<O.OLB_X58WM57CL(N>G(')Q
M"B)/H"=G-T>IT6NOQL']NW/[=BBRKYP0_[3O*=871:N*,DU%Z^4T24"\N(0-
MO28K\R#>X3?Y":2D8GK9!4/<VS\@H16_Z;(>[$:T6;W]W2[/7S0%^U=W]!=0
M2P,$%     @ 5((&49>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#
M, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M
M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD
M%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3
MY?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^
M-8+)#^Q^ %!+ P04    " !4@@91:OX]5D<%   ,+P  #P   'AL+W=O<FMB
M;V]K+GAM;,6:6U/;.!2 _XHF3]V999/X1LL09KBURPZE&<+PNJ/82J+!EE))
MAM)?OY(-Y8B2,_MR\%-LV;$_Z_8=70X?M+E;:GW'?C2ULK/1QKGMP7ALRXUH
MN/U+;X7R5U;:--SY4[,>VZT1O+(;(5Q3CY/)I!@W7*K1T>'SL^9F#$^T$Z63
M6OG$D' KQ8-]N1Y.V;VT<BEKZ1YGH^ZX%B/62"4;^5-4L]%DQ.Q&/_RMC?RI
ME>/UHC2ZKF>C:7_A5A@GR]^2%P'RAB]ME^+X\II[D-FHF/@'KJ2QKKNC>S[W
MC/?"W]R?M4Y_EK43YHP[\<7H=BO5.CS&?\48?$:7#\^_?28>F/^3C7JUDJ4X
MTV7;".7Z?#2B#H#*;N36CICBC9B-3O6],&S.UR)\E'_+1=5_H/-D(+O,@?07
MS$75,5+RJ$HH*RKFCZRN9>4Y*G;":ZY*P0!D@D F T+^FP#(%(%,!X%<!!S_
M5P"9(9#9@)!13N8(9#XD9 H@"P2R&!(R Y#[".3^D) Y@/R(0'ZDA3P3MC1R
M&]*97K&3UDHEK 5PGQ"X3[1PB[9IN'D,8 NY5M+_C2O'CLM2M\I)V(E/L%Y\
M0HMYH>Z%=>$F)A7[1TM_<.O/6A-Y!A7-D*:)6O444\V4V#6?N33LEM>M8%\%
MMSX#PQ_LG^R4VPT[AYB8;*;$MKGP<9-:AY>R8VM% +SRK^*J8E^TKB FIILI
ML6^.R^^M?VE(ATB87*;$=KGTI2I@[S+%+#(EUTC3R*[AVJ[P?-MP/C85JI0Q
M)&:1*;E&FL9WS@NGRSO(A$EC2FR-#F;OA/<=2N.?9/GK:H9Y8THLCM :+[6U
M;.[C_<6&&]]0G3-RV?J12PU[Y0031T(NCE(W@MWP'U%U2S!3),2F6(AU9[*N
M,Q-Z;?AV(TMVH?JG04QT4$)LBNN0Z&O?G!OWR&X,]S6P&QI'&8E)(B&6Q*)=
M6O&]#7EY?A^Z& B&:2$AU@(:547#D 1314*L"AP3ABP)YI!DF*'(4V0%AR()
M9I&$V")H9!47.B:6A%@L:&058V)^28C] B(K]N$F*,7^ 2=",*FDQ%+I0ZPW
ML3"OI.0CD)<PYDTXS"8IL4UVQ3-/H! 3G>0B5@H:UL13<9A@4FK!8"%$C(D)
M)B46S(ZI#_;A3#@N:XB)"28E%@SN02B8%!-,2BP8'!/.=J688%)RP>R<JPD%
M#S$QP:3$@L&C"IB;&>::C-@U.&8!,3'W9(/.?NU#3,Q"V9"S7U'$FV$6RH@M
MA&/"#BE#%UN(+81C1DT(LU!&;"$<,VI"F(4R8@OA@7E4-S$+9<06PC&CNHE9
M*!MTF!/53<Q"V3L.<_;8W%-X6U[Z__J^U)L=+EAB%LJ)+11CPK,0UD&GYYB%
M<F(+O<+LRKVG-5Y&'&)B%LJ)+11C_E93(29FH9S80D_#W#UVQ8WA8</)<^ >
M#2MS3$$YL8)^,78'O^90NX&E9X68Z(K_NRS*>,R%?UC5^J+V[>;;5H1L56NX
M#27'%)0/N5K#]B FIJ#\'==KWJZ2F'GR@59N0NG[2Q 3,T].O?*_&S.T=[@+
M!3-/06P>!//:#S,A)F:>@GI-9S?F5V[@JF*!F:<8:A8NU,UHWJC S%-0+^SL
MQ@QQ/,3$Y%-0S\+MQCQOMG!ZJ\#D4Q#+!Y_3C/:;H1O.B.6#8\*!18')IR ?
M_[RL*+\IGP*33T$M'W1B."IK3#X%L7QVKRUW^H&["S'Y[%/+Y_4"<QP,0TQ,
M/OO]1NSN9GMT6(F55**Z\J^P/KWD=3DW+/STN\.R/.SL6+5U?>K3OJE+S:OG
MS=S/&]&/_@-02P,$%     @ 5((&4; % +TV @  '"H  !H   !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<\W:2VZC0!2%X:U8+""X[HND%6?4DTRC;  Y
MY8=B&T312K+[MIR!?5 />A)Q1JA 7'XQ^(2 QY=\:,=]=RJ[?5\6G\?#J:RJ
MW3CVO^JZK'?YV):[KL^G\Y%--QS;\;P<MG7?KM_;;:YEN8QZN)U1/3W>SER\
M?O7Y?R9VF\U^G7]WZS_'?!K_,;C^Z(;WLLMYK!:O[;#-XZJJ/P_7W:6^;-+=
M>7*U>'Y;5</S6ZKJN8,$@F3^((4@G3_((,CF#W((\OF# H)B_J &@IKY@^XA
MZ'[^H <(>I@_*"U1QB5!T@1K JT3<IT(O$X(=B(0.R'9B<#LA&@G K43LIT(
MW$X(=R*0.R'=B<#NA'@G KT%]18"O07U%@*]9?*P3:"WH-Y"H+>@WD*@MZ#>
M0J"WH-Y"H+>@WD*@MZ#>0J"WH-Y"H+>BWDJ@MZ+>2J"WHMY*H+=.7I80Z*VH
MMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VHMQ'H;:BW$>AMJ+<1Z&VH
MMQ'H;9.7W01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>COJ[01Z.^KM!'H[
MZNT$>COJ[01Z.^KM!'K[Y&,E@=Z.>CN!WHYZ.X'>CGH[@=Z.>CN!WH%Z!X'>
M@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WC'YV81 [T"]@T#O0+V#0.] O8-
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M<YL_CA^?96>;_BV?C?^:/'\!4$L! A0#%     @ 5((&40=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !4@@91SD>NN>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !4@@91F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %2"!E%D
M,H_<-@4  %T5   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !4@@91;^1;)\@'   ('0  &
M    @(%Y#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M5((&4:@HVHY !   P@P  !@              ("!=Q4  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %2"!E'6<NTS<@8  *(:   8
M          " @>T9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " !4@@91:L_BG0 $  !E#0  &               @(&5(   >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 5((&40H>Z*C@"@  XT4
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M965T,3 N>&UL4$L! A0#%     @ 5((&4; :R5\C#0  \"8  !D
M     ("!VFD  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %2"!E$?UVE.RP0  (H*   9              "
M@1F2  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 5((&
M47.K4=?P"   HA8  !D              ("!&Y<  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " !4@@91[.,FN0H$  #&"0  &0
M        @(%"H   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( %2"!E%QFX1U'!(  )LZ   9              " @8.D  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 5((&4721Y=!B!   P0L
M !D              ("!UK8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " !4@@91B$RFRNX#  #2"0  &0              @(%ONP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %2"!E%=LF,X
M0P,  "L'   9              " @92_  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ 5((&4?3)ILA.!    PH  !D
M ("!#L,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !4
M@@91O^)G\-L"  !#!@  &0              @(&3QP  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %2"!E&_$RIL!2P  -6<   9
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M970R.2YX;6Q02P$"% ,4    " !4@@91QE=,2$(#  !=!P  &0
M    @(%%"0$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M %2"!E&SVOMI.P,   D'   9              " @;X, 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ 5((&47-,0@;U @  &P8  !D
M             ("!,! ! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " !4@@919&()'&<'   7%   &0              @(%<$P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %2"!E'4%WQP7 0
M -\*   9              " @?H: 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ 5((&47V-:3L8 P  A 8  !D              ("!
MC1\! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !4@@91
M-#I)$ 4"  ! !   &0              @('<(@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( %2"!E$46<#HPP0  +L4   9
M      " @1@E 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ 5((&4;3F?M6: P  #!(  !D              ("!$BH! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !4@@919&5 P4\'  "T(@
M&0              @('C+0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( %2"!E&^&PQCK ,  -0.   9              " @6DU 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 5((&49D8%Q&.
M @  S08  !D              ("!3#D! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " !4@@919<M1H%,#  #_"0  &0
M@($1/ $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( %2"
M!E%E-+)^]P8  #TR   9              " @9L_ 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ 5((&4042O $J!0  UQD  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( %2"!E$CRV--K0(  &L'   9
M  " @81; 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M5((&41V4OTCR!   /1<  !D              ("!:%X! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " !4@@91I_&F8J4#   M#0  &0
M            @(&18P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( %2"!E$(OTT1O0(  /H'   9              " @6UG 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 5((&4>R?8.XC P
M7@L  !D              ("!86H! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " !4@@914^*W8\H"  !Z"0  &0              @(&[
M;0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( %2"!E&Z
M2C37*0(  'L%   9              " @;QP 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ 5((&42["KB>X @  I <  !D
M     ("!'',! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %2"!E%QE@>62 ,  +@*   9              "
M@>V- 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ 5((&
M47I^ *ZB @  ! @  !D              ("!;)$! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    " !4@@91Q54>N; #  #2#@  &0
M        @(%%E $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( %2"!E%J7_(#K@,  .,0   9              " @2R8 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ 5((&407!3&H1 P  # L
M !D              ("!$9P! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    " !4@@91S,#A5*T#  #%"P  &0              @(%9GP$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( %2"!E&6TH 3
M%P0   \2   9              " @3VC 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ 5((&4>JF!<8> @  ;P0  !D
M ("!BZ<! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " !4
M@@91TBA+<OP"  #S"0  &0              @('@J0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( %2"!E& H4R-J@(    (   9
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M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !4@@91L 4 O38"   <*@
M&@              @ &TNP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !4@@91X<M&R/T!   ]*0  $P              @ $BO@$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/ * 5  !0P $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>302</ContextCount>
  <ElementCount>409</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders??? Equity (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Investment in Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/InvestmentinJointVenture</Role>
      <ShortName>Investment in Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Condensed Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Intangible Assets, Net and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill</Role>
      <ShortName>Intangible Assets, Net and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151112 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2157114 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2160115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2162116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Intangible Assets, Net and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables</Role>
      <ShortName>Intangible Assets, Net and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Acquisition</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommonStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2343308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2352309 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2358310 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentandGeographicInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/DescriptionofBusiness</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Investment in Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/InvestmentinJointVentureDetails</Role>
      <ShortName>Investment in Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/InvestmentinJointVenture</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Acquisition - Patent License Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails</Role>
      <ShortName>Acquisition - Patent License Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Acquisition - Acquisition of Bellwether Bio (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails</Role>
      <ShortName>Acquisition - Acquisition of Bellwether Bio (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Acquisition - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Acquisition - Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Acquisition - Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Leases - Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesLeaseInformationDetails</Role>
      <ShortName>Leases - Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails</Role>
      <ShortName>Leases - Schedule of Operating Liability Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/CommonStockTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Market-based Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2456433 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/IncomeTaxes</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Segment and Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SegmentandGeographicInformationDetails</Role>
      <ShortName>Segment and Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://guardanthealth.com/role/SegmentandGeographicInformationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gh-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Subsequent Events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://guardanthealth.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="gh-20200630.htm">gh-20200630.htm</File>
    <File>gh-0630x2020x10qxex311.htm</File>
    <File>gh-0630x2020x10qxex312.htm</File>
    <File>gh-0630x2020x10qxex321.htm</File>
    <File>gh-0630x2020x10qxex322.htm</File>
    <File>gh-20200630.xsd</File>
    <File>gh-20200630_cal.xml</File>
    <File>gh-20200630_def.xml</File>
    <File>gh-20200630_lab.xml</File>
    <File>gh-20200630_pre.xml</File>
    <File>gh-directorcompensatio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gh-20200630.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "contextCount": 302,
   "dts": {
    "calculationLink": {
     "local": [
      "gh-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gh-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "gh-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gh-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gh-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "gh-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 569,
   "entityCount": 1,
   "hidden": {
    "http://guardanthealth.com/20200630": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 6
   },
   "keyCustom": 50,
   "keyStandard": 359,
   "memberCustom": 23,
   "memberStandard": 53,
   "nsprefix": "gh",
   "nsuri": "http://guardanthealth.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://guardanthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i4c371c7313944545b101f6d1cd5d0524_D20190101-20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Investment in Joint Venture",
     "role": "http://guardanthealth.com/role/InvestmentinJointVenture",
     "shortName": "Investment in Joint Venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Condensed Consolidated Balance Sheet Components",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents",
     "shortName": "Condensed Consolidated Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Intangible Assets, Net and Goodwill",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill",
     "shortName": "Intangible Assets, Net and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:AssetAcquisitionAndBusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Acquisition",
     "role": "http://guardanthealth.com/role/Acquisition",
     "shortName": "Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gh:AssetAcquisitionAndBusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Leases",
     "role": "http://guardanthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Commitments and Contingencies",
     "role": "http://guardanthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Common Stock",
     "role": "http://guardanthealth.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iacfffb20a4ae41eea78d5a346088bc97_D20200526-20200526",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Stock-Based Compensation",
     "role": "http://guardanthealth.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iacfffb20a4ae41eea78d5a346088bc97_D20200526-20200526",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151112 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155113 - Disclosure - Income Taxes",
     "role": "http://guardanthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157114 - Disclosure - Segment and Geographic Information",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformation",
     "shortName": "Segment and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160115 - Disclosure - Related Party Transactions",
     "role": "http://guardanthealth.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162116 - Disclosure - Subsequent Events",
     "role": "http://guardanthealth.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables",
     "shortName": "Condensed Consolidated Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Intangible Assets, Net and Goodwill (Tables)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables",
     "shortName": "Intangible Assets, Net and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Acquisition (Tables)",
     "role": "http://guardanthealth.com/role/AcquisitionTables",
     "shortName": "Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Leases (Tables)",
     "role": "http://guardanthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - Common Stock (Tables)",
     "role": "http://guardanthealth.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352309 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358310 - Disclosure - Segment and Geographic Information (Tables)",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformationTables",
     "shortName": "Segment and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i99b5f92b87414a408b2f164b39aa615c_I20180531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://guardanthealth.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "icccb78a249d8444998f95593e619a75a_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i30305f98796b4fcca95cd1f896a623dc_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "role": "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i30305f98796b4fcca95cd1f896a623dc_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Investment in Joint Venture (Details)",
     "role": "http://guardanthealth.com/role/InvestmentinJointVentureDetails",
     "shortName": "Investment in Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "gh:VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:RevenuefromPrecisionOncologyTesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
     "shortName": "Condensed Consolidated Statements of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "gh:RevenuefromPrecisionOncologyTesting",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Condensed Consolidated Balance Sheet Components - Narrative (Details)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails",
     "shortName": "Condensed Consolidated Balance Sheet Components - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "if118daccbf7d4722ae57d06c7ab08a96_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Activity In Level 3 Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "ib1a2f825e010452bab2dda62203c3a5b_I20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "ie6a2fe3c28ec43dbb430a92bb0b27a35_D20200101-20200630",
      "decimals": null,
      "lang": "en-US",
      "name": "gh:MarketableSecuritiesMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "role": "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements, Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gh:DebtSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "gh:DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Schedule of Intangible Assets by Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Intangible Assets, Net and Goodwill - Narrative (Details)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)",
     "role": "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails",
     "shortName": "Intangible Assets, Net and Goodwill - Schedule of Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Acquisition - Patent License Acquisition (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
     "shortName": "Acquisition - Patent License Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i6bf9235dd4864475b23df2375dff74b4_D20200301-20200331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Acquisition - Acquisition of Bellwether Bio (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
     "shortName": "Acquisition - Acquisition of Bellwether Bio (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i3510d8a915044bd2bbd4d045d52db61f_D20190401-20190430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Acquisition - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisition - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "id02ea36157704a95bf6f694669d5f017_I20190430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iab30d7be41ac42b6aaef61bf9bfb2147_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Acquisition - Intangible Assets Acquired (Details)",
     "role": "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails",
     "shortName": "Acquisition - Intangible Assets Acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i2f640c6e83784ea4850b868a4ac72489_I20190430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Leases - Narrative (Details)",
     "role": "http://guardanthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Leases - Lease Information (Details)",
     "role": "http://guardanthealth.com/role/LeasesLeaseInformationDetails",
     "shortName": "Leases - Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details)",
     "role": "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails",
     "shortName": "Leases - Schedule of Operating Liability Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i142f8879551e4d50a8780dbc93bb85f2_D20180701-20180731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i142f8879551e4d50a8780dbc93bb85f2_D20180701-20180731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i8a23b00d18d54d7a8ee8e67372a2dc8f_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Common Stock (Details)",
     "role": "http://guardanthealth.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iebb665707a6f47049ff619543a4f305f_D20200601-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "icccb78a249d8444998f95593e619a75a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "gh:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "if388d8698b394ac4be606c9d2c0a3489_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "if388d8698b394ac4be606c9d2c0a3489_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "id12141ace9b64b28bea2fdaaf6db601b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Stock-Based Compensation - Restricted Stock Activity (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "id12141ace9b64b28bea2fdaaf6db601b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i669e37f9d5744052b446c5ed68ecebe5_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Stock-Based Compensation - Market-based Restricted Stock Units (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Market-based Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i669e37f9d5744052b446c5ed68ecebe5_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "ifdb07b2046094271b6b1529b0c747445_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i7197fb0a0a9f4c809f047f3f280fd077_D20190401-20190630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i9a4d5a5383ae4a4090e8f9bce88c7e9d_D20200401-20200630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "role": "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i03ad8e1de0c64735bb9c30b5e0a66dee_D20200401-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)",
     "role": "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456433 - Disclosure - Income Taxes (Details)",
     "role": "http://guardanthealth.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "id7bf014e46b74204b10a4f0400b47d54_D20190101-20190630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Segment and Geographic Information (Details)",
     "role": "http://guardanthealth.com/role/SegmentandGeographicInformationDetails",
     "shortName": "Segment and Geographic Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i3a05f1e0143d47aa8aac871e977a2d93_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i202eb5acfb1b413ca52faa339625a6f2_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited) (Parenthetical)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders\u2019 Equity (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i0bb034afda014a85b1b0e2b6b26d774f_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Related Party Transactions - Narrative (Details)",
     "role": "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "i0bb034afda014a85b1b0e2b6b26d774f_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "ie657fc31977a42088ce4640db6c02671_I20200731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:NumberOfOperatingLeasesLeaseNotYetCommenced",
      "reportCount": 1,
      "unique": true,
      "unitRef": "numberofleases",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Subsequent Events - Narrative (Details)",
     "role": "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails",
     "shortName": "Subsequent Events - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "ie657fc31977a42088ce4640db6c02671_I20200731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gh:NumberOfOperatingLeasesLeaseNotYetCommenced",
      "reportCount": 1,
      "unique": true,
      "unitRef": "numberofleases",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://guardanthealth.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gh-20200630.htm",
      "contextRef": "iefbd5a1e324e4a18889d3a45e32f0106_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gh_A2018IncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Incentive Award Plan [Member]",
        "label": "2018 Incentive Award Plan [Member]",
        "verboseLabel": "Shares available for issuance under the 2018 Incentive Award Plan"
       }
      }
     },
     "localname": "A2018IncentiveAwardPlanMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AccruedClinicalTrialsandStudies": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Trials and Studies",
        "label": "Accrued Clinical Trials and Studies",
        "terseLabel": "Accrued clinical trials and studies"
       }
      }
     },
     "localname": "AccruedClinicalTrialsandStudies",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AccruedExpensesPropertyandEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Expenses, Property and Equipment, Current",
        "label": "Accrued Expenses, Property and Equipment, Current",
        "terseLabel": "Purchases of property and equipment included in accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesPropertyandEquipmentCurrent",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AccruedRoyaltiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Royalties, Noncurrent",
        "label": "Accrued Royalties, Noncurrent",
        "terseLabel": "Obligation related to royalty"
       }
      }
     },
     "localname": "AccruedRoyaltiesNoncurrent",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AmortizationOfRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization Of Right Of Use Asset",
        "label": "Amortization Of Right Of Use Asset",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfRightOfUseAsset",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_AssetAcquisitionAndBusinessCombinationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition And Business Combination Disclosure",
        "label": "Asset Acquisition And Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAndBusinessCombinationDisclosureTextBlock",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/Acquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_AssetAcquisitionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Policy Text Block]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_AssetAcquisitionTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Transaction Costs",
        "label": "Asset Acquisition, Transaction Costs",
        "terseLabel": "Asset acquisition, transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionTransactionCosts",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_BellweatherBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bellweather Bio, Inc. [Member]",
        "label": "Bellweather Bio, Inc. [Member]",
        "terseLabel": "Bellweather Bio, Inc."
       }
      }
     },
     "localname": "BellweatherBioInc.Member",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_BusinessCombinationContingentConsiderationMaximumAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Maximum Amount Payable",
        "label": "Business Combination, Contingent Consideration, Maximum Amount Payable",
        "terseLabel": "Maximum contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationMaximumAmountPayable",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CapitalizedLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capitalized License Fees",
        "label": "Capitalized License Fees",
        "terseLabel": "Capitalized license fees"
       }
      }
     },
     "localname": "CapitalizedLicenseFees",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CashCashEquivalentsandDebtSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents and Debt Securities, Fair Value",
        "label": "Cash, Cash Equivalents and Debt Securities, Fair Value",
        "terseLabel": "Cash, cash equivalents and debt securities, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsandDebtSecuritiesFairValue",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ChargeOfInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Charge Of In Process Research And Development",
        "label": "Charge Of In Process Research And Development",
        "terseLabel": "Charge of in-process research and development costs with no alternative future use",
        "verboseLabel": "In process research and development expensed"
       }
      }
     },
     "localname": "ChargeOfInProcessResearchAndDevelopment",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercialization Milestones [Member]",
        "label": "Commercialization Milestones [Member]",
        "terseLabel": "Commercialization Milestones"
       }
      }
     },
     "localname": "CommercializationMilestonesMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CommonStockSubjecttoRepurchaseorCancellation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Subject to Repurchase or Cancellation",
        "label": "Common Stock Subject to Repurchase or Cancellation",
        "terseLabel": "Stock subject to repurchase (in shares)"
       }
      }
     },
     "localname": "CommonStockSubjecttoRepurchaseorCancellation",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration [Member]",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Prior Year Revenue, Change in Measure of Progress",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Prior Year Revenue, Change in Measure of Progress",
        "negatedLabel": "Change in estimate of development services revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToPriorYearRevenueChangeInMeasureOfProgress",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostofDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of Development Services",
        "label": "Cost of Development Services",
        "terseLabel": "Cost of development services"
       }
      }
     },
     "localname": "CostofDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostsofPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs of Precision Oncology Testing",
        "label": "Costs of Precision Oncology Testing",
        "terseLabel": "Cost of precision oncology testing"
       }
      }
     },
     "localname": "CostsofPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_CostsofPrecisionOncologyTestingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs of Precision Oncology Testing [Policy Text Block]",
        "label": "Costs of Precision Oncology Testing [Policy Text Block]",
        "terseLabel": "Costs of Precision Oncology Testing"
       }
      }
     },
     "localname": "CostsofPrecisionOncologyTestingPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_CovenantsNotToCompeteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Covenants Not To Compete [Member]",
        "label": "Covenants Not To Compete [Member]",
        "terseLabel": "Covenants Not To Compete"
       }
      }
     },
     "localname": "CovenantsNotToCompeteMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer C",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer D",
        "label": "Customer D [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_CustomerEMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer E",
        "label": "Customer E [Member]",
        "terseLabel": "Customer E"
       }
      }
     },
     "localname": "CustomerEMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost",
        "label": "Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost",
        "totalLabel": "Amortized cost, cash and cash equivalents and debt securities available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_DebtSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities [Table Text Block]",
        "label": "Debt Securities [Table Text Block]",
        "terseLabel": "Schedule of Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesTableTextBlock",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_EarnOutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earn-Out Consideration [Member]",
        "label": "Earn-Out Consideration [Member]",
        "terseLabel": "Earn-Out Consideration"
       }
      }
     },
     "localname": "EarnOutConsiderationMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_EquityMethodInvestmentSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Shares Purchased",
        "label": "Equity Method Investment, Shares Purchased",
        "terseLabel": "Equity method investment, shares purchased (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentSharesPurchased",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_EstimatedLitigationLiabilityLegalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Litigation Liability, Legal Fees, Current",
        "label": "Estimated Litigation Liability, Legal Fees, Current",
        "terseLabel": "Accrued legal expenses"
       }
      }
     },
     "localname": "EstimatedLitigationLiabilityLegalFeesCurrent",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Net Income (Loss) For The Period",
        "terseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityNetIncomeLossForThePeriod",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_GuardantHealthAMEAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Guardant Health AMEA, Inc [Member]",
        "label": "Guardant Health AMEA, Inc [Member]",
        "terseLabel": "Guardant Health AMEA, Inc"
       }
      }
     },
     "localname": "GuardantHealthAMEAIncMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_GuardantHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Guardant Health, Inc.",
        "label": "Guardant Health, Inc. [Member]",
        "terseLabel": "Guardant Health, Inc. [Member]"
       }
      }
     },
     "localname": "GuardantHealthIncMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_IntangibleAssetsGrossIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets, Gross (Including Goodwill)",
        "label": "Intangible Assets, Gross (Including Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossIncludingGoodwill",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_KeyGenePatentLicenseAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "KeyGene Patent License Acquisition [Member]",
        "label": "KeyGene Patent License Acquisition [Member]",
        "terseLabel": "KeyGene Patent License Acquisition"
       }
      }
     },
     "localname": "KeyGenePatentLicenseAcquisitionMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Weighted Average Term of Contract",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Weighted Average Term of Contract",
        "terseLabel": "Weighted-average estimate lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedWeightedAverageTermOfContract",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_MarketableSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marketable Securities, Maturity Period",
        "label": "Marketable Securities, Maturity Period",
        "terseLabel": "Maturity period (years)"
       }
      }
     },
     "localname": "MarketableSecuritiesMaturityPeriod",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_NonemployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonemployee Stock Option [Member]",
        "label": "Nonemployee Stock Option [Member]",
        "terseLabel": "Nonemployee stock option"
       }
      }
     },
     "localname": "NonemployeeStockOptionMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_NumberOfOperatingLeasesLeaseNotYetCommenced": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Operating Leases, Lease Not yet Commenced",
        "label": "Number Of Operating Leases, Lease Not yet Commenced",
        "terseLabel": "Number Of Operating Leases, Lease Not yet Commenced"
       }
      }
     },
     "localname": "NumberOfOperatingLeasesLeaseNotYetCommenced",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofCompaniesthatInfringedonaPatent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Companies that Infringed on a Patent",
        "label": "Number of Companies that Infringed on a Patent",
        "terseLabel": "Number of companies that infringed on a patent"
       }
      }
     },
     "localname": "NumberofCompaniesthatInfringedonaPatent",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofPetitionsDenied": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Petitions Denied",
        "label": "Number of Petitions Denied",
        "terseLabel": "Number of petitions denied"
       }
      }
     },
     "localname": "NumberofPetitionsDenied",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_NumberofPetitionsFiled": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Petitions Filed",
        "label": "Number of Petitions Filed",
        "terseLabel": "Number of petitions filed"
       }
      }
     },
     "localname": "NumberofPetitionsFiled",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gh_OfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Offering Costs Incurred But Not Yet Paid",
        "label": "Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Follow-on public offering issuance costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "OfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PatentandCovenantRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patent and Covenant Rights [Member]",
        "label": "Patent and Covenant Rights [Member]",
        "terseLabel": "Patent and Covenant Rights"
       }
      }
     },
     "localname": "PatentandCovenantRightsMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PaymentInConnectionWithaLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment In Connection With a License Agreement",
        "label": "Payment In Connection With a License Agreement",
        "terseLabel": "Payment in connection with a license agreement"
       }
      }
     },
     "localname": "PaymentInConnectionWithaLicenseAgreement",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Related to Settlement of Debt and Buyout of Royalty Obligations",
        "label": "Payment Related to Settlement of Debt and Buyout of Royalty Obligations",
        "negatedTerseLabel": "Payments made on royalty obligations"
       }
      }
     },
     "localname": "PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing [Member]",
        "label": "Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing [Member]",
        "terseLabel": "Personal Genome Diagnostics, Inc. and Foundation Medicine, Inc, vs. Guardant Health, Inc. Subsequent Filing"
       }
      }
     },
     "localname": "PersonalGenomeDiagnosticsInc.andFoundationMedicineIncvs.GuardantHealthInc.SubsequentFilingMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]",
        "label": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member]",
        "terseLabel": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc."
       }
      }
     },
     "localname": "PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing [Member]",
        "label": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing [Member]",
        "terseLabel": "Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Subsequent Filing"
       }
      }
     },
     "localname": "PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.SubsequentFilingMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PrecisionOncologyTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Precision Oncology Testing [Member]",
        "label": "Precision Oncology Testing [Member]",
        "terseLabel": "Cost of precision oncology testing"
       }
      }
     },
     "localname": "PrecisionOncologyTestingMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_PreferredStockSharesIssuedUponConversionOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred Stock, Shares Issued Upon Conversion Of Common Stock",
        "label": "Preferred Stock, Shares Issued Upon Conversion Of Common Stock",
        "terseLabel": "Common stock reclassified and converted into preferred stock (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssuedUponConversionOfCommonStock",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_RevenuefromDevelopmentServices": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from Development Services",
        "label": "Revenue from Development Services",
        "terseLabel": "Development services"
       }
      }
     },
     "localname": "RevenuefromDevelopmentServices",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_RevenuefromPrecisionOncologyTesting": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from Precision Oncology Testing",
        "label": "Revenue from Precision Oncology Testing",
        "terseLabel": "Precision oncology testing"
       }
      }
     },
     "localname": "RevenuefromPrecisionOncologyTesting",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected To Vest",
        "terseLabel": "Number of MSUs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Cost Of Equity Interest Rate",
        "terseLabel": "Risky rate, cost of equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCostOfEquityInterestRate",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period During Vesting",
        "terseLabel": "Market-based stock units holding period during vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriodDuringVesting",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Goal Period",
        "terseLabel": "Market-based restricted stock share price goal"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePriceGoalPeriod",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Annual Increase In Shares Available",
        "terseLabel": "2018 plan annual increase (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross",
        "terseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period, Gross",
        "negatedTerseLabel": "Granted (in shares)",
        "terseLabel": "Total market-based restricted stock units approved and granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gh_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableforGrantRollForward",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gh_SoftBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SoftBank [Member]",
        "label": "SoftBank [Member]",
        "terseLabel": "SoftBank"
       }
      }
     },
     "localname": "SoftBankMember",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gh_StockIssuedDuringPeriodValueStockOptionsExercisedEarly": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised Early",
        "label": "Stock Issued During Period, Value, Stock Options Exercised Early",
        "terseLabel": "Vesting of common stock exercised early"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedEarly",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_UnauditedInterimCondensedFinancialStatementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unaudited Interim Condensed Financial Statements [Policy Text Block]",
        "label": "Unaudited Interim Condensed Financial Statements [Policy Text Block]",
        "terseLabel": "Unaudited Interim Condensed Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimCondensedFinancialStatementsPolicyTextBlock",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gh_UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrealized Translations Gain (Loss) On Obligation Related To Royalty",
        "label": "Unrealized Translations Gain (Loss) On Obligation Related To Royalty",
        "negatedTerseLabel": "Unrealized translation gains (loss) on obligation related to royalty"
       }
      }
     },
     "localname": "UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gh_VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase",
        "label": "Variable Interest Entity, Fair Value Of Joint Venture Threshold For Share Purchase",
        "terseLabel": "Fair value of joint venture threshold"
       }
      }
     },
     "localname": "VariableInterestEntityFairValueOfJointVentureThresholdForSharePurchase",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return",
        "label": "Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return",
        "terseLabel": "Threshold percentage of fair value that is no less than internal rate of return"
       }
      }
     },
     "localname": "VariableInterestEntityThresholdPercentageofFairValuethatisNoLessThanInternalRateofReturn",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gh_WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share",
        "terseLabel": "Stock subject to repurchase, per share (in usd per share)"
       }
      }
     },
     "localname": "WeightedAverageNumberofSharesCommonStockSubjecttoRepurchaseorCancellationPerShare",
     "nsuri": "http://guardanthealth.com/20200630",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r294",
      "r453",
      "r454",
      "r457",
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [
      "r174",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chief Operating Officer [Member]",
        "terseLabel": "President and Chief Operating Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r390",
      "r391",
      "r396",
      "r397",
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r390",
      "r391",
      "r396",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r100",
      "r107",
      "r199",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r100",
      "r107",
      "r199",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r100",
      "r107",
      "r199",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r172",
      "r277",
      "r281",
      "r537"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r297",
      "r299",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r493",
      "r535",
      "r538"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r297",
      "r299",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r493",
      "r535",
      "r538"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r172",
      "r277",
      "r281",
      "r537"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r286",
      "r297",
      "r299",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r493",
      "r535",
      "r538"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r286",
      "r297",
      "r299",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r493",
      "r535",
      "r538"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails",
      "http://guardanthealth.com/role/LeasesNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r277",
      "r280",
      "r536",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r277",
      "r280",
      "r536",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r174",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Topic 606 adoption"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201807Member": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2018-07 Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.",
        "label": "Accounting Standards Update 2018-07 [Member]",
        "terseLabel": "ASU 2018-07 adoption"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201807Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r18",
      "r175",
      "r176"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r17",
      "r92",
      "r454",
      "r457",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable from related parties"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premium (discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r13",
      "r514",
      "r525"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued tax liabilities"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r35"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r35"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty obligations"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r238"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r48",
      "r49",
      "r50",
      "r526",
      "r546",
      "r550"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r97",
      "r98",
      "r99",
      "r395",
      "r541",
      "r542"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Remaining Weighted Average Useful Life",
        "verboseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Condensed Consolidated Balance Sheet Components"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r349"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r361",
      "r362",
      "r363",
      "r364",
      "r496",
      "r497",
      "r498",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r300",
      "r302",
      "r352",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Adjustments to additional paid in capital, stock issued, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r302",
      "r333",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r178",
      "r202",
      "r204",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r79",
      "r221",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r152",
      "r157",
      "r164",
      "r194",
      "r390",
      "r396",
      "r418",
      "r513",
      "r524"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r43",
      "r90",
      "r194",
      "r390",
      "r396",
      "r418"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r185",
      "r210"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost, debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r183",
      "r186",
      "r210",
      "r516"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated fair value, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r303",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office and laboratory space"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r296",
      "r298",
      "r372",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r380",
      "r381",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r78",
      "r386"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Re-valuation of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r379",
      "r382",
      "r385"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Initial fair value of contingent consideration at acquisition date",
        "verboseLabel": "Contingent liability from business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Identified intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Net liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r81"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Estimated fair value, cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r81",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r421"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosures of Noncash Investing and Financing Activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r90",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r126",
      "r127",
      "r128",
      "r194",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June\u00a030, 2020 and December\u00a031, 2019; 99,312,237 and 94,261,414 shares issued and outstanding as of June\u00a030, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r63",
      "r519",
      "r533"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Guardant Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r54",
      "r56",
      "r62",
      "r388",
      "r400",
      "r518",
      "r532"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r172",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r172",
      "r415",
      "r416",
      "r552"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r172",
      "r415",
      "r416",
      "r552"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r131",
      "r523"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r136",
      "r137",
      "r172",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r134",
      "r136",
      "r137",
      "r138",
      "r415",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r172",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r265",
      "r266",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenue from cash collections exceeding estimated variable consideration"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r278"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r287",
      "r295",
      "r551"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r135",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as current.",
        "label": "Debt Securities, Current",
        "terseLabel": "Debt securities, short-term"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Noncurrent",
        "terseLabel": "Debt securities, long-term"
       }
      }
     },
     "localname": "DebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "auth_ref": [
      "r284",
      "r285"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Cash proceeds received for unvested shares"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79",
      "r150"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in usd per share)",
        "verboseLabel": "Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r121",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Net effect of foreign exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock based compensation not recognized, period for recognition (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock based compensation not recognized, other than options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock based compensation not recognized, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for issuance under the 2018 Employee Stock Purchase Plan",
        "verboseLabel": "ESPP obligation"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options issued and outstanding",
        "verboseLabel": "Shares underlying outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r102",
      "r109",
      "r111",
      "r125",
      "r199",
      "r255",
      "r262",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage",
        "verboseLabel": "Ownership interest in joint venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment in Joint Venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVenture"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r407",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r409",
      "r410",
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r287",
      "r288",
      "r293",
      "r295",
      "r407",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r287",
      "r288",
      "r293",
      "r295",
      "r407",
      "r467"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r407",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Level 3 Activity"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value \u2014 end of period",
        "periodStartLabel": "Fair value \u2014 beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r412",
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r437",
      "r443"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments made on capital lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Acquired"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Intangible assets subject to amortization, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.",
        "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r222",
      "r225",
      "r229",
      "r233",
      "r495",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r229",
      "r499"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets subject to amortization, gross carrying amount",
        "verboseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r222",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r229",
      "r495"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets subject to amortization, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofFutureAmortizationDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Gain contingency, patents allegedly infringed upon, number"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r215",
      "r216",
      "r512"
     ],
     "calculation": {
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r219",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r95",
      "r152",
      "r156",
      "r160",
      "r163",
      "r166"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r365",
      "r367",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r110",
      "r111",
      "r151",
      "r356",
      "r366",
      "r368",
      "r534"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedLabel": "Change in deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Benefit from income tax differences"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of effect of acquisition:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r224",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": 1.0,
       "parentTag": "gh_IntangibleAssetsGrossIncludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r224",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r220",
      "r227"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r149",
      "r432",
      "r433",
      "r520"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r42"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r69",
      "r148"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Lease renewal terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liability Maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r90",
      "r158",
      "r194",
      "r391",
      "r396",
      "r397",
      "r418"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r90",
      "r194",
      "r418",
      "r515",
      "r528"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r90",
      "r194",
      "r391",
      "r396",
      "r397",
      "r418"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Financial and nonfinancial liabilities, fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Acquired license",
        "verboseLabel": "Acquired license"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionIntangibleAssetsAcquiredDetails",
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails",
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Settlement of prior dispute between parties"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r34"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "negatedLabel": "Adjustment of redeemable noncontrolling interest",
        "negatedTerseLabel": "Adjustment of redeemable noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r112",
      "r113",
      "r117",
      "r120",
      "r152",
      "r156",
      "r160",
      "r163",
      "r166"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to Guardant Health, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-compete agreements and other covenant rights"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r152",
      "r156",
      "r160",
      "r163",
      "r166"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesScheduleofOperatingLiabilityMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r438",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Estimate aggregate base rent payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r446",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r445",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/LeasesLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r35"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r402",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r45",
      "r48",
      "r419",
      "r420",
      "r422"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r56",
      "r58",
      "r61",
      "r255",
      "r423",
      "r428",
      "r429",
      "r517",
      "r531"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r56",
      "r388",
      "r389",
      "r394"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss attributable to redeemable noncontrolling interest"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax impact:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of offering costs related to public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r71",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Business acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Payments to acquire interest in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Market-based restricted stock units",
        "verboseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount per share used to calculated dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount",
        "terseLabel": "Preferred stock dividend rate (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering, net of underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r336"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuances of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r52",
      "r55",
      "r75",
      "r90",
      "r101",
      "r110",
      "r111",
      "r152",
      "r156",
      "r160",
      "r163",
      "r166",
      "r194",
      "r388",
      "r392",
      "r393",
      "r399",
      "r400",
      "r418",
      "r521"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r237"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r239",
      "r530"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails",
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r177",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r252",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "terseLabel": "Adjustment of redeemable noncontrolling interest"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.",
        "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value",
        "terseLabel": "Redeemable noncontrolling interest, redemption value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r294",
      "r453",
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r294",
      "r453",
      "r457",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r451",
      "r452",
      "r454",
      "r458",
      "r459"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r355",
      "r565"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r86",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Cost of Development Services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Shares underlying unvested restricted stock units",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r262",
      "r349",
      "r527",
      "r545",
      "r550"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r102",
      "r109",
      "r111",
      "r199",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r541",
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r146",
      "r147",
      "r155",
      "r161",
      "r162",
      "r168",
      "r169",
      "r172",
      "r276",
      "r277",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from samples processed in the previous year"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r66",
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r90",
      "r146",
      "r147",
      "r155",
      "r161",
      "r162",
      "r168",
      "r169",
      "r172",
      "r194",
      "r418",
      "r521"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r444",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r136",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionAcquisitionofBellwetherBioDetails",
      "http://guardanthealth.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://guardanthealth.com/role/AcquisitionPatentLicenseAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r90",
      "r193",
      "r194",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r222",
      "r228",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillScheduleofIntangibleAssetsbyClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r222",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r232",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/AcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r93",
      "r455",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r159",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r159",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule of Performance-based Restricted Stock Units Vesting Conditions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r303",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r308",
      "r319",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r88",
      "r126",
      "r127",
      "r245",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r246",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock by Class"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/IntangibleAssetsNetandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r134",
      "r136",
      "r137",
      "r138",
      "r415",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r144",
      "r145",
      "r152",
      "r154",
      "r160",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SegmentandGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Weighted-average derivative service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Market-based stock unit vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "terseLabel": "Canceled (unaudited) (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Granted (unaudited) (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of MSU (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "periodEndLabel": "Ending balance of options outstanding (in usd per share)",
        "periodStartLabel": "Beginning balance of options outstanding (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending unvested balance (in shares)",
        "periodStartLabel": "Beginning unvested balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Vested (unaudited) (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "terseLabel": "Discount for post-vesting restrictions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate, ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending number of shares, available for grant (in shares)",
        "periodStartLabel": "Beginning number of shares, available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable, weighted average exercise price per share (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, grants in period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r310",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending number of shares, outstanding (in shares)",
        "periodStartLabel": "Beginning number of shares, outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance of options outstanding (in usd per share)",
        "periodStartLabel": "Beginning balance of options outstanding (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and exercisable, number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r301",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails",
      "http://guardanthealth.com/role/StockBasedCompensationRestrictedStockActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche 1 - $120 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche 3 - $200 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche 2 - $150 per share"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r86",
      "r303",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r326",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://guardanthealth.com/role/StockBasedCompensationValuationofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options vested and exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and exercisable, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price of common stock (as a percent of the fair value of common stock)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price of stock issued (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetComponentsPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r88",
      "r90",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r126",
      "r127",
      "r128",
      "r194",
      "r255",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r97",
      "r98",
      "r99",
      "r102",
      "r109",
      "r111",
      "r125",
      "r199",
      "r255",
      "r262",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r125",
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r255",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r255",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in public offering, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r15",
      "r16",
      "r255",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r255",
      "r262",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited",
      "http://guardanthealth.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r255",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r255",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in public offering, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStockDetails",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r255",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r22",
      "r23",
      "r90",
      "r179",
      "r194",
      "r418"
     ],
     "calculation": {
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r262",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r430",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r430",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r430",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r430",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r38",
      "r90",
      "r194",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesActivityInLevel3InstrumentsDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Common stock subject to repurchase"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r361",
      "r362",
      "r363",
      "r364",
      "r496",
      "r497",
      "r498",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofRedeemableNoncontrollingInterestandStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesCashEquivalentsandMarketableSecuritiesDetails",
      "http://guardanthealth.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r132",
      "r133",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r390",
      "r391",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://guardanthealth.com/role/InvestmentinJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/StockBasedCompensationMarketbasedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://guardanthealth.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://guardanthealth.com/role/NetLossPerShareAttributabletoGuardantHealthIncCommonStockholdersScheduleofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "24(b)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876444-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876444-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876444-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876446-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL116876446-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r566": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r567": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r568": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r569": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r570": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r571": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001628280-20-011994-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-011994-xbrl.zip
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M:6=L];KZZBWVRN9AU-=2Y(;U"ULWGWW=O?AT5^_M?P(X^R]02P,$%     @
M5((&4927VEV'"   @C   !H   !G:"TP-C,P>#(P,C!X,3!Q>&5X,S$R+FAT
M;>U;;7,B-Q+^GE^AX,K&KN)E .,7\+J*Q3A+U9[M>-G:RZ<K,=* 8LUH(FG
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MHNQ$&/)K1C6$LYR3:YXJ;8E*R+G2,:D'E5^)BL@O(, HS/0CI]).RF20A%5
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M+"\AW!3&/+!V"_(U(-]_M2 ?WD/$NYVC1OVP8W(8Y^4>DJ&*(@&/NV;/P65
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MT)^S[V+I-PO%T5HH;DP;#Q"Y.>%L#$P \U0PQ!LU*J'(K-0 5K&011#"=JL
M!$!4T)&0PLXQMZ\;%L/#8<?!PB/[GNA2(>P(_#:?4)KI%&!I7"T2A@HW>6"
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MT9%1,K.\DZ]U\.P;\?FGOYWO_I_ Z?\ 4$L#!!0    ( %2"!E&1DQT+S04
M  D>   :    9V@M,#8S,'@R,#(P>#$P<7AE>#,R,2YH=&WM65ESVS80?N^O
MV,K3Q)X13UW6$<\HDM*XDUJ.I4R:IPY(@B)JDF!!T++ZZ[L 25L^XBJ9)G52
M>V2-B&//;Q?8Y>C'Z7RR_' Z@T@F,9R^>_GF> (-P[+>MR:6-5U.X?7RUS?0
M-FT'EH*D.9.,IR2VK-E) QJ1E-G LM;KM;ENF5RLK.69I4BUK9CSG)J!#!I'
M(S6"WY0$1S^,?C0,F'*_2&@JP1>42!I D;-T!>\#FI^#852K)CS;"+:*)+BV
M:\-[+L[9!2GG)9,Q/:KIC*SR>61I)B./!YNC4< N@ 4O&BP@;:]G>T[7]9PV
M<6W2:U'?(Z$;]FW'][W?'132PN7EGEQN8OJBD;#4B*CB/VAU,SE<LT!& \>V
M?QHV],*C4<A3B=P$[BY_ED3ND)+T4AHD9JMTH!4:)D2LD+SDV4"1KAX]+B5/
M]$BC)%X3\(A_OA*\2 /#YS$7 ['R]MU.IUG_@VW:!\-R;L_6?T-%P A)PN+-
MX/F2)32'$[J&,YZ0]'DS1V\:.14L+!?F["^*VB%O_;@N->\AG9BEM+:$XVKU
M9Y<1\YB$EFLZ-W6_7VL?G43%8]=J,CM;'K\ZGHR7Q_,3C(:SQ;OQR1*6\^]'
M1><0WID+<V+"8C;1:CJMCMV$\0+&T_GI<C;]/O6NM>W;79B_@N7K&2S&9R_'
M)[.%,?_MS>P#C"=+->/:MKN+VG\4N63AYMN)Y/;]ACE.P>=I2GV5V&'-9 0R
MHO"V( +=&F_@C&9<2. A_(QC 4%57E,2RZ@)QZEOPKY:_FSOT'7MX80G&4DW
M^LD9'@!2?,5% HYMO(60"TTZ0TEY #0-,/'_4J3TV9[3M8<M1*'.\R2'D,4X
M=R7,@OJ%P),'U29I +-+/R+IBN(!D20LSY7@^%$K SQ-(**"HKC;@I5*U'*A
MY.!3H?S7A*P0>:&TDARNHT/)U!M6P8$2D8!GZJ#:7EVM49!"=EI0(CR2TMR8
M7\9T V-?VTU!JHGS! 7H' X?1A=#LZ1R8#B'Z+^,! $>C$9,P^H0^@X1Z)BU
M11ZOE#<<X=AF1YMUB2ZOPB,L8HP5'_$?*YA>05?0/PLFJ+JDY H+BRK0G-8^
MP?@0X'3V@X,K_%P#_0KD%8B<?JM=(C'1D8-0Z@]5.#S!Z2:<W&\:3BS%-)D0
MC1',RY+@U@!'-3QJK!&F$G,F:*Y@U533)(X!MZ$T)$;0Y1GB+&_J72%+2>JK
M<208Z N\3J.XJH@UMCBF9,TRKX%8)7+S,T]"Q[F#'#V$T)'$B^F55[@(J% >
MB4F6TT']8QBP/(O)9L!2;3N]:7BA4K9/XHHO,JKNY/V^V>WU];5<XEU<!C7]
MZLINEE=V2P9W)_NFW6]]?/K!O0].MKIFK]WY$I0[IMW[(B*W<?:PO^-F2YNZ
M-#?Z+4>\O&BT&O6.&N(*#FYV>07Y"@YJ:,>8W(*:BI?;,"@)W@JIK60GRK K
MT;=C378/?!]SXBM+TBF&O[Y@P*UJM'+E8W.2:[J=C_EIV\[_8(F=+7K3$3OJ
MU3@:%RM,<- M;Z=7IKUMU.[C,.HNR/_&D*VM$%"?EV?4 % NK$QP&<K];*_=
M&^;Z&\N2.-G +):\.(\V.P=!?=:D7%-\(+M=^_@_<."G:O $SJ^3=I]0]X2Z
MKX^Z2<1HB$4B%HR275"8AR'SJ7B"WQ/\O@;\]D\%PYHRPZ+R#@8/_@406KKB
M^W]T8%79CT4_77'U#JSL2R*F=)W.<O"H&@X+D;(\HEB1\9AB]2\Y$-\OR_3M
MYL N[4PL_I%PRF5-7+=;57\6=V<\IS=;58>?T9ZZP05%\51K Z]PF;K%(3-O
M X*&5-#45S-*&]0#!5'RW&Q"-&$=47P6D)" (B5E+-4Z(Z&DXG;;MXET5T0$
M,<VU%HKLBJ94(%2O)5!ZQ2A_05:*/>2%'U7</][SV!5H][P1W**"]M4]F(&@
M,5%QL_UB<?M]8^/^;<1#!!22#BO&]B>_F*R^RY>D^G7MT=]02P,$%     @
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MYD1 ((5@@4GLL.1Z 7K!X%U&%+HU6L$Y2Z32($/X&<<H057>,!+I11E.1.#
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M'YV:!F?]\?#\_>EOX[#W_ID7!Z^XK)[6_:2=DPOK<Y00FEL[&F,_T>7YW=$
ME'1_=\7TC,L+,G6O;A,?J&\</FW/X='[LP_/<)BQ/SXB[(V/[J3!R:3]PFKQ
M<>OS9_>_:(B].SVX]D$D5S?Z:_)0;64O;O+)#=[HR>4RA'#W;97]Y9/X=J_^
MIG_JX8BC]SWZ=M2]ZKY\KKS[?[>?/$]'=(+MS^5P-FH?(I[^%1T7!ZX0=??M
MEUHE]4>]\+Y=?WF/3]ZX'IV<>J^'_</_K%&__>+Y&FL!8;[_ZPF-L54O;=-_
MS[JO_[/V<- ?LVZW]\Y/^1W2]-M_UL;T=GQWTGEW[_^/__$_?AUWQSVZ?WC4
MOI3TKW>G/_UZ=WKC.,CG]W_-W=>MT?B\1_]9R]W1:0_/[_4'?>+'=]_>JR?2
M</JQFS/U)Q_Y>(?-R[";ID]_.]ZE\I^U+I68#4K2"@A0>N]#U@B&?RA""OMR
M8](4-@?M#^CKXTE]-'7OK;/%RM5J/>KAX5JKF_F66?]Q'C<&KY^HW=?[>OLL
M'V^^/G@<CG=.MF1G[U%O_^31R<[&YGEGXYG8W^L==8Y?Z9T_M]YU-O[@W_??
M[;_[O?M$=WK[[TZ[G;T7;P_^_/WHX/CP[?;Q,]%YO&GV]_9-YUVON_WNF>3?
MU;;:/M_O>?%$'9SO_YELY]V6V=[C<X^/^!Z'LK/Q2O-YHG.R^6;_W1]'V_7[
MG]MZ9^/5Z_SX43<^?F&WWSTXX>>\.CAY]J9SO'7>>?SB?+\^X_C5&[[7N_T_
M.]V=C7QTL)<NKOF#GV7Z!WN#=]N/#_B==D\.-M;5]O&6.-C[_9C?YWQG;_UM
M9Z-SM*^VH*,>]3K2OWVRMSG>?B[XW_67#KV5F'S;1R_:$,"T@V/4)AF5U!I-
ML67M?L'>B'Z]^XD(;U*BEV[H47>4L+=/.'S$OXQ6LOV:;,\_EJUVV:<L4KL
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M$=/\QZ-FI5E99ZMDY+Y$4,PO47.P6)>=U9)9))9&9+<]'C4C^105643229(
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M,#7)6ON0&F"#5PA>( 3?O@VF6LW;"6>4#9 5!4Q&1Z-,IIJU^CF+:.B 6C,
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M^D</SC\^\J&VU'HIW5ZW'MB<O,@R^DF6G&2:(SBXD&!%\2'JZ,F) ,B!8FJ
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M*!J-)SN-3-)+CP8]5KW1Q3Z[K<W_GDVV\UX% 8MA#9N#YG]FPAG2;A4$K(*
M14#PM]IC+:]ICQ_BZ*CUJ#=XL^+&"V.CF@/+?V18*S;#BANO#.LB(/B;#2O4
M?1K&W*#Q8+)B:QG2,5:VMEF-_C:X2OG/C.T"^?A%1E>#(/3M2>"7F8KJ%C(5
M5]!9G);-!CK;V,?#B<>[&,,9M3:ZHW0V&M7%S'6<9[V/O?-1=Q**?'"4U9-.
MJP'7<W9I=-:[_;G@5;2R\J"70-;_<#9X@:C;(L.K01CZ9CL(ZL*%ZE6R_PHZ
MWPR=9[60;G<\6=W?6NJI^\GK5G_/K]R[?.-*%WJ#T5FMBK$>!V>756A:N]W1
MJZ;JTXH#+$2COQ&:QJ_"Z)4A_V>6S5QP %B%T2OH?#-T'DZS)$:3:/CI<) H
M5X?85"BMW-]"-/H;06C^X93=97-J=M:\I^]6;5DEKGR'E5J5I)EO21KPES5I
M/A2E^?_9^]:FMHZLW;^BTCMU*JE2.WV_V'-416SL(6^ Q";)P5]<?36RA<3H
M8AO_^M.])9 P&",08DNLF4H"VFSMWMVKGV?UNNX?_&?[]?(*TMR;O -*KM%8
MX$0':OGU4"3("DNX@.C49V3+$9W?XWO;G1SE8ED<.,O5YEBT/I)WN[-<$3^)
MP9T)Z'4[].)GQ+<%_DR0G85EI_CM&B^M'_4'$ 5;&_Y8'Z&[)>GQ%9,>J.SU
M&=D2@$M!&"R(SJU%YZ_>7'/L-[8[Z? R26=NS+70+NZ]OX95^\[IT1#.A;5A
MF_61T5M2I()S(>#<[8MC8@AS!=&YM>B\B,E621Y_G92&NK'7Z0_FJ'%=10IH
ML!:#7E 8X:0(6'9;+&,0Z0FB<VO1V<U?FT^(*>:#X5SJP[J*$M!?+0:]H!#"
M*1 P[+88)J?T)^ 4"**SL.CLCX[BH+'3FW0CS]^SKD($Q%>+02\H?G#N _2Z
M+7J9*?%)./>!Z"PL.MM?CCJN ZVCZD,=ZR-PM^2[+'620A5. ,TZR/#"H*EH
ML_TF+Y@=K<8^!L<$@,TSN9/L.MC\952:&YQ]?@X1[7^[P2_?W'1MENFQ';SO
M],ZDDM"3)4C%(MW0KYG@2^F=M$*;E_NO_]EZ_0+]OK__OSM[KQIO#K8.MG>W
M]P[>W.2U/XR'HTXZK<U+7I*BR4L>''6&I4+1(*]1][3Q.I[T!Z-&O]=XV1\<
M-PA&?[8:G9[OCLN&KPH$#Z.O2ADV1IU1-X8J<Y7B9V=S\K O6SWX:6>4U\#?
MY/5G%1WK,?[K1SNM.EF/H2XZU<NLE5F'][_^;5O5MB#/&J4EC.WTAHW4'WRV
M@X"Z_?['LI>&L[X%@_@^7RD?IG%1 !KQ4_5YF8'^>'#VZ6 Z&:,C.VK8_(&S
MI3IWGJKR1WX\&.2[&O'+2=ZADYEJ-6)&H>/\H/QC'D#T=CC]WI-!_\-D)^??
MAXW/L=LM_RT[_.R;7.QV8IK\N1T.Q\<GDS_/BU$>>'R^=^8APE95S<IU-Q[F
M>1GF)U?O<+["_FR%)Q<&LR7NGR_QY)(OS1Q2:>;0J@91!M?IA8RL@]/J@]C[
MU!GT>V4,^4+C\U'''^57F7Y1?#+?'**:M<DX8^-S?Q"&C>$X_WE^Z2F$5>_[
M*9XOW?3C8WOZ[4>?.]WNMY^=S?2WGQ<!Z/3&ESXO=?!\Y^2*.S[WQ]UP^6NN
M^'!X=-6GG4RXO7#V89FGLR%6HG'^YY_LH&//ES1/[G Z,9/9'G;RQK"#(E!Y
MC8:392EB-_G^+'FC?J-3FEAEGKM&O)\T#JJOOF8##$^B_9@%.3.0/1M,HY2;
MG_S\(XJ:2&@>V7#LBE"7@0TZPX]YO..>SSIMWH#G$<GSDGR^DT(GI8[/<EAN
MS:\;.GY4C3MK4GG;Y/?VHW&6W3-AS3)1W1/+-LCCRG+=G8BD#5F)'L;\6QKT
MC_,3^OG5IU.8IZQ3<.WZV9IF$TT&=UQ )6^$<8FC'E1H,NBX<9Z9/-!*?B?#
MB/D]AV?BW<I[;_)>O?ZHT<WK.*I6JS4=3I@ \60X?^2);>RT&M,LN-9:\_G%
M=*PZO,&/&?ULD\;N,'XN$E=6I<#?5J]79.ZRP/]OD9]JCYS&LD&KS?@B^GCL
MXN#__ ^1^!DCK0;%Q+1F2SRWQNNMM&W4(E\/;&?KG/FLTP_3E=ZU@[SO)RM,
M\02LR[=5WL9!]2V%T#/E=C.@=T9'D\8>3]X\^38[8_N+/[*]][&T%CWN5!C?
M:DP?^6;[^9/&/T?E.ZY![@MJ2+EM$.VPWZL:XLUK(I>5AD9&MW)#9LTXP;K\
MVVGUA<>V8-AI?]R8$%P%8X."J9.''.>!Q<F)=V0_%I1K]%T^=56/JL _?NI,
M '-\4M'(R3A?]Q5$7P>^U7R7/YF\12MK%+&:U<Q*=@K^Y4UZ63(Z,[=NZQN]
M+7])M1B?\R"R"O;%QY-1^8K"&JY,T7_'G9([XTX;7?OYR2V.DS<_?J_).73;
M9I&>$G_>#L<3370*4Z7Q;5Z52WK2)<TI2]BW'XV'\]OO3*>9/&)<Y+9LQKQ[
M,M''PJ_=;M&*/Q5ARX+T*N_.D#6UQG^B[8Z.,H+V_).\XS+:YI4KLNK[@Y.I
M$6:Z$[, ^/F&.5DI&79")RM;L5)(NED3F,G'1/K"DPEL?W=%3_K#2F=^FK=!
M54HXZZ!A=#0Q!DVGDLE+EKCSVZS+ \IJP[.I 0;/W_^C"F%3VTVQ,,J9W>8J
M&9S_=_G*3OB_S9O4I&^>W70TF-DUWT?D\D;\B&S*HWAJNY_MZ;#YRX7!'N=Q
M35^?FDG/U$LO]C#&1WT3P:^9[?'.8[ZYZ5$UVP<52U2-K<N)XDIWX;?[8/W,
MB),*;Y7IACY[N;.WM?=\9^OWBR7>OMWT-]PVK+D1,S0M/'7;UF.WG#QYU>3]
MR&ZMZS^;5U+6 H;ZFK_>=T3C5]O-HI&UUJ,8,P'_-#Z3I9]O[:-8@[7^J5/T
MX?XX?TFQVDPUS>%144PJ(U]6:2:_Y5FRWY^*.8(O#/H-A+#)1%2.H/.9Z \R
MZ)=9Z-J387QZ]L.ST!F>=.WITTZO&F]UT[=^Q?R<&4L_P5.FGCKHIP^87G\R
MN7;F_[QP4=$G3.CO7[_VYNLOXB=$F5O>G.^][J+$UUZ^YN*/ABPEO>'-BP9$
M7"WF-0Z/^.& ISO^+D.>!X;9UC57[-P;(\!%X+CA6S7;OXU[L<'PQ!YPOLD7
M*!,+ZUOK]3TS[37.K'H7UGA]TE@N,&^G\/CH*3)S-TR^@4S.<1>_Q=29C2<,
MMO7FS?:WP0$+%6M>:-:G#%R6E132+ZI0X^PM[[PI'SHFKB:3LSZ1\INRM[X3
M^O=\ZI.VPV'6[Y_6L"+Z8W_^IM$0Y4_4FFT5-MDJ)6JBG/ZJ\(GB:_ADNY=-
M)=^<$AY@?;ZK8UWYIO>M9/WK6\5YN1,S"82]?F8F(C8YI]5H9O[=^?*TU^^]
M'-A)Y-^XUQF]+F;>\3 TJY"$_)K5!QUM*7,8!Z*#X$%9':..4C%%+0U>IW<[
MY8B")</-1HB^<VR[P__;1!DF)LZT_!5?1D][X^/0'TVO-QL]>QS+P]![:T^>
M%O'>ZH7RG^V9;&^-GMO!X#3/XM^V.XX9=O(LQPJ *GM@8'^?NA?]3[_3UY\.
MV>XX?-C^]/:5^;!_O$/V#EYV#X]?'N^_V#[=>_$G/CSH'NU]^,CV_]GYNO?B
M[_SYX=?#K[]U?F=[W<.O)YV]@[^^O/WGMZ.W']Y_V?WP)]Y[M2T.#P[%WM=N
M9_?KGR1_3G?I[NEA5W_9ZYAC?_RRM__AM^.W!W]^WOWPZ_'>\6\?#C_\*?+?
M\,.#CS3?_W7WQ>'IX?'VE]U7NZ>_L]='A\=?NOO'?Y+=#Z&S_^I/MO?B[<>]
M@]?=O>.WG;<?]O+UP\^'].V'M\>[Y.V+/]G9/?E9X[?T+_GVQ5^G>W2'OWWA
M\5[^GKU7?]&WQ[\=[]*7^?Y?\WU[QX=?__ZX]R*DW5/\Y?>#[='N&_SY70PT
M8JDM\E)YQ)DWR&*9D%,A8JXT#<(UVT3REE3DW[]<%(WV-UZL!]Y)]0.9J^?G
MH?5OH "@@*51@/?>J<P#W 3-.3=&)R.$85$28Y6PA0*((901H( Z4<#7<PHP
MPILHN$;$:(ZXD0KI)"T*VF"&,4U,RTP!G+4HU4 !=Z> 3;,RK.W1Z<U1?S!"
M)3BH<5SUY9ZXO.;J-EYK=J#+7K*;R/EWUFR=*60%IXC=\^6=A41.;4Q ' L0
MQ][SN;-#7J"HG)3(<(81M]@A;3U'@F-'0Y)>T]1L*\5:I-0FN7?BN-V&6B/B
M>&B;'X#?6NK/ 'Y+ [^9UNRHT2:O"S(N),2I,<@HYY'0R063R<Q@T6PS95I"
M<0"_>FK-X'"XA=:\Y7T>3)7'ZF,^C6=<:35Z<72_VO+M3H4;2!@KT);/5OCU
M^0+OQ1$PQBT8X\V<NDR$\2I$AACS65W&B2%#E4-$8:H--RPYWVQSTL)$@9EE
M(RSM '[KIRT#^"T/_.;496:4$$DAJTQ /'B/\L)19 EWA%.>A$P9_%3+: G@
M5T]M&6S,M]"6=WHE2;@_. 5C\J:HQ^=+FHD!&&$11NC,J<,R.FZ(-0B'*!'W
MSB$32?[5T$"2X"X%U6Q3W&("["=@/ :P>QAU&,#N]F W4W])PI9'E=5?&CWB
MUD9DG</Y5^IIB)AH0IMM(EKY!P"[>JJ_8"R^A?K[QR">V$ZHB@/UAM,Z1)/2
M1?Y"C@=8CS=%/9XN^?9DQ;=ZH>J+LU6M,MA1;D$D\_':R2J*G;,H).JRULPX
M<C)19*4I,I,<MB(3"6D1#.':8$0&#'P8K1DP<.D8.%.F(PM!B,20),X@SI)'
M#@>,L/8"4T6-#[+"0*8-8& ]E>F'M"57A?/63I,^Z(]*->T5*LV+G1+ODH._
MSFRRBG@,X(U;\L;^?+RR(EI@31R2F$O$L0W(\2"0-$HXKD2D(F3>:&&"6PRS
MVMEA;K3#UHA7'JU%^K%"Y2JB-P J;P^5,Q6;"IDY30@D!,M0R8E&FK*$""=>
M61:]C*[9%D:UF%A%3N#C!LI-LV:O85FBB0[^>[],\P/E"X+]YF'S!??Z/0^\
MLCBOS,= &\X5B8DCRPS-O!(D<LI8A(-*CC.7&&4EUURV"(%<<[!? _[5)V40
M\.^V^#?3JSF-A'%&LB)=RBVE1)#VBB&LA!(8>Q)E:+:IU"VE5V& V'C\VS3;
M]=JJSG\,2I?&T;21XW_'G9-)*\E[3QR$8,%5AGY,%OF/KNV-MGIA^VR=(7AP
MP0)-!UN%,":*\]:[P%F@VBH4"26($\N0UBS_2_G(,F<XYW"S+63+&%$[:\P:
MLL:CM4QO,/RM).H#X&]Y\'=Z#G_2TY"7RJ!@I47<"(DT%PYE&N-<&B.)%,TV
M9RTIZV>,7D/X6Q-[<XTF\75Y$NHG5!HW?Q.; 6:0M=5G]R<=ZGOO?X]V&*M%
MWD]_#6/E901$7PC1MR\HM$Z0*+! QFN%>%(8&44ITB8%29.4QK-FF^F66$D<
MQL:;0< ,O'GXMP*%%O!OJ?@WTV@%HQGJDD;)F(0XUQ098BFRT0?+B:?&NV:;
MFA;AJZB<N?'X!V;@FIB!=WHCVWO?*7$3$S49+, ;I3'/UG<2B;<71]M??'=<
M9O!5OQ\^=[I=((Z%B&-G7G'.NC%6)8=<"A=1Z76-+,,8E<0_;C+U2YZ:;:(R
M<8 I!"S! (,/534#8'#Y,#C3GYW@),5 4>8SAKA/'AGK+<+)"6$%H5F);K9U
M2U"H'513]1D"D&^A/I]A!T0:;XK"#&QP*S;8G5>*,VMS+PU!EI3J2C$ZI!DK
M6>&>!%>,*2JS 6M1 \84,"8#TCV,3@Q(=UNDF[,;JWS0]X(@18E%//&$K"8>
M><R%Q3Y81AT@7:WU7C ;WZK)^4EGE&?F:PR-;L>7HCJ-%*%#7^WUX D%O#]Z
M.K>"OT\6\&5>/^""A;C@SPNFX.B(BXPCS8U#7*J$=# >:1TD9H);(GBS+2 @
M&,S  &JK57D![Y:&=S/=-R,<P40+%&T2&>]"0,:(#'H46Y:<Y)S19ENV]$IT
MWXV'/+#YUD3WK4I'0I7D]=!W;QY:-RL("HG5MZ2'ORZ$%#.3#&4890IGB%/B
MD,.EVUX2C!=NES'3@VB1E;@$-]XT D;@S8.]5404 ^PM _9F6K%-W*B$.<*,
M&L2]H4A'2Y#+2V<$TR88UVSSEM848*^>6C%8A&]=#GGK@E8\')^L>KCRB;C)
M>+]9RRP>^15^(C_GD8]/OE7G5R9+B]4AK=?>_-=:E)=<9VU@986M@?X7HO_#
M^5,/T9BR8 .**6;ZQ]HBIZA'."7"K"<QED!(TJ)*M01;16O=QUVJM0:. J /
MH(\:T,?*BGT#?2Q*'[/3(_$A"B$\,N7,R#EF2!LND/!,2NT<RRO6;!M),WG4
MSY&\:>0!+I=5'R[5MX<U/*GSO;/UZ\[O.P<[VV]:C=?;+[:W=[=^_7V[L;>_
M]WP_;\W]WW_?V7O5V-D[V'Z]_>:@L;7WHO'F8/_Y__YG__<7VZ_?_)__T92H
M9XWM/__:.3C\@=-F:=;3N>W \G8(_7%)L[UA7XGOV58?VK9;O]D!$]"#FX F
MNW3:Y:/1[5C7Z58UBI_>8:^M(G;G,3Y_TUAM;7LQ;WF?!S,:-D[L:2GM??5>
M>;AEJ9=^MM03XEW\(NM\"%R%#7$JU7],A!I:/]WF4/AQWJ8HO1,Q6HN8427)
MA%&4U5F.C TB!D^Y\[39)J)EP*>X(:$4 /H ^FME^0/07PKHSRR!U"KN1(@(
M&VX0IYHA@R5!(4KFC3!!:I5!7[:(40#Z];3U/:0589U/18-Q+(MP?!)[0UL$
M&M(*-^5T\"*FF+DA/)];W=^G]J)3H(U;T,:'"YU)$DW&^4203Z;0ALVTP:1!
M+F*%/68N>)]IHU1BJE_PP1K2QD,;\P &UU)?!AB\#QB<:<^*<,4,UBCXK$)S
M1DHM(A=08DQIYF2P)0J[P*!8A?:\\3 (/H6::<_Q2\$5:(&].9KS=&5_GSE7
M@2=NPQ,7^YZ$O$C&2T1D=(@G;Y"E1B'L-%>1VT1Y;+8I;^&5U.W8>"M+#4SK
M@'WKIRX#]BT-^^8S%4T^A8B$K#(<<>T3<BEHQ#1E7"0MJ&,9^T1+0<^GNNK(
M8&&^A8Y\=OAN#.*GV!M_)^X&S"KKIR,_S\\K(_FG,SIZ/A[F"8T#,*O<B3(N
M=#MQ3&G' T$N.(FX$+901D1.&,U,RI=)R6XC+:[KEYVPAI0!UN7-@\$5J,L
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MR(-^MUO"P#L9FP=Q. (7P::<$V9KO7=AJ7>F*[W]WW')P[>#P6G^=.NX=$X
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M]V [CWWWG<=2.)4D"AIGG8-R@:ST&#$MBW<G2!?9]7KI=Z3I=L=VD*:UEJ9
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M)$0"!]1F=8 #EL !V+AHG ]<",F=LYH;QQSUDIKDE/.% XB9<D#^ 3B@+AR
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M0& ]UJ[6MFF P#M#X,PL[9AF1'J!DO8&\4@<<BX$%!461N)2TS(TVY2V)-8
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M^,!!R "!2X+ N0H5U/IH=%Z=H (K*K9'SE&.C-?:*.RIH3$KVRULH+0P0"!
MX /'$P,$+@L"Y[1 FKP7S")"G<U:(%;(&D>1EB(::J3FJA06;AFQBM9' ($
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M*P#AEH)P,U6/":ZIS+@FG)6("YLF"!>2X51:+!46S3:'(KV <8\'X];$%@Q
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MR6M_=!0'57K7(![%WK#S*3:Z_>$0DKSJ=.K;=$<^A$6!@(. @X#78.E P$'
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MU)G6%C%WBW7DF5X6\PENGA#\Z.I\=!D(8*TS&GY^B"*!'U[\W4SX92.)=Y
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MS*@A.)I]YL9)3D40(5EM)9ABK?KP'>\3-L%\@J#OQ>:5&W1G8S\"#9D93C(
M(U)02JQ61482)&=\BEGH(B-4=/D-2XU6-L%$%4$5015IP9#-(2)%0(+A@0N=
MRJ(B<2NY5;Z\ZR*C6BIT4K5".\XWG]E2VQ_WE:_JD!G1UM<&RIP1'X0EU ;&
M-76&ZE!3AFR7"8R!/WHKR@=.ULW-?QXZ6??LDIJ?[0T2#"8OB9OY0O,+G+[@
MZOJXMRRW=VL\/FZ2>X>YC'IMCE(NM)!,IS?H'!V'?B^6([G\]N!CMS. 2?W<
MV1OE"^-)DQ/\KWGVZ'(!7(A)*J5E"-Y*5Q-1HN:N\&>(^Z\;FI24D>;%#S>)
MW$B?CL>3PS(+X[WA10^)VCUB:W#:-J(ASGJOD,[N>'.(^9;ST>?.)OU\X;]Y
M\[G\5A_^]]W)A[_24>!2EW.6^]T^V=G[\*G\!MUY_?/A]E^__+W[^H\R+N_*
M/?_R:?=U.MC^>I!W7F^KW=?%?/_TQY?MO:TOVY_W@XF1&D\)!:.(Y!F(HSX1
M)X(48+/.GJZM&W[=&W1S_OE#90!>)Y'O4?*2Y?DUU;+\U<,+V=U&;7GDZK;K
MG4>0( 3XHR6R>IZS=M*+I*PTAEFJ:;$0:9&L;#*3/Q"G.3-:+T3I]7$5U+?E
M1H=IFNA:!J$Y-,8TU_DDZG*::Z8N&LLC"2'QFK]$B576DY054%=L>LM]W<.+
M&=6E"ZD*0&)$8FS'U*'R(\!7&.!SK$D#I3PK20,55'K'@^,L4@$I>\-<3K=8
MD]Y7]?_T_6.X+OJX+KV5Z%_./7.I@"082:A0OHA^W7]&*D8B3QIH,>R<Y6OK
M0KJN64CN&3(B,F([I@XE'P&. $> (\"7$^"+C;.@3?N4-NVU4+5(VC,620S)
M$$F=))[)2'1263!/-<T4K=IV!Z0?IWO4LPA('Q^5E_ %1K$W;HY.WQX>57B/
M'S<$.%]6QI)IRJ,937<;M>4AB!:D/"+ 5S@$V!S<G?+;FU/B2Q@.G,>*^OU*
M.-!3RY56EO#D-9$R^F)#<4-2RE(PQY*+JNY,K03K:L-;E_"')(DDB58  AP!
M_AS"@=\W -"-<BL#X')HL,R"%BEP$ARC1$;.B7>9DA0U>.-SXDFLK<NN<RC^
MR(W/A1M1_!'@"' $. )\60&^A(%!M&X?P+J]&B34GJELC"$BFD@DYYH$)1U)
MQDK/<N362[1OVQPBQ)K5'X4(_X3QI%QRC0'633-&O5CW53V-$A;>>^1@X$HG
MF& &%690K33 ES48^.Z<Z9J/;7SVH[0#D]W\RW"4H3<Y'F&IX'S&4^]*;#!R
MQT(VEK#(/9$B<>*ET 0DE4%XS7S6-3;(J,;L*N3+9\*7:! @P!'@"' $. (<
M 8X 1X CP!'@"/"E #B6\#RQ?_Y2!<]9\4[J@!_U3[!DIWV$L.H!.TQG0( C
MP!'@+9@Z!#@"?(4!OMARBVD@]>/!_ EG;ZHIBEEG\P1.KV[UZ;T#SUT@SE))
MI%&1^) CL;0<85S$2.7:.FO?+F[(?LA^*.\(< 0X AP!C@!_NH(*M%\7:K]>
MK9H(TFKFK2=0:R4D39X4D]81PS0SV7E&640+MK4AF7O$)]DTH-+R<6R>?!)\
MC9W$X>$1#,:^XN^;RH+15(RF8KH  AP!C@!'@"/ $>!+!?"6]JJZU4ZKM5JM
ML50W9PS5=_#_CGOCW@1^A]$_O0C35>T[B,./@^97F@4N+F/G6,;N7MWU1D&T
M8)0AUJ6RB+6\O*))$):\#BR%J)A96Q==SA36KR&5/A,J15L! 8X 1X CP)<5
MX"UM;87&<+N,X:LQ'6,$!-"<"*LTD2$;$ACC!)+E-H!W.7LTA]L<UL%*FQ]5
MVEQPT+095@(X]*$/G0+F2HRC8;]\ZV.G5SBRMLK"DIM%J%!FT68#.;!,I?/>
M"1&!*YVD9*"]OW4^P)G4%&GH^_&XE\LH-M'_W;P'AT?#D1^=[ V+?)1[+!AX
M4V1E@KD <^G&[U/-F#I1ML2^8-(*93P!")1(KCAQWGGB=)DN6J95!E%4@U),
M!<!4J&="?9CKAP!'@"/ $> (< 0X AP!C@!'@"]VZOX]A_^!I^2$X X$X]++
MX"1-1F9OR@B9%-PM_ _C,E+E%3HB%NF(V/[]S(&]07<V]@N:G8I*$1Y-(M(P
M1WQBG.005; &8J#A9E?$?R,#(@,^9P9\@#@@,N!3,."5$)X/QDN5"5.9$>DU
M$,=H(C2IG(VVDDF/#-C*V-W*EV3M3@Y@U!1CC>  !N/>/]#I#\=C+,EJT_)M
MU</NF,.$ $> (\!;,'4(< 0X AP!C@!?3H#/X5ZQD5MG@I )E 23K&=)1>JI
M<SE981\RS;I99VW.+K.V!F75!?]7UEK-_G=[_@OZ6>;PLVSO;4QV9SS-VQO[
M$F2RRE/B>*1$^FA(4-J0++R14E)-4VU_TZ6,8:HT$N(S(414? 3X2@.\I855
MJ/B/H/C;>]N3:7PYGNSN;>W'Q)AE01,>0!$I(!!OP1,:C1(V:JLAH>2W.<)R
MCWCT<D18RK/^J!&5E8Z68T(<IH,@P!'@"' $. (< 8X 1X CP!'@"' $^-(7
MI=S:E?AV-,R]274<HL-P+H?AF\GVM"M&=1A^+F.PGZSA3%A+DO&42)<UL5Y9
MPHTL,PL!G'%KZXQU,1T;V0_9[Q$+4I#]%L%^E\,E.25--0/"@LQ$&BV)IT80
MI[EQG"D9J4?V:VNHY!$"S4T#M=F!;%EGN)]]WP\B=/RX=H;[S_$ IF,M:+=3
M&>;F3G +&^0P'"48-2<H ]H9#_N]U/FO!CO3(Z>G$N5@&A[7EG;-T6N3TRHX
M_^OI8J+W'=!V2NP\.8G 0/&DG6,@J?9.*F N6VI<>=_&_:U[)R:<%WI.JSLW
M_6AT4L9NX[#<R61K$/O'=2C?#D?U6C<FDU$O'$]J.\:]X<ZE?HQ;I^T849?G
MT^6MR46)?%,@F@W795E)B5>&$<F2)194(EHK'F+D!G)9E$C=M0MIV/<4CVSK
M2! 3PAY!YI:4IL>U__7X*E.79U;8H)4I:Z$,8!,M1G4J_PH6-94W,_76SB]S
M4'73>'N\>SP93_R@CMPYTU)DVMLQ[>52_++JH 4/FFB?-)'4 _%62&(2DT('
M8Q4K3.MX85I=L,&1;9\SV^(Z M<1;1K0>=81=U*GZSV[FRU[#X;],F9C[ 9S
M)PG:N6SL%\V1C (GS#-;C'U:S'ZA#0&O0)?Y@2QKE1(J#RH/*@\J3SL&= [E
M 0K4T1 D9"85]S[QX'G@B5(>DTX/X,%"4;J_*%U>%_GH=-!.D!!R(K+N-Q1B
MD(1G)VWR+'!&:QT-X[;KA$5Q0G%"<4)Q:L> SB%.QJK(3/#&FB@Y]8%;SZ(,
MFG,N?.0H3FT0I]W+*Z8H<M) +=$F92(%U<1YFTB9)L==\H9'7L5)2(G"A,*$
MPH3"U(X!G2>U#I)(FK/ E/&2>QF\X%G5##OFHP7Z;66:/Z,.)>K^<:6+O.(F
MLTY##$I93Z**0*0M2RG/N28I&BH"-QRL7EL73'8M=8^;6H<"A0*% M7*QZ1M
M C7/;K \%(EBA@&3DH(,Q?2V(5KK0HC:"EPYM4.6+B=\%^,A@XJ&9.<DD2DK
M$AQH8AWU229(3A19LDQUI<'%TQ.GB__49%F>)3//[/%]-!SWZH2\'$'?3WK_
MP*O/O30YF"9)GR9,2_["J/.D[FO?]*&,WO$$7IT.&9W]B1MV%)_.0X2:XOGJ
MT(\^]@;-/.CK@[FHE'%&?Y0SSIM[,5>2PF?^/1A=H/<CD# "_S?QN=SC2]__
M[$_&:S]=&HK#<M=7QO?:L$T'8_U_PJA\]X8SS_[<=!Q/I\!.A[*9]/.QG.*Z
MC%7?'XWAY=F+5ZDW/NK[DY>]07/'S9>N/C5E?BXN[P4]O<33(H33$YP>?S$]
M=N61GAX4[(76]MO'O_OE[Q[4+YR\ZP_3%^Q[!X5R=_PN7C%>\9QG-2^XE4MU
MQ<LWQN6*U6W'^ ?%5K<4J$?-UQ;N7@G;/[SB4Z6^SS7?;"#9*Z)K%F @_=[[
MTMDNYS@8=]X,BI':%'YUIC5?G-YB47^FEL68A9NG S^Z.A]=AL=_K3,:?GZ(
MTHT?7OS=%E3+1A'O( $<-J;SY:*TSEE5VEU\?_=!QGW']MIU/J5BK Y0-H>'
MA\/!=,G=.)AN[1E^' 9K-^:0IQX8?AOEZJH#QO<[C8?@K>\ETAM,_]CT1[V)
M[W\/BS?,!B+H>2$HQN/#X[Z?%#MXNEOG%#N7MNR<MI;O_+MV2;D63$0\(9ZN
M>9\KAF:AU;SQ&G(O]KYK.B& GCN ]H9%LSJSP;JF0Z1YU9D&[>;I@].2M=D3
MFW'WOO#VH'D9 3VMLF_->O%^7(>(> B;J^F%LVA$+)*_GM-'6[9MS6KT8GL-
M$0X#C$[[L;''ZL<VUT#/862U*B/D01/;YFNM^.,A6_K4->HYLXJ*;'R0"6K:
M6@HA,>==TM&<%OTP+ACV5'OHU+?WG[?_>B]VOFZ([:\?#LIOJP^O?SG8?;TM
MW^]MJ=V:SK:W\7GG4[]_+?7MT\:7#Y^BV'X=O^X<OBGWT?][^Z\W<OOKP<'V
MI[_EAU_?];=?;_#=O_[,9UU^MG^GY?-_T'TF'654!>*8CD1Z%DG0P1)0*ACI
M*6/*KZU+U]4+Z:CV.(]DZV@,NT _P'I_:8CVQJYH(E/ON&8R6"IY%IZYH#0X
M[Y5-EMN;N1:[HBV4*[_.<*7:YYJK;(,@5H5$9/"*.-"66)],L(4H%0MKZTYV
MR[1V)5M$FC#RY1/R)5KK:*T_H;5^-P5Y1IW+%B83[$(FWG_9-]05H0!+F ^.
MR)@Y"<Q'PF/*5C)0CNK%]"U#=4!U0'5XGNI@N+>2,T9%\C(QYT(1BBR3S"$Z
MP?,#^')0..XK'&)&.+[N!TV-=4P2[:@@4BE)K#"1I)"Y,$%8ZDW36TS1+G7H
MCD$!00%I.=276$!2EBI*K:1@64;NK%)<6@=".Y<X?8A@  K(?05$S0@(VZ=<
M)TL#)RKE2*2K;2I!)$*9H2D% ,VGS2D9KCY0/% \6@[UMHG'/%VZG.8Z1N&#
MY%1JK7S@6@6I1$@V9.^^K1[8I>L)8L(7^VQM\)W/^T$:P;D7!#3CM<MQ),X$
M2XHQ$+@IZX\RMVOK0O'';]*%*H(J@BJR0BHRAXC$&(.QGDN7K)3%GK79*>5$
M827GC?*X!&F%=LQTR-_9V+>,IVQ](BH (T4P @E4EI6(XSXIZ845<FW=.-L5
M3N R!+=6OMI1JS=(,)B\)&[F"\TO</J"JZ=KJW7+[-^M\?BX2?\=YC+JM::Z
M7&@AF4YOT#DZ#OU>+$=R^>W!QVYG )/ZN;,WRA?&DR9K^%_S=,3-(2G/0' )
MTC-KK4O"2U7>R)1173>;Y[2\JIO-EQ?W:3VXD3X=CR>'98+&>\.+FMU:K;LU
M."W3;3BU#@.DL\'8'&*FYGS,NK-)/U\X=WY3Y;?Z\+_O3C[\E8X"EWIW;UML
M'VZ=?'C]D;__]//!SJ];HIRS5ZZ]7-^[P]V_RMV^[O>W]][EG=?;:O?U!MWY
M],>7[;VM+]L;^UD5K# >".1(B=1>$NL<$&5]C@R:;O^-JTA<CS/<G+O^4-F#
M\W4^7+(<P:8 D+]ZZGZ1RZ=E+>A)C !_\"18K@O59)=B42]IHPQ@O (36;'Y
M#43Z ^6:,QOV0I9>'U>U?5MN=)BF2;)E$)I#8TR1G4^D+J?(JJB]X4X0RNH.
M)%0DXI+4A&=FDA9EDB&LK<NN8+RK6KA'.Q(C$B,J/P(< ?Z8?CTEM+:<BB+H
M(*DQUD<9@\TT9<48YP^Y8/V&ZO_I^\=P7?1Q97HKT;^<M\:34U$)0T2H-83.
M"N*4!:*3HI'+)%QF-5HD%U1$B(R(C-B.J4/)1X CP!'@"/#E!'A+@S!HTSZ"
M37LUC@TT!Z,9)=IF0Z0,D03F F&*9L@JE>,.K=IV1ZL?I_G4LXA6'Q^5E_ %
M1K$W;HY.WQX>57B/'S<$.%_*QI)IRJ,937<;M>4AB!;D0R+ 5S@$V!S<G?+;
MFU/B2Q@.G,>*^OU*.# Z;W)4FK@<%)$J%1N*YTP<,&VXRDY4&TH7&THIT[I<
M0*1(I$BT 1#@"/#G$ S\OORC$^56\G\Y,$B3=PY<)M312*3@F5@-C C'N03M
MG;)F;5UTE;0H_LB-SX0;4?P1X AP!#@"?%D!OH1A0;1N'\"ZO1HBI-JJJ)4B
M264@4FM&?#%U"95,<2]DU%RC?=OF "&6L_XH0/@GC"?EDFL$L&ZW,>K%N@GB
M:8RP\-XCAP)7.KT$\Z<P?VJE ;ZLH<!WYTS7?&SCLQ^E'9CLYE^&HPR]R?$(
M"P7G,YYZ5R*#+$MGHE"D_,N(S,81IY0EN<RK88(ZI>7:.E==33DF5R%A/A/"
M1(L  8X 1X CP!'@"' $. (< 8X 1X O!<"Q@N>)'?27"GC.:G=2!_RH?X(5
M.^TCA%6/V&$^ P(< 8X ;\'4(< 1X"L,\,766TPCJ1\/YL\X>U--44P[FR=R
M>G674!=M=%DK$@5+1.:0B764$P6^0$84C/NPMLXU9IPA^ST3]D-Y1X CP!'@
M"/!E!?AB*RK0?EVH_7JU;$)*;W("17R9/"*EH"1(JTG47-+(H],ZH07;VI ,
MUDS\*"2S>6G;KX9>"J,E&'7@\*@_/ $X/79T/(H'?@R=H[X?8"%%^^RC50_9
M8D["<@!\60LIWISR7?.AMZ=L][:0'99/S&-$[5[=9RE0!I%K3;AACDCA.;$,
M$O$LIF+1*)V,75M7MLNTQ/()I,EG0I-H!R# 5QK@2]A7[9LF +I1YK, +H<!
M+6-)9"Y)TCP2R000IUPD(1LCP01-M:J])YQ:A!\%^1'YL1U3AP8  AP!C@!'
M@"\GP)>PMQI:N ]DX5X-%"IAHJ<A$BM\(%(Y03R ()JKS(+F04N*-FZ;8X7W
MR*M@TTA?R\>Q>>9)\+7.*@X/CV P]A5_W]0>S +!-"=,<T* (\ 1X AP!#@"
M?*D WM( S$;Z=#R>',)@,MX;;I0!K!?G^V]]+VT--OU1;^+[349&8ZENSABJ
M[^#_'??&O0G\#J-_>A&FZ]IW$(<?!\VO-$M<7,G.LY*]N@].E-0%G1114BHB
MDP;B!"2BM%/4* U"YK*.Y5VF!":](I<^$RY%8P$!C@!'@"/ EQ7@+0W6H#7<
M+FOX:EPG&Y5I\$!4HI;(D"EQU@*)/KBH9$R,*[2'6QW8P2*P'Q6!79#0=.^<
M!'#H0Q\Z!<R5&4?#?OG6QTZOD&3=60?+OQ8A0R:$&*)2D7(F T3G=<XV>9O
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M=<[JHN[B?;H/,NX[MM>N\RD58W6 LCD\/!P.IDN^QL5Q:]_DXS!8NS&'//7
M\-LH5U=].;[?:7P%;WTOD=Y@^L>F/^I-?/][6+QA-A!!SPM!,1X?'O?]I-C!
MT_TB+[4U[TS[FG?^75MT7(MD(9002M<<GY5Z9E'5O/$:<B_VOFLU(8">.X#V
MAD6N.K.1HJ8]H7G5F4:,YFG"TI)EV1-;</>^\/:@>1D!/2WQ;LU2\7Y<AXAX
M"'.K:<2R:$0LDK^>TT>Q$=@C- )[#1$. XQ.FX&QQBUOV]H,#!.K[DO=2Y\]
ME86UR6IG@W#21QE 4QU=XI%Z(6V3W<LLXX)A6Z\'SK[Z](?8^?I>O/_4_[3S
M-99K^$V5WY8?/OW9V_[K/2_G$KNO#PZV7U_/OMK9BV+G4^KM_K5=?F/GT\[K
M?KF/@\.=<OX/G]Z7^XIR]]<WGYOLJ]ZT9F7[=_IYW^48@@%!K ^12/"4N-IO
MN.DO+$P! -1MR5C7+E-#K^5,K&I!VN_Y^=O1M>L61O'24.V-K;FBHT[$6C>1
MM92".<>3<;'6592G#^S-;(NMN1;*EE_/V9)#LB&;3(2(E,CH(@E%&8D-(4N1
M N6U(XI572MX5RJ)C+GRC(E&.QKM3VZTWTU&GD\/K<5I!3O7BN"58-X!X4%8
M(HVQQ#(="(,L0"FGK)9+U3T+)0(E B6B5:,VAT3(8IU2EWV03$A7_LLCTUZE
M++PPT3V$7P?5X[[J(<[5 T#(LM#@1&F;B 0+Q$8*Q'LE4PI1)5Y6&D;++A5+
MU.0*-00U!#6D5:,V3^N/PDDALYP%UT&"SCX5*:$L2@JL_$=_6T3.6W^@9#RL
M9*ASR6 14M#1$.!<$2DL)T%P1P!T#-'SLAAA:^OVNEJTL:<'"@4*!0I%JT9M
MKNT74_+"%=,T>2W+8L/3H )W-C >G-/Y%D*!RX[%A8//=GG:WMAWD$%JR@A8
MGXDT#(A35!%(W(+VV7MJU]:YI5WCKG?A0"E!*4$I:1W@VR8E<RB)RU) L$Q!
M !F%<HQS%J01P@1JO$2_52L$Y.1<0((IDT,E)4!Y)))+3JS)AD3O,]ALBS$0
MU]:E%5VFEJ@+[G*JR&/D]#["-N@S?:":G^T-$@PF+XF;^4+S"YR^X.KZN+<L
M!7AS6BY6*PX+]"!..CY].AY/#LM-55KJ[ V/>K&CJ2X'AD<5^#=G!#]4.M9*
M;PO?E%7Q5P_/'*N^\_=M3<Q'>. 1X AP!#@"' &. $> (\ 1X AP!#@"O+4
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MEH4:$DTD!+ DQ<1B9I&5.6N:0#"%V8?HNT8&?.(B163 AV' "]-8<9.,B)R
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M-E#,8VZ]&7QW]X'[%GFV:!"G=0WC*QL+-?V@FTYW_=."AD(-W68OHF'NE.&
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M]N"BB3S_DIM%KH.F 86 ;)S^?JVJH&,!6&;GC*NF4<V(CD"DI^MFX/-9717
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MJYI(LW#CSC(\7 ^0($URUJA?[ ^_RK*9C?GE+^64."T]M#RB E[3:1][GM%
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M?+SBB/LB#,.DB&24L8 IL&VCK(@]64BI?)8:&Y?M;-QO+HY*[[*U<6/?4UD
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MT'86<_6KD0E>__F-3BE!2HT5)YB)%]]_6>*'2W#N_7M>=^F%9\K-:\4_N+R
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M[6L1&L:R@^VR()F-^1R_ON<\7W<@NP]3PX(KEOQL"IH5O*@'@M'@K>2J(<V
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MW P&QBQW[.73Q2.:MKN)-!7?2T42O067CV@P-QCIVO?GMZ\89G'M ?M2KAX
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MD+O@1"0MIDU"-[X /M>V"TG;]1SNEJV)AYV)=4<K&E0 L',1CG8XZ:JQ:*W
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MFNR@^H'+]?-S%QUK&00(T _0OWCH)SA:':IV)=Q182GW1@@LK+*!67=#I1B
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M$[<N><GN6*L/U.0E(M[,#6Z#8\Q8BIRR&'$E(G(Q.&2]YU([0[.Q _4X /$
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MCJ$_9L07_7YWJ/[[LT/K%Z^70^I759(GTO?,W:JH?8HAQN-*(2I]#O,-O:P
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MS^ED$]!:_3<-T!H$,.I&;K, 1A36F60#(MR4/L")(*>S@9K)C6(1@@Q*KRZ
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MC5I9IV15JR5+S;LC$U8/W:IY]%!+KEIR55=RU6F1KTV6M=[-SL$95B%@@U3
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MJ#RXN^1.N'!.E&=_Z7QH=N:3QYZ&LLR?_YR?'ETX"+JSW&7 UD%;0P3FW 6
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MIVR-C"/[!64-1P.;%QEE23GID;K6F&MCBXKV'R7E7=O6K1OM<%ST(1E=@%T
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M M.5KA7UBF+ZBU?4Q;34\B 6T:.UWKZ\$+]_\-/HOI'WNH;X^T#\O'>=4F<
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MP%W[??CZ80<H,Z8)W,"8L0-DM6\S/^2".;D2YVR LHA.CN.8C;36^ O6O9W
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M?_9OO=56;0$>%$A ,5$7I1<H>#$;#\=9^0?2M2?#<:'Z372P#_E#2MAN9AL
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MMS%*!!$,8IB!N>&L1CD&$S'FE))!\FC<RKI8)4JLXB=7#P!\!, /R - H)2
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MU](2UGBCO$.$V4S<C$'64HFX( 0KART6=&5=Z56N9E/1WVO[Y:M;]ED\I%A
MH'@LUV<%#A]K<+@_.)P'$6FA;>)$(26" X,N,&2%THB9%+CUCH T7 D."XL-
M=(&P8:D60JZ(HGD@/MP]G&9P)PRH0VH>#QK.0VH$M=&;'$TCN$> $1*YR#QR
M1 5O-='!$H &N89)O1KR4D-JZN?_JN<OV&K8DO@3)EC_9!Z%VK.[()Z]>O26
MPQ]TJYIBTZG9SZ9P3=7N0M5.IJPXYUCP45JDK"'9L<.1Y8DC+#%55GNBN%A9
MEX*O"C%;3^A^/IY?,?L?:,<]ZNRO[;@GL.,F<[\VY9X '\B4EX?C0"-%*AJP
MYXS R&13SE.9!/%2""Q7UL4:_Q5Q;?>;E8NJ@A]@R;W4E='7_OQZ9?@^$^F/
MG&6B72\-OYP%GZ=8&7[?ZZ?8&H[@E>KEX?MR@ZWIU!(A8258"L@DPQ&GFB"3
M:QH3APT72B;#PLHZH:L<+]$*4 T62^LW>.#R\!1"3(R*&ASN!@[GC@4ON?2&
M>D2-!'"0+B&7:$1"",8(R(3%?F6=FU4]!QP6-W:D7A]^X7Z%.2!0>Q8>#R#.
M/0L^,&F%Y2CJ0!'G42%GL44X2"92I *HW<JZ7E.S^6?J->)ZC;A^_K-[%IYV
MQ^3UZ2\I7HHME)_C8 AJ(M=8K<K"9I4X*/8OQ;(_2?++>@5SFF@$(!I>$- N
MGG,<B*/"Y!!%S)6EDHB%]5O4$>T/)!W3NQ"5PLPIQQ C.F2714)&&H>\$HXK
M1[&PI<M"KFK&EVBYLX:*90Y5J1>K;QZ\>C6Q7DVLG__LG/\Y4]XO-^?WEU<I
MZXSW3[U6N;2<OUZK? 3BW]C>R*2_(O\;>YC%8)PGR,)((QX-1\82BSRQ27B>
MN#<Y 0E;9:+.@O]"X.(AQ+]>35J,P:N=_;6SOW[^LQ/_VME_(_%OV/[W.$0E
MRROZM>=_03S_GL=$*8N"6LJ3L#HPD;@4$2OJ-,4+:P74GO^'&@#OS@R YN;.
M<6-_SWIAM- :.>-ST($5\(DQA)47*GKM%*4Y"R$S9)5P7:\ O!#(J%< :D.@
M7@%8$("JGU^O +R2HK=_CKIQ7/ 6YX*W%"^2^]_U^B'VRR? 2!2#7KL5BMQ'
MRZ?@[V82:$N9PS@0'00/RNH8=92**3 1@M<IE^EXMMT(=2G<IS$!&AM[CO/H
ME;;(4V\1%X$@$SQ#%@S$%+QG8 _F8KA:\E5!9^G_$GC9:MAXI;!1E\E]++PX
M.<,+%;DB#G-D9"Z42XQ%3DB!K'4JR2!RJI3L+M R%RV838&P:'CQ?+QOL:9]
M7>OL$;=PW0\5ZT*Y2P*'S7/ZE&((.;$G<D1*@$,FD5%4(1&%Q9Z[A'5<62=L
MC<Q2IWH9]X4LXSY_I,+B#=YU=7+OM<.UKI.[[*AY3B*YDLE)HI&EDB*N%4=.
M"@ZCK9-36*2@<A6%-597RJW9X\MECX_"&NM*N4N)AEOG'!+4(94)4T0#<X"&
M- (N6C"IHU6>$:$4MBOK5,I51F83@]0L\LXL\J4%@RW!&M#?<9#CO@ ZBK'M
MF1WX#U\2>N! 3/EMV=&P"+U1;M4='+<+L:;Y;$$OUW3?^-#X89>.UH[QA7",
M5Y-RHQO>_3R*.2YSNY>_FIJ@M;_\'LK]X[2_W)D8 LM%H$#%(^X]0\Y%CW3.
M\2-$I"+AO+Z&"5_5ABU\D=_GTY&+A0:/:O$\).IJJ2R>Q?:73P%?[2]_1#B<
M\I='(IP3WJ/(O4$\& Q(:#7"S%M%#%%4IY5UN69FRYW7P8XO)-CQ^>-Y%V_P
MEM5=?C5D7N4N)S5HW@XTSSEDI!A4(HM(TJ01CR(@)Y5%VB8J7%+!2%V"YJ.X
MRVOR6)/'Y\;!17*7/PXZ7G27D]I??D<XG/*7<RXQMXRB"+*,N",!62\PBB8Y
MFYB/(!0KZT3@52I_1=3%BZ>1I;_\MV$6XXE+]BK?-*5KXK)[>OS=5/\<C@;#
M5CIYV[']_59WTKOZ^=S8^B8O-BV1\I_D;+?CPK;RHNK+@4=EM[Y+*<($^''F
M<[?=D>V?%*1RN*\6\#KYRCQ';+M8P)H&C[&?N LOW?[8]?T(9WSL7MI/L.R&
M?3O^[^>3W6_AR%$N=^#\)OU*=S</.EL?X)S-/P\:G8^GC</O<$Z#-#]\/FAN
M?J>-3C,U3M_1/4R)4M@HQ*4E8)I+@5P2$EDM,>-6)4ES-J!5J7-D[U7V>24?
M6<)\K]/I=<=;_5WT,(B%G71U'NZB-1B,RIU!,'-BOQ@>1)!%HHN_VK:[FN74
MYIP!H_8PWRX?[1V!:5'*(WR1!78$N %?>/@CCVS1&@]M<=3O_6@-\IEP73^V
MNFN7EI0N$>7+>+:@.'7S<EL%5!O[^_VX;X<1>F3,.XH?F7A AQY!G^:L_V6/
MAA;@0C_F07!Q>!QCV6%%A/>&CHVA2+;5'U\Z'H1RL-HG@#$7ASBO[977CGUE
M, 8M7U[5.X\:6(4&(3@+P77Q! :TG)=KQ39<..P-RR&\V."SH2_//+M[*(Y!
M0/[K#GPQF9!T3-RF"'Q1$.>X)]PX:S0#H-)CD.)7@!02OW!E9J:4XW;NFRM"
M+N0K0ZOFX09NGC9^-DZ_DZWM[R?-C3V-DV01,V2T]X!=+B#C-4,V*BR83(!@
M/F<R6R,SL%7 _&MGT<GR>Q=Y4L2HY+#%UB3N-38)<Y58HM"8@)7*\D3,6)[@
M0RU/RR%/I/%IS^L0K3<,2:<CR%.PR,KHD5>6JXBC4WG5CF"]-KMB=R906<5E
MZ!H>]&,L /"&!X!?@)ZAC'@H)L$.I>1E$5G-ZNZHHFGMD]4[2Z2G'%1PU$KZ
MQ(7T3H4DG7!@+BG)([V!AM42N3 2>;I!]EP$0NTT1]1Z(&5<4V0<2RA2&[A4
M*2:3Z\SBZT3PKA+$+0X\8JY)T#S98&W0P/PB32(:F_P8TTB-:0LO0>].]@S'
MC'CF@,=ST(H 6\AIZY$R% :4&1HU:$5"Y-IL8O\9%!NT?MX=PRZQ[A?&LC-I
M/1ZO>B!;+7M4Z<R*D+GW1>X\8;#C?&<W\]<K%LNANZ,3UB=''"?,6T&3M8P9
ML,^L3/0&'OOHJ^953JXK*H.5!S>A,]Y#7UR<DJ_-R)ZB&;2QN?&S<;Q'* W2
MAX P9PQQCT&,+#<P51GUV),8@EM9YWQ-SN&M-V+[%?*#C8O&^<"%D-PYJ\$&
M8HYZ24URROD;>&LM/XLA/Z=;G_:(M\ &8D+$:0(4@3MD6:0H)BF " JP;1E0
M!+)FY@#\4>P7I;?F%Q#512EU6(OBHX@BO />,UY0$J1$FG&*N$T6&6"*B$C-
M-7<14P7\E(LU,9L%($M,Y2^\C]@$Y4 \0&2D4YQB[@BV'*QOC!U70? ;6&HM
M-L\F-A]_[IG$M!=:(1\81]RPD*O@"H0-CU)0@4O,XFR-S>:<GX-9-2V=H:7O
M1[E,0N65':?>]5-R77;=J/NCVI$Q8:57[<2XLYOUGLOR=[$<WW6.VKV3&+_$
M_H^6C_.G;[,W?L5RI@Y*XW#Z^!^]P;#9&^Y$:+?O[7>AA\.7W&7C2?UJ3<>M
M[<;IGHS.&R\Q8DD+Q)W P$PI02HQRJQ2-@2ULD[IVFPIVHGEN%H<'[3\0='*
M3OMJ?T$Q[!4NKT%,.KSH 4@6=M:*.BJA-(OD<T7&/9F055KB?:\__BJ?MZ1!
M<?=?<-S>.&[N[Y% M5<:#![EP?ZAWB,;-4>8)2-YRLG'P/ZA:^+R>EV11VQP
M-8PO(&:7#W[3 @%I^0LHKN:C^%3-I!*6BJ\Y6_K%-W[LJ7&)%OF#&$;MN)7.
MQ/R\466;RB9M9*7:&IYLYW7=;6C [VTX],H$&MI-&OM[+."DP2A#WK(,FZI,
MC*51"L8%8J#[=5HI(FB6HTPV^D &7QS]V"@&HTXGQY:,EVXS(-KN29FS6+T=
MS*\#4-BQ&(&R\.U17BLN+^[<HH+ A? !6H8/G*U&GP44E-_T8[M<U6YU*RV0
MN4RK)#^IUV[WC@=O;L,,/?#_V)^,3(X5R_%-%P>*L&JDRJBILZ&J-D7"4+3M
MT2"^F7QX&UJ#H[8]>=/JEAU:7G0Y?@R>\_:X%88';XQ8XX26H9OC7<SC^U>'
MR5H5UGDIMJTZ*/F:E/+JX]=>C-?(=0<EOO;P-0>O?2IA:UJ*Y6NRNN7%-VQ'
MO^7\?JY,S<_:FOO$:][8X/'T?OR=)>82@*I?$,XYGT844XD\[K-)H![TA1[T
MB0L*C7U01>F$*K(7JLANJ*+T0]TE)\98Q6>EMEC"\.H:=F6JX4=)6E%WYSV[
MLU;B=VR-J?'\]N6]1ET+)A$@^FVJ+4V,B6ZO&V\0A+FG+D^)C$4UA.?5O=B,
M/N9D*F/W>KGO@I@')#JJ<YP^]U:I.Y;>)I1P8GTT3G)'M8N6IF!MDL&!&>KR
MP@@QA#+R#!F!WOUGU!J>?.R"L3#*7PZV\KZ)[0/;'2^'G+D 7U)*H,/&S^:W
M9FOW<+>]N_V5[QQ^/FANYV?]?;BUN<&:IY\/&IN>;VV_.[V\?[%Q^H[LT#\[
MS<[?[>;V00O:2!KYO;XU.%S#X._CYNF^:&PW4Z.%3_ZO*KMQO.>#(IICBR3)
M"8$(8<APXE'05F,MF;%>KZQS(U<)FXWZJ1.@OH(=W:\F >I5\1WW0LK'"^NX
M/1A>$6U<@^*M0!&?@2(1V I,! I<.\2CE<@YHQ"1,5"?HHP^K*QKNH;K-/HO
M+P$JJ6I9+WI'?KA4J'I!DJK4&9:>@*Q+P8-F-)A($_=".H4EQU(;S[Q-.C[*
MCO:G5U07(Q-K_707_70R1=I!.;EH5$(X)IM3=&-DJ#%(\,0")<;X8%;6"96K
MFLV&6B\L8M0UEA^7N#X0-7XA@[T(##6-?0A,G--8SY5E1 44$HV()\>!QGJ#
M% %C)21A6?0KZTJLF5^1Q_]UY"5:'$?UDM#8*NOWHCF2:I?S[5:"7B6-_7OL
M;*EI[)WU4_./:1J+65#!:(2--(C;G##%1XRH<"(%8U*,.1F]6)5S*K?>9NGQ
M>2#C@33V42&CIK&_DL9>!(::QCX$)LYI+.! L$EY!!-#Y9H5 0%>6"2MDA1D
MRR6C5]8U7J.J]L8N)HU]^=[8/W)L1;MVQ]9$=HF([/M>/\56S67OJ:2^3'%9
MS!5-2D8DI)"(&TJ0B0*H+664<9 *G4Q.^;?*Q.Q&\OMQV=HE6W/9)\>&43]G
M-*N)[/TQXIS(<NH(!IL62:8IXH+$'&O%D;-")F)P,IY4_MC919O:'[L01+8.
M''[4ZJ@OSH-[[?Z-UUZ$-)&0I-+."1ISU0S'G/-,&>.\"$2%9RU"6H<</Z4:
MG XY-E8Q1HQ%1L6$N*<".8,YBHH[&I21*><!%9*OXCGQ=8OF]JU#CNN0XT<W
M$^Z'E'7(\;*!XKEM8*,Q@IN %*<&\20QTL1'9*G3(@@OA8HKZYJLD5GW0>WD
MOI]M<+&&U$RQ0O@[3\I6=V0KS3.5?N6H-R@S9;TI4[BT?L1Q+I22,H_I,Z=K
M2IQQ_)DKK0-V.!K&M^.1P-.WN#(/SVRR%[GX.7CHY8V%4S\/^N>2NA^1ZT?[
M'=D$+_G&MH_MR6#EMXNYM."U+W7P3+\]M#=2>K)Z6.50 F3WJLI!;\;U:UK5
MAE>[=&TN#OI98_VCY80@T=FD">6<6V.E4<8Q+I*6S%.WIU;6RYQ<V8C,15BS
M6OGW;W9]GFA<FGJ5+N'8:IL=*#X8#O\9;*C&QNB0N!!!5CH4KHEA(YL*6@G.
M"58>TP3O975PB1M&B&2!@4I]>;FN[I1J\XKL58^6>?-^'&9!,F^>W:FZZ#+]
M>;79.!O;'W-!&F>LL,D9A&V.W*%*@KA%C[@(44GA8,J%E76FUF97Y']A/LY[
M.=OK?)R+(&6-7$:+)^L4<18QXB3B@0MD!6%(2F( 7$"K\"QEYU6T7E$^SL9T
M(L+;).=\8:INJULT[$E!Y:1@:,ZN^'L/IEF9W:(%(#+L]4&='>7:B] Q.=_B
MI-;)W=R6PAC+N*>2$L-]D$9XH82D$EB.(E5^=T /026:?'B><J*3:I;PL')#
M1;6KHC5>V__0[PT&RVZ@WQ]2#M^)K>V-DWS?K<VR2A\FWAL5' I!)\2M\TBS
MQ)#7,KF4+%>*WM7%3:AQ06E"O*:<$NRD4AIS$RV344I:R\IRRDI.4FQ-L,@
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MI(P7A#OLK *>+GD=1U(C7HUX\Q /.^,E3UA;P#Z2G Y)>>T4,]R).#__?4T
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M!%/T(KL/:3F'MP\B3+)<\:S5+2=*T4O%$+Y,,!N*'WDZY&\&PY[_7O2J25'
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MP2FCX6 (Z%[J!0#YB^);J;!\JT$+E )@/7S9B<,#>,H_RRS.$X'LM (ZZK4
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M6(/%LH#%14<0 2:9"-,H>9D0M\$A%XE"F@;XWB;LC+XM6)3.H-_*DAGK\^J
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M9$":*8:T\EA1[8C1>F6=LE6CYQANYX Y#8YG)87G0!Z@UDR%UA*P\DVN=26
MU5-B[N5%2&T,!U@)S O.(S-@OPFO+(_*"LQ4=BG,RA*=$I=OX_9L5,UIE@[)
M7JH _BZR=-["5RM3GTZ:^WO626EELDB*1$"FK$":*X(8 2L[$DLD#,;5'N&K
MQQI&4<<8M&=6<VRBE0H8J#'03D:H<?/=1_58/^%81Q(TM2XA9Y)!W!*.\KB
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M!\8_,/YO*L,8&/]#,7Y+,OZ+CZ:%3-^Q]0B$M.ZDMJF'=LSU)(B]*')\.V+
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M!8S%@6_RT/>9E83V7;;#>B,R9:JMJ?6^94Z5K/5^\_EX>KCX .L[>O>7\^$
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M*T4ZX:Q"UKW4'<#UT]@V<:P0V#Q! #+%<XPD\F+#\GQ3ZA-^7Y@<'O_>DR8
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M?H)D?.-*$2<D\'.)U1AR@%%V0V?=SI6]H!=.I(E)!,1B!0I'" ]5">=_GI4
M6,&@T6=Z\O?A@8Z_8+0<R*6L9\(8Q0Q3+NL7X7PFDZ8Y&.5AB3M'=&AM'2EE
MD0+P*4FKXXD2;YM,='FB ELPIQ]X2,Q'9'#GY)X#_$L4M38$U:*L-$*2G5""
M*+55@;BQFU%L\>EL4BPX? N!(+ <WCWG5'DR(0L<DU8*4C^2)NT>\RCJ;$*4
MQ6DH5^.R0P<K%4FH]!M4RTN F?#'IBP6K.0<E!7TF N9CM7$<&/KJ&C\.[*Z
M#YC#9"Z2ZF83X'6JPF]6 ^>(U0'3/+BJ<9&<U5E""Y9UJS=+PWS9 F=<H(!H
M A[P)DPLJ4FZE!RY)<ZPPN3>ZK/PV2(,Q&?'@#IR19AG!&P$ =R_6P! 2+\E
M6.,>.!YJ=<W^_%L0@27)/)+,4*1?)>OE3B.]2RGB8I$S1?YU67W1T+7(F$>'
M%V\"/ JKR>:;9O%= .G^*?)=P])$A5W#T-"!5\U7MIT7I?#DH0.!0-94DU2(
M.*00SZ@Z'YM2#4DRMTB2\8<DF2%)YFZ29';.?&O8J Q&@F:-;%O8U]U\":IP
M()<>Z<IGZ&;(16]&,FDHEH;<OA5;,AHHY..T2$2D7I0NS1H=XS%EN9YV!9-4
M@95\$E)N+#IXE**#19-R/*&I-@#&*Q7?-4^@S%"#32GGHIMD(3-)]\C#P[\P
M5.Y&*^5E4[80ZBTE_RBW;UO>#0H,S1G#L5"MK2IU8:EW3<D+2I(:5A!WSG_.
M/H.4FO-9I:0>:EU]T:7 )HRL2^LNT1L#RB0BY1CL29Z?B6)M0,.RSN8]M[.,
M]V +F3J6P;&5JC!9F"RUNUDV$_@K0H#"-&Z-7]'")))U:5^O/3WIX6?],=GE
MI9F3M*Q"8=\88%^Y-)NI6R&;H_*MNJVJT )&$Y1%1(ET(FQ&U@7'DO2*$$U&
MSZ3=@0EJ6L+0':.JER*&J?E-M7-S-C)?>R,.4,%UQ%-1?,U[=N:]:8?WSS]^
M%Y4CH[4D/-+(GYE)OPZ:%"I+'6]_^>(_AZ_?OA1HW1A"+TY^>[-/;UC(  85
M&_*I2*Z;2:N'*D-+ZLFC^NR@14RE8DTAHZA+Q<R-3KH'?KJKUS=!4E:6+#^3
MG8H:_\HEASJB3PN^)ZLID6_@%&#T:!=-.2N(I93*4B>3D<"$"YG=TSQ\.]3X
MCA'<'5 -J%&SD@3G0+:RN(&F!*)S4#9X: #:28-5)(_B;HQE6A@(PR(-H/M%
M-]U*]$#H,"=*&Q#U5ONS,IL(I_Y%M\"7 8\!OB%7@R.@JTKX,A$-\)--SR\A
M&F6]$OE?EUR?C?M#UO9A'HA(DE"[14]K*0J[L(5KSYLB&FJ0:U9( U6_JVJ
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MUA4N:]!:;1VM,F*_9('):FD@<#D<=8D+MR;(LGFQJ8$C(AUHTIA3T1@GE/X
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M.P#9<.AW>>AF>/^'_LC.=2=TBX&<?]!C7R+H*\2TRJB!I6Z#YG?_"[M?C!W
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M7A3')/$J/')!]JA>],$%C_()+/@OXD%BK0Q@FY^1'*PZRL"<]U5<6/\9X)M
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M3'Z!!<RI$Y5^#WX8Y^KAE';"AV%0?3H^L'*\DDGJ.NLP!_'L=4;%GL&7#>V
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MN?C;LV^"V7#HR9E83+S>8# 04S&:CJ>S_F"XF(SZ?F_V?^-G/WPB\$6\<-[
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MK-,YAY_ ^NS/(7X&WH&G9 +37<FYN_E[ 3I'7,(J)$P(QH;Q?(G/TYNTR#2
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MB%U,8.1()E<QJ)[T)LWD"E8?P-'EQ%05.%O"VG[_^.8?;_32;_3"?X?'X%-
MT33-48?!*:Q5(%8/]K$4<82V<;0(:+XA:#]<;$&*XGE<"=8,WJ3V@R]QYX&^
MCE6)Y)=4Q1GV5%=R];H@Z*;0P6C[ZLJ\)F8PISS# C=T_G?M]Y_MLAT>%TMZ
MK)8;3#:NLZP_ETEISE_*BQF(VN<+L8!5O13AM;A)GWU?+<D+)I)-SBTJW944
MB\6#E6&GC9MCF6TJX/W2@6G)!!_#N8O6S=E9)G+QMV??'*[ /0;+G<HD@Y"]
M@4^B3/[U>_%#'5^<FY5\O8R=E909'1Y^$E"1>22$46M_^6;2\\:OX(M$8M ]
M;XR>^TG"T\#RJN [*K??@23.+Q*TD_K91_EG+B,?E1WH/Z!QD"Z556#.'+0-
MGIP?LL/RF07Q>BF2E?!EGM690.!+WLX$\BSWY(XFT+Y)@B26MM#$[8Y/,X6F
M;G=PM"6TY=]03P0XDX'7<-%@@U["&E+=&* T.[")0DJ/I%D^#[#!PC+PR5[)
MPTQQYR+,_4PW,M@RK(R56WHP<6)<,/37Y [?"5[=)I[:?=K=@>N-ID<2S'4*
MIZ/O#GO'O094,X:C [3!AA+VLG(@@IK.3!HWQ9@P[W_[_1W]TM746L*,A;,$
M1H>WJ^LD$\M^V=@_'><UOJ0(;4K]OWG_KW<_7>"&PI;(5>"[:( &$79;,+0'
MFP7GNA3A@E13G;VJ=@-?6LAK6?HBUN9@+P?AS 4RC=FBF4C!OR9*HLE6L GR
MQSY6IT7.)+:"H"G&>4;6P<YE=9SW,/XBSW)X0TW.N0*C"E6-XM>=:F(%1NH,
MN&H.<P92WSC!:BU\9-793?W'"G80BX6D)\'.#N)Y79>*<]*U=1"*'=&>7N_$
ML%H1[/&FG?&=@SV]4B-3K,<;UL5ZYOO6@TI#R_.FLL.^#C-M%.$O_P-,H+E\
M'U.3,X>QQPC?TUX)/%29!S)K(B]S$,HX 4%:P_A7,$PQ/QPAE%DUWK&?LAWG
MW]*17\A?1#&L7;=($BRCO2*7B1RE'6NY>VREY_5 J3XDIQ*]VQ $PNW>RX;
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MAZ]#=UM$L"VD;7JXF 67;I@3J#R,"8-[1.'WU-5C2])]1._@"JR:2_A7*J,
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M)LBB $-(K>9*T+67,;)TAAG%F/.9P78H/+L=_56'25I<CZ;J\@E;V.M31QE
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MVW>%3L6RAJ>^DYCKH^"&BK>A#J;?6MI/5:VJ'A^JU(AE+N@@EWT:4FB#5'R
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MM50P[%Y7_;?8D3FX*YBH&9H\D'UB2@DO1%1LGY>(N3['0]VZD+!X1"R=0EA
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M=$C"$Q%4C[[>0ZTH I6JHYAIM<)*0H4?EXBY0?5MW)(8KOU=I'/QI_-+&,^
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MJ[F#YT?9!/3@M50DB<I QH4,5$_Q2O_DLZ>5:E ?8[>H7)I60\5]);9ZP!L
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M18.WGG=/HUC'^;=MXG[!V:/C,B<+M["B]06(-J8W1T]W;\@<+.&@P-X:NMD
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M07.,-F<PH ZTUYI(5[ ?Q>!)"'SPX*AN7'D@%?+.JE@MMU(OC.,T""&3<_U
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M+?X_VS7=FOJB8[6J/XQQ,CWYU%']/U5BLVR(T@5>$H%6$1^]R"I)A?WWH$\
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M=CPM)(L?)GUI[&'F$@;$\"'D/G5E:'2%?>G,O P($6'$<.12(3WA\AB49VI
MR5(HM0&:%^A>,H$I9H[2W%','FG^Z.>)A+_NT5S4\4\X(!(Y0:'F&X%V5H(9
M9VDZ5L49_3PCL?:X3SHSY-XCF'M5Q[4-YR+N9KP[K99=#N^I',0]-)6T'^&+
ML>CR(;1P &7H&[GGX48 -P@QXVY#2+0,[C,"D92XQW\Q-,_$)1"A]7SRP)G#
M(03D/K#IWS%!H.4",RC.G>\#[KLD"&_^B*@8;T)'5JR(68^.P#5=1H^FE4*S
MM4))M1#4"Z4K]M]_.6U;)_^#= 7W:K<)M-?IC&RJ5F:%/&ZU3K:ND'L/R#!E
MX7!PZ_/WS<R'6>9F=3EIM4Z7F@=!$%*2:FJ(KDGH!'0DN7'O*@HI(V%8'LG%
MY :LVE;+LG2F@(:.S\,H(/++E(^$)>%4=R"NB<#47Q6/A(L)%KL%?\O"@GZ.
M6=9II+Q$PR$.QMQ[H7U&/9@0F+ATU*H 3"]/8& <2BI 59*?>2QU+)7/F0$M
M9BP!2[%&4]XH8;Y';ZZW-X5B*33;+;N='8+ET01O)?ZT'Y;S +Q*CW#ML,9<
M3:!V6D>=U4#50O:0SG?^ PYDZNJ-5)XDE^1OGCZ/[54L,12>R-O/KKF8R%U:
M;N03F3%C#K16)R^?:?A]0UI00J)9+TYLE8E?7B^2&NBT7:H.2%:BELIRQ]X@
MD)=!'&7_RRD3O\)'Z-KRX.=R,+M;IU86S"DK1!E2S%#,;0])=>-<Q,@\VLYL
MM0Y2%J!:CI[")4>Y.,"93)&L<1TSQ=0XQJR6E86PS-HEFDK8@[FHWZOZP-59
M&QUAR^ID/:2*P-;1&ZX PY/>AC1^@A]E+EYFM$?2\%6VPNL4:K38%ACMHU6U
MHHF22GQ"JAHJQS^IR-[*FQ%</I):18A9+3JV6I!<42WJ'5-50 ="CR B[LW'
M2!)4SSNO+LJL#K:ME@-75(=8-$IDUU(K;C$-?L5^1+X2+'M2K87)=3!I+]^P
M+[^"^?R*@^_0.3#;OA G"JBHE!9=18C9/3RRLO.%E(:4.)26]TDO[Z5$JGEA
M*A1-I>X5H PV55W(U4697<KC3C8>7X,RU-'-7 &JF,+E[%D^"RCK7^&05I]%
M-E@'\_1R8JOM VO7HV9"ZB*9KTMJAE35]K-/-8@O'?#DJ!C?L7OR1OS.'0M%
MH X;_%!-*U$-L[*=VJVSS2A;4C5TQY"J'.J@5/7V"E<-Z>7CHG4*-2O3F6VU
M-J-,]8Z=5D"P7*D?J5/5:F14N';+MC++V>M1N"K^60TU\DYFU_H4>N(R#(D(
M'XC,MGWAW'VG?H5-O@5\C-&73,]GTC)3ADAS_(2 IT(OX;J'*>Z(J@%4*6[&
M&*G=[BQ:$BN$K(XQD+FWIUL!YLOUQET?+[%;<TWRS :[8UN999<R^,_N/,A0
MH-X8J5KLC7$&N>4=QXI\S<C;MK5@MT(9Y.OM^Y4=EK>1W$-P.>2!H/]6==Z8
M!<@795:!(]M:ROC/#GXM':7%UU(Q+AWP3D/%K3S$:2*S<W5L91<Y4M3U[.BJ
M'E.6U.P>G72RZPDI'G5T@U+-?\("VG%/';E>EGI>V=!5X&FV:*>V9<2KB31_
M% N8!;/>1BOUD7M7Q/??"0 57%&^"I[%7,V(GME6)J:<133]31Y#FLA (*3V
MH*HY7#T("$#EWE/<H[[.58=A-"3N2NB69V^$&:)0RS2[R6\ZL$AD*8\D)0W%
MXNH.^+S/F/37*B@7\31#:]E69OEL%MIL^#A!N8YHWA,<5G%JXO)&][$C]Z?/
MHZ ):]>S59W&&2JCOPA_LAE035Y'5U&W?/E\1PZ]V=S8MI590(TAJ'OJ0G>#
M^O>.>3P8+I>6,+,QHW-DMS,KDA-TU >4XEECE*;9G?@6+M9/O)WQ5RR672=<
MAKD9T6.[G5GRFR":SA--1$W<MC&:"MM#70Z-WZV-@@WL]W!O"NXN'PZI.FLF
M5]F[7)WF)*S:G0(F)F87\,3*;BU*<5,1U0R_/32K'26OPM0\ZD[M]H+340;H
M:N_KR-[A3-WD50VPA,@\ELZL[,XJ3:UO#ZMG3U<_1#A/:@RO[%9GT4&/::_7
M,<A*]>%2!FJ.UFB';,MN9Q:-9P&HH:E1+;\"%\B5YXD("W&U-< <>J,! B\L
MN]-.,6HJ3BC-JO985+[@Q\3%;*(ZG6R>+0^7.IJKQ5VKGCZ.](*1WJ9>_<J6
MJIS-ILZVVYG-$;E QC\A+6BZU7YO#I,N6N%"IG+\S&@>V>W,PK !S7K[SHM[
M_)F$(J".NHP5?E_S."W@;D;WV&YGTNX&=*>RXF&['Z\9//36>ODJ&7<.FF\@
MN7KB<24I9O1/['8F*C"@KV4VE="L*BBY>SV8G3\S3^,S\NN<HXMDF'7@U&Z7
M=[N2V7K!3['0O0),ND2>W%$?N)?RI=9E  JXFT$_L]N9A*8!](DL=;5>RE_;
MC_?4J!N.?#XF1/WZ% 7. $K(:W/6!'@A?R/D1RV[D\F[&2!/I,5P)_+4/4"U
M!/V!"/D^ER<2O QP0"[C]_7*,%3P+S&2?U=(WC$GE1^*7X=0'OZ5)1GS'T>6
ME3VX(C>JJ[?5@%"DI**T6"0X2@0C+?D3 MD',RFL6/Q>)THC536[LB9YQCS,
M4;N37>Q:IW[4,7>S*G#3E>@Y3I7GEHW7Q#P+=>Q.)OFZ5N6:74I?P'H_=ZT"
M^B43U*5^)#,\*QRZ_U$5,BNC;7<V.A/.*6.ZJOM3]Z +Y!5_5#NU/24R^SC@
MY"PXHBFID2*O9T\O<8PR0VL>4<=VQ]COM=3U%]*7>TWD 53"^P$>#:B3VJI9
M(2XL8&0>$R=6]LQJS%$?4IWP3&\DW>.4]$3EI=!2[,R^^&DGNUFF&+,Z>M@%
MO5T]!U..G]D<GMF=)89<+8WD,_&Q?I>E&+\&F(7840G&\HCE<C":Q>.6E3WX
M&K-"BA=*,]LCLL*NSM(<C:/JV+([%1#;KTE'O9#\$4$#;MY(I9=/9"C-(ZEM
M90\<3UD@S:/&';_*F[4*.)D'3,?N% -3IW'RR^%'>(Y'(PJ3KGRBOS/&==W5
M(WA"?/W26PEF?_"[.F&;/L+-W.3-G1#\]RC3GL&DEU_)A[CRU39JW M%  ;I
MHN%A/R0-Q/"07#16X,BH[TLG[Z(A@@@8?O0"GYZ/2$"Y*QMZT7"C((XO0L!:
M4!');U\"'HTN&KHX%6380$(59YRQ:'@N$A%W\)MDU#C,Z0Z5Z;@+PXBXUY&\
M?O=)"5?W%:97)&\^2.!0 .4&!_XXMR^695>E(_1O/7V3_47#"8A+1<G^T4^&
MG,'(",:%O5/T2N^O9-@C0;HW=/5U9Y2EWI06N'R(*2MLY*\XH%)\4JT;!@+&
MDQLU'[WTFZ9>!U!$9L9NN<[Z)6N*N2JQ+O;K[R7H(B"7[XPK[*/)X1(A7Z=
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M"'.GF&G^K+8UB9Y &/8!L4!?]S1G_S87M17)W:Z+KJJ3V=N>:M[5>%HD,W^
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M#Y-UN!X%-]?QF30A,FH@.UDB9S:#RUR""M+28+V3;6K3[D!KG\+>%?&U>[^
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M"/-*R4P9;=) :5M"^Y1LV3O ;:W)&@F7FQ)X.YE/9"HB5[$\!@2$*#>!=!9
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MHDZ[&*./#E/:BR)<X'E\.K"%G._2KW:E_]EL1B;7*(M(P_&:6>^0Z:!("5-
M)JU-!BU7JO 6;%^\_ILG=PLIWN52[\KEFS'$\2E)#F<CCCDH;R+3: A*H8T&
ME!6,9^0I*970F1:$WL#PS;.ZK3SO4FMVI?9Z9+]"/"5CTFIOJE-9&,A,>S3,
M.YX9Z(+2^L1#\4V/+@L8 Q)\P]W:G-8=9+G*&OONPGGV]W3:T:GV']_/I^?X
M]8?=9$XGY!]/%R_\Q_<S_%B_V58=9M/YZ.:Y^<?)?*&>S_X<ST;*<YL%::>,
M@DX8T10&T15F@"?(?G$D[Z$4](X;"D'_6E:&^T ,J!+W>+OO49$M..T&ENV
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M\!0.$/RVA.OM^7PVATGMA#I*Q6BEI:^IB[3+8J0-5J-FV:B,VN@BD]J+<MP
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MXG4@'N%V.9C,!PQU7X?IJGUL#U1#'ZK7P]G_@7H8NA[@?P=9#WQ0O@>=H4-
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MZY'E$TSG7ZZOC7G()?CLF;3)TU)4(O-!9!9U\5(EJ[08T)-P%\ C-/H'D?6
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M)[L5,L8FA_Z5:)ZR'NU.3X.KBMN@:.3I$I=/MH!/P')1D6FA:H\*F9GB 40
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M'M8 K/ N)TT?@"V-G@<1'L;,&9C9?GJS(RT-S)F'@6HTQF((M-.F1-,'#?,
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MZ.F2VX2>@SA7^@#\RR6W'9\;>UFV(>,PCMSDO>8I,)HQ^>(N+$C%F>4JHU2
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M$J_+?UDM_Y'G6*(((%*IK4AKKUJG&(@L*>93/LBTSS"I<ZY.>[+Z:C7#0M,
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MBAGI$B3FZIW+3)+.)8!3S'/#7,K89E9)7QR<:D;!N:/ULVA\F.,/3/8\2.Z
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M&];(R+XE\&(L:7"2[X2][XW0G]?QN<XDCOEX<1^=W^]_RGH?G6/@B0U0S&C
M[ H4KZ64@05;AM57=1<WK\9Q<DQL./ Z^J#XZF;YF8>)GX?LU>;(DWD>>6=8
M#,H"^MJV2Z0"P0I=3[>SX<6053;I;KH?>2\.BPVTM@%<Y[O^_G4CN)K/;S_=
MEUW<]>G^<?QYG/(D71/_(W*F(SEF"G*1=3) =. L";$PQXOFEEDSK+J#?3E[
M<9 >%E8V6,/Y.KGOXO ?TQMZS UY7TL>*;ITOKAZ3!SJY(Z X)BV]9C86Q\]
M#WY8;2'VY^W5(LZ,EPTV<;[N[)MXO![/__73+-<[R'E&T?R20PQ),:L4<+WL
M>)')P4J>0]0A1NN-#V+X.\0FSE[MX:Q8V6 -1Q]N]L5</=A]6^Z#\@<,*EN*
M<8G RE1M4.'KR"%)/Q:FT"N7</T2>Y\YRRZDOAAT#U+W&\#=3Z>YOKBL'3"F
MM\O1W^^(X<]WN=O["US+0H44!3*F%83(POW6%A/D$$I*@2'#\TP/Z)?/%V,H
MEX"C#79SOD/8M:'KMXN/TUDM\1F5[+0TA8,F-Z_>SB4]U(DBC"4O%/&:2YLY
MH7US\HK]DV)A [H//I0]FJ._XU_C3[>?OA;"W89YG(V75GWGRQ6-J7@$9FIB
M55%0@[+6J?G K78^6S,LD#_!T"O6SX&,#9#OYX1W5S7;MFY;[VYG\2.N.F>_
M+?37GZ:3Y2V!=WD6Z5.C%&K3;"WJS-8"BG$-/CL/!I7&DD72=EB==9]DZ67"
M_OSHV #\XT]5=PV\_FJN2XKO>;E!\L"8%MQR37Z71HI<6-'UNU*KX&*P"C6Y
M:$U0?1B]+P^R)]#KACM-!Y]]4LC]P#IH?_C_.2X6T^O\YXJ\Z>QOM8O#S<U2
MCB-#7A!/(D+PDNS&J !>L0@F21)-X#DQ?#)KTN6-+P9!+36Q 3$''V@2G6LU
M*W<.]73E4'=A@HQC^4<CKR1GQAOPR^6XT$KL?<A@G"O)69UT<D_"JG>R7A+V
MSJO3#0 ]^HSQQUSR;/98DM_<A8?-<7X=8UB> _WM!N?S<1GG]-MT$F_IK\E5
M$!;)([",!%H4U%JL>G6.=LAH.%?HBRI-^J'U1/^+ ?$Y];X!O\>?!_;6M),)
M:8VU!E2L9SF1OB.>(B1KDV&(UL<V'?U>8+_>HYS'LVA\F/UZH_$V2QZ@2(K-
M*"@3@,Q&8(EI*= '9YLTAGAF_7H[ 6%GO]XN"KF45J?[\/3:K[=[O]Y.6#E%
MS]-#%'TI(%Y>B[1"@)&UIZ*D&# PJ<#;D+T32133;A[%18"W4[_>P6&WBWY;
M]H'ZUH)GU<P39<[1,PNBL S*%'TG*>$E,RXQQ]MT MQ*T0!#G>8*W]8,XRAM
M->C"M]90^ _2S/SZ]S]6Q 6A%7'+(0A#1J<"!Z_I"P9/- O&K6QRIV(G5:]P
MZE%K#5:F;4V&?1:2$!U H26RO-?@$WUG%9<.+1;'FY2Y/N]VT,? J ]-M>SD
M]J#%.1I%*Z5#X$XO6YQG<$YIT#9YEXHT%,(WW]1>@=.3AGIL9?;AX^BWZ21O
MW5\=FLAT+1=*"NN)LH=@"@-A$MIB-*)?\X8V'&'L>L,+AD.?LN^Q$==\MAA=
M5UDL X>DO,N<&="U$9C*B18S7B<E"1N1\QB5WJ?(EA[Z8-6@G]97C$=O?9D9
MJL,%W^,N\I6(%0CW(:-#,FE_'/2_/#R=]SE" ^LZ/$)\/3J5Z^2P8$S)VD!0
M,8$*9!:HG 4G?*@;#6=QG_*Q86AQ2P*D?R5VD5K/REN5.JX(X:YPI3-M*R74
MX266@RLF0&1%<R9J\Z7>U/?HS:?;I8^2_;0/P?68)E@20J)Z0$A,)NI0(*.@
M/=TI 8XE#M9:S-(98T)OV^FC-U^@!@\67,\V^'Z\J"[!+Y-4+YO?XLUR82G*
M> PQ0DZ*0CV>"OA,KKOS2LE@A-JO9G$O36ZDX.4Z2<<KI,<(:B-!_QPO/E[G
MN]*A^<?QG^^G;R:+\>++*EK8A]2^G:J.-)[>\>I!J[LPTD EK=>9)TC6S#D6
M'8>L5:&%%3,$)RPPD[2R+H>XUTBHRT'/#H?OO.#IHHF>0?.WC^-<WOR5XVT=
M5_:VE'',L_L]4Z'V'!T89.3U)*4@>)8@H.:1EEMKRSZ]0O8"R XZ3NMZ--7=
MM'_!]^QN+LEZ2]LYUGNNC\GR3L40.*].6/6AC 7O40*R(JRP.I6P3Q9X?SQL
MIN,9XZ$'P9]W0.3:T=A5)'!7V?0[+O*)MS0<'MF%O[51DHRB&+)K&RS]W[#D
M5.$YV8+<"R.XVS)*\HDWGGVP)/>%"64]N%CQ;G6 P*.#$.OLVU30J&%U4?CU
M[(,EGVR&^G4NQ_7TYN:GZ:S^T<@I%46BY00925NIHB'4AGW,<L5U1%_TL$9,
M'L3F ,]S^K6!T[74/1I%0QH[N3^W=Y=T1@)+QGI'P0=&.G&^U((,VCA)1=6G
MM\D/:YI 5PXOR%). -736]4!.#M'\6Q/';E'26O4QFE ZZH/:AF@J4/*E94F
MIVQR:'/'^D0,OIK36<SI")0UJ'UJQ^<_EOKXRJ<007D5&%B)]5@Q1' V&DBQ
M3I?0Z(1J4MIY*@9?K>DLUG0$RAK,MVS')VFAY/%#5@MW0B=$*+HN'#$9J .A
M(7/:A+/@*N.%S2+YCL=7FSJ+31V'M1X+ZT[OV]H8O6#> <;D:E.@0*H)Y.!J
MK4-D*')H,F7Y3#'4(%7QRV0Q&T_FX[CL3/G07'),4:(N@"'5^DZ)$+BIVHG9
M2,:X&-BTF!Z8OJ U\&+20_T@[*)BVRV\CZ+R622*-V*L5?0Z!7#.1)"1\^6A
MK_'/PZ0NR(Y.#N1S6V G%%Z4V3T.]M>X+C%'%C$"YY&X1G*H/"=KB2BB=X@R
M[56.,B#;V\7NJP$.P ![P^,%IZ+6N+:9Y2AL)O6(6+E&\*@3"!^ER+D4L=[*
M<.A6N(O=5RL<@!7VAL=+3&'=SO)\C67'HW)>DX)2$* BH_A;A@#,&.MMSA1%
M7%C4O9775_L;@/WU@\3+3'2MKS9!<H%! 6>!5ALF-* QM-I$AD%:8[)GEV5Z
M>\5_!ZBFMTL<F+7FT0A@03E0 LDFLLJ@.=/1! (=;U.G\0+;,!Z5B#J+QH?9
MAC&([(2P%K D ZIPDJBC+UPDB>A3,6T&WS^S-HR=@+"S#6,7A5Q*![M]>'IM
MP]B]#6,GK)RBE=TABKX4$)N4N0S<@;%,T8Z#"IQR I+DV0<3H\ V398O!KR=
MVC .#KM=]-L L[L[L5D5?.U."1*K-T];2CVGCR"L$#PH)2(V\>9?0O^\3HKO
MU#^OB]:V5JB?Y++3WW'VK[P(]=>;6.KYTM.>;VMX^>D0?M<N08E4&$O,.\&5
MRC)Z%W34N3!DR3,GMUR"VO/-9[\,987W4H@ 2G$DCS8FP% <)*>Y+B$EYX:5
M/_CUV,M0QTPG?C)Y<3^3_OVTYHA'FG&=K<Y@G:<U!Z4 +VD)0E6%S)5FH>RV
MK!-2.\!UOE_\]C&?NB4"6MQ>ZBWTS;1]EF(\).$2J%PSJYQV.H;!"OH=!<-M
M;E.\P*S7(: ^K\:'F?5B&JW2Q@%Y811\,*U)CADAYI08YUY(TR26>V99KTY
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M>X%U$D=!^BP:'TJ=Q./+F)&)Q!1A2K-:F:JDI9VH.(@E6Z&+3\8U<>.?61>
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M+T)%)R/P92/T.D W"/K"4\KDA<M49)-2KJ<(ZRDW5,NO'KQJG.<C)6-&&RC
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ML*BTRED&S?P)@'"V>5G]:&LW!@X0==<#]=6OZY> \_P?_^=_ 5!+ P04
M" !4@@91:_,7?64/ 0 _9 L $P   &=H+3(P,C P-C,P7VQA8BYX;6S<O7MS
MY#B2)_C_?@I<S=I<M9G0Q0= @CV/-66FLEJ[6:G<E*IZ^\K.PO"4V!5BJ(,,
M56H^_0$D(X**!P-@D!3K;*:SE$J2</^!_,'=X7#_]__Q[7$.GN4R3Q?9?WSG
M_]G[#LB,+T2:W?_'=S_??83DN__QG__MO_W[_P7A_WGW]1/XL."K1YD5X/U2
MTD(*\'M:/("_"9G_!M1R\0C^MEC^ECY3"/^SO.G]XNEEF=X_%"#P F_W7Y=_
MH20(.2$*!BQ $"'*(<5^!$,5A[[O)YX7R(O[O\2QXDA(#C%% 40$<\BH()#Z
MGA\3&E E2?G0>9K]]A?S!Z.Y!%JY+"__^A_?/13%TU]^^.'WWW__\S>VG/]Y
ML;S_(?"\\(?UU=_5EW_;N_[WL+S:3Y+DA_)?-Y?FZ:$+]6/]'_[/3Y]N^8-\
MI##-\H)FW R0IW_)RU]^6G!:E)B?E L<O<+\#:XO@^97T ]@Z/_Y6RZ^^\__
M!D %QW(QEU^E N:_/W^]/CID\H.YXH=,WIN9_2*7Z4+<%G19?*),SK7TY=.*
MER?Y']_EZ>/37*Y_]["4ZO!CY\OEJZ<:*1,CI1\9*?_EV& _G"%^3_(6^[+V
M(%RI[N>^9&S#]'-OXMYI?I##"]P8YFR1JQ?J*A-CO;N;H<X6?7B)^WHM%@6=
MC_!:;(=IB#PWO_BD?ZJ',0]J(=-RG)JZ&Z+*;X7,A*S8\M6C02K^XSO]TVR5
MPWM*GV:W#W0IWVFB%>\7CT\RRTO^OEPN:78OS9+X[F5[R1?Z8GYU^3M=BJM_
MKM+BY5HO LMRZ<QOB@>YO'N@V<V3>43^HWY$D5]GU8LT\V/*XBABT$.*0Q3B
M"!*")8PY(WY )4O\8%9LOI69S.#/MVNU2MG?1O#O'&:B.,(H2YDO5DN^78L?
MYX<66+VVFM68_)#11YD_T?H&K;TQ6RI _K.43ELHWZ<9R(V"^9_^_8<M2!.:
M\?D?=A[GPTYAJ0\TUHT 3:5!0VO 7D#SNEIS4*I^ 2KE04-[4*H/"JT_J &X
M !4$0+\J%0A'WY0%?Z7MW-AQB^7NM"WXFTW;*[XMITS1G)68UR+]8$SQ'^2\
MR->_@>8WT/-KV_%?1I?]A[VO\7*Y!IHN^8E7L;[B![[05O93 5^]E<8K>=L9
M*19O^R%7;ZH&Z3NP6 JYU'[> < W]'?_,+M=J.(=S7[[23XRN9S%/L9(A3%D
M7A!#Q+F 2>1C*!,/B40*B@-ILR+M/7EJ2\9:.KMU8A^H=B(_2_VAF;86#/Q:
MB?;_=H5 U &"\IT>!HI70TP!$NLUX:C:%6G?/Y1$[$6A5]+P_N6C\.11*==$
M=OP"-Z8YFQ!KVKM9%2;"8H)6UUFQ3+,\Y;_0^4K.6"2C$',"I< ,(LHXI $+
M(<<1"R13$8O$*+;T*4FGQH2UO&"Q%?@"T/O[9>F3:3NI%AX\&^E'LJM/3O?
MAG2?DSA]RWEC&]\TWX&-QN"7UID?STZVG95)&,8GA?UC6,*VF/=F^EH/V&T%
M*@WISXML\2276B3S=+YXE%??C(QR%GNAIWQ??R@^(A"9K0KJ*VFLX(CA*!01
M\5V6D?;A)K<6E/YR6HH(OI>5D'^Z )DLW(C_!,IV[-T?=@-3< 5;4U)P76-8
M"WL\'N7,GG:H]$F!)T8<E<?LM-\E(\N[WL:F?>W*_[A<Y/E,AGZ,N1!0$#^
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M^CH!1L\97\=&&SO;ZX36!S*]3MW1C2\^KI;:3%DM35;JQ_2;^6E]!H-)%K
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MX)\<:-C0KHF6?=3?WBR2*I$X#J'D@8)(80H9B@E,)!-,B2B)E%/I-5<!IN9
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M TWM3%)'I5^O+=0'PGR,,MVNHDVB%'='/&W+;7=]_!E$WZ@ \UEC4[?*I"+
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MO]?KY@C^(Q72='7E]"DMZ+S.%-GV>'4TG=HGP(["SL=S',ZJY5QG!VQ$71_
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M8/#HN6WDV\QE[\TG1U9C_!:6;S-/!QMAOI$H7>L!'#XPLDY,E<Q76EP889%
MA$W+&8\'4$8RH-1C?A0+M[( ;<--;:T[>K3+M4I *\9V*TM_R V\"!P_#S=$
MZ0 ;4/JM(- ZXLB%!&RTWZ\G8'57UXS-!9=2Y*:TFDGG,H5[S:$ULY5<ADQF
M"0H"/\$QC(B(3;@B@$QR"6.6^![&?BA")T8Y.>+42&4M<%7RZ&G%YBD'"U/M
M2+/[!<ADV3%WE6G0?S?UZK2-(]*<+U:FI+@QM\W&?)KG[A7F3T^.'17U"OG
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MR)O6<V9'ED/,Q, ,68L,FC*#M=" K0J@Q08OL@!&\!Y[GCE"U6OK,]NQQ^V
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M@[ 6:RKY$:XX.N1-.#_Z[,HWEYDX,,BVQ=@V2*02Q&,6,:AM,Q^B."&0)#2
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MP>7[N^M?KN^NKV[_XD8H'>;!CFF&17=@"M+"5UF::_%-IL;W1@.09G\"&R7
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MQE?-CC<]X^NL<%Z5:,XU&QC/UD_(.%%Q+ 5$::3_4#R"A'"F(W4J4<+BC+/
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M[O%LF2M87L^;60\^[1DT5TR.SJ4YWV"XB&@E9K71/Y6YJ 8L5J^>[O3]3&W
M0G!-/U*#3Q@.(&(ZQ<*!8M"L=F44Z8")"E?=T(LCSHV0]@:#9Q:;E7EC<U\-
MQ4#<[9C**YHC,]2U0 Z2 [4"Q[<"Z.5!)Q?]M,+@E,ZGW84#F<=(BS3*R!_R
ME7RO^:Q<2"D4PC&!,J!$LPV6D$6:;1*%&9%IR%,AG=CFU"BS8YA*P'LGZ?V[
M,114EKJRRDE,+9GD6J3&9H\!(+DSQB40O++$R8&F989+OAZQP<4/#UW5_=>V
MK&4U[PHC&;SB^5(^TY6[*TS \WE=/&H"$J^>?BVE>+\Z$1?M-8 3F2@5,(@B
M&9C#H (2GJ8P((IF41A((9W:T8QAY-SXI^.C$6E<MUZ"5:NFJ?_5_,Q-'K$M
M*_TG4.Q2#;KS\&^NB\XC/ &V:]4O.Z^C+W$_F]*=@^!8H-/(<IIY;1TUX=@/
MO]:3_./)A'(4%>,Q)\3O\OH(=DZ\*C\>TL>+^2..Y5S&\>N*;D6^,??7O)H_
MZ,A6&,$7\2Y?46T97>[RZO)SL<SYT[Z53,1#R1-I:K##"*(D$Q#+)(,Z7E6,
MR2S$J>T)E"O,F-NK8^<*:'P!.V? SIO]JI/ENMZ54W7Y#3#=!(S,\:[8@]]K
M7ZQZ!/F<#^N*DXGF9:)*E%'GQZ5,Q0.L9\M7KKGW5&4M'OSOE+OXN)O;FZM<
M;Q8?]"OP6_7 ZK=EO4*H2!!@Q"04D400D01!*LU>=4"Q?A]QEJ96:R6G;S^W
M-\W>0A.NNJVZG@'P\GOB>EA&YG]'1*P9X[+C%V)I?6$GCM9_.XRAS]QY$AZX
M[%7[_>[YU+"%CE\HO\]7<OUTNZH*E[\;;F@JJYA,&0D# <-0*8A202#CC$(5
M!%1E.N1,$Z=]WPMCS>T;O3.U4AR1K;%N2PB7L+5;"?"$V,A?]N=@[>P<H6#-
M @^?^?2EX29-BRW\/LQN;2X9WOBL$2*NC^ETCGPM,LREC+E.1:/0+'2*%!+3
M BC@*(F$RB*:6*F=V PV-]+H"M3?-&KSH-C;ZRY";P6Y[6ZL'R!'WXC=BY.W
M6N8W5H<*!_4FZT/$=RNRL^--WGFLS_-3C<9ZKQFL-% \R#OZY\F^B8(1$4<0
M824A"D@$<1CHE")B61C&69915XV!<V/-C4Z:I7!MJX^6B)= MF,03]"-3""#
M41LB+="'AV=1@;/#32TGT.?W"2&!WDN&<<<764I]T;V.<MZ87CU%%>>T&OPH
MDF$<)P*BF*80A5D",5,QC$44RQ0+KI,:%_:X.-K<^*,UMHK*Q=[<84T.+@-M
MQR#>X!N90YXAU['4?_,#*T1\LLCE 2?E$2O?#YG$[J*!<B1;5NI4W]SO<9^I
MAX$,5:"19"G284AJ&G*%40II+'@0TRR(W/JBG!QE;MRQ-Q)45CI*>9P$THXC
MKH9G9&XX1&:$58Z+$'@5D3@YT+1:#Y=\/9)DN/CAB36(&C&'3AKT#YE_N]](
M<?LHU_2;?/NG7/.\E)_7.9<+3!.:*I)!RD.JTY=()S(9ES")PC2)4\EBD2Z^
MRW5>B*\;NMY8DLDTUKM\_PY]&.^K^$I^RU<KL[#"J/X%EZ8$LZ@=.UIWV98"
M:-/J]1?'Y9>IGA%)XPPQ$4-): *1E 02*4*HD)"2TI2C+&N>D;<K\1=_0EH/
MQGL^WM:S_W_)PV'Y^IS?=(_]0KY>J6JG1=7Q_@:T_H,& - B "H(9J!&-6S.
M9B%#Y6CZ7T-_:MA\>!.>&CC\L+BI&;B\*RKA66W.MLQ7LBQE^5%N/BE3.-G\
M1BP8(Q'A.GT*3"\DA%0$J5&*9215+-9O/,&" 6V07&RP8JSINR*U%@.ZE^^]
MJ0K:]>NJJFFGC0-N;R6GZ;%[M7A'>Z)VQ8W9IIB\,0_L+;^IJLXUUE6=^6T?
MUL[</@0TGP3M-/ZD+#L$F4.J''0/3[O>M]O-?;'._Z._/P*1,$I%!E-I-JE$
M+"&)>&S."$8LT/^CH9.P[(6QYK90='+/F^[,];CEW<%[X([W,!1?8,,;["T=
M<;O[&(Y1=[L[P[WL9O>QW[U[W2<N&:QIP#5AU>>5O^3EOSNGZKEFBY @#C.D
MX=0LDD!,0P%Q$.OL/XQYECF5VUT8:WXLTC$5&%NODB\X"[$M<7@!;G3B&(39
M$*6"/C0\:Q2<'6YJ=8(^OT_H$O1>,C#;6ILCK9NGS_H1V'0K^GY>%V6Y0&E,
M(L8"2&A ()*40"QI BD52<BB$$MEI>]K-]S<V*.U]GFM[@WX9HQU3)LNXVR9
M*'E#;^S4J#'T!E2F/B_?O0$_7\3//16R@L5K\G-YQ&G3'2OOCQ(<NZL&DPJ7
M4I3OM+%5L-,L(+7+1&*1IB0-TH!!$2,,$:<Z&B$LU7^-:815G.'8ZF"I]8@S
MI);*X%JR.2_+;;N5P#N)#]A^US_*=GE8_[;^YV:[P9F">F;%FH7\83T^$75@
MKE54&G-WJ^X^%V5LH?%,1CV#3LU'=AB<H"3+"X>QTJ]??RX>Y7IE6.Z-9)N]
M]&5;D$,1S5*:04FQJ0O.!&0*15!@$5$J98IDZ$)*?0/.C9-^_>GK3^#;SF0@
MM,V@W!GMQC:]:-N1C4\,1^::7[^"O:W &-N1P1VAFL<6&I]<TSOFI%1CB\ A
MTUA?-[#RA]]+L5W*3^JK_&;&^"*_%VNCZ_%^I8KU0Z,IU_RRH[819"S,L@S2
MA,9U&S%,)84930@/,)<,.1UQ&FC'W&BI=:/20:MM!3M/0,>5FVHWOOZ$8ZG%
MP!FS+)T8?Q[&+H48,@7@]ZKSN5]E!T^8>BU5&&C*M*4'U^%U5$IPY>W<B+7;
M=/MS6^/UAF[D0B8DBD1,81R(!"*11I"&3$=P68A0@' 24"OEN[,CS(T,=QW>
M:RO!6W.00-MIQW?G@;S,9%[@&9FCG)&QYIQ>[SWTO7]^W\F[WI]TZU3/^],?
M'+IGM=1_+<RJ]J/LE"&5MROQL>JH=O+7=_JGTL@OZMSPPT[P-4.(1X1PB!$B
M]8H2)9)#+JA*,AZ&2>PHV>W/N+F1R#/?GI4SFH7:[M\[?36?7W2%7J_/6;?=
M=WN9N1Q]HVZ::1RPL^<?;[];@1[MFWCOT#^RQYN-(XPQ^ #_09_PMP_?E\63
ME%_DTE12?L@IRY=5ZKY(N2(DC!,88Y*8Y3NI8\%00,F%X"2C4KJESRZ#SXWA
M;SE?;Z4PFPF[0E_G8_WVT-O1\%B CDRSK=G@A];P'XT4=&L[:(P''>N]:@$X
M8^99',!^_*G5 IR1.2$?X'X/]]SU[6J3;YZ^R&^YD298;4RKK852)B956"..
M3>H:Z-"5B QF>B*4X '*0JO2BG,#S(V2:AO!WLBJ,9Q]WGH2Q/ZT]5IH1B87
M1U2<<M9+KE^1LIZ\[609ZR6GN@GKQ<]=(R>T$SK=J=R@(,:QP &,TDJ3U+1?
M$%$*&0^DP$S0)"7N4D)'X\SM"]T(XNSLO%)!Z!A7ZZCB6K3&#R"<@1HH&G06
M!O^"0<=#O8!8T%E_3PL%G?_XP&XNG&\?ME6D4*78YES=6M[KB%OG1O60S6YW
M1#*&@DC"-#.2IP)1R*A^Y2<JQ2FF* N$D]B']<AS8XV.X<VRQ#/3G_?I<.RL
M8CT;=LPR"L8C<\WMI]?OP>UFL\[9=E-MOVT*\)FNY2B"(LX(>6U*8CWXM)U&
M7#$Y:A_B?(.)!4JJ/[[(^EBI_"K7CSF7]<9 N,!82203"96,=5H3$@3U,TMA
M)@5):)BEDC@548UBY=Q(L3U.#6FC"*!G,7^LEVC+VG)0BUM,)"%Q<8KMV//%
M)VYDIO4@#U']!^Q<!8VOS0[F#'0@;*9B%JH/%PW]:V@\V&#M3='!:K"![=_;
M)E8?S(I:NX#V9'8.MFL3ARP(EY0'B,. 9('.ER,"<80%Y%E(1" (BMV$[WI'
MG!O=?RA6WZ >Z*'33W!9+3$O+=:0!Z)NQ]I>L1R9@?=M^BIC;W8K\$\W8&^P
MQZ;OMMAX;?;>.^BT3=YM,3AJ[FY]X3#:>9>O-)-]T!&3Z5&D'Y-<)S^W92DW
MY>V#*4W[3\6-C:#G/R5=O],/X@*C,,*1(#!EIK< 99J+N/XI%HH0%"$NB1,7
M#3-C;@2EGT7DQC\#X;<CI?%!'9FI:@=@Y0'8NP J'VXJ]5]>"8)UO+D!QA%@
M//%'8=<AZ9/7!EHR*=E=A]8A UYY-U\5%)_7\CO-Q1NII.9=T0QWNZH7&VI[
M%JG0H9BF1*A(IFDQ23*(589AHN(LQ4K1 .$!NEK#K+'Z(D^OL-68WJJ>EU75
M55$M:3:O-$ K^Z\MO+":L:$E&-XFX$6+,=JY:,ROIJ)>7;Z]/ 4>"C)<$!RW
M-,/*DA<NTG!!J[]<P^EN@_=X3"G5E^*)+DU>]KK)IP(J5"1UY!AS$FJ*C&-(
M!%$Z?,Q0R$)*XA Y[NB<&F=NH6%;6;:N['P"!5LVC0,=>>X<KM9[,]>B-?9.
M3 /4SL0;\-IW1MJ#@N?=EI-#3;VW<LG?$SLI%S\^R?%.LPFWX"D3*!8)5(G$
MIILZA83*$"99$B5Q&LI .$EP#;!A;D1RS9E"QP*3(3-FN<DQ[CR,O84QRA2,
M?9:S"^(+GN.LS)CS&<XN3E>>WWQVJV&L^1M=Y^8V50-Q66[J^KS/Z_R!KI]>
MR954.<_UCTV%!L94A1&6,!(Z[438M/M,I( D9#JRRA CS*F8WVWXN7%E:SUH
MS0>U_6XTZ#@%=@PX'K CD]\Y3&] 8SSH6#]"[<PPX'P2GJ,%DW+=,'0.:6[@
M70;J"Y6:3M^6&WWSC2P7F2!!&J 8AL0T+,9$0(88ARPC-&*9_C_D)''V_/9S
M8ZA?:WFRG7V.8D'/H;-CGN& C,PLAUAH1BF6.=<DTOQW%$6,TW!X%?]Y/L*T
M4C\GO3L2]CG]J8$+/]7J49,S[HK254B"*$$I3$(C$D9Y!*EB$J8ACWB4(A%R
MI_JVDZ/,[=O]^MEZ]M\<%WI.XFBYS',M.F,O\E3V[59V1JGLOXB!UR6>DP--
MN\!SR=>CY9V+'QZZ7_:HXP23]-25MFWDL* J84I%&"J%$$0I"2"+A8))2F/]
MGB<RQ4XK..<&FMM7?Q<=YY69KGM99]"TW:VZ'J/1]Z-:$YN3"S>[?,+GGM-E
M'/SN*IT9:^)]H\L>'^\,]7Q^X%)OH39_T+794&I_[#0'?EV4FU;-DA'.(A93
MR&6J()(XAE@2#$6<T204@5*94[1O/?+<^,(4HFXWIN5A8[;C4JTUXI8+M&/@
M./:R;&-HM8N]^TNW77AE]Q@-@EW1\KK^:CWXM*NNKI@<K;4ZW\"-K,KUQC2(
M*'5N*4SM2[7(D<NR:DRB4I8H;)1$D=#I"@\5I %-H.(BP(2H-)96':0N#3(_
M"MK;"5I#G5J^7(3T,O'X FIDCAF$D36?V(!P@3KTY1W:T'\[I(R+]Y^$'6P\
M;(G ZK.#F\<=G@VL^M/=T3\7@A$2LC"#"39;*$I&D)$HUM__B(6!D"%1>+$I
M-G1I%Y)<&,N) 78CCAN$[(\4+PO3!O/@3.S/6[H61F_C[Y(N-_<F;.<_.7>2
M.PN^773B"=+1N>+L >U=ETMM\<V9<\=>.\WUP>6YT]S9X:;N--?G]XE.<[V7
MN%'.M_O%Y[7D>9D7JT]&!:[X]G2G4ZQ\]:V)R)%@G*28PH":6"-, \B4U %'
MR@6C*D"(6DEP]HXTOX"CK+X$WUNK0=&8#3:UW7;$T@_Q95KQ"MS(I+(S%+26
M@L;4_KS&$331:-=610W3@/=LR'F":,V^UL#4W/OMON+3((V#BDW[+Y^$2ZV]
M:)G4_H*)Y1?>T7S]&UUNS=F1[4/;(Z<^0?0F?\R%7(DO1M,[2R(9,!Y D@D.
M44P8)"A,8!2E(LZXP)E;A?+H%L^-UW?GLD1C)'C*Y7(J#0;K>;9<"9O3[(V]
M@G:]-H/Q&E1N@X[?G;-ZK>O@BQ>1^<FG:1:Z#=9&_S4T'%SGP)N>@_/ SK'_
M\SY)547HO@].RE,49I+!5.KP'R5I"@G6.0"A"444(<F$51N.GG'F]G[HUD\?
M]/O2R? CS9?&?*B*-2SITG(GI _KWA3 %X(C<_11@S3[;D%.>%E'_[YPFRCV
MOP(_E]#?!I6S@?_%BZ<*^VT\Z 3]5A]WWZ'Y(K_KF;_7Q'W[;2UEO?6S-=O4
MW^EZ\V3D:=\4#S1?+902.,VB#*:TZFF$4ZA_0#"-*.*)$92-I.V6C?6H<Z/6
MKI65)#+XO3;480?''O+^+9U1@!Q]W=890Z<='F=,KMWRL1]PLCT@9PRZFT+N
M%P_LQUU'BN5=<<O_>YNOY=GNWXM,A&$8" 2#U)2YD32 .*8!%%S&+ J01(D<
M(/Q@;X'5]^<%Q!Z:B2KK==[:^*I 0[:6.W;CMI\3N_S>,\03K0(W1IO=HL9L
MT-I] RK+;RJ4W_:B[-ZLVQDPKUV[[4>?MGVW,RI'?;S=[^"<C>KT^,%T!:?+
M1C7GEWPIRTVQVK671@D-TS!)H5 D@B@(&*2IE!#14 =3/$[BS*I>UV:P^05/
M!P:#O<76254_Q+V9J%?@QM_D/HN9^XY4/WC6::E7$"?*3:\#TR4]M4;G;([:
M?X>I$E5K7SK9JOTU0]L6W=$_WPO]R.0JY]4('[?5 YS$..21X##,@@"B* P@
M"6+3>I<D$0U#F2''_D5G1IH;N];&FHH7\-Q<4-OKVM+H',"7Z=4K;"-SZV#$
M!K0[ZD'CZKY'Y^X_<0.D'C>/.R'U73 LLWRU+7---:6F(9:OJON^+E9FC[S*
M95=E+BK9UV*U4WQ=Q%&HDH@AR$FL($)809Q@##$AL42*1;&;%LX &^9&*>]7
M^493.%!FT_&QVG34:2;?>6%^W+L!Z 907FMWF[\*Z_[?UTQ;&E,A)(H@B9 .
MHT5D)(R0@I)F42A"EI P7CS*-2MF,G%=6\8,=7:3U(IW/P'SC06L<:\[5^-/
MD]UBP<C0C_P^::T''?-O0&<FGGG0T07WMWAP!8 ^5Q&&F#'I<L(5.!VN*UQS
MJV%OMY^+0OR1+Y>WJR/%WC=YR9=%N5UW=AHC' 4Q1R%D)$XADHGF2BF$)LPH
MC5@8A3*)75YL;L//[YWV7.:ZK&O%S6)>ZY@;&SK.AAT1CH?QR!S8&EX!>H0U
MV!L/?A]%;F08<#ZYS]&"26EO&#J'C#?P+H./$CT4JZ\;?:?7]'N^H<NJU*C\
M(DT'*BG>%>MWVXT>\'U9;JE&8<%Y%B8<Z4 >(6XZ&"O(:"+T/*E $1PKE6(7
MOG.V8&Z45SL 2N/!#2@KX\&ZL1ZH8@U493_(&P? #_FJ^9QCKT/WV;+CPU'G
M8((E7 W_UQK^QORZQK,$7[K34+L 6A^\GE :!I_G<TN.1DQ]FFD81B?.. V\
MT8#]ID>YHJM-^;'8W!55<>:F;2::!@S'-)&08!:9]L_ZIZIA0ARR((BB+(ZL
M:/#R,//CNL94H&T%=P5HK'78(CD/J<7.DA>@1B>DTQ@-V4\Z#Y;#3I(7T";;
M0QH*GMO^42\F%W:.SE\[W9Y1K_W/=HOZ/SVPQ&A=J'QCS@0OD(@R@1($0Y0F
M1BDK@3C-%$QYQE@8IQ29#K#VY\[WMW;BP F.F9M\UAPN=ZS\V4,5BHP)A1*H
M:" @PA&&+*(1%"H)$ I#:5FD<"54$[PNKH;*+GP=!L#(KP'C^\&I>?W7Y5:8
M<YJ?C>RV.9ET<';>-,8K5AMMW[(68_<M*G8,E=?RIOW=IRU?.O+JJ#SI^!.#
M6VOI*34W>J?-J)<BMWJNFDZ'Q:I\)76RT9R^OZ-_RO*7?%6L\\U3.YM58M^]
MBRF-VCS](C?WA=AKFI4+F2 N5"1@$ 2:4U400Q8@ K&@2<8C*O0?+IPZH>US
M(VUC+F"5=Z:0\[$^/VVRPEKA$&R,M\X]NR9[%.R(<*83/#+3/F/9>A=N[SK8
M^][.?^T1J%T"'9]N6L*ND+D9GXU?8+X\]R*;S/RI&YA-/2\GNIY-;H)[L=C=
MFIIXYNO3 RN6BRR4G(N80Y1A80Z$1I 2$L&0!@P'*$P12FV+PY[=>6YQ;6,<
MJ*VS+_UZ#M=E3K\*A)$9U])_IT*ND[Y>4;CU_'Z3%6J==*-;F'7Z \."T0^R
M+*5\WF3[3JX?/BE#&)7BND1$$B,"PK$P#2D0@UCB%(HH"I)0JDQ()SF0_B'G
M]F6M3 1ZI >W\,X"7+NHS"]D(W^U:V-OP,Y<4-E[ XS%ICZMM=E?%&2/C\_@
MQ6+426,.>Q0.0P6'*]VW0.[I^IO\I$S3U8+K@<PVB[[!O0XN.GJV"Z)X)*(T
MA@%-4X@0"B'%2D<"-$(LB .4<JOCR_9#SHUF:K/--R1?P>^UY=4VL#&]JM<0
M'2UG7FDY_Y%O[L&J '2I+33%38^RW2S>E@Z;*K:31%/!6:@G"1$*D508,D85
MI*%@<1 J$6-D5\PYSC1-4[OY?@5ZIZ?I[FTI^N0P!?U[7/YA'7N_JW[P/RF=
M((/&:-!:#;3971%S[X#:[X/Y!W:J/3$O #OMC[EA=7ZOS/(^D^V;N?G5W4-S
MO-+Y13M8!*I.ZM^ORLVZ>AC+J@GZW3U=?7JN"'57_&::L.@7=<1E$L-4F@[F
M$G-((QY"$40,AQBE*;,M7)C*YKF]ZNM#-.95_\O77TOW<JXII[OWA3/'21SY
MC>5!*+!90^YX#RKWP4;[#SX=Z0;>%>"W2TO'+_9\6+\_Y_B<3/0"GN'SXO(V
MGWKFSH8#DQDR53PQ-;*=@&3RH:\[3//^X3O-UU+<<OV-W2Z-@$_]3\:$JM0#
MRQ3'2"&8)EEL!- 2B'EFJHA2(I,H3F+B5!5C/?+<HHN]=2;"^';5J9E^V.V6
M,$<!<^2W?&OS#6BMO@$=NT$'YP^7:I0&'Y*Q!FN,\S']@[_(T1AK3,Z=BK&_
M@7,*5IVQN=T?V[W37%I27A\Y+#?E J$,4RE"&"8T,T=? HB93IUHI7@KXI2S
MS#)UZAMK;J14V=L]TWP#-GN3Z^5,Z^"V%^C>I,4G?"/34(W<;1>YCK5U4S]_
MR%F'\SX1G"@,OPI)EX#9%INS@6[O#:8*4&T]Z026UI<,;(#1J&>;S:E]W&KN
M_*Y8'T>L^WBVO%U6DZ8__4F=CGXK^UY5BG,'<M"4D("(%,- F$4OG%!321G"
M0(891P2E*K9JB/BB7LSMG= 50G^6%E>=D4QMY<F$N .&#LAV<)B[G$VTZ]:G
M.L4VJ#AVXGB1!\XNK)[]8S3A0MR)Y^.F?I*::1]%ZWP6,^&U*<>+.#)MHXZ7
MG*NCYATO:HQ[,[_:CO=&1&4EJ[?Z/_+-/?V0<[/AO5.D7L1QFF$E$&0Q(SK7
MB17$,4DA3TE(J(Q11FQS'=LQY_9^:QDI-_E-:WE=LT'!LC8>T-9Z^[YUME/0
MFP6- >S(C-]B^MZ\TW>8_J/&M+$;W(Z'J7U7P!&PG:H_H!^,G5H%.J)UOFF@
M[8TF:Q_HZ%FWD:#KI3Y;"BY82N*8HA@*FB*(DAA#BI2 FKV%#!+!J%U#D<O#
MS(VS/Q8KR&EY7\NQ-*$E[QCLHXW?5;WW9D3&O>&W.0!EP'Q;E\.-W>]NE'CX
M]$@SZ"QW-J*\_&GW0SH?Y#>Z?%OIP9KF\PN9I3A+90:)D7%"(@LA1BJ$,DSC
M2(99%!!K#>>#>\^-#BKS0&T?^-U8:*F^<0JWR]_Z*]$8^:ON H33L9TS+E]Q
M<.?PCI,=W3GC2O?PSKF/..=AA\IN/Z^+LMSI [2;78LPS ABG.@OJ(@ADD1"
M*BF!/ YP%*N0!"JU.0%N/:+3%WB"<]N5E> U7:^?S%F4VP?3*<DZ+;!$N3?1
M\H_=R%_W$S*<-9(_[#4H6K/MBQ8MX;3.L?S#.E&&Y0=>EP3+#:JSZ97E;:9*
MKMR\ZJ16CA<.2ZRJPB@3@ZWEO0[#\D>Y/T[]46X^J3OZ9R/DTM5QN2N>ZP:T
MQ[$7(4MP:"1_4H(P1 $FD,1AJO^:$)71D".6#>BRYME,JZ_;]*W8GCE8B0H!
M>B">LY9")]35WU;/E1OR/N6&2>;?+FM\B>F<YJ54%[P^G\@#A20CFE0HH[]Q
M\W(:22/-@,^LUK>)DZ;#(^%[F$>/-<R@MG6-8NG7+?N7Y)M-L6\"6JQ?&Y72
MY;(.EW@H,L$)AP2;Y#S-$LA226 FF*)1A%&$A4,'.]MQYY:X5U:#LC:[)O?6
M\$'G;9SFH#<?& O9D0FX*Y4,ONZQW9NN'VG0-7X<?)VZX(V!\X0-\3SA[=H=
MSQ6UBXWRK&\V9<\\5P\/VN<Y7SZTDU[3;!RKD/$841BJE$ 4AAG$/(YA$B,1
MA %)D)U>].&-YT;<[1*C4]_V([3ZEUJ'8C RQ=JZ/Z#'W;FNZ@-;VDW9,_V<
M$\<-Z[QT/C\EB%+]\;'8_%-NS-=?:GO%%[F2?]"ET4H)%YC@%,>,P2S$)CN/
M,TA89FK]L0Z[B,[=8ROQLFN,F-N7N99.6M<65A)*CA*9@V;"+D\>&]_1-V3.
MZ"S5F!OU\R=I>IHU;MR QI%*B&E<\25;&,>68^JUX\4%FFR1LI%LLK[7,%+\
MHG/8=6X.=KZFI9&M,/\QAT$?Z=*4(Y[^UZ;; *4BQ6$0Z' E2B&*T@1BJ5\L
MIH]GP@+!,DY=R/$:8^9&DL;(2D"H^J%CKF,0Y&6B[+AS*OC'SF>'(^_,DSX@
M\\F75]DS*6_Z0.Z0/[W<TV>YG8^#]S^O39..]ZO/<IT;@5[MX:K,^6^F,_!"
M4RQ-XS2$7,::=XG.)*G *4Q23A,54".T>WTYW]ANS(V[*UNE #]L5W0K<OWC
MC]7RXK840+^<ZV5&QR9M+_2 V#'__*=]Y'?&=%HN-2#F]$ -B5&7;T !%2HW
M33F+^7T]WM@%EE/-\_@%G*-[,H,"T:EFRZX =3)KW%[+Y7JSN%4J7^:F$J%>
M1&I;I(F$AC&/(<8DTTF+%!"'$NDO-<6(RXS*@-B\,L\/,;?7V=Y*("LS[=Y<
M%S"\_%;Q@\S(C-\!I5V=]=9+KA^ "U2H+^[0H/[;(05>N/LD]-3O74L=%I\<
M%FV_D4JNU\^9J"*?ZLW</4ZY:__^>DG+,E>Y%&8C?ZNO-M+'A,5Q%",8*2.#
M+WD"&=/1-"&I0IQ' C.GTS">[)H;@52)=*6.+(611^8R;[OG;JN&(?HO]=:[
M6TSL:QKM@MP7F)R1.:SUZ'G(VHU1G\LJ[/RZ 7O/ZO,\M6_^(DW/8/L,'7V9
M-FDLZ!G/P^#.]^VOV:&K5KS?R)*O\RH^_)"OY/N-?"@7*2(HH8S#E!FE>J7I
M&J- ZO@M0W$<TSC&B?MFW-GQYD;#[>90LR74,1G\;HP&E=6.Z\I]F+MLNWE!
M<J(=MJ$@#MQ*ZX7&_Z[9^2%?8(.LU__3>V']ESG77;ZC^;I*+7_1]]ZN*U8S
MZ@V_K@IF>L6;:L_WJ^_;3?E%&A>KZ%4/K?^F22Y??=,);KZGP8]RTVFG5NB\
M5M9Y[")36&1!&,%4" $1"@1D* CT3RR+X@S31''+FLVI;)X;X[6=@JM0<W,O
MS>JK-M.Z_G"RN;[,DC.=P9&9UKC<+FEVO*ZE4KI^@]IQ\-QS4]K0^ XJYY_%
MKT=]E(%& 6@8FF75^3TBUN6M<WQ4)BJ-G><CXU)E._7DG:W0G<R0J:I[IT:V
M4QD\^="#FY"OZWBI_F\E,5-U>C,",Z^WY4:/N=Z9L4@8CWD4"YCIN,0T_D*0
MT(A!R07)8IE1JIPVCQW'GUNPL5M-6<M'N=I:-EH;"KY=7C4BI".__5O+P0^M
M[3^:3<_6_)K26P<Z/.VUC?80[#RWPG8R8>IVUD/P.=&2>M!M_!5QEWN!510&
M(=7?8YB0Q"CZ!@S2F M( DQ9*#.E4B=*NSS<W!BL-N_Z6NS25;'6'TP3K?X<
MU%>7X/=1]&/M<!F[8+I\(456.^]MBJ!/7#6,/G:1W)N\Y,O"!'/E+2OKOLV)
M4&D@: !%2G0\1(2"1! *$XH850EFA#LM+U\:;&[4L<^\0,=:\'MKK^.J\D6<
M[3C%%WJ3K7*X N?,)C:(^.22B^--RB0VGA_RB-4UPUCDENM0IZI^>C!* ?]I
MY)K-0*9RK[Q=B<\Z2\RW#^7[:G^\VCE;)$I119(8*IZ9?"N+(5.9@(*)0,5*
M9)+B 4HOPZRQ^@I-+^C2]<%H?GRO+0<_B,:='X'^Q0-=_UO6TA^ER;'S3>X:
M]PR<0SON&G%*)JJ.:AT /W1=^-%,R<Z+ZI!%ZX>I8]UYXH_SKD/2)QL.M&12
MGKP.K4,&O?)N[D?C7QL!19U$OBZ$7##%$\5D# 7*="HG=!:',ZK9$JL *Y8&
M*+:JTSR\\=PB+V,;,,8!8YW]R?AG8%VFI6L@&)EH++UW.AA_RM4K#L8_N]UD
M!^-/.=$]&'_R]\/"F=?&&K-D4ZU9Y^6_7SV]DBM^;]ZRE<0M0PPI13)(8B3-
M_G4(F5 ,IEFB*!<,!RER28SZ!IS=5[1K+S &@YV]3OK!UHC;A1D^<1S[>WX%
MA,Y!@RTN/L.#WC$G#01L$3A\Y5M?-S!Q>J3YTH3MI@L.7<JON^#]C62;_=\6
M(L$A-^KC::1,FX) 0H(2#",DF!*IIJ'$B7%L!YX;\[PM-_E#=4A!F76&QWIK
M7&B;AR<^MG-@F>J,@.S(7&0, WO+;L#.!ZB*-2RU%QX3&$=\O*8LMF-/FZ0X
M(G*4EKA>/S0J*JL4I^ER42XXYT1F.((94D:K2U*(0Q5 &8DDQ@$B.DJR45T_
M-X 3]TP@LGYGQJA[^%:9?K';,Y&-Q:Y!SP&@MD'.<)A&#VI:;-[V(3(@ACGM
MMM^8Y6",B6.4TQX>QR1G/C=0J6&CWZ=FI:(^EVI./!0KLW!1!=ZQ)"J)102Q
M3%*(:*0@30(. R%3GF:,9(&3I,W%T687;=1'V/=&#DIN+@-L]Z7W!MO(#.",
MF/N1?1LDO)ZLOSC@M ?@;7P_.J=N=9'[XF036#R%$;O+-TNY2 154F82)HIE
M$"F-)J49AAEA249(R#$/;1<H#V\^-V:HC#*+_V'T _NQ#9XM#Y*?1*]_Q?(:
M3$;^VKO"X;1\><[O*Y8PCVXYV3+F.6>Z2YEG/W.MI%VEY=O*/B1" X,5Y$HD
M$&6IZ6&K7^Q)%,:<(1[&U*DR[.0H<_O:[HULY*9_7>47=N<<X+1[C5\-TLC?
MXR-\_&E 6$$PCO1;=Z 7TG0[X>MYL;93'W8^UK=;*?N@D_]OM#XLV-2<5OW9
MWDE9OFX$ R(9II2A&$J19*;7(8$L3!1,4ZI8+&B:*-LVUB[CSHT>S ;O5C_[
MRZH-H%M6[PKY9<(8$<BQ,X#="NW>[NZIH[K%HK']!KSN45FX"F#K\V5C 3W1
M&3&?@+N<[!H"V]G364XWF^J$U1 /.Z>D!ET^4/]G5]+W274E*[[(I3&@6C':
MRU<T8F3[ M24Q)0BBF% B="96ZPS-\4#J**0L8Q*BH55:8D?<^;V5NCI_SRX
M)OC*2;.+.*>;BI'?*QYFP5VTQPMX7K5ZKK-H6HD>+^@=*?/XN:N[?.(O^2I_
MV#XT^5Y(41(BLQ">, I1*BG43!E"%9.,)S(.X\BJ._C1G>?&?HUQ]A*)SW&Z
MS%)7>3\RX31V>99!/.GMM>J'SV\ZF>CA25^Z6H>G/^"<R@Y66OU[L32-;NO#
MY&^VYN3Y;SK+UO]9X$PP&2H&:1+K[R]2*:1Q*F @&&,\"U606C6:&L>\V9%
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M1"463D=O;$:=&_,T1E<+OO29V<,:%]I!;T<\W@$=F7VZ6#ZW>,3VA4X@>3T
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MDE4SO3B]A'3O/90.+\F[I%RF9N62(ZJ<@MOW;SVU*;M5#UP[T^]KL,Y.DA=
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M\X(C/D;*W9B(.Y)U:!R'INYC 4=7@'5*6P8^?/5":81:KZ\$3Z'LZV$L'"O
M'KFXWQ1P:Q;)S&XY?5+,D&B3KO \RY3A^%CD,(T%AC@6&61"*"@BE.4LDIG.
MY.Q)K?C2E?:/2/)Y7;KR!EP\6G(#RU9=,+?Z@ODND\./@(XA[$8Y 5 ;F&2V
M&H)*Q:MM6M5S.$HY@T)($CDF:E3:.&/O:Z(X]_'^98X*69CE[.VJ7M#^K-;W
M2UGO4BOUS?#1K:Y\TA^?]S_<?JRNYX-2I5DB&&3,.I$TS2');9$4$J4ISW22
M)MBW/%(HY:;F:^[4->/5!EW5YH%6<;,2,Q;:^+[*QBIPZ]!E[>?[EV8*]@BX
M$=Y;#>S +/DF8]JKG%1H\$.7H0JFW^CEJT(C>ZCL57 9/><.=6<CV;ZJ1[O9
MN;C;'NISFG.)&84J0390C',S!<0<:BP$5I%,,?=K=75$T.0XO=83;!7MW7'^
M*+2._!H L*&YL@]6_EQW!HB@O'5,UK@<=,;B/3XY]_F^_4?$ROJI[U7][\WB
M6@A[0E)^54*99:YU%D06*<QX"KE"$N(\%I#+G$#&A=8ZC5*6\]FB:NTFO[O3
MA8MLIS>!UF_"G@;#O16MHF"UU?0*+$Y4J^@/OAN3!,-RK)8DM9K@AU;AO]@4
MA2VL.Z5#=B1QARAL1Q('N2-W)'%'8K\CB<>U/?V5M7F-+=G=ZKJTD]UWVR_X
MM)UK=4K3))<8(A4QX\88CN)Q1J!6*:6V7%(4>357\Y0_.>^F5=\N7@[69NOM
M[7@.C*,3-!S<0_M&(9#V]Y7ZX174A?)485S/JA\^>PY7S]OTY3RS$&PJ\=8K
MP%F$A"$V32#G$D&<RA@2E2F8ZAC'PKAC:>;5]6U?Q-1.&>O-_JZ>?_X3B5'^
M]V:SQ9>M]B#5.+$!E!I28L,JM3W+C8F $8E2JHC(B!#^8;*7 ?N'"7,]@&?*
MTC@RJP"($5$0QP1!:OM\I32B/)5*Y;%WF&H(-*<=9GH 2->9\A)H!I\,=\K]
MCW9W]'48YQ>V4B'3P8XC$G:ZVY,R\HQVS,K]2>OH)WOFG]:IL66S56DCG>P#
M;^MDE#.<I83'.H5$XM3,4%A!DJ?2OOZI3)A.TTCVV!<X)7.B^P%M;K[Q Y=:
M&PXRW&"K/=D-@KE5PC[\CQL^+\3V YYYIZ<&PHT^+L9UI.S21LW=V4NK:560
M)V#(MPL@0?-'3\D;-V74P?*]+%&7:X(54'ZW-$ZVK([2EXOO*[8HZQ15-)-9
MRN-$Y@9@3HS3P3(;+ZU@3EG$"4(LTXG/<M]'^-36^K7'_&AN=V]WTT17[XLK
M(A\? C>^&0K8@?GG<"WC%YJ#CNJ#%B@^B]? U8>/RW_KTL)GD7&H&WS^'GTS
M/1:V"V-]WZ]%^>_OYC[OEP^L6,SB6&JSI#5K)$Z-ST1R!:F()<QBJC3/&=;(
MJ36R@ZRID=4+58'5%5AEP:^UNIZ;D:= =N.G0- -3$>]4>N1]G$6C["I'\?%
MC9S^<=;N_120\Y?TXXYND?*%/+!5P".L!>()U"(5-G@OAD3D'"JI***2:J%C
MGVW!<P*GN4G8T=KV&9!*/51[#$?R1*O ^U ;BV>'R(U^0@(_, =UFS-8),^@
MYLT\KE"$I)^S,D?E(%<$7A.1\W7]V*@YVS6OTK>U&7BVDN4OC[:N91PA'-&F
M?2]%B%"42RB%LI248<B0DM!P$2(XBC.-J8]/XR1U:M[-]^5C(4 698#)Y:/_
M LP-:C=J"0[@P/RRTQ=L%0:UQL"J#",:L)MR+Y1"4H^;X%'YQPN+UR3D=W%O
M)MH\;*J]U*HBXX&C6-MQKNT"-M,91T+&!,99QB#.D@PR*B*8:XGC-$&88Z^L
M>D_Y4V.GCOI@696)%2_B%8K* F_&\AH29^X:"NCA66R+<5V*U[$S8E!*ZP->
M8'+S4F%LFNN#SP'"ZW6;WC&ZYH;F/N^+4LR7Y6:E=HV649P*++&&L<15\Y6X
M[AVKTSC#(H]4&CDUG'(1-C52:UXHHZQO'NA)2-UX*A10 Y/2#B.P4Q3\.DBS
M:A=( D?6'I<W=D3M6<L/1-*>OZ9G-)FX5W(S5^6M?K%3=:OM7M6/S_;K1R;,
M:':(A-,8QS@QBSB10ZSBZC _@H0IGB.D;=,(KRA:?QVFQB];$^KXSNX^K/F%
M->#*Y@56>[*U*9Z!0#V&R8V<!@9_8,[RQ[W)O@2#T-H%8 :-0NJAQKAA2OUQ
MVHMCNN!6_2AS6[#_Q^?MM_]1J)6YT?WS)_5DD+--&'E$,!$LAM*0(\1:8,A2
M1:!2J1"9BJ2,O9:5;F*G1HR[-B%@JVRU,?SY^A]>O2X]T7<CO_"8#LQWE\#I
MS69^Z(0D,$?)HW*6'QJO:<KSZLM",+\OFU[&-XNU>7J*;8OC61Y3R141,%;$
MK@%3"AE/S)(P3E)BV G%47I!'.91P4ZOT!L$8[;A4,99*+8J U;IW"_J\CCV
M;I04!LJ1XR_7R[9%.]BIVS1O#Q^$>1::(2(QCPM]DW#,LQ@<B\D\?V$_[OFJ
MRO6J$.NF-<@OBV)=?OWV2W,8E9,L5E(F,%?".$-4"DA9EMFZ9%02%4=2>-6/
M."EM:CY07?H3;!8&S7E5NF]3U^R08+6UHVE!M+&6^#'/:>2ECAC&7$&6&9['
M(HD@%]3\*)7 440H,HSO51$N&/;CU(7[.CC$;L0>#+:!2;V#5QU37VD*?C"Z
MEG\9X&S5"9>0C'Y:X*AL[F3[:R9WNVCDEK0_L]^+A\W#AX?'^?)9*5NF2*R*
M*KC!=H>:Z3C"S,:QRC01$!OV@<32$$(8FT5RQE/I=?@PE*)3FSL:=8%J] 5E
M1^&J3]T5^/#MRY>1&L.>&V;'/<<)#-[0&Y.7MVUMA[ZU%G3-K?KG3:#SJN.(
M3**1ZCE=_QA]41T1#];FU%5>L'RNKTHL[Q:VQ_J--$H4NF#;14JS=I'7"]F-
M9RS+S8/J_F;&*:$L5A3JG!BWEU$$"1((<B21H 0K1G"/C8Z!U)WH]HB-.YEW
M WIKQ2].%PLRPFY3S5L.V%LFH>V,!%TKFSV9=K=&5GO'W9CMQM2K[B\'S5L+
M.1H#I[@%4?6ML^%"XNV0.!=47,]:^3;NJI;8+-C3.%5(R Q2@6.((TPASV0*
M8TU0'$O&6!;Y+$;V)$QM%5''&)[9CW4$SXUW+X)D8,;LHC' AL91TX/6N]\3
M,FZE^V,V[M6X/_K!?B_S3VJA5FQN*.-:/A2+HJR.^Y_4A]^M3ZMFG!.L19I"
MG0H.,5$9) 1',$^27-"817GLU?7HC+RIO>B-NM6TSEXH#%2ML=_K?PYN-S((
M".+ U-#%[Z6NX,,9_+QYPA&5D*QQ3N2H'.)H_VM&<;W,CU_N[F>?-Y:?EOJ+
M6A?6=2G?JT5ANRXF(DND2*&J.NQ*GD)":0;3.$I$FH@\RS,72CDN8FHL4JMI
M#\4?6T6!K#1U8X\38)XFC# 0#<P1.W2V.H+W8="12[&Q&R^5ZSPP2B]D30HM
M9R8]#T1-GG?W%2%&61)5='CBNE$8\+S>+>DY?+)G$*-9GRU$P>8W"T.@U8-0
MQ<VE*H]YD@C(!#/^4V)XCF!"H,P2EHA(DCA17E&+A^5,C?&V:H*=GOW"$X_@
MZN8H!4!K8/+K Y1_X.%I&()&&AX1-6YHX6E[]V()SWR\'R/8NB2W^KK)2&\6
M^R+&-%)F$85S$=?1(]26P152R50IFB;,JV#Z(2%3XX*J9HZ9KUHM>U8=.HBG
M&PU<BM+ '' J!S]\K:%38(1D@H-RQNUX?\+2O9[UIS[;,V_>#*DLYAN[F/JF
MQ&95;;Y^^%W,-^9M_VC4M2>'FW637O&!K6R%Z/*+6E4'A]</]J&8)7F22!(1
M: .*(59,0B+-NBFB<90C%&-EFR![9-.'T&IJ%-,U"I1;JX!JS +VX:CR[AO#
M+!^IQC2S*%O5/>_!#\6B_J[\BV="?I"Q=F.ST4=P:/KK#M[.(/#AQ>"]>SEX
MK55F%;2J@SZN0&U9P)3^D$ '3?0/HMBXZ?\AL=PK"A#TYGU+!4BEBT6Q5I^,
M%O)U-/B/SS^S?RU7[^:L+*L%C! Z93R/(,YR#3%GU/!ZSF&D8RTX4TA*XE<]
MP$O^U!A\ISZ<6_WW\QYZ+1]]1\6-@0?$>F"NO1SF'J4)>H$5MEJ!GPHC%S#H
MA<]^38-^M^F]W75$TB^ETIOYIT*K6:*$R&*=PU2GMLFI0) BDL&4$RKR-*4"
M>;FN+D*GQFNU9F!N5 ,_/!N7T]>S=$+:>3<L*'[#;XU9GOITD*>N0(.L53KH
M3IDS1(&WS<[+'7L/S1F) QMJ[M?V(Z"ZQJ9UZY8+M5@WU:<I91Q)QB"/,#9.
M59Q"I@2%3!-%)2,1EEX-"@Y*F1K%- U_MEKVW%\[C*@;LUR,T\!4X@^1-W.<
MA" D51P6-"HWG+3U-1F<_K#?VR]5,?M@%GOKYVLIS0-2-O]\*A8*S5)"):**
MP0B;=QYG-+?M25)(4XX2:KV.V*F.TDDIDWO[*T5!H^)5^PVPRH+;A6-\TFE@
M3Y- ,+B&)H&^2#ES@1,2.RXH6S(HE?CKW?+I?YKK#1R(VF^@_:;S^I^^]RBO
MOY-Y[>OO]N%^D_][Q=>[?1Y;>'ZSLMWM9@E73-E<R$CE".)<$DABS"%+->)*
M2LECKQ7',4%3(P&K9V??^PK,EXL[:"0_^/D 1X%U<P-"P#4P"51(?>L@M=,R
MG"]P#H>0[L!16:-Z!.<L?NT4G/U\SX(]J^6C6JV?OY@Q7U\OI/4]'NUY_F>U
MGD4QR:E.,RB1W7$5S'@&3'-($H8$C8CDS&MQ<$K8U BBU;4*Q%6MHE=@H8X_
M]OX(,RHP,CX8S(EF$".50$)D!F,<:6V\LY1FTJ=!2C"$1VB.,@[";CP<"K>!
MN;A5\PI4BF[[FS3(?3Z!G'^M(P=(@I8Y.B5OW I'#I;O%3=RN2;TSG%Y_;!<
MK8O_JD[IFNCS_Z/8ZKL9%S5+48+CG$BHL++G932"!%';]5K)1*89%\*K2&Y/
M/:9&[.;Q2T)M*)\>@$OWF(/!^K;;SE;SJIA/UYPK8"T!E2EC;$8[83G._O1I
M52:R9>V$E_LNMMOM>G>PM$&HPM[Z9F&(^,ZNFIMP1Z1P@G,40T4DAEAK 9F*
M-209ST0:H5A0K[)OIX1-C>FZNH)B 1X;;;U[5QZ'UXWB0H$V,(^]QJM5=( ,
M71=$ O>O/"YO[ :69RT_T,'R_#5]BT8^J<5&U1%/MG*W6/^S6-^_VY3KY8-:
M?5G."_&\JVC/9!PI)#5,\EQ '!&S(J:8PH@H&J$TS5/LU1'73_S4"*;1OBWU
MX=]'SA-]-[89#M.!^:>%LXG>K%4'OQG=0:L\^+56?YCF ?V0"UL9T4N#D4LE
M]D%GOW9BK[OT;-!K:%*I3XJ5ZKW:%LVJVD_,XB1--&(I)"JN2I H2#63,(\R
M*7@N$I5[U4,\(6MJO%6K>@4J9:] 1]VF-X=G(, IF-TX*Q!X Q/4!;CYM]D]
MCTC0#KLGQ(W;7/>\W7M]=1TNZ7ELN.WV9'N;[(KV?555/[EWRW)=[M7L*W<3
M=B))GB&N(=,)@5A2:JL^*Y@0@FD:Q3ABTNMT\3)]IL9#5?5<^.->B4[/(\@+
M!\GQI'(\Z =FL8,%3SLU48?I-Q<(OZ 'H1>J-.YY:1C\]HY5 ]W6N];+/]BJ
M*D1WLS!,H\IU'?FQ[<QRJ__WLEBL_V&DV5Y[9MA+VRO]X[).P&G;ALPH9YCI
M-(91'D40H\AP+8DHI!F1AEP9SV+L6!HFC$93X]BJ7]%3U:]HJ<&_K G@J;8!
MK%LCG,NF!!JUTY3[)F,Q,.FV!H'6(E";= 4Z#:5N-:CL HUA8&L9,*;528N@
M-6[L,7.NC#/^V(U42&?$,?0IP!,6[Z/U>@*)&:N\3UA4.M6  M_XPG#F;^:A
M5[>K+ZOE4V$@F2%$=43-$D-+Q2%6)(6$8P:3C.D,Q7&6,Z=XQG."IC;-O0[5
MK=0UD()6X9Y1S:_Q/3USA41MX FI/V#]@YN/H!$JOOGU[=\FQ/F(D4>CG(]]
M_I(=S]M'94LR+NZJ39&VD/-SZ[Y_53:CPMST5G\T_C^;VZ/H&482&Z]909JF
M"<2$2$BQEE!&D@F:2"W]SG;ZJS(U<MDJ:5UH.R_VV1[M-28^NZ=#(SW2YNK6
MC':;=6O)E>URR(WWQ IIZ^MW!J6VJ(JI";T%>PFLX7=H>VGS!ANXEZ!V>'_W
MHCOZD6FY6C=):#^K]?U2WM3- M5G\_@V68Y9RC**6 218!ABFDE(LHQ"EB8Y
M0ICKC#KY6>=%38T,:PV;@%OS.<_D40=L3Y->6,0&)C5_L)Q9RAV'$RQD;M)A
M(//3:_9QD#(*N[A;V[*'QQ47=+6P>Z8K=:\69?%DEH1B^: ^+<ORLUK?ZN_L
M]QDB*>:9B"');:,+DIKU&*'*YI&D,=,41W'BD^#@(M2+,49(=*B[/8BNTJ"H
MM 8_S(W>GO4MG' 7&DG)5&J>XU1"G+$<,D:$<68SFL9(*Q1YG;P%QWVTGB,O
M<;=X#P"WFY\:&L2!R;O&[X6^X*9Y;JW*?ZDR3JS[:?0.W+W$$:7@#4W.R1V_
MQXDC$@?;GKA>VW>M;1S1\IJ75133+%,X283*;&PDL;&1 A)A*_7&+$\33E":
M>34^>7G[J9%+K1WXM=7/.V3H!7:NZ]R^B R^=G4%H\<B])#-81>6+R2,O%@\
M9-W^ O#@IWH6V:WR,=XU:>JI$)'2,H&I2(Q_QK2 -)4:YBK59FD7"ZTB'__L
MQ=VGYHA]MS) DSAM>TEZ-R-["9[;6]L;DH%?VEJO*_ N=#+_08.#5G-](6#<
MJJR';-NKKGKP0SW+=KTNO=I.&1%1BL<ZAB)*.<1I@B'#B$$I4";,RDH2[5>Y
MZXB@J4V\^W6,>T_"1[%U>[%#(#;T*5<OL/Q+>9U!(F@UKV.RQBWH=<;BO9I>
MYS[_)A7S/Q4+=;-6#^4LUDF.-<\A%1FJ6XSQ+(Z-+Y\8)HD95=3+>0^EV-38
M)U#I=?"KM1!4)GJ25K A=_1>WF @AW9\QAS#L6OH[P$^H3+Z.]W^2)7T]Q -
M7$Q___[]YH(JF\#&6AD:K#?^M_Z,4%RK/*>02Z8@IKF"-$H8Y"0E&=8IPLRI
M@>1Y45/CZZZF?_X3B5'^]ZK6T/KY;WZT>P)=-R(-@]G U-A5\G^ I@CL]7J]
M*KAY?FWLYWH)OK!5W7,MO"-Y'J20='9"VJ@$==[JUY3C<$4_$OEQ4QHZ*DO#
M6+Q8-*D057;W?REY(\VX%[H*_VS*>@@C?*7D]4*V$0F&^LS?-@_[-4"J+>GO
M]VSQTW(I?ROF\UF2$H6$CJ#*K=?)A8),IQ(2GK%,9$JQ//+AI5&UGQK5M?89
M!Z;8%>'IL\LU[D/@1I^3'=J!&;FU&W0,OP([TT'7]K8C26M]52"N8S]H +C:
M[V)R!>KCOK6! ;0XA"/V-QF^D'/%N :,.OV\R=B\GM'>1HF^V0=5\H.9;8W'
M_YZM67L@0'@24RESR*D4$*M<&#];(9AQE"F$D!2I4^_B<X*F-O4TP?0=98'5
M]NS1@A^ZIR>*D)@-O2O;$ZX>F0>GL;@X\^#([4?./#AMY'[FP9G/]UQ^;[.$
MNWG$G<3R'Y_W$HFO?V,K>5N5:RAO-^O2]K(M%G=?E_/YQ^7*_G%F2RU'4D20
MRLA0"DT5)(PD,)-YGL58YT1[924,H^;4"*DRH03?-OQ?2JSMHK51'W3T]]P
M&&9\'3</WGS4AMYXZ!1EZ)KXHC(#?P8'BS=86Z[:$;[J#C'XU9H+&GM#;E0,
M.B!!-SF&T73<#9)!T=[;7!E66E^?TRCSL%Q4.S\UO77DS*A J9 YAA&/B"WV
M3(SGF6E($<H2DL6IDIYYKZ?$38WN&X>J5AE4.E^!9@[P)GQ'Q%V]T5 XCN.3
M]H:PAV_J@LS%'NI)(2/[J2X&[WNK3E?U\UF_KQ0K-ZOGZN:UG*:PKU R9HIQ
M* F+K-MIJ"3)$%0")23FVBQPO:H#'I4T-2II7H#2Z@G*G?^X4H]>A4?.0^SF
M^04!;F#N:'5L::/!,'S9Y+-@A'2<C@L;U?<Y:_-K]^7\!3T7N!M>%K)@YLYL
MKFYU=?_MX?4LS[2FBJ>0Y$D.L6(YY,;U@)QF*>7*L FA7@O5D^*F1AL[;<VL
M:?2U(2.5QA=$^IP!W''E& S&H5> ER'HOX)S B;H2NRTQ'%75$[6[ZV,W*[R
M+H97^37\Q(J+/^\^<F#%=?W$BKD]'-#+U4_FHG7UI2P67]2J6,J?5LNRG%&5
MI8B)%"J49Q!++"&1$D$N,H%PG$B4T=E"W=FZ?]^=*N:-H;;3&TKK-W1/^>'>
MUDI3)<$/A?&5*J_4,8MUK-&.F":)X#'DD91F.J)FH!G);%X:Y2QC@L9. :U3
M&N81Y[,Z5>:!K?ZMULUVFRWVM2JJ3CZU=[Q9%.L2L,?'U?*I.6N^JQ^+:3T*
MIR?*"0[P'V:O%6PM!\9T4)E]5?]35AU4*OOM;YS3KL=Z*)S+.4[MX1BIV&/(
M#7G?!\*G^N.8PW.T-N0H2HQ5.7),1#MU)4<5VS_N0RQ7C\M5I5M5N>[=<K-8
MKY[?+:6::97%6:H%5$RF$",L(,$Z@EF41SE+-,?$<Q/^I+RI^0S;L(:.SIW"
MBHWFP*KN'Q%R"G?7K?A@:(ZS%W\1D+UB11S@"1 R<DK*Z)$C#B8?"B!QN<Q[
M&>Q4Z.W]1EUK\SK;^FX?S2,WRW',B<PIS'AL4_>T6=?&,8-9%JL,RQP3Y!1T
MUE>!J=&0F9S3:C%BH_X4LZHZNY[]1N#L F-P7 <F))?:E*T95\ 8 BK8ZQZO
MUI:!!\#9F1]\($;RSH<;$!_?^R(TCSK3_>XZEG=\D<T==_>R^_0]P7E\G%>^
M-)N_8^7]Q_GRMYN%\9<?:E^[36CC&BG$<0R)B#.(,VF;AIOO,IT3S!E*$NWD
MQWK*G=I$TE4;[!K%E/9DPIH!K!V@8XAO2J'C<+@>] 0'>? 3GPZ^!P$=)L?0
M#ZBP)T!NHD<^"O+"8_],R._RR_(2J[R/LFHUVZ2 M%5S\RC.,Y0BJ'B>0YS'
M*60"I9#3-.4Z3S@7<9]<PJ,2IT97VTRQCL97;2J8;YEB=]S=V"DHF@/STJ5
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M&8P8)"E)8,Z(RB*>Z(@Z-;P[(V=JC/!EM7PJ2AM:8D\;?^"UEM71L(T;MS:
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M4@%1K!7$",>0:)E!$2D5I2A5BF@?9@\#Z&BI=&P@6)VW"B\':_CMP===,*Y
MHV;0[<#32 3> CPB;.QMO],V']CJ.W-!H//0MG2**G]:+<MRIN(TCK3BD MJ
M6)?:-CXQY5#SE*2,1WF.D _KGA,X-?*M(J5LX1*P>5PN@)WDBL7=A6>=KT'N
M><QY 71O<,*YT_8*5/H.>+IY!)E!#S9?RWS;,\TC")P]SCQVG?_IP;O-P\9N
M]#VI#UHKL:Y;EMWJZ^:8KMV ,_Y;JE,-N1+<1DTSR"FWL18HYL+X($@YU3=Q
M%SDYBMEJ#6JUKYH^AG:WNU6]Q^F!XP"</S0(#^O ]!,(4:_3 S^0+CTT<)0V
MVEF!G_7=(P+/*_NY.=_-9>:6NV:+5;HX2C(99P1#P<P7G*,4,I$@2".IN*2*
M:NY5OO^@E,FQS7)N=%ZNZM>CHVRU$=/]N6YVM[YG"_#RHCY)^X='P,WQN1C7
MH>EF<$B]/:*3D(5T@PX+&M7W.6GK:X?G](>#=ANW';"^&SGB7MTN5!-(E$BB
M8TX9I)9N<!YK2#&R>S HRYE9:3'N5_C#7?;4F*C1#R  P7]'<;3K\1VDQ?=!
M^-T(9R!0!Z:A@_VR=P_Z%6@!-\H/$-;5 [01NE@?%#^%!M2G<''L'7WR%I>6
M'JA2;7]\KLX:ZTR17.$XCY(<1BD3$%.>0II$"<RQDIQ3NPWOM0%_0M;4J*J;
MMUZGJ//GYNB]5V+.*9@=*2H,>$-34G_<+LCD/XK(,'GZ^^+>* O_J-W'<^R/
M7Q+4%=K-0F>:W+<M[+<M[JNSFIO%>E4LRD)49XVS.(ZTCFRW3R5M2(+QH1C1
M#'),#"&I6"?2:]TVAM)38[2MSK;0=)VE?67[A=8JUZ$,0=RPL$-_D?_V9@,Z
MHN/7-?C%TM,0[T$'T9I]!1K#;47?SG/QI7DNMI;7D1B#^XR##-0(SF98O:?@
MI0XR$H[N[3"R>Q9Q;P-=.B>P/RMF U[D[>*KS?PRPNZ,AD7YRV+)2[5ZLM/I
MS>)QLS9_-H-@KJKLVM5^0HG@.#)36!HK6P0TL5GO>0[SG$JJDU@D)/<J[3Z
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M7>N99(RB5'!(2:(@EA&#W%)9;BLKQX)2R?TWB (K.3GBZU1.J37T]4.'&,E
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MLHC03/G%CODK,;7)9V<#6+PP A2-%;[!93T&QFT!,#3< \\^':1?Z@]: ZY
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MPQ(7N>,>EG@@L7=8XG/M,5[J#NHG\]W_^F_M;\P76R'E?_VW_PM02P,$%
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M%[.K-UV"4682O R"6$?1(PK*$1<0Z(P%'@5' 2G=&SR>)64KM)C6T=*?M)L
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MH&'=GQKHZ47T#6Q1-Z7QZQV6BZ183I'@9JK+M#5-K!&EGZ0![H3GV5:I(']
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MG71('.ZKK)8!B)'DA1^G:Q?]W?>2*@&4Z%+0*_F6:6=!I9B("A+%&,NL;!J
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M0%^C%Y#>=.>%C]7UB8OUG8H/R]3*^!LL6]&O6?0JX())C.B@<IG.QC'4B90
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M)_F.A5XN)L:T<]($PITJA6I*DZ"D(DI:S90+4;@JAWP;J1GV#FUC6][A^FH
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M) @:B/7)><JE<UM-4=J[$<N+% X\"+<5:-;1: -0?3^>CA?P$>7WL"7-[W/
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ME*5(+&3E(:10"I9L'6LR@V#H0:=MQVZ.T:9RZP"77\^==2P\$G]L<>02HPB
M3&2P+@?'<B@I-YF\/@A'S?JDF^/H(#Y/VW)Z;^CT>K$+>/(1'*H<P<A$J!=,
MU[5X&AB*K$L*WK.G>TWW^ZYI^Y>;8:0-KSMPV.[Q.;^G*7(MO"BACJ1(H)PL
M$)2,0)ZIQ!),"KG)&\D^AYNVJ_D$E]O(\AD-<R<ND'Z#J[K/Z7-N5 C]W>>?
MI.#Y<:HF*6Q&QW7Q)@%C-I"+I QY1RF!*9P%0G!(;<HW3EK8?/LQY[?OBLUG
M1A@N-:>@A?-"/$@.Z-:WP$+!I$0A![+)2\CCQSJG N8A*/HNZ!Q/..??#O)]
MDTSS3I"'O_+$32![TCZ)F20_CGE.*FRP#FBN20K/BP*N5+3.$\^QR6/52<WD
M8R_CW[=MO<LU^TU6J.8IUQ$O_CMCW<R+44=!?DERO(YR07#$(8@499-WG*WG
MIWY5WO?LYV1PA^!Q2 *DA9@[>%091O(;,C'O_\P7G_.O2S)G= <E*Z65Y'&G
MNDJT/A9X;NKUEJ1GFC&7FDQ'..[8Y]1=?3H\'R7<LX-R5=;W?RYG2!K)"@O@
ML[!UPX4"QSV'% 6Q5OBL30<(OC[M.;5-GPZXAXCR//%* ,PS&QF7/!D064<B
MTRG DC3(D+DI7GEMF@2F!YYWVLQ@UY@=+,ZS1.VKY>5J9HO@O"8]4U&^ND4!
MT&8'6FC4L1A.^MD':.MQI\T4]HS9P<*<-C$TC, 7A;[T*Y7,*XW!:D"32#%E
M*N!=$E"\LUP&Z6S9J<.])UMTQ &F33.V!^$)Q=.WW:SU3<PH;Z57(+-TH)S@
MX+25($M,P4=3G&NS3?SXFK-F6<PN[.!0X?2;5]K6,*WGVT+6P6^FM__Q2*^?
M#YYGI'?,'R[7\T5>KU\N/X7Y8GO$;_O8N;(90WV<X9F#XM:#0UG'WBD,P@6;
M4Y,^M,<.=<0]M\7J+8:2RMSS3?>-0U6>$X2MJ_/_:IZ>%T N&6A>LL88>-3Q
MR5ONX*^?]F5Q-(3<NM).(XE^\SFW2#]T"NWW'S&^Q6DX7_915&74UA5/O@J2
M?5"*'!:G2ZY++3TFEGT.36:?M+ [W[=EO<MQ^6%15[N\3B2D>9GG=-- <%5
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M3A925JP4$61@39W5\]XC, @$>V:+ATBD4V#=37 5H:VI[V?6.$UJ&1DX\DY
M1IN$]75:4M-%+V>6+1XD_\'9XB'"Z#1;K&3B.;@"9-1K:3U3X(L*( I7F6<1
M77G"*3OC;/$@^>V1+1["S#ZMS;>8B.FL@^(.O*N9;W060E8>"M=.\Q""\TU"
MS*.SQ?V4@H]\H1TFFXYP-L8[T$M<U_DC/]&/?,:+FF^:>4&,9MI"#&AJ/V4&
M#$(!\A0M-\YHF4X4\8Q(5G>V\T#X-7P3/!(+STPSGGXA-76U6TH*DDAUZ"I=
M3\C0D=Q2$C77(&/38M9^WM*GR:[WHC?C(J4#-?IZ[D!J[J,0D)S(I/[D[KM<
M=Q@8([1AD=C=Q&D9!+YIDNK'@.\@_G8QZFM,M;GU-[/B#'HE.-19V*"B-N %
M738R:RN3U3'I??9"3&I*;_U-QSGY7HSFH=(?K@;^2@T6^0-N<GK?I;/Q)F]F
M+*HBE=? *9*IM=$2G"*SD%) J;-*QC:M)QZ)CHZ3[[U@?ZBT#W<)EAN\.%&B
M\J$E[6-D)Y_Z[/%3DH.H.44>,EF>C4 )Q?':GZPX>"\\^)I5\B6@"Z<JW!DM
M#_E(CO^K_JS?XFKS[8GHUC&N'H5\UMJY8NLL0XI0O;" REIBCM56)!Y9.?6>
MSWW/WL>3Q-%H&S AIHE4.PB8'DJ7('GWA@4)(3%6!XX3!=(92%F3F2>C'W-3
MM[:K!.;)<;%G3G.(D#K%VMTTC([.*18]$*_2E6OAA61@F$Q92,RF-'W /;.<
MYB#Y#\YI#A%&ISG-I)SG)I%O6K8%U8[N 702&,:0C$>*SIX>?G6N.<U!\MLC
MISF$F1U8FR%CY2B,UQRE@J+JUBF1/& *"IP3+$:*:8B#)W;%^EJY/O4-V$J8
M?>/T_A%VVJ;$= ',68(RZ.AW/(%.TO 2(V,83HS5\YXI.0@OQ\Z4'""\#K#Y
M\ [G)$N)SBA(4D=0F45 Z1Q(X0MZEDO*39[\CENLW<\<RB$XV'NQ]A"A=("N
M)];)7!/%,F=21 KH0UTJ(ZP %-E"BMDASTYCFQ7N>YVNVUMY=-2-+ZP.$+A'
MR\ZW-WCC32[2%>">R%+!"P@FQ#I^2#MM'>-MIE<,.>2T:>>IO<1FXNP JJ<M
M^Y!D)X32LCXE<)*")DO!!((,AG.7.6K>Q,GLKT"HF<O0#JR3%@P-04X':G54
MTZ8RR1A9%R.B3J"0<PC1D>G27"7'14RZS2:GULVWS3R6DX'^9'+MN1GWEXSK
M?$#^^OK?C92;ON\4(^6=KS[Z:^[/1]2.1 1%JER[+CCXDCB4&*PTPI32QD.[
M>XRC@^XZ*2G_]L=V4LCBP]6'OR>._4 _]>\9-]:P*!PPYQ!4D87 F0)YW-(7
MFP1%>DVNYL>/->U=>@0.OHNNQ^-^OPOCKJFJE_[!YN'Z7X]J).X[41M3H3$7
MBH0]6*R#'IQ5X 3)T7H=N$XL:=YD>]G8IH(^K6Z@WS+N&TJU]5(JIJ D%ND"
M,QF"U C"F%243:R(=H;P^_-T91R&2/Y[XW \OSMP>N^S<5^'H/V*F\L5_>\.
MB44D9(Q$CHZ7:E,-A!08N64FZ<""][Q)M=(!9YW6Q1T5;FWEU/L%]097E?+/
M^>!*S <^9]1+Z_%3MKF^BHY). I.C#2&I)P<>!4<2)FU+B%%J\_B^JKXWG[F
MCWD=5_,_OKT#&F5=X"Y!3,Y4O7& R=:79&E9(6)9:9-@>OA,75UC0Q!POUTY
MGN\37F7KU6;VCL+YJQ5(@L=2.!+UK*9PR?VORZ$I8,?H4N ^^;*/.M"'W@(*
M_6D7)'>^=6HXC"3#Y;$,[0$%U^DGG;33OF1@2E%T)G,&[X2!.M2MU)5_0>U3
M:KX_#J;,/1\AL5V9'\"^B:7^ZWQ1YZ=>']QS;PIQ %*JZZ>"#N!STB"]QF)#
M#MKM\R:RE]SO?//$DC]$;LLQF#BU]*^FY]YLF"J.>ZW(Y16%H%\-7V!2@PO*
M<Q3,);]/:+*?]&]_\S2!QFC2/YB)W82PN]??M]R!L$'E6&\_7@?P"*LAU*RR
MCT8EXA%&T3!<??!<4X>FX_H,+831#;;NAMWO\^K3;Z4.\[YZ869*^*0M<!V(
M+*T-1?5* DN<.&4QH6P4?SUUM!Z]T@.1L,=KR!%BZ0!H=VGYZ:\_\F*=9QX+
M]X%IL%J2/0\V@"N,D6$6T68RZM8TZ9>\]S0]&JQQX'0\\WM_/MO^^GI1EJM/
MV\\\\A7MH8\;]3%MKS.W>5,3 D-A0@(O28*R*@+FE,"4F A(47+5Z,5IS#>U
MN[#>J7%XEVL=Z&WCR6?,IQ*$9E"D<=5F"KKX8P:15# BVTR^9'MS\_1!I[[8
M#L;*XX9G9 EU=ZOMT/?C?!WKRI-WN,EO\RH2ZV=29<^++Z!R(/J4$>"X4L",
M"RYFK)FUDR/PGH-.?1>>!H''2JCW6_%F>.>R?&/#3DYMGM='WI7#OF34&_0(
M^MK<JUQS9:07Y)134*G(6H'WA-0H%#+F9#3L3*NROO+U9N/=E?4F._!;>45J
MA!?_G7$U*]FJ5-5%RZA!)6]JF[8 1K_EW&DNI6C#@$./W-5=.P0_@S+HXTFM
M@UMW+TI_O,QO2,G?_YDO/N=?*6K^N)YY9WUA2.PU%"FKY!3XD!/X'(2****2
M3?R_0P_<U2W<')O'2NR,D%FU[OV?RYF0LLA"3'0659TSP"%P01%Y4<YJ'4RK
MUM)AYYRVU6H"'!XBGW.#'^$ISQ0691RQ4&=9ZN ,!.)E D5*1VZP%5(UF8X\
M^*33#NN<"H*#971F('RUO"3OPP0?DG;D?:12Z\PC*5G*$!A/)CDBOLTH^Z$'
MG79FYD00'"RA:<<C[4O:BT)?]Y6^JDG%V0C&U 'ZK*XP\:).R2B<!5UK3'>B
MEGMF)QWTU=/NAQP!4R?A^1E9M1G+N0Z(BF IJ")=*:DR49.N!%:'4\BDFC1*
M[GO O1!G.T9<4XF,-L2W$=+^L4C7;Y8Y_?17G5%QM59[9JVWN6Y1E:;4G5]8
MZ3,(T:LZG]YS4YJL2#OHM'MAT)T[!D>153^3U!^@<F:=ELQ23"Z]TJ L8NV"
M=^!+L%K$((B+[5,:7\^S%[;\&6!K#'[WW[$]Z E_QN\2UBA),>,3IBEV:?R:
MJ/C?A[/ZY?+3I_EF>R'B(M42(CI"7L3Y(2VQCWW82&S;^[PC97%N?=^+G>^K
M*<*+Y?IRE;\M"<Y:& I]@"450"FNP4>9P9;Z5,DQ"<9;&+Q!ISS6VN_U9=]:
M\4+";!V%A(Z8 \I'01%B07+NK4FU;DFS)I/+AAUSVEQ/.Y3M7AT-A==OROL1
MHW%\<^60#V]O!$_2ACD,KD([D3DAAV7F:Y#%P1.J@-F"7MKBI&[RB'=2H[@=
M 77K&Z\WGG)76%V,%'D=P9&,K.D""]H569#3_XDV-3WWG>:<3-P0S'SG'1\M
MBHG[>GXAI^_#5C OR4?<]K49F;$PRR $E&2'36U)21:,8Z96'_E@1FON^?[K
MIT7."/)<CL;<KJ#QGO[%]5!3RX4L=0DA9Z%NJ*R)<!T3:):*#+5X0^RSJ>0
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M--YFR0,421>;TG4$(+.1;A6FI4 ?7)NFK6>YR640$A[=Y#)$+!U@ZG#&/3)
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M(@?&6>KJHAB; _ME3=DS4\/NQ# (B.>LP=M?WF5BWWJ^N7GZN+FHE?4^.L?
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MJ@Q&IJ)E3$R')AOIGTMFW7-FT1L#H5C28$-F!K-0($1.):)*Z',3'^?OS/I
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M[V?3SP]IDCKEA+6@,4N&ED%T"(&\$4A)"\&#MCXUN<%\(L-Y<FS&!\2QZNT
M&2]LM^]^)E($(W3 0)ML-+G>/DKP/A;(T7G!,Z8HFR2S["-<+_E:;<\MS<S5
M 00O\0=.;W$QT9@4"JX@,E8CO$6#*\F"J!&2+ 3#W.1Y]H, ??E4QYOVV4.,
M 7KN-Q2TZF;](<QO[C[-PW015FT'#@[^;!UII'#/?I*.%.#9]K&?+GKTK$AC
M$]3,=E!&(SAEZ;\4>NNR<E8V"?3L$NQX&MD\_J:['K39T98>@$3UH$2I57$S
M XR<&4Q6F]SDQO$ &<]+1J.BZ#D1M;'4Z^.J]V$^#S7%='#@>N^1&W/9RS,Y
M%;<5H9%Q*<$D1]NC4;8>K1+D+&KSKJ*L:U+!I#6W/1XSMWWIS=TO?UD>-#5'
MDV3MM*EK1:<2!;@L#,28R3UU+@C7)J0_1-K.^>X09&T/;+>R7A>G^'VFM@S$
M)7)T!*(D)I<65!(1O-49N&:")V>\;-/N='\1>PF&-\/+GCORD<;K#)8/?>^M
M][1<'9AH:UUD*<#G[,!K0=Z39M'S)I58GXO2)^<=:_07L#7  F>^9[DH99G?
MBOGM].;JYNZA;(%047"2FZO:X=!S2WZXB1"*ELHIQ33?YUG$7I<LFT7H!SM#
MC#H;5<.=\<R3Q?08N?&U>+"3B>:#AM23B)D%_> Y(T,F<SFIV]U=_/3,6]TP
M0W4!O&54K[Y(?#*U*UQ,E$P8;*33*J\U9"V1=DQ*@F99"\U3C++)8Y*M$O5#
M6<<;?G-L]4@K= "GB[2\Y5Q<8L*K'W6UK<V'%9.+,QKJ PY0*#1$[2+Y12K(
M6'M+\2;5)78)=EX>:PJN46W2;Y#LXVU<X%^W--A;6DPW0[(XUT<8*U_S1<G&
MRLQ<^\C/T /G45A5$(1R=/AVZ,!Q24>L(E54)M%!J4U6XA:!C@YFK8W[&.S5
M+LE@R,V(1DI0C"&$Q(@Z'0\U?3F'T*;-X#:)SAP'& ,1SX)1HVC_];#(\2'V
MG2,V8IF3A-2W8DQ%+[7D#(RSM?4N^73.D1.F1,XRJ>J+M6E2?QK6N7<D$FW!
MC/P'X%A+QA6NP+-4P$ER++*,D;DF1^1-PG3*-8?@8 ?7'*[S#@[$'^:S[TBG
MN@_7M&0OIOGM7[=7WVNBQIN[3S3$,CS&T'#)>6WGDA%48)%T9 K8K&0F4N96
MM:G]N%NVKE U  #/V]N-:HV> 58G])"<J*7Q620@7Y(V9%J1X#Q3I$$7 B-M
M!MVJ5>(NV<X+L-'QL"_>!AJG [R]N26-7DV_K.*L*G(=O;:0T=8@A56DG>J8
M%A8$BTZ&V*1>WZ]B=(JBH5:>C:;R#@"S3N(/ZRH9\A,X$U!<9*!0*X@Z)) ^
M<<<P6UW:M(O9+,^9 ]EC[W1C:+U/\*P6E"L8N$5.>M&UXR<7$*5+D(TW(FLF
MG3N%L]_+3C:*O7=C:(#R^T/10\WFJ'E0)+I/-9$>#?&HY EL4%HARJA9F[HQ
MFZ3I#CU#+/TR?@:HO3_L/(;D@_+&H$F L>[HM)(@,%I>-@FAZ-?:=?@$\'EW
MT$ULLY+]K3>P87H_(WZ^?)T\M,[\DTZ'H;[)>(=A@8OES_>SF__B32WYC=.$
M>9)X,=Q$#=9F"8HF 4X;#\$S[TL1.9FU4-)ZG/&P#W;%-P.-.VNNZ0[XY]<I
M?0AWU;%83+A#KY,)D$KM,FUT63W'D2H9J3S&-FV9-XO3U>'Y.#2-J/?SLL\[
M7"P0?YW&I@6QUN_W$\Z__5E^FTWOX[?DF]KL@ZSOO$HM@BW <4?'R5"\*H[I
M+.5.7AI%E*[VMZ,9Z_36Z8#+]IWT)4[Q[W!=)\LGM-"8+X:!%G6.62,=(H(%
M;WD,S!F=<Y,'YT.$/6_7FR8\V-QF[>^"5W^H/R()_N]__!]02P,$%     @
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M<7AE>#,Q,2YH=&U02P$"% ,4    " !4@@91E)?:78<(  "",   &@
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M'0  9V@M,C R,# V,S N:'1M4$L! A0#%     @ 5((&4:2V-A9-%   7MT
M  \              ( !:BD# &=H+3(P,C P-C,P+GAS9%!+ 0(4 Q0    (
M %2"!E'61C:"\B<  *.N 0 3              "  >0] P!G:"TR,#(P,#8S
M,%]C86PN>&UL4$L! A0#%     @ 5((&493^FFM*=0  -E0% !,
M     ( !!V8# &=H+3(P,C P-C,P7V1E9BYX;6Q02P$"% ,4    " !4@@91
M:_,7?64/ 0 _9 L $P              @ &"VP, 9V@M,C R,# V,S!?;&%B
M+GAM;%!+ 0(4 Q0    ( %2"!E&QE66%?J<  .O:!P 3              "
M 1CK! !G:"TR,#(P,#8S,%]P<F4N>&UL4$L! A0#%     @ 5((&40B>F)RS
M#@  <FD  !H              ( !QY(% &=H+61I<F5C=&]R8V]M<&5N<V%T
<:6\N:'1M4$L%!@     +  L Y@(  +*A!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
